PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G				Sadasivam, S; Gupta, S; Radha, V; Batta, K; Kundu, TK; Swarup, G			Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis	ONCOGENE			English	Article						p53; ipaf; caspase-1; apoptosis; transcriptional activation; gene expression	PROTEIN TYROSINE PHOSPHATASE; CELL-DEATH; P53; CANCER; PUMA; ASC; INFLAMMASOME; EXPRESSION; GENERATION; MECHANISM	The tumor suppressor protein p53 regulates transcription of many genes that mediate cell cycle arrest, apoptosis, DNA repair and other cellular responses. Here we show that Ipaf, a human CED-4 homologue and an activator of caspase-1, is induced by p53. Overexpression of p53 by transfection in U2OS and A549 cells increased Ipaf mRNA levels. Treatment of p53-positive cell lines U2OS and MCF-7 with the DNA damaging drug, doxorubicin, which increases p53 protein level, induced expression of Ipaf mRNA but similar treatment of MCF-7-mp53 ( a clone of MCF-7 cells expressing mutant p53) and p53-negative K562 cells showed much less induction of Ipaf gene expression. Expression analysis for Ipaf mRNA in doxorubicin-treated human tumor cell lines suggests that p53-dependent as well as p53-independent mechanisms are involved in the regulation of Ipaf gene expression in a cell-type-specific manner. The Ipaf promoter was activated by normal p53 but not by His(273) mutant of p53. A functional p53-binding site was identified in the Ipaf promoter. A dominant-negative mutant of Ipaf inhibited p53-induced and doxorubicin-induced apoptosis by about 50%. Ipaf-directed small hairpin RNA downregulated p53-induced Ipaf gene expression and also reduced p53-induced apoptosis. Doxorubicin-induced apoptosis was also inhibited by Ipaf-directed small hairpin RNA. Our results show that p53 can directly induce Ipaf gene transcription, which contributes to p53-dependent apoptosis in at least some human cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Swarup, G (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	gshyam@ccmb.res.in	gupta, sanjeev/B-2824-2008; Gupta, Sanjeev/AAG-9749-2020	gupta, sanjeev/0000-0002-4691-6853; Gupta, Sanjeev/0000-0002-4691-6853; Swarup, Ghanshyam/0000-0002-8098-0509; Sadasivam, Subhashini/0000-0002-7875-7180; Kundu, Tapas/0000-0001-7790-214X				Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Gupta S, 2001, J BIOL CHEM, V276, P10585, DOI 10.1074/jbc.C100025200; Gutierrez O, 2004, FEBS LETT, V568, P79, DOI 10.1016/j.febslet.2004.04.095; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liedtke C, 2003, J BIOL CHEM, V278, P27593, DOI 10.1074/jbc.M304077200; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Matsuda K, 2002, CANCER RES, V62, P2883; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	40	45	47	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					627	636		10.1038/sj.onc.1208201	http://dx.doi.org/10.1038/sj.onc.1208201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580302				2022-12-28	WOS:000226420400010
J	Proikas-Cezanne, T; Waddell, S; Gaugel, A; Frickey, T; Lupas, A; Nordheim, A				Proikas-Cezanne, T; Waddell, S; Gaugel, A; Frickey, T; Lupas, A; Nordheim, A			WIPI-1 alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy	ONCOGENE			English	Article						WD-repeat; ATG18; WIPI49; tumor; homology modeling; autophagy	WD-REPEAT PROTEIN; VACUOLE TARGETING PATHWAY; CELL-DEATH; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; CYTOPLASM; IDENTIFICATION; ARCHITECTURE; SUPERFAMILY; PEXOPHAGY	WD-repeat proteins are regulatory beta-propeller platforms that enable the assembly of multiprotein complexes. Here, we report the functional and bioinformatic analysis of human WD-repeat protein Interacting with Phospho-Inosides (WIPI)-1alpha (WIPI49/Atg18), a member of a novel WD-repeat protein family with autophagic capacity in Saccharomyces cerevisiae and Caenorhabditis elegans, recently identified as phospholipid-binding effectors. Our phylogenetic analysis divides the WIPI protein family into two paralogous groups that fold into 7-bladed beta-propellers. Structural modeling identified two evolutionary conserved interaction sites in WIPI propellers, one of which may bind phospholipids. Human WIPI-1alpha has LXXLL signature motifs for nuclear receptor interactions and binds androgen and estrogen receptors in vitro. Strikingly, human WIPI genes were found aberrantly expressed in a variety of matched tumor tissues including kidney, pancreatic and skin cancer. We found that endogenous hWIPI-1 protein colocalizes in part with the autophagosomal marker LC3 at punctate cytoplasmic structures in human melanoma cells. In addition, hWIPI-1 accumulated in large vesicular and cup-shaped structures in the cytoplasm when autophagy was induced by amino-acid deprivation. These cytoplasmic formations were blocked by wortmannin, a classic inhibitor of PI-3 kinase-mediated autophagy. Our data suggest that WIPI proteins share an evolutionary conserved function in autophagy and that autophagic capacity may be compromised in human cancers.	Univ Tubingen, Inst Cell Biol, Dept Mol Biol, Tubingen, Germany; Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA USA; Max Planck Inst Dev Biol, Tubingen, Germany; Univ Tubingen, Inst Cell Biol, Proteome Ctr Tuebingen, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Massachusetts System; University of Massachusetts Worcester; Max Planck Society; Eberhard Karls University of Tubingen	Proikas-Cezanne, T (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Mol Biol, Morgenstelle 15, Tubingen, Germany.	tassula.proikas-cezanne@uni-tuebingen.de		Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X; Waddell, Scott/0000-0003-4503-6229				Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Frickey T, 2004, BIOINFORMATICS; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Georgakopoulos T, 2001, YEAST, V18, P1155, DOI 10.1002/yea.764; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; Honore B, 2002, ONCOGENE, V21, P1123, DOI 10.1038/sj.onc.1205186; Jeffries TR, 2004, MOL BIOL CELL, V15, P2652, DOI 10.1091/mbc.E03-10-0732; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Lee CY, 2001, DEVELOPMENT, V128, P1443; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Munafo DB, 2001, J CELL SCI, V114, P3619; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Paoli M, 2001, PROG BIOPHYS MOL BIO, V76, P103, DOI 10.1016/S0079-6107(01)00007-4; Paoli M, 2001, NAT STRUCT BIOL, V8, P744, DOI 10.1038/nsb0901-744; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simonsen A, 2004, J CELL SCI, V117, P4239, DOI 10.1242/jcs.01287; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stromhaug PE, 2004, MOL BIOL CELL, V15, P3553, DOI 10.1091/mbc.E04-02-0147; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Van de Peer Y, 2002, GENE, V295, P205, DOI 10.1016/S0378-1119(02)00689-3; van Nocker S, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-50; Waddell S, 2001, ONCOGENE, V20, P6001, DOI 10.1038/sj.onc.1204702; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470	47	254	273	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9314	9325		10.1038/sj.onc.1208331	http://dx.doi.org/10.1038/sj.onc.1208331			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602573				2022-12-28	WOS:000225764100003
J	Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD				Ducker, CE; Stettler, EM; French, KJ; Upson, JJ; Smith, CD			Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase	ONCOGENE			English	Article						palmitoylation; protein; palmitoyl acyltransferase; RAS; intracellular signaling	ACYL TRANSFERASE-ACTIVITY; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; H-RAS; SACCHAROMYCES-CEREVISIAE; N-RAS; LOCALIZATION; PURIFICATION; CANCER; CELLS	Protein palmitoyltransferases (PATs) represent an exciting new target for anticancer drug design due to their pivotal roles in the subcellular localization of a number of oncogenes. We show that the Huntingtin interacting protein 14 (HIP14) is a PAT with a preference for the farnesyl-dependent palmitoylation motif found in H- and N-RAS. Characterization of HIP14 in mouse cells has revealed that it has the ability to induce colony formation in cell culture, anchorage-independent growth, and tumors in mice. Activity of the enzyme and its ability to transform cells is dependent on critical residues in the active site of the enzyme.	Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Smith, CD (corresponding author), Penn State Univ, Dept Pharmacol, Coll Med, H078,500 Univ Dr, Hershey, PA 17033 USA.	cdsmith@psu.edu			NCI NIH HHS [R01 CA75248, R01 CA075248-09, R01 CA075248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; Danesi R, 1996, MOL PHARMACOL, V49, P972; Das AK, 1997, J BIOL CHEM, V272, P11021; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Eummer JT, 1999, BIOORGAN MED CHEM, V7, P241, DOI 10.1016/S0968-0896(98)00202-8; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hiol A, 2003, BBA-MOL CELL BIOL L, V1635, P10, DOI 10.1016/j.bbalip.2003.10.001; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; Leonard DM, 1997, J MED CHEM, V40, P2971, DOI 10.1021/jm970226l; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Roth AF, 2002, J CELL BIOL, V159, P23, DOI 10.1083/jcb.200206120; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Schroeder H, 1997, BIOCHEMISTRY-US, V36, P13102, DOI 10.1021/bi9709497; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Singaraja RR, 2002, HUM MOL GENET, V11, P2815, DOI 10.1093/hmg/11.23.2815; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Ueno K, 1997, J BIOL CHEM, V272, P13519, DOI 10.1074/jbc.272.21.13519; Varner AS, 2003, BIOCHEM J, V373, P91, DOI 10.1042/BJ20021598; Varner AS, 2002, ANAL BIOCHEM, V308, P160, DOI 10.1016/S0003-2697(02)00212-9; Waddick KG, 1998, BIOCHEM PHARMACOL, V56, P1411, DOI 10.1016/S0006-2952(98)00211-1	39	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9230	9237		10.1038/sj.onc.1208171	http://dx.doi.org/10.1038/sj.onc.1208171			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489887	Green Accepted			2022-12-28	WOS:000225638000008
J	Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM				Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM			PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways	ONCOGENE			English	Article						PKC; glioblastoma; mTOR; Akt; proliferation	PROTEIN-KINASE-C; GROWTH-FACTOR; MESSENGER-RNAS; PHAS-I; EXPRESSION; ALPHA; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; TRANSLATION	We previously demonstrated that protein kinase C-eta (PKC-eta) mediates a phorbol 12-myristate-13-acetate (PMA)-induced proliferative response in human glioblastoma (GBM) cells. In this report, we show that PMA-stimulated activation of PKC-eta in U-251 GBM cells resulted in activation of both Akt and the mammalian target of rapamycin (mTOR) signaling pathways and an increase in cell proliferation. Expression of a kinase dead PKC-eta (PKC-etaKR) construct reduced the basal and PMA-evoked proliferation of PKC-eta-expressing U-251 GBM cells, as well as abrogated the PMA-induced activation of Akt, mTOR, and the mTOR targets 4E-BP1 and STAT-3. Treatment of cells with the PI-3 kinase inhibitor LY294002 (10 muM) or the mTOR inhibitor rapamycin (10 nM) also reduced PMA-induced proliferation and cell-cycle progression. Expression of a constitutively active PKC-eta (PKC-etaDeltaNPS) construct in a GBM cell line with no endogenous PKC-eta (U-1242) also provided evidence that PKC-eta targets the Akt and mTOR signaling pathways. Moreover, activation of 4E-BP1 and STAT-3 in both PMA-treated U-251 and PKC-etaDeltaNPS-expressing U-1242 GBM cells was inhibited by rapamycin. However, activation of Akt, but not mTOR was inhibited by the PI-3 kinase inhibitor LY294002. This study identifies Akt and mTOR as downstream targets of PKC-eta that are involved in GBM cell proliferation.	Univ Virginia, Dept Pathol & Neurol, Charlottesville, VA 22908 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Virginia; Columbia University	Aeder, SE (corresponding author), Univ Virginia, Dept Pathol, 415 Lane Rd,POB 800904, Charlottesville, VA 22908 USA.	sea4s@virginia.edu			NCI NIH HHS [CA90851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BENZIL DL, 1992, CANCER RES, V52, P2951; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Choe Y, 2003, J NEUROENDOCRINOL, V15, P508, DOI 10.1046/j.1365-2826.2003.01023.x; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fadden P, 1997, J BIOL CHEM, V272, P10240; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guizzetti M, 1998, EUR J PHARMACOL, V359, P223, DOI 10.1016/S0014-2999(98)00620-7; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hesselager G, 2003, CANCER RES, V63, P4305; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; Konopka G, 2003, CURR MOL MED, V3, P73, DOI 10.2174/1566524033361609; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krasagakis K, 2004, J CELL PHYSIOL, V199, P381, DOI 10.1002/jcp.10434; Livneh E, 1996, ONCOGENE, V12, P1545; MAYER M, 1994, DEVELOPMENT, V120, P143; MAYER M, 1993, GLIA, V8, P12, DOI 10.1002/glia.440080103; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NAVE BT, 1999, BIOCHEM J, V1, P427; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Okada Y, 2000, VERH DEUT G, V84, P33; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Rajan P, 1998, J NEUROSCI, V18, P3620; Resnick MS, 1997, CANCER RES, V57, P2209; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Rooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9; Sano T, 1999, CANCER RES, V59, P1820; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; TODO T, 1991, NEUROSURGERY, V108, P11; WANG X, 1998, BIOCHEM J, V183, P261; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weis J, 1999, J NEURO-ONCOL, V44, P243, DOI 10.1023/A:1006303221064; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yamamoto M, 2002, ANTICANCER RES, V22, P4265; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	66	80	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9062	9069		10.1038/sj.onc.1208093	http://dx.doi.org/10.1038/sj.onc.1208093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489897				2022-12-28	WOS:000225492800007
J	Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M				Kameoka, Y; Tagawa, H; Tsuzuki, S; Karnan, S; Ota, A; Suguro, M; Suzuki, R; Yamaguchi, M; Morishima, Y; Nakamura, S; Seto, M			Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma	ONCOGENE			English	Article						array CGH; diffuse large B-cell lymphoma; Fragile Histidine Triad; 3p14.2	COMPARATIVE GENOMIC HYBRIDIZATION; FHIT GENE; CHROMOSOMAL IMBALANCES; EXPRESSION; CLASSIFICATION; TRANSCRIPTS; PROTEIN; ACID; SITE	Deletions of the 3p arm have been detected in various solid tumors, but no study to date has investigated this deletion in diffuse large B-cell lymphoma (DLBCL). Recently, we demonstrated that 3p14.2 was deleted in approximately 30% of DLBCL cases by use of a genome-wide array-comparative genomic hybridization (CGH). For a more detailed examination of the genomic losses at 3p14.2, here we made use of contig BAC array for 3p14.2, and found that 12 DLBCL samples displayed losses. All of the deleted regions were located within the fragile histidine triad (FHIT) gene, and the most frequent region of loss was mapped to 0.4 Mbp of the region encompassing the introns 4 and 5 and exon 5 of the FHIT gene. Concomitant analysis of transcripts showed that the FHIT gene was aberrantly transcribed in 31% of the DLBCL samples examined and that the lost exons of the aberrant transcripts were correlated with genomic deletions. These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts.	Mie Univ, Sch Med, Dept Internal Med 2, Tsu, Mie 514, Japan; Aichi Canc Ctr, Dept Hematol & Chemotherapy, Aichi, Japan; Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Aichi, Japan; Aichi Canc Ctr, Res Inst, Div Mol Med, Aichi, Japan	Mie University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp	Nakamura, Shigeo/I-1571-2012; Ota, Akinobu/CAC-5999-2022; Ota, Akinobu/AAI-9396-2020; Ota, Akinobu/H-4510-2019	Ota, Akinobu/0000-0002-6296-2921; Suzuki, Ritsuro/0000-0002-5974-7614; Yamaguchi, Motoko/0000-0002-7094-6489; Tsuzuki, Shinobu/0000-0002-3209-3550				Albitar M, 2001, LEUKEMIA RES, V25, P859, DOI 10.1016/S0145-2126(01)00042-X; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Berglund M, 2002, MODERN PATHOL, V15, P807, DOI 10.1097/01.MP.0000024375.04135.2B; Chen PM, 2004, ONCOL REP, V11, P349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Dave BJ, 2002, CANCER GENET CYTOGEN, V132, P125, DOI 10.1016/S0165-4608(01)00548-9; Druck T, 1997, CANCER RES, V57, P504; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Gemma A, 1997, CANCER RES, V57, P1435; Hallas C, 1999, CLIN CANCER RES, V5, P2409; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; HARRIS NL, 1994, BLOOD, V84, P1361; Hendricks DT, 1997, CANCER RES, V57, P2112; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Iwai T, 1998, CANCER RES, V58, P5182; Karnan S, 2004, GENE CHROMOSOME CANC, V39, P77, DOI 10.1002/gcc.10298; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Peters UR, 1999, ONCOGENE, V18, P79, DOI 10.1038/sj.onc.1202256; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Tagawa H, 2004, CANCER RES, V64, P5948, DOI 10.1158/0008-5472.CAN-03-4056; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297	33	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9148	9154		10.1038/sj.onc.1208136	http://dx.doi.org/10.1038/sj.onc.1208136			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480422				2022-12-28	WOS:000225492800017
J	Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE				Mongroo, PS; Johnstone, CN; Naruszewicz, I; Leung-Hagesteijn, C; Sung, RK; Carnio, L; Rustgi, AK; Hannigan, GE			beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer	ONCOGENE			English	Article						parvin; ILK; tumor suppression; PKB/GSK3b; EGF; breast cancer	CALPONIN HOMOLOGY DOMAINS; GLYCOGEN-SYNTHASE KINASE; FOCAL ADHESION PROTEIN; TUMOR-SUPPRESSOR PTEN; CYCLIN D1 GENE; CAENORHABDITIS-ELEGANS; EXPRESSION INCREASES; CHROMOSOME 22Q13; PROSTATE-CANCER; BINDING PROTEIN	We analysed breast tumors and breast cancer cell lines for the expression of beta-parvin (ParvB), an adaptor protein that binds to the integrin-linked kinase (ILK). Quantitative RT-PCR indicated that ParvB mRNA was downregulated, by at least 60%, in four of nine breast tumors, relative to patient-matched normal mammary gland tissue. We also found that ParvB protein levels were reduced by greater than or equal to90% in five of seven advanced tumors, relative to matched normal breast tissue. Conversely, ILK protein and kinase activity levels were elevated in these tumors, suggesting that downregulation of ParvB stimulates ILK signaling. Western blot analyses indicated very low levels of ParvB protein in MDA-MB-231 and MCF7 breast cancer cells, facilitating functional studies of the effects of ParvB on ILK signaling. Expression of ParvB in MDA-MB-231 and MCF7 cells increased cell adhesion to collagen. ParvB inhibited ILK kinase activity, anchorage-independent cell growth and in vitro matrigel invasion by MDA-MB-231 cells. EGF-induced phosphorylation of two ILK targets, PKB (Ser473) and glycogen synthase kinase 3beta (Ser9), was also inhibited by ParvB. These results indicated that ParvB inhibits ILK signaling downstream of receptor tyrosine kinases. Our results suggest that loss of ParvB expression is a novel mechanism for upregulating ILK activity in tumors.	Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Div Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Hannigan, GE (corresponding author), Hosp Sick Children, Res Inst, Canc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hannigan@sickkids.ca	Hannigan, Greg/A-5092-2009					Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Barker N, 2000, BIOESSAYS, V22, P961; Cairns P, 1997, CANCER RES, V57, P4997; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Castells A, 2000, CANCER RES, V60, P2836; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; Coffer PJ, 1998, BIOCHEM J, V335, P1; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Edwards Lincoln A, 2004, Cancer Treat Res, V119, P59; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Gimona M, 1998, CURR BIOL, V8, pR674; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HRESKO MC, 1994, J CELL BIOL, V124, P491, DOI 10.1083/jcb.124.4.491; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Korenbaum E, 2001, GENE, V279, P69, DOI 10.1016/S0378-1119(01)00743-0; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin XY, 2003, CURR BIOL, V13, P922, DOI 10.1016/S0960-9822(03)00372-5; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marotta A, 2003, BRIT J CANCER, V88, P1755, DOI 10.1038/sj.bjc.6600939; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Olski TM, 2001, J CELL SCI, V114, P525; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Price JT, 1999, CANCER RES, V59, P5475; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Youssoufian H, 1998, BIOTECHNIQUES, V24, P198, DOI 10.2144/98242bm05; Yu X, 2000, J CELL SCI, V113, P2139; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	57	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8959	8970		10.1038/sj.onc.1208112	http://dx.doi.org/10.1038/sj.onc.1208112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467740				2022-12-28	WOS:000225354600011
J	Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H				Sakamoto, N; Terai, T; Ajioka, Y; Abe, S; Kobayasi, O; Hirai, S; Hino, O; Watanabe, H; Sato, N; Shimoda, T; Fujii, H			Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors	ONCOGENE			English	Article						flat-type colorectal tumor; RASSF1A; 3p LOH; K-ras; tumor suppressor gene; methylation	K-RAS MUTATIONS; EPIGENETIC INACTIVATION; SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; CPG ISLAND; CANCER; METHYLATION; CARCINOMA; LUNG; 3P21.3	Flat colorectal tumors, characterized by high-grade dysplasia from early small. at mucosal lesions, exhibit a relatively aggressive clinical behavior and are known for their infrequent K-ras mutations. In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48. at colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias). RASSF1A hypermethylation was detected in 39 of 48 (81.3%) tumors and RASSF1A methylation was also detected in 19 of 39 (49%) normal colonic mucosal tissues. 3p21.3 LOH was detected in 20 of 42 (47.6%) cases, but RASSF1 methylation was detected in cases with LOH (14 cases) and retention of 3p21.3 ( 20 cases). K-ras mutations were detected in seven of 48 (14.6%) tumors and the concordant occurrence of K-ras mutation and RASSF1A methylation was detected in three of 48 cases (6.3%). Overall, there was a statistically significant mutually exclusive relationship between K-ras mutations and RASSF1A methylation. In conclusion, promoter hypermethylation of RASSF1A is a frequent event and may start early in the background normal mucosa in this tumor type. An alternative cascade of abnormalities in RAS transduction pathways may be responsible for the. at morphology and aggressive nature of. at colorectal neoplasms.	Juntendo Univ, Sch Med, Dept Pathol 2, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Gastroenterol, Tokyo 1138421, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Course Mol & Cellular Med, Dept Mol Genet,Div Mol & Cellular Med, Niigata 9518514, Japan; Tokyo Rinkai Hosp, Div Pathol, Tokyo, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Pathol, Tokyo 104, Japan; Natl Canc Ctr, Res Inst & Hosp, Div Clin Lab, Tokyo 104, Japan	Juntendo University; Juntendo University; Niigata University; Japanese Foundation for Cancer Research; National Cancer Center - Japan; National Cancer Center - Japan	Fujii, H (corresponding author), Juntendo Univ, Sch Med, Dept Pathol 2, 2-1-1 Hongo, Tokyo 1138421, Japan.	hfujii@med.juntendo.ac.jp						Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chiang JM, 1998, CANCER RES, V58, P3289; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FENOGLIO CM, 1974, CANCER, V34, P819, DOI 10.1002/1097-0142(197409)34:3+<819::AID-CNCR2820340706>3.0.CO;2-S; Fujii H, 2002, J PATHOL, V197, P298, DOI 10.1002/path.1122; FUJIMORI T, 1994, INT J CANCER, V57, P51, DOI 10.1002/ijc.2910570110; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2001, CANCER RES, V61, P3573; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kuroki T, 2003, CANCER RES, V63, P3724; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; MINAMOTO T, 1994, CANCER RES, V54, P2841; Morrissey C, 2001, CANCER RES, V61, P7277; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; Mueller JD, 1998, AM J PATHOL, V153, P1977, DOI 10.1016/S0002-9440(10)65711-2; Olschwang S, 1998, INT J CANCER, V77, P366, DOI 10.1002/(SICI)1097-0215(19980729)77:3<366::AID-IJC10>3.0.CO;2-6; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rubio CA, 1996, DIS COLON RECTUM, V39, P143, DOI 10.1007/BF02068067; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Sparks AB, 1998, CANCER RES, V58, P1130; Spugnardi M, 2003, CANCER RES, V63, P1639; TADA S, 1994, CANCER, V74, P2430, DOI 10.1002/1097-0142(19941101)74:9<2430::AID-CNCR2820740907>3.0.CO;2-C; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Yashiro M, 2001, CANCER RES, V61, P2676; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; YUKAWA M, 1994, GUT, V35, P1258, DOI 10.1136/gut.35.9.1258	44	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8900	8907		10.1038/sj.onc.1207993	http://dx.doi.org/10.1038/sj.onc.1207993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480433				2022-12-28	WOS:000225354600005
J	Iwanaga, R; Komori, H; Ohtani, K				Iwanaga, R; Komori, H; Ohtani, K			Differential regulation of expression of the mammalian DNA repair genes by growth stimulation	ONCOGENE			English	Article						DNA repair gene; cell growth; gene expression; E2F	CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTOR E2F; MISMATCH REPAIR; DEPENDENT EXPRESSION; MICROARRAY ANALYSIS; DAMAGE RESPONSE; PROTEIN; RAD51; REPLICATION; PROMOTER	During DNA replication, DNA becomes more vulnerable to certain DNA damages. DNA repair genes involved in repair of the damages may be induced by growth stimulation. However, regulation of DNA repair genes by growth stimulation has not been analysed in detail. In this report, we analysed the regulation of expression of mammalian MSH2, MSH3 and MLH1 genes involved in mismatch repair, and Rad51 and Rad50 genes involved in homologous recombination repair, in relation to cell growth. Unexpectedly, we found a clear difference in regulation of these repair gene expression by growth stimulation even in the same repair system. The expression of MSH2, MLH1 and Rad51 genes was clearly growth regulated, whereas MSH3 and Rad50 genes were constitutively expressed, suggesting differential requirement of the repair gene products for cell proliferation. MSH3 gene is located in a bidirectionally divergent manner with DHFR gene that is regulated by growth stimulation, indicating that bidirectionally divergent promoters are not necessarily coordinately regulated. Promoter analysis showed that the growth-regulated expression of MLH1 and Rad51 genes was mainly mediated by E2F that plays crucial roles in regulation of DNA replication, suggesting close relation between some of the repair genes and DNA replication.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kiyo.gene@cmn.tmd.ac.jp						Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; HAWN MT, 1995, CANCER RES, V55, P3721; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Lin WC, 2001, GENE DEV, V15, P1833; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Meyers M, 1997, CANCER RES, V57, P206; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; WILSON TM, 1995, CANCER RES, V55, P5146; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	36	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8581	8590		10.1038/sj.onc.1207976	http://dx.doi.org/10.1038/sj.onc.1207976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467751				2022-12-28	WOS:000224988800003
J	Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y				Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y			Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G(2)/M arrest	ONCOGENE			English	Article						RASSF1A; microtubules; apoptosis; cell cycle arrest	FREQUENT EPIGENETIC INACTIVATION; POLYPOSIS-COLI PROTEIN; CELL-CYCLE; CPG ISLAND; PROMOTER HYPERMETHYLATION; BREAST CANCERS; GENE-PRODUCT; LUNG-CANCER; ALLELE LOSS; SPINDLE	RASSF1A is a putative tumor suppressor gene that is inactivated in a variety of human tumors. Expression of exogenous RASSF1A has been shown to inhibit tumor growth in vitro and in animals. However, the molecular mechanisms by which RASSF1A mediates its tumor suppressive effects remain to be elucidated. Here, we report that RASSF1A is a microtubule-binding protein that interacts with and stabilizes microtubules. We have identified the RASSF1A region harboring a basic domain that appears to mediate the interactions between RASSF1A and microtubules. The basic domain-containing RASSF1C isoform also interacts with and stabilizes microtubules. We further show that in addition to G(1) arrest, RASSF1A promotes growth arrest in the G(2)/M phase of the cell cycle and endogenous RASSF1A also interacts with microtubules. Based on our results, we propose that RASSF1A may mediate its tumor suppressive effects by inducing growth arrest in the G(1) and G(2)/M phases. Together, these results provide important new insights into the molecular mechanisms by which this novel tumor suppressor mediates its biological effects.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK62136-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alberts B., 2002, MOL BIOL CELL, P907; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; ERIMANN JDR, 2002, NATURE, V416, P850; Goedert M, 1996, J CELL SCI, V109, P2661; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Huang Y, 2001, CANCER RES, V61, P6918; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Lo KW, 2001, CANCER RES, V61, P3877; Lodish H, 2000, MOL CELL BIOL, P795; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nogales E, 2001, ANNU REV BIOPH BIOM, V30, P397, DOI 10.1146/annurev.biophys.30.1.397; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Schuyler SC, 2001, J CELL SCI, V114, P247; Shimoda SL, 2002, CELL, V109, P9, DOI 10.1016/S0092-8674(02)00712-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SMITH KJ, 1994, CANCER RES, V54, P3672; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wistuba II, 2000, CANCER RES, V60, P1949; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	55	75	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	2004	23	50					8216	8230		10.1038/sj.onc.1207901	http://dx.doi.org/10.1038/sj.onc.1207901			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378022				2022-12-28	WOS:000224749500004
J	Shupnik, MA				Shupnik, MA			Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation	ONCOGENE			English	Review						estrogen receptor; progesterone receptor; IGF-1 receptor; EGF-receptor; transcription; cell proliferation	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; HUMAN PROGESTERONE-RECEPTORS; ALPHA ER-ALPHA; ESTROGEN-RECEPTOR; SIGNALING PATHWAYS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; TRANSACTIVATION FUNCTION; MEDIATED TRANSCRIPTION	Both steroids and growth factors stimulate proliferation of steroid-dependent tumor cells, and interaction between these signaling pathways may occur at several levels. Steroid receptors are typically classified as ligand-activated transcription factors, and steps by which they bind ligand, dimerize, recruit coregulatory molecules, and activate target gene transcription are well understood. Several steroid responses are functionally linked to c-Src or tyrosine kinase receptors, and the physiological impact and the precise molecular pathways involved in these responses are under intensive investigation. Ligand-independent stimulation of steroid receptor-mediated transcription by growth factors is now believed to occur through activated protein kinases that phosphorylate the receptors and receptor coregulators. Recently, steroid hormones themselves have been shown to rapidly activate intracellular signaling cascades, via binding to cognate cytoplasmic or membrane-associated receptors. In some contexts, steroid receptors interact directly with c-Src and other cytoplasmic signaling molecules, such as Shc, PI3K, and p130 Cas. Crosstalk between growth factors and steroids in both the cytoplasm and nucleus could have profound impact on complex biological processes such as cell growth, and play a significant role in the treatment of steroid-dependent cancers. The potential roles of progesterone and estrogen receptors in this crosstalk are discussed in this review.	Univ Virginia, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Box 800578 HSC, Charlottesville, VA 22908 USA.	mas3x@virginia.edu						Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Ahola TM, 2002, ENDOCRINOLOGY, V143, P3376, DOI 10.1210/en.2001-211445; Ankrapp DP, 1998, J CELL PHYSIOL, V174, P251, DOI 10.1002/(SICI)1097-4652(199802)174:2<251::AID-JCP12>3.0.CO;2-F; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Bamberger AM, 1996, P NATL ACAD SCI USA, V93, P6169, DOI 10.1073/pnas.93.12.6169; Barletta F, 2004, MOL ENDOCRINOL, V18, P1096, DOI 10.1210/me.2003-0335; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; Clarke R, 2001, PHARMACOL REV, V53, P25; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; EDWARDS DP, 1993, BREAST CANCER RES TR, V27, P41, DOI 10.1007/BF00683192; Faulds MH, 2004, MOL ENDOCRINOL, V18, P412, DOI 10.1210/me.2003-0290; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Foley EF, 2000, CANCER RES, V60, P245; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Fuqua SAW, 2003, CANCER RES, V63, P2434; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Hom YK, 1998, ENDOCRINOLOGY, V139, P913, DOI 10.1210/en.139.3.913; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jazaeri AA, 2001, ONCOGENE, V20, P6965, DOI 10.1038/sj.onc.1204809; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JORDAN VC, 1988, CRC CR REV CL LAB SC, V26, P97, DOI 10.3109/10408368809106860; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 2004, MOL ENDOCRINOL, V18, P269, DOI 10.1210/me.2003-0331; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moe-Behrens GHG, 2003, MOL ENDOCRINOL, V17, P2630, DOI 10.1210/me.2003-0006; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Norris JD, 1997, MOL ENDOCRINOL, V11, P747, DOI 10.1210/me.11.6.747; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Petz LN, 2002, ENDOCRINOLOGY, V143, P4583, DOI 10.1210/en.2002-220369; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Qiu M, 2003, J STEROID BIOCHEM, V85, P147, DOI 10.1016/S0960-0760(03)00221-8; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Razandi M, 2003, MOL CELL BIOL, V23, P1633, DOI 10.1128/MCB.23.5.1633-1646.2003; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; RICKETTS D, 1991, CANCER RES, V51, P1817; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Salh B, 1999, ANTICANCER RES, V19, P731; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Segars JH, 2002, TRENDS ENDOCRIN MET, V13, P349, DOI 10.1016/S1043-2760(02)00633-1; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singleton DW, 2003, ENDOCRINOLOGY, V144, P121, DOI 10.1210/en.2002-220625; Song RX, 2004, P NATL ACAD SCI USA, V101, P2076, DOI 10.1073/pnas.0308334100; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; STRAWN EY, 1995, AM J OBSTET GYNECOL, V172, P1837, DOI 10.1016/0002-9378(95)91420-X; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sun M, 2001, CANCER RES, V61, P5985; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Toran-Allerand CD, 2004, ENDOCRINOLOGY, V145, P1069, DOI 10.1210/en.2003-1462; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Tsai HW, 2004, ENDOCRINOLOGY, V145, P2730, DOI 10.1210/en.2003-1470; van der Flier S, 2000, INT J CANCER, V89, P465, DOI 10.1002/1097-0215(20000920)89:5<465::AID-IJC11>3.0.CO;2-O; van der Flier S, 2001, INT J BIOL MARKER, V16, P172, DOI 10.1177/172460080101600303; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Westin S, 2000, ADV PHARMACOL, V47, P89; WONG CW, 2002, P NATL ACAD SCI USA, V192, P5696; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	125	158	166	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7979	7989		10.1038/sj.onc.1208076	http://dx.doi.org/10.1038/sj.onc.1208076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489915				2022-12-28	WOS:000224558300008
J	Wang, KY; Shen, CKJ				Wang, KY; Shen, CKJ			DNA methyltransferase Dnmt1 and mismatch repair	ONCOGENE			English	Article						Dnmt1; microsatellite instability; mismatch repair	EMBRYONIC STEM-CELLS; MICROSATELLITE INSTABILITY; CANCER SUSCEPTIBILITY; MAMMALIAN DEVELOPMENT; REPLICATION FOCI; METHYLATION; MUTATION; GENES; PCNA; HYPOMETHYLATION	We have examined the relationship between DNA mismatch repair and deficiency of DNA methylation in a mouse embryonic cell line, Dnmt1(-/-) ES, with homologous deletion of the gene coding for the maintenance DNA methyltransferase Dnmt1. With the use of a sensitive PCR for the assay of two mononucleotide- and three dinucleotide microsatellite markers that exhibited instabilities in mismatch repair-deficient cells, significantly higher frequencies of instability were detected at three of the five markers in Dnmt1(-/-) ES than the wildtype ES. The data suggest that Dnmt1 enzyme plays an integrating role in DNA replication and/or repair. The implication that Dnmt1 enzyme and/or cytosine methylation may participate in the strand discrimination of mismatch repair during eukaryotic DNA replication is discussed.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	ckshen@ccvax.sinica.edu.tw	shen, Che-Kun James/L-1343-2015					BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Luria SE, 1943, GENETICS, V28, P491; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	34	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7898	7902		10.1038/sj.onc.1208111	http://dx.doi.org/10.1038/sj.onc.1208111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378011				2022-12-28	WOS:000224331600016
J	Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O				Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O			P38(SAPK2) phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation	ONCOGENE			English	Article						cell cycle; cyclin D3; p38(SAPK); proteasome; cancer	ACTIVATED PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CELL CARCINOMA; D GENES; D1; EXPRESSION; COMPLEXES; PROLIFERATION; LOCALIZATION	Cyclin D3 plays a critical role in maturation of precursor T cells and their levels are tightly regulated during this process. Alteration of cyclin D3 levels has been proposed to be important in the development of different human cancers, including malignancies of the lymphoid system. Thus, we have analysed the mechanisms involved in the regulation of cyclin D3 levels. Our results indicate that cyclin D3 is degraded via proteasome and that Thr-283 is essential for its degradation. Wild-type cyclin D3 but not the Thr-283A mutant accumulated ubiquitylated forms after treatment with proteasome inhibitors. We also observed that different type of stresses promote the Thr-283-dependent in vivo degradation of cyclin D3. The analysis of the kinases involved in Thr-283 phosphorylation indicates that all the members of the p38(SAPK) family of serine - threonine kinases are able to phosphorylate cyclin D3 at this specific site. Moreover, we found that the overexpression of p38alpha(SAPK2) induce the decrease of cyclin D3 in vivo. These results indicate that p38(SAPK) might be involved in the regulation of cyclin D3 levels and suggest that this mechanism is involved in the maturation of precursor T-cells. Alterations of this mechanism might be important for oncogenesis.	Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@.ub.edu	Jaumot, Montserrat/F-2640-2016; Agell, Neus/E-9640-2016; Casanovas, Oriol/L-5210-2014	Agell, Neus/0000-0002-1205-6074; Casanovas, Oriol/0000-0002-4298-3995; Jaumot, Montserrat/0000-0003-2864-357X				Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buschges R, 1999, BRAIN PATHOL, V9, P435; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Filipits M, 2002, CLIN CANCER RES, V8, P729; Florenes VA, 2000, CLIN CANCER RES, V6, P3614; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ito Y, 2001, ANTICANCER RES, V21, P1043; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MAYOL X, 1995, ONCOGENE, V11, P801; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morin CI, 2004, CANCER RES, V64, P1893, DOI 10.1158/0008-5472.CAN-03-3448; NEET K, 1995, MOL CELL BIOL, V15, P4908; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sen J, 1996, J IMMUNOL, V156, P4535; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7537	7544		10.1038/sj.onc.1208040	http://dx.doi.org/10.1038/sj.onc.1208040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326477				2022-12-28	WOS:000224176500010
J	Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE				Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE			Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death	ONCOGENE			English	Article						adenovirus; E4orf4; cell death; nuclear localization signal; nucleus; nucleolus; arginine-rich motif	REV TRANS-ACTIVATOR; NUCLEOLAR-LOCALIZATION; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TAT PROTEIN; B-ALPHA; VIRUS; HIV-1; SEQUENCE	The adenovirus E4orf4 protein induces p53-independent death of human cancer cells by a mechanism requiring interactions with the Balpha subunit of protein phosphatase 2A. When expressed alone E4orf4 localizes predominantly in the nucleus, although significant levels are also present in the cytoplasm. While tyrosine phosphorylation of E4orf4 and recruitment of Src have been linked with E4orf4 cytoplasmic cell death functions, little is known about the functions of E4orf4 in the nucleus. In this study, we identified an arginine-rich motif (E4ARM; residues 66-75) that is necessary and sufficient for nuclear and nucleolar localization. This motif, which is highly homologous to the arginine-rich nuclear and nucleolar localization motif of some lentiviral proteins, was shown to target heterologous proteins to the nucleus and to nucleoli, functions found to be dependent on the overall charge of the motif rather than on specific residues. Furthermore, mutation of arginine residues to alanines but not to lysines in E4ARM was shown to block such targeting activity and, when introduced into full-length E4orf4, to decrease induction of cell death. Finally, coexpression of the ARM motifs of E4orf4, HIV-1 Tat or Rev along with full-length E4orf4 was seen to decrease E4orf4-dependent cell killing. Thus it appears that targeting of E4orf4 to the nucleus and cell nucleoli by E4ARM is an important component of E4orf4-induced cell death.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Laval University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca		Lavoie, Josee N/0000-0001-6912-1132				Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CASTIGLIA CL, 1983, MOL CELL BIOL, V3, P662, DOI 10.1128/MCB.3.4.662; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Champagne C, 2004, J BIOL CHEM, V279, P25905, DOI 10.1074/jbc.M400933200; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUNDR M, 1995, J CELL SCI, V108, P2811; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Hiscox JA, 2002, ARCH VIROL, V147, P1077, DOI 10.1007/s00705-001-0792-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; LEDINKO N, 1972, VIROLOGY, V49, P79, DOI 10.1016/S0042-6822(72)80008-4; Lee TWR, 2003, J GEN VIROL, V84, P3423, DOI 10.1099/vir.0.19546-0; Lee TWR, 2004, J GEN VIROL, V85, P185, DOI 10.1099/vir.0.19352-0; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matthews DA, 2001, J VIROL, V75, P1031, DOI 10.1128/JVI.75.2.1031-1038.2001; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PUVIONDUTILLEUL F, 1993, EUR J CELL BIOL, V61, P168; RASKAS HJ, 1970, VIROLOGY, V40, P893, DOI 10.1016/0042-6822(70)90135-2; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; RUBEN S, 1989, J VIROL, V63, P1; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Strom AC, 2001, GENOME BIOL, V2; Truant R, 1999, MOL CELL BIOL, V19, P1210; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989	63	30	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7458	7468		10.1038/sj.onc.1207919	http://dx.doi.org/10.1038/sj.onc.1207919			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334069				2022-12-28	WOS:000224176500002
J	Sauvageau, G; Iscove, NN; Humphries, RK				Sauvageau, G; Iscove, NN; Humphries, RK			In vitro and in vivo expansion of hematopoietic stem cells	ONCOGENE			English	Review						hematopoietic stem cells; self-renewal; expansion; Hoxb4	SELF-RENEWAL DIVISIONS; BLOOD CD34(+) CELLS; WNT GENE FAMILY; HOMEOBOX GENES; DIFFERENTIAL EXPRESSION; REPOPULATING ACTIVITY; SELECTIVE EXPANSION; EMBRYONIC ORIGINS; HOXB4 EXPRESSION; OVEREXPRESSION	The capacity for sustained self-renewal-the generation of daughter cells having the same regenerative properties as the parent cell-is the defining feature of hematopoietic stem cells (HSCs). Strong evidence exists that self-renewal of HSC is under extrinsic biological control in vivo. A variety of cytokines, morphogenic ligands and associated signaling components influence self-renewal in culture and in vivo. Specific homeobox transcription factors act as powerful intrinsic agonists of HSC self-renewal in vitro and in vivo when supplied either as transduced cDNAs or as externally delivered proteins. These findings provide tools for deepening our knowledge of mechanism and for achievement of clinically useful levels of HSC expansion.	Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E3, Canada	Universite de Montreal; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; British Columbia Cancer Agency; University of British Columbia	Sauvageau, G (corresponding author), Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hemopoiet Stem Cells, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca; khumphri@bccrc.ca		Sauvageau, Guy/0000-0002-4333-7266; Humphries, Richard/0000-0003-0540-7005				Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Audet J, 2002, BIOTECHNOL BIOENG, V80, P393, DOI 10.1002/bit.10399; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Baron MH, 2003, EXP HEMATOL, V31, P1160, DOI 10.1016/j.exphem.2003.08.019; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; BESLU N, 2004, IN PRESS BLOOD  0629; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Brun ACM, 2003, MOL THER, V8, P618, DOI 10.1016/S1525-0016(03)00237-5; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cashman JD, 1999, BLOOD, V93, P481, DOI 10.1182/blood.V93.2.481.402k20_481_487; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Faloon P, 2000, DEVELOPMENT, V127, P1931; Fox N, 2002, J CLIN INVEST, V110, P389, DOI 10.1172/JCI200215430; FRASER CC, 1990, BLOOD, V76, P1071; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Gammaitoni L, 2003, EXP HEMATOL, V31, P261, DOI 10.1016/S0301-472X(02)01077-9; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GIAMPAOLO A, 1995, STEM CELLS, V13, P90; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; HARRISON DE, 1991, BLOOD, V78, P1237; Helgason CD, 2003, BLOOD, V102, P3541, DOI 10.1182/blood-2002-12-3939; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Hoffman R, 1999, Curr Opin Hematol, V6, P184, DOI 10.1097/00062752-199905000-00010; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kirito K, 2003, BLOOD, V102, P3172, DOI 10.1182/blood-2003-03-0944; Kojika S, 2001, EXP HEMATOL, V29, P1041, DOI 10.1016/S0301-472X(01)00676-2; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; Marshall CJ, 2001, BRIT J HAEMATOL, V112, P838, DOI 10.1046/j.1365-2141.2001.02537.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; MORETTI P, 1994, GENE, V144, P213, DOI 10.1016/0378-1119(94)90380-8; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; Nicolini FE, 2004, LEUKEMIA, V18, P341, DOI 10.1038/sj.leu.2403222; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Petzer AL, 1997, BLOOD, V90, P64; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Schiedlmeier B, 2003, BLOOD, V101, P1759, DOI 10.1182/blood-2002-03-0767; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251	75	147	158	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7223	7232		10.1038/sj.onc.1207942	http://dx.doi.org/10.1038/sj.onc.1207942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378082				2022-12-28	WOS:000223998800008
J	Kluza, J; Marchetti, P; Gallego, MA; Lancel, S; Fournier, C; Loyens, A; Beauvillain, JC; Bailly, C				Kluza, J; Marchetti, P; Gallego, MA; Lancel, S; Fournier, C; Loyens, A; Beauvillain, JC; Bailly, C			Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells	ONCOGENE			English	Article						doxorubicin; mitoxantrone; apoptosis; mitochondrial proliferation; cardiotoxicity	ADENOCARCINOMA MTLN3 CELLS; RAT MAMMARY ADENOCARCINOMA; CARDIOMYOCYTE APOPTOSIS; DIFFERENTIAL REGULATION; OXIDATIVE STRESS; DYSFUNCTION; DNA; ANTHRACYCLINES; CARDIOTOXICITY; INCREASE	Doxorubicin is one of the most largely prescribed antitumor drug for the treatment of breast, liver and colon cancers as well as leukemia, but the cardiotoxicity of this anthracycline derivative limits its clinical use. Although doxorubicin is toxic to both cancer and cardiac cells, there are evidences suggesting that the mechanism of cell death is different for the two cell types. To investigate further this issue, we have compared the proapoptotic effects of doxorubicin and the functionally related anthracenedione compound mitoxantrone, which is also used in the clinic for the treatment of cancer. After evaluating the toxicity of the two drugs to mammary adenocarcinoma MTLn3 cells and H9C2 cardiomyocytes, we dissected the drug-induced apoptotic machinery by measuring the effects on the cell cycle progression, DNA condensation and fragmentation, production of endogenous peroxides and caspase activation. Both doxorubicin and mitoxantrone are potent inducers of apoptosis in H9C2 cardiomyocytes and MTLn3 breast cancer cells, but there are significant differences between the two cell types in terms of kinetics and order of the events. In particular, flow cytometry measurements of drug-induced changes in mitochondrial transmembrane potential and mitochondrial mass with different fluorescent probes suggested that the two drugs induced a progressive increase in mitochondrial mass in the cancer cells but not in the cardiac cells. The hypothesis was validated by means of electron microscopy, which revealed a significant increase in the number of mitochondria in drug-treated MTLn3 but not in H9C2 cells. The mitochondrial proliferation precedes the nuclear apoptosis in doxorubicin-treated MTLn3 cells. The changes in the architecture and number of mitochondria are linked to the drug-induced perturbation of the cell cycle progression and apoptosis. The proliferation of mitochondria could explain the higher toxicity of doxorubicin to cancer cells compared to cardiac cells and this suggests novel therapeutic opportunities to better control the cardiotoxicity of anthracyclines.	IRCL, INSERM, U524, F-59045 Lille, France; IRCL, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France; Fac Med Lille, INSERM, U459, F-59045 Lille, France; Fac Med Lille, EA2689, F-59045 Lille, France; Ctr Oscar Lambret, Dept Biostat, F-59020 Lille, France; Univ Lille 2, INSERM, U422, F-59045 Lille, France; Univ Lille 2, Serv Imagerie, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Bailly, C (corresponding author), IRCL, INSERM, U524, Pl Verdun, F-59045 Lille, France.	bailly@lille.inserm.fr	Kluza, Jérome/B-6312-2012; BAILLY, Christian/AAK-2799-2021; Lancel, Steve/C-4387-2012; , Lancel/H-9047-2019	Kluza, Jérome/0000-0002-7346-1305; BAILLY, Christian/0000-0002-2973-9357; , Lancel/0000-0002-3292-5433; MARCHETTI, Philippe/0000-0002-4663-6800				ALDERTON PM, 1992, CANCER RES, V52, P194; Arola OJ, 2000, CANCER RES, V60, P1789; Bellarosa D, 2001, J PHARMACOL EXP THER, V296, P276; Bonavita F, 2003, FEBS LETT, V536, P85, DOI 10.1016/S0014-5793(03)00029-2; Bossy-Wetzel E, 2003, CELL DEATH DIFFER, V10, P757, DOI 10.1038/sj.cdd.4401244; Camilleri-Broet S, 1998, EXP CELL RES, V239, P277, DOI 10.1006/excr.1997.3899; Childs AC, 2002, CANCER RES, V62, P4592; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eliseev RA, 2003, EXP CELL RES, V289, P275, DOI 10.1016/S0014-4827(03)00278-7; EVANS DP, 1986, CANCER CHEMOTH PHARM, V18, P137; Favory R, 2004, CRIT CARE MED, V32, P495, DOI 10.1097/01.CCM.0000109452.36271.FA; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Herman EH, 1997, J MOL CELL CARDIOL, V29, P2415, DOI 10.1006/jmcc.1997.0477; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Huigsloot M, 2001, BIOCHEM PHARMACOL, V62, P1087, DOI 10.1016/S0006-2952(01)00755-9; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2001, J CELL SCI, V114, P281; Kluza J, 2002, BIOCHEM PHARMACOL, V63, P1443, DOI 10.1016/S0006-2952(02)00899-7; Kluza J, 2000, CANCER RES, V60, P4077; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1007/BF02254978; Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchetti P, 1999, CANCER RES, V59, P6257; Marchetti P, 1996, CANCER RES, V56, P2033; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; PAGLIACCI MC, 1993, EUR J CANCER, V29A, P1573, DOI 10.1016/0959-8049(93)90297-S; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rebbaa A, 2001, CANCER CHEMOTH PHARM, V48, P423, DOI 10.1007/s002800100375; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Solem LE, 1996, J MOL CELL CARDIOL, V28, P1023, DOI 10.1006/jmcc.1996.0095; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Toyota N, 1998, INT J CANCER, V76, P499; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou SY, 2001, CANCER RES, V61, P771; Zucchi Riccardo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P151, DOI 10.2174/1568011033353434	49	151	157	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7018	7030		10.1038/sj.onc.1207936	http://dx.doi.org/10.1038/sj.onc.1207936			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273722				2022-12-28	WOS:000223885100003
J	Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG				Tang, SH; Bhatia, B; Zhou, JJ; Maldonado, CJ; Chandra, D; Kim, E; Fischer, SM; Butler, AP; Friedman, SL; Tang, DG			Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells	ONCOGENE			English	Article						15-lipoxygenase 2; gene expression; Sp1; Sp3; prostate cancer; gene regulation	TRANSCRIPTION FACTORS; HISTONE DEACETYLASE; CANCER CELLS; PROMOTER; ACTIVATION; FAMILY; IDENTIFICATION	In this project, we studied the gene regulation of 15-lipoxygenase 2 (15-LOX2), the most abundant arachidonate-metabolizing LOX in adult human prostate and a negative cell-cycle regulator in normal human prostate (NHP) epithelial cells. Through detailed in silico promoter examination and promoter deletion and activity analysis, we found that several Sp1 sites (i.e., three GC boxes and one CACCC box) in the proximal promoter region play a critical role in regulating 15-LOX2 expression in NHP cells. Several pieces of evidence further suggest that the Sp1 and Sp3 proteins play a physiologically important role in positively and negatively regulating the 15-LOX2 gene expression, respectively. First, mutations in the GC boxes affected the 15-LOX2 promoter activity. Second, both Sp1 and Sp3 proteins were detected in the protein complexes that bound the GC boxes revealed by electrophoretic mobility shift assay. Third, importantly, inhibition of Sp1 activity or overexpression of Sp3 both inhibited the endogenous 15-LOX2 mRNA expression. Since 15-LOX2 is normally expressed in the prostate luminal epithelial cells, we subsequently explored whether androgen/androgen receptor may directly regulate its gene expression. The results indicate that androgen does not directly regulate 15-LOX2 gene expression. Together, these observations provide insight on how 15-LOX2 gene expression may be regulated in NHP cells.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, 1808 Pk R 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NATIONAL CANCER INSTITUTE [R01CA090297, T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90297, T32 CA09480-16] Funding Source: Medline; NIDDK NIH HHS [R01 DK 37340] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chopra DP, 1996, J CELL PHYSIOL, V169, P269, DOI 10.1002/(SICI)1097-4652(199611)169:2<269::AID-JCP6>3.0.CO;2-M; Frith MC, 2001, BIOINFORMATICS, V17, P878, DOI 10.1093/bioinformatics/17.10.878; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaluz S, 2003, CANCER RES, V63, P917; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; STRACHAN T, 2000, HUM MOL GENET, P169; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698	34	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6942	6953		10.1038/sj.onc.1207913	http://dx.doi.org/10.1038/sj.onc.1207913			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15247906				2022-12-28	WOS:000223750700011
J	Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R				Scherberich, A; Tucker, RP; Degen, M; Brown- Luedi, M; Andres, AC; Chiquet- Ehrismann, R			Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38(MAPK) activity for BMP-2 and TNF-alpha induced expression in vitro	ONCOGENE			English	Article						tumor stroma; extracellular matrix; breast cancer; p38(MAPK); alpha 8 integrin	ACTIVATED PROTEIN-KINASE; C SPLICE VARIANTS; BREAST-CANCER; NECROSIS-FACTOR; DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; GROWTH-FACTOR; CELL-LINES; HA-RAS; P38	Tenascins represent a family of extracellular matrix glycoproteins with distinctive expression patterns. Here we have analyzed the most recently described member, tenascin-W, in breast cancer. Mammary tumors isolated from transgenic mice expressing hormone-induced oncogenes reveal tenascin-W in the stroma around lesions with a high likelihood of metastasis. The presence of tenascin-W was correlated with the expression of its putative receptor, alpha8 integrin. HC11 cells derived from normal mammary epithelium do not express alpha8 integrin and fail to cross tenascin-W-coated filters. However, 4T1 mammary carcinoma cells do express alpha8 integrin and their migration is stimulated by tenascin-W. The expression of tenascin-W is induced by BMP-2 but not by TGF-beta1, though the latter is a potent inducer of tenascin-C. The expression of tenascin-W is dependent on p38(MAPK) and JNK signaling pathways. Since preinflammatory cytokines also act through p38MAPK and JNK signaling pathways, the possible role of TNF-alpha in tenascin-W expression was also examined. TNF-alpha induced the expression of both tenascin-W and tenascin-C, and this induction was p38(MAPK)- and cyclooxygenase-dependent. Our results show that tenascin-W may be a useful diagnostic marker for breast malignancies, and that the induction of tenascin-W in the tumor stroma may contribute to the invasive behavior of tumor cells.	Friedrich Miescher Inst, Novartis Res Fdn, CH-4058 Basel, Switzerland; Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA; Univ Bern, Dept Clin Res, Fac Med, CH-3004 Bern, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of California System; University of California Davis; University of Bern; University of Geneva	Chiquet- Ehrismann, R (corresponding author), Friedrich Miescher Inst, Novartis Res Fdn, Maulbeerstr 66, CH-4058 Basel, Switzerland.	ruth.chiquet@fmi.ch	Scherberich, Arnaud/H-9554-2019; Degen, Martin/H-5791-2013	Scherberich, Arnaud/0000-0003-3468-6955; Degen, Martin/0000-0002-4356-3714				Adams M, 2002, CANCER RES, V62, P3289; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P986, DOI 10.1016/j.biocel.2003.12.002; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Fischer D, 1997, MOL BIOL CELL, V8, P2055, DOI 10.1091/mbc.8.10.2055; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Geffrotin C, 2000, BBA-GEN SUBJECTS, V1524, P196, DOI 10.1016/S0304-4165(00)00158-6; Goepel C, 2000, GYNECOL ONCOL, V79, P372, DOI 10.1006/gyno.2000.5978; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Hasegawa K, 1997, ACTA NEUROPATHOL, V93, P431, DOI 10.1007/s004010050636; Huang WT, 2001, CANCER RES, V61, P8586; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kaya H, 2002, EUR J GYNAECOL ONCOL, V23, P261; Latijnhouwers MAHE, 1998, MATRIX BIOL, V17, P305, DOI 10.1016/S0945-053X(98)90083-X; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; LI F, 1994, INT J CANCER, V59, P560, DOI 10.1002/ijc.2910590421; Liu LX, 2002, WORLD J GASTROENTERO, V8, P631, DOI 10.3748/wjg.v8.i4.631; MACKIE EJ, 1987, P NATL ACAD SCI USA, V84, P4621, DOI 10.1073/pnas.84.13.4621; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Munarini N, 2002, J CELL SCI, V115, P25; Neidhardt J, 2003, MOL CELL NEUROSCI, V23, P193, DOI 10.1016/S1044-7431(03)00012-5; Nikolova Z, 1998, J CELL SCI, V111, P2741; Ocvirk J, 2000, MELANOMA RES, V10, P253, DOI 10.1097/00008390-200010030-00007; Pouliot F, 2003, CANCER RES, V63, P277; QIN ZH, 1993, J EXP MED, V178, P355, DOI 10.1084/jem.178.1.355; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Scherberich A, 2004, J CELL SCI, V117, P571, DOI 10.1242/jcs.00867; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schultz RM, 2003, PROG DRUG RES, V60, P59; Schwalbe M, 2003, INT J ONCOL, V23, P89; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; Weber P, 1998, J NEUROBIOL, V35, P1; Xiong SB, 2001, CANCER RES, V61, P1727; Zweers MC, 2004, J INVEST DERMATOL, V122, P885, DOI 10.1111/j.0022-202X.2004.22401.x	43	74	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1525	1532		10.1038/sj.onc.1208342	http://dx.doi.org/10.1038/sj.onc.1208342			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592496				2022-12-28	WOS:000227218200005
J	Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S				Xin, BZ; Platzer, P; Fink, SP; Reese, L; Nosrati, A; Willson, JKV; Wilson, K; Markowitz, S			Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia	ONCOGENE			English	Article						colon cancer; secreted proteins; serum markers	CLINICAL-PRACTICE GUIDELINES; COLORECTAL-CANCER; TUMOR-MARKERS; FECAL DNA; PREVENTION; EXPRESSION; UPDATE; BREAST; STOOL; SERUM	Cancers of the colon and rectum are the second leading cause of cancer death among adult Americans. When detected at early stages, colon cancer is highly curable. Colonoscopy, an effective but invasive screening test, has been limited in its public acceptance. The goal of this study was to identify novel serum markers of colon cancers and precancerous colon adenomas as potential candidates for noninvasive detection of early colon neoplasms. Employing expression microarrays, we identified colon cancer secreted protein-2 (CCSP-2) as a novel transcript whose expression is generally absent in normal colon and other normal body tissues, but that is induced an average of 78-fold in Stage II, III, and IV colon cancers, as well as in colon adenomas and colon cancer cell lines. These findings were validated by real-time PCR analysis in an independent panel of colon cancer cases. Moreover, CCSP-2 was shown to encode a secreted protein that circulates stably and is detectable in the blood of mice bearing human cancer xenografts transfected with epitope-tagged CCSP-2. As a novel secreted protein that is markedly induced in colon adenomas and cancers, CCSP-2 is a novel candidate for development as a diagnostic serum marker of early stage colon cancer.	Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Prot Design Labs, Fremont, CA 94555 USA	Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Markowitz, S (corresponding author), Case Western Reserve Univ, Howard Hughes Med Inst, Wolstein Res Bldg,3rd Floor,Mailstop 7285,10900 E, Cleveland, OH 44106 USA.	sxm10@cwru.edu		Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [U01CA088130, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, U01CA88130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Bast RC, 1996, J CLIN ONCOL, V14, P2843; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; Bond JH, 2000, MED CLIN N AM, V84, P1163, DOI 10.1016/S0025-7125(05)70281-9; Brunschwig EB, 2003, CANCER RES, V63, P1568; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Grady WM, 2001, CANCER RES, V61, P900; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hibi K, 1998, CANCER RES, V58, P1405; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Platzer P, 2002, CANCER RES, V62, P1134; Schoen RE, 2002, NAT REV CANCER, V2, P65, DOI 10.1038/nrc705; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; Traverso G, 2002, LANCET, V359, P403, DOI 10.1016/S0140-6736(02)07591-8; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	21	16	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					724	731		10.1038/sj.onc.1208134	http://dx.doi.org/10.1038/sj.onc.1208134			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580307				2022-12-28	WOS:000226420400020
J	Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE				Petre-Draviam, CE; Williams, EB; Burd, CJ; Gladden, A; Moghadam, H; Meller, J; Diehl, JA; Knudsen, KE			A central domain of cyclin D1 mediates nuclear receptor corepressor activity	ONCOGENE			English	Article						androgen receptor; TR beta 1; ER alpha; LxxLL; corepressor; prostate cancer	ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; DEPENDENT-KINASE; TRANSCRIPTIONAL ACTIVITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; GENE-EXPRESSION; CO-REPRESSOR; ACTIVATION; PHOSPHORYLATION	Regulation of nuclear receptor activity is the focus of numerous ongoing studies to develop novel therapies for the treatment of hormone-related cancer. Although cyclin D1 functions to control the activity of several nuclear receptors, the region(s) of the protein responsible for such transcriptional comodulation remain poorly defined. Herein, we map the region of cyclin D1 required for binding and repression of the androgen receptor (AR) to a central, exclusively alpha-helical domain. Deletion of this domain disrupted AR binding and corepressor activity. Further investigations showed that this domain is sufficient for AR interaction and possesses the ability to bind histone deacetylase 3. Strikingly, overexpression of this repressor region attenuates cell cycle progression in prostatic adenocarcinoma cells. The requirement of this domain for nuclear receptor repression was conserved with respect to thyroid hormone receptor beta-1, whereas cyclin D1 activation of the estrogen receptor occurred independently of the central region. Together, these data identify a minimal repression module within cyclin D1 and demonstrate that the coactivator and corepressor functions of cyclin D1 are distinct. In addition, our data suggest that properties of the cyclin D1 central domain could be exploited to develop novel prostate cancer therapeutics.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Ctr Environm Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Dept Biomed Engn, Cincinnati, OH 45267 USA; Univ Penn, Ctr Canc, Abramson Family Canc Res Ctr, Philadelphia, PA 19104 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Pennsylvania; Pennsylvania Medicine	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	Meller, Jaroslaw/A-1971-2011	Meller, Jaroslaw/0000-0002-1162-8253; Burd, Craig/0000-0002-6899-6751; Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [R01CA099996, R01CA093237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099996, CA93237] Funding Source: Medline; NICHD NIH HHS [HDO7200-15] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamczak R, 2004, PROTEINS, V56, P753, DOI 10.1002/prot.20176; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BURD CJ, IN PRESS MOL ENDOCRI; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; KATO J, 1993, GENE DEV, V7, P331; Khan OY, 2003, CURR OPIN DRUG DISC, V6, P692; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Knudsen KE, 1999, CANCER RES, V59, P2297; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Maruvada P, 2004, MOL BIOL CELL, V15, P1895, DOI 10.1091/mbc.e03-09-0636; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; POROLLO A, 2004, BIOINFORMATICS  0408; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; ROSENBERG CL, 1991, ONCOGENE, V6, P449; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schulze-Gahmen U, 2002, NAT STRUCT BIOL, V9, P177, DOI 10.1038/nsb756; SHAO ZH, 1995, ONCOGENE, V10, P221; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Summers M. D., 1987, TEX AGR EXP STA B, V1555; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	55	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					431	444		10.1038/sj.onc.1208200	http://dx.doi.org/10.1038/sj.onc.1208200			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558026				2022-12-28	WOS:000226279700014
J	Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ				Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ			Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation	ONCOGENE			English	Article						Rho GTPase; Rho GDI; Tiam1; cyclin D1; NF-kappa B	RHO-FAMILY GTPASES; CRYSTAL-STRUCTURE; NIH3T3 CELLS; INDEPENDENT PATHWAYS; RAS TRANSFORMATION; DEPENDENT PATHWAY; GENE-EXPRESSION; ACTIVATION; PROTEINS; TIAM1	A novel splice variant of Rac1, designated Rac1b, is expressed in human breast and colon carcinoma cells. Rac1b contains an additional 19 amino-acid insert immediately behind the switch II domain, a region important for Rac1 interaction with regulators and effectors. Recent studies showed that Rac1b exhibited the biochemical properties of a constitutively activated GTPase, yet it showed impaired interaction with downstream effectors, suggesting that Rac1b may be defective in biological activity. Whether Rac1b is a biologically active protein was not addressed. Therefore, we evaluated the biochemical, signaling and growth-promoting properties of authentic Rac1b. Similar to previous observations, we found that Rac1b showed enhanced intrinsic guanine nucleotide exchange activity, impaired intrinsic GTPase activity, and failed to interact with RhoGDI. Surprisingly, we found that Rac1b, like the constitutively-activated and transforming Rac1(Q61L) mutant, promoted growth transformation of NIH3T3 cells. Rac1b-expressing cells also showed a loss of density-dependent and anchorage-dependent growth. Surprisingly, unlike activated Rac1(61L), Rac1b did not show enhanced activation of the nuclear factor kappaB (NF-kappaB) transcription factor or stimulate cyclin D1 expression, the signaling activities that best correlate with Rac1 transforming activity. However, Rac1b did promote activation of the AKTserine/threonine kinase. Therefore, we suggest that Rac1b selectively activates a subset of Rac1 downstream signaling pathways to facilitate cellular transformation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Chicago, Dept Obstet & Gynecol, Div Gynecol Oncol, Chicago, IL 60637 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Lengyel, Ernst/D-9220-2014; Singh, Anurag/C-7347-2014	Lengyel, Ernst/0000-0001-8624-1507; Singh, Anurag/0000-0003-4705-8683; Der, Channing/0000-0002-7751-2747; Sondek, John/0000-0002-1127-8310	NCI NIH HHS [CA63071] Funding Source: Medline; NIGMS NIH HHS [GM62299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h	46	138	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9369	9380		10.1038/sj.onc.1208182	http://dx.doi.org/10.1038/sj.onc.1208182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516977				2022-12-28	WOS:000225764100008
J	Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY				Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY			Dickkopf-3/REIC functions as a suppressor gene of tumor growth	ONCOGENE			English	Article						hepatoma; hepatocellular carcinoma; dickkopf; dkk-3; REIC; tumor suppressor gene	BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; DOWN-REGULATION; CELL CARCINOMA; C-MYC; REIC/DKK-3; MUTATIONS; IDENTIFICATION; ANTAGONIST; EXPRESSION	To identify putative tumor suppressor genes in hepatocarcinogenesis, we combined the representational difference analysis and reverse northern blot identifying downregulated genes in human hepatoma tissues. One of them was Dkk-3/REIC. Dkk-3/REIC was downregulated in 11 out of the 20 human hepatoma tissues as compared to their counterparts of noncancerous liver tissues by northern blot analysis. It was also downregulated in 29 out of 48 human cancer samples including the kidney, urinary bladder, prostate, pancreas and lung cancers. Its gene product, Dkk-3/REIC, was found to be N-glycosylated and have two isoforms, the 55 kDa in the cytosol and 50 kDa secreted in the medium. Ectopic expression of Dkk-3/REIC in HeLa, Hep3B and Huh 7 cells led to suppression of cell growth, which was primarily attributable to induction of cell apoptosis. The suppression phenomenon was found to be cell-type related ( most prominent in HeLa and least in Hep3B cells) and cell-density dependent ( attenuated as the cell density increased). Transduction of Dkk-3/REIC into HeLa and Hep3B cells caused suppression on colony formation in vitro and reduced tumor growth rate in inoculated athymic nude mice. In conclusion, these data indicate that Dkk-3/REIC functions as a suppressor for human tumor growth.	Chang Gung Mem Hosp, Liver Res Ctr, Tao Yuan 333, Taiwan; Chang Gung Univ, Sch Med, Dept Microbiol & Immunol, Tao Yuan 333, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, No 5 Fu Hsin Rd, Tao Yuan 333, Taiwan.	siming@adm.cgmh.org.tw						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; CARDIGAN KM, 1997, GENE DEV, V11, P3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gao S, 2004, INT J CANCER, V109, P230, DOI 10.1002/ijc.11592; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lin CH, 2001, CANCER RES, V61, P4238; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Micsenyi A, 2004, GASTROENTEROLOGY, V126, P1134, DOI 10.1053/j.gastro.2003.12.047; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sasaki T, 2003, CANCER RES, V63, P801; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD	30	144	163	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9183	9189		10.1038/sj.onc.1208138	http://dx.doi.org/10.1038/sj.onc.1208138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516983				2022-12-28	WOS:000225638000003
J	Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M				Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M			Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays	ONCOGENE			English	Article						mucinous cystic neoplasm; oligonucleotide microarray; 'ovarian-type' stroma	MULTIPLE GENES; FLUID ANALYSIS; DIFFERENTIAL-DIAGNOSIS; CELL-DIFFERENTIATION; ABERRANT METHYLATION; SERIAL ANALYSIS; TUMOR-MARKERS; CPG ISLANDS; K-RAS; NOTCH	Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon neoplasms usually located in the body or tail of the pancreas and usually in females (>90% of cases). Clinically, they are often misdiagnosed as non-neoplastic pseudocysts leading to failed opportunities for curative resection. To better understand the biology of MCNs and to identify markers of the disease, we performed global gene expression profiling of MCNs using oligonucleotide microarrays. Using laser capture microdissection applied to frozen sections, RNA was extracted from the neoplastic epithelium of MCNs, from the adjacent 'ovarian-type' stroma of MCNs, from histologically normal pancreatic ductal epithelium, from pancreatic acinar tissue and from fibrous stroma in pancreata affected by chronic pancreatitis. Each RNA sample was subjected to two rounds of linear amplification followed by hybridization with U133A gene chips (Affymetrix). The expression patterns of selected genes were confirmed by quantitative RT-PCR and by immunohistochemistry using tissue microarrays containing 19 resected MCNs. A total of 114 known genes were overexpressed in the neoplastic epithelium compared to normal pancreatic ductal epithelium (>3-fold) including S100P, PSCA, c-myc, STK6/STKI5, cathepsin E and pepsinogen C. Activation of the Notch pathway in the epithelial component of MCNs was evident by the demonstration of overexpression of Jagged1 and the downstream Notch pathway member Hes1. In the 'ovarian-type' stroma, several genes involved in estrogen metabolism were overexpressed including STAR and ESR1 genes. Some of the genes identified as overexpressed in these neoplasms may be useful as markers that can distinguish MCNs from non-neoplastic pancreatic cystic lesions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol Med & Oncol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P573; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Deichmann M, 2003, J CUTAN PATHOL, V30, P363, DOI 10.1034/j.1600-0560.2003.00073.x; Demos TC, 2002, AM J ROENTGENOL, V179, P1375, DOI 10.2214/ajr.179.6.1791375; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Fukushima N, 1997, PATHOL INT, V47, P806, DOI 10.1111/j.1440-1827.1997.tb04462.x; Fukushima N, 1999, ADV ANAT PATHOL, V6, P65, DOI 10.1097/00125480-199903000-00001; HAMMEL P, 1995, GASTROENTEROLOGY, V108, P1230, DOI 10.1016/0016-5085(95)90224-4; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Hruban RH, 2001, CANCER J, V7, P251; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Izumo A, 2003, ONCOL REP, V10, P515; Jabara S, 2003, J CLIN ENDOCR METAB, V88, P484, DOI 10.1210/jc.2002-021274; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Klein AP, 2001, CANCER J, V7, P266; KOWITZ A, 1992, EUR J IMMUNOL, V22, P1199, DOI 10.1002/eji.1830220514; Li DH, 2003, CLIN CANCER RES, V9, P991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logsdon CD, 2003, CANCER RES, V63, P2649; Luttges J, 2002, AM J SURG PATHOL, V26, P466, DOI 10.1097/00000478-200204000-00008; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Miao XP, 2004, CANCER RES, V64, P2680, DOI 10.1158/0008-5472.CAN-04-0651; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohhashi K., 1982, PROG DIG ENDOSC, V203, P348; RUBIN D, 1994, SURGERY, V115, P52; Ryu B, 2002, CANCER RES, V62, P819; Ryu B, 2001, CANCER RES, V61, P1833; Sand JA, 1996, SURGERY, V119, P275, DOI 10.1016/S0039-6060(96)80113-9; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Sato N, 2003, CANCER RES, V63, P3735; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; SESSA F, 1994, VIRCHOWS ARCH, V425, P357; Seth P, 2002, CANCER RES, V62, P4540; SOLCIA E, 1997, TUMORS PANCREAS, P220; Sorianello E, 2002, EUR J ENDOCRINOL, V147, P387, DOI 10.1530/eje.0.1470387; Sperti C, 1997, AM J GASTROENTEROL, V92, P672; Sperti C, 1996, CANCER, V78, P237, DOI 10.1002/(SICI)1097-0142(19960715)78:2<237::AID-CNCR8>3.0.CO;2-I; Su GH, 2001, P NATL ACAD SCI USA, V98, P3254, DOI 10.1073/pnas.051484398; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Thompson LDR, 1999, AM J SURG PATHOL, V23, P1, DOI 10.1097/00000478-199901000-00001; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; van der Heijden MS, 2003, CANCER RES, V63, P2585; WARSHAW AL, 1990, ANN SURG, V212, P432, DOI 10.1097/00000658-199010000-00006; Yoshizawa K, 2002, VIRCHOWS ARCH, V441, P437, DOI 10.1007/s00428-002-0645-6; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005; Zamboni G.K.G., 2000, WHO CLASSIFICATION T, P234	69	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9042	9051		10.1038/sj.onc.1208117	http://dx.doi.org/10.1038/sj.onc.1208117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489895				2022-12-28	WOS:000225492800005
J	Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T				Hagihara, A; Miyamoto, K; Furuta, J; Hiraoka, N; Wakazono, K; Seki, S; Fukushima, S; Tsao, MS; Sugimura, T; Ushijima, T			Identification of 27 5 ' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers	ONCOGENE			English	Article						methylation; pancreatic cancer; CpG island; silencing	REPRESENTATIONAL DIFFERENCE ANALYSIS; TUMOR-SUPPRESSOR GENE; REDUCED EXPRESSION; HUMAN BREAST; ADENOCARCINOMA; CARCINOMA; CELLS; LUNG; RAS; INACTIVATION	Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA). MS-RDA isolated 111 DNA fragments derived from CpG islands (CGIs), and 35 of them were from CGIs in the 5' regions of known genes. Methylation-specific PCR (MSP) of the CGIs in seven pancreatic cancer cell lines and two pancreatic ductal epithelial cell lines showed that 27 CGIs in the 5' regions were aberrantly methylated in at least one of the cancer cell lines. Quantitative reverse-transcription-PCR analysis showed that downstream genes of all the CGIs were either not expressed or only very weakly expressed in cancer cell lines with the aberrant methylation. In the pancreatic ductal epithelial cell lines, 18 genes were expressed at various levels, and nine genes were not expressed at all. Treatment of a cancer cell line with a demethylating agent, 5-aza-2'-deoxycytidine, restored the expression of 13 genes, RASGRF2, ADAM23, NEF3, NKX2-8, HAND1, EGR4, PRG2, FBN2, CDH2, TLL1, NPTX1, NTSR1 and THBD, showing their silencing by methylation of their 5' CGIs. MSP of 24 primary pancreatic cancers showed that all these genes, except for THBD, were methylated in at least one cancer. Some of those were suggested to be potentially involved in pancreatic cancer development and progression.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Osaka City Univ, Grad Sch Med, Dept Pathol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Internal Med, Abeno Ku, Osaka 5458585, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Cancer Center - Japan; Osaka Metropolitan University; Osaka Metropolitan University; National Cancer Center - Japan; University of Toronto	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Ushijima, Toshikazu/AAP-5742-2021	Tsao, Ming Sound/0000-0002-9160-5405; Ushijima, Toshikazu/0000-0003-3405-7817				Agathanggelou A, 2003, CANCER RES, V63, P5344; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Asada K, 2003, ONCOLOGY-BASEL, V64, P380, DOI 10.1159/000070297; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Clark TG, 1999, DEVELOPMENT, V126, P2631; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Furukawa T, 1996, AM J PATHOL, V148, P1763; GRIFFIN CA, 1994, GENE CHROMOSOME CANC, V9, P93, DOI 10.1002/gcc.2870090204; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HERMAN JG, 1995, CANCER RES, V55, P4525; Horikoshi N, 1999, BIOCHEM BIOPH RES CO, V261, P864, DOI 10.1006/bbrc.1999.1123; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kaneda A, 2003, ANN NY ACAD SCI, V983, P131, DOI 10.1111/j.1749-6632.2003.tb05968.x; Kaneda A, 2002, CANCER RES, V62, P6645; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mitchell MS, 2000, CANCER RES, V60, P6448; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Omeis IA, 1996, GENOMICS, V36, P543, DOI 10.1006/geno.1996.0503; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Qiu CP, 2003, ONCOGENE, V22, P1253, DOI 10.1038/sj.onc.1206233; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Rozenblum E, 1997, CANCER RES, V57, P1731; Sato N, 2003, CANCER RES, V63, P3735; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wilentz RE, 2000, CANCER RES, V60, P2002	36	94	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8705	8710		10.1038/sj.onc.1207783	http://dx.doi.org/10.1038/sj.onc.1207783			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467763				2022-12-28	WOS:000224988800018
J	Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J				Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J			Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer	ONCOGENE			English	Article						Chk2 kinase; truncating mutation; DNA damage; tumour suppressor; p53; urinary bladder carcinomas	DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; BREAST-CANCER; IN-VIVO; PROSTATE-CANCER; CHEK2 VARIANTS; KINASE CHK2; LUNG-CANCER; P53; MUTATIONS	Checkpoint kinase 2 (Chk2) is a tumour suppressor and signal transducer in genome integrity checkpoints that coordinate cell-cycle progression with DNA repair or cell death in response to DNA damage. Defects of Chk2 occur in subsets of diverse sporadic malignancies and predispose to several types of hereditary carcinomas. However, the status of Chk2 in tumours of the urinary bladder remains unknown. Here, we report that among 58 advanced ( grade T2 - T4) human bladder carcinomas, immunohistochemical analysis revealed tumour-specific reduction or lack of Chk2 protein in 6 ( 10.3%) cases. Genetic analysis of the latter subset showed that a Chk2-negative carcinoma # 668 harboured a truncating mutation 1100delC, in one Chk2 allele and loss of the corresponding second allele. The 1100delC mutation was also found in the germ line of this patient. Sequencing of TP53 in tumour # 668 identified two missense mutations. Furthermore, the vast majority of the tumours showed 'unscheduled' activatory phosphorylation on Thr68 of Chk2 in the absence of any DNA-damaging treatment. Our results indicate that the otherwise dormant DNA damage signal transducer Chk2 is aberrantly and constitutively activated in invasive urinary bladder carcinomas, and that such likely proapoptotic checkpoint signalling can be disabled by inactivation of Chk2 and/or p53 tumour suppressors in subsets of these tumours.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Clin Biochem, DK-8200 Aarhus, Denmark	Danish Cancer Society; Aarhus University	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Gronbaek, Kirsten/0000-0002-1535-9601				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lee SB, 2001, CANCER RES, V61, P8062; Lukas C, 2001, CANCER RES, V61, P4990; LUKAS C, 2003, NAT CELL BIOL, V421, P952; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	48	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8545	8551		10.1038/sj.onc.1207878	http://dx.doi.org/10.1038/sj.onc.1207878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361851				2022-12-28	WOS:000224870700015
J	Niida, A; Hiroko, T; Kasai, M; Furukawa, Y; Nakamura, Y; Suzuki, Y; Sugano, S; Akiyama, T				Niida, A; Hiroko, T; Kasai, M; Furukawa, Y; Nakamura, Y; Suzuki, Y; Sugano, S; Akiyama, T			DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway	ONCOGENE			English	Article						DKK1; Wnt; beta-catenin; TCF; TCF-binding element; negative feedback	CYCLIN D1; TRANSCRIPTION; ACTIVATION; GENE; HEPATOBLASTOMAS; IDENTIFICATION; EXPRESSION; DICKKOPF-1; MUTATIONS; PROTEINS	Wnt signaling plays an important role in embryonic development and tumorigenesis. These biological effects are exerted by activation of the beta-catenin/TCF transcription complex and consequent regulation of a set of downstream genes. TCF-binding elements have been found in the promoter regions of many TCF target genes and characterized by a highly conserved consensus sequence. Utilizing this consensus sequence, we performed an in silico screening for new TCF target genes. Through computational screening and subsequent experimental analysis, we identified a novel TCF target gene, DKK1, which has been shown to be a potent inhibitor of Wnt signaling. Our finding suggests the existence of a novel feedback loop in Wnt signaling.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Database,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp						Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; HE TC, 1998, SCIENCE, V278, P1606; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Koch A, 1999, CANCER RES, V59, P269; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Polakis P, 2000, GENE DEV, V14, P1837; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Shinya M, 2000, MECH DEVELOP, V98, P3, DOI 10.1016/S0925-4773(00)00433-0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Tago K, 2000, GENE DEV, V14, P1741; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	32	413	436	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8520	8526		10.1038/sj.onc.1207892	http://dx.doi.org/10.1038/sj.onc.1207892			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378020				2022-12-28	WOS:000224870700012
J	Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R				Treff, NR; Dement, GA; Adair, JE; Britt, RL; Nie, R; Shima, JE; Taylor, WE; Reeves, R			Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells	ONCOGENE			English	Article						high mobility group A1; stem cell factor; malignant transformation; chromatin; MCF-7; OCC1	C-KIT; IN-VIVO; EXPRESSION; PROTEIN; COEXPRESSION; RECEPTOR; GENE; ACTIVATION; APOPTOSIS; SEQUENCE	KIT ligand (KL) and its receptor, c-kit, are coexpressed in many types of cancer cells and have been implicated in tumor growth and angiogenesis. While Sertoli cell-specific regulation of the KL promoter has been well characterized, regulation in cancer cells remains to be elucidated. We recently reported microarray results demonstrating that increased high-mobility group (HMG) A1a protein expression correlates with increased KL transcription in MCF-7 human breast cancer cells. Sequence analysis indicates a potential for multiple HMGA1 binding sites within the human KL promoter. In order to better de. ne the underlying molecular mechanisms that HMGA1 uses to facilitate malignant transformation of cancer cells, we have used a variety of methods to determine whether HMGA1a directly regulates the human KL promoter in breast and ovarian cancer cells. Our results indicate that: (i) KL promoter activity is significantly higher in MCF-7 cells overexpressing HMGA1a; (ii) HMGA1a protein binds to AT-rich regions of the KL promoter DNA both in vitro and in vivo; (iii) mutation of the AT-rich regions inhibits HMGA1a binding in vitro; and (iv) HMGA1a-specific inhibition significantly decreases transcription of KL in OCC1 human ovarian cancer cells. In addition, MCF-7 cells with transgenic HMGA1 overexpression stained positive for the KL protein by immunocytochemistry and immunohistochemistry, and were growth-inhibited by KL neutralization. The cumulative evidence indicates that HMGA1 positively regulates the human KL promoter in breast and ovarian cancer cells and implicates serum KL as a diagnostic marker for HMGA1-positive carcinomas.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Charles R Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA	Washington State University; Charles R. Drew University of Medicine & Science	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu		Adair, Jennifer/0000-0003-4599-016X	NIGMS NIH HHS [GM-46352, T-32 GM008336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Bellone G, 2001, CANCER RES, V61, P2200; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Caceres-Cortes JR, 2001, CANCER RES, V61, P6281; ELTON T, 1987, P NATL ACAD SCI USA, V84, P6531; Flohr AM, 2003, HISTOL HISTOPATHOL, V18, P999, DOI 10.14670/HH-18.999; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Grimaldi P, 2003, BIOL REPROD, V69, P1979, DOI 10.1095/biolreprod.103.019471; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; HIBI K, 1991, ONCOGENE, V6, P2291; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hines SJ, 1999, BREAST CANCER RES TR, V58, P1, DOI 10.1023/A:1006272527435; Huss R, 1996, ANN HEMATOL, V72, P253, DOI 10.1007/s002770050168; INOUE M, 1994, CANCER RES, V54, P3049; Jiang CY, 1997, GENE, V185, P285, DOI 10.1016/S0378-1119(96)00668-3; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Langelotz C, 2003, BRIT J CANCER, V88, P1406, DOI 10.1038/sj.bjc.6600935; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Liu J, 2003, MOL REPROD DEV, V66, P81, DOI 10.1002/mrd.10323; Parrott JA, 2000, BIOL REPROD, V62, P1600, DOI 10.1095/biolreprod62.6.1600; Pedulla ML, 2001, GENE, V271, P51, DOI 10.1016/S0378-1119(01)00500-5; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Simak R, 2000, HISTOL HISTOPATHOL, V15, P365, DOI 10.14670/HH-15.365; Taylor WE, 1996, ENDOCRINOLOGY, V137, P5407, DOI 10.1210/en.137.12.5407; Timeus F, 1997, EXP HEMATOL, V25, P1253; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; Treff NR, 2004, ONCOGENE, V23, P777, DOI 10.1038/sj.onc.1207167; Zhang W, 2000, CANCER RES, V60, P6757	34	29	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8557	8562		10.1038/sj.onc.1207926	http://dx.doi.org/10.1038/sj.onc.1207926			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378028				2022-12-28	WOS:000224870700017
J	van Haaften, G; Plasterk, RHA; Tijsterman, M				van Haaften, G; Plasterk, RHA; Tijsterman, M			Genomic instability and cancer: scanning the Caenorhabditis elegans genome for tumor suppressors	ONCOGENE			English	Article						genomic instability; RNAi; mutator genes; C. elegans; DNA damage; DNA repair; carcinogenesis	DNA-DAMAGE RESPONSE; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; RNA INTERFERENCE; MISMATCH-REPAIR; CHECKPOINT PROTEIN; WIDE SCREEN; GENES; TRANSPOSON; MUTATIONS	Maintaining the stability of the genome is critical to normal cell growth and development. The early notion that cancer is the result of mutations in genes controlling cellular growth implied that gene or genome integrity is vital to the prevention of oncogenesis, and many genes and pathways that prevent genomic deterioration have been identified over the past decades. Recent progress in reverse genetic approaches, principally RNA interference, now allows the systematic analysis of gene function on a genomic scale in an animal system. Here, we discuss genomic approaches in the model organism Caenorhabditis elegans, aimed to identify genes and genetic networks that contribute to genome stability and are thus potentially involved in human carcinogenesis.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Tijsterman, M (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	tijsterman@niob.knaw.nl	Tijsterman, Marcel/H-5663-2018; van Haaften, Gijs/G-7832-2012	Tijsterman, Marcel/0000-0001-8465-9002; van Haaften, Gijs/0000-0003-3033-0329				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; Chang M, 2002, P NATL ACAD SCI USA, V99, P16934, DOI 10.1073/pnas.262669299; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Colaiacovo MP, 2002, GENETICS, V162, P113; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; CUPPLES CG, 1990, GENETICS, V125, P275; Degtyareva NP, 2002, P NATL ACAD SCI USA, V99, P2158, DOI 10.1073/pnas.032671599; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GREENWALD IS, 1980, GENETICS, V96, P147; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanway D, 2002, P NATL ACAD SCI USA, V99, P10605, DOI 10.1073/pnas.152264899; HARTMAN PS, 1982, MOL GEN GENET, V187, P116, DOI 10.1007/BF00384393; HENDERSON ST, 1993, GENETICS, V134, P57; HODGKIN J, 1979, GENETICS, V91, P67; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly KO, 2000, GENETICS, V156, P617; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LINK CD, 1988, DEVELOPMENT, V103, P485; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; MEYER BJ, 1997, C ELEGANS, V2, P209; Miller JH, 1998, MUTAT RES-DNA REPAIR, V409, P99, DOI 10.1016/S0921-8777(98)00049-4; Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; Plasterk Ronald H.A., 1997, Cold Spring Harbor Monograph Series, V33, P97; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Stergiou L, 2004, CELL DEATH DIFFER, V11, P21, DOI 10.1038/sj.cdd.4401340; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tijsterman M, 2002, GENETICS, V161, P651; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; VANHAAFTEN G, 2004, IN PRESS P NATL ACAD; Vastenhouw NL, 2004, TRENDS GENET, V20, P314, DOI 10.1016/j.tig.2004.04.011; Vastenhouw NL, 2003, CURR BIOL, V13, P1311, DOI 10.1016/s0960-9822(03)00539-6; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	63	13	14	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8366	8375		10.1038/sj.onc.1208011	http://dx.doi.org/10.1038/sj.onc.1208011			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517018				2022-12-28	WOS:000224815900007
J	Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M				Martin-Caballero, J; Flores, JM; Garcia-Palencia, P; Collado, M; Serrano, M			Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice	ONCOGENE			English	Article						INK4a; ARF; p21Cip1; p27Kip1; tumorigenesis	DEPENDENT KINASE INHIBITOR; TUMOR SUPPRESSION; SUBCELLULAR-LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL LYMPHOMAS; CYCLIN-E; P27(KIP1); EXPRESSION; RB; TUMORIGENESIS	The control exerted by the INK4a/ARF locus on cellular proliferation is crucial to restrict tumor development. In agreement with this, mice with defects in this locus are highly tumor prone. However, the potential contribution of other pathways in modulating tumorigenesis in the absence of INK4a/ARF is largely unexplored. In the present study, we investigated the consequences of the combined loss of either of two cyclin-dependent kinase inhibitors, p21 and p27, in cooperation with deletion of the INK4a/ARF locus. Our results show a clear differential effect in tumorigenesis depending on the CKI that is absent. The absence of p21 produced no overt alteration of the lifespan of the INK4a/ARF-null mice, although it modified their tumor spectrum, causing a significant increase in the incidence of fibrosarcomas and the appearance of a small number of rhabdomyosarcomas. In contrast, deficiency of p27 resulted in a significant increase in lethality due to accelerated tumor development, especially in the case of T-cell lymphomas. Finally, combined deficiency of INK4a/ARF and p27 resulted in a significant increase in the number of metastatic tumors. These results demonstrate genetically the oncogenic cooperation between defects on INK4a/ARF and p27, which are common alterations in human cancer.	Spanish Natl Canc Ctr, Mol Oncol Program, E-28029 Madrid, Spain; Univ Complutense Madrid, Fac Vet, Anim Surg & Med Dept, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Mol Oncol Program, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	mserrano@cnio.es	Collado, Manuel/K-8140-2014; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Serrano, Manuel/0000-0001-7177-9312; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Carneiro C, 2003, ONCOGENE, V22, P361, DOI 10.1038/sj.onc.1206163; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Cipriano SC, 2001, MOL ENDOCRINOL, V15, P985, DOI 10.1210/me.15.6.985; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Erlanson M, 1998, BLOOD, V92, P770; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Hurteau JA, 2001, GYNECOL ONCOL, V83, P292, DOI 10.1006/gyno.2001.6376; Jackson RJ, 2003, CANCER RES, V63, P3021; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lebel M, 2001, CANCER RES, V61, P1816; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Myung N, 2000, CANCER LETT, V153, P129, DOI 10.1016/S0304-3835(00)00359-1; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Sanchez-Beato M, 2001, AM J PATHOL, V159, P205, DOI 10.1016/S0002-9440(10)61686-0; SanchezBeato M, 1997, AM J PATHOL, V151, P151; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Singh SP, 1998, CANCER RES, V58, P1730; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsihlias J, 1999, ANNU REV MED, V50, P401; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yang WC, 2001, CANCER RES, V61, P565; Zhang W, 2002, RARE METALS, V21, P48; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	57	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8231	8237		10.1038/sj.onc.1207863	http://dx.doi.org/10.1038/sj.onc.1207863			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378017	Bronze			2022-12-28	WOS:000224749500005
J	Tomita, M; Choe, J; Tsukazaki, T; Mori, N				Tomita, M; Choe, J; Tsukazaki, T; Mori, N			The Kaposi's sarcoma-associated herpesvirus K-bZIP protein represses transforming growth factor beta signaling through interaction with CREB-binding protein	ONCOGENE			English	Article						KSHV; K-bZIP; TGF-beta; Smad; CBP	FACTOR-KAPPA-B; MULTICENTRIC CASTLEMANS-DISEASE; EPSTEIN-BARR-VIRUS; TGF-BETA; DNA-SEQUENCES; TRANSCRIPTIONAL ACTIVATION; COACTIVATORS CBP/P300; NUCLEAR INTEGRATION; GENE-EXPRESSION; SMAD PROTEINS	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is involved in the pathogenesis of KS, primary effusion lymphoma, and multicentric Castleman's disease. K-bZIP, the protein encoded by the open reading frame K8 of KSHV, is a member of the basic region-leucine zipper family of transcription factors. We studied the mechanisms that underlie KSHV-induced oncogenesis by investigating whether K-bZIP perturbs signaling through transforming growth factor beta (TGF-beta), which inhibits proliferation of a wide range of cell types. K-bZIP repressed TGF-beta-induced, Smad-mediated transcriptional activity and antagonized the growth-inhibitory effects of TGF-beta. Since both K-bZIP and Smad are known to interact with CREB-binding protein (CBP), the effect of CBP on inhibition of Smad-mediated transcriptional activation by K-bZIP was examined. K-bZIP mutants, which lacked the CBP-binding site, could not repress TGF-beta-induced or Smad3-mediated transcriptional activity. Overexpression of CBP restored K-bZIP-induced inhibition of Smad3-mediated transcriptional activity. Competitive interaction studies showed that K-bZIP inhibited the interaction of Smad3 with CBP. These results suggest that K-bZIP, through its binding to CBP, disrupts TGF-beta signaling by interfering with the recruitment of CBP into transcription initiation complexes on TGF-beta-responsive elements. We propose a possibility that K-bZIP may contribute to oncogenesis through its ability to promote cell survival by repressing TGF-beta signaling.	Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Nagasaki Univ, Grad Sch Biomed Sci, Div Orthopaed Pathomech, Nagasaki 8528588, Japan	University of the Ryukyus; Korea Advanced Institute of Science & Technology (KAIST); Nagasaki University	Mori, N (corresponding author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.	n-mori@med.u-ryukyu.ac.jp	Choe, Joonho/F-3066-2011					Alkan S, 1997, BRIT J HAEMATOL, V96, P412, DOI 10.1046/j.1365-2141.1997.d01-2040.x; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan HM, 2001, J CELL SCI, V114, P2363; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lin SF, 1999, J VIROL, V73, P1909, DOI 10.1128/JVI.73.3.1909-1917.1999; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Memar OM, 1995, J MOL MED-JMM, V73, P603; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Mori N, 2003, INT J CANCER, V105, P661, DOI 10.1002/ijc.11146; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mori N, 2000, BLOOD, V95, P3915; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Portes-Sentis S, 2001, J GEN VIROL, V82, P507, DOI 10.1099/0022-1317-82-3-507; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	52	34	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8272	8281		10.1038/sj.onc.1208059	http://dx.doi.org/10.1038/sj.onc.1208059			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467747				2022-12-28	WOS:000224749500009
J	Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL				Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL			A novel p21(WAF1/CIP1) transcript is highly dependent on p53 for its basal expression in mouse tissues	ONCOGENE			English	Article						p21; p53; alternate transcript	KINASE INHIBITOR; CELL-CYCLE; GENE; P21; ARREST; CLONING; WAF1	p21(WAF1/CIP1) is an important transcriptional target of p53 and it plays a critical role in growth arrest after DNA damage. Here, we report the identification of a novel alternate mouse p21 transcript that is conserved in evolution. It differs from the classical p21(WAF1/CIP1) transcript in the first exon, which is located at approximately 2.8 kb upstream of transcriptional start site of p21(WAF1/CIP1) and is sandwiched between two p53 binding sites. This novel p21 transcript is present in most mouse tissues with highest levels of expression in the spleen. In contrast to the classical p21(WAF1/CIP1) transcript, this new transcript is highly dependent on p53 for its basal expression, as evidenced by its absence in nearly all of p53(-/-) mouse tissues. This transcript is also absent at nonpermissive temperature in a 10-1 mouse cell line lacking endogenous p53 and harboring temperature-sensitive p53 mutant. However, this novel transcript is induced to appreciable levels in the presence of high p53 activity at the permissive temperature. Our data suggest that p53-dependent induction of p21 may be an additive effect conferred by individual increases in the alternate and classical p21 transcripts.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St, Chicago, IL 60612 USA.	atyner@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK56283, R01 DK056283-05, R01 DK056283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hogga I, 2002, DEVELOPMENT, V129, P4915; HUPPI K, 1994, ONCOGENE, V9, P3017; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAO L, 1995, CANCER RES, V55, P2995; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; QUELLE DE, 1995, CELL, V83, P993; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Wang XD, 2004, NAT GENET, V36, P231, DOI 10.1038/ng1301; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	23	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8154	8157		10.1038/sj.onc.1207820	http://dx.doi.org/10.1038/sj.onc.1207820			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361845				2022-12-28	WOS:000224692500013
J	Massimi, P; Gammoh, N; Thomas, M; Banks, L				Massimi, P; Gammoh, N; Thomas, M; Banks, L			HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation	ONCOGENE			English	Article						transformation; human papillomavirus; E6; PDZ domains	HUMAN HOMOLOG; PROTEINS TARGET; CANCER-CELLS; RECOGNITION; INDUCTION; POLARITY; BINDING; GROWTH; APC	The high-risk HPV E6 proteins have been shown to directthe degradation of a variety of cellular proteins that contain PDZ domains. Although some of these proteins are involved in regulating processes of cell growth and polarity in Drosophila, little is known about their function in higher eukaryotic epithelial cells. In HPV-containing cells derived from cervical tumours, we find that the patterns of expression of the E6 targets hDlg (discs large), hScrib (Scribble), and MUPP1 are consistent with their being substrates for E6-induced degradation. It is also clear that, in the case of hDlg, E6 is specifically targeting nuclear pools of the protein rather than membrane-bound forms. We have also analysed the activity of a subset of E6 target proteins in the suppression of oncogene-induced cell transformation. Interestingly, Dlg, MAGI-1 and MUPP1 efficiently suppressed cell transformation, while MAGI-2 and MAGI-3 were ineffective in this assay. These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org						Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Banks L, 2003, TRENDS BIOCHEM SCI, V28, P452, DOI 10.1016/S0968-0004(03)00141-5; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2003, J BIOL CHEM, V278, P42477, DOI 10.1074/jbc.M302799200; Mantovani F, 2001, J CELL SCI, V114, P4285; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Reuver SM, 1998, J CELL SCI, V111, P1071; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	36	96	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8033	8039		10.1038/sj.onc.1207977	http://dx.doi.org/10.1038/sj.onc.1207977			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378012				2022-12-28	WOS:000224692500001
J	Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD				Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD			Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; estrogen receptor; ER fusion; malignant transformation	NF-KAPPA-B; INTERLEUKIN-6 GENE-EXPRESSION; TRANSCRIPTION FACTOR; DNA-BINDING; V-REL; HODGKINS-DISEASE; LINE RC-K8; TRANSACTIVATION; ACTIVATION; DOMAINS	Overexpression of the human REL transcription factor can malignantly transform chicken spleen cells in vitro. In this report, we have created and characterized a cDNA encoding a chimeric protein (RELDelta424 - 490- ER) in which sequences of a highly transforming REL mutant ( RELD424 - 490) are fused to the ligand-binding domain of the human estrogen receptor ( ER). Surprisingly, RELDelta424 - 490- ER is constitutively nuclear in A293 cells, and RELDelta424 - 490- ER activates transcription in the absence, but not in the presence, of estrogen in kappaB-site reporter gene assays. Furthermore, RELDelta424 - 490- ER transforms chicken spleen cells in the absence of estrogen, but the addition of estrogen blocks the ability of RELDelta424 - 490- ER-transformed cells to form colonies in soft agar, even though estrogen induces increased nuclear translocation of RELDelta424 - 490- ER in these cells. ERalpha can also inhibit REL-dependent transactivation in trans in an estrogen-dependent manner, and ERalpha can interact with REL in vitro. Thus, the RELDelta424 - 490- ER fusion protein shows an unusual, reverse hormone regulation, in that its most prominent biological activities ( transformation and transactivation) are inhibited by estrogen, probably due to an estrogen-induced interaction between the ER sequences and sequences in the Rel homology domain. Nevertheless, these results indicate that the continual activity of REL is required to sustain the transformed state of chicken spleen cells in culture, suggesting that direct and specific inhibitors of REL may have therapeutic efficacy in certain human lymphoid cancers.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HORIGOME T, 1988, ENDOCRINOLOGY, V123, P2540, DOI 10.1210/endo-123-5-2540; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Maia DM, 2000, LEUKEMIA LYMPHOMA, V39, P365, DOI 10.3109/10428190009065836; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; RAY A, 1994, J BIOL CHEM, V269, P12940; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sharma RV, 2001, J APPL PHYSIOL, V91, P2400, DOI 10.1152/jappl.2001.91.5.2400; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARK JJ, 1981, ANN INTERN MED, V95, P186, DOI 10.7326/0003-4819-95-2-186; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tzagarakis-Foster C, 2002, J BIOL CHEM, V277, P44772, DOI 10.1074/jbc.M205355200; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; VANGOOL A, 2002, KEYSTONE S NF KB BEN; Walker AK, 1996, ONCOGENE, V12, P2515; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	30	8	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7580	7587		10.1038/sj.onc.1207912	http://dx.doi.org/10.1038/sj.onc.1207912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326488				2022-12-28	WOS:000224176500015
J	Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC				Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC			Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes	ONCOGENE			English	Article						Bcl-2; ERK1/2; c-jun; c-fos; AP-1; LEDGF; lens	NF-KAPPA-B; PROGRAMMED CELL-DEATH; STRESS-RELATED GENES; C-JUN; DEPENDENT PATHWAY; OXIDATIVE STRESS; DOWN-REGULATION; MESSENGER-RNA; MAP KINASE; EXPRESSION	The proto-oncogene, bcl-2, has various functions besides its role in protecting cells from apoptosis. One of the functions is to regulate expression of other genes. Previous studies have demonstrated that Bcl-2 regulates activities of several important transcription factors including NF-kappaB and p53, and also their downstream genes. In our recent studies, we reported that Bcl-2 substantially downregulates expression of the endogenous alphaB-crystallin gene through modulating the transcriptional activity of lens epithelium-derived growth factor ( LEDGF). In the present communication, we report that human Bcl-2 can positively regulate expression of the proto-oncogenes c-jun and c-fos. Moreover, it enhances the DNA binding activity and transactivity of the activating protein-1 (AP-1). Furthermore, we present evidence to show that Bcl-2 can also activate both ERK1 and ERK2 MAP kinases. Inhibition of the activities of these kinases or the upstream activating kinases by pharmacological inhibitors or dominant-negative mutants abolishes the Bcl-2-mediated regulation of AP-1, LEDGF and their downstream genes. Together, our results demonstrate that through activation of the ERK kinase signaling pathway, Bcl-2 regulates the transcriptional activities of multiple transcription factors, and hence modulates the expression of their downstream genes. Thus, our results provide a mechanism to explain how Bcl-2 may regulate expression of other genes.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ USA	University of Minnesota System; Hunan Normal University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Li, David/AAN-9205-2021	xiang, hua/0000-0003-0369-1225; Mao, Yingwei/0000-0001-7339-1565	PHS HHS [NEI 11372] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011372] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chen DB, 2003, MOL CELL ENDOCRINOL, V200, P141, DOI 10.1016/S0303-7207(02)00379-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Feng LX, 1999, J CELL BIOCHEM, V74, P576, DOI 10.1002/(SICI)1097-4644(19990915)74:4<576::AID-JCB7>3.0.CO;2-N; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kubo E, 2002, J MOL BIOL, V320, P1053, DOI 10.1016/S0022-2836(02)00551-X; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Kumar NV, 2001, J BIOL CHEM, V276, P32362, DOI 10.1074/jbc.M103677200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; McDermott JB, 1997, INVEST OPHTH VIS SCI, V38, P951; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; NIESON DA, 1983, P NATL ACAD SCI USA, V80, P5198; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	64	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7310	7321		10.1038/sj.onc.1208041	http://dx.doi.org/10.1038/sj.onc.1208041			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326476				2022-12-28	WOS:000224021400002
J	Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL				Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL			Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles	ONCOGENE			English	Article						colon cancer; cancer-associated stroma; cancer microenvironment; COX2	GROWTH-FACTOR; TUMOR-GROWTH; CELLS; TUMORIGENICITY; ACCELERATION; SUPPRESSION; INHIBITION; PROSTATE; MICE	The cancer microenvironment and interaction between cancer and stromal cells play critical roles in tumor development and progression. The molecular features of cancer stroma are less well understood than those of cancer cells. Cancer-associated stromal fibroblasts are the predominant component of stroma associated with colon cancer and its functions remain unclear. Fibroblast cell cultures were established from metastatic colon cancer in liver, liver away from the metastatic lesions, and skin from three patients with metastatic colorectal cancer. We generated expression profiles of cancer-associated fibroblasts using oligochip arrays and compared them to those of uninvolved fibroblasts. The conditioned media from the cancer-associated fibroblast cultures enhanced proliferation of colon cancer cell line HCT116 to a greater extent than cultures from uninvolved fibroblasts. In microarray expression analysis, cancer-associated fibroblasts clustered tightly into one group and skin fibroblasts into another. Approximately 170 of 22 000 genes were upregulated in cancer-associated fibroblasts ( fold change >2, P<0.05) as compared to skin fibroblasts, including many genes encoding cell adhesion molecules, growth factors, and COX2. By immunohistochemistry in-vivo, we confirmed COX2 and TGFB2 expression in cancer-associated fibroblasts in metastatic colon cancer. The distinct molecular expression profiles of cancer-associated fibroblasts in colon cancer metastasis support the notion that these fibroblasts form a favorable microenvironment for cancer cells.	Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Surg Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Frankel, WL (corresponding author), Ohio State Univ, Dept Pathol, 410 W 10th Ave,401 E Doan Hall, Columbus, OH 43210 USA.	frankel-1@medctr.osu.edu	Thomson, Axel/A-7893-2013; Davuluri, Ramana/D-7348-2011; Martin Jr, Edward/E-3604-2011	Frankel, Wendy/0000-0003-1658-1009	NCI NIH HHS [CA67941, CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067941, P30CA016058, U01CA067941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bartholin L, 2002, ONCOGENE, V21, P2227, DOI 10.1038/sj.onc.1205294; BRATTAIN MG, 1982, J NATL CANCER I, V69, P767; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Conze D, 2001, CANCER RES, V61, P8851; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gho YS, 2001, CANCER RES, V61, P4253; GLEAVE M, 1991, CANCER RES, V51, P3753; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill DP, 2002, GENOME RES, V12, P1982, DOI 10.1101/gr.580102; Holen I, 2002, CANCER RES, V62, P1619; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Matrisian LM, 2001, CANCER RES, V61, P3844; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PICARD O, 1986, CANCER RES, V46, P3290; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Studeny M, 2002, CANCER RES, V62, P3603; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; WESTERMARK B, 1991, CANCER RES, V51, P5087; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	37	183	192	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7366	7377		10.1038/sj.onc.1208013	http://dx.doi.org/10.1038/sj.onc.1208013			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326482				2022-12-28	WOS:000224021400007
J	Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW				Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW			Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix	ONCOGENE			English	Article						cervical cancer; HPV; genomic instability; telomere erosion; telomerase	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS TYPE-16; COMPARATIVE GENOMIC HYBRIDIZATION; REVERSE-TRANSCRIPTASE GENE; HTERT GENE; CHROMOSOME INSTABILITY; HUMAN CANCER; AMPLIFICATION; DYSFUNCTION; ACTIVATION	Although human papillomavirus (HPV) has been defined as the pathogen for cervical carcinomas, molecular events underlying the oncogenic process are unclear. As telomere dysfunction-mediated chromosomal instability and telomerase activation have been suggested as key events in carcinogenesis, we dissected the dynamic changes in telomere length, checkpoint response, and temporal pro. le of telomerase expression during the evolution from precursor lesions ( cervical intraepithelial neoplasia, CINs) to invasive cancers of the uterine cervix in sequential samples from 16 patients. Telomeres were significantly shortened in all CIN samples and no further substantial attritions occurred in most cases with the acquisition of malignant phenotype. Very short telomeres were coupled with constitutive activation of the DNA damage response pathway (Chk2 phosphorylation) and increased cellular proliferation in those cervical specimens. Telomerase reverse transcriptase ( hTERT) expression was preferably induced at advanced CINs or invasive cancers. The present finding demonstrates that excessive telomere shortening predominantly occurs in the early carcinogenesis of the uterine cervix largely prior to telomerase activation. Widespread over-erosion of telomeres or telomere dysfunction in very early stages of cervical tumorigenesis might fuel transformation processes by driving chromosomal instability.	Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden; Univ Umea Hosp, Cytol Lab, SE-90187 Umea, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Peking Univ, Peoples Hosp, Dept Gynecol, Beijing 100083, Peoples R China; Shandong Univ, Qilu Hosp, Dept Urol, Jinan 250108, Peoples R China; Karolinska Univ Hosp, Karolinska Inst, Dept Urol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Umea University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Peking University; Shandong University; Karolinska Institutet; Karolinska University Hospital	Wallin, KL (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden.	Keng-Ling.Wallin@cmm.ki.se; Dawei.Xu@cmm.ki.se		Xu, Dawei/0000-0003-3141-4524; Wang, Jianliu/0000-0003-0338-0427				Anderson S, 1997, AM J PATHOL, V151, P25; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018; Heselmeyer-Haddad K, 2003, AM J PATHOL, V163, P1405, DOI 10.1016/S0002-9440(10)63498-0; Jarboe EA, 2002, ONCOGENE, V21, P664, DOI 10.1038/sj.onc.1205073; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kyo S, 1997, CANCER RES, V57, P1863; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Meeker AK, 2002, CANCER RES, V62, P6405; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Oh H, 2003, P NATL ACAD SCI USA, V100, P5378, DOI 10.1073/pnas.0836098100; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pihan GA, 2003, CANCER RES, V63, P1398; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Snijders PJF, 1998, CANCER RES, V58, P3812; Southern SA, 1997, CANCER RES, V57, P4210; Takakura M, 1998, CANCER RES, V58, P1558; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vukovic B, 2003, ONCOGENE, V22, P1978, DOI 10.1038/sj.onc.1206227; Zhang AJ, 2002, GENE CHROMOSOME CANC, V34, P269, DOI 10.1002/gcc.10071; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	40	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7441	7447		10.1038/sj.onc.1207527	http://dx.doi.org/10.1038/sj.onc.1207527			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15318175				2022-12-28	WOS:000224021400015
J	Das, D; Shah, RB; Imperiale, MJ				Das, D; Shah, RB; Imperiale, MJ			Detection and expression of human BK virus sequences in neoplastic prostate tissues	ONCOGENE			English	Review						polyomavirus BK; large T antigen; p53; postatrophic hyperplasia; proliferative inflammatory atrophy; in situ hybridization; immunohistochemistry; immunofluorescence; high-grade prostate intraepithelial neoplasia	LARGE-T-ANTIGEN; PROLIFERATIVE INFLAMMATORY ATROPHY; POLYMERASE-CHAIN-REACTION; P53 PROTEIN; HUMAN-PAPILLOMAVIRUS; HUMAN POLYOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; MONOCLONAL-ANTIBODIES; JC-VIRUS; CYTOPLASMIC SEQUESTRATION	BK virus (BKV) is ubiquitous in the human population and establishes a lifelong, subclinical persistent infection in the urinary tract. When the immune system is compromised, it can cause severe disease in the kidney and bladder. Detection of BKV sequences in urinary tract neoplasms has led to the postulate that this virus may induce human oncogenesis through the function of its large tumor antigen (TAg). In this study, examination of prostate tumor tissue sections using in situ hybridization shows the presence of BKV sequences in atrophic epithelium. Solution polymerase chain reaction on DNA extracted from the tissues and sequence analysis of the products reveal the presence of BKV regulatory and early region sequences. In addition, immunohistochemical analysis using monoclonal antibodies specific to TAg or p53 shows the expression of TAg in some of the samples and p53 staining that can be correlated to TAg expression. Although the normal cellular localization of TAg and p53 is nuclear, double immunofluorescence labeling with anti-p53 and TAg antibodies indicates colocalization of p53 and TAg to the cytoplasm in the glandular epithelial cells of the sections. Although BKV DNA was found in benign and atrophic lesions, TAg and p53 coexpression was observed only in atrophic lesions.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6304, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	imperial@umich.edu						Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; BERG DT, 1988, NUCLEIC ACIDS RES, V16, P9057, DOI 10.1093/nar/16.18.9057; BERGER CN, 1986, EMBO J, V5, P85, DOI 10.1002/j.1460-2075.1986.tb04181.x; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOSARI S, 1995, AM J PATHOL, V147, P790; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO;2-7; Brewster SF, 1999, J UROLOGY, V161, P1238, DOI 10.1016/S0022-5347(01)61646-X; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; COLCHER D, 1981, P NATL ACAD SCI-BIOL, V78, P3199, DOI 10.1073/pnas.78.5.3199; CUZICK J, 1995, CANCER SURV, V23, P91; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Flaegstad T, 1999, CANCER RES, V59, P1160; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P617, DOI 10.1002/path.1700680234; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GARDNER SD, 1973, BMJ-BRIT MED J, V1, P77, DOI 10.1136/bmj.1.5845.77; GARDNER SD, 1971, LANCET, V1, P1253; GARDNER WA, 1987, J UROLOGY, V137, P53, DOI 10.1016/S0022-5347(17)43869-9; GARDNER WA, 1992, PATHOLOGY PATHOBIOLO, P129; Geetha D, 2002, TRANSPLANTATION, V73, P1933, DOI 10.1097/00007890-200206270-00015; Gonzalgo ML, 2003, J UROLOGY, V170, P2444, DOI 10.1097/01.ju.0000085381.20139.b6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; HIRAOKA A, 1991, BONE MARROW TRANSPL, V7, P107; Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9; IBRAHIM GK, 1992, J UROLOGY, V148, P1822, DOI 10.1016/S0022-5347(17)37040-4; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Imperiale MJ, 2001, ONCOGENE, V20, P7917, DOI 10.1038/sj.onc.1204916; IWASAKA T, 1993, GYNECOL ONCOL, V48, P104, DOI 10.1006/gyno.1993.1016; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Jorgensen GEK, 2000, MED PEDIATR ONCOL, V35, P593, DOI 10.1002/1096-911X(20001201)35:6<593::AID-MPO22>3.0.CO;2-I; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; Knippschild U, 1996, ONCOGENE, V12, P1755; Kuefer R, 2002, AM J PATHOL, V161, P841, DOI 10.1016/S0002-9440(10)64244-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li RM, 2002, TRANSPLANTATION, V74, P1497, DOI 10.1097/00007890-200212150-00004; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P619, DOI 10.1097/00000478-198808000-00003; MCNICOL PJ, 1991, J UROLOGY, V145, P850, DOI 10.1016/S0022-5347(17)38476-8; Melamed J, 1997, CLIN CANCER RES, V3, P1867; MOENS U, 2001, HUMAN POLYOMAVIRUSES, P215; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NAKASHATRI H, 1988, J VIROL, V62, P4613; NEGRINI M, 1991, J VIROL, V65, P5092, DOI 10.1128/JVI.65.9.5092-5095.1991; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Noda T, 1998, UROL RES, V26, P165, DOI 10.1007/s002400050041; Nuovo G. J., 1996, PCR IN SITU HYBRIDIZ; Nupponen N, 1999, EUR UROL, V35, P351, DOI 10.1159/000019907; Osman I, 1999, CLIN CANCER RES, V5, P2082; PADGETT B, 1981, HUMAN PAPOVAVIRUSES, P339; Pappo O, 1996, MODERN PATHOL, V9, P105; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PORTOLANI M, 1975, J VIROL, V15, P420, DOI 10.1128/JVI.15.2.420-422.1975; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Randhawa PS, 1999, TRANSPLANTATION, V67, P103, DOI 10.1097/00007890-199901150-00018; Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813; ROTOLA A, 1992, INT J CANCER, V52, P359, DOI 10.1002/ijc.2910520306; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; RUBINSTEIN R, 1987, J VIROL, V61, P1747, DOI 10.1128/JVI.61.5.1747-1750.1987; Ruska KM, 1998, AM J SURG PATHOL, V22, P1073, DOI 10.1097/00000478-199809000-00005; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEIF I, 1979, CELL, V18, P963, DOI 10.1016/0092-8674(79)90209-5; Shah KV, 1996, FIELDS VIROLOGY, P2027; Shah R, 2001, AM J PATHOL, V158, P1767, DOI 10.1016/S0002-9440(10)64132-6; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SHINOHARA T, 1993, J MED VIROL, V41, P301, DOI 10.1002/jmv.1890410408; SIMMONS DT, 1995, ONCOGENIC MECH, P27; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; SUNDSFJORD A, 1990, J VIROL, V64, P3864, DOI 10.1128/JVI.64.8.3864-3871.1990; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vilchez RA, 2002, AIDS RES HUM RETROV, V18, P237, DOI 10.1089/088922202753472793; Vivaldi A, 2003, J CLIN ENDOCR METAB, V88, P892, DOI 10.1210/jc.2002-020436; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Volter C, 1997, VIROLOGY, V237, P389, DOI 10.1006/viro.1997.8772; WATANABE S, 1989, VIROLOGY, V169, P204, DOI 10.1016/0042-6822(89)90056-1; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Wiedorn KH, 1999, HISTOCHEM CELL BIOL, V111, P89, DOI 10.1007/s004180050338; YANG RCA, 1979, SCIENCE, V206, P456, DOI 10.1126/science.228391; Yang XMJ, 2002, AM J SURG PATHOL, V26, P921, DOI 10.1097/00000478-200207000-00011; Zambrano A, 2002, ONCOGENE, V21, P5725, DOI 10.1038/sj.onc.1205692; Zambrano A, 2002, PROSTATE, V53, P263, DOI 10.1002/pros.10157	113	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7031	7046		10.1038/sj.onc.1207920	http://dx.doi.org/10.1038/sj.onc.1207920			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258563				2022-12-28	WOS:000223885100004
J	Bajou, K; Maillard, C; Jost, M; Lijnen, HR; Gils, A; Declerck, P; Carmeliet, P; Foidart, JM; Noel, A				Bajou, K; Maillard, C; Jost, M; Lijnen, HR; Gils, A; Declerck, P; Carmeliet, P; Foidart, JM; Noel, A			Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth	ONCOGENE			English	Article						PAI-1; cancer invasion; tumoral angiogenesis; serine protease; protease inhibitor	BREAST-CANCER; CHOROIDAL NEOVASCULARIZATION; UROKINASE RECEPTOR; CELL-MIGRATION; MOUSE MODEL; SYSTEM; METASTASIS; TYPE-1; MICE; VASCULARIZATION	Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells ( after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.	Univ Liege, CRCE, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Katholieke Univ Leuven, Fac Med, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	University of Liege; KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Noel, A (corresponding author), Univ Liege, CRCE, Lab Tumor & Dev Biol, Tour Pathol B23, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Carmeliet, Peter/AAQ-5140-2020; Lijnen, Roger/AAA-4085-2020; Declerck, Paul J/A-2330-2017	Carmeliet, Peter/0000-0001-7961-1821; Declerck, Paul J/0000-0003-1259-9105; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Almholt K, 2003, ONCOGENE, V22, P4389, DOI 10.1038/sj.onc.1206601; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Curino A, 2002, ONCOGENE, V21, P8830, DOI 10.1038/sj.onc.1205951; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Eitzman DT, 1996, BLOOD, V87, P4718; Foekens JA, 2000, CANCER RES, V60, P636; Gutierrez LS, 2000, CANCER RES, V60, P5839; Isogai C, 2001, CANCER RES, V61, P5587; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lijnen HR, 2004, J THROMB HAEMOST, V2, P16, DOI 10.1111/j.1538-7836.2003.00533.x; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Stephens RW, 1998, BREAST CANCER RES TR, V52, P99, DOI 10.1023/A:1006115218786	26	122	129	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6986	6990		10.1038/sj.onc.1207859	http://dx.doi.org/10.1038/sj.onc.1207859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286708	Green Submitted			2022-12-28	WOS:000223750700015
J	Bakhanashvili, M; Novitsky, E; Lilling, G; Rahav, G				Bakhanashvili, M; Novitsky, E; Lilling, G; Rahav, G			P53 in cytoplasm may enhance the accuracy of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase	ONCOGENE			English	Article							ESCHERICHIA-COLI; POLYMERASE-ALPHA; MUTATION-RATE; IN-VITRO; FIDELITY; PROTEIN; EXPRESSION; CELLS; REPLICATION; EXTENSION	The tumor suppressor protein p53 displays 3'-->5' exonuclease activity and can provide a proofreading function for DNA polymerases. Reverse transcriptase (RT) of human immunodeficiency virus (HIV)-1 is responsible for the conversion of the viral genomic ssRNA into the proviral DNA in the cytoplasm. The relatively low fidelity of HIV-1 RT was implicated as a dominant factor contributing to the genetic variability of the virus. The lack of intrinsic 3'-->5' exonuclease activity, the formation of 3'-mispaired DNA and the subsequent extension of this DNA were shown to be determinants for the low fidelity of HIV-1 RT. It was of interest to analyse whether the cytoplasmic proteins may affect the accuracy of DNA synthesis by RT. We investigated the fidelity of DNA synthesis by HIV-1 RT with and without exonucleolytic proofreading provided by cytoplasmic fraction of LCC2 cells expressing high level of wild-type functional p53. Two basic features related to fidelity of DNA synthesis were studied: the misinsertion and mispair extension. The misincorporation of noncomplementary deoxynucleotides into nascent DNA and subsequent mispair extension by HIV-1 RT were substantially decreased in the presence of cytoplasmic fraction of LCC2 cells with both RNA/DNA and DNA/DNA template-primers with the same target sequence. The mispair extension frequencies obtained with the HIV-1 RT in the presence of cytoplasmic fraction of LCC2 cells were significantly lower (about 2.8-15-fold) than those detected with the purified enzyme. In addition, the productive interaction between polymerization ( by HIV-1 RT) and exonuclease ( by p53 in cytoplasm) activities was observed; p53 preferentially hydrolyses mispaired 3'-termini, permitting subsequent extension of the correctly paired 3'-terminus by HIV-1 RT. The data suggest that p53 in cytoplasm may affect the accuracy of DNA replication and the mutation spectra of HIV-1 RT by acting as an external proofreader. Furthermore, the decrease in error-prone DNA synthesis with RT in the presence of external exonuclease, provided by cytoplasmic p53, may partially account for lower mutation rate of HIV-1 observed in vivo.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Lab Expt Chemotherapy, IL-52621 Tel Hashomer, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Bar Ilan University	Bakhanashvili, M (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bakhanashvili M, 1996, ARCH BIOCHEM BIOPHYS, V334, P89, DOI 10.1006/abbi.1996.0433; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Bakhanashvili M, 2001, ONCOGENE, V20, P7635, DOI 10.1038/sj.onc.1204956; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Genini D, 2001, FASEB J, V15, P5; Gila L, 2003, ONCOGENE, V22, P233, DOI 10.1038/sj.onc.1206111; Goodman MF, 1998, GENETICS, V148, P1475; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOWLEY PM, 1991, CANCER RES, V51, pS5019; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; Mansky LM, 1997, TRENDS GENET, V13, P134, DOI 10.1016/S0168-9525(97)01062-7; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Menendez-Arias L, 2002, PROG NUCLEIC ACID RE, V71, P91, DOI 10.1016/S0079-6603(02)71042-8; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nermut MV, 2003, J VIROL, V77, P8196, DOI 10.1128/JVI.77.15.8196-8206.2003; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; Shaheen F, 1996, J VIROL, V70, P3392, DOI 10.1128/JVI.70.6.3392-3400.1996; Shakked Z, 2002, ONCOGENE, V21, P5117, DOI 10.1038/sj.onc.1205667; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Svarovskaia ES, 2003, FRONT BIOSCI-LANDMRK, V8, pD117, DOI 10.2741/957; SZEKELY L, 1995, ONCOGENE, V10, P1869; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996	44	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6890	6899		10.1038/sj.onc.1207846	http://dx.doi.org/10.1038/sj.onc.1207846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286711				2022-12-28	WOS:000223750700006
J	Wakabayashi, K; Kambe, F; Cao, X; Murakami, R; Mitsuyama, H; Nagaya, T; Saito, K; Yoshida, J; Seo, H				Wakabayashi, K; Kambe, F; Cao, X; Murakami, R; Mitsuyama, H; Nagaya, T; Saito, K; Yoshida, J; Seo, H			Inhibitory effects of cyclosporin A on calcium mobilization-dependent interleukin-8 expression and invasive potential of human glioblastoma U251MG cells	ONCOGENE			English	Article						interleukin-8; cyclosporin A; glioblastoma; calcium mobilization; migration; proliferation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; HUMAN GLIOMA-CELLS; AUTOCRINE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; NUCLEAR FACTOR-KB; INTRACELLULAR CALCIUM; MELANOMA-CELLS; IN-VITRO	Interleukin (IL)-8 produced from glioblastoma is suggested to contribute to its own proliferation and progression. Since various external stimuli have been shown to increase intracellular Ca2+ in glioma cells, we investigated Ca2+ mobilization-dependent IL-8 expression and effect of cyclosporin A (CsA), an inhibitor of calcineurin (Cn), on the expression and invasive potential of human glioblastoma U251MG cells. Combined treatment with Ca2+-ionophore and phorbol-myristate-acetate (A23187/PMA) increased IL-8 mRNA and protein levels. This increase was suppressed by CsA and by another Cn inhibitor FK506. Luciferase reporter gene assay and electrophoretic mobility shift assay revealed that activation of p65-containing nuclear factor-kappaB was essential for A23187/PMA-dependent activation of IL-8 promoter. CsA suppressed the promoter activity by attenuating IkappaB-alpha degradation. U251MG cells expressed IL-8 receptors CXCR-1 and -2, and Matrigel invasion assay revealed that CsA attenuated A23187/PMA-dependent stimulation of invasive potential, probably by inhibiting IL-8 production. In addition, IL-8-dependent proliferation was also suppressed by CsA. Taken together, these results demonstrate the novel inhibitory effects of CsA on glioblastoma cell functions, suggesting CsA as a potential therapeutic adjuvant for glioma treatment.	Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Kambe, F (corresponding author), Nagoya Univ, Environm Med Res Inst, Div Mol & Cellular Adaptat, Dept Endocrinol & Metab,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	kambe@riem.nagoya-u.ac.jp						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bando Kazuhiko, 1995, Neurologia Medico-Chirurgica, V35, P631, DOI 10.2176/nmc.35.631; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi C, 2001, CANCER RES, V61, P3084; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DeBernardi MA, 1996, J BIOL CHEM, V271, P6092, DOI 10.1074/jbc.271.11.6092; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Hayes IM, 1998, ARTERIOSCL THROM VAS, V18, P397, DOI 10.1161/01.ATV.18.3.397; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; Iseki A, 2000, ENDOCRINOLOGY, V141, P4373, DOI 10.1210/en.141.12.4373; Iseki A, 2000, BIOCHEM BIOPH RES CO, V276, P88, DOI 10.1006/bbrc.2000.3452; KAMBE F, 1988, MOL ENDOCRINOL, V2, P181, DOI 10.1210/mend-2-2-181; Kasahara T, 1998, EUR CYTOKINE NETW, V9, P47; Kehlen A, 1999, J NEUROIMMUNOL, V101, P1, DOI 10.1016/S0165-5728(99)00111-3; Kelly JS, 2001, TRANSPLANT P, V33, P2217, DOI 10.1016/S0041-1345(01)01945-5; Kikumori T, 1998, ENDOCRINOLOGY, V139, P1715, DOI 10.1210/en.139.4.1715; Kikumori T, 2001, BIOCHEM J, V354, P573, DOI 10.1042/0264-6021:3540573; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUGAYA A, 1995, BRAIN RES, V682, P151, DOI 10.1016/0006-8993(95)00345-Q; Kuhns D, 1998, J IMMUNOL, V161, P4332; Luca M, 1997, AM J PATHOL, V151, P1105; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Miyamoto M, 1998, CANCER IMMUNOL IMMUN, V47, P47, DOI 10.1007/s002620050503; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Palma C, 1998, J NEUROIMMUNOL, V81, P127, DOI 10.1016/S0165-5728(97)00167-7; Pita I, 1999, INT J DEV NEUROSCI, V17, P813, DOI 10.1016/S0736-5748(99)00063-5; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiland J, 1999, PROSTATE, V41, P78; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; Saqr HE, 1999, NEUROCHEM INT, V35, P411, DOI 10.1016/S0197-0186(99)00092-3; Sarkar D, 2000, ENDOCR J, V47, P63, DOI 10.1507/endocrj.47.63; Sato M, 1996, J RHEUMATOL, V23, P432; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; SMYTH MJ, 1991, J IMMUNOL, V146, P3815; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; Wilson AJ, 1999, CLIN SCI, V97, P385, DOI 10.1042/CS19980351; YAMANAKA R, 1995, J NEURO-ONCOL, V25, P59, DOI 10.1007/BF01054723; Yamanaka Ryuya, 1993, Neurologia Medico-Chirurgica, V33, P744, DOI 10.2176/nmc.33.744; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	58	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6924	6932		10.1038/sj.onc.1207778	http://dx.doi.org/10.1038/sj.onc.1207778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286717				2022-12-28	WOS:000223750700009
J	Wakeford, R				Wakeford, R			The cancer epidemiology of radiation	ONCOGENE			English	Review						ionizing; nonionizing; risk; dose-response	ATOMIC-BOMB SURVIVORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; X-RAY TREATMENT; CHERNOBYL EMERGENCY WORKERS; CANADIAN FLUOROSCOPY COHORT; NONMELANOMA SKIN-CANCER; 2ND MALIGNANT NEOPLASMS; RATE IONIZING-RADIATION; FEMALE BREAST-CANCER; RADIUM DIAL WORKERS	Ionizing radiation has been the subject of intense epidemiological investigation. Studies have demonstrated that exposure to moderate-to-high levels can cause most forms of cancer, leukaemia and cancers of the breast, lung and thyroid being particularly sensitive to induction by radiation, especially at young ages at exposure. Predominant among these studies is the Life Span Study of the cohort of survivors of the atomic bombings of Japan in 1945, but substantial evidence is derived from groups exposed for medical reasons, occupationally or environmentally. Notable among these other groups are underground hard rock miners who inhaled radioactive radon gas and its decay products, large numbers of patients irradiated therapeutically and workers who received high doses in the nuclear weapons programme of the former USSR. The degree of carcinogenic risk arising from low levels of exposure is more contentious, but the available evidence points to an increased risk that is approximately proportional to the dose received. Epidemiological investigations of nonionizing radiation have established ultraviolet radiation as a cause of skin cancer. However, the evidence for a carcinogenic effect of other forms of nonionizing radiation, such as those associated with mobile telephones or electricity transmission lines, is not convincing, although the possibility of a link between childhood leukaemia and extremely low-frequency electromagnetic fields cannot be dismissed entirely.	BNFL, Warrington WA4 4BG, Cheshire, England		Wakeford, R (corresponding author), BNFL, 1100 Daresbury Pk, Warrington WA4 4BG, Cheshire, England.	R.Wakeford@bnfl.com	Wakeford, Richard/I-1978-2019	Wakeford, Richard/0000-0002-2934-0987				ADAMS EE, 1980, J OCCUP ENVIRON MED, V22, P583; Advisory Group on Non-Ionising Radiation (AGNIR), 2003, DOC NRPB, V14, P1; *AGIR, 2000, DOC NRPB, V11; *AGNIR, 2002, DOC NRPB, V13, P1; *AGNIR, 2001, DOC NRPB, V12; *AGNIR, 1994, DOC NRPB, V5, P77; *AGNIR, 1992, DOC NRPB, V3; Ahlbom A, 2001, ENVIRON HEALTH PERSP, V109, P911, DOI 10.2307/3454653; Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; [Anonymous], 1999, Lancet, V354, P1925; [Anonymous], 1994, SOURC EFF ION RAD, P16; Astakhova LN, 1998, RADIAT RES, V150, P349, DOI 10.2307/3579983; Atkinson W. D., 1994, Journal of Radiological Protection, V14, P109, DOI 10.1088/0952-4746/14/2/001; Atkinson WD, 2002, P 4 INT C HLTH EFF L; Band PR, 1996, AM J EPIDEMIOL, V143, P137; Bataille V, 2004, EUR J CANCER, V40, P429, DOI 10.1016/j.ejca.2003.09.030; BAVERSTOCK KF, 1989, BIR REPORT, V21, P72; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 2001, HLTH HAZARDS DEPLE 1, P75; Berrington A, 2001, BRIT J RADIOL, V74, P507, DOI 10.1259/bjr.74.882.740507; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Blettner M, 2003, INT J CANCER, V106, P946, DOI 10.1002/ijc.11328; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1985, J NATL CANCER I, V74, P955; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; Boice JD, 1999, TERATOLOGY, V59, P227, DOI 10.1002/(SICI)1096-9926(199904)59:4<227::AID-TERA7>3.0.CO;2-E; Boice JD, 2000, HEALTH PHYS, V79, P576, DOI 10.1097/00004032-200011000-00016; BOICE JD, 2002, J RADIOL PROT, V22, P102; BOICE JD, 2002, 200216 SSI SWED RAD; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; BRENNER DJ, 2003, NATURE, V421, P691; CARDIS E, 1995, RADIAT RES, V142, P117, DOI 10.2307/3579020; CARPENTER L M, 1990, Radiation Research, V124, P351; Carpenter LM, 1998, BRIT J CANCER, V78, P1224, DOI 10.1038/bjc.1998.659; Carr ZA, 2002, RADIAT RES, V157, P668, DOI 10.1667/0033-7587(2002)157[0668:MNARTF]2.0.CO;2; Cartwright RA, 2002, BRIT J CANCER, V86, P1721, DOI 10.1038/sj.bjc.6600276; Cartwright RA, 2002, BRIT J CANCER, V86, P1727, DOI 10.1038/sj.bjc.6600277; Cheng KK, 2000, BRIT J CANCER, V83, P1573, DOI 10.1054/bjoc.2000.1550; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; *COMARE, 1988, 2 COMARE; *COMARE, 1996, 4 COMARE; [COMARE (Committee on Medical Aspects of Radiation in the Environment) Crown], 2002, 7 COMARE; Cox DR, 2003, J ROY STAT SOC A STA, V166, P241, DOI 10.1111/1467-985X.00272; Dalager NA, 2000, J OCCUP ENVIRON MED, V42, P798, DOI 10.1097/00043764-200008000-00006; DARBY SC, 1995, JNCI-J NATL CANCER I, V87, P378, DOI 10.1093/jnci/87.5.378; Darby SC, 2003, RADIAT PROT DOSIM, V104, P321, DOI 10.1093/oxfordjournals.rpd.a006195; DARBY SC, 1992, BRIT MED J, V304, P1005, DOI 10.1136/bmj.304.6833.1005; DAVIS FG, 1989, CANCER RES, V49, P6130; Davis S., 2002, HANFORD THYROID DIS; de Vathaire F, 1999, BRIT J CANCER, V79, P1884, DOI 10.1038/sj.bjc.6690300; Dennis LK, 2003, ANN INTERN MED, V139, P966, DOI 10.7326/0003-4819-139-12-200312160-00006; Dickman PW, 2003, INT J CANCER, V106, P580, DOI 10.1002/ijc.11258; Dolk H, 1997, AM J EPIDEMIOL, V145, P10, DOI 10.1093/oxfordjournals.aje.a009026; Dolk H, 1997, AM J EPIDEMIOL, V145, P1, DOI 10.1093/oxfordjournals.aje.a009025; Doll R, 1999, BRIT J CANCER, V81, P3, DOI 10.1038/sj.bjc.6690642; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Doll R, 1997, BRIT J RADIOL, V70, P130, DOI 10.1259/bjr.70.830.9135438; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; Elwood JM, 1999, ENVIRON HEALTH PERSP, V107, P155, DOI 10.2307/3434480; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Fears TR, 2002, CANCER RES, V62, P3992; FOLLEY JH, 1952, AM J MED, V13, P311, DOI 10.1016/0002-9343(52)90285-4; Freedman DM, 2002, OCCUP ENVIRON MED, V59, P257, DOI 10.1136/oem.59.4.257; Fry SA, 1998, RADIAT RES, V150, pS21, DOI 10.2307/3579805; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; Garwicz S, 2000, INT J CANCER, V88, P672, DOI 10.1002/1097-0215(20001115)88:4<672::AID-IJC24>3.0.CO;2-N; GIBSON BES, 1988, LANCET, V2, P630; Gilbert ES, 1998, JNCI-J NATL CANCER I, V90, P1654, DOI 10.1093/jnci/90.21.1654; Gilbert ES, 2000, RADIAT RES, V154, P246, DOI 10.1667/0033-7587(2000)154[0246:LCIMW]2.0.CO;2; Gilliland FD, 2000, HEALTH PHYS, V79, P365, DOI 10.1097/00004032-200010000-00004; Gilman EA, 1998, BRIT J CANCER, V77, P842, DOI 10.1038/bjc.1998.137; Grosche B, 2002, RADIAT ENVIRON BIOPH, V41, P75, DOI 10.1007/s00411-001-0136-1; Groves FD, 2002, AM J EPIDEMIOL, V155, P810, DOI 10.1093/aje/155.9.810; Guizard AV, 2001, J EPIDEMIOL COMMUN H, V55, P469, DOI 10.1136/jech.55.7.469; Gundestrup M, 1999, LANCET, V354, P2029, DOI 10.1016/S0140-6736(99)05093-X; Hahn K, 2001, RADIAT RES, V156, P61, DOI 10.1667/0033-7587(2001)156[0061:TCADAO]2.0.CO;2; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; Harrison JD, 2003, INT J RADIAT BIOL, V79, P1, DOI 10.1080/0955300021000038671; *HARV CTR CANC PRE, 1996, CANC CAUS CONTR S1, V7, pS41; Hatch EE, 2000, EPIDEMIOLOGY, V11, P189, DOI 10.1097/00001648-200003000-00019; HATCH MC, 1990, AM J EPIDEMIOL, V132, P397, DOI 10.1093/oxfordjournals.aje.a115673; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; Hocking B, 1996, MED J AUSTRALIA, V165, P601, DOI 10.5694/j.1326-5377.1996.tb138661.x; HOLLINGSWORTH DR, 1963, MEDICINE, V42, P47, DOI 10.1097/00005792-196301000-00003; Howard JE, 1997, HEALTH PHYS, V73, P190, DOI 10.1097/00004032-199707000-00016; HOWE GR, 1995, RADIAT RES, V142, P295, DOI 10.2307/3579139; Howe GR, 1996, RADIAT RES, V145, P694, DOI 10.2307/3579360; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; *IARC, 1992, IARC MON EV CARC RIS, V55; *IARC, 2002, IARC MON EV CARC R 1, V80; IARC, 2001, IARC MON EV CARC R 2, V78; *ICRP, 1998, PUBL ICRP, V79; ICRP, 1991, ANN ICRP, V22; *ICRP, 1991, PUBL ICRP, V60; *IEGMP, 2000, MOB PHON HLTH; Institute of Medicine, 2000, 5 SER STUD MORT MIL; International Agency for Research on Cancer (IARC), 2000, IARC MON EV CARC R 1, V75; Ivanov EP, 1998, RADIAT ENVIRON BIOPH, V37, P53, DOI 10.1007/s004110050092; Ivanov V. K., 1997, Journal of Radiological Protection, V17, P137, DOI 10.1088/0952-4746/17/3/003; Ivanov VK, 2004, RADIAT ENVIRON BIOPH, V43, P35, DOI 10.1007/s00411-003-0223-6; Ivanov VK, 1997, RADIAT ENVIRON BIOPH, V36, P9, DOI 10.1007/s004110050049; Ivanov VK, 2003, HEALTH PHYS, V84, P46, DOI 10.1097/00004032-200301000-00004; Ivanov VK, 2002, RADIAT ENVIRON BIOPH, V41, P195, DOI 10.1007/s00411-002-0163-6; Ivanov VK, 2001, HEALTH PHYS, V81, P514, DOI 10.1097/00004032-200111000-00005; Izumi S, 2003, INT J CANCER, V107, P292, DOI 10.1002/ijc.11400; Jacob P, 2000, RADIAT ENVIRON BIOPH, V39, P25, DOI 10.1007/PL00007681; Karagas MR, 2002, J NATL CANCER I, V94, P224, DOI 10.1093/jnci/94.3.224; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; Kesminiene A, 2002, J Radiol Prot, V22, pA137, DOI 10.1088/0952-4746/22/3A/324; KINLEN LJ, 2000, RADIOL PROT B, V226, P9; Kleinerman RA, 2000, AM J EPIDEMIOL, V151, P512, DOI 10.1093/oxfordjournals.aje.a010237; Koshurnikova NA, 2000, RADIAT RES, V154, P237, DOI 10.1667/0033-7587(2000)154[0237:BCIMW]2.0.CO;2; Kossenko MM, 2002, RADIAT ENVIRON BIOPH, V41, P45, DOI 10.1007/s00411-001-0132-5; Kreisheimer M, 2003, RADIAT ENVIRON BIOPH, V42, P129, DOI 10.1007/s00411-003-0198-3; Lagarde F, 2001, EPIDEMIOLOGY, V12, P396, DOI 10.1097/00001648-200107000-00009; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; LAND CE, 1993, LANCET, V342, P237, DOI 10.1016/0140-6736(93)92324-M; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; Langner I, 2004, RADIAT ENVIRON BIOPH, V42, P247, DOI 10.1007/s00411-003-0214-7; Laurier D, 2001, HEALTH PHYS, V81, P272, DOI 10.1097/00004032-200109000-00009; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; Little MP, 2001, RADIAT RES, V156, P695, DOI 10.1667/0033-7587(2001)156[0695:TBEICC]2.0.CO;2; Little MP, 2002, INT J RADIAT BIOL, V78, P145, DOI 10.1080/09553000110095714; Little MP, 2002, INT J RADIAT BIOL, V78, P1001, DOI 10.1080/0955300021000013803; Little MP, 1999, RADIAT RES, V151, P218, DOI 10.2307/3579773; Little MP, 1997, INT J RADIAT BIOL, V71, P589, DOI 10.1080/095530097143923; Little MP, 1999, RADIAT RES, V152, P280, DOI 10.2307/3580328; LITTLE MP, 1990, HEALTH PHYS, V59, P765, DOI 10.1097/00004032-199012000-00001; Little MP, 2001, INT J RADIAT BIOL, V77, P431, DOI 10.1080/09553000010022634; Lubin JH, 2004, INT J CANCER, V109, P132, DOI 10.1002/ijc.11683; Lubin JH, 2003, RADIAT PROT DOSIM, V104, P315, DOI 10.1093/oxfordjournals.rpd.a006194; Lubin JH, 1997, J NATL CANCER I, V89, P49, DOI 10.1093/jnci/89.1.49; Lubin JH, 1998, JNCI-J NATL CANCER I, V90, P294, DOI 10.1093/jnci/90.4.294; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; Lubin JH, 1997, RADIAT RES, V147, P126, DOI 10.2307/3579412; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; McKenzie DR, 1998, AUST NZ J PUBL HEAL, V22, P360, DOI 10.1111/j.1467-842X.1998.tb01392.x; Michelozzi P, 2002, AM J EPIDEMIOL, V155, P1096, DOI 10.1093/aje/155.12.1096; Milan T, 2002, BRIT J DERMATOL, V147, P509, DOI 10.1046/j.1365-2133.2002.04870.x; Mohan AK, 2003, INT J CANCER, V103, P259, DOI 10.1002/ijc.10811; Mohan AK, 2002, J NATL CANCER I, V94, P943, DOI 10.1093/jnci/94.12.943; Morgan RW, 2000, EPIDEMIOLOGY, V11, P118, DOI 10.1097/00001648-200003000-00007; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Muirhead C. R., 1999, Journal of Radiological Protection, V19, P3, DOI 10.1088/0952-4746/19/1/002; Muirhead CR, 2003, OCCUP ENVIRON MED, V60, P165, DOI 10.1136/oem.60.3.165; National Council on Radiation Protection and Measurements [NCRP], 2001, 135 NCRP; Naumburg E, 2000, BMJ-BRIT MED J, V320, P282, DOI 10.1136/bmj.320.7230.282; *NCR COMM HLTH RIS, 1999, HLTH EFF EXP RAD BEI; *NCRP, 2001, 136 NCRP; [NCRP] National Council on Radiation Protection and Measurements, 1993, 115 NCRP; Nekolla EA, 2000, RADIAT RES, V153, P93, DOI 10.1667/0033-7587(2000)153[0093:IOMBTI]2.0.CO;2; Nicholas JS, 1998, J OCCUP ENVIRON MED, V40, P980, DOI 10.1097/00043764-199811000-00008; *NRC COMM BIOL EFF, 1990, HLTH EFF EXP LOW LEV; *NRPB, 1995, DOC NRPB, V6; NRPB, 1993, DOC NRPB; Omar RZ, 1999, BRIT J CANCER, V79, P1288, DOI 10.1038/sj.bjc.6690207; Parkin DM, 1996, BRIT J CANCER, V73, P1006, DOI 10.1038/bjc.1996.197; Pearce N, 1997, CANCER CAUSE CONTROL, V8, P139, DOI 10.1023/A:1018407927076; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; Pierce DA, 2003, RADIAT RES, V159, P511, DOI 10.1667/0033-7587(2003)159[0511:JEORAS]2.0.CO;2; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Pierce DA, 2000, RADIAT RES, V154, P178, DOI 10.1667/0033-7587(2000)154[0178:RRCRAL]2.0.CO;2; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; Preston RJ, 2003, J RADIOL PROT, V23, P263, DOI 10.1088/0952-4746/23/3/303; Puskin JS, 2003, HEALTH PHYS, V84, P526, DOI 10.1097/00004032-200304000-00012; Ron E, 1998, CANCER CAUSE CONTROL, V9, P393, DOI 10.1023/A:1008867617415; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RON E, 1994, RADIAT RES, V137, pS98, DOI 10.2307/3578894; ROONEY C, 1993, BRIT MED J, V307, P1391, DOI 10.1136/bmj.307.6916.1391; Rothman KJ, 2000, LANCET, V356, P1837, DOI 10.1016/S0140-6736(00)03244-X; Scotto J, 1996, CANC EPIDEMIOLOGY PR, P355; Shakhtarin VV, 2003, INT J EPIDEMIOL, V32, P584, DOI 10.1093/ije/dyg205; Shilnikova NS, 2003, RADIAT RES, V159, P787, DOI 10.1667/0033-7587(2003)159[0787:CMRAWA]2.0.CO;2; Shore RE, 2002, RADIAT RES, V157, P410, DOI 10.1667/0033-7587(2002)157[0410:SCAXRT]2.0.CO;2; Shu XO, 2002, CANCER EPIDEM BIOMAR, V11, P177; Sigurdson AJ, 2003, CANCER-AM CANCER SOC, V97, P3080, DOI 10.1002/cncr.11444; Simonsen LC, 2000, HEALTH PHYS, V79, P515, DOI 10.1097/00004032-200011000-00008; SKINNER J, 2000, BRIT J CANCER, V87, P1257; SORAHAN T, 1995, BRIT J OBSTET GYNAEC, V102, P831, DOI 10.1111/j.1471-0528.1995.tb10851.x; Steiner M, 1998, RADIAT ENVIRON BIOPH, V37, P87, DOI 10.1007/s004110050099; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; Stewart AM, 2000, INT J EPIDEMIOL, V29, P708, DOI 10.1093/ije/29.4.708; Straume T, 2003, NATURE, V424, P539, DOI 10.1038/nature01815; Takahashi T, 2003, J EPIDEMIOL, V13, P99, DOI 10.2188/jea.13.99; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Travis LB, 1996, J CLIN ONCOL, V14, P565, DOI 10.1200/JCO.1996.14.2.565; Travis LB, 2003, RADIAT RES, V160, P691, DOI 10.1667/RR3095; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; Travis LB, 2001, RADIAT RES, V156, P136, DOI 10.1667/0033-7587(2001)156[0136:MACAWO]2.0.CO;2; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT; Vajdic CM, 2003, INT J CANCER, V105, P117, DOI 10.1002/ijc.11057; van Leeuwen FE, 2003, JNCI-J NATL CANCER I, V95, P971, DOI 10.1093/jnci/95.13.971; Veierod MB, 2003, J NATL CANCER I, V95, P1530, DOI 10.1093/jnci/djg075; Wakeford R, 2003, INT J RADIAT BIOL, V79, P293, DOI 10.1080/0955300031000114729; Wang JX, 2002, HEALTH PHYS, V82, P455, DOI 10.1097/00004032-200204000-00004; Wang ZY, 2002, AM J EPIDEMIOL, V155, P554, DOI 10.1093/aje/155.6.554; Wei L, 2000, J Radiat Res, V41 Suppl, P1; WEISS HA, 1994, INT J CANCER, V59, P327, DOI 10.1002/ijc.2910590307; WEISS HA, 1995, RADIAT RES, V142, P1, DOI 10.2307/3578960; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WHELDON TE, 1989, J ROY STAT SOC A STA, V152, P327, DOI 10.2307/2983130; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; WHO World Health Organization, 1994, ENV HLTH CRIT, V160; Wick RR, 1999, RADIAT RES, V152, pS8, DOI 10.2307/3580103; Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845; Wing S, 1997, ENVIRON HEALTH PERSP, V105, P52, DOI 10.2307/3433062; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; Zeeb H, 2003, AM J EPIDEMIOL, V158, P35, DOI 10.1093/aje/kwg107	217	136	143	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6404	6428		10.1038/sj.onc.1207896	http://dx.doi.org/10.1038/sj.onc.1207896			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322514				2022-12-28	WOS:000223468800008
J	Hu, JT; Bianchi, F; Ferguson, M; Cesario, A; Margaritora, S; Granone, P; Goldstraw, P; Tetlow, M; Ratcliffe, C; Nicholson, AG; Harris, A; Gatter, K; Pezzella, F				Hu, JT; Bianchi, F; Ferguson, M; Cesario, A; Margaritora, S; Granone, P; Goldstraw, P; Tetlow, M; Ratcliffe, C; Nicholson, AG; Harris, A; Gatter, K; Pezzella, F			Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer	ONCOGENE			English	Article						lung cancer; angiogenesis; gene expression	LON PROTEASE; TUMOR-GROWTH; THROMBOSPONDIN-1; TRANSLATION; RELEVANCE; VEGF	Angiogenesis is regarded as essential for tumour growth. However, we have demonstrated that some other aggressive non-small-cell lung carcinomas (n-SCLC) do not have angiogenesis. In this study, using cDNA microarray analysis, we demonstrate that angiogenic and nonangiogenic tumour types can be distinguished by their gene expression profiles. Tissue samples from 42 n-SCLC patients were obtained with consent. In all, 12 tumours were nonangiogenic and 30 angiogenic. The two groups were matched by age, sex, smoking and tumour stage. Total RNAs were extracted followed by microarray hybridization and image scan procedure. Data were analysed using GeneSpring 5.1 software. A total of 62 genes were found to be able to separate angiogenic from nonangiogenic tumours. Nonangiogenic tumours have higher levels of genes concerned with mitochondrial metabolism, mRNA transcription, protein synthesis and the cell cycle. Angiogenic tumours have higher levels of genes coding for membrane vesicles, integrins, remodelling, angiogenesis and apoptosis. These results further support our first finding that nonangiogenic lung tumours are fast-growing tumours filling the alveoli in the absence of vascular remodelling. We raise the hypothesis that in nonangiogenic tumours, hypoxia leads to a higher activation of the mitochondrial respiratory chain, which allows tumour growth without triggering angiogenesis.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Canc Res UK,Tumour Pathol Grp, Oxford OX3 9DU, England; IFOM FIRC, Inst Mol Oncol, I-20139 Milan, Italy; Catholic Univ Rome, Dept Surg Sci, Div Thorac Surg, I-00168 Rome, Italy; Royal Brompton Hosp, Dept Thorac Surg, London SW3 6NP, England; Radcliffe Infirm, NTRAC Coordinating Ctr, Oxford OX2 6HE, England; Royal Brompton Hosp, Dept Histopathol, London SW3 6NP, England; Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England	Cancer Research UK; University of Oxford; IFOM - FIRC Institute of Molecular Oncology; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Royal Brompton Hospital; Radcliffe Infirmary; Royal Brompton Hospital; Cancer Research UK; University of Oxford	Pezzella, F (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Canc Res UK,Tumour Pathol Grp, Oxford OX3 9DU, England.	francesco.pezzella@cancer.org.uk	Bianchi, Fabrizio/B-5995-2017; Harris, Adrian L/ABA-3343-2020; Bianchi, Fabrizio/W-7037-2019; CESARIO, Alfredo/O-4215-2015	Bianchi, Fabrizio/0000-0001-7412-8638; Harris, Adrian L/0000-0003-1376-8409; Bianchi, Fabrizio/0000-0001-7412-8638; CESARIO, Alfredo/0000-0003-4687-0709				Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; GIL SG, 1994, J INVEST DERMATOL, V103, P31; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Miller LD, 2002, CANCER CELL, V2, P353, DOI 10.1016/S1535-6108(02)00181-2; Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015; Pastorino U, 1997, J CLIN ONCOL, V15, P2858, DOI 10.1200/JCO.1997.15.8.2858; Pezzella F, 1996, EUR J CANCER, V32A, P2494, DOI 10.1016/S0959-8049(96)00377-2; Pezzella F, 2000, LANCET, V355, P1787; Pezzella F, 1997, AM J PATHOL, V151, P1417; Smeitink J, 1998, HUM GENET, V103, P245, DOI 10.1007/s004390050813; Su JD, 2003, CANCER RES, V63, P3585; Van Coillie E, 2001, AM J PATHOL, V159, P1405, DOI 10.1016/S0002-9440(10)62527-8; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349	20	59	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1212	1219		10.1038/sj.onc.1208242	http://dx.doi.org/10.1038/sj.onc.1208242			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592519				2022-12-28	WOS:000226898700008
J	Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P				Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P			Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number	ONCOGENE			English	Article						mismatch repair; MLH1; recombination; reciprocal translocations; radiation	DOUBLE-STRAND BREAKS; COLORECTAL CANCERS; MICROSATELLITE INSTABILITY; HOMOLOGOUS RECOMBINATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; SOLID TUMORS; DNA-REPAIR; CARCINOMAS; INACTIVATION	An important anticarcinogenic function of the mismatch repair (MMR) system is its role in preventing recombination between similar, but nonidentical (homeologous) sequences, thus preventing chromosomal rearrangements. We recently identified a novel chromosomal instability (CIN) phenotype in an MMR defective colon cancer cell line (HCA7) characterized by an ongoing tendency to multiple reciprocal chromosomal translocations. To analyse the relation between MMR and chromosomal changes more closely, the HCA7 stem clone was divided into three stocks. The first was stably transfected with MLH1 expression plasmid, the second was regularly exposed to the demethylating agent 5-azacytidin to re-express the hypermethylated MLH1 gene, and the third was an unmanipulated control stock. All stocks were propagated in vitro for 55 - 80 passages and, furthermore, some of the early passages were irradiated to induce DNA double-strand breaks. Multiplex-fluorescent in situ hybridization (M-FISH) analysis showed that all three stocks acquired varying numbers of reciprocal translocations and other structural changes at some point. Interestingly, the control stock, which is MMR defective, maintained its numerical chromosomal stability, while some of the MMR-proficient clones showed additional numerical instability. Although the control stock was less sensitive to irradiation, its surviving clones showed marked stability of chromosome structure and number compared to the MMR-competent stocks. These results show that restoring MMR does not prevent the development of reciprocal translocations but rather predisposes cells to numerical CIN after irradiation. Thus, the accumulating data suggest that MMR defect may not be necessary for the development of reciprocal chromosomal translocations but might be permissive.	Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Pathol, Helsinki, Finland; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Med Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Wael-Abdel-Rahman@helsinki.fi	Lohi, Hannes/F-4596-2011	Lohi, Hannes/0000-0003-1087-5532; Peltomaki, Paivi/0000-0001-8819-2980; Abdel-Rahman, Wael/0000-0002-2149-1043	NATIONAL CANCER INSTITUTE [R01CA082282] Funding Source: NIH RePORTER; NCI NIH HHS [CA82282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bocker T, 1996, J PATHOL, V179, P15; Buermeyer AB, 1999, CANCER RES, V59, P538; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Deans B, 2003, CANCER RES, V63, P8181; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Harfe BD, 2000, MUTAT RES-FUND MOL M, V451, P151, DOI 10.1016/S0027-5107(00)00047-6; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kim NG, 2001, CANCER RES, V61, P36; Lambert B, 1998, MUTAT RES-FUND MOL M, V405, P161, DOI 10.1016/S0027-5107(98)00133-X; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Limoli CL, 2001, BRIT J CANCER, V84, P489, DOI 10.1054/bjoc.2000.1604; Moynahan ME, 2001, CANCER RES, V61, P4842; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Risinger JI, 1998, CANCER RES, V58, P2978; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsuji T, 2003, J GASTROENTEROL, V38, P1185, DOI 10.1007/s00535-003-1229-1; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yu VPCC, 2000, GENE DEV, V14, P1400	34	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					706	713		10.1038/sj.onc.1208129	http://dx.doi.org/10.1038/sj.onc.1208129			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580308				2022-12-28	WOS:000226420400018
J	Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF				Reddy, J; Shivapurkar, N; Takahashi, T; Parikh, G; Stastny, V; Echebiri, C; Crumrine, K; Zochbauer-Muller, S; Drach, J; Zheng, YY; Feng, ZD; Kroft, SH; McKenna, RW; Gazdar, AF			Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors	ONCOGENE			English	Article						cytokine signaling pathway; methylation; hematopoietic tumors	EPSTEIN-BARR-VIRUS; MONOCLONAL GAMMOPATHY; NEGATIVE REGULATOR; HYPERMETHYLATION; SHP1; EVENTS; SOCS-1; SYK; PCR	The perturbations of the cytokine signaling pathway play an important role in lymphoid/hematopoietic tumors. Aberrant promoter methylation is the major mechanism of gene silencing in tumors. We examined 150 lymphoid/ hematopoietic tumors or potential premalignant specimens, 55 control specimens and 12 EBV-transformed B lymphoblastoid cultures and 10 lymphoma/leukemia (L/L) or multiple myeloma ( MM) cell lines for the methylation ( and, in cell lines, of the expression status) of three genes involved in the cytokine signaling pathway. The genes were: SHP1, a protein tyrosine phosphatase; SYK, a protein kinase; and SOCS1, a suppressor of cytokine signaling. Our major findings were: ( 1) one or more of the three genes was frequently methylated in L/L and MM cell lines and there was good concordance ( 90 100%) between methylation and loss of gene expression; ( 2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 protein and downregulation of phosphorylated STAT3 in L/L cell lines; ( 3) all 55 control specimens and the lymphoblastoid cultures were negative for methylation of the three genes; ( 4) non-Hodgkin's lymphomas ( 100%), and leukemias (94%) had almost universal methylation of SHP1 and relatively less frequent (<30%) methylation of SOCS1 and SYK; ( 5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent methylation of SHP1 (<20%), and occasional methylation of SOCS1 and SYK; and ( 6) comparable methylation frequencies for SOCS1 were observed in MM and MGUS, suggesting that SOCS1 methylation is an early event in MM pathogenesis. At least one gene was methylated in 119 of 130 (93%) of the malignant and 12 of 20 (60%) of the MGUS samples. Our findings demonstrate that the perturbations of cytokine signaling via silencing of these three genes are almost universal in lymphoid/ hematopoietic tumors but the patterns of gene methylated for L/L and plasma cell dyscrasias are different.	UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; UT SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Hosp, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University Hospital Vienna; Fred Hutchinson Cancer Center	Gazdar, AF (corresponding author), UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu	Kroft, Steven/AAE-2543-2020; Zöchbauer-Müller, Sabine/B-8399-2012; Parikh, Gunjan/AAS-1375-2020	Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Parikh, Gunjan/0000-0002-8447-1349	NATIONAL CANCER INSTITUTE [U01CA084971] Funding Source: NIH RePORTER; NCI NIH HHS [5U01CA8497102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Chim CS, 2004, LEUKEMIA, V18, P356, DOI 10.1038/sj.leu.2403216; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Guillerm G, 2001, BLOOD, V98, P244, DOI 10.1182/blood.V98.1.244; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jebbink J, 2003, J MOL DIAGN, V5, P15, DOI 10.1016/S1525-1578(10)60446-1; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Krebs DL, 2000, J CELL SCI, V113, P2813; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kyle RA, 2003, BLOOD, V102, P3759, DOI 10.1182/blood-2003-03-0801; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Oka T, 2002, CANCER RES, V62, P6390; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yuan YF, 2001, CANCER RES, V61, P5558	25	48	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					732	736		10.1038/sj.onc.1208032	http://dx.doi.org/10.1038/sj.onc.1208032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580314				2022-12-28	WOS:000226420400021
J	Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R				Tamura, Y; Maruyama, M; Mishima, Y; Fujisawa, H; Obata, M; Kodama, Y; Yoshikai, Y; Aoyagi, Y; Niwa, O; Schaffner, W; Kominami, R			Predisposition to mouse thymic lymphomas in response to ionizing radiation depends on variant alleles encoding metal-responsive transcription factor-1 (Mtf-1)	ONCOGENE			English	Article						cancer susceptibility; lymphoma; positional cloning; gamma-radiation; radical scavenger	PLACENTAL GROWTH-FACTOR; TUMOR-SUSCEPTIBILITY; HOMOZYGOUS DELETIONS; GENETIC DISSECTION; POINT MUTATIONS; COMPLEX TRAITS; CANDIDATE; LOCUS; MICE; MODIFIER	Genetic predisposition to cancers is significant to public health because a high proportion of cancers probably arise in a susceptible human subpopulation. Using a mouse model of gamma-ray-induced thymic lymphomas, we performed linkage analysis and haplotype mapping that suggested Mtf-1, metal-responsive transcription factor-1 (Mtf-1), as a candidate lymphoma susceptibility gene. Sequence analysis revealed a polymorphism of Mtf-1 that alters the corresponding amino acid at position 424 in the proline-rich domain from a serine in susceptibility strains to proline in resistant strains. The transcriptional activity of Mtf-1 encoding serine and proline was compared by transfecting the DNA to Mtf-1-null cells, and the change to proline conferred a higher metal responsiveness in transfections. Furthermore, the resistant congenic strains possessing the Mtf-1 allele of proline type exhibited higher radiation inducibility of target genes than susceptible background strains having the Mtf-1 allele of serine type. Since products of the targets such as metallothionein are able to suppress cellular stresses generated by irradiation, these results suggest that highly inducible strains having Mtf-1 of proline type are refractory to radiation effects and hence are resistant to lymphoma development.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Niigata 9518122, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Niigata University; Niigata University; Kyoto University; University of Zurich	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Asahimachi 1-757, Niigata 9518122, Japan.	rykomina@med.niigata-u.ac.jp		Maruyama, Masaki/0000-0002-9534-4652				Adini A, 2002, CANCER RES, V62, P2749; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demant P, 1992, Semin Cancer Biol, V3, P159; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; Hellsten E, 2001, DEV BIOL, V240, P641, DOI 10.1006/dbio.2001.0476; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KOROPATNICK J, 1989, RADIAT RES, V119, P356, DOI 10.2307/3577626; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lichtlen P, 2001, BIOESSAYS, V23, P1010, DOI 10.1002/bies.1146; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sato H, 2003, CANCER SCI, V94, P668, DOI 10.1111/j.1349-7006.2003.tb01500.x; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Smirnova IV, 2000, J BIOL CHEM, V275, P9377, DOI 10.1074/jbc.275.13.9377; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Wang Y, 2004, FASEB J, V18, P1071, DOI 10.1096/fj.03-1282com; Wright AF, 2001, GENOME BIOL, V2; Zhang H, 2003, CURR BIOL, V13, P1625, DOI 10.1016/j.cub.2003.08.054	42	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					399	406		10.1038/sj.onc.1208197	http://dx.doi.org/10.1038/sj.onc.1208197			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516976				2022-12-28	WOS:000226279700011
J	Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS				Kaur, GP; Reddy, DE; Zimonjic, DB; de Riel, JK; Athwal, RS			Functional identification of a BAC clone from 16q24 carrying a senescence gene SEN16 for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; BAC contig; BAC transfer; functional complementation	CHROMOSOME ARM 16Q; TUMOR-SUPPRESSOR GENE; CARCINOMA IN-SITU; ALLELIC IMBALANCE; HETEROZYGOSITY REGION; CELLULAR SENESCENCE; FREQUENT LOSS; DELETION; PHENOTYPE; WFDC1	We have identified an 85 kb BAC clone, 346J21, that carries a cell senescence gene (SEN16), previously mapped to 16q24.3. Transfer and retention of 346J21 in breast cancer cell lines leads to growth arrest after 8-10 cell doublings, accompanied by the appearance of characteristic senescent cell morphology and senescence-associated acid beta-galactosidase activity. Loss of transferred BAC results in reversion to the immortal growth phenotype of the parental cancer cell lines. BAC 346J21 restores senescence in the human breast cancer cell lines, MCF.7 and MDA-MB468, and the rat mammary tumor cell line LA7, but not in the human glioblastoma cell line T98G. We postulate that inactivation of both copies of SEN16 is required for the immortalization of breast epithelial cells at an early stage of tumorigenesis. Positional mapping of 346J21 shows that SEN16 is distinct from other candidate tumor suppressor genes reported at 16q24.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.	pkaur001@temple.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, R01CA074983, ZIABC010038] Funding Source: NIH RePORTER; NCI NIH HHS [CA74983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; Bando K, 2000, GENE CHROMOSOME CANC, V28, P38, DOI 10.1002/(SICI)1098-2264(200005)28:1<38::AID-GCC5>3.0.CO;2-A; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Callen DF, 2002, CANCER GENET CYTOGEN, V133, P76, DOI 10.1016/S0165-4608(01)00565-9; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; Chin RK, 1998, CANCER GENET CYTOGEN, V103, P155, DOI 10.1016/S0165-4608(97)00407-X; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Godfrey TE, 1997, CANCER GENET CYTOGEN, V98, P36, DOI 10.1016/S0165-4608(96)00392-5; Hansen LL, 2002, CANCER GENET CYTOGEN, V139, P1, DOI 10.1016/S0165-4608(02)00620-9; Hansen LL, 1998, CANCER RES, V58, P2166; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1974, J AM GERIATR SOC, V22, P1; Huang Y, 2001, MOL BIOL REP, V28, P185, DOI 10.1023/A:1015726217890; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Kawakami M, 1999, INT J ONCOL, V15, P715; Kochetkova M, 2002, CANCER RES, V62, P4599; LAKHANI SR, 1995, J CLIN PATHOL, V48, P611, DOI 10.1136/jcp.48.7.611; Larsen M, 2000, MAMM GENOME, V11, P767, DOI 10.1007/s003350010135; LINDBLOM A, 1993, CANCER RES, V53, P3707; Mejia JE, 1997, GENOME RES, V7, P179, DOI 10.1101/gr.7.2.179; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Powell JA, 2002, GENOMICS, V80, P303, DOI 10.1006/geno.2002.6828; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 2000, ONCOGENE, V19, P217, DOI 10.1038/sj.onc.1203264; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Saffroy R, 2002, EUR J HUM GENET, V10, P239, DOI 10.1038/sj.ejhg.5200795; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; Sato M, 1998, GENE CHROMOSOME CANC, V22, P1; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; TSUDA H, 1994, CANCER RES, V54, P513; Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V82, P1, DOI 10.1016/0165-4608(95)91129-7	44	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					47	54		10.1038/sj.onc.1208175	http://dx.doi.org/10.1038/sj.onc.1208175			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558027				2022-12-28	WOS:000226125800007
J	Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas	ONCOGENE			English	Article						gliomas; invasion; cathepsin and uPAR; RNA interference; angiogenesis	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; CYSTEINE PROTEINASE-INHIBITORS; IN-VIVO; UROKINASE RECEPTOR; CYSTATIN-C; TISSUE INHIBITORS; COLORECTAL-CANCER; MICE; LOCALIZATION	RNA interference (RNAi) provides a powerful method for gene silencing in eukaryotic cells, including proliferating mammalian cells. Here, we determined whether RNAi could be utilized to inhibit the expression of proteases implicated in the extracellular matrix degradation, which is characteristic of tumor progression. We have previously shown that antisense stable clones of uPAR and cathepsin B were less invasive and did not form tumors when injected intracranially ex vivo. Since antisense-mediated gene silencing does not completely inhibit the translation of target mRNA and high molar concentrations of antisense molecules are required to achieve gene silencing, we used the RNAi approach to silence uPAR and cathepsin B in this study. We found that the expression of double-stranded RNA leads to the efficient and specific inhibition of endogenous uPAR and cathepsin B protein expression in glioma cell lines as determined by Western blotting. We also found the RNAi of uPAR and cathepsin B reduces glioma cell invasion and angiogenesis in in vitro and in vivo models. Intratumoral injections of plasmid vectors expressing hpRNA for uPAR and cathepsin B resulted in the regression of pre-established intracranial tumors. Further, RNAi for uPAR and cathepsin B inhibited cell proliferation and reduced the levels of pERK and pFAK compared to controls. Taken together, our findings indicate for the first time that RNAi operates in human glioma cells with potential application for cancer gene therapy.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216, CA 92393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Alonso DF, 1998, ANTICANCER RES, V18, P4499; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Evens DM, 1998, CLIN EXP METASTAS, V16, P353; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hazen LGM, 2000, J HISTOCHEM CYTOCHEM, V48, P1421, DOI 10.1177/002215540004801012; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; Kisker O, 2001, CANCER RES, V61, P7669; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kos J, 2000, CLIN CANCER RES, V6, P505; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; LEUNIG M, 1992, CANCER RES, V52, P6553; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McGuire PG, 2003, INVEST OPHTH VIS SCI, V44, P2736, DOI 10.1167/iovs.02-1160; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 2002, ONCOGENE, V21, P7824, DOI 10.1038/sj.onc.1205893; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Planus E, 1997, J CELL SCI, V110, P1091; REDWOOD SM, 1992, CANCER, V69, P1212; REMPEL SA, 1994, CANCER RES, V54, P6027; Reuning U, 1998, INT J ONCOL, V13, P893; Sato S, 2002, FEBS LETT, V528, P212, DOI 10.1016/S0014-5793(02)03311-2; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; SINHA AA, 1995, PROSTATE, V26, P171, DOI 10.1002/pros.2990260402; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Vallera DA, 2002, J NATL CANCER I, V94, P597; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	57	121	138	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8486	8496		10.1038/sj.onc.1207879	http://dx.doi.org/10.1038/sj.onc.1207879			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378018				2022-12-28	WOS:000224870700009
J	Vanhecke, D; Janitz, M				Vanhecke, D; Janitz, M			High-throughput gene silencing using cell arrays	ONCOGENE			English	Article						RNA interference; microarray; reverse transfection; cell array	SMALL INTERFERING RNAS; DROSOPHILA CULTURED-CELLS; DOUBLE-STRANDED-RNA; GENOME-WIDE RNAI; MAMMALIAN-CELLS; CAENORHABDITIS-ELEGANS; EXPRESSION; MICROARRAYS; APOPTOSIS; IDENTIFICATION	A recently established transfected cell array (TCA) technology has opened new experimental dimensions in the field of functional genomics. Cell arrays allow for transfection of several thousands different DNA molecules in microarray format. The effects of overexpression of hundreds of proteins on cellular physiology can be observed in a single experiment. The TCA technique has also found its application in RNA interference (RNAi) research. Small interfering RNAs (siRNA) as well as plasmid expressing short hairpin RNAs can be transferred into the cells through the process of reverse transfection. The silencing of numerous genes in spatially separated manner can be thus monitored. This review will provide an overview on current concepts concerning combination of cell array and RNAi for high-throughput loss-of-function studies.	Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany	Max Planck Society	Janitz, M (corresponding author), Max Planck Inst Mol Genet, Dept Vertebrate Genom, Fabeckstr 60-62, D-14195 Berlin, Germany.	janitz@molgen.mpg.de	Janitz, Michael/E-9823-2015	Janitz, Michael/0000-0002-4878-0259				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cerutti H, 2003, TRENDS GENET, V19, P39, DOI 10.1016/S0168-9525(02)00010-0; Chang FH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh029; Colosimo A, 2000, BIOTECHNIQUES, V29, P314, DOI 10.2144/00292rv01; Crnkovic-Mertens I, 2003, ONCOGENE, V22, P8330, DOI 10.1038/sj.onc.1206973; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dieterich C, 2003, NUCLEIC ACIDS RES, V31, P55, DOI 10.1093/nar/gkg007; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mishina YM, 2004, J BIOMOL SCREEN, V9, P196, DOI 10.1177/1087057103261880; MIYAGISHI M, 2002, NUCL ACIDS RES S, V2, P113; Mousses S, 2003, GENOME RES, V13, P2341, DOI 10.1101/gr.1478703; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Price JH, 2002, J CELL BIOCHEM, P194, DOI 10.1002/jcb.10448; REDMOND TM, 2004, MOL CELL PROTEOMICS; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; van Huijsduijnen RH, 2002, DRUG DISCOV TODAY, V7, P1013, DOI 10.1016/S1359-6446(02)02438-8; VANHECKE D, 2004, IN PRESS ENCY REFERE; Wang JC, 2004, J BIOL CHEM, V279, P29270, DOI 10.1074/jbc.M401242200; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WOLF DE, 2003, METHOD CELL BIOL, V73, P319; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Yoshikawa T, 2004, J CONTROL RELEASE, V96, P227, DOI 10.1016/j.jconrel.2004.01.024; Zemanova L, 2003, DRUG DISCOV TODAY, V8, P1085, DOI 10.1016/S1359-6446(03)02833-2; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	59	40	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8353	8358		10.1038/sj.onc.1208027	http://dx.doi.org/10.1038/sj.onc.1208027			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517016	Bronze			2022-12-28	WOS:000224815900005
J	Ayrault, O; Andrique, L; Larsen, CJ; Seite, P				Ayrault, O; Andrique, L; Larsen, CJ; Seite, P			Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes	ONCOGENE			English	Article						p14(ARF); Topo I; chromatin; ChIP; rRNA genes	DNA TOPOISOMERASE-I; NUCLEAR-MATRIX; CELL-LINES; P53; TRANSCRIPTION; P19(ARF); MDM2; PROTEINS; STABILIZATION; BIOGENESIS	The tumor suppressor Arf (Alternative Reading Frame) protein (p14(ARF) in human and p19(ARF) in mouse) is mainly located in the nucleolus consistent with its subcellular localization, the protein has been shown to specifically interact with 5.8S rRNA and with B23/Nucleophosmin and to regulate ribosome biogenesis. Here, we show that the p14(ARF) protein interacts with chromatin and is recovered by chromatin immunoprecipitation (ChIP) in a fraction that contains a DNA sequence of the rRNA gene promoter. In addition, topoisomerase I (Topo I) that has been shown to interact with p14(ARF) coprecipitates with p14(ARF) containing chromatin. These data, in view of the function for Topo I in rRNA transcription, are consistent with a role for the p14(ARF)-Topo I complex in rRNA transcription and/or maturation.	Lab Oncol Mol EA 3805, F-86022 Poitiers, France		Seite, P (corresponding author), Lab Oncol Mol EA 3805, Pole Biol SAnte 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; QUELLE DE, 1995, CELL, V83, P993; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SMITH HC, 1987, BIOCHEM GENET, V25, P863, DOI 10.1007/BF00502606; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	34	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8097	8104		10.1038/sj.onc.1207968	http://dx.doi.org/10.1038/sj.onc.1207968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361825				2022-12-28	WOS:000224692500007
J	Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F				Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F			HIV-Tat promotes cellular proliferation and inhibits NGF-induced differentiation through mechanisms involving Id1 regulation	ONCOGENE			English	Article						HIV-1 TAT; NGF; neuronal signaling; Id1	LOOP-HELIX PROTEIN; NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; DNA-BINDING; MYELOID DIFFERENTIATION; NEURONAL APOPTOSIS; SIGNALING PATHWAYS; ACTIVATION; RECEPTOR	Id1 is a helix - loop - helix transcriptional factor that controls growth and survival of neuronal cells. Downregulation of Id1 expression is required to initiate differentiation and cell-cycle withdrawal in primary neuronal culture as well as in PC12 cells. The HIV-1 transactivating factor, Tat, has been suspected of causing neuronal dysfunction that often leads to the development of HIV-associated dementia in AIDS patients. We found that the expression of Tat in PC12 cells promotes serum-independent growth, formation of large colonies in soft agar, and the acceleration of tumor growth in nude mice. In addition, Tat showed the ability to inhibit the nerve growth factor (NGF)-induced neuronal differentiation of PC12 cells. Our results show that the Tat-mediated signaling events, which lead to serum-independent growth and the inhibition of NGF-induced differentiation, have a common cellular target: the upregulation of Id1 expression. In the absence of NGF, expression of Id1 is required to promote serum-independent proliferation of PC12/Tat cells, as the inhibition of Id1 by antisense DNA restored the serum-dependent growth of PC12/Tat cells. In the presence of NGF, Tat utilizes an additional pathway that involves phosphorylation of Stat5a, to upregulate Id1 expression and block neuronal cell differentiation. Suppression of Stat5a by use of its dominant-negative mutant reversed the transient expression of Id1 and the blockage of NGF-mediated differentiation in PC12/Tat cells. Finally, the treatment of PC12 cells with recombinant Tat also enhanced the NGF-induced Id1 expression, further pointing to Id1 as a target for Tat. Taken together, these studies suggest additional targets for Tat action in neuronal cells and provide new insights into the mechanisms involved in the dysregulation of neuronal functions.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Fdn Don C Gnocchi, Milan, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; IRCCS Fondazione Don Carlo Gnocchi Onlus	Peruzzi, F (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 12th North St, Philadelphia, PA 19122 USA.	fperuzzi@temple.edu	Peruzzi, Francesca/M-9804-2014; delbue, serena/A-1145-2010	Delbue, Serena/0000-0002-3199-9369				Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Borgatti P, 1998, BIOCHEM BIOPH RES CO, V242, P332, DOI 10.1006/bbrc.1997.7877; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Bovolenta C, 2002, J IMMUNOL, V169, P4443, DOI 10.4049/jimmunol.169.8.4443; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cai L, 2000, DEVELOPMENT, V127, P3021; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Cantaluppi V, 2001, AIDS RES HUM RETROV, V17, P965, DOI 10.1089/088922201750290087; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI F, 1994, VIROLOGY, V200, P668, DOI 10.1006/viro.1994.1230; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; Israel MA, 1999, CANCER RES, V59, p1726S; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Lin CQ, 2000, CANCER RES, V60, P1332; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; MIN X, 2003, EMBO J, V22, P893; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x; Recio JA, 1997, J BIOL CHEM, V272, P26807, DOI 10.1074/jbc.272.43.26807; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, CLIN CANCER RES, V7, P2134; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; Seve M, 1999, ARCH BIOCHEM BIOPHYS, V361, P165, DOI 10.1006/abbi.1998.0942; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; Wang JY, 2003, VIROLOGY, V305, P66, DOI 10.1006/viro.2002.1690; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823; Zhong HY, 2001, LIFE SCI, V68, P2269, DOI 10.1016/S0024-3205(01)01015-3	59	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7701	7711		10.1038/sj.onc.1207828	http://dx.doi.org/10.1038/sj.onc.1207828			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361847				2022-12-28	WOS:000224306700011
J	Petroziello, J; Yamane, A; Westendorf, L; Thompson, M; McDonagh, C; Cerveny, C; Law, CL; Wahl, A; Carter, P				Petroziello, J; Yamane, A; Westendorf, L; Thompson, M; McDonagh, C; Cerveny, C; Law, CL; Wahl, A; Carter, P			Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer	ONCOGENE			English	Review						non-small-cell lung cancer; subtractive hybridization; expression profiling; quantitative PCR	TUMOR-TRANSFORMING GENE; RIBOSOMAL-PROTEIN; BINDING-PROTEIN; MOLECULAR-CLONING; BREAST-CANCER; HUMAN HOMOLOG; PULMONARY ADENOCARCINOMAS; THIOREDOXIN REDUCTASE; CDNA MICROARRAYS; HUMAN CARCINOMAS	Expression array data for >3000 individual clones from two suppression subtractive hybridization libraries revealed 147 genes overexpressed in non-small-cell lung cancer (NSCLC) cell lines. Of these 147 genes, 30 genes have previously unknown cancer association and 65 genes have been associated with cancers other than NSCLC. The identification of 52 genes previously associated with NSCLC by different methodologies supports the validity of the strategy used here. Of the 147 genes, 19 have no prior named Unigene cluster designation, and are designated herein as L1 to L19. Quantitative real-time PCR and cancer pro. ling arrays were used as independent validation tools to confirm tumor overexpression for five of the 'L' genes in tumor cell lines and patient samples from NSCLC and other cancers. Follow-up studies for candidate NSCLC-associated genes can be useful in providing valuable insight into the etiology of lung cancer as well as providing potentially interesting diagnostic or therapeutic targets for further investigation.	Seattle Genet Inc, Dept Antibody Technol, Bothell, WA 98021 USA; Seattle Genet Inc, Dept Biochem, Bothell, WA 98021 USA	Seattle Genetics; Seattle Genetics	Carter, P (corresponding author), Seattle Genet Inc, Dept Antibody Technol, 21823 30th St SE, Bothell, WA 98021 USA.	pcarter@seagen.com						Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Balsara BR, 1997, CANCER RES, V57, P2116; Bangur CS, 2002, ONCOGENE, V21, P3814, DOI 10.1038/sj.onc.1205480; BARR LF, 1991, CANCER RES, V51, P5514; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bennett KL, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046925; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chambers AF, 1996, LUNG CANCER-J IASLC, V15, P311, DOI 10.1016/0169-5002(95)00595-1; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; CORSON JM, 1982, AM J PATHOL, V108, P80; Cribier B, 2001, BRIT J DERMATOL, V144, P977, DOI 10.1046/j.1365-2133.2001.04185.x; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Dalerba P, 2001, INT J CANCER, V93, P85, DOI 10.1002/ijc.1307; DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218; DeRisi J, 1996, NAT GENET, V14, P457; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Echchakir H, 2001, CANCER RES, V61, P4078; FAITH A, 1992, CLIN EXP IMMUNOL, V87, P272; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Fujii T, 2002, CANCER RES, V62, P3340; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GALEOTTI T, 1970, European Journal of Biochemistry, V17, P485, DOI 10.1111/j.1432-1033.1970.tb01191.x; GANAPATHI R, 1988, BRIT J CANCER, V58, P335, DOI 10.1038/bjc.1988.214; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garcia-Lora A, 2003, INT J CANCER, V106, P521, DOI 10.1002/ijc.11241; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; HEINRICH PC, 1976, CANCER RES, V36, P3189; HENRY JL, 1993, CANCER RES, V53, P1403; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360, DOI 10.1165/ajrcmb.22.3.3845; Jaju RJ, 1999, BLOOD, V94, P773; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Ji SJ, 2003, NUCLEIC ACIDS RES, V31, P2534, DOI 10.1093/nar/gkg358; Jiang HP, 1997, ONCOGENE, V14, P473, DOI 10.1038/sj.onc.1200858; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATAGIRI A, 1993, BRIT J CANCER, V68, P125, DOI 10.1038/bjc.1993.299; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Le Roux LG, 2003, J VIROL, V77, P2330, DOI 10.1128/JVI.77.4.2330-2337.2003; Lewis BC, 2000, CANCER RES, V60, P6178; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; LOY TS, 1994, AM J CLIN PATHOL, V102, P764, DOI 10.1093/ajcp/102.6.764; Maeda T, 2003, J HEPATOL, V38, P615, DOI 10.1016/S0168-8278(03)00052-7; Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518; MARANGOS PJ, 1982, CANCER LETT, V15, P67, DOI 10.1016/0304-3835(82)90077-5; Matsuda S, 2000, CANCER RES, V60, P13; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Morino M, 1994, In Vivo, V8, P285; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Niehans GA, 1996, AM J PATHOL, V149, P129; Oshita F, 2002, ANTICANCER RES, V22, P1065; Palackal NT, 2002, J BIOL CHEM, V277, P24799, DOI 10.1074/jbc.M112424200; Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; PONNAZHAGAN S, 1992, PIGM CELL RES, V5, P155, DOI 10.1111/j.1600-0749.1992.tb00453.x; Porkka KP, 2001, J PATHOL, V193, P73, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH751>3.0.CO;2-Y; Rao S, 2001, BIOCHEMISTRY-US, V40, P2096, DOI 10.1021/bi002323d; Rattner JB, 1997, CLIN INVEST MED, V20, P308; Redondo M, 1998, EUR J IMMUNOGENET, V25, P385, DOI 10.1046/j.1365-2370.1998.00116.x; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Robert C, 1999, CLIN CANCER RES, V5, P2094; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salicioni AM, 2000, GENOMICS, V69, P54, DOI 10.1006/geno.2000.6315; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schraml P, 1997, CANCER RES, V57, P3669; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; SILINI EM, 1994, VIRCHOWS ARCH, V424, P367; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Soria JC, 2000, CANCER RES, V60, P4000; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Su AI, 2001, CANCER RES, V61, P7388; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Suzuki T, 1996, BIOCHEM BIOPH RES CO, V219, P708, DOI 10.1006/bbrc.1996.0299; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANAKA M, 1995, CANCER LETT, V89, P195, DOI 10.1016/0304-3835(94)03687-E; Tarantul VZ, 2000, AIDS RES HUM RETROV, V16, P173, DOI 10.1089/088922200309511; Tarazona R, 2000, J IMMUNOL, V165, P6776, DOI 10.4049/jimmunol.165.12.6776; Taxman DJ, 2003, CANCER RES, V63, P5095; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; TONIN PN, 1989, ONCOGENE, V4, P1117; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; TSYBIKOVA EB, 1996, VESTN ROS AKAD MED+, V12, P3; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG NS, 1992, ULTRASTRUCT PATHOL, V16, P439, DOI 10.3109/01913129209057829; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yan-Sanders Y, 2002, CANCER LETT, V183, P215, DOI 10.1016/S0304-3835(02)00168-4; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Yasuda M, 1999, CANCER RES, V59, P533; Yazawa T, 2003, PATHOL INT, V53, P58, DOI 10.1046/j.1440-1827.2003.01428.x; Yoshida Y, 2003, CANCER RES, V63, P3729; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Yu Q, 1997, BIOCHEMISTRY-US, V36, P5868, DOI 10.1021/bi962400y; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156	124	62	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7734	7745		10.1038/sj.onc.1207921	http://dx.doi.org/10.1038/sj.onc.1207921			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334068				2022-12-28	WOS:000224306700015
J	Shinohara, S; Rothstein, JL				Shinohara, S; Rothstein, JL			Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells	ONCOGENE			English	Article						inflammation; interleukin 24; Mda7; RET/PTC; thyroid	DIFFERENTIATION-ASSOCIATED GENE; PAPILLARY THYROID-CARCINOMA; HUMAN-MELANOMA DIFFERENTIATION; LYMPHOCYTIC THYROIDITIS; TYROSINE KINASE; SUPPRESSOR GENE; BRAF MUTATIONS; IN-VITRO; CANCER; EXPRESSION	Thyroid cancers, like hematological malignancies, are commonly associated with chromosomal translocations leading to the formation of fusion proteins. Through altered signaling by fusion proteins, cell death and survival pathways are disrupted and the physiological balance of cell - cell communication may be lost. A consequence of this disruption is the release of factors by stressed cells that alert the host. One type of host response is leukocytic infiltration that may develop into chronic inflammation or autoimmune disease. Although inflammation can be associated with neoplastic tissue, the mechanism driving this process is largely unknown. Therefore, to address the mechanism of cancer inflammation we investigated the effects of an oncogene in a murine model system. A comprehensive genetic analysis revealed several soluble factors that were induced by RET/papillary thyroid carcinoma (PTC) 3 gene expression including several proinflammatory cytokines, chemokines and immunologically relevant costimulatory molecules. Following a large genetic screen using RP3-expressing thyroid cells, we identified a highly abundant transcript and later identified it as interleukin 24 (Il24), a cytokine with diverse tumor suppressor and inflammatory activities. We show that RET/PTC3 induces Il24 expression in rat thyrocytes and that this expression is dependent on the signaling properties of its tyrosine kinase. Likewise, RET/PTC3 induces large amounts of Il24 following expression in murine thyrocytes, but its expression is dramatically reduced in poorly differentiated carcinomas, a finding that parallels the loss of RET/PTC3 expression. Consistent with its behavior as a tumor suppressor, the loss of Il24 coincided with the loss of RET/PTC3 in poorly differentiated mouse tumors. A functional role of Il24 in the autocrine growth/survival of RET/PTC3-expressing thyroid cells was identified helping to support its role in cellular transformation. These data suggest that the induction of Il24 by oncogenes may support tumor growth at the early stages of cancer.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	jay.rothstein@jefferson.edu	Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091	NCI NIH HHS [CA-76259, T32-CA09678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, T32CA009678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aust G, 1996, EXP CLIN ENDOCR DIAB, V104, P64, DOI 10.1055/s-0029-1211705; Basolo F, 1998, CLIN CANCER RES, V4, P381; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; DAILEY ME, 1955, AMA ARCH SURG, V70, P271; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; JHIANG SM, 1992, ONCOGENE, V7, P1331; Jiang HP, 1995, ONCOGENE, V11, P2477; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kimura ET, 2003, CANCER RES, V63, P1454; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; OTT RA, 1987, AM SURGEON, V53, P442; PASQUALE D, 2001, HUM PATHOL, V32, P24; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell DJ, 1998, CANCER RES, V58, P5523; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Ramesh R, 2003, CANCER RES, V63, P5105; Rasmussen AK, 2000, DAN MED BULL, V47, P94; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Russell JP, 2004, J IMMUNOL, V172, P4059, DOI 10.4049/jimmunol.172.7.4059; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sarkar D, 2002, BIOTECHNIQUES, P30; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Soo C, 1999, J CELL BIOCHEM, V74, P1; Stassi G, 2003, CANCER RES, V63, P6784; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI K, 1995, PATHOL INT, V45, P366, DOI 10.1111/j.1440-1827.1995.tb03470.x; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Winterrowd GE, 1999, J IMMUNOL METHODS, V226, P105, DOI 10.1016/S0022-1759(99)00049-6; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; YOSHIDA M, 1992, CANCER RES, V52, P464; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	52	29	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7571	7579		10.1038/sj.onc.1207964	http://dx.doi.org/10.1038/sj.onc.1207964			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326486				2022-12-28	WOS:000224176500014
J	Frattini, M; Ferrario, C; Bressan, P; Balestra, D; De Cecco, L; Mondellini, P; Bongarzone, I; Collini, P; Gariboldi, M; Pilotti, S; Pierotti, MA; Greco, A				Frattini, M; Ferrario, C; Bressan, P; Balestra, D; De Cecco, L; Mondellini, P; Bongarzone, I; Collini, P; Gariboldi, M; Pilotti, S; Pierotti, MA; Greco, A			Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer	ONCOGENE			English	Article						papillary thyroid cancer; BRAF mutation; RET and TRK rearrangement	HIGH PREVALENCE; MICROARRAY DATA; CARCINOMAS; TUMORS; ACTIVATION	Papillary thyroid carcinoma (PTC) is associated with RET and NTRK1 rearrangements and BRAF mutations. A series of 60 PTCs collected in a single center from Italian patients were histologically re-examined and subclassified as well differentiated or tall cell variant. The sample collection was analysed for the presence of all the reported PTC-associated genetic alterations through DNA or cDNA amplification, followed by automated sequencing. The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant. Oncogenic rearrangements of RET and NTRK1 receptors were found in 33 and 5% of cases, respectively. No Ras mutations were detected. Overall, genetic alterations were detected in two-thirds of samples, and in no single case more than one mutational event was found simultaneously. Gene expression pro. ling of a subset of 31 tumors performed using cDNA microarray chips showed no strong differences in global gene expression among the different cases. However, a supervised analysis of the obtained data identified a subset of genes differentially expressed in tumors carrying BRAF mutation or RTK rearrangement.	Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Pathol Expt Mol Pathol, I-20133 Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; angela.greco@istitutotumori.mi.it	Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022; De Cecco, Loris/K-7036-2016; Collini, Paola/K-7354-2016; Bongarzone, Italia/B-9544-2017; Gariboldi, Manuela/K-4744-2016	Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; De Cecco, Loris/0000-0002-7066-473X; Collini, Paola/0000-0002-6158-210X; Bongarzone, Italia/0000-0003-2530-9170; Gariboldi, Manuela/0000-0001-8406-165X				Bunone G, 2000, CANCER RES, V60, P2845; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DECECCO L, 2004, IN PRESS ONCOGENE; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kehlen A, 2004, INT J CANCER, V109, P833, DOI 10.1002/ijc.20022; Kimura ET, 2003, CANCER RES, V63, P1454; Klugbauer S, 1995, ONCOGENE, V11, P2459; Knauf JA, 2002, J CLIN ENDOCR METAB, V87, P2150, DOI 10.1210/jc.87.5.2150; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PILOTTI S, 1995, SEMIN DIAGN PATHOL, V12, P249; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Xu XL, 2003, CANCER RES, V63, P4561; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	22	210	225	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7436	7440		10.1038/sj.onc.1207980	http://dx.doi.org/10.1038/sj.onc.1207980			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15273715				2022-12-28	WOS:000224021400014
J	Nakshatri, H; Rice, SE; Bhat-Nakshatri, P				Nakshatri, H; Rice, SE; Bhat-Nakshatri, P			Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase	ONCOGENE			English	Article						parthenolide; TRAIL; apoptosis; JNK; NF-kappa B; breast cancer	KAPPA-B ACTIVATION; SESQUITERPENE LACTONE PARTHENOLIDE; ALPHA-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; GROWTH-FACTOR RECEPTOR; MEDIATED APOPTOSIS; DEATH RECEPTORS; SIGNAL-TRANSDUCTION; SERINE-PROTEASE; IN-VIVO	The antitumor activity of the sesquiterpene lactone parthenolide, an active ingredient of medicinal plants, is believed to be due to the inhibition of DNA binding of transcription factors NF-kappaB and STAT-3, reduction in MAP kinase activity and the generation of reactive oxygen. In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), which is independent of inhibition of NF-kappaB DNA binding and generation of reactive oxygen species. Parthenolide reversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Cancer cells treated with a combination of TRAIL and parthenolide underwent massive typical apoptosis and atypical apoptosis involving the loss of plasma membrane integrity. JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. Cytochrome c but not Smac/DIABLO was released from the mitochondria in cells treated with parthenolide alone. Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis ( XIAP). Enhanced XIAP cleavage correlated with increased and prolonged caspase 3 activity and PARP cleavage, suggesting that the sensitization to TRAIL involves 'feed forward' activation of caspase 3. These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels.	Indiana Univ, Sch Med, Dept Surg, Indiana Canc Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Univ, Sch Med, Dept Surg, Indiana Canc Res Inst, 1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu	Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Nakshatri, Harikrishna/0000-0001-8876-0052	NCI NIH HHS [R01-CA89153] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berman PA, 1997, FREE RADICAL BIO MED, V22, P1283, DOI 10.1016/S0891-5849(96)00508-4; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Eid MA, 2002, INT J ONCOL, V21, P111; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hell K, 2003, CELL DEATH DIFFER, V10, P1234, DOI 10.1038/sj.cdd.4401298; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pozarowski P, 2003, CYTOM PART A, V54A, P118, DOI 10.1002/cyto.a.10057; Pozarowski P, 2003, CELL CYCLE, V2, P377, DOI 10.4161/cc.2.4.420; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Sah NK, 2003, J BIOL CHEM, V278, P20593, DOI 10.1074/jbc.M211010200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh TR, 2003, CANCER RES, V63, P5390; Sobota R, 2000, BIOCHEM BIOPH RES CO, V267, P329, DOI 10.1006/bbrc.1999.1948; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VANHAMME L, 1988, CARCINOGENESIS, V9, P653, DOI 10.1093/carcin/9.4.653; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2001, CANCER RES, V61, P7339; Zhou Q, 2000, CANCER RES, V60, P2611	65	137	147	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7330	7344		10.1038/sj.onc.1207995	http://dx.doi.org/10.1038/sj.onc.1207995			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286701				2022-12-28	WOS:000224021400004
J	Saleh, AZM; Fang, AT; Arch, AE; Neupane, D; El Fiky, A; Krolewski, JJ				Saleh, AZM; Fang, AT; Arch, AE; Neupane, D; El Fiky, A; Krolewski, JJ			Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor	ONCOGENE			English	Article						interferon; intramembrane protease; presenilin; protein kinase C	PROTEIN-KINASE-C; GAMMA-SECRETASE ACTIVITY; CONVERTING-ENZYME; SIGNAL-TRANSDUCTION; I INTERFERON; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; ALZHEIMERS-DISEASE; TYROSINE KINASE	The type I interferons (IFNs) bind surface receptors, induce JAK kinases and activate STAT transcription factors to stimulate the transcription of genes downstream of IFN-stimulated response elements (ISREs). In this study, we demonstrate that IFNaR2, a subunit of the type I IFN receptor, is proteolytically cleaved in a regulated manner. Immunoblotting shows that multi-step cleavage occurs in response to phorbol ester (PMA) and IFN-alpha, generating both a transmembrane 'stub' and the intracellular domain (ICD), similar to Notch proteolysis. Isolated membrane fractions process IFNaR2 to release the ICD. A chimeric receptor construct is utilized to show that cleavage requires the presenilins and occurs in response to epidermal growth factor and protein kinase C-delta overexpression, as well as PMA and type I IFNs. Fluorescence microscopy demonstrates that a green fluorescent protein ICD fusion localizes predominantly to the nucleus. A fusion between the ICD and the Gal4 DNA-binding domain represses transcription, in a histone deacetylase-dependent manner, of a Gal4 upstream activating sequence-regulated reporter, while overexpression of the ICD alone represses transcription of a reporter linked to an ISRE. Proteolytic cleavage events may facilitate receptor turnover or, more likely, function as a mechanism for signaling similar to that employed by Notch and the Alzheimer's precursor protein.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Krolewski, JJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	jkrolews@uci.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chill JH, 2003, STRUCTURE, V11, P791, DOI 10.1016/S0969-2126(03)00120-5; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kubota S, 2001, DNA CELL BIOL, V20, P563, DOI 10.1089/104454901317094972; Kumar KGS, 2003, EMBO J, V22, P5480; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Nguyen VP, 2002, J BIOL CHEM, V277, P9713, DOI 10.1074/jbc.m111161200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Saleh AZM, 2002, BIOCHEMISTRY-US, V41, P11261, DOI 10.1021/bi025913f; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	54	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7076	7086		10.1038/sj.onc.1207955	http://dx.doi.org/10.1038/sj.onc.1207955			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15286706				2022-12-28	WOS:000223885100008
J	Moore, R; Champeval, D; Denat, L; Tan, SS; Faure, F; Julien-Grille, S; Larue, L				Moore, R; Champeval, D; Denat, L; Tan, SS; Faure, F; Julien-Grille, S; Larue, L			Involvement of cadherins 7 and 20 in mouse embryogenesis and melanocyte transformation	ONCOGENE			English	Article						cell adhesion molecule; melanoma; orthologous gene; anterior regionalization; segmentation; modifier	NEURAL CREST; EXPRESSION; ADHESION; CANCER; INVASION; TUBE; IDENTIFICATION; MIGRATION; LINEAGE; CLONING	We have determined the expression profiles of cdh7, and the related cdh20 during development. Both transcripts are found in the adult brain, but only cadherin-20 mRNA was detected during embryogenesis. In mouse embryos, cadherin-20 is synthesized by the forebrain, anterior neural ridge, developing visual system, primitive external granular layer of the cerebellum and a subset of neural crest cells likely to develop into melanoblasts. We found that the other embryonic tissues in which cadherin-20 was synthesized depended on genetic background. Melanoma cell lines contained transcripts for cadherin-7 but not for cadherin-20. The majority of the malignant melanoma cell lines produced N-cadherin (N-Cad) and/or cadherin-7 whereas melanocyte cell lines did not. The converse was observed for E-cadherin (E-Cad). Our data suggest that during development cadherin-20 is a key player in compartmentalization of the neural tube and establishment of neural circuitry. Finally, during oncogenesis, cadherin-7, N-cad and E-cad could be used as an efficient marker set for melanoma.	Inst Curie, CNRS, UMR146, F-91405 Orsay, France; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia; Inst Curie, INSERM, U520, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Larue, L (corresponding author), Inst Curie, CNRS, UMR146, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Larue, Lionel/F-7355-2013; faure, florence/P-9064-2016; Larue, Lionel/I-6532-2016	faure, florence/0000-0002-8359-4283; 				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; ESPESETH A, 1995, MOL CELL NEUROSCI, V6, P199, DOI 10.1006/mcne.1995.1017; Faulkner-Jones BE, 1999, MOL CELL NEUROSCI, V14, P1, DOI 10.1006/mcne.1999.0764; Feltes CM, 2002, CANCER RES, V62, P6688; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Goding CR, 2000, GENE DEV, V14, P1712; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haenig B, 2002, MECH DEVELOP, V117, P321, DOI 10.1016/S0925-4773(02)00196-X; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; Kawano R, 2002, J BIOL CHEM, V277, P47679, DOI 10.1074/jbc.M205328200; Kools P, 2000, GENOMICS, V68, P283, DOI 10.1006/geno.2000.6305; Le Douarin NM, 1999, NEURAL CREST, V2; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Locascio A, 2002, P NATL ACAD SCI USA, V99, P16841, DOI 10.1073/pnas.262525399; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Posthaus H, 2003, FEBS LETT, V536, P203, DOI 10.1016/S0014-5793(02)03897-8; REDIES C, 1995, EXP CELL RES, V220, P243, DOI 10.1006/excr.1995.1313; SHIMAMURA K, 1992, DEV BIOL, V152, P242, DOI 10.1016/0012-1606(92)90132-Z; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Stoykova A, 1997, DEVELOPMENT, V124, P3765; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Tomita K, 2000, CANCER RES, V60, P3650	33	39	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6726	6735		10.1038/sj.onc.1207675	http://dx.doi.org/10.1038/sj.onc.1207675			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273735				2022-12-28	WOS:000223653600004
J	Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E				Opdam, FJM; Kamp, M; de Bruijn, R; Roos, E			Jak kinase activity is required for lymphoma invasion and metastasis	ONCOGENE			English	Article						integrin; adhesion; G-protein; CXCR4 migration	ZAP-70 TYROSINE KINASE; JAK/STAT PATHWAY; ACTIVATION; PHOSPHORYLATION; MIGRATION; CXCR4; LFA-1; CELLS; DISSEMINATION; INVASIVENESS	Jak tyrosine kinases are activated by interleukins and other growth factors, and promote survival and proliferation of cells in multiple tissues. These kinases are constitutively active in many hematopoietic malignancies and certain carcinomas. We have investigated whether Jak kinases play a role in lymphoma invasion and metastasis. Proliferation and survival of a highly metastatic T-lymphoma was made independent of its constitutively active Jak by expression of active forms of both STAT3 and PI3-kinase. Jak activity was then blocked by the isolated JH2 'pseudokinase' domain of Jak2. In vitro invasion was blocked by the JH2 domain, and the metastatic capacity of the JH2-expressing cells was much reduced. The Jak inhibitor AG490 inhibited invasion as well. Invasion and metastasis of these cells requires activation of the integrin LFA-1 by the CXCR4 chemokine receptor. We show that Jak kinases act downstream of LFA-1. We conclude that Jak kinase activity is essential for lymphoma invasion and metastasis, independent of its role in survival and proliferation, and independent of STAT and PI3K signaling. This indicates that Jak kinases contribute in multiple ways to the induction of malignant behavior.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Roos, E (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	E.ROOS@NKI.NL						Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Carron C, 2000, BLOOD, V95, P3891; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; LARIVIERE G, 1988, CANCER RES, V48, P3405; LARIVIERE G, 1993, J LEUKOCYTE BIOL, V53, P381, DOI 10.1002/jlb.53.4.381; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371; Soede RDM, 2001, J IMMUNOL, V166, P4293, DOI 10.4049/jimmunol.166.7.4293; Soede RDM, 1999, J IMMUNOL, V163, P4253; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	33	16	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6647	6653		10.1038/sj.onc.1207887	http://dx.doi.org/10.1038/sj.onc.1207887			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235585				2022-12-28	WOS:000223530800012
J	Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K				Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K			Identification of novel RAR beta 2 transcript variants with short 5 '-UTRs in normal and cancerous breast epithelial cells	ONCOGENE			English	Article						RAR beta 2; 5 '-UTR; transcript variants; breast cancer; translation	ACID RECEPTOR-BETA; RETINOIC ACID; CARCINOMA; NUCLEAR; LINES; TRANSLATION; EXPRESSION; ISOFORMS; PROTEIN; TISSUE	Functional significance of RARbeta2 as a putative tumor suppressor gene has been studied in breast cancer and other tumors. The long 5'-untranslated region (5'-UTR) of its transcript with multiple open-reading frames (uORFs) is considered as a regulatory unit for translation. Here, for the first time we identified RARbeta2 transcript variants with short 5'-UTRs in both normal and malignant breast epithelial cells. The 5'-RACE analysis of RARbeta2 mRNA in these cells demonstrated the existence of short RARbeta2 transcript variants that are identical to the sequence of known RARbeta2, but lack all the uORFs present in the full-length 5'-UTR. By RT-PCR analysis, we found that the expression of both transcripts with short and full-length 5'-UTR is mediated by retinoic acid, while cellular sensitivity is preferentially correlated to upregulation of short RARbeta2 transcript variants in response to retinoic acid. The transfection and in vitro translation assay indicated that the short 5'-UTR has no inhibitory effects on translation, while the presence of full-length 5'-UTR inhibited translation by 60%. In addition, no promoter activity was detectable in RARbeta2 full-length 5'-UTR region. Our data suggest that the RARbeta2 transcript variants with short 5'-UTR may serve as major transcripts for RARbeta2 protein translation as well as potential targets for retinoids in breast cancer prevention and therapy studies.	Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Christov, K (corresponding author), Univ Illinois, Dept Surg Oncol, 840 S Wood St,M-C 820, Chicago, IL 60612 USA.	christov@uic.edu			NATIONAL CANCER INSTITUTE [R01CA082316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARMICHAEL J, 1987, CANCER RES, V47, P936; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200; DENG G, 1996, SCIENCE, V249, P1577; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; PENG X, 2004, IN PRESS CANC RES; Peng XJ, 2004, INT J ONCOL, V25, P961; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TALLMAN MS, 1992, J CLIN PHARMACOL, V32, P868, DOI 10.1002/j.1552-4604.1992.tb04633.x; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1997, CANCER RES, V57, P4992; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	22	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1296	1301		10.1038/sj.onc.1208284	http://dx.doi.org/10.1038/sj.onc.1208284			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558014				2022-12-28	WOS:000226898700018
J	Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF				Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF			Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression	ONCOGENE			English	Article						parathyroid; parafibromin; tumor suppressor; hyperparathyroidism; jaw tumor syndrome; parathyroid carcinoma; cyclin D1	FAMILIAL ISOLATED HYPERPARATHYROIDISM; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; ADENOMAS; MUTATIONS; FIBROMAS; 1Q21-Q32; MAPS	Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism-jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parabromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parabromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.	NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simonds, WF (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bldg 10,Room 8C-101,10 Ctr DR MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Woodard, Geoffrey/A-8608-2009; Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold A, 2002, J BONE MINER RES, V17, pN30; ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; DINNEN JS, 1977, J CLIN PATHOL, V30, P966, DOI 10.1136/jcp.30.10.966; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; FIRAT D, 1968, AM J MED, V44, P421, DOI 10.1016/0002-9343(68)90112-5; Fujikawa M, 1998, EUR J ENDOCRINOL, V138, P557, DOI 10.1530/eje.0.1380557; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; INOUE H, 1995, CLIN ENDOCRINOL, V43, P225, DOI 10.1111/j.1365-2265.1995.tb01919.x; JACKSON CE, 1990, SURGERY, V108, P1006; JACKSON CE, 1958, ANN INTERN MED, V49, P829, DOI 10.7326/0003-4819-49-4-829; KAKINUMA A, 1994, INTERNAL MED, V33, P123, DOI 10.2169/internalmedicine.33.123; KENNETT S, 1971, ORAL SURG ORAL MED O, V31, P502, DOI 10.1016/0030-4220(71)90347-1; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MALLETTE LE, 1987, ANN INTERN MED, V107, P54, DOI 10.7326/0003-4819-107-1-54; Marx SJ, 2002, GENETIC BASIS HUMAN, P475; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; ROSEN IB, 1981, AM J SURG, V142, P494, DOI 10.1016/0002-9610(81)90382-2; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; STREETEN EA, 1992, J CLIN ENDOCR METAB, V75, P362, DOI 10.1210/jc.75.2.362; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2114, DOI 10.1210/jc.83.6.2114; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Vasef MA, 1999, MODERN PATHOL, V12, P412; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Visset J, 1992, Chirurgie, V118, P223; WARNAKULASURIYA S, 1985, ORAL SURG ORAL MED O, V59, P269, DOI 10.1016/0030-4220(85)90165-3; WASSIF WS, 1993, J CLIN ENDOCR METAB, V77, P1485, DOI 10.1210/jc.77.6.1485; Yoshimoto K, 1998, CLIN ENDOCRINOL, V48, P67, DOI 10.1046/j.1365-2265.1998.00354.x	33	119	127	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1272	1276		10.1038/sj.onc.1208274	http://dx.doi.org/10.1038/sj.onc.1208274			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580289				2022-12-28	WOS:000226898700014
J	Petrella, BL; Lohi, J; Brinckerhoff, CE				Petrella, BL; Lohi, J; Brinckerhoff, CE			Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma	ONCOGENE			English	Article						von Hippel-Lindau; MT1-MMP; HIF-2 alpha; renal cell carcinoma	PAS DOMAIN PROTEIN-1; TUMOR-SUPPRESSOR; ENDOTHELIAL-CELLS; MESSENGER-RNAS; GROWTH; INVASION; EXPRESSION; CANCER; GENE; TRANSCRIPTION	Metastatic renal cell carcinoma (RCC) resulting from the hereditary loss of the von Hippel - Lindau (VHL) tumor suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic tumor(s). VHL functions in the destruction of the alpha subunits of the heterodimeric transcription factor, hypoxia-inducible factor (HIF-1alpha and HIF-2alpha), in normoxic conditions. When VHL function is lost, HIF-alpha protein is stabilized, and target hypoxia-inducible genes are transcribed. The process of tumor invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes. Here, we describe a connection between the loss of VHL tumor suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein. Specifically, MT1-MMP is upregulated in VHL -/- RCC cells through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1. Further, we identify a functional HIF-binding site in the proximal promoter of MT1-MMP. To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL tumor suppressor function and an increase in MMP gene and protein expression.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, Lebanon, NH 03756 USA; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Brinckerhoff, CE (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, 1 Med Ctr Dr,Rubin Bldg,HB 7936, Lebanon, NH 03756 USA.	constance.e.brinckerhoff@dartmouth.edu			NCI NIH HHS [CA-77267, R01 CA077267] Funding Source: Medline; NIAID NIH HHS [T32 AI007363] Funding Source: Medline; NIAMS NIH HHS [AR-26599, R01 AR026599, R37 AR026599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hes FJ, 2001, NETH J MED, V59, P225, DOI 10.1016/S0300-2977(01)00165-6; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maquoi E, 2004, CLIN CANCER RES, V10, P4038, DOI 10.1158/1078-0432.CCR-04-0125; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Ottino P, 2004, MOL VIS, V10, P341; Richards FM, 1998, J INTERN MED, V243, P527; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Singh AD, 2001, SURV OPHTHALMOL, V46, P117, DOI 10.1016/S0039-6257(01)00245-4; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Zimmer M, 2004, MOL CANCER RES, V2, P89	46	144	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2005	24	6					1043	1052		10.1038/sj.onc.1208305	http://dx.doi.org/10.1038/sj.onc.1208305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592504	Green Accepted			2022-12-28	WOS:000226749200010
J	Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK				Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK			Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively	ONCOGENE			English	Article						interferon; p53; IRF1; CD95; apoptosis	INTERACTING PROTEIN KINASE-2; TRANSCRIPTION FACTOR IRF-1; DAMAGE-INDUCED APOPTOSIS; NUCLEAR-BODIES; PREMATURE SENESCENCE; CARCINOMA-CELLS; BREAST-CANCER; HOST-DEFENSE; I INTERFERON; P53 ACTIVITY	Type I interferon (IFN) enhances the transcription of the tumor suppressor gene p53. To elucidate the molecular mechanism mediating IFN-induced apoptosis, we analysed programmed cell death in response to type I (IFNalpha) or type II (IFNgamma) treatment in relation to p53 status. In two cell lines (MCF-7, SKNSH), IFNalpha, but not IFNgamma, enhanced apoptosis in a p53-dependent manner. Furthermore, only IFNalpha upregulated p53 as well as p53 target genes (Noxa, Mdm2 and CD95). The apoptotic response to IFNalpha decreased in the presence of ZB4, an anti-CD95 antibody, suggesting that CD95 is involved in this process. When p53 was inactivated by the E6 viral protein or the expression of a p53 mutant, IFNalpha-induced apoptosis and p53 target genes upregulation were abrogated. Altogether these results demonstrate that p53 plays a pivotal role in the IFNalpha-induced apoptotic response. IFNalpha-induced PML was unable to recruit p53 into nuclear bodies and its downregulation by siRNA did not alter CD95 expression. In contrast, IFNgamma-induced apoptosis is p53-independent. CD95 and IFN-regulatory factor 1 (IRF1) are directly upregulated by this cytokine. Apoptotic response to IFNgamma is decreased in the presence of ZB4 and strongly diminished by IRF1 siRNA, implicating both CD95 and IRF1 in IFNgamma-induced apoptotic response. Taken together, these results show that in two different cell lines, IFNalpha and IFNgamma, induce p53-dependent - independent apoptosis, respectively.	Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France; CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS)	Chelbi-Alix, MK (corresponding author), Inst Andre Lwoff, CNRS, UPR 9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Espert, Lucile/ABF-5614-2021	Nejmeddine, Mohamed/0000-0003-0160-2727; Tovey, Michael/0000-0002-3058-0494				Abadie A, 2004, ONCOGENE, V23, P4911, DOI 10.1038/sj.onc.1207614; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chelbi-alix MK, 2003, ONCOGENE, V22, P9121, DOI 10.1038/sj.onc.1207090; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FAN SJ, 1995, CANCER RES, V55, P1649; Ferbeyre G, 2002, LEUKEMIA, V16, P1918, DOI 10.1038/sj.leu.2402722; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Koshiji M, 1997, BIOCHEM BIOPH RES CO, V240, P376, DOI 10.1006/bbrc.1997.7657; Li CX, 2004, ONCOGENE, V23, P1608, DOI 10.1038/sj.onc.1207273; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pfeffer LM, 1998, CANCER RES, V58, P2489; Prives C, 1999, J PATHOL, V187, P112; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sandoval R, 2004, J BIOL CHEM, V279, P32275, DOI 10.1074/jbc.M313830200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STRANDER H, 1986, ADV CANCER RES, V46, pR9; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WADLER S, 1990, CANCER RES, V50, P3473; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	59	80	85	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					605	615		10.1038/sj.onc.1208204	http://dx.doi.org/10.1038/sj.onc.1208204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580300				2022-12-28	WOS:000226420400008
J	Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J				Abounader, R; Reznik, T; Colantuoni, C; Martinez-Murillo, F; Rosen, EM; Laterra, J			Regulation of c-Met-dependent gene expression by PTEN	ONCOGENE			English	Article						receptor tyrosine kinase; tumor suppressor; hepatocyte growth factor; scatter factor; microarrays; epidermal growth factor receptor	FACTOR/HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR EXPRESSION; TUMOR-SUPPRESSOR PTEN; HUMAN GLIOBLASTOMA; PTEN/MMAC1; MUTATIONS; PATHWAYS; RECEPTOR; 3-KINASE/AKT; MULTIFORME	Receptor tyrosine kinases (RTK) and the tumor suppressor PTEN co-regulate oncogenic cell signaling pathways. How these interactions influence gene transcription is inadequately understood. We used expression microarrays to investigate the effects of PTEN on gene expression changes caused by activating c-Met in human glioblastoma cells. c-Met activation by scatter factor/hepatocyte growth factor (SF/HGF) altered the expression of 27-fold more genes in PTEN-null U-373MG cells than in PTEN homozygous primary normal human astrocytes (523 vs 19 genes). Restoring wt-PTEN in U-373MG cells dramatically altered patterns of c-Met regulated gene expression. This effect was varied depending on the specific gene in question. PTEN reduced the number of c-Met regulated transcripts from 931 to 502, decreased the relative number of genes upregulated by c-Met from 46 to 25%, and increased the relative number of downregulated genes from 54 to 75%. PTEN and c-Met co-regulated many genes involved in cell growth regulation such as oncogenes, growth factors, transcription factors, and constituents of the ubiquitin pathway. c-Met activation in PTEN-null ( but not PTEN reconstituted) cells led to upregulation of the EGFR agonist TGFalpha and subsequently to EGFR activation. Using PTEN mutants, we found that PTEN's transcriptional effects were either lipid-phosphatase dependent, protein-phosphatase dependent, or phosphatase-independent. These results show that PTEN has critical and mechanistically complex effects on RTK-regulated gene transcription. These findings expand our understanding of tumor promoter/suppressor inter-relationships and downstream transcriptional effects of PTEN loss and c-Met overexpression in malignant gliomas.	Kennedy Krieger Res Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Lombardi Canc Ctr, Dept Oncol, Washington, DC USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Abounader, R (corresponding author), Kennedy Krieger Res Inst, 707 N Broadway,Room 400, Baltimore, MD 21205 USA.	abounader@kennedykrieger.org; laterra@kennedykrieger.org		Colantuoni, Carlo/0000-0001-6818-6380	NINDS NIH HHS [R01 NS045209, R01 NS032148, R01 NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045209, R01NS043987, R01NS032148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Abounader R, 2001, J NEUROCHEM, V76, P1497, DOI 10.1046/j.1471-4159.2001.00158.x; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bowers DC, 2000, CANCER RES, V60, P4277; Cheney IW, 1998, CANCER RES, V58, P2331; Colantuoni C, 2002, BIOTECHNIQUES, V32, P1316, DOI 10.2144/02326mt02; Davies MPA, 1999, BRIT J CANCER, V79, P1542, DOI 10.1038/sj.bjc.6690246; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Koochekpour S, 1997, CANCER RES, V57, P5391; Laterra J, 1997, LAB INVEST, V76, P565; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rosen EM, 1996, INT J CANCER, V67, P248, DOI 10.1002/(SICI)1097-0215(19960717)67:2<248::AID-IJC16>3.0.CO;2-7; Sano T, 1999, CANCER RES, V59, P1820; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	29	51	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9173	9182		10.1038/sj.onc.1208146	http://dx.doi.org/10.1038/sj.onc.1208146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516982				2022-12-28	WOS:000225638000002
J	Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J				Tanami, H; Imoto, I; Hirasawa, A; Yuki, Y; Sonoda, I; Inoue, J; Yasui, K; Misawa-Furihata, A; Kawakami, Y; Inazawa, J			Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines	ONCOGENE			English	Article						malignant melanoma; BRAF; mutation; gene amplification; comparative genomic hybridization	COMPARATIVE GENOMIC HYBRIDIZATION; B-RAF; CUTANEOUS MELANOMAS; POTENTIAL TARGET; MUTATIONS; AMPLIFICATION; CANCER; IDENTIFICATION; ACTIVATION; PATHWAY	Comparative genomic hybridization (CGH) using 40 cell lines derived from malignant melanomas (MMs) revealed frequent amplification at 7q33-q34 containing BRAF gene, which often is mutated in MM. We found this gene to be amplified to a remarkable degree in the MM cell lines that exhibited high-level gains at 7q33-q34 in CGH. Among 40 cell lines, the eight lines that revealed neither BRAF nor NRAS mutations showed even higher levels of BRAF mRNA expression than the 32 mutated lines, although DNA amplification at 7q33-q34 was not detected in every lines overexpressing BRAF. MM cells that carried wild-type BRAF and NRAS showed constitutive overexpression of B-Raf protein and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), even after serum starvation. Not only downregulation of the endogenously overexpressed wild-type B-Raf by antisense oligonucleotide but also a treatment with an inhibitor of mitogen-activated protein kinase kinase (MAPKK, MEK) reduced phosphorylated ERK1/2 and cell growth, whereas the exogenously expressed wild-type B-Raf promoted cell growth in MM cells. Our results provide the evidence that overexpression of wild-type B-Raf, in part but not always as a result of gene amplification, is one of the mechanisms underlying constitutive activation of the MAPK pathway that stimulates growth of MM cells.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Keio University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kawakami, Yutaka/E-7429-2013	Kawakami, Yutaka/0000-0003-4836-2855; Imoto, Issei/0000-0002-4150-7938				Ariyama Y, 1998, J HUM GENET, V43, P187, DOI 10.1007/s100380050067; Balazs M, 2001, CYTOMETRY, V46, P222, DOI 10.1002/cyto.1131; Bastian BC, 1998, CANCER RES, V58, P2170; Brose MS, 2002, CANCER RES, V62, P6997; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Hoa M, 2002, CANCER RES, V62, P7154; Imoto I, 2003, CANCER RES, V63, P5691; Imoto I, 2001, CANCER RES, V61, P6629; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KUKITA A, 1989, Journal of Investigative Dermatology, V92, p210S, DOI 10.1111/1523-1747.ep13075564; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Metzelaar-Blok JAW, 1999, HUM IMMUNOL, V60, P962, DOI 10.1016/S0198-8859(99)00067-1; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683	32	69	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8796	8804		10.1038/sj.onc.1208152	http://dx.doi.org/10.1038/sj.onc.1208152			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467732				2022-12-28	WOS:000225165100009
J	Poulin, G; Nandakumar, R; Ahringer, J				Poulin, G; Nandakumar, R; Ahringer, J			Genome-wide RNAi screens in Caenorhabditis elegans: impact on cancer research	ONCOGENE			English	Article						RNAi; C. elegans; Ras; apoptosis; cancer; synthetic interaction	PROGRAMMED CELL-DEATH; KSR-1 GENE ENCODES; C-ELEGANS; FATE DETERMINATION; VULVAL DEVELOPMENT; BINDING-PROTEIN; NURD-COMPLEX; INTERFERENCE; ANTAGONIZE; NEMATODE	Genes linked to human cancers often function in evolutionary conserved pathways, and research in C. elegans has been instrumental in dissecting some of the pathways affected, such as apoptosis and Ras signalling. The advent of RNA interference (RNAi) technology has allowed high-throughput loss-of-function analyses of C. elegans gene functions. Here we review some of the most recent genome-wide RNAi screens that have been conducted and discuss their impact on cancer research and possibilities for future screens. We also show that genes causally implicated in human cancers are significantly more likely to have a C. elegans homologue than average, validating the use of C. elegans as a cancer gene discovery platform. We foresee that genome-wide RNAi screens in C. elegans will continue to be productive in identifying new cancer gene candidates and will provide further insights into cancer gene functions.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England	University of Cambridge	Ahringer, J (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	j.ahringer@gurdon.cam.ac.uk		Poulin, Gino/0000-0003-1016-348X	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berry LW, 1997, DEVELOPMENT, V124, P925; Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; de Jager M, 2002, GENE DEV, V16, P2173, DOI 10.1101/gad.1025402; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fay DS, 2000, GENESIS, V26, P279, DOI 10.1002/(SICI)1526-968X(200004)26:4<279::AID-GENE100>3.0.CO;2-C; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harris TW, 2004, NUCLEIC ACIDS RES, V32, pD411, DOI 10.1093/nar/gkh066; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kostic I, 2003, DEV BIOL, V263, P242, DOI 10.1016/S0012-1606(03)00452-4; LETTRE G, 2004, IN PRESS CELL DEATH; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Sherwood DR, 2003, DEV CELL, V5, P21, DOI 10.1016/S1534-5807(03)00168-0; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Sternberg PW, 2001, CELL, V105, P173, DOI 10.1016/S0092-8674(01)00308-7; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tijsterman M, 2002, GENETICS, V161, P651; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; VANHAAFTEN, COMMUNICATION; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941	43	41	46	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8340	8345		10.1038/sj.onc.1208010	http://dx.doi.org/10.1038/sj.onc.1208010			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517014				2022-12-28	WOS:000224815900003
J	Sachse, C; Echeverri, CJ				Sachse, C; Echeverri, CJ			Oncology studies using siRNA libraries: the dawn of RNAi-based genomics	ONCOGENE			English	Article						RNA interference; gene silencing; siRNA; functional genomics; screening	SHORT-INTERFERING RNAS; DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; GENE-FUNCTION; VALIDATION; DUPLEXES; PATHWAY; ELEGANS; SCREENS; PLANTS	High-throughput, human cell-based applications of RNA-mediated interference (RNAi) have emerged in recent years as perhaps the most powerful of a 'second wave' of functional genomics technologies. The available reagents and methodologies for RNAi screening studies now enable a wide range of different scopes and scales of investigation, from single-parameter assays applied to focused subsets of genes, to comprehensive genome-wide surveys based on rich, multiparameter readouts. As such, RNAi-based screens are offering important new avenues for the discovery and validation of novel therapeutic targets for several disease areas, including oncology. By enabling a 'clean' determination of gene function, that is the creation of direct causal links between gene and phenotype in human cells, RNAi investigations promise levels of pathophysiological relevance, efficiency, and range of applicability never before possible on this scale. The field of oncology, with its many assays using readily transfectable cell lines, has offered particularly fertile ground for showcasing the potential of RNAi-based genomics. However, like any other technology before it, RNAi is not without its own challenges, limitations, and caveats. Many of these issues stem directly from the choice of silencing reagent to be used in such studies, and the design of the overall screening strategy. Here, we discuss the basic design issues, potential advantages, and technical challenges of large-scale RNAi screens based on the use of chemically synthesized siRNA libraries.	Cenix Biosci GmbH, D-01307 Dresden, Germany		Echeverri, CJ (corresponding author), Cenix Biosci GmbH, Tatzberg 47, D-01307 Dresden, Germany.	echeverri@cenix-bioscience.com						Arts GJ, 2003, GENOME RES, V13, P2325, DOI 10.1101/gr.1332603; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; KRONKE A, 2004, DRUG DISCOV WORLD, V5, P53; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; SACHSE C, 2004, IN PRESS METHODS ENZ, V392; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; SONNICHSEN B, UNPUB GENOME WIDE SC; Xin H, 2004, J BIOMOL SCREEN, V9, P286, DOI 10.1177/1087057104263533; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	32	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8384	8391		10.1038/sj.onc.1208072	http://dx.doi.org/10.1038/sj.onc.1208072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517020				2022-12-28	WOS:000224815900009
J	Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S				Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S			Expression of the NF-kappa B-responsive gene BTG2 is aberrantly regulated in breast cancer	ONCOGENE			English	Article						BTG2; breast cancer; cell cycle; cyclin D1; NF-kappa B	MULLERIAN-INHIBITING SUBSTANCE; CYCLIN D1 TRANSCRIPTION; NERVE GROWTH-FACTOR; CELL-GROWTH; DOWN-REGULATION; TIS21 PROTEIN; DNA-DAMAGE; IN-VIVO; CARCINOMA; PC3	BTG2, a p53-inducible antiproliferative gene, is stimulated in breast cancer cells by activation of nuclear factor kappa B (NF-kappaB). In rat mammary glands, BTG2 is expressed in epithelial cells and levels decreased during pregnancy and lactation but recovered during involution. Estrogen and progestin suppress BTG2 expression, suggesting that these steroids, which stimulate proliferation and lobuloalveolar development of mammary epithelial cells, may downregulate BTG2 in the mammary gland during pregnancy. Consistent with the report that BTG2 inhibits cyclin D1 expression, suppression of BTG2 mRNA in the mammary gland during gestation, and by estrogen and progestin, correlated with stimulation of cyclin D1. Ectopic expression of BTG2 inhibited breast cancer cell growth by arresting cells in the G1 phase, an effect reversed by cyclin D1. BTG2 expression was very low or undetectable in human breast cancer cell lines compared with nontumorigenic mammary epithelial cells, and nuclear expression of BTG2 was absent in 65% of human breast tumors compared with adjacent matched normal glands. Spontaneous mammary tumors arising in a mouse model with targeted expression of the early region of the SV40 large tumor Ag demonstrated loss of BTG2 protein very early during the tumorigenic process. Thus deregulation of BTG2 may be an important step in the development of mammary tumors.	Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NYU Med Ctr, Dept Urol, New York, NY 10016 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; New York University	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Dept Surg Oncol, Jackson 904,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu			NCI NIH HHS [CA84441, CA89138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740, R01CA089138, R01CA084441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CMARIK JL, 1994, MOL CARCINOGEN, V11, P115, DOI 10.1002/mc.2940110209; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kuo ML, 2003, CANCER RES, V63, P1046; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, BIOCHEM MOL BIOL INT, V45, P871; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; NANDI S, 1958, J NATL CANCER I, V21, P1039; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sakaguchi T, 2001, MECH DEVELOP, V104, P113, DOI 10.1016/S0925-4773(01)00374-4; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2002, P NATL ACAD SCI USA, V99, P239, DOI 10.1073/pnas.221599298; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	44	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8310	8319		10.1038/sj.onc.1208008	http://dx.doi.org/10.1038/sj.onc.1208008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378000				2022-12-28	WOS:000224749500013
J	Wang, ZX; Fukuda, S; Pelus, LM				Wang, ZX; Fukuda, S; Pelus, LM			Survivin regulates the p53 tumor suppressor gene family	ONCOGENE			English	Article						survivin; apoptosis; p53; p63; p73	CELL-CYCLE ENTRY; MDM2 ONCOPROTEIN; APOPTOSIS; P73; P21(CIP1/WAF1); EXPRESSION; PROTEIN; CANCER; P63; CLEAVAGE	Survivin regulates cell division and inhibits apoptosis by blocking caspase activation. The tumor suppressor p53 inhibits cell cycle progression and induces apoptosis. Since Survivin overexpression and loss of wild-type p53 expression/function occur in most cancers, we investigated whether Survivin regulates p53. Stable overexpression of Survivin protects BaF3 cells from Adriamycin-induced apoptosis, while dominant-negative (T34A) and antisense (AS) Survivin accelerate apoptosis. In BaF3 cells and transiently transfected MCF7 breast cancer cells, elevation of total and phospho-Ser(15)-p53 in response to Adriamycin is blocked by Survivin and enhanced by Survivin disruption. Furthermore, in Adriamycin-treated MCF7 cells, ectopic Survivin decreased p53 mRNA and increased mRNA and protein of the p53 homologues DeltaNp63 and TAp73 and mRNA for DeltaNp73, suggesting that Survivin may differentially regulate p53 family transcription. Concomitant with decreasing p53 mRNA, Survivin decreased Mdm2 mRNA. Survivin disruption by T34A or AS Survivin resulted in reduced Mdm2 protein. The caspase inhibitor, Z-VAD-FMK, blocked the decrease in Mdm2 as well as the increase in p53 resulting from Survivin disruption, indicating that Survivin regulates Mdm2 at the post-translational level. Proteosome inhibition confirmed that reduced p53 protein observed in cells overexpressing Survivin is due to enhanced p53 degradation resulting from Survivin-mediated inhibition of Mdm2 cleavage by caspases. In summary, our results identify regulatory interactions between Survivin and p53 at the mRNA and protein levels, and suggest that the p53 homologues DeltaNp63, TAp73 and DeltaNp73 may also be regulated by Survivin.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Pelus, LM (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 950 W Walnut St, Indianapolis, IN 46202 USA.	lpelus@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079654] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079654] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chumakov PM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P28; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Goetz AW, 2001, CANCER RES, V61, P7635; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashibara T, 2002, NUTR CANCER, V44, P192, DOI 10.1207/S15327914NC4402_12; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kostrouchova M, 2003, P NATL ACAD SCI USA, V100, P5240, DOI 10.1073/pnas.0730770100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McKay TR, 2003, ONCOGENE, V22, P3539, DOI 10.1038/sj.onc.1206417; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; NYLANDER K, 2003, J PATHOL, V198, P5686; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	48	69	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8146	8153		10.1038/sj.onc.1207992	http://dx.doi.org/10.1038/sj.onc.1207992			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361831				2022-12-28	WOS:000224692500012
J	Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M				Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M			Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles	ONCOGENE			English	Article						GIST; KIT; PDGFRA; mutations; microarray; gene expression	OF-FUNCTION MUTATIONS; SIGNAL-TRANSDUCTION; C-KIT; ERM PROTEINS; CANCER; IMATINIB; SITE; MICROARRAYS; MODULATION; APOPTOSIS	Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Pathol, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Med Ctr, Dept Anat Pathol, Seattle, WA 98195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Med, Portland, OR 97201 USA	Stanford University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; University of Hong Kong; University of Hong Kong; Stanford University; University of British Columbia; University of British Columbia; Cleveland Clinic Foundation; Oregon Health & Science University	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	mrijn@stanford.edu	Leung, Suet Yi/C-4340-2009; Ou, Wen-Bin/J-1142-2019; Chu, Kent/C-4251-2009; Heinrich, Michael/AAC-6745-2019; PATEL, Rajiv Michael/AAI-9424-2021; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	PATEL, Rajiv Michael/0000-0002-1521-4947; West, Robert/0000-0002-8330-8283; Subramanian, Subbaya/0000-0002-2544-480X; , Wenbin/0000-0002-6311-9442; Heinrich, Michael/0000-0003-3790-0478; Leung, Suet Yi/0000-0001-8614-4619; van de Rijn, Matt/0000-0002-1909-9739	NCI NIH HHS [CA85129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonescu CR, 2003, CLIN CANCER RES, V9, P3329; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; BESMER P, 1997, MOL CELL BIOL, P369; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Breiner JA, 2000, CANCER GENET CYTOGEN, V120, P111, DOI 10.1016/S0165-4608(00)00212-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2004, J PATHOL, V202, P430, DOI 10.1002/path.1546; Debiec-Rychter M, 2004, EUR J CANCER, V40, P689, DOI 10.1016/j.ejca.2003.11.025; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gunawan B, 2004, J PATHOL, V202, P421, DOI 10.1002/path.1537; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Kohno T, 1999, CANCER RES, V59, P4170; Koon N, 2004, GUT, V53, P235, DOI 10.1136/gut.2003.021238; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plo I, 2001, ONCOGENE, V20, P6752, DOI 10.1038/sj.onc.1204877; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rubin BP, 2001, CANCER RES, V61, P8118; Sanders KM, 1999, NEUROGASTROENT MOTIL, V11, P311; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	47	113	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7780	7790		10.1038/sj.onc.1208056	http://dx.doi.org/10.1038/sj.onc.1208056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15326474				2022-12-28	WOS:000224331600004
J	Califice, S; Castronovo, V; Bracke, M; van den Brule, F				Califice, S; Castronovo, V; Bracke, M; van den Brule, F			Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3	ONCOGENE			English	Article						galectin-3; prostate cancer; nucleus; cytoplasm	HUMAN BREAST-CARCINOMA; IGE-BINDING-PROTEIN; CELL-CYCLE ARREST; INDUCED APOPTOSIS; OVEREXPRESSION PROTECTS; SURFACE EXPRESSION; EPITHELIAL-CELLS; 3T3 FIBROBLASTS; NITRIC-OXIDE; LINE LNCAP	Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.	Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium; State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Liege, Dept Gynecol, Liege, Belgium	University of Liege; Ghent University; Ghent University Hospital; University of Liege	van den Brule, F (corresponding author), Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium.	f.vandenbrule@ulg.ac.be						Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Akahani S, 1997, CANCER RES, V57, P5272; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bowen C, 2000, CANCER RES, V60, P6111; Bracke M E, 2001, Methods Mol Med, V58, P91, DOI 10.1385/1-59259-137-X:091; CALIFICE S, IN PRESS INT J ONCOL; COWLES EA, 1990, J BIOL CHEM, V265, P17706; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gaudin JC, 2000, BIOL CELL, V92, P49, DOI 10.1016/S0248-4900(00)88763-8; Gelmann EP, 2003, PROSTATE, V55, P111, DOI 10.1002/pros.10210; GILLES C, 1993, INT J CANCER, V53, P872, DOI 10.1002/ijc.2910530527; GRITZMACHER CA, 1988, J IMMUNOL, V141, P2801; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HO MK, 1982, J IMMUNOL, V128, P1221; Honjo Y, 2001, CLIN CANCER RES, V7, P661; Honjo Y, 2000, CLIN CANCER RES, V6, P4635; Hughes RC, 2001, BIOCHIMIE, V83, P667; Kim HRC, 1999, CANCER RES, V59, P4148; Kim MJ, 2002, CANCER RES, V62, P2999; Kleeff J, 2000, INT J CANCER, V86, P399, DOI 10.1002/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Korkmaz KS, 2000, GENE, V260, P25, DOI 10.1016/S0378-1119(00)00453-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LeMarer N, 1996, ANTICANCER RES, V16, P2767; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Locigno R, 2002, INT J ONCOL, V20, P69; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.3.CO;2-E; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paron I, 2003, BIOCHEM BIOPH RES CO, V302, P545, DOI 10.1016/S0006-291X(03)00151-7; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sanjuan X, 1997, GASTROENTEROLOGY, V113, P1906, DOI 10.1016/S0016-5085(97)70010-6; SATO S, 1994, J BIOL CHEM, V269, P4424; Song YK, 2002, AM J PATHOL, V160, P1069, DOI 10.1016/S0002-9440(10)64927-9; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tsay YG, 1999, EXP CELL RES, V252, P250, DOI 10.1006/excr.1999.4643; van den Brule FA, 2000, INT J CANCER, V89, P361, DOI 10.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.3.CO;2-L; VANDENBRULE F, 2000, LECT PATHOLOGY; VandenBrule FA, 1997, INT J ONCOL, V11, P261; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; VandenBrule FA, 1996, HUM PATHOL, V27, P1185, DOI 10.1016/S0046-8177(96)90313-5; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Warfield PR, 1997, INVAS METAST, V17, P101; WIERDER R, 1999, CELL GROWTH DIFFER, P1; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Yoshii T, 2001, INT J ONCOL, V18, P787; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200	70	135	138	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7527	7536		10.1038/sj.onc.1207997	http://dx.doi.org/10.1038/sj.onc.1207997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326483				2022-12-28	WOS:000224176500009
J	Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S				Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S			A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and-4 processing	ONCOGENE			English	Article						IL-18 isoform; alternative splicing; caspase-1; caspase-4	GAMMA-INDUCING FACTOR; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA ISOFORMS; NECROSIS-FACTOR-ALPHA; CANCER CELL-LINES; 2 IL-15 ISOFORMS; INTERFERON-GAMMA; HUMAN INTERLEUKIN-18; FIBRONECTIN ISOFORM; EPITHELIAL-CELLS	Interleukin-18 (IL-18) is a proinflammatory cytokine synthesized as a 24 kDa inactive precursor (pro-IL-18) by several cell types, and is processed to a bioactive molecule of 18 kDa by the proteinases caspase-1 or caspase-4. All ovarian carcinoma cell lines express pro-IL-18, only in some instances coexpress caspase-1, and always express caspase-4; in any case, they display a defective processing of IL-18. We analysed whether pro-IL-18, present in two ovarian carcinoma cell lysates, could be processed 'in vitro' by recombinant active caspase-1. While most of pro-IL-18 could be cleaved by caspase-1, a residual of pro-IL-18 appeared to be resistant. Cloning and sequence analysis of the whole pro-IL-18 open reading frame demonstrated the existence of an alternatively spliced mRNA variant, which lacked exon-3 (Delta3pro-IL-18). The 12 bp exon-3 encodes for the AEDD amino-acid sequence, which is N-terminal with respect to the cleavage site of caspase-1. Both pro-IL-18 and D3pro-IL-18 mRNA isoforms were detected in all ovarian cancer cell lines analysed, while Delta3pro-IL-18 mRNA was undetectable in normal ovarian epithelial cells. The Delta3pro-IL-18 cDNA induced synthesis of an alternative Delta3pro-IL-18 protein upon transfection into a murine cell line. The Delta3pro-IL-18 protein was resistant to proteolytic activation by caspase-1 and -4, although it was capable to bind caspase-1. Aternative splicing of pro-IL-18 exon-3 may represent a novel mechanism of regulation of bioactive IL-18 production in human ovarian tumors.	Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Genoa; IRCCS AOU San Martino IST; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ferrini, S (corresponding author), Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	silvano.ferrini@istge.it	Figini, Mariangela/K-8753-2016; Rubartelli, Anna/AAA-1259-2021; Mezzanzanica, Delia/C-2607-2017	Figini, Mariangela/0000-0001-9001-8754; Mezzanzanica, Delia/0000-0002-9664-6871; Ferrini, Silvano/0000-0001-7254-2616				Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099; Cameron LA, 1999, EUR RESPIR J, V14, P553, DOI 10.1034/j.1399-3003.1999.14c12.x; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; FANTUZZI G, 1999, EUR CYTOKIN E NETW, V9; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Galmozzi E, 2001, FEBS LETT, V502, P31, DOI 10.1016/S0014-5793(01)02659-X; Gardella S, 1999, J LEUKOCYTE BIOL, V66, P237, DOI 10.1002/jlb.66.2.237; Gardella S, 2000, FEBS LETT, V481, P245, DOI 10.1016/S0014-5793(00)02015-9; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Kalina U, 2002, EUR J IMMUNOL, V32, P2635, DOI 10.1002/1521-4141(200209)32:9<2635::AID-IMMU2635>3.0.CO;2-N; Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kohno K, 1997, J IMMUNOL, V158, P1541; Kost ER, 1999, GYNECOL ONCOL, V72, P392, DOI 10.1006/gyno.1998.5257; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Lu H, 2000, J IMMUNOL, V165, P1463, DOI 10.4049/jimmunol.165.3.1463; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 2000, INT J CANCER, V87, P574, DOI 10.1002/1097-0215(20000815)87:4<574::AID-IJC18>3.3.CO;2-K; Meazza R, 1996, ONCOGENE, V12, P2187; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naik SM, 1999, J INVEST DERMATOL, V113, P766, DOI 10.1046/j.1523-1747.1999.00750.x; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nash MA, 1998, CLIN EXP IMMUNOL, V112, P172; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Onu A, 1997, J IMMUNOL, V158, P255; Osaki T, 1999, GENE THER, V6, P808, DOI 10.1038/sj.gt.3300908; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Stoll S, 1997, J IMMUNOL, V159, P298; Sugawara S, 2001, J IMMUNOL, V167, P6568, DOI 10.4049/jimmunol.167.11.6568; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Tatsumi T, 2002, CANCER RES, V62, P5853; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; USHIO S, 1996, J IMMUNOL, V156, P4272; Wang ZY, 2002, INT J CANCER, V98, P873, DOI 10.1002/ijc.10268; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; WU S, 1993, CANCER RES, V53, P1939; Xiang Y, 2001, J VIROL, V75, P9947, DOI 10.1128/JVI.75.20.9947-9954.2001; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535	49	23	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7552	7560		10.1038/sj.onc.1208036	http://dx.doi.org/10.1038/sj.onc.1208036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326478				2022-12-28	WOS:000224176500012
J	Zhang, YJ; Yang, HY; Zhang, XC; Yang, HL; Tsai, ML; Lee, MH				Zhang, YJ; Yang, HY; Zhang, XC; Yang, HL; Tsai, ML; Lee, MH			Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth	ONCOGENE			English	Article						ARF; HER2; p27; Akt	DEPENDENT KINASE INHIBITOR; CELL-CYCLE PROGRESSION; TAXOL-INDUCED APOPTOSIS; P14(ARF) GENE-TRANSFER; HUMAN-BREAST-CANCER; CYTOPLASMIC LOCALIZATION; P53-DEPENDENT APOPTOSIS; MAMMALIAN-CELLS; STABILIZES P53; S-PHASE	HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and antiapoptotic activity in cancer cells. Strong expression of HER2/neu in cancers has been associated with poor prognosis. Alternative reading frame protein (ARF), a tumor suppressor protein encoded by a gene located in the Ink4a/ARF gene locus, is frequently inactivated in human cancers. Little is known about the tumor suppressor role of ARF in HER2/neuoverexpressing cancers. Here, we applied the ARF gene as a tumor-suppressive agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. W e found that ARF antagonized protein kinase B (PKB)/Akt-mediated p27(Kip1) phosphorylation and increased p27 stability in HER2/neu-overexpressing cells. ARF expression also led to decreased levels of Cul1 and Skp2, two proteins involved in p27 degradation. W e also found that ARF caused apoptosis in HER2/neu-overexpressing cells, and sensitized cells to apoptosis induced by the chemotherapeutic agents taxol and 2-methoxyestradiol. Most significantly for clinical application, we found that ARF inhibited HER2/neu-mediated cell growth, transformation, and tumorigenesis. These findings indicate that modulation of ARF activity may be a useful therapeutic intervention in HER2-overexpressing cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	mhlee@notes.mdacc.tmc.edu		Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01CA (089266)] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2003, CANCER RES, V63, P3395; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deng XY, 2002, BIOCHEM BIOPH RES CO, V296, P792, DOI 10.1016/S0006-291X(02)00948-8; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Katner AL, 2002, J UROLOGY, V168, P766, DOI 10.1016/S0022-5347(05)64742-8; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; MILLER SJ, 1995, ONCOL REP, V2, P497; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Saadatmandi N, 2002, CANCER GENE THER, V9, P830, DOI 10.1038/sj.cgt.7700505; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tango Y, 2002, HUM GENE THER, V13, P1373, DOI 10.1089/104303402760128595; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Uhrbom L, 2002, CANCER RES, V62, P5551; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7132	7143		10.1038/sj.onc.1207918	http://dx.doi.org/10.1038/sj.onc.1207918			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273726	Bronze			2022-12-28	WOS:000223885100014
J	Abulrob, A; Giuseppin, S; Andrade, MF; McDermid, A; Moreno, M; Stanimirovic, D				Abulrob, A; Giuseppin, S; Andrade, MF; McDermid, A; Moreno, M; Stanimirovic, D			Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae	ONCOGENE			English	Article						caveolin-1; glioblastoma; epidermal growth factor receptor; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; PLASMA-MEMBRANE; KINASE-ACTIVITY; DOWN-REGULATION; IN-VITRO; EXPRESSION; PROTEIN; CHOLESTEROL; METASTASIS; ACTIVATION	Epidermal growth factor receptor (EGFR) amplification and type III mutation ( EGFRvIII), associated with constitutive tyrosine kinase activation and high malignancy, are commonly observed in glioblastoma tumors. The association of EGFR and EGFRvIII with caveolins was investigated in human glioblastoma cell lines, U87MG and U87MG-EGFRvIII. Caveolin-1 expression, determined by RT-PCR, real-time quantitative PCR and Western blot, was upregulated in glioblastoma cell lines (two-fold) and tumors (20-300-fold) compared to primary human astrocytes and nonmalignant brain tissue, respectively. U87MG-EGFRvIII expressed higher levels of caveolin-1 than U87MG. In contrast, the expression of caveolin-2 and -3 were downregulated in glioblastoma cells compared to astrocytes. A colocalization of EGFR, but not of EGFRvIII, with lipid rafts and caveolin-1 was observed by immunocytochemistry. Association of EGFR and EGFRvIII with caveolae, assessed in vitro by binding to caveolin scaffolding domain peptides and in vivo by immunocolocalization studies in cells and caveolae-enriched cellular fraction, was phosphorylation-dependent: ligand-induced phosphorylation of EGFR resulted in dissociation of EGFR from caveolae. In contrast, inhibition of the EGFRvIII constitutive tyrosine phosphorylation by AG1478 increased association of EGFRvIII with caveolin-1. AG1478 also increased caveolin-1 expression and reduced glioblastoma cell growth in a semi-solid agar. The evidence suggests that the phosphorylation-regulated sequestration of EGFR in caveolae may be involved in arresting constitutive or ligand-induced signaling through EGFR responsible for glial cell transformation.	Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, D (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	Danica.Stanimirovic@nrc.ca		Freitas-Andrade, Moises/0000-0002-5649-9053				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bender FC, 2000, CANCER RES, V60, P5870; Cameron PL, 2002, GLIA, V37, P275, DOI 10.1002/glia.10036; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Emrich JG, 2002, AM J CLIN ONCOL-CANC, V25, P541, DOI 10.1097/00000421-200212000-00001; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Ge GX, 2001, BIOCHEM BIOPH RES CO, V282, P511, DOI 10.1006/bbrc.2001.4600; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Han YC, 1996, CANCER RES, V56, P3859; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Jakobisiak M, 2003, INT J ONCOL, V23, P1055; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mamot C, 2003, CANCER RES, V63, P3154; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mischel PS, 2003, BRAIN PATHOL, V13, P52; NAGANE M, 2001, CANC LETT, V162, P17; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ringerike T, 2002, J CELL SCI, V115, P1331; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schlegel A, 2000, FRONT BIOSCI-LANDMRK, V5, pD929, DOI 10.2741/schlegel; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Thompson TC, 1998, CANCER METAST REV, V17, P439, DOI 10.1023/A:1006110326366; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Worm K, 1999, HUM PATHOL, V30, P222, DOI 10.1016/S0046-8177(99)90280-0; Yang G, 1998, CLIN CANCER RES, V4, P1873; YONG VW, 1992, J NEUROL SCI, V111, P92; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	49	110	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6967	6979		10.1038/sj.onc.1207911	http://dx.doi.org/10.1038/sj.onc.1207911			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273741				2022-12-28	WOS:000223750700013
J	Schmelz, K; Wieder, T; Tamm, I; Muller, A; Essmann, F; Geilen, CC; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Schmelz, K; Wieder, T; Tamm, I; Muller, A; Essmann, F; Geilen, CC; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappa B	ONCOGENE			English	Article						tumor necrosis factor alpha (TNF alpha); apoptosis; NF-kappa B; mitochondria; caspase-8; drug resistance	TRAIL-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; IRRADIATION-INDUCED APOPTOSIS; HUMAN CARCINOMA-CELLS; IONIZING-RADIATION; LYMPHOMA-CELLS; CD95 FAS/APO-1; DEATH DOMAIN; TNF-ALPHA; CONFORMATIONAL-CHANGE	The Hodgkin cell line HD-MyZ is resistant to apoptosis induced by tumor necrosis factor alpha (TNFalpha). In the present work, we show that pretreatment with TNFalpha sensitized the cells to apoptosis induced by antineoplastic agents and ceramide. TNFalpha pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide. No caspase-8 activation was detectable, although caspase-8 could be activated in cell-free extracts. Inhibition of caspase-8 by z-IETD-fmk did not block the sensitizing effect of TNFalpha. Furthermore, exogenous ceramide, a mediator of TNFalpha signaling, could not substitute for TNFalpha in sensitization to drug-induced apoptosis. In contrast, we observed mitochondrial changes following cotreatment of cells with TNFalpha and drugs. Mitochondrial permeability transition, cytochrome c release and subsequent processing of caspase-9 preceded the onset of apoptosis, and were enhanced by TNFalpha pretreatment. Interestingly, although transcription factor NF-kappaB protected HD-MyZ cells from drug-induced apoptosis, TNFalpha-mediated sensitization was independent of NF-kappaB, since overexpressing a dominant-negative IkappaB mutant did not alter the TNFalpha effect. Sensitization for drug-induced apoptosis by TNFalpha was abrogated by Bclx(L). Thus, the sensitizing effect of TNFalpha is mediated by the mitochondrial pathway and involves processing of caspase-2, - 3 and - 9, but appears to be independent of caspase-8 processing, Bid cleavage and NF-kappaB signaling. Therefore, sensitization by TNFalpha is mediated at least in part through different pathways, as reported for TRAIL. There, sensitization occurs through a FADD/caspase-8-dependent mechanism. Regarding TNFalpha, the sensitizing effect was also observed in myeloid leukemia cells. Therefore, TNFalpha or alternate molecules activating its pathways might be useful as sensitizers for chemotherapy in hematological malignancies.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Free Univ Berlin, Univ Med Ctr, Dept Dermatol, D-1000 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013; Essmann, Frank/ABG-7409-2020	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Essmann, Frank/0000-0003-4369-8456				Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BARGOU RC, 1993, J EXP MED, V177, P1257, DOI 10.1084/jem.177.5.1257; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BEYAERT R, 1993, CANCER RES, V53, P2623; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; DANIEL PT, 1994, J IMMUNOL, V152, P5624; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 1997, EUR J IMMUNOL, V27, P1029, DOI 10.1002/eji.1830270433; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DHEIN J, 1994, BIOCHEM SOC T, V22, P598, DOI 10.1042/bst0220598; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fiers W, 1996, J INFLAMM, V47, P67; Fortis C, 1999, EUR J IMMUNOL, V29, P3654, DOI 10.1002/(SICI)1521-4141(199911)29:11<3654::AID-IMMU3654>3.0.CO;2-B; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Gridley DS, 1997, ONCOL RES, V9, P217; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; He Q, 2004, ONCOGENE, V23, P1321, DOI 10.1038/sj.onc.1207212; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Heyninck Karen, 2001, Molecular Cell Biology Research Communications, V4, P259, DOI 10.1006/mcbr.2001.0295; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; Kimura K, 1999, CANCER RES, V59, P1606; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; Kronke M, 1999, CHEM PHYS LIPIDS, V102, P157, DOI 10.1016/S0009-3084(99)00084-5; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Shatrov VA, 2000, INT J CANCER, V85, P93, DOI 10.1002/(SICI)1097-0215(20000101)85:1<93::AID-IJC17>3.0.CO;2-I; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; SUFFYS P, 1989, ANTICANCER RES, V9, P167; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; VAN AD, 1996, SCIENCE, V274, P787; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallach D, 2002, ARTHRITIS RES THER, V4, pS189, DOI 10.1186/ar585; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	94	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6743	6759		10.1038/sj.onc.1207848	http://dx.doi.org/10.1038/sj.onc.1207848			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273737				2022-12-28	WOS:000223653600006
J	Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR				Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR			Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis	ONCOGENE			English	Article						lung cancer; orthotopic model; prognostic marker; expression profiling; metastatic model	BREAST-CANCER; ADENOCARCINOMA; EXPRESSION; ESTABLISHMENT; CARCINOMAS; RECEPTOR; NCI-H460-LNM35; ACTIVATION; SURVIVAL; PROFILES	Endobronchial implantation of NCI-H460 cells into the nude rat generates a primary lung tumor with mediastinal lymph node spread, but rarely systemic metastases. We isolated tumor cells from mediastinal nodes, orthotopically reimplanted the cells into nude rats and repeated this four times to derive a cell line, designated H460SM, that spontaneously metastasizes to bone, kidney, brain, soft tissue and contralateral lung. H460SM cells demonstrated higher invasive activity in vitro than parental NCI-H460 cells. Spectral karyotyping revealed a new inversion within 17q and loss of an extra normal copy of chromosome 14 present in parental NCI-H460 cells. Expression pro. ling of orthotopic primary tumors revealed differential expression of 360 genes. Of these, 173 were represented in the probe set of a 19.2K OCI cDNA microarray previously used to pro. le the gene expression of surgically resected lung cancer specimens. We have computationally validated clinical importance of these genes by using in silico analysis of 18 cases of pulmonary adenocarcinoma, which were split into two patient groups with markedly different clinical outcome. The model identifies additional novel candidate genes for the progression of lung cancer to systemic metastases and poor prognosis.	Princess Margaret Hosp, Univ Hlth Network, Div Thorac Surg, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Cellular Mol Biol, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Johnston, MR (corresponding author), Toronto Gen Hosp, Div Thorac Surg, Suite EN10-230,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	michael.johnston@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Navab, Roya/AGD-7380-2022; Blackhall, Fiona H/N-2186-2015	Tsao, Ming Sound/0000-0002-9160-5405; Blackhall, Fiona H/0000-0001-8716-3395; Hu, Jim/0000-0001-9134-7103; Sultan, Mujahid/0000-0001-6721-4044				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CARNEY DN, 1985, CANCER RES, V45, P2913; Fontao L, 2003, MOL BIOL CELL, V14, P1978, DOI 10.1091/mbc.e02-08-0548; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Gorogh T, 1999, INT J CANCER, V83, P750, DOI 10.1002/(SICI)1097-0215(19991210)83:6<750::AID-IJC9>3.0.CO;2-V; Howard RB, 1999, CLIN EXP METASTAS, V17, P157, DOI 10.1023/A:1006637712294; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liu J, 2002, SURG ONCOL, V11, P217, DOI 10.1016/S0960-7404(02)00053-1; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MERCER KE, 2003, BIOCHIM BIOPHYS ACTA, V1653, P23; Miura K, 2002, CANCER RES, V62, P3244; Nakamura H, 2003, CANCER-AM CANCER SOC, V97, P2798, DOI 10.1002/cncr.11406; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; SAIGA T, 1987, IN VITRO CELL DEV B, V23, P850; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shindo-Okada N, 2002, JPN J CANCER RES, V93, P50, DOI 10.1111/j.1349-7006.2002.tb01200.x; Shindo-Okada N, 2001, JPN J CANCER RES, V92, P174, DOI 10.1111/j.1349-7006.2001.tb01080.x; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Wigle DA, 2002, CANCER RES, V62, P3005; Wigle Dennis A, 2004, Genome Biol, V5, P309, DOI 10.1186/gb-2004-5-2-309	31	24	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6316	6324		10.1038/sj.onc.1207795	http://dx.doi.org/10.1038/sj.onc.1207795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247903				2022-12-28	WOS:000223399000016
J	Corcoran, CA; He, Q; Huang, Y; Sheikh, MS				Corcoran, CA; He, Q; Huang, Y; Sheikh, MS			Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis	ONCOGENE			English	Article						p53; COX-2; NSAIDs; transcription; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; CANCER-CELLS; HUMAN FIBROBLASTS; GENOTOXIC STRESS; HUMAN COLON; DEATH; LOCALIZATION; INHIBITION; SYNTHASE-2	Cyclooxygenase-2 (COX-2) has been implicated in a variety of human malignancies and, accordingly, COX-2 selective inhibitors are being investigated as important chemopreventive and therapeutic agents. How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate their chemopreventive effects are issues that remain poorly understood. Here we report that the tumor suppressor p53 upregulates COX-2 expression and that COX-2 can in turn inhibit p53-dependent transcription. Additionally, a COX-2-selective inhibitor potentiates p53-induced apoptosis, which also supports the notion that COX-2 activity appears to interfere with p53 function. Expression of exogenous COX-2 in p53 wildtype cells does not affect the cytoplasmic or nuclear levels of p53, suggesting that COX-2 may not affect p53 turnover or subcellular localization. We further demonstrate that endogenous COX-2 interacts with p53 and that COX-2 and p53 interactions are a physiologically relevant event. Thus, p53 upregulates COX-2 and COX-2 in turn appears to negatively affect p53 activity via mechanisms that could involve physical interactions between COX-2 and p53. Based on our results, we propose that p53-dependent upregulation and activation of COX-2 appear to be yet another novel mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@upstate.edu			NCI NIH HHS [CA086945, CA105300] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086945, R03CA105300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Corcoran CA, 2004, CANCER BIOL THER, V3, P721, DOI 10.4161/cbt.3.8.1068; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Gallo O, 2003, AM J PATHOL, V163, P723, DOI 10.1016/S0002-9440(10)63699-1; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grewal S, 2003, J CELL SCI, V116, P2303, DOI 10.1242/jcs.00446; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Huang Y, 2001, CANCER RES, V61, P6918; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Lloyd DR, 2002, CANCER RES, V62, P5288; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, CANCER RES, V58, P1593; Shureiqi I, 2001, CANCER RES, V61, P4879; Smigel K, 2000, J NATL CANCER I, V92, P297, DOI 10.1093/jnci/92.4.297; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Swamy MV, 2003, CANCER RES, V63, P5239; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	35	57	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1634	1640		10.1038/sj.onc.1208353	http://dx.doi.org/10.1038/sj.onc.1208353			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608668				2022-12-28	WOS:000227218200017
J	Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL				Yau, TO; Chan, CY; Chan, KL; Lee, MF; Wong, CM; Fan, ST; Ng, IOL			HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing	ONCOGENE			English	Article						HDPR1; Dapper; beta-catenin; WNT/beta-catenin signaling; JNK signaling	BETA-CATENIN; CYCLIN D1; C-JUN; DISHEVELLED OVEREXPRESSION; MATRIX METALLOPROTEINASE-1; TRANSCRIPTIONAL ACTIVITY; WNT PATHWAY; E-CADHERIN; EXPRESSION; CANCER	Oncogenic activation of the WNT/beta-catenin signaling pathway is common in hepatocellular carcinoma (HCC). Dishevelled (Dvl), a key activator of the pathway, inhibits the adenomatous polyposis coli complex, and this leads to the accumulation of beta-catenin and promotes tumorigenesis. Recently, a novel inhibitor of Dishevelled, namely Dapper (Dpr), was isolated in Xenopus. To explore whether HDPR1, the human homologue of Dpr, has an anti-oncogenic role in hepatocarcinogenesis, we studied the expression of this gene in HCCs. We found that there were two alternatively spliced transcripts of HDPR1, designated as alpha and beta forms, in human liver. Downregulation of the gene expression was observed in 31 (43%) of the 72 human HCC samples using the primer pair that amplified both transcripts. Furthermore, the HDPR1alpha was downregulated in 42 (58%) of 72 human HCCs and the downregulation significantly correlated with accumulation of beta-catenin. Also, downregulation of HDPR1 by RNA interference in HLE cells led to cytoplasmic accumulation of beta-catenin. Furthermore, a CpG island located at the promoter region and exon 1 of the HDPR1 gene was methylated in 22 (51%) of human HCCs. We showed that downregulation of HDPR1, in hepatoma cell lines, was associated with methylation of this CpG island using bisulfite sequencing and 5-aza-2'-deoxycytidine demethylation experiment. In addition to methylation-mediated downregulation of HDPR1, allelic loss (13-28% of informative cases) was detected using microsatellite markers flanking the HDPR1 locus. To conclude, downregulation of HDPR1 is common in HCCs, frequently involves hypermethylation of the promoter region, and allelic loss of the HDPR1 locus may also play a role.	Univ Hong Kong, Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Ng, IOL (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Room 127B,Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.	iolng@hku.hk	WONG, Chun-Ming/A-6739-2009; Fan, Sheung Tat/C-4138-2009	WONG, Chun-Ming/0000-0002-2497-7858; Ng, Irene Oi-lin/0000-0001-7532-2029				Chan CF, 2004, CLIN CANCER RES, V10, P4140, DOI 10.1158/1078-0432.CCR-03-0574; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Katoh M, 2003, INT J ONCOL, V22, P907; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Miyoshi Y, 1998, CANCER RES, V58, P2524; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Okazaki I, 1997, HEPATOLOGY, V25, P580, DOI 10.1002/hep.510250315; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Polakis P, 2000, GENE DEV, V14, P1837; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Theise Neil D, 2002, Clin Liver Dis, V6, P497, DOI 10.1016/S1089-3261(02)00006-5; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uematsu K, 2003, CANCER RES, V63, P4547; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459	31	74	91	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1607	1614		10.1038/sj.onc.1208340	http://dx.doi.org/10.1038/sj.onc.1208340			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15580286				2022-12-28	WOS:000227218200014
J	Kanzawa, T; Zhang, L; Xiao, LC; Germano, IM; Kondo, Y; Kondo, S				Kanzawa, T; Zhang, L; Xiao, LC; Germano, IM; Kondo, Y; Kondo, S			Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3	ONCOGENE			English	Article						arsenic trioxide; autophagy; BNIP3; glioma; LC3	ACUTE PROMYELOCYTIC LEUKEMIA; INDUCED CYTOTOXICITY; GROWTH-FACTOR; APOPTOSIS; EXPRESSION; INDUCTION; HYPOXIA; LINES; GENE; MODULATION	Arsenic trioxide (As2O3) has shown considerable efficacy in treating hematological malignancies with induction of programmed cell death (PCD) type I, apoptosis. However, the mechanisms underlying the antitumor effect of As2O3 on solid tumors are poorly defined. Previously, we reported that As2O3 induced autophagic cell death (PCD type II) but not apoptosis in human malignant glioma cell lines. The purpose of this study was to elucidate the molecular pathway leading to autophagic cell death. In this study, we demonstrated that the cell death was accompanied by involvement of autophagy-specific marker, microtubule-associated protein light chain 3 (LC3), and damage of mitochondrial membrane integrity, but not by caspase activation. Analysis by cDNA microarray, RT-PCR, and Western blot showed that cell death members of Bcl-2 family, Bcl-2/adenovirus E1B 19-kDa- interacting protein 3 (BNIP3) and its homologue BNIP3-like (BNIP3L), were upregulated in As2O3-induced autophagic cell death. Exogenous expression of BNIP3, but not BNIP3L, induced autophagic cell death in malignant glioma cells without As2O3 treatment. When upregulation of BNIP3 induced by As2O3 was suppressed by a dominant-negative effect of the transmembrane-deleted BNIP3 (BNIP3DTM), autophagic cell death was inhibited. In contrast, BNIP3 transfection augmented As2O3-induced autophagic cell death. These results suggest that BNIP3 plays a central role in As2O3-induced autophagic cell death in malignant glioma cells. This study adds a new concept to characterize the pathways by which As2O3 acts to induce autophagic cell death in malignant glioma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 64, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10510 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit 64, 1515 Holcombe Blvd, Houston, TX 77030 USA.	seikondo@mdanderson.org	germano, isabelle m/J-8327-2017	germano, isabelle m/0000-0002-3992-373X; Zhang, Li/0000-0003-0517-7860; KANZAWA, TAKAO/0000-0002-8165-5652	NATIONAL CANCER INSTITUTE [R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA88936, CA106310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akao Y, 1999, FEBS LETT, V455, P59, DOI 10.1016/S0014-5793(99)00841-8; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brandes A A, 2001, Expert Rev Anticancer Ther, V1, P357, DOI 10.1586/14737140.1.3.357; Burton E C, 2000, Curr Treat Options Oncol, V1, P459, DOI 10.1007/s11864-000-0073-2; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen GQ, 1996, BLOOD, V88, P1052; Clifford JL, 2003, MOL CANCER THER, V2, P453; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grad JM, 2001, BLOOD, V98, P805, DOI 10.1182/blood.V98.3.805; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hunter M, 2003, HUM MUTAT, V22, P129, DOI 10.1002/humu.10240; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Ishitsuka K, 2002, LEUKEMIA LYMPHOMA, V43, P1107, DOI 10.1080/10428190290021461; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanzawa T, 2003, CANCER RES, V63, P2103; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Kitamuro T, 2000, J NEUROCHEM, V75, P1826, DOI 10.1046/j.1471-4159.2000.0751826.x; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KONDO S, 1995, CANCER RES, V55, P6166; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liau LM, 2000, CANCER RES, V60, P1353; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Maeda H, 2001, CANCER RES, V61, P5432; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Miller WH, 2002, ONCOLOGIST, V7, P14; Miller WH, 2002, CANCER RES, V62, P3893; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sowter HM, 2001, CANCER RES, V61, P6669; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Terzis AJ, 1997, BRIT J CANCER, V75, P1744, DOI 10.1038/bjc.1997.298; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836; Zheng XH, 2003, TOXICOLOGY, V187, P39, DOI 10.1016/S0300-483X(03)00025-8; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	56	333	348	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					980	991		10.1038/sj.onc.1208095	http://dx.doi.org/10.1038/sj.onc.1208095			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592527				2022-12-28	WOS:000226749200004
J	Wasylyk, C; Criqui-Filipe, P; Wasylyk, B				Wasylyk, C; Criqui-Filipe, P; Wasylyk, B			Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net	ONCOGENE			English	Article						Ubc9; E3 ligase; ternary complex factor; Elk-3; Sap-2; Erp	UBIQUITIN-CONJUGATING ENZYME; ACTIVATED STAT; ANDROGEN RECEPTOR; PROTEIN INHIBITOR; SUMO MODIFICATION; FAMILY PROTEINS; FOS PROMOTER; NUCLEAR; REPRESSION; BINDING	Net (Elk-3, Sap-2, Erp) and the related ternary complex factors Elk-1 and Sap-1 are effectors of multiple signalling pathways at the transcriptional level and play a key role in the dynamic regulation of gene expression. Net is distinct from Elk-1 and Sap-1, in that it is a strong repressor of transcription that is converted to an activator by the Ras/Erk signalling pathway. Two autonomous repression domains of Net, the NID and the CID, mediate repression. We have previously shown that the corepressor CtBP is implicated in repression by the CID. In this report we show that repression by the NID involves a different pathway, sumoylation by Ubc9 and PIAS1. PIAS1 interacts with the NID in the two-hybrid assay and in vitro. Ubc9 and PIAS1 stimulate sumoylation in vivo of lysine 162 in the NID. Sumoylation of lysine 162 increases repression by Net and decreases the positive activity of Net. These results increase our understanding of how one of the ternary complex factors regulates transcription, and contribute to the understanding of how different domains of a transcription factor participate in the complexity of regulation of gene expression.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Wasylyk, B (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Long JY, 2003, P NATL ACAD SCI USA, V100, P9791, DOI 10.1073/pnas.1733973100; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sharrocks AD, 2002, BIOCHEM SOC T, V30, P1; Shaw PE, 2003, INT J BIOCHEM CELL B, V35, P1210, DOI 10.1016/S1357-2725(03)00031-1; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	43	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					820	828		10.1038/sj.onc.1208226	http://dx.doi.org/10.1038/sj.onc.1208226			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580297				2022-12-28	WOS:000226577100008
J	Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC				Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC			The expression of TA and Delta Np63 are regulated by different mechanisms in liver cells	ONCOGENE			English	Article						p63; TP53 family; DNA-damage; liver; HCC; topoisomerase inhibitor	KINASE C-ABL; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; APOPTOTIC RESPONSE; P53 PROTEIN; P73; P63; FAMILY; GENE; CANCER	The TP63 gene, a member of the TP53 gene family, encodes several isoforms with (TAp63) or without (DeltaNp63) transactivating properties. Whereas the role of p63 in the normal development of squamous epithelia is well established, its function in other cell types remains to be elucidated. Here, we have analysed the expression of TA and DeltaNp63 isoforms in liver cells, by using both primary hepatocytes from wild type and p53-null mice and three human hepatocellular carcinoma (HCC) cell lines, according to the transformation state and the TP53 status of the cells. We observed the expression of DeltaNp63 isoforms only in a p53-null context. On the other hand, the expression of TAp63 isoforms was restricted to the HCC cell lines, whatever the TP53 status. We then studied the expression of TP63 upon genotoxic treatment. When treated with UVB or H2O2, hepatocytes did not exhibit any change in p63 mRNA level. At the opposite, upon treatment with topoisomerase II inhibitors ( doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells. The same treatment did not induce any variation in the expression of DeltaNp63 isoforms, both at mRNA and protein levels. In HCC cell lines, doxorubicin or etoposide treatment also resulted in an increase of TAp63 transcripts only. This increase was accompanied by an increase in the intracellular level of TAp63 alpha protein. In parallel, we observed an upregulation of some p53-target genes related to cell cycle regulation, such as WAF1/CIP1, PIG3, 14-3-3sigma or GADD45, independently of the TP53 status of cells. In conclusion, we report for the first time that TA and DeltaNp63 alpha proteins are present in liver cells. Furthermore, our results suggest that p63 may partially substitute for wild-type p53, in counteracting uncontrolled liver cell proliferation in response to certain forms of DNA-damage.	Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, F-69008 Lyon, France; Int Agcy Res Canc, F-69372 Lyon 08, France; Inst Cochin Genet Mol, CNRS, UMR 8104, INSERM,U567, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Fromentel, CC (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, 28 Rue Laennec, F-69008 Lyon, France.	carondef@lyon.fnclcc.fr	de Fromentel, Claude Caron/Y-9715-2019; Hainaut, Pierre/B-6018-2012	de Fromentel, Claude Caron/0000-0001-7566-3958; Hainaut, Pierre/0000-0002-1303-1610				Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Chou YY, 1997, J GASTROEN HEPATOL, V12, P569, DOI 10.1111/j.1440-1746.1997.tb00487.x; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Gillet R, 2000, ONCOGENE, V19, P3498, DOI 10.1038/sj.onc.1203671; Gong JG, 1999, NATURE, V399, P806; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Mueller H, 1996, ANTICANCER RES, V16, P3845; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	37	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					512	519		10.1038/sj.onc.1208215	http://dx.doi.org/10.1038/sj.onc.1208215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543231				2022-12-28	WOS:000226279700021
J	Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A				Tchevkina, E; Agapova, L; Dyakova, N; Martinjuk, A; Komelkov, A; Tatosyan, A			The small G-protein RalA stimulates metastasis of transformed cells	ONCOGENE			English	Article						Ras; Ral; metastasis; signal transduction	ROUS-SARCOMA VIRUS; RAS ONCOGENES; CANCER-CELLS; N-RAS; KINASE; TUMORIGENICITY; FIBROBLASTS; GROWTH; ACTIVATION; MECHANISMS	RAS oncogenes play a critical role in oncogenic transformation and metastases formation. Here we show that Ha-ras greatly stimulates spontaneous metastatic activity of transformed cells through the Ras/RalGDS/RalA intracellular signaling pathway. Introduction of RalA alone leads to a drastic increase of metastatic activity of transformed cells. We demonstrate that metastatic ability of cells could be dramatically enhanced by RalA stimulation or, conversely, hampered by RalA suppression. Furthermore, we found that during in vivo selection cells acquire high metastatic properties as a result of endogenous RalA activation. The ability of RalA to induce metastasis was demonstrated in spontaneously transformed as well as in virus transformed fibroblasts.	Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	Russian Academy of Medical Sciences	Tatosyan, A (corresponding author), Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	tatosyan@space.ru	Komelkov, Andrei/E-4567-2012; Tchevkina, Elena/R-8909-2019	Komelkov, Andrei/0000-0003-0766-163X; 				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BOS JL, 1989, CANCER RES, V49, P4682; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEICHMAN GI, 1992, INT J CANCER, V51, P903, DOI 10.1002/ijc.2910510612; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; DEICHMAN GI, 1989, INT J CANCER, V44, P904, DOI 10.1002/ijc.2910440526; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gildea JJ, 2002, CANCER RES, V62, P982; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Mizenina O, 2001, J BIOL CHEM, V276, P34006, DOI 10.1074/jbc.M011320200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TOPOL LZ, 1993, MOL CARCINOGEN, V8, P167, DOI 10.1002/mc.2940080307; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Yamazaki Y, 2001, BIOCHEM BIOPH RES CO, V280, P868, DOI 10.1006/bbrc.2000.4233; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961	31	32	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					329	335		10.1038/sj.onc.1208094	http://dx.doi.org/10.1038/sj.onc.1208094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15467745				2022-12-28	WOS:000226279700004
J	Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T				Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T			Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells	ONCOGENE			English	Article						E1B-55kDa; PML; p53; nucleocytoplasmic shuttling	E1B 55-KILODALTON ONCOPROTEIN; E1B-58KD TUMOR-ANTIGEN; 5 E4ORF3 PROTEIN; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; MONOCLONAL-ANTIBODIES; SUMO-1 MODIFICATION; INFECTED-CELLS; CELLULAR P53	The 55-kDa gene product from subgroup C adenovirus type 5 (Ad5) early region 1 (E1B-55kDa) plays a central role in the oncogenic transformation of primary rodent cells primarily by inactivating transcriptional and presumably other functional properties of the tumor suppressor protein p53. We have previously shown that Ad5 E1B-55kDa possesses a leucine-rich nuclear export signal (NES), which confers rapid nucleocytoplasmic shuttling via the CRM1-dependent export pathway. In this study we report that an export-deficient mutant of the viral protein (E1B-NES) substantially enhances focus formation of primary baby rat kidney cells in combination with Ad E1A. Transformed rat cells stably expressing the E1B-NES protein exhibited increased tumorigenicity and accelerated tumor growth in nude mice compared to transformants containing the wild-type E1B product. This 'gain of function' correlated with enhanced inhibition of p53 transactivation in transient reporter assays and the accumulation of the mutant protein and p53 in several dot-like subnuclear aggregates. Interestingly, these structures also contained a large fraction of cellular promyelocytic leukemia protein (PML), a known regulator of p53. These data indicate that E1B-NES promotes oncogenic transformation by combinatorial mechanisms that involve modulation of p53 in the context of PML nuclear bodies. In sum, these results extend our previous observation that inhibition of PML activities by E1B-55kDa is required for efficient focus formation and provide further support for the view that blocking p53 transcriptional functions is the principal mechanism by which the Ad protein contributes to complete cell transformation in conjunction with Ad E1A.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93047 Regensburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	University of Regensburg; Heinrich Pette Institute	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Landshuterstr 22, D-93047 Regensburg, Germany.	thomas.dobner@klinik.uni-regensburg.de						Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	59	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					55	64		10.1038/sj.onc.1208170	http://dx.doi.org/10.1038/sj.onc.1208170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15480414				2022-12-28	WOS:000226125800008
J	Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ				Li, YH; Lu, WY; He, X; Schwartz, AL; Bu, GJ			LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution	ONCOGENE			English	Article						LRP6; beta-catenin; Writ signaling; proliferation; tumorigenesis	RECEPTOR-RELATED PROTEIN-5; WNT SIGNALING PATHWAY; ACTIVATION; MECHANISM; COMPLEX; PHOSPHORYLATION; OSTEOSARCOMA; DICKKOPF-1; MICE	The Wnt signaling pathway plays key roles in both embryogenesis and tumorigenesis. The low-density lipoprotein (LDL) receptor-related protein-6 (LRP6), a novel member of the expanding LDL receptor family, functions as an indispensable co-receptor for the Wnt signaling pathway. Although the role of LRP6 in embryonic development is now well established, its role in tumorigenesis is unclear. We report that LRP6 is readily expressed at the transcript level in several human cancer cell lines and human malignant tissues. Furthermore, using a retroviral gene transfer system, we find that stable expression of LRP6 in human fibrosarcoma HT1080 cells alters subcellular beta-catenin distribution such that the cytosolic beta-catenin level is significantly increased. This is accompanied by a significant increase in Wnt/beta-catenin signaling and cell proliferation. Finally, we demonstrate that LRP6 expression promotes tumorigenesis in vivo. These results thus indicate that LRP6 may function as a potential oncogenic protein by modulating Wnt/beta-catenin signaling.	Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol,Div Neurosci, Boston, MA 02115 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Li, YH (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.	li_yo@kids.wustl.edu						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; BAO B, 2002, NATURE, V417, P664; BAO B, 2001, NATURE, V411, P321; BRENNAN K, 2004, ONCOGENE; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Klingelhofer J, 2003, ONCOGENE, V22, P1181, DOI 10.1038/sj.onc.1206245; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X	32	67	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9129	9135		10.1038/sj.onc.1208123	http://dx.doi.org/10.1038/sj.onc.1208123			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15516984				2022-12-28	WOS:000225492800014
J	Lodygin, D; Diebold, J; Hermeking, H				Lodygin, D; Diebold, J; Hermeking, H			Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression	ONCOGENE			English	Article						epigenetic silencing; CpG methylation; tumor suppressor; p53; 14-3-3 sigma; prostate cancer	HISTONE DEACETYLASE INHIBITION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; CELL CARCINOMA; EXPRESSION; ADENOCARCINOMA; TUMORIGENESIS; DEMETHYLATION; INACTIVATION; RECEPTOR	In order to identify tumor suppressive genes silenced by CpG methylation in prostate carcinoma (PCa), we determined genome-wide expression changes after pharmacological reversal of CpG methylation-mediated transcriptional repression in three PCa cell lines using microarray analysis. Thereby, epigenetic silencing of the 14-3-3sigma gene was detected in the cell line LNCaP. 14-3-3sigma encodes a p53-regulated inhibitor of cell cycle progression. Laser microdissection was used to isolate different cell types present in diseased prostatic tissue. Subsequent methylation-specific PCR analysis showed CpG methylation of 14-3-3sigma in all 41 primary PCa samples analysed, which was accompanied by a decrease or loss of 14-3-3sigma protein expression. In contrast, normal prostate epithelial and benign prostate hyperplasia cells showed high levels of 14-3-3sigma expression. PCa-precursor lesions (prostatic intraepithelial neoplasia) also displayed decreased levels of 14-3-3sigma expression in luminal cells, which are known to contain shortened telomeres. RNA interference-mediated inactivation of 14-3-3sigma compromised a DNA damage-induced G(2)/M arrest in the PCa cell line PC3. The generality of CpG methylation and downregulation of 14-3-3sigma expression in PCa suggests that it significantly contributes to the formation of PCa, potentially by allowing the escape from a DNA damage-induced arrest elicited by telomere shortening.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Inst Pathol, D-80337 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2002, J CLIN INVEST, V110, P1717, DOI 10.1172/JCI200216588; Meeker AK, 2002, CANCER RES, V62, P6405; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; SAKR WA, 1994, IN VIVO, V8, P439; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Singal R, 2001, CANCER RES, V61, P4820; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	29	74	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9034	9041		10.1038/sj.onc.1208004	http://dx.doi.org/10.1038/sj.onc.1208004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489902				2022-12-28	WOS:000225492800004
J	Saleh-Gohari, N; Helleday, T				Saleh-Gohari, N; Helleday, T			Strand invasion involving short tract gene conversion is specifically suppressed in BRCA2-deficient hamster cells	ONCOGENE			English	Article						homologous recombination; BRCA2; strand invasion; sister chromatid exchange; gene conversion; DNA double-strand break	HOMOLOGY-DIRECTED REPAIR; DNA-REPAIR; CHROMOSOMAL TRANSLOCATIONS; CANCER SUSCEPTIBILITY; MAMMALIAN-CELLS; RAD51 PROTEIN; BREAK REPAIR; BRCA2 LEADS; RECOMBINATION; DEFICIENCY	The BRCA2 tumour suppressor protein is involved in maintaining genetic stability through its role in homologous recombination (HR), where it mediates RAD51-dependent strand invasion. Here, we show that BRCA2-defective cells are not completely impaired in HR by strand invasion although the spontaneous HR rate is 10-fold lower than that in wild-type cells. Furthermore, a DNA double-strand break (DSB) triggers HR repair by strand invasion also in BRCA2-defective cells, but less efficiently. Thus, either the strand invasion pathway(s) in which BRCA2 operates is still operative in the absence of a functional BRCA2, albeit at a reduced frequency, or there is a separate pathway for strand invasion still functional in BRCA2-deficient cells. Consistent with the latter hypothesis, we show that HR events occurring in BRCA2-defective cells differ from HR events in wild-type cells. These data suggest that BRCA2-defective hamster cells are impaired in short tract gene conversion but maintain proficiency in sister chromatid exchange.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Univ Stockholm, Arrhenius Lab, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden	University of Sheffield; Stockholm University	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Gohari, Nasrollah Saleh/ABB-4209-2020	Gohari, Nasrollah Saleh/0000-0003-1256-0323; Helleday, Thomas/0000-0002-7384-092X				Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Friedman LS, 1998, CANCER RES, V58, P1338; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400	28	16	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9136	9141		10.1038/sj.onc.1208178	http://dx.doi.org/10.1038/sj.onc.1208178			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480413				2022-12-28	WOS:000225492800015
J	Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V				Wiederhold, T; Lee, MF; James, M; Neujahr, R; Smith, N; Murthy, A; Hartwig, J; Gusella, JF; Ramesh, V			Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2	ONCOGENE			English	Article						NF2; merlin; tumor suppressor; Grb2; cytoskeleton	ALDRICH-SYNDROME PROTEIN; HUMAN SCHWANNOMA CELLS; TYPE-2 GENE-PRODUCT; NEUROFIBROMATOSIS TYPE-2; TERMINAL DOMAIN; SH3 DOMAINS; F-ACTIN; N-WASP; NHE-RF; MEMBRANE	Neurofibromatosis 2 (NF2) is a dominantly inherited disorder characterized by bilateral vestibular schwannomas and meningiomas. Merlin, the neurofibromatosis 2 tumor suppressor protein, is related to the ERM ( ezrin, radixin, moesin) proteins and, like its family members, is thought to play a role in plasma membrane-cytoskeletal interactions. We report a novel protein as a merlin-specific binding partner that we have named magicin ( merlin and Grb2 interacting cytoskeletal protein) and show that the two proteins interact in vitro and in vivo as well as colocalize beneath the plasma membrane. Magicin is a 24 kDa protein that is expressed in many cell lines and tissues. Magicin, similar to merlin, associates with the actin cytoskeleton as determined by cofractionation, immunofluorescence and electron microscopy. Analysis of the magicin sequence reveals binding motifs for the adaptor protein Grb2. Employing affinity binding, blot overlay and co-immunoprecipitation assays, we demonstrate an interaction between Grb2 and magicin. In addition, merlin is capable of forming a ternary complex with magicin and Grb2. These results support a role for merlin in receptor-mediated signaling at the cell surface, and may have implications in the regulation of cytoskeletal reorganization.	Massachusetts Gen Hosp, Mol Neurosci Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Div Expt Med, Longwood Med Res Ctr, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurosci Unit, Bldg 149,13th St,Rm6222, Charlestown, MA 02129 USA.	ramesh@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; JANNATIPOUR M, 2001, J BIOL CHEM, V29, P29; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Liu CH, 2002, BIOCHEM BIOPH RES CO, V290, P602, DOI 10.1006/bbrc.2001.6119; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; Mayer BJ, 2001, J CELL SCI, V114, P1253; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251	47	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8815	8825		10.1038/sj.onc.1208110	http://dx.doi.org/10.1038/sj.onc.1208110			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467741				2022-12-28	WOS:000225165100011
J	Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R				Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R			Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology	ONCOGENE			English	Article						Mixed -Lineage Leukemia; trithorax; chromatin; Drosophila	ALL-1 GENE; TRITHORAX; TRANSLOCATIONS; DOMAINS; LINEAGE; MUTANTS; MICE; METHYLTRANSFERASE; PHENOTYPES; HOMOLOG	The Mixed Lineage Leukemia (MLL) gene is involved in lymphoblastic and myeloid leukemia through chromosome translocations leading to fusion of MLL to partner genes, or through internal MLL rearrangements. MLL is the mammalian counterpart of the Drosophila trithorax (trx) gene, involved in maintaining active gene expression states. We have used transgenic Drosophila to assess the molecular targets and cellular processes affected by MLL and two of its leukemic fusion proteins. We find that whereas expression of normal human MLL in flies does not result in phenotypic alterations, overexpressing the human MLL-AF9 and MLL-AF4 proteins causes larval to pupal lethality, which interestingly resembles the phenotypes displayed by certain Drosophila trx mutant alleles. MLL-AF9 and MLL-AF4 transgenic flies exhibit antagonistic alterations in cell cycle progression. Additionally, flies expressing MLL-AF9 display impairment in higher order chromatin integrity, evidenced in decondensation of mitotic figures. The effects of MLL fusion proteins in Drosophila suggest that alteration of chromatin structure by MLL fusion proteins may contribute to the lethal phenotype. Our results indicate that the mode(s) of action of MLL-AF9 in Drosophila varies from that of MLL-AF4. Taken together, the expression of MLL fusion proteins in Drosophila provides a new and powerful system to reveal and characterize biological activities associated with MLL fusion proteins.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; Weizmann Inst Sci, IL-76100 Rehovot, Israel; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Ruprecht Karls University Heidelberg; Weizmann Institute of Science; University of Minnesota System; University of Minnesota Twin Cities; Jefferson University	Paro, R (corresponding author), Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany.	paro@sun0.urz.uni-heidelberg.de						Asha H, 2003, GENETICS, V163, P203; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bernardoni R, 1997, DEV BIOL, V191, P118; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CRONMILLER C, 1993, MECH DEVELOP, V42, P159, DOI 10.1016/0925-4773(93)90005-I; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HIDALGO A, 1995, DEVELOPMENT, V121, P3703; Isnard P, 2000, BLOOD, V96, P705; Ito K, 1997, DEVELOPMENT, V124, P761; Kimbrell DA, 2002, GENESIS, V34, P23, DOI 10.1002/gene.10134; Krause SA, 2001, MOL CELL BIOL, V21, P5156, DOI 10.1128/MCB.21.15.5156-5168.2001; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MURRAY MA, 1995, DEV BIOL, V168, P150, DOI 10.1006/dbio.1995.1068; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8639	8648		10.1038/sj.onc.1207904	http://dx.doi.org/10.1038/sj.onc.1207904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378024				2022-12-28	WOS:000224988800010
J	Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH				Xu, XM; Wang, D; Shen, Q; Chen, YQ; Wang, MH			RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells	ONCOGENE			English	Article						colon cancer; oncogenic phenotype; receptor tyrosine kinase; RNA interference	MACROPHAGE-STIMULATING PROTEIN; SPLICING VARIANT; POINT MUTATIONS; INVASIVE GROWTH; TUMOR-FORMATION; BETA-CATENIN; C-MET; IDENTIFICATION; EXPRESSION; CANCER	Altered expression of receptor tyrosine kinases contributes to tumorigenic behaviors of epithelial cancers. In this study, the pathogenic roles of receptor tyrosine kinase RON (recepteur d'origine nantais) in regulating oncogenic phenotypes in colorectal epithelial cells were studied. Increased expression of RON and its variants resulted in colony formation and motile activities of colonic epithelial AA/C1 cells as evident in soft-agar and migration assays, respectively. These results suggest that overexpression of wild-type RON mediates the transformed phenotypes in immortalized colon epithelial cells. In colorectal cancer cells (HT-29, HCT116, and SW620) that naturally express RON, the RON gene expression was silenced by RNA interference. The introduction of RON-specific small interfering ( si) RNA significantly affected cancer cell proliferation, motility, and led to increased apoptotic cell death. Focus-forming activities and anchorage-independent growth of colon cancer cells were also dramatically reduced. Moreover, it was demonstrated in tumor growth assays that silencing RON gene expression significantly reduces tumorigenic activities of SW620 cells in vivo. By analysing signaling proteins involved in colon carcinogenesis, we found that the effect of RON-specific siRNA is associated with diminished expression of beta-catenin, a critical component in the Wnt signaling pathway. Taken together, our results demonstrate that altered expression of RON in colon cancer cells is required to maintain tumorigenic phenotypes. Thus, silencing RON gene expression could have potential to reverse malignant activities of colon tumors in vivo.	Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; Zhejiang Univ, Coll Med, Affiliated Hosp 1,Inst Infect Dis, Lab Cheung Kong Scholars Program Biomed Sci, Hangzhou 310027, Peoples R China	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Zhejiang University	Wang, MH (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter Dr, Amarillo, TX 79106 USA.	minghai.wang@ttuhsc.edu			NCI NIH HHS [R01 CA91980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Crawford J., 1994, GASTROINTESTINAL TRA; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; Earp H Shelton 3rd, 2003, Trans Am Clin Climatol Assoc, V114, P315; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	45	61	72	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8464	8474		10.1038/sj.onc.1207907	http://dx.doi.org/10.1038/sj.onc.1207907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378025				2022-12-28	WOS:000224870700007
J	Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH				Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH			Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis	ONCOGENE			English	Article						PDCD4; apoptosis; retinoic acid receptor; breast cancer; cell cycle	RETINOIC ACID RECEPTORS; MAMMARY EPITHELIAL-CELLS; TRANSFORMATION SUPPRESSOR; GROWTH-INHIBITION; CYCLIN D1; PROTEIN; ARREST; ALPHA; CARCINOMA; DEATH	The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better de. ne the genes involved in RAR-mediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RARalpha-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2/neu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER+, RAR(+)) and MDA-MB-231 (ER-, RAR(-)) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2/neu antagonist in breast cancer cells and its potential role in apoptosis in these cells.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Saga Med Sch, Dept Internal Med, Saga 8498501, Japan	New York University; New York University; Saga University	Afonja, O (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave, New York, NY 10016 USA.	afonjo01@popmail.med.nyu.edu			NCI NIH HHS [K12CA01713] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMOS B, 1990, METHOD ENZYMOL, V190, P217; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grunt TW, 2003, CANCER LETT, V189, P147, DOI 10.1016/S0304-3835(02)00512-8; Gumireddy K, 2003, CLIN CANCER RES, V9, P4052; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; Jansen Aaron P., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P938; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MATSUHASHI S, 1987, EXP CELL RES, V170, P351, DOI 10.1016/0014-4827(87)90312-0; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Offterdinger M, 2003, J CELL PHYSIOL, V195, P260, DOI 10.1002/jcp.10237; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Orlandi M, 2003, MED PRIN PRACT, V12, P164, DOI 10.1159/000070753; Pratt MAC, 2003, J CELL BIOCHEM, V90, P692, DOI 10.1002/jcb.10682; Raffo P, 2000, ANTICANCER RES, V20, P1535; ROMAN SD, 1993, CANCER RES, V53, P5940; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Suzuki T, 2001, BREAST CANCER RES TR, V65, P31, DOI 10.1023/A:1006433929792; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Veselska R, 2003, ONCOL REP, V10, P1049; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Wilcken NRC, 1997, INT J CANCER, V70, P291, DOI 10.1002/(SICI)1097-0215(19970127)70:3<291::AID-IJC8>3.3.CO;2-B; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Ye XF, 2004, INT J BIOCHEM CELL B, V36, P98, DOI 10.1016/S1357-2725(03)00143-2; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	58	135	145	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8135	8145		10.1038/sj.onc.1207983	http://dx.doi.org/10.1038/sj.onc.1207983			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361828				2022-12-28	WOS:000224692500011
J	Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O				Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O			Global transcription analysis of immature avian erythrocytic progenitors: from self-renewal to differentiation	ONCOGENE			English	Article						self-renewal; differentiation; SAGE; erythroid progenitors	STEM-CELLS; GENE-EXPRESSION; SERIAL ANALYSIS; GLUCOCORTICOID-RECEPTOR; CANCER; ADULT; SAGE; PHOSPHORYLATION; CANDIDATE; INDUCE	The molecular mechanisms regulating the cell fate decision between self-renewal and differentiation/apoptosis in stem and progenitor cells are poorly understood. Here, we report the first comprehensive identification of genes potentially involved in the switch from self-renewal toward differentiation of primary, non-immortalized erythroid avian progenitor cells (T2EC cells). We used the Serial Analysis of Gene Expression ( SAGE) technique in order to identify and quantify the genome fraction functionally active in a self-renewing versus a differentiating cell population. We generated two SAGE libraries and sequenced a total of 37 589 tags, thereby obtaining the first transcriptional pro. le characterization of a chicken cell. Tag identification was performed using a new relational database (Identitag) developed in the laboratory, which allowed a highly satisfactory level of identification. Among 123 differentially expressed genes, 11 were investigated further and for nine of them the differential expression was subsequently confirmed by real-time PCR. The comparison of tag abundance between the two libraries revealed that only a small fraction of transcripts was differentially expressed. The analysis of their functions argue against a prominent role for a master switch in T2EC cells decision-making, but are in favor of a critical role for coordinated small variations in a relatively small number of genes that can lead to essential cellular identity changes.	Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Damiola, F (corresponding author), Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, Bat Gregore Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Damiola@cgmc.univ-lyon1.fr; Keime@cgmc.univ-lyon1.fr; Gonin@cgmc.univ-lyon1.fr; Dazy@cgmc.univ-lyon1.fr; Gandrillon@cgmc.univ-lyon1.fr		Damiola, Francesca/0000-0002-0238-1252; KEIME, Celine/0000-0001-7604-3814				ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Antica M, 1997, IMMUNOL LETT, V55, P47, DOI 10.1016/S0165-2478(96)02682-X; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Becquet C, 2002, GENOME BIOL, V3; Boheler KR, 2003, TRENDS BIOTECHNOL, V21, P55, DOI 10.1016/S0167-7799(02)00031-8; Cao A, 2002, PEDIATR RES, V51, P415, DOI 10.1203/00006450-200204000-00003; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; Detmer K, 2000, BLOOD CELL MOL DIS, V26, P360, DOI 10.1006/bcmd.2000.0318; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Fortunel NO, 2003, SCIENCE, V302, P393; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; Heller S, 1998, P NATL ACAD SCI USA, V95, P11400, DOI 10.1073/pnas.95.19.11400; HINSSEN H, 1987, J CELL BIOL, V105, P1425, DOI 10.1083/jcb.105.3.1425; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Ivanova NB, 2003, SCIENCE, V302; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; KEIME C, 2004, UNPUB; Keith WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Man MZ, 2000, BIOINFORMATICS, V16, P953, DOI 10.1093/bioinformatics/16.11.953; Margulies EH, 2000, BIOINFORMATICS, V16, P650, DOI 10.1093/bioinformatics/16.7.650; Marone M, 2002, LEUKEMIA, V16, P94, DOI 10.1038/sj.leu.2402334; Matsumura F, 2001, CELL STRUCT FUNCT, V26, P639, DOI 10.1247/csf.26.639; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roessler E, 1999, HUM GENET, V105, P489, DOI 10.1007/s004390051135; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhou GL, 2001, P NATL ACAD SCI USA, V98, P13966, DOI 10.1073/pnas.241526198	44	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7628	7643		10.1038/sj.onc.1208061	http://dx.doi.org/10.1038/sj.onc.1208061			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15378009				2022-12-28	WOS:000224306700004
J	Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M				Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M			Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions	ONCOGENE			English	Article						budesonide; lung cancer; chemoprevention; A/J mice; expression profile	FEMALE A/J MICE; PULMONARY CARCINOGENESIS; APOPTOSIS; MYOINOSITOL; PROGRESSION; CARCINOMAS; RESISTANCE; MECHANISMS; HORMONES; PATHWAYS	Budesonide, a glucocorticoid, was proven to be a highly effective agent in preventing the development of lung tumors in A/J mice. In a lung tumor bioassay, budesonide produced 70% inhibition of tumor multiplicity and 94% reduction of total tumor load compared to benzopyrene ( B[ a] P) treated mice. Gene expression array analysis was performed on mouse lung tumors from this bioassay using Affymetrix U74Av2 GeneChips to determine gene expression changes associated with budesonide treatment. We found 363 genes that were changed between lung tumors induced by treatment with B[ a] P and similar tumors treated with budesonide. Among them, 243 genes were overexpressed and 120 genes were underexpressed after budesonide treatment. In addition, 108 genes differentially expressed during mouse lung tumorigenesis (50 genes overexpressed and 58 genes underexpressed) were modulated back to normal levels after budesonide treatment when compared with the controls group. These genes are involved in a broad range of different pathways including control of cell cycle, signal transduction, and apoptosis and may play a role in the observed preventive effect. Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9. Using the pathway visualization tool GenMapp, G protein pathway and MAPK cascade were also regulated by budesonide. Thus, we have determined, for the first time, the expression profiles of genes modulated by budesonide during murine lung tumorigenesis. Our results indicate that the chemopreventive effects of budesonide in the mouse lung tumorigenesis assay involved increase and decrease expression of a wide variety of genes in multiple signaling pathways.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						*AM CANC SOC, 2003, CANC FACTS FIG 2003, P4; BELMAN S, 1972, CANCER RES, V32, P450; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Herr I, 2003, CANCER RES, V63, P3112; Herzog CR, 1997, J CELL BIOCHEM, P49; HUANG J, 2003, J BIOL CHEM, V16, P16; KITAZONO AA, 2003, MOL GENET GENOMICS, V24, P24; Li Xia, 2003, Journal of Shanghai Fisheries University, V12, P12; MALKINSON AM, 1992, CANCER RES, V52, pS2670; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 2000, CARCINOGENESIS, V21, P179, DOI 10.1093/carcin/21.2.179; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; Yao RS, 2003, NEOPLASIA, V5, P41, DOI 10.1016/S1476-5586(03)80016-7; Yao RS, 2002, ONCOGENE, V21, P5814, DOI 10.1038/sj.onc.1205422; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7746	7752		10.1038/sj.onc.1207985	http://dx.doi.org/10.1038/sj.onc.1207985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361829				2022-12-28	WOS:000224306700016
J	Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K				Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K			TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions	ONCOGENE			English	Article						TGF-beta; HGF; JNK; MAPK; Smad; PAI-1	TRANSFORMING-GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; FUNCTIONAL-CHARACTERIZATION; IDENTIFICATION; INHIBITOR; RECEPTOR; P15(INK4B); MECHANISM; PATHWAYS; PROMOTER	Although hepatocyte growth factor (HGF) can act synergistically or antagonistically with transforming growth factor-beta (TGF-beta) signaling, molecular mechanism of their crosstalk remains unknown. Using antibodies which selectively distinguished receptor-regulated Smads (R-Smads) phosphorylated at linker regions from those at C-terminal regions, we herein showed that either HGF or TGF-beta treatment of normal stomach-origin cells activated the JNK pathway, thereafter inducing endogenous R-Smads phosphorylation at linker regions. However, the phosphorylation at their C-terminal regions was not induced by HGF treatment. The activated JNK could directly phosphorylate R-Smads in vitro at the same sites that were phosphorylated in response to TGF-beta or HGF in vivo. Thus, the linker regions of R-Smads were the common phosphorylation sites for HGF and TGF-beta signaling pathways. The phosphorylation induced by simultaneous treatment with HGF and TGF-beta allowed R-Smads to associate with Smad4 and to translocate into the nucleus. JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals. Moreover, a combined treatment with HGF and TGF-beta led to a potent increase in plasminogen activator inhibitor type 1 transcriptional activity through Smad3 phosphorylation at the linker region. In contrast, HGF treatment reduced TGF-beta-dependent activation of p15(INK4B) promoter, in which Smad3 phosphorylation at the C-terminal region was involved. In conclusion, HGF and TGF-beta transmit the signals through JNK-mediated R-Smads phosphorylation at linker regions.	Kansai Med Univ, Dept Internal Med 3, Osaka 5708507, Japan; Univ Tsukuba, Inst Clin Med, Div Gastroenterol, Tsukuba, Ibaraki 3058576, Japan; Inst Chem & Phys RIKEN, RIKEN Cell Bank, Tsukuba, Ibaraki 3050074, Japan; Kansai Med Univ, Dept Med Chem, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Osaka 5708507, Japan	Kansai Medical University; University of Tsukuba; RIKEN; Kansai Medical University; Kansai Medical University	Matsuzaki, K (corresponding author), Kansai Med Univ, Dept Internal Med 3, 10-15 Fumizonocho, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Gutierrez LS, 2000, CANCER RES, V60, P5839; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; WRANA JL, 2000, SCI STKE, pRE1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	37	162	174	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7416	7429		10.1038/sj.onc.1207981	http://dx.doi.org/10.1038/sj.onc.1207981			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326485				2022-12-28	WOS:000224021400012
J	Henry, MD; Triplett, AA; Oh, KB; Smith, GH; Wagner, KU				Henry, MD; Triplett, AA; Oh, KB; Smith, GH; Wagner, KU			Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice	ONCOGENE			English	Article						mammary gland; differentiation; Cre recombinase; tumorigenesis; mouse mammary tumor virus; transgenics	PROGENITOR CELLS; EXPRESSION; GLAND; POPULATION; PREGNANCY; PATHOLOGY; DELETION; TSG101; BREAST	Using a Cre-lox-based genetic labeling technique, we have recently discovered a parity-induced mammary epithelial subtype that is abundant in nonlactating and nonpregnant, parous females. These mammary epithelial cells serve as alveolar progenitors in subsequent pregnancies, and transplantation studies revealed that they possess features of multipotent progenitors such as self-renewal and the capability to contribute to ductal and alveolar morphogenesis. Here, we report that these cells are the cellular targets for transformation in MMTV-neu transgenic mice that exhibit accelerated mammary tumorigenesis in multiparous animals. The selective ablation of this epithelial subtype reduces the onset of tumorigenesis in multiparous MMTV-neu transgenics. There is, however, experimental evidence to suggest that parity-induced mammary epithelial cells may not be the only cellular targets in other MMTV-promoter-based transgenic strains. In particular, the heterogeneous MMTV-wnt1 lesions predominantly express the ductal differentiation marker Nkcc1 that is absent in MMTV-neu-derived tumors. Our observations support the idea that tumors originate from distinctly different epithelial subtypes in selected MMTV-promoter-driven cancer models and that diverse oncogenes might exert discrete effects on particular mammary epithelial subtypes.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,Room 8009, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NCI NIH HHS [CA036727, CA93797] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010021, P30CA036727, R01CA093797, Z01BC010021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brisken C, 2000, GENE DEV, V14, P650; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARSTENS MJ, 2004, UNPUB; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Kisseberth WC, 2004, CANCER RES, V64, P857, DOI 10.1158/0008-5472.CAN-03-2701; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; Reed W, 2003, INT J SURG PATHOL, V11, P65, DOI 10.1177/106689690301100201; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rowse GJ, 1998, CANCER RES, V58, P2675; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wagner KU, 2003, MOL CELL BIOL, V23, P150, DOI 10.1128/MCB.23.1.150-162.2003; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WELLINGS SR, 1975, J NATL CANCER I, V55, P231	20	93	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6980	6985		10.1038/sj.onc.1207827	http://dx.doi.org/10.1038/sj.onc.1207827			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286714				2022-12-28	WOS:000223750700014
J	Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME				Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME			INK4a/Arf is required for suppression of EGFR/Delta EGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma	ONCOGENE			English	Article						INK4a/Arf; EGFR; TP53; ERK; glioma	GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; EGF RECEPTOR; GENE AMPLIFICATION; HUMAN GLIOBLASTOMA; SIGNALING PATHWAY; TUMOR SUPPRESSION; P16(INK4A) GENE; CYCLE ARREST; P53	Amplification of the epidermal growth factor receptor ( EGFR) or expression of its constitutively activated mutant, DeltaEGFR(2-7), in association with the inactivation of the INK4a/Arf gene locus is a frequent alteration in human glioblastoma. The notion of a cooperative effect between these two alterations has been demonstrated in respective mouse brain tumor models including our own. Here, we investigated underlying molecular mechanisms in early passage cortical astrocytes deficient for p16(INK4a)/p19(Arf) or p53, respectively, with or without ectopic expression of DeltaEGFR(2-7). Targeting these cells with the specific EGFR inhibitor tyrphostin AG1478 revealed that phosphorylation of ERK was only abrogated in the presence of an intact INK4a/Arf gene locus. The sensitivity to inhibit ERK phosphorylation was independent of ectopic expression of DeltaEGFR(2-7) and independent of the TP53 status. This resistance to downregulate the MAPK pathway in the absence of INK4a/Arf was confirmed in cell lines derived from our mouse glioma models with the respective initial genetic alterations. Thus, deletion of INK4a/Arf appears to keep ERK in its active, phosphorylated state insensitive to an upstream inhibitor specifically targeting EGFR/DeltaEGFR(2-7). This resistance may contribute to the cooperative tumorigenic effect selected for in human glioblastoma that may be of crucial clinical relevance for treatments specifically targeting EGFR/DeltaEGFR( 2-7) in glioblastoma patients.	Univ Hosp CHUV, Dept Neurosurg, Lab Tumor Biol Genet, CH-1011 Lausanne, Switzerland; Natl Ctr Competence NCCR Mol Oncol, ISREC, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research	Hegi, ME (corresponding author), Univ Hosp CHUV, Dept Neurosurg, Lab Tumor Biol Genet, BH19-110, CH-1011 Lausanne, Switzerland.	Monika.Hegi@chuv.hospvd.ch	KOBAYASHI, Hiroyuki/G-8990-2012; Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; BOGLER O, 1995, CANCER RES, V55, P2746; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Choe G, 2003, CANCER RES, V63, P2742; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; D'Amico M, 2003, CANCER RES, V63, P3395; Davies MA, 1998, CANCER RES, V58, P5285; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gazzeri S, 1998, CANCER RES, V58, P3926; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Getz G, 2003, BIOINFORMATICS, V19, P1153, DOI 10.1093/bioinformatics/btg143; Godard S, 2003, CANCER RES, V63, P6613; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HAEDER M, 1988, CANCER RES, V48, P1132; Han YC, 1996, CANCER RES, V56, P3859; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hegi ME, 2000, CANCER RES, V60, P3019; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Ichimura K, 2000, CANCER RES, V60, P417; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kleihues P, 2000, PATHOLOGY GENETICS T; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Kuo ML, 2003, CANCER RES, V63, P1046; Labuhn M, 2001, ONCOGENE, V20, P1103, DOI 10.1038/sj.onc.1204197; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li B, 2003, CANCER RES, V63, P7443; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Okada Y, 2003, CANCER RES, V63, P413; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QUELLE DE, 1995, CELL, V83, P993; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Reich A, 1999, DEVELOPMENT, V126, P4139; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Steinbach JP, 2002, BRAIN PATHOL, V12, P12; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	62	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6854	6863		10.1038/sj.onc.1207872	http://dx.doi.org/10.1038/sj.onc.1207872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273738				2022-12-28	WOS:000223750700002
J	Parkin, DM				Parkin, DM			International variation	ONCOGENE			English	Article						geography; incidence; mortality; migrants; ethnicity	HEMOGLOBIN ADDUCT LEVELS; S-TRANSFERASE M1; CANCER-MORTALITY; CERVICAL-CANCER; GASTRIC-CARCINOMA; AFRICAN MIGRANTS; C VIRUS; EPIDEMIOLOGY; BREAST; RISK	There were an estimated 10 million new cases, 6 million deaths and 22 million persons living with cancer in the year 2000. The most common cancers are, in terms of new cases, lung (1.2 million), breast (1.05 million), colon rectum (945000), stomach (876 000) and liver (564 000). The geographic distributions of some 20 types of cancer for which national estimates have been made are summmarized. These patterns are examined with respect to the likely reasons in terms of variation in exposure to carcinogens (in the external environment or through lifestyle choices) or in genetic susceptibility to them. Related data from studies of migrant populations (that allow comparisons of genetically similar populations living in different environments) and from comparisons between different ethnic groups living in the same country are used to help in the interpretation of the geographic patterns. Information on the burden of disease also has a very important role in the planning and monitoring of programmes of cancer control.	Int Agcy Res Canc, Unit Descript Epidemiol, F-69372 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC)	Parkin, DM (corresponding author), Int Agcy Res Canc, Unit Descript Epidemiol, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	parkin@iarc.fr						[Anonymous], 1997, DIET NUTR PREV CANC; Arbyn M, 2002, INT J CANCER, V102, P649, DOI 10.1002/ijc.10761; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BASSETT MT, 1995, INT J CANCER, V63, P29, DOI 10.1002/ijc.2910630107; Bergstrom A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1053&gt;3.0.CO;2-T; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Bouchardy C, 1996, INT J EPIDEMIOL, V25, P5, DOI 10.1093/ije/25.1.5; BOUCHARDY C, 1991, CANCER EPIDEM BIOMAR, V1, P21; BOUCHARDY C, 1995, CANCER CAUSE CONTROL, V6, P539, DOI 10.1007/BF00054163; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; Brinton LA, 1997, INT J CANCER, V73, P349, DOI 10.1002/(SICI)1097-0215(19971104)73:3<349::AID-IJC8>3.0.CO;2-#; COGGON D, 1990, BRIT J CANCER, V61, P573, DOI 10.1038/bjc.1990.128; CORREA P, 1973, JNCI-J NATL CANCER I, V51, P1449, DOI 10.1093/jnci/51.5.1449; Doll R, 1981, CAUSES CANC; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Dorn HF, 1959, PUBLIC HLTH MONOGRAP, V56; EASTON DF, 1994, BRIT MED BULL, V50, P527, DOI 10.1093/oxfordjournals.bmb.a072908; FERLAY J, 2000, IARC CANC BASE, V5; Fu Y S, 1987, Appl Pathol, V5, P47; Geddes M, 1993, IARC SCI PUBLICATION, V123; GOEDDE HW, 1992, HUM GENET, V88, P344; GRIFFITH GW, 1968, BRIT J CANCER, V22, P163, DOI 10.1038/bjc.1968.23; Gustafsson L, 1997, INT J CANCER, V71, P159, DOI 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#; HARTGE P, 1992, CANCER RES, V52, pS5566; Hirsch A, 1883, HDB GEOGRAPHICAL HIS, VI; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V61; Ishibe N, 1997, CANCER CAUSE CONTROL, V8, P504, DOI 10.1023/A:1018421724776; Kolonel LN, 1980, GENETIC ENV FACTORS, P327; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEE HP, 1988, IARC SCI PUBLICATION, V91; MAHBOUBI E, 1973, BRIT J CANCER, V28, P192, DOI 10.1038/bjc.1973.138; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCMICHAEL AJ, 1980, INT J CANCER, V25, P431, DOI 10.1002/ijc.2910250402; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Miller BA, 1996, NIH PUBLICATION, V96-4104; MUNOZ N, 1988, INT CONGR SER, V795, P51; Munoz N, 1997, SALUD PUBLICA MEXICO, V39, P318; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; Munoz N, 1992, IARC SCI PUBLICATION; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Norppa H, 1997, ENVIRON HEALTH PERSP, V105, P829, DOI 10.2307/3433290; Parkin DM, 1999, CANCER SURV, V33, P5; PARKIN DM, 1989, EUR J CANCER CLIN ON, V25, P1917; PARKIN DM, 1994, INT J CANCER, V59, P494, DOI 10.1002/ijc.2910590411; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1996, EUR J CANCER, V32A, P761, DOI 10.1016/0959-8049(96)00062-7; PARKIN DM, 1993, CANCER EPIDEM BIOMAR, V2, P537; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Parkin DM, 2003, IARC SCI PUBLICATION, V153; Parkin DM, 2002, IARC SCI PUBLICATION, VVIII; Peto R, 1994, MORTALITY SMOKING DE; PHAM THA, 2002, INT J CANCER, V104, P213; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; PUKKALA E, 2001, CANC SOC FINLAND PUB, V62; ROSE EF, 1975, BRIT J CANCER, V31, P197, DOI 10.1038/bjc.1975.26; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sadjadi A, 2003, INT J CANCER, V107, P113, DOI 10.1002/ijc.11359; Shapiro Sidney, 1979, AM CHINA 30 YEARS PE; Shibata A, 1997, PROSTATE, V32, P65; SIGURDSSON K, 1995, EUR J CANCER, V31A, P728, DOI 10.1016/0959-8049(94)00531-9; Silvi John, 2003, Epidemiol Bull, V24, P1; SITAS F, 1992, GUT, V33, P1582, DOI 10.1136/gut.33.11.1582; SMANS M, 1992, IARC SCI PUBLICATION, V107; TANAKA H, 1994, CANCER CAUSE CONTROL, V5, P409, DOI 10.1007/BF01694754; TUYNS AJ, 1975, INT J EPIDEMIOL, V4, P55, DOI 10.1093/ije/4.1.55; TUYNS AJ, 1973, INT J EPIDEMIOL, V2, P241, DOI 10.1093/ije/2.3.241; TYCZYNSKI J, 1994, EUR J CANCER, V30A, P478, DOI 10.1016/0959-8049(94)90423-5; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; World Health Organization, 2002, NAT CANC CONTR PROGR; YATANI R, 1982, INT J CANCER, V29, P611, DOI 10.1002/ijc.2910290602; Yokoyama A, 2002, CARCINOGENESIS, V23, P1851, DOI 10.1093/carcin/23.11.1851; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; YU MC, 1995, CANCER EPIDEM BIOMAR, V4, P861; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819	76	538	578	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6329	6340		10.1038/sj.onc.1207726	http://dx.doi.org/10.1038/sj.onc.1207726			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322508				2022-12-28	WOS:000223468800002
J	King, TJ; Gurley, KE; Prunty, J; Shin, JL; Kemp, CJ; Lampe, PD				King, TJ; Gurley, KE; Prunty, J; Shin, JL; Kemp, CJ; Lampe, PD			Deficiency in the gap junction protein Connexin32 alters p27(Kip1) tumor suppression and MAPK activation in a tissue-specific manner	ONCOGENE			English	Article						gap junction; connexin; p27(Kip1); radiation; lung; liver; carcinogenesis; Connexin32; mouse; knock-out (KO)	DEPENDENT KINASE INHIBITOR; INTERCELLULAR COMMUNICATION; INDUCIBLE EXPRESSION; EPITHELIAL-CELLS; MICE DEFICIENT; BETA-CATENIN; LUNG-TUMORS; MOUSE; LIVER; TUMORIGENESIS	Connexin32 knockout mice (Cx32-KO) exhibit increased chemical- and radiation-induced liver and lung tumor formation with many lung tumors demonstrating decreased levels of the tumor suppressor p27(KIP1). To determine if p27 deficiency alters Cx32-influenced tumorigenesis, we have generated a Cx32/p27 double-deficient mouse strain (DKO) and show here that exposure of these mice to X-ray radiation resulted in an increase or decrease in tumorigenesis depending on the tissue. Several tissues were highly sensitive to loss of p27 tumor suppressor function ( intestine, adrenal, pituitary) resulting in an increased overall tumor burden in DKO mice compared to both wild-type (P<0.005) and Cx32-KO mice ( P = 0.066). However, additional deletion of p27 in a Cx32-KO background resulted in a statistically significant decrease in the liver tumor incidence suggesting that Cx32 and p27 pathways mechanistically interact. Immunohistochemical analysis revealed an increased percentage of Cx32-KO liver and lung tumors harboring active mitogen-activated protein kinase (Erk1, Erk2) pathways in contrast to lower percentages of activated wild-type (P<0.005) and DKO tumors ( P = 0.027). Increased MAPK activation in liver tumors did not correlate with Ha-ras codon-61 mutation status. This study demonstrates that tissues dependent on Cx32 tumor suppression, such as the liver and lung, exhibit altered tumorigenesis and tumor biology (MAPK pathway activation) related to p27 status.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Res Progam, Seattle, WA USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Canc Biol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	King, TJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Res Progam, 1100 Fairview Ave N,M5-C800, Seattle, WA USA.	tking@fhcrc.org			NIAID NIH HHS [T32-AI07509] Funding Source: Medline; NIAMS NIH HHS [AR47963] Funding Source: Medline; NIGMS NIH HHS [R01 GM055632, GM55632] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham V, 2001, AM J PHYSIOL-LUNG C, V280, pL1085, DOI 10.1152/ajplung.2001.280.6.L1085; Avanzo JL, 2004, CARCINOGENESIS, V25, P1973, DOI 10.1093/carcin/bgh193; Aydinlik H, 2001, ONCOGENE, V20, P7812, DOI 10.1038/sj.onc.1204982; Defamie N, 2003, LAB INVEST, V83, P449, DOI 10.1097/01.LAB.0000059928.82702.6D; Evert M, 2002, CARCINOGENESIS, V23, P697, DOI 10.1093/carcin/23.5.697; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; King TJ, 2000, CARCINOGENESIS, V21, P1097, DOI 10.1093/carcin/21.6.1097; King TJ, 2004, CARCINOGENESIS, V25, P669, DOI 10.1093/carcin/bgh071; King TJ, 2004, CANCER RES, V64, P7191, DOI 10.1158/0008-5472.CAN-04-0624; King TJ, 2002, MOL CARCINOGEN, V35, P29, DOI 10.1002/mc.10071; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Koval M, 2002, AM J PHYSIOL-LUNG C, V283, pL875, DOI 10.1152/ajplung.00078.2002; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lo CW, 1999, DEV GENET, V24, P1, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<1::AID-DVG1>3.0.CO;2-U; Lumniczky K, 1998, MOL CARCINOGEN, V21, P100, DOI 10.1002/(SICI)1098-2744(199802)21:2<100::AID-MC4>3.3.CO;2-Z; Maronpot R, 1999, PATHOLOGY MOUSE; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Moennikes O, 1999, CARCINOGENESIS, V20, P1379, DOI 10.1093/carcin/20.7.1379; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nelles E, 1996, P NATL ACAD SCI USA, V93, P9565, DOI 10.1073/pnas.93.18.9565; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Richard G, 2001, Adv Dermatol, V17, P243; Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384; Scherer SS, 1998, GLIA, V24, P8, DOI 10.1002/(SICI)1098-1136(199809)24:1<8::AID-GLIA2>3.0.CO;2-3; Schwarz M, 2003, TOXICOL PATHOL, V31, P99, DOI 10.1080/01926230390173932; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Temme A, 2001, PFLUG ARCH EUR J PHY, V442, P961, DOI 10.1007/s004240100623; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Upham BL, 2003, INT J CANCER, V104, P12, DOI 10.1002/ijc.10899; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yao RS, 2003, NEOPLASIA, V5, P41, DOI 10.1016/S1476-5586(03)80016-7; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623	43	45	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1718	1726		10.1038/sj.onc.1208355	http://dx.doi.org/10.1038/sj.onc.1208355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608667				2022-12-28	WOS:000227345100008
J	Xiao, Z; Xue, J; Sowin, TJ; Rosenberg, SH; Zhang, HY				Xiao, Z; Xue, J; Sowin, TJ; Rosenberg, SH; Zhang, HY			A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation	ONCOGENE			English	Article						5-fluorouracil (5-FU); antimetabolites; phospho-histone H2A.X; Chk1; premature chromosomal condensation (PCC); mitotic catastrophe	DNA-DAMAGE CHECKPOINT; INDUCED CELL-DEATH; TUMOR-CELLS; NUCLEOSIDE ANALOGS; APOPTOSIS; SURVIVAL; PATHWAY; 5-FLUOROURACIL; INHIBITION; PROTEASE	Chk1 is the major mediator in the activation of cell-cycle checkpoints in response to a variety of genotoxic stresses. We have previously shown that inhibition of Chkl sensitizes tumor cells to topoisomerase inhibitors such as camptothecin and doxorubicin through abrogation of cell-cycle arrest (S or G2/M checkpoints). However, it was not clear whether inhibition of Chkl could potentiate antimetabolites, a mainstay of cancer therapy, which confer genotoxic stress through a different mechanism than topoisomerase inhibitors. 5-Fluorouracil (5-FU) is the most widely used antimetabolite in the treatment of colorectal, breast and other major types of cancers. Here we demonstrate that 5-FU activates Chk1 and induces an early S-phase arrest. Chk1 downregulation abrogates this arrest and dramatically sensitizes tumor cells to the cytotoxic effects of 5-FU. 5-FU confers S-phase arrest through Chk1-mediated Cdc25A proteolysis leading to inhibition of Cdk2. Chkl elimination stabilizes the Cdc25A protein and results in the abrogation of the S checkpoint and resumption of DNA synthesis, which leads to excessive accumulation of double-stranded DNA breaks. As a result, downregulation of Chk1 potentiates 5-FU efficacy through induction of premature chromosomal condensation followed by apoptosis. Interestingly, the profiles of various cell-cycle markers indicate that cells progress to early M phase to induce apoptosis after checkpoint abrogation. Yet, cells fail to increase their DNA content to 4N as revealed by FACS analysis, probably due to the dramatic induction of double-stranded DNA breaks and chromosomal fragmentation. This is significantly different from the cell-cycle profiles observed in the potentiation of topoisomerase inhibitors by Chk1 siRNA, which showed mitotic progression with 4N DNA content leading to mitotic catastrophe after abrogation of the S or G2 checkpoint. Thus, our results illustrate a novel mode of checkpoint abrogation and cell death conferred by Chk1 inhibition. Additionally, we show that Chkl deficiency potentiates 5-FU efficacy through the preferential induction of the caspase-8 pathway and subsequent caspase-3 activation. In conclusion, we have clearly demonstrated that inhibition of Chk1 not only potentiates the toxicity of conventional DNA-damaging agents such as ionizing radiation and topoisomerase inhibitors, but also enhances the toxicity of antimetabolites in cancer cell lines. This discovery reveals novel scope of checkpoint abrogation and will significantly broaden the potential application of Chk1 inhibitors in cancer therapy if they do not potentiate the toxicity of 5-FU in normal cells. Published online 20 December 2004.	Abbott Labs, Canc Res, N Chicago, IL 60064 USA	Abbott Laboratories	Zhang, HY (corresponding author), Abbott Labs, Canc Res, 100 Abbott Pk Rd, N Chicago, IL 60064 USA.	zhan.xiao@abbott.com						Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen ZH, 2003, MOL CANCER THER, V2, P543; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Eastman A, 2002, MOL CANCER THER, V1, P1067; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Johnston PG, 2001, ANTI-CANCER DRUG, V12, P639, DOI 10.1097/00001813-200109000-00001; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Liu QH, 2000, GENE DEV, V14, P1448; Lock RB, 1996, CANCER RES, V56, P4006; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwartzberg LS, 2002, CLIN CANCER RES, V8, P2488; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Shi Z, 2001, CANCER RES, V61, P1065; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Torres K, 1998, CANCER RES, V58, P3620; TOUNEKTI O, 1993, CANCER RES, V53, P5462; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	29	80	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1403	1411		10.1038/sj.onc.1208309	http://dx.doi.org/10.1038/sj.onc.1208309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608676				2022-12-28	WOS:000227092600010
J	Blanc, E; Le Roux, G; Benard, J; Raguenez, G				Blanc, E; Le Roux, G; Benard, J; Raguenez, G			Low expression of Wnt-5a gene is associated with high-risk neuroblastoma	ONCOGENE			English	Article						Wnt-5a; metastatic neuroblastoma; retinoic acid; differentiation	KINASE-C-THETA; NEURAL CREST; NEURONAL DIFFERENTIATION; RETINOIC ACID; GROWTH-FACTOR; LUNG-CANCER; CELLS; PROTEIN; SHAPE; OVEREXPRESSION	Disseminated forms of neuroblastoma (NB), a tumor derived from neuroectodermal tissue, pose a major therapeutic challenge for pediatric oncology. By performing a comparative cDNA array analysis of metastatic neuroblasts versus primary xenograft from the human IGR-N-91 NB model, we were able to identify a set of downregulated developmental genes in metastatic neuroblasts. One of these genes was Wnt-5a, a member of the Wnt signaling pathway, known to be involved in the development of neural crest cells. Since we also found a significant decrease in Wnt-5a mRNA in unfavorable versus favorable categories in 37 primary NB tumors (P<0.007), we wondered whether retinoic acid (RA), which has a role in neural crest induction and differentiation, might reverse the aberrant negative regulation of Wnt-5a in metastatic malignant neuroblasts. Following treatment with 10 muM RA for 6 days, the MYCN-amplified IGR-N-91 cell lines underwent neuronal differentiation as assessed by reduced MYCN gene expression and neuritic extension. In these conditions, data showed an upregulation of Wnt-5a and PKC-theta isoform expressions. Our study highlights, for the first time, the involvement of Wnt-5a, which has a role in embryonic and morphogenetic processes, in the response of malignant neuroblasts to RA. In conclusion, we demonstrated that RA, which is used in the treatment of high-risk NB patients with recurrent/residual disease in the bone marrow, is able to upregulate Wnt-5a gene expression.	Univ Paris Sud, Inst Federat Rech 54, Inst Gustave Roussy, CNRS,UMR 8126, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Genet, Dept Biol, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Raguenez, G (corresponding author), Univ Paris Sud, Inst Federat Rech 54, Inst Gustave Roussy, CNRS,UMR 8126, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	raguenez@igr.fr						AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Cha KB, 2004, MECH DEVELOP, V121, P183, DOI 10.1016/j.mod.2003.12.002; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERRANDIS E, 1994, CANCER RES, V54, P2256; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; IOZZO RV, 1995, CANCER RES, V55, P3495; Jansson M, 2001, J CELL SCI, V114, P2043; Jonsson M, 2002, CANCER RES, V62, P409; Katoh M, 1996, ONCOGENE, V13, P873; Katoh M, 2002, INT J MOL MED, V10, P683; KORNER M, 1994, J NEUROCHEM, V62, P1716; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; Passalacqua M, 1999, BIOCHEM J, V337, P113, DOI 10.1042/0264-6021:3370113; Polakis P, 2000, GENE DEV, V14, P1837; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Slepko N, 1999, J NEUROSCI RES, V57, P33, DOI 10.1002/(SICI)1097-4547(19990701)57:1<33::AID-JNR4>3.0.CO;2-6; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V279, P589, DOI 10.1006/bbrc.2000.3950; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V275, P149, DOI 10.1006/bbrc.2000.3258; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L	40	80	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1277	1283		10.1038/sj.onc.1208255	http://dx.doi.org/10.1038/sj.onc.1208255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592517				2022-12-28	WOS:000226898700015
J	Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A				Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A			Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization	ONCOGENE			English	Article						centrosome; MAP; mitosis; mitotic spindle; cell; cycle arrest; RNA interference	DNA-REPLICATION; ETHIDIUM-BROMIDE; MITOTIC SPINDLE; KEN BOX; S-PHASE; CENTROSOME; CHECKPOINT; CYTOKINESIS; PHOSPHORYLATION; SIMIAN-VIRUS-40	Here we describe the identication of a novel vertebrate-specific centrosome/spindle pole-associated protein (CSPP) involved in cell-cycle regulation. The protein is predicted to have a tripartite domain structure, where the N- and C-terminal domains are linked through a coiled-coil mid-domain. Experimental analysis of the identified domains revealed that spindle association is dependent on the N- terminal and the coiled-coil mid domain. The expression of CSPP at the mRNA level was detected in all tested cell lines and in testis tissue. Ectopic expression of CSPP in HEK293T cells blocked cell-cycle progression in early G(1) phase and in mitosis in a dose-dependent manner. Interestingly, mitosis-arrested cells contained aberrant spindles and showed impairment of chromosome congression. Inhibition of CSPP gene expression by small interfering RNAs induced cell-cycle arrest/delay in S phase. This phenotype was characterized by elevated levels of cyclin A, decreased levels of cyclin E and hyperphosphorylation of the S-phase checkpoint kinase Chk1. The activation of Chk1 may indicate a replication stress response due to an inappropriate G(1)/S-phase transition. Taken together, we demonstrate that CSPP is associated with centrosomes and microtubules and may play a role in the regulation of G(1)/S-phase progression and spindle assembly.	Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Radiat Biol, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Hans-Christian, A (corresponding author), Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway.	h.c.asheim@labmed.uio.no	Patzke, Sebastian/G-9909-2019	Patzke, Sebastian/0000-0001-6821-197X; Delabie, Jan/0000-0001-5023-0689; Sivertsen, Einar Andreas/0000-0003-0591-3653				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOHMER RM, 1981, CYTOMETRY, V2, P31, DOI 10.1002/cyto.990020107; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clay-Farrace L, 2003, EMBO J, V22, P704, DOI 10.1093/emboj/cdg046; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Odeberg J, 2000, BIOMOL ENG, V17, P1, DOI 10.1016/S1389-0344(00)00057-5; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Patzke S, 2002, VIROLOGY, V303, P164, DOI 10.1006/viro.2002.1615; Pfleger CM, 2000, GENE DEV, V14, P655; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	59	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1159	1173		10.1038/sj.onc.1208267	http://dx.doi.org/10.1038/sj.onc.1208267			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580290				2022-12-28	WOS:000226898700004
J	Boulanger, CA; Wagner, KU; Smith, GH				Boulanger, CA; Wagner, KU; Smith, GH			Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta 1 expression	ONCOGENE			English	Article						mammary; transplantation; stem cells; TGF-beta 1; cell fate; pregnancy	GLAND; DIFFERENTIATION; CARCINOGENESIS; MORPHOGENESIS; POPULATION; SENESCENCE; PREGNANCY	A parity-induced mammary population, marked by beta-galactosidase expression conditionally activated through cre-lox recombinase originates in WAP-Cre/Rosa-lox-STOP- lox-LacZ (WAP-Cre/Rosa-LacZ) female mice during pregnancy, lactation and involution. During subsequent pregnancies, these parity-induced mammary epithelial cells (PI-MEC) proliferated to produce new secretory acini composed of secretory luminal cells and myoepithelium. In serial transplantation assays, PI-MEC were able to self-renew over several transplant generations and to contribute significantly to the resulting mammary outgrowths. In limiting dilution transplantation, they proliferated to produce both luminal and myoepithelial cells, comprised both lobule-limited and duct-limited epithelial outgrowths, and differentiated into all the cellular subtypes recognized in murine mammary epithelium. TGF-beta1 expression from the whey acidic protein promoter (WAP) in triply transgenic females did not prevent the appearance of PI-MEC after pregnancy despite the absence of full lactation or their ability to proliferate and produce progeny with diverse cellular fates in situ upon subsequent pregnancies. However, in transplants from triple transgenic parous females, the WAP-TGF-beta1-positive PI-MEC did not contribute to the newly recapitulated mammary outgrowths, suggesting that they were incapable of expansive cellular proliferation (self-renewal). This result is consistent with our earlier publication that WAP-TGF-beta1 expression in mammary epithelium induces premature stem cell senescence in mammary transplants and decreases mammary cancer risk in mouse mammary tumor virus (MMTV)-infected females even after multiple pregnancies.	NCI, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Univ Nebraska, Sch Med, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B56,9000 Rockville Pike, Bethesda, MD 20892 USA.	gs4d@nih.gov	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [Z01BC010021, ZIABC010021] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; DEOME KB, 1978, CANCER RES, V38, P2103; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Robinson GW, 1996, DEV DYNAM, V206, P159, DOI 10.1002/(SICI)1097-0177(199606)206:2<159::AID-AJA5>3.0.CO;2-H; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Sivaraman L, 2001, P NATL ACAD SCI USA, V98, P12379, DOI 10.1073/pnas.221459098; SMITH GH, 1991, J VIROL, V65, P6365, DOI 10.1128/JVI.65.11.6365-6370.1991; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6	19	154	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					552	560		10.1038/sj.onc.1208185	http://dx.doi.org/10.1038/sj.onc.1208185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580303	Bronze			2022-12-28	WOS:000226420400003
J	Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP				Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP			Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice	ONCOGENE			English	Article						fatty acid synthase; HER2; neu; transgenic	BREAST-CANCER; PROSTATE-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; FOOD-INTAKE; OVEREXPRESSION; PROGRESSION; CARCINOMAS; HER-2/NEU; CELLS; GENE	High levels of fatty acid synthase (FAS) have been found in cancer precursor lesions of the colon, stomach, esophagus, oral cavity, prostate, and breast. Inhibition of FAS with C75 has led to a significant antitumor effect in both human breast and prostate cancer xenografts. Recently, HER2/neu, which has also been identified in preneoplastic breast lesions, has been shown to regulate FAS expression through the PI3K/Akt signal transduction pathway rendering them susceptible to FAS inhibition. Utilizing the neu-N transgenic mouse model of mammary cancer, weekly treatment of the neu-N mice with C75 (30 mg/kg) for 10 weeks significantly delayed tumor progression. Only 20% of the C75-treated transgenic mice developed mammary carcinoma by 220 days, compared to 50% in the vehicle control animals. Two C75-treated animals never developed mammary cancer. Analysis of mammary tissue following 10 weeks of C75 treatment revealed a significant delay in mammary maturation as manifested by a reduction of the number and caliber of mammary ducts and budding epithelial structures. Apoptotic changes were increased, DNA synthesis was decreased, and the expressions of FAS, neu, Akt, phospho-Akt, and p21(waf1) were all decreased when compared to vehicle controls and FVB/N mice. Importantly, these effects were restricted to the breast epithelial cells that overexpressed neu, not involving other normal duct structures in the skin, liver, or kidney. C247, an FAS inhibitor chemically distinct from C75, significantly delayed mammary maturation similar to C75. Thus, pharmacological inhibition of FAS affects the expression of key oncogenes involved in both cancer development and maintenance of the malignant phenotype. Moreover, these data identify FAS as a potential novel drug target for breast cancer chemoprevention.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; FASgen Inc, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Bldg AA,Room 154A,4940 Eastern Ave, Baltimore, MD 21224 USA.	fkuhajda@jhmi.edu		Jaffee, Elizabeth/0000-0003-3841-6549	NCI NIH HHS [1R44CA99435, 1P50CA88843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA099435, P50CA088843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 2001, AM J CLIN PATHOL, V116, P129; Boggio K, 2000, CANCER RES, V60, P359; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fabian CJ, 2001, BREAST CANCER RES, V3, P99, DOI 10.1186/bcr279; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Jordan VC, 2000, J STEROID BIOCHEM, V74, P269, DOI 10.1016/S0960-0760(00)00103-5; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Lofts F J, 1992, Cancer Treat Res, V61, P161; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; McFadden JM, 2002, ORG LETT, V4, P3859, DOI 10.1021/ol026685k; MCFADDEN JM, 2004, UNPUB J MED CHEM; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Nemoto T, 2001, PATHOBIOLOGY, V69, P297, DOI 10.1159/000064636; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Reilly R T, 2001, Curr Opin Investig Drugs, V2, P133; Reilly R Todd, 2002, Methods Mol Med, V69, P233; Reilly RT, 2000, CANCER RES, V60, P3569; Reilly RT, 2001, CANCER RES, V61, P880; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Visca P, 1999, CLIN CANCER RES, V5, P4111; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG HQ, 2003, P AM ASSOC CANC RES, V44, P1100; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu RL, 2002, MODERN PATHOL, V15, P116, DOI 10.1038/modpathol.3880503; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zhou WB, 2003, CANCER RES, V63, P7330	42	131	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					39	46		10.1038/sj.onc.1208174	http://dx.doi.org/10.1038/sj.onc.1208174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15489885				2022-12-28	WOS:000226125800006
J	Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M				Sorli, SC; Bunney, TD; Sugden, PH; Paterson, HF; Katan, M			Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants	ONCOGENE			English	Article						phosphoinositide-specificc phospholipase C epsilon; splice variants; Ras; colorectal tumors; epigenetic silencing	HUMAN CANCERS; RAS EFFECTOR; CYCLIC-AMP; ACTIVATION; GENE; SUPPRESSOR; PROTEIN; PATHWAYS; PLC; PHOSPHORYLATION	Phospholipase Cepsilon (PLCepsilon) is a novel member of phosphoinositide-specific phospholipase C enzymes with a unique regulatory link to Ras GTP-ases. In the present studies, we establish existence of two splice variants (PLCepsilon1a and PLCepsilon1b) derived from human PLCepsilon1 gene. When expressed in COS or HEK293 cells, PLCepsilon1a and PLCepsilon1b have similar potential to be stimulated by diverse signaling pathways via tyrosine kinase and G-protein coupled receptors and share the ability to function as an effector of Ras. The expression pattern shows broader mRNA expression of PLCepsilon1a in normal tissues; furthermore, in most cell lines expressing PLCepsilon, PLCepsilon1a is the only splice variant present. Analysis of normal/tumor matched pairs derived from colon and rectum demonstrates greatly reduced expression levels in tumor tissues. Further studies in a colorectal tumor cell line lacking PLCepsilon show restoration of transcription of PLCepsilon1a and PLCepsilon1b by demethylating agent 5-aza-2'-deoxycytidine, suggesting epigenetic silencing through hypermethylation. In addition, expression of exogenous PLCepsilon in this cell line demonstrates inhibitory effects of PLCepsilon on cell viability and proliferation. Taken together, our findings suggest that regulatory mechanisms controlling expression of PLCepsilon, broadened by diversity introduced by splice variants, could play important role in PLCepsilon regulation in normal and tumor cells.	Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, London SW7 2AZ, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Katan, M (corresponding author), Inst Canc Res, Chester Beatty Labs, Canc Res UK Ctr Cell & Mol Biol, Fulham Rd, London SW3 6JB, England.	matilda@icr.ac.uk		Bunney, Tom/0000-0002-0281-8813				ALVAREZ RA, 1995, GENOMICS, V29, P53, DOI 10.1006/geno.1995.1214; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nagano K, 1999, J BIOL CHEM, V274, P2872, DOI 10.1074/jbc.274.5.2872; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Wells A, 2000, ADV CANCER RES, V78, P31; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wu DM, 2003, EUR J NEUROSCI, V17, P1571, DOI 10.1046/j.1460-9568.2003.02591.x	35	48	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					90	100		10.1038/sj.onc.1208168	http://dx.doi.org/10.1038/sj.onc.1208168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558028				2022-12-28	WOS:000226125800011
J	Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas	ONCOGENE			English	Article						caspase-8; mutation; hepatocellular carcinoma; apoptosis; caspases	CELL-DEATH; CANCER; APOPTOSIS; MECHANISMS	Evidence exists that alterations of the genes encoding apoptosis-related proteins contribute to either development or progression of human cancers. Caspase-8 plays a crucial role in the initiation phase of apoptosis. To explore the possibility that the genetic alteration of caspase-8 gene is involved in the development of hepatocellular carcinomas (HCCs), we have analysed the entire coding region of human caspase-8 gene for the detection of somatic mutations by polymerase chain reaction-single-strand conformation polymorphism in 69 HCCs with low-grade dysplastic nodule (LGDN, n = 2) or high-grade dysplastic nodule (HGDN, n = 2) or without any dysplastic nodules (n = 65). Overall, we detected a total of nine somatic mutations in 69 HCCs (13.0%). Interestingly, all of the nine mutations were an identical frameshift mutation with two base-pair deletion (1225_1226delTG), which would result in a premature termination of amino-acid synthesis in the p10 protease subunit. In a patient sample, we detected the 1225_1226delTG mutation both in HCC and LDGN lesions, suggesting that caspase-8 mutation could be involved in the early stage of HCC carcinogenesis. We expressed the tumor-derived caspase-8 mutant in the cells and found that the mutant abolished cell death activity of caspase-8. Our data indicate that caspase-8 gene is frequently mutated in HCC and the majority of the mutations may be the frameshift mutation 1225_1226delTG. Also, the data suggest that caspase-8 gene mutation might lead to the loss of its cell death function and contribute to the pathogenesis of HCC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					BAE JM, 2002, CANC RES TREAT, V34, P708; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, CANCER RES, V59, P3068; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maggioni M, 2000, HEPATOLOGY, V32, P942, DOI 10.1053/jhep.2000.18425; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341	26	82	89	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					141	147		10.1038/sj.onc.1208244	http://dx.doi.org/10.1038/sj.onc.1208244			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531912				2022-12-28	WOS:000226125800016
J	Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U				Perry, E; Tsruya, R; Levitsky, P; Pomp, O; Taller, M; Weisberg, S; Parris, W; Kulkarni, S; Malovani, H; Pawson, T; Shpungin, S; Nir, U			TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3	ONCOGENE			English	Article						TMF/AR160; Stat3; ubiquitination; degradation	TYROSINE KINASE FER; ELEMENT MODULATORY FACTOR; IN-VIVO; CARCINOMA CELLS; UBIQUITIN; PHOSPHORYLATION; INDUCTION; NUCLEAR; COMPLEX; GROWTH	TMF/ARA160 is a Golgi resident protein whose cellular functions have not been conclusively revealed. Herein we show that TMF/ARA160 can direct the proteasomal degradation of the key cell growth regulator-Stat3. TMF/ARA160 was dispersed in the cytoplasm of myogenic C2C12 cells that were grown under low-serum conditions. The cytoplasmic distribution of TMF/ARA160 was accompanied by its transient association with the tyrosine kinase Fer and with Stat3, which underwent proteasomal degradation under those conditions. Moreover, serum deprivation induced the association of ubiquitinated proteins, with the TMF/ARA160 complex. However, TMF/ARA160 did not bind Stat1, whose cellular levels were increased in serum-starved C2C12 cells. Amino-acid sequence analysis identified a BC-box element in TMF/ARA160 that mediated the binding of this protein to elongin C. Ectopic expression of TMF/ARA160 in serum-starved C2C12 cells drove the ubiquitination and proteasomal degradation of Stat3, an effect that was not caused by TMF/ARA160 devoid of the BC-box motif. Thus, the Golgi apparatus harbors a novel BC-box-containing protein that can direct Stat3 to proteasomal degradation. Interestingly, the level of TMF/ARA160 was significantly decreased in malignant brain tumors, implying a suppressive role of that protein in tumor progression.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Bar Ilan University; Rabin Medical Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Nir, U (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il						Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman JR, 1999, MOL UROL, V3, P11; Colanzi A, 2003, CURR OPIN CELL BIOL, V15, P462, DOI 10.1016/S0955-0674(03)00067-X; Conaway JW, 1998, BBA-REV CANCER, V1377, pM49, DOI 10.1016/S0304-419X(97)00035-8; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Daino H, 2000, BLOOD, V95, P2577; DEAN BL, 1990, RADIOLOGY, V174, P411, DOI 10.1148/radiology.174.2.2153310; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Fridmann-Sirkis Y, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-18; GARCIA JA, 1992, P NATL ACAD SCI USA, V89, P9372, DOI 10.1073/pnas.89.20.9372; Halachmy S, 1997, ONCOGENE, V14, P2871, DOI 10.1038/sj.onc.1201145; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Kamura Takumi, 2002, Prog Mol Subcell Biol, V29, P1; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; KIM L, 1995, MOL CELL BIOL, V15, P4553; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LETWIN K, 1988, ONCOGENE, V3, P621; Lu ZM, 2001, MOL BIOL CELL, V12, P795, DOI 10.1091/mbc.12.4.795; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Magrassi L, 1999, J NEUROSURG, V91, P440, DOI 10.3171/jns.1999.91.3.0440; Mori K, 2002, FEBS LETT, V520, P127, DOI 10.1016/S0014-5793(02)02803-X; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Orlovsky K, 2002, ONCOGENE, V21, P4997, DOI 10.1038/sj.onc.1205624; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Schwartz Y, 1998, FEBS LETT, V434, P339, DOI 10.1016/S0014-5793(98)01003-5; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Taler M, 2003, MOL ENDOCRINOL, V17, P1580, DOI 10.1210/me.2002-0328; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Weisberg S, 2001, AM J PATHOL, V159, P1193, DOI 10.1016/S0002-9440(10)62504-7; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	55	46	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8908	8919		10.1038/sj.onc.1208149	http://dx.doi.org/10.1038/sj.onc.1208149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467733				2022-12-28	WOS:000225354600006
J	Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R				Vidal, CI; Mintz, PJ; Lu, K; Ellis, LM; Manenti, L; Giavazzi, R; Gershenson, DM; Broaddus, R; Liu, JS; Arap, W; Pasqualini, R			An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients	ONCOGENE			English	Article						antibodies; heat-shock proteins; HSP90; ovarian cancer; phage display	HEAT-SHOCK-PROTEIN; PROGNOSTIC-FACTORS; EXPRESSION; AUTOANTIBODIES; CARCINOMA; ANTIGENS; DISPLAY; MARKERS; SURFACE; HSP90	To gain insight into the mechanisms of molecular recognition and humoral immune response in ovarian cancer, we used fingerprinting, a phage display-based combinatorial selection to isolate peptide ligands to tumor-related antibodies present in ascites from patients with advanced disease. First, we have isolated a consensus motif (sequence CVPELGHEC) in 86% of the peptides screened; this enriched motif was selected from a total of 108-109 unique random sequences present in the library. Next, we identified the heat-shock protein 90 kDa (HSP90) as the native antigen mimicked by the motif. Finally, we evaluated the expression of HSP90 and the presence of antibodies against the HSP90-mimic peptide in a large panel of ovarian cancer patients and controls. In tissue microarrays, we show that the expression of HSP90 is ubiquitous. However, the corresponding humoral immune response against HSP90 is restricted to a subset of patients with stage IV disease. Together, these results show that screening humoral response can identify tumor antigens that may serve as molecular targets in ovarian cancer. Recognition of such relevant proteins in the immunobiology of malignant tumors may lead to the development of therapies.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Mario Negri Inst Pharmacol Res, Dept Oncol, Lab Biol & Therapy Metastasis, I-24125 Bergamo, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	warap@mdanderson.org; rpasqual@mdanderson.org	Giavazzi, Raffaella/J-7424-2018; Giavazzi, Raffaella/ABB-9768-2020	Giavazzi, Raffaella/0000-0001-5249-8208	NCI NIH HHS [CA836393] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; BOOKMAN MA, 2000, PRINCIPLES PRACTICE, P403; BRINTON LA, 2000, PRINCIPLES PRACTICE, P3; BUICK RN, 1985, CANCER RES, V45, P3668; COHEN IR, 1990, ISRAEL J MED SCI, V26, P673; Conroy SE, 1998, EUR J CANCER, V34, P942; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kenderov A, 2002, CLIN EXP IMMUNOL, V129, P169, DOI 10.1046/j.1365-2249.2002.01887.x; Luo LY, 2002, BRIT J CANCER, V87, P339, DOI 10.1038/sj.bjc.6600439; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; Marsden DE, 2000, SEMIN SURG ONCOL, V19, P11, DOI 10.1002/1098-2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3; Meyer T, 2000, BRIT J CANCER, V82, P1535; Mintz PJ, 2003, NAT BIOTECHNOL, V21, P57, DOI 10.1038/nbt774; Neckers L, 2003, NATURE, V425, P357, DOI 10.1038/425357a; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SRIVASTAVA PK, 2001, PRINCIPLES PRACTICE, P1; Taylor DD, 1998, ONCOL REP, V5, P1519; Trieb K, 2000, BRIT J CANCER, V82, P85, DOI 10.1054/bjoc.1999.0881; Witkin SS, 2001, EUR J GYNAECOL ONCOL, V22, P249	24	49	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8859	8867		10.1038/sj.onc.1208082	http://dx.doi.org/10.1038/sj.onc.1208082			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480432				2022-12-28	WOS:000225354600001
J	Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M				Irimia, M; Fraga, MF; Sanchez-Cespedes, M; Esteller, M			CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer	ONCOGENE			English	Article						K-ras; methylation; NORE1A; lung cancer	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; CELL-LINES; MUTATIONS; METHYLATION; RASSF1A; IDENTIFICATION; TUMORIGENESIS; PROTEIN	Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event. To test whether this inverse association exists, we have analysed the K-ras mutational status and NORE1A CpG island hypermethylation of 61 non-small-cell lung carcinomas and the methylation status of the two other Ras effectors, RASSF1A and HRASLS. No association was found between the methylation status of NORE1A, RASSF1A and HRASLS or the status of K-ras with respect to the latter two genes. However, our results demonstrate that the epigenetic alteration of NORE1A is confined to lung tumors with a wild-type K-ras: 88% (15 of 17) of the tumors with NORE1 hypermethylation did not harbor a K-ras mutation (P=0.008, Fisher's exact test). Thus, the mutual exclusivity of the epigenetic and genetic alterations in the two genes of the Ras pathway suggests that they play a critical and cooperative role in human tumorigenesis.	Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Lung Canc Res Grp, Mol Pathol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Mol Pathol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es	Sanchez-Cespedes, Montse/H-8485-2012; Irimia, Manuel/E-3040-2010; Esteller, Manel/L-5956-2014; Fraga, Mario F/H-7824-2017	Sanchez-Cespedes, Montse/0000-0002-6045-5627; Irimia, Manuel/0000-0002-2179-2567; Esteller, Manel/0000-0003-4490-6093; Fraga, Mario F/0000-0001-8450-2603				Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; AOYAMA Y, 2004, ONCOGENE        0308; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Dammann R, 2003, ONCOGENE, V22, P3806, DOI 10.1038/sj.onc.1206582; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2001, CANCER RES, V61, P2816; Esteller M, 2000, CANCER RES, V60, P129; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Ito H, 2001, CYTOGENET CELL GENET, V93, P36, DOI 10.1159/000056944; Kaneda A, 2002, CANCER RES, V62, P6645; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim DH, 2003, CANCER RES, V63, P6206; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramirez JL, 2003, CANCER LETT, V193, P207, DOI 10.1016/S0304-3835(02)00740-1; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Schimanski CC, 1999, CANCER RES, V59, P5169; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Sparks AB, 1998, CANCER RES, V58, P1130; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	37	45	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8695	8699		10.1038/sj.onc.1207914	http://dx.doi.org/10.1038/sj.onc.1207914			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378027				2022-12-28	WOS:000224988800016
J	Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH				Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH			AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity	ONCOGENE			English	Article						AP-1; breast cancer; proliferation; apoptosis	DOMINANT-NEGATIVE MUTANT; C-JUN; RETINOIC-ACID; DISTINCT MECHANISMS; E OVEREXPRESSION; FAMILY-MEMBERS; APOPTOSIS; GROWTH; D1; ACTIVATION	The AP-1 transcription factor is a central component of signal transduction pathways in many cells, although the exact role of AP-1 in controlling cell growth and malignant transformation is unknown. We have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells, and that blocking AP-1 by overexpressing a dominant-negative form of cJun (cJun-DN, TAM67) inhibits breast cancer cell growth both in vivo and in vitro. We hypothesized that TAM67 inhibits cell growth by altering the expression of cell cycle regulatory proteins, thus causing a cell cycle block. In the present study, we used clones of MCF7 breast cancer cells that express TAM67 under the control of an inducible promoter. First, we determined the effect of AP-1 blockade on cell growth, then we performed H-3-thymidine incorporation and flow cytometry assays to investigate whether TAM67 inhibits the cell cycle. We observed that in the presence of serum TAM67 inhibited cell growth and caused a block in the G1 phase of the cell cycle. Next, we performed Western-blotting and CDK kinase assays to determine the effects of TAM67 on retinoblastoma (Rb) phosphorylation, the expression of cell cycle regulatory proteins, and CDK activity. We discovered that TAM67 inhibited Rb phosphorylation and reduced E2F activity. We also found that TAM67 decreased the expression of D and E cyclins, reduced CDK2 and CDK4 activity, and increased the CDK inhibitor p27. The studies of gene expression at the RNA level showed that TAM67 decreased cyclin Ds mRNA expression. Our study suggests that in the presence of serum, TAM67 inhibits breast cancer growth predominantly by inducing inhibitors of cyclin-dependent kinases ( such as p27) and by reducing the expression of the cyclins involved in transitioning from G1 into S phase of the cell cycle. These studies lay the foundation for future attempt to develop new agents for the treatment and prevention of breast cancer.	Baylor Coll Med, Baylor Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Baylor Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Baylor Breast Ctr, Dept Med, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Shen, Qiang/0000-0002-1491-5434; Brown, Powel/0000-0002-3398-163X				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HERBER, 1994, ONCOGENE, V9, P2105; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Preston GA, 1996, MOL CELL BIOL, V16, P211; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sauter ER, 1999, CANCER RES, V59, P4876; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHULE R, 1991, COLD SH Q B, V56, P119; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SMITH MJ, 1992, BLOOD, V79, P2107; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang LM, 1997, CANCER RES, V57, P4652; Yang LM, 2001, ONCOGENE, V20, P8025, DOI 10.1038/sj.onc.1204911; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhao BH, 1997, MOL CARCINOGEN, V19, P180, DOI 10.1002/(SICI)1098-2744(199707)19:3<180::AID-MC6>3.3.CO;2-O	38	56	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8238	8246		10.1038/sj.onc.1207889	http://dx.doi.org/10.1038/sj.onc.1207889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378019				2022-12-28	WOS:000224749500006
J	Kalia, LV; Gingrich, JR; Salter, MW				Kalia, LV; Gingrich, JR; Salter, MW			Src in synaptic transmission and plasticity	ONCOGENE			English	Review						long-term potentiation; ND2; NMDA receptor; phosphotyrosine phosphatase; protein tyrosine kinase; STEP	LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; PROTEIN-TYROSINE KINASES; POSTSYNAPTIC DENSITY FRACTION; DOG CEREBRAL-CORTEX; NMDA-RECEPTOR; GAIN-CONTROL; PROTEOMIC ANALYSIS; COUPLED RECEPTORS; CHANNEL ACTIVITY	In the central nervous system (CNS), Src and other Src family kinases are widely expressed and are abundant in neurons. Src has been implicated in proliferation and differentiation during the development of the CNS. But Src is highly expressed in fully differentiated neurons in the developed CNS, implying additional functions of this kinase. Over the past decade, a large body of evidence has accumulated showing that a main function of Src is to upregulate the activity of N-methyl-D-aspartate (NMDA) receptors and other ion channels. NMDA receptors (NMDARs) are a principal subtype of glutamate receptors, which mediate fast excitatory transmission at most central synapses. In this review, we focus on Src as a regulator of NMDARs and on the role of Src in NMDAR-dependent synaptic plasticity. We also describe recent studies that give insights into the regulation of Src itself at glutamatergic synapses. By upregulating the function of NMDARs, Src gates the production of NMDAR-dependent synaptic potentiation and plasticity. Thus, Src may be critical for processes underlying physiological plasticity, including learning and memory, and pathological plasticity, such as pain and epilepsy.	Univ Toronto, Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON 5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON 5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Salter, MW (corresponding author), Univ Toronto, Hosp Sick Children, Programme Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mike.salter@utoronto.ca		Kalia, Lorraine/0000-0002-9384-1305				Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLOMBERG F, 1977, J CELL BIOL, V74, P204, DOI 10.1083/jcb.74.1.204; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chen SJ, 1996, J NEUROCHEM, V67, P194; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; CONTRACTOR A, 2002, SCI STKE, pRE14; COOKE M P, 1989, New Biologist, V1, P66; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guo W, 2002, J NEUROSCI, V22, P6208; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Koles L, 2001, NEUROCHEM RES, V26, P925, DOI 10.1023/A:1012380416876; Lauri SE, 2000, NEUROREPORT, V11, P997, DOI 10.1097/00001756-200004070-00020; Lei G, 2002, EMBO J, V21, P2977, DOI 10.1093/emboj/cdf292; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Manabe T, 2000, J NEUROSCI, V20, P2504; Marino MJ, 1998, P NATL ACAD SCI USA, V95, P11465, DOI 10.1073/pnas.95.19.11465; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; OYAMA T, 1995, NEUROSCIENCE, V69, P869, DOI 10.1016/0306-4522(95)00278-Q; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Petrone A, 2003, EMBO J, V22, P4121, DOI 10.1093/emboj/cdg399; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Satoh K, 2002, GENES CELLS, V7, P187, DOI 10.1046/j.1356-9597.2001.00505.x; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Soltys BJ, 2000, INT REV CYTOL, V194, P133; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Wan Q, 1997, J NEUROSCI, V17, P5062; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiong ZG, 1998, MOL PHARMACOL, V54, P1055, DOI 10.1124/mol.54.6.1055; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yoshimura Y, 2004, J NEUROCHEM, V88, P759, DOI 10.1046/j.1471-4159.2003.02136.x; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	77	119	127	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8007	8016		10.1038/sj.onc.1208158	http://dx.doi.org/10.1038/sj.onc.1208158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489918				2022-12-28	WOS:000224558300011
J	Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E				Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E			Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance	ONCOGENE			English	Article						telomerase; TRAIL; apoptosis; ATRA; APL	LEUKEMIA-CELL LINE; CATALYTIC SUBUNIT; CANCER-CELLS; EXPRESSION; LENGTH; SENESCENCE; INHIBITION; MATURATION; RESISTANCE; MECHANISM	Human telomerase has been implicated in cell immortalization and cancer. Recent works suggest that telomerase confers additional function required for tumorigenesis that does not depend on its ability to maintain telomeres. This new action may influence tumor therapy outcomes by yet unraveled mechanisms. Here, we show that overexpression of the catalytic subunit of telomerase (hTERT) protects a maturation-resistant acute promyelocytic leukemia (APL) cell line from apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis- inducing ligand (TRAIL) and not from apoptosis induced by chemotherapeutic drugs such as etoposide or cisplatin. Conversely, in these cells, TRAIL-induced cell death is magnified by all-trans retinoic acid ( ATRA) treatment, independently of telomerase activity on telomeres. Of note, this response is subordinated neither to maturation nor to telomere shortening. This work underlines that retinoids and death receptor signaling cross-talks offer new perspectives for antitumor therapy.	Hop St Louis, Inst Hematol, INSERM, U496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, Inst Hematol, INSERM, U496, 1 Ave Claude Vellefaux, F-75010 Paris, France.	Evelyne.Segal-Bendirdjian@stlouis.inserm.fr	PENDINO, Frederic/G-6630-2017	Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; LANOTTE M, 1991, BLOOD, V77, P1080; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Ludwig A, 2001, CANCER RES, V61, P3053; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; RUBIO MA, 2004, IN PRESS EXP CELL RE; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Yuan Zhang, 2002, Hematol J, V3, P201, DOI 10.1038/sj.thj.6200177	32	65	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7469	7474		10.1038/sj.onc.1208029	http://dx.doi.org/10.1038/sj.onc.1208029			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326479				2022-12-28	WOS:000224176500003
J	Hoang, T				Hoang, T			The origin of hematopoietic cell type diversity	ONCOGENE			English	Review						lineage diversification; chaos theory; nonlinear dynamics; transcription factor networks; hematopoietic growth factors	COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; SELF-RENEWAL; IN-VIVO; LINEAGE COMMITMENT; PROGENITOR CELLS; TRANSGENIC MICE; GENE-EXPRESSION; SIGNALING PATHWAY; ALPHA-BETA	The hematopoietic system remains robust with regards to extrinsic perturbations, in sharp contrast with the stochastic behavior of hematopoeitic stem cells (HSCs) at the single cell level, suggesting that stability may be achieved within a stem cell system that undergoes constant self-renewal, commitment to differentiation and generates cell type diversification. Converging evidence at the interface of cellular, molecular and numerical studies suggests that diversity is generated by the chaotic dynamics of transcription factor networks within a cell and of the combination of growth factors and cytokines in the environment, both involving cooperation and competition. Current evidence indicates that HSCs are primed for multilineage gene expression. A subtle shift in transcription factor dosage is sufficient to perturb this equilibrium and to drive lineage commitment that involves a resolution of complexity at the molecular level and a transition towards less chaotic behavior. This dynamical instability establishes a state of responsiveness to extrinsic signals. Evolutionary conserved environmental cues that drive pattern formation or migratory behavior during embryonic development operate in the adult to influence the decision between self-renewal and differentiation in HSCs, as exemplified by the role of Notch1, Wnt proteins, BMPs and VEGF. In contrast, a network of cytokines uniquely present in mammalians influences later developmental stages, from progenitors with more restricted potentials (tri-, bi- or unipotent) to mature functional cells. The se cytokines have co-opted the ancient Jak-STAT pathway but also appear to trigger lineage-affiliated transcription factors, thus linking environmental signaling to cell fate decisions.	Univ Montreal, Inst Immunovirol & Canc IRIC, Montreal, PQ H3C 2J7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Hoang, T (corresponding author), Univ Montreal, Inst Immunovirol & Canc IRIC, POB 6128,Downtown Stn, Montreal, PQ H3C 2J7, Canada.	trang.hoang@umontreal.ca						Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Barndt R, 1999, J IMMUNOL, V163, P3331; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Bruno L, 2004, MOL CELL BIOL, V24, P741, DOI 10.1128/MCB.24.2.741-756.2004; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Caceres-Cortes JR, 2001, STEM CELLS, V19, P59, DOI 10.1634/stemcells.19-1-59; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; CHEN HM, 1995, ONCOGENE, V11, P1549; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Furusawa C, 2000, PHYS REV LETT, V84, P6130, DOI 10.1103/PhysRevLett.84.6130; Furusawa C, 2001, J THEOR BIOL, V209, P395, DOI 10.1006/jtbi.2001.2264; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Goardon N, 2002, BLOOD, V100, P491, DOI 10.1182/blood.V100.2.491; Gratrix S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.014101; Guidos CJ, 2002, SEMIN IMMUNOL, V14, P395, DOI 10.1016/S104453230200074X; Halsey TC, 2004, NATURE, V428, P127, DOI 10.1038/428127a; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Herblot S, 2002, MOL CELL BIOL, V22, P886, DOI 10.1128/MCB.22.3.886-900.2002; Herbomel P, 2001, DEV BIOL, V238, P274, DOI 10.1006/dbio.2001.0393; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ikawa T, 2004, IMMUNITY, V20, P349, DOI 10.1016/S1074-7613(04)00049-4; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2004, EXP HEMATOL, V32, P11, DOI 10.1016/j.exphem.2003.10.010; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Lemischka IR, 2003, NATURE, V425, P778, DOI 10.1038/425778a; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Martin R, 2004, DEVELOPMENT, V131, P693, DOI 10.1242/dev.00968; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; Miller CL, 1997, BLOOD, V89, P1214, DOI 10.1182/blood.V89.4.1214; Miller CL, 1996, EXP HEMATOL, V24, P185; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OGAWA M, 1993, BLOOD, V81, P2844; Oh IH, 2002, ONCOGENE, V21, P4778, DOI 10.1038/sj.onc.1205592; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Parichy DM, 2000, DEVELOPMENT, V127, P3031; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Riley RL, 2002, EXP HEMATOL, V30, P1412, DOI 10.1016/S0301-472X(02)00953-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Stoffel R, 1999, P NATL ACAD SCI USA, V96, P698, DOI 10.1073/pnas.96.2.698; Strogatz S. H., 1994, NONLINEAR DYNAMICS C, P1; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; THUAN TX, 2001, CHAOS HARMONY PERSPE, P63; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wallenfang MR, 2003, SCIENCE, V301, P1490, DOI 10.1126/science.1090070; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zon LI, 2001, NAT IMMUNOL, V2, P142, DOI 10.1038/84239	115	37	37	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2004	23	43					7188	7198		10.1038/sj.onc.1207937	http://dx.doi.org/10.1038/sj.onc.1207937			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378079				2022-12-28	WOS:000223998800005
J	Singh, SK; Clarke, ID; Hide, T; Dirks, PB				Singh, SK; Clarke, ID; Hide, T; Dirks, PB			Cancer stem cells in nervous system tumors	ONCOGENE			English	Review						brain tumor stem cell; neural stem cell; flow cytometry; CD133	PEDIATRIC BRAIN-TUMORS; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; AVIAN-SARCOMA VIRUS; PROSPECTIVE IDENTIFICATION; SUBEPENDYMAL PLATE; NEURAL PROGENITORS; ADULT BRAIN; IN-VITRO; RATS	Most current research on human brain tumors is focused on the molecular and cellular analysis of the bulk tumor mass. However, evidence in leukemia and more recently in solid tumors such as breast cancer suggests that the tumor cell population is heterogeneous with respect to proliferation and differentiation. Recently, several groups have described the existence of a cancer stem cell population in human brain tumors of different phenotypes from both children and adults. The finding of brain tumor stem cells (BTSCs) has been made by applying the principles for cell culture and analysis of normal neural stem cells (NSCs) to brain tumor cell populations and by identification of cell surface markers that allow for isolation of distinct tumor cell populations that can then be studied in vitro and in vivo. A population of brain tumor cells can be enriched for BTSCs by cell sorting of dissociated suspensions of tumor cells for the NSC marker CD133. These CD133+ cells, which also expressed the NSC marker nestin, but not differentiated neural lineage markers, represent a minority fraction of the entire brain tumor cell population, and exclusively generate clonal tumor spheres in suspension culture and exhibit increased self-renewal capacity. BTSCs can be induced to differentiate in vitro into tumor cells that phenotypically resembled the tumor from the patient. Here, we discuss the evidence for and implications of the discovery of a cancer stem cell in human brain tumors. The identification of a BTSC provides a powerful tool to investigate the tumorigenic process in the central nervous system and to develop therapies targeted to the BTSC. Specific genetic and molecular analyses of the BTSC will further our understanding of the mechanisms of brain tumor growth, reinforcing parallels between normal neurogenesis and brain tumorigenesis.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Program Dev Biol, Dept Lab Med & Pathobiol, Div Neurosurg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Dirks, PB (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Suite 1504,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	peter.dirks@sickkids.ca	Singh, Sheila K/W-2799-2018	Singh, Sheila K/0000-0003-1272-5300				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bailey P, 1926, CLASSIFICATION TUMOR; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Buzanska L, 2001, J NEUROSCI RES, V65, P17, DOI 10.1002/jnr.1123; COPELAND DD, 1977, ACTA NEUROPATHOL, V38, P1, DOI 10.1007/BF00691268; COPELAND DD, 1975, J NEUROPATH EXP NEUR, V34, P340, DOI 10.1097/00005072-197507000-00004; Corbeil D, 1998, BLOOD, V91, P2625, DOI 10.1182/blood.V91.7.2625.2625_2625_2626; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Globus J.H., 1944, J NEUROPATH EXP NEUR, V3, P1; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HOPEWELL JW, 1969, CANCER RES, V29, P1927; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KOESTNER A, 1971, AM J PATHOL, V63, P37; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEWIS PD, 1968, NATURE, V217, P974, DOI 10.1038/217974a0; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; MACKILLOP WJ, 1985, CHILD NERV SYST, V1, P163, DOI 10.1007/BF00735732; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RUBINSTEIN LJ, 1972, J NEUROPATH EXP NEUR, V31, P7, DOI 10.1097/00005072-197201000-00002; Singh SK, 2003, CANCER RES, V63, P5821; SMART I, 1961, J COMP NEUROL, V116, P325, DOI 10.1002/cne.901160306; Tamaki S, 2002, J NEUROSCI RES, V69, P976, DOI 10.1002/jnr.10412; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TOHYAMA T, 1992, LAB INVEST, V66, P303; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uhrbom L, 2002, CANCER RES, V62, P5551; VICK NA, 1977, ACTA NEUROPATHOL, V40, P63, DOI 10.1007/BF00688574; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	54	520	575	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7267	7273		10.1038/sj.onc.1207946	http://dx.doi.org/10.1038/sj.onc.1207946			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378086				2022-12-28	WOS:000223998800012
J	Pettersson, F; Couture, MC; Hanna, N; Miller, WH				Pettersson, F; Couture, MC; Hanna, N; Miller, WH			Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK	ONCOGENE			English	Review						ER-negative breast cancer; retinoids; protein kinase C inhibitors; MAPK; apoptosis	PROTEIN-KINASE-C; HUMAN HEPATOCELLULAR-CARCINOMA; RECEPTOR-ALPHA EXPRESSION; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; ACID RECEPTOR; X-RECEPTOR; LEUKEMIA-CELLS; RAR-GAMMA; DIFFERENTIAL REGULATION	Retinoids are vitamin A derivatives, which cause growth inhibition, differentiation and/or apoptosis in various cell types, including some breast cancer cells. In general, estrogen receptor (ER)-positive cells are retinoic acid (RA) sensitive, whereas ER-negative cells are resistant. In this report, we show that ER-negative MDA-MB-231 cells are strongly growth inhibited by retinoids in combination with a PKC inhibitor. While neither RA nor GF109203X (GF) has a significant growth inhibitory effect in these cells, RA+GF potently suppress proliferation. We found that RA+GF induce apoptosis, as shown by an increase in fragmented DNA, Annexin-V-positive cells and caspase-3 activation. Apoptosis was also induced by GF in combination with two synthetic retinoids. Expression of phosphorylated as well as total PKC was decreased by GF and this was potentiated by RA. In addition, treatment with GF caused a strong and sustained activation of ERK1/2 and p38-MAPK, as well as a weaker activation of JNK. Importantly, inhibition of ERK but not p38 or JNK suppressed apoptosis induced by RA+GF, indicating that activation of ERK is specifically required. In support of this novel finding, the ability of other PKC inhibitors to cause apoptosis in combination with RA correlates with ability to cause sustained activation of ERK.	McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Miller, WH (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	wmiller@ldi.jgh.mcgill.ca	Pettersson, Frank/AAZ-5408-2020					Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; Adan Y, 2003, CANCER LETT, V194, P67, DOI 10.1016/S0304-3835(03)00146-0; Appierto V, 2004, CELL DEATH DIFFER, V11, P270, DOI 10.1038/sj.cdd.4401349; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Boskovic G, 2002, J BIOL CHEM, V277, P26113, DOI 10.1074/jbc.M201185200; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Busby EC, 2000, CANCER RES, V60, P2108; Cho YH, 2001, EXP CELL RES, V269, P97, DOI 10.1006/excr.2001.5298; Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S; Clark AS, 2003, CANCER RES, V63, P780; Crowe DL, 2003, MOL CANCER RES, V1, P532; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; DeLuca LM, 1995, SCI AM SCI MED, V2, P28; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gauthier ML, 2003, BIOCHEM BIOPH RES CO, V307, P839, DOI 10.1016/S0006-291X(03)01273-7; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hail N, 2001, CANCER RES, V61, P6698; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Kizaki M, 1996, BLOOD, V87, P1977; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 2000, CLIN CANCER RES, V6, P260; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee MO, 2000, BIOCHEM PHARMACOL, V59, P485, DOI 10.1016/S0006-2952(99)00355-X; Lee YJ, 2003, BBA-MOL CELL RES, V1593, P219, DOI 10.1016/S0167-4889(02)00392-0; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; Li LW, 1999, MOL CELL BIOL, V19, P8547; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mandil R, 2001, CANCER RES, V61, P4612; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Mann K K, 2001, Curr Oncol Rep, V3, P209, DOI 10.1007/s11912-001-0052-1; Marchetti P, 1999, CANCER RES, V59, P6257; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; McCracken MA, 2003, MOL CANCER THER, V2, P273; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller WH, 1998, CANCER, V83, P1471, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; Ortiz MA, 2001, CANCER RES, V61, P8504; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; Rigobello MP, 1999, BIOCHEM PHARMACOL, V58, P665, DOI 10.1016/S0006-2952(99)00149-5; Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261; Rosenauer A, 1998, CANCER RES, V58, P5110; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; RUBIN M, 1994, CANCER RES, V54, P6549; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sausville Edward A., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P47, DOI 10.2174/1568011033353560; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; She QB, 2001, CANCER RES, V61, P1604; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shih A, 2002, J CLIN ENDOCR METAB, V87, P1223, DOI 10.1210/jc.87.3.1223; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2493; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tenzer A, 2001, CANCER RES, V61, P8203; Tillman DM, 2003, CANCER RES, V63, P5118; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yen A, 1998, CANCER RES, V58, P3163; Yung Benjamin Yat-Ming, 1995, Journal of Biomedical Science, V2, P154, DOI 10.1007/BF02253066; Zhao X, 2001, CELL DEATH DIFFER, V8, P878, DOI 10.1038/sj.cdd.4400894; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	102	37	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7053	7066		10.1038/sj.onc.1207956	http://dx.doi.org/10.1038/sj.onc.1207956			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273718				2022-12-28	WOS:000223885100006
J	Furuta, M; Weil, RJ; Vortmeyer, AO; Huang, S; Lei, JQ; Huang, TN; Lee, YS; Bhowmick, DA; Lubensky, IA; Oldfield, EH; Zhuang, ZP				Furuta, M; Weil, RJ; Vortmeyer, AO; Huang, S; Lei, JQ; Huang, TN; Lee, YS; Bhowmick, DA; Lubensky, IA; Oldfield, EH; Zhuang, ZP			Protein patterns and proteins that identify subtypes of glioblastoma multiforme	ONCOGENE			English	Article						malignant glioma; astrocytoma; microdissection; two-dimensional gel electrophoresis; protein sequencing; mass spectrometry	GENE-EXPRESSION; GLIOMAS; DNA; IDENTIFICATION; CLASSIFICATION; MICROARRAY; PROFILES; SURVIVAL; DATABASE; AGE	Glioblastoma multiforme (GBM) has been subdivided into two types based on clinical and genetic findings: primary tumors, which arise de novo, and secondary tumors, which progress from lower grade gliomas to GBMs. To analyse this dichotomy at the protein level, we employed selective tissue microdissection to obtain pure populations of tumor cells, which we studied using two-dimensional protein gel electrophoresis (2-DGE) and protein sequencing of select target proteins. Protein patterns were analysed in a blinded manner from the clinical and genetic data. 2-DGE clearly identified two distinct populations of tumors. 2-DGE was reproducible and reliable, as multiple samples analysed from the same patient gave identical results. In addition, we isolated and sequenced 11 proteins that were uniquely expressed in either the primary or the secondary GBMs, but not both. We demonstrate that specific proteomic patterns can be reproducibly identified by two-dimensional gel electrophoresis from limited numbers of selectively procured, microdissected tumor cells and that two patterns of GBMs, primary versus secondary, previously distinguished by clinical and genetic differences, can be recognized at the protein level. Proteins that are expressed distinctively may have important implications for the diagnosis, prognosis, and treatment of patients with GBM.	NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Saga Med Sch, Dept Neurosurg, Saga, Japan; Vanderbilt Univ, Sch Med, Dept Neurosurg, Nashville, TN 37212 USA; Transmedix Inc, Rockville, MD USA; Linden Biosci, Woburn, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Saga University; Vanderbilt University	Weil, RJ (corresponding author), NINDS, Surg Neurol Branch, NIH, Bldg 10,Room 5D 37, Bethesda, MD 20892 USA.	weilr@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F. M., 1999, SHORT PROTOCOLS MOL; Batchelor TT, 2004, CLIN CANCER RES, V10, P228, DOI 10.1158/1078-0432.CCR-0841-3; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Fuller GN, 2002, BRAIN PATHOL, V12, P108; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Godard S, 2003, CANCER RES, V63, P6613; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash SM, 2002, PROTEOMICS, V2, P69, DOI 10.1002/1615-9861(200201)2:1<69::AID-PROT69>3.3.CO;2-#; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Khatua S, 2003, CANCER RES, V63, P1865; Kim S, 2002, MOL CANCER THER, V1, P1229; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 2000, PATHOLOGY GENETICS T; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Lal A, 1999, CANCER RES, V59, P5403; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Moore RE, 2002, J AM SOC MASS SPECTR, V13, P378, DOI 10.1016/S1044-0305(02)00352-5; Nutt CL, 2003, CANCER RES, V63, P1602; Palmer-Toy DE, 2000, CLIN CHEM, V46, P1513; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Simmons ML, 2001, CANCER RES, V61, P1122; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; STONE KL, 1993, PRACTICAL GUIDE PROT; Tortosa A, 2000, NEUROPATH APPL NEURO, V26, P544, DOI 10.1046/j.0305-1846.2000.00290.x; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vortmeyer AO, 2003, NEUROLOGY, V61, P1626, DOI 10.1212/01.WNL.0000096168.85260.60; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	36	67	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6806	6814		10.1038/sj.onc.1207770	http://dx.doi.org/10.1038/sj.onc.1207770			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15286718				2022-12-28	WOS:000223653600012
J	Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ				Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ			Altered SMRT levels disrupt vitamin D-3 receptor signalling in prostate cancer cells	ONCOGENE			English	Article						histone deacetylation inhibitors; 1 alpha,25-dihydroxyvitamin D-3; prostate cancer; SMRT; GADD45 alpha	HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTORS OCT-1; 1,25-DIHYDROXYVITAMIN D-3; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PRIMARY CULTURES; GENE-EXPRESSION; P53-INDEPENDENT INDUCTION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA	We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity. To explore this possibility, we examined nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often associated with reduced sensitivity to 1alpha,25-dihydroxyvitamin D-3 (1alpha, 25(OH)(2)D-3). For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05). Similarly, 10/15 primary tumour cultures ( including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated. Corepressor proteins often have associated histone deacetylases (HDAC) and reflectively the antiproliferative action of 1 alpha, 25(OH)(2)D-3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines. To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA after 6 h. Examination of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA cooperatively upregulated eight (outof1176) genes, including MAPK-APK2 and GADD45 alpha. MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation. Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA ( siRNA) approach and found that GADD45 alpha induction by 1 alpha, 25(OH)(2)D-3 alone became very significantly enhanced. The same distortion of gene responsiveness, with repressed induction of GADD45 alpha was found in primary tumour cultures compared and to matched peripheral zone ( normal) cultures from the same donor. These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes associated with antiproliferative action and apparent 1 alpha,25(OH)(2)D-3-insensitivity. This can be targeted therapeutically by combination treatments with HDAC inhibitors.	Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Inst Biomed Res, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA	University of Birmingham; University of Birmingham; Stanford University	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, 2nd Floor, Birmingham B15 2TT, W Midlands, England.	m.j.campbell@bham.ac.uk	Campbell, Moray J/A-1311-2013; Campbell, Moray/ABF-1264-2021	Campbell, Moray/0000-0002-3355-0928				Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Chen TC, 2003, TRENDS ENDOCRIN MET, V14, P423, DOI 10.1016/j.tem.2003.09.004; Cohen LA, 2002, ANTICANCER RES, V22, P1497; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; DeFouw LM, 2000, TISSUE CELL, V32, P238, DOI 10.1054/tice.2000.0111; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hudelist G, 2003, BREAST CANCER RES TR, V78, P193, DOI 10.1023/A:1022930710850; Ingles SA, 1998, CANCER RES, V58, P1620; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Kawashima H, 2003, BIOCHEM J, V369, P163, DOI 10.1042/BJ20020743; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krishnan AV, 2003, RECENT RESULTS CANC, V164, P205; Kubota T, 1998, CANCER RES, V58, P3370; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Peehl DM, 2004, J CELL BIOCHEM, V91, P185, DOI 10.1002/jcb.10691; Peehl DM, 2003, ENDOCR-RELAT CANCER, V10, P131, DOI 10.1677/erc.0.0100131; PEEHL DM, 1994, CANCER RES, V54, P805; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Rashid SF, 2001, ONCOGENE, V20, P1860, DOI 10.1038/sj.onc.1204269; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Ratnam AV, 1996, J INVEST DERMATOL, V106, P522, DOI 10.1111/1523-1747.ep12343898; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Tong WM, 1998, INT J CANCER, V75, P467, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;467::AID-IJC22&gt;3.0.CO;2-4; Wang DF, 2004, BIOORG MED CHEM LETT, V14, P707, DOI 10.1016/j.bmcl.2003.11.062; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3; Zierold C, 2002, ARCH BIOCHEM BIOPHYS, V404, P18, DOI 10.1016/S0003-9861(02)00238-2; Zinser G, 2002, DEVELOPMENT, V129, P3067	72	109	111	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6712	6725		10.1038/sj.onc.1207772	http://dx.doi.org/10.1038/sj.onc.1207772			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15300237	Green Submitted			2022-12-28	WOS:000223653600003
J	Kinlen, L				Kinlen, L			Infections and immune factors in cancer: the role of epidemiology	ONCOGENE			English	Article						infections; immune impairment; cancer	EPSTEIN-BARR-VIRUS; CHILDHOOD LEUKEMIA; HUMAN-PAPILLOMAVIRUS; BREAST-CANCER; HEPATITIS-B; RISK; CARCINOMA; AFLATOXIN; EXPOSURE; TRANSPLANTATION	An infective, mostly viral, basis has been found in an increasing number of different human cancers. In all cases, the neoplasm is a rare response to the relevant infection, which is usually present in persistent form, and requiring specific cofactors for malignancy to develop. In some cases, epidemiological evidence of infectivity preceded and promoted identification of the specific infection involved and even the discovery of the microbe itself, as in Burkitt's lymphoma and cervix cancer. In other cases, the discovery of the agent came first as in stomach and nasopharynx cancers, and epidemiology has been concerned mainly with confirming the relationship, measuring the size of the risk and identifying cofactors. Infection-linked cancers include some of the commonest malignancies in certain large world regions, amounting to over 20% of all cancer in the developing countries. In addition to these cancers are others such as childhood leukaemia that show features indicative of an infective basis though no underlying agent has been identified. Advances in this field invite speculation about possible future discoveries and how these might be promoted. However, in that majority of cancers that are unrelated to sexual behaviour, there will be nothing even at the population level to suggest an infective basis because what is transmitted from one individual to another is not the neoplasm itself, but the underlying, often silent, infection to which the malignancy is an uncommon response. The increasing prevalence of immune impairment in human populations, as a result of the use of immunosuppressive drugs with organ transplants and the spread of HIV infection, has produced marked effects on cancer incidence in the affected groups including increases, of skin cancers, non-Hodgkin's lymphoma and Kaposi's sarcoma and to a lesser extent of many other cancers, in some cases at least due to the release from immunological control of incipient infection-based malignancies.	Radcliffe Infirm, Canc Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Kinlen, L (corresponding author), Radcliffe Infirm, Canc Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	leo.kinlen@dphpc.ox.ac.uk						Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; Alexander FE, 1999, EUR J CANCER, V35, P439, DOI 10.1016/S0959-8049(98)00385-2; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BEASLEY RP, 1981, LANCET, V2, P1129; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Boutou O, 2002, BRIT J CANCER, V87, P740, DOI 10.1038/sj.bjc.6600529; BURKITT D, 1962, NATURE, V194, P232, DOI 10.1038/194232a0; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CRAWFORD DH, 1981, INT J CANCER, V28, P705, DOI 10.1002/ijc.2910280608; DANESH J, 1999, INFECT HUMAN CANC CA, V33; DEMETER LM, 1993, J INFECT DIS, V168, P38, DOI 10.1093/infdis/168.1.38; Dickinson HO, 1999, BRIT J CANCER, V81, P144, DOI 10.1038/sj.bjc.6690664; Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; Doll R, 1999, BRIT J CANCER, V81, P3, DOI 10.1038/sj.bjc.6690642; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Franceschi S, 2000, LANCET, V356, P871, DOI 10.1016/S0140-6736(00)02673-8; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; GREAVES MF, 1988, LEUKEMIA, V7, P349; HANTO DW, 1981, CANCER RES, V41, P4253; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; HERRINGTON MM, 1996, CANC EPIDEMIOLOGY PR; HOOVER R, 1973, LANCET, V2, P55; *IARC, 1994, MON EV CARC RISKS HU, V61; IARC, 1994, MON EV CARC RISKS HU; *IARC, 1995, IARC MON EV CARC RIS, V64; Infante-Rivard C, 2000, BRIT J CANCER, V83, P1559, DOI 10.1054/bjoc.2000.1495; Jourdan-Da Silva N, 2004, BRIT J CANCER, V90, P139, DOI 10.1038/sj.bjc.6601384; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1971, LANCET, V2, P398; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1995, CANCER CAUSE CONTROL, V6, P445, DOI 10.1007/BF00052185; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KINLEN LJ, 1994, BRIT MED J, V309, P1197, DOI 10.1136/bmj.309.6963.1197; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; KINLEN LJ, 2000, RADIOL PROT B, V226, P9; KINLEN LJ, UNPUB; Koushik A, 2001, CANCER CAUSE CONTROL, V12, P483, DOI 10.1023/A:1011266413087; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lin CT, 1997, AM J PATHOL, V150, P1745; LITTLE J, 1999, IARC SCI PUBLICATION, V149; Ma X, 2002, BRIT J CANCER, V86, P1419, DOI 10.1038/sj.bjc.6600274; MACMAHON B, 1966, CANCER RES, V26, P1189; Magrath I, 1999, JNCI-J NATL CANCER I, V91, P1349, DOI 10.1093/jnci/91.16.1349; Newton R, 1999, CANCER SURV, V33, P291; Newton R, 1996, BRIT J CANCER, V74, P1511, DOI 10.1038/bjc.1996.581; Newton R, 1999, CANCER SURV, V33, P237; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; PARKIN DM, 1999, INFECT HUM CANC CANC, V33; Petridou E, 1996, BRIT J CANCER, V73, P1278, DOI 10.1038/bjc.1996.245; PETRIDOU E, 1993, BRIT MED J, V307, P774, DOI 10.1136/bmj.307.6907.774; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; Rigoni-Stern D, 1842, G SERVIRE PROGR PA 2, V2, P507; Rosenbaum PF, 2000, AM J EPIDEMIOL, V152, P1136, DOI 10.1093/aje/152.12.1136; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Smith EM, 1998, LARYNGOSCOPE, V108, P1098, DOI 10.1097/00005537-199807000-00027; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; Thomas L, 1959, CELLULAR HUMORAL ASP, P529; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VIZCAINO P, 1994, CANCER CAUSE CONTROL, V5, P517, DOI 10.1007/BF01831379; VONKA V, 1984, INT J CANCER, V33, P61, DOI 10.1002/ijc.2910330111; WARREN JR, 1983, LANCET, V1, P1273; WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K; Xue SA, 2003, BRIT J CANCER, V89, P113, DOI 10.1038/sj.bjc.6601027; Yasui Y, 2001, CANCER EPIDEM BIOMAR, V10, P9; YU MW, 1993, CANCER RES, V53, P790	80	63	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6341	6348		10.1038/sj.onc.1207898	http://dx.doi.org/10.1038/sj.onc.1207898			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322509				2022-12-28	WOS:000223468800003
J	Gaggioli, C; Deckert, M; Robert, G; Abbe, P; Batoz, M; Ehrengruber, MU; Ortonne, JP; Ballotti, R; Tartare-Deckert, S				Gaggioli, C; Deckert, M; Robert, G; Abbe, P; Batoz, M; Ehrengruber, MU; Ortonne, JP; Ballotti, R; Tartare-Deckert, S			HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1	ONCOGENE			English	Article						melanoma; fibronectin; HGF; B-RAF; Egr-1; signaling	TRANSCRIPTION FACTOR EGR-1; HUMAN ENDOTHELIAL-CELLS; SERUM RESPONSE ELEMENT; GENE-EXPRESSION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; MALIGNANT-MELANOMA; MESANGIAL CELLS; UP-REGULATION; NGFI-A	The matrix fibronectin protein is a multifunctional adhesive molecule that promotes migration and invasiveness of many tumors including melanomas. Increased fibronectin synthesis has been associated with the metastatic potential of melanoma cells; however, the molecular mechanisms underlying fibronectin overexpression during melanoma development are poorly understood. We report that hepatocyte growth factor/scatter factor (HGF) induces fibronectin expression and its extracellular assembly on the surface of melanoma cells through activation of mitogen-activated protein (MAP) kinase pathway, and induction and transcriptional activation of Early growth response-1 (Egr-1). Inhibition of B-RAF/ MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF. Exogenously expressed Egr-1 increased fibronectin levels, while blockage of Egr-1 activation by expression of the Egr-1 corepressor NAB2 interfered with the upregulation of fibronectin synthesis induced by HGF, indicating that Egr-1 exerts a significant role in fibronectin expression in response to HGF. Finally, analysis of the expression pattern of fibronectin in melanoma cells demonstrated that fibronectin levels are correlated with constitutive MAP kinase signaling. Our data define a novel mechanism that might have important implications in regulation of melanoma progression by autocrine HGF signaling or by constitutive activation of MAP kinase pathway.	INSERM, Unite 597, Equipe Labellisee Ligue 2001, IFR 50,Fac Med, F-06107 Nice 2, France; Hop Archet, INSERM, Unite 576, F-06202 Nice, France; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Zurich	Tartare-Deckert, S (corresponding author), INSERM, Unite 597, Equipe Labellisee Ligue 2001, IFR 50,Fac Med, 28 Ave Valmbrose, F-06107 Nice 2, France.	tartare@unice.fr	Gaggioli, Cedric/F-3658-2011; BALLOTTI, Robert/F-8825-2013; Deckert, Marcel/T-3566-2019; robert, guillaume/O-1935-2017; gaggioli, cedric/L-5363-2019; Gaggioli, Cedric/Q-2642-2019; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/M-4998-2016	Gaggioli, Cedric/0000-0002-4710-1605; Deckert, Marcel/0000-0003-2094-559X; robert, guillaume/0000-0002-6350-2222; Gaggioli, Cedric/0000-0002-4710-1605; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brose MS, 2002, CANCER RES, V62, P6997; Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chavey C, 2003, J BIOL CHEM, V278, P11888, DOI 10.1074/jbc.M209196200; Choudhury GG, 2004, CELL SIGNAL, V16, P31, DOI 10.1016/S0898-6568(03)00094-9; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fu MG, 2003, GENE, V315, P33, DOI 10.1016/S0378-1119(03)00730-3; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goding CR, 2000, GENE DEV, V14, P1712; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guo BL, 2004, DIABETES, V53, P200, DOI 10.2337/diabetes.53.1.200; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Herlyn M, 1996, AM J PATHOL, V149, P739; Hingorani SR, 2003, CANCER RES, V63, P5198; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; HUMPHRIES MJ, 1989, CANCER INVEST, V7, P373, DOI 10.3109/07357908909039866; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; Jiang YQ, 2002, ONCOGENE, V21, P2270, DOI 10.1038/sj.onc.1205278; Lee BH, 2002, BIOCHEM BIOPH RES CO, V297, P1218, DOI 10.1016/S0006-291X(02)02356-2; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Medico E, 2001, NAT BIOTECHNOL, V19, P579, DOI 10.1038/89343; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Noonan FP, 2000, CANCER RES, V60, P3738; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Recio JA, 2003, CANCER RES, V63, P1576; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Sage EH, 2001, J CLIN INVEST, V107, P781, DOI 10.1172/JCI12683; Satyamoorthy K, 2003, CANCER RES, V63, P756; Silletti S, 1998, INT J CANCER, V76, P120, DOI 10.1002/(SICI)1097-0215(19980330)76:1<120::AID-IJC19>3.3.CO;2-G; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wu SQ, 2002, BLOOD, V100, P4454, DOI 10.1182/blood-2002-02-0415; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	53	67	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1423	1433		10.1038/sj.onc.1208318	http://dx.doi.org/10.1038/sj.onc.1208318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608673				2022-12-28	WOS:000227092600012
J	Li, FZ; Ling, X; Huang, HY; Brattain, L; Apontes, P; Wu, JG; Binderup, L; Brattain, MG				Li, FZ; Ling, X; Huang, HY; Brattain, L; Apontes, P; Wu, JG; Binderup, L; Brattain, MG			Differential regulation of survivin expression and apoptosis by vitamin D-3 compounds in two isogenic MCF-7 breast cancer cell sublines	ONCOGENE			English	Article						vitamin D-3; survivin; apoptosis; p38 MAPK; MCF-7 breast cancer cell	BETA-INDUCED APOPTOSIS; RECEPTOR-TYPE II; GROWTH-INHIBITION; CRYSTAL-STRUCTURE; D ANALOGS; IN-VIVO; PROTEIN; GENE; IAP; FAMILY	Although both the antiapoptotic function of survivin and vitamin D-3 (VD3)-mediated cell growth inhibition and apoptosis have been extensively studied, it is not known whether survivin plays a role in VD3 compound-mediated cell growth inhibition and apoptosis induction. Using an isogenic model of MCF-7 breast adenocarcinoma cells (MCF-7E and MCF-7L sublines that are sensitive and resistant to VD3 compounds), we found that VD3 compounds effectively downregulated survivin in VD3-sensitive MCF-7E cells, which was associated with VD3-induced apoptosis. In contrast, VD3 compounds failed to downregulate survivin in VD3-resistant MCF-7L cells, which showed resistant to VD3-induced apoptosis. However, inhibition of survivin expression by small interfering RNA (siRNA) induced cell death per se and further sensitized VD3-induced apoptosis in MCF-7L cells, indicating that the inability of these cells to respond to VD3 is due to the failure to downregulate survivin. Forced expression of survivin not only blocked VD3-mediated G1 cell accumulation but also increased S and G2/M cell populations. VD3 treatment rapidly triggered the activation of p38 MAPK signaling in MCF-7E cells but not in MCF7L cells. Moreover, inhibition of p38 activation diminished VD3-mediated survivin inhibition and partially rescued VD3-induced cell death. We further showed that VD3 increased the expression of TGFbeta1 and TGFbeta receptor 2, and that blocking the function of TGFbeta receptor 2 diminished VD3 compound-mediated survivin downregulation. Thus, we propose that the VD3 compound-induced growth inhibition and apoptosis induction are at least partially dependent on survivin downregulation via VD3-induced TGFbeta signaling and the activation of p38 MAPK pathway. Targeting survivin through these pathways may lead to novel applications for cancer therapeutics. Published online 20 December 2004.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Li, FZ (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	fengzhi.li@roswellpark.org	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [R01 CA072001, R01 CA38173, R01 CA109481, P30 CA016056, R01 CA109481-01, R01 CA72001, R01 CA038173, R37 CA038173, CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038173, P30CA016056, R37CA038173, R01CA072001, R01CA109481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blutt SE, 2000, CANCER RES, V60, P779; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Choi KS, 2003, CANCER GENE THER, V10, P87, DOI 10.1038/sj.cgt.7700531; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Diaz GD, 2000, CANCER RES, V60, P2304; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Hansen CM, 2000, CURR PHARM DESIGN, V6, P803, DOI 10.2174/1381612003400371; Hershberger PA, 1999, CANCER RES, V59, P2644; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; James SY, 1998, BRIT J PHARMACOL, V125, P953, DOI 10.1038/sj.bjp.0702103; Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Ko Y, 1998, INT J ONCOL, V12, P87; Ko Y, 1998, J CELL PHYSIOL, V176, P424, DOI 10.1002/(SICI)1097-4652(199808)176:2<424::AID-JCP21>3.3.CO;2-N; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Narvaez CJ, 2001, J BIOL CHEM, V276, P9101, DOI 10.1074/jbc.M006876200; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Padgett RW, 1999, CANCER METAST REV, V18, P247, DOI 10.1023/A:1006325408261; PEEHL DM, 1994, CANCER RES, V54, P805; Pennati M, 2002, J CLIN INVEST, V109, P285; Reed JC, 1999, NAT CELL BIOL, V1, pE199, DOI 10.1038/70227; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shen CX, 2003, CANCER GENE THER, V10, P403, DOI 10.1038/sj.cgt.7700581; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; Wu GF, 1997, ONCOGENE, V15, P1555, DOI 10.1038/sj.onc.1201329; Xia CY, 2002, MOL CANCER THER, V1, P687; Yang LM, 2001, J CELL PHYSIOL, V188, P383, DOI 10.1002/jcp.1125; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3	59	52	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1385	1395		10.1038/sj.onc.1208330	http://dx.doi.org/10.1038/sj.onc.1208330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608672	Green Accepted			2022-12-28	WOS:000227092600008
J	Gonzalex-Sancho, JM; Aguilera, O; Garcia, JM; Pendas-Franco, N; Pena, C; Cal, S; de Herreros, AG; Bonilla, F; Munoz, A				Gonzalex-Sancho, JM; Aguilera, O; Garcia, JM; Pendas-Franco, N; Pena, C; Cal, S; de Herreros, AG; Bonilla, F; Munoz, A			The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer	ONCOGENE			English	Article						Wnt; DICKKOPF-1; beta-catenin; T-cell factor4; gene regulation	PROMOTER-HYPERMETHYLATION; EXPRESSION; MECHANISM; PROTEINS; RECEPTOR; DKK1; OVEREXPRESSION; INHIBITION; SUPPRESSOR; CELLS	Wnt glycoproteins regulate homeostasis and development by binding to membrane Frizzled-LRP5/6 receptor complexes. Wnt signaling includes a canonical pathway involving cytosolic beta-catenin stabilization, nuclear translocation and gene regulation, acting as a co-activator of T-cell factor (TCF) proteins, and noncanonical pathways that activate Rho, Rac, JNK and PKC, or modulate Ca2+ levels. DICKKOPF-1 (DKK-1) encodes a secreted Wnt antagonist that binds to LRP5/6 and induces its endocytosis, leading to inhibition of the canonical pathway. We show that activation of canonical signaling by Wnt1 or ectopic expression of active beta-catenin, TCF4 or LRP6 mutants induces transcription of the human DKK-1 gene. Multiple beta-catenin/TCF4 sites in the DKK-1 gene promoter contribute to this activation. In contrast, Wnt5a, which signals through noncanonical pathways, does not activate DKK-1. Northern and Western blot studies show that activation of the Wnt/beta-catenin pathway by treatment with lithium or Wnt3a-conditioned medium, or by stable expression of either Wnt1 or beta-catenin, increases DKK-1 RNA and protein, thus initiating a negative feedback loop. However, we found that DKK-1 expression decreases in human colon tumors, which suggests that DKK-1 acts as a tumor suppressor gene in this neoplasia. Our data indicate that the Wnt/beta-catenin pathway is downregulated by the induction of DKK-1 expression, a mechanism that is lost in colon cancer.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Hosp Univ Puerta Hierro, E-28035 Madrid, Spain; Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Pompeu Fabra University	Munoz, A (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Gonzalez-Sancho, Jose/AAA-6010-2019; Munoz, Alberto/O-6393-2014; de Herreros, A Garcia/H-3104-2014	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Munoz, Alberto/0000-0003-3890-4251; de Herreros, A Garcia/0000-0001-5270-0808				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Millar JBA, 2002, GENOME BIOL, V3; Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Roessler E, 2000, CYTOGENET CELL GENET, V89, P220, DOI 10.1159/000015618; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sambrook J., 1989, MOL CLONING LAB MANU; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shinya M, 2000, MECH DEVELOP, V98, P3, DOI 10.1016/S0925-4773(00)00433-0; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	38	315	337	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1098	1103		10.1038/sj.onc.1208303	http://dx.doi.org/10.1038/sj.onc.1208303			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592505				2022-12-28	WOS:000226749200016
J	Barnes, EA; Heidtman, KJ; Donoghue, DJ				Barnes, EA; Heidtman, KJ; Donoghue, DJ			Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC	ONCOGENE			English	Article						Gli1; hedgehog; nevoid basal cell carcinoma syndrome	BASAL-CELL CARCINOMA; HUMAN EMBRYONAL CARCINOMA; SONIC-HEDGEHOG GENE; D-TYPE CYCLINS; HUMAN HOMOLOG; NUCLEAR-LOCALIZATION; MISSENSE MUTATIONS; SIGNALING PATHWAY; PREMATURE MITOSIS; RECEPTOR COMPLEX	Mutations in the transmembrane receptor patched1 (ptc1) are responsible for the majority of basal cell carcinoma (BCC) cases. Many of these mutations, including ptc1-Q688X, result in premature truncation of the ptc1 protein. ptc1-Q688X has been identified in patients with both BCC and nevoid basal cell carcinoma syndrome, an inheritable disorder causing a predisposition to cancer susceptibility. Here we describe a mechanism by which ptc1-Q688X causes constitutive cellular signaling. Cells expressing ptc1-Q688X demonstrate an increase in cell cycle progression and induce cell transformation. The ptc1-Q688X mutant enhances Gli1 activity, a downstream reporter of sonic hedgehog (shh)-ptc1 signaling, independent of shh stimulation. In contrast to wild-type ptc1, ptc1-Q688X fails to associate with endogenous cyclin B1. Expression of nuclear-targeted cyclin B1 derivatives promotes Gli1-dependent transcription, which correlates temporally with cyclin B1-cdk1 kinase activity. Coexpression of wild-type ptc1 with a nuclear-targeted cyclin B1 derivative, mutated to mimic constitutive phosphorylation, dramatically decreases Gli1 activity. In addition, the coexpression of this constitutively nuclear cyclin B1 derivative with ptc1-Q688X substantially enhances foci formation. These studies therefore describe a molecular mechanism for the aberrant activity of ptc1-Q688X that includes the premature activation of the transcription factor Gli1.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, 9500 Gilman Dr,Urey Hall,6114, La Jolla, CA 92093 USA.	ddonoghue@ucsd.edu			NCI NIH HHS [T32-CA09523, P30CA23100-18, T32 CA009523] Funding Source: Medline; NIGMS NIH HHS [GM65490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey EC, 2003, CANCER RES, V63, P1636; Bailey EC, 2002, J BIOL CHEM, V277, P33632, DOI 10.1074/jbc.M202203200; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chidambaram A, 1996, CANCER RES, V56, P4599; Cimini D, 1998, CHROMOSOMA, V107, P479, DOI 10.1007/s004120050332; Cohen MM, 1999, INT J ORAL MAX SURG, V28, P216, DOI 10.1034/j.1399-0020.1999.283280314.x; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Ghosh S, 1996, EXP CELL RES, V227, P165, DOI 10.1006/excr.1996.0262; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Green J, 1998, BRIT J DERMATOL, V139, P911; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JHA MN, 1994, CANCER RES, V54, P5011; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Lowrey JA, 2002, J IMMUNOL, V169, P1869, DOI 10.4049/jimmunol.169.4.1869; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Reifenberger J, 1998, CANCER RES, V58, P1798; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; Unden AB, 1996, CANCER RES, V56, P4562; Wicking C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wicking C, 1997, AM J MED GENET, V73, P304; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang H, 2001, AM J PATHOL, V158, P381, DOI 10.1016/S0002-9440(10)63980-6	63	42	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					902	915		10.1038/sj.onc.1208240	http://dx.doi.org/10.1038/sj.onc.1208240			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592520				2022-12-28	WOS:000226577100016
J	Wei, L; Yang, Y; Zhang, X; Yu, Q				Wei, L; Yang, Y; Zhang, X; Yu, Q			Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis	ONCOGENE			English	Article						Src; anoikis; lung; cancer; tyrosine phosphorylation	TYROSINE KINASE-ACTIVITY; FOCAL ADHESION KINASE; HUMAN-COLON CARCINOMA; C-SRC; EPITHELIAL-CELLS; V-SRC; PREMALIGNANT EPITHELIA; PP60C-SRC ACTIVITY; GENE-PRODUCT; CANCER CELLS	Src plays an important role in cell proliferation, differentiation, adhesion, and migration. Altered Src activity has been strongly implicated in the development, growth, progression, and metastasis of human cancers. We have analysed the change and regulation of Src upon cell detachment in anoikis-resistant human lung adenocarcinoma cells and compared with that of relatively normal and anoikis-sensitive epithelial cells. We found that Src activity was increased in the anoikis-resistant lung tumor cells when they were detached and cultured in suspension. The detachment-induced Src activation in the tumor cells compensates for the loss of cell survival signals caused by disruption of cell-matrix interactions and contributes to anoikis resistance of the tumor cells. Pyk2, rather than PI 3K/Akt or Erk, appears to be the key downstream effecter of Src in mediating the cell survival signals. The increased Src activity is mainly due to the phosphorylation of Tyr-419, rather than the dephosphorylation of Tyr-530 of Src protein. PDGFR, not FAK or EGFR, appears to be the upstream protein tyrosine kinase responsible for the detachment-induced Src activation in the lung tumor cells. The increased Src activity upon cell detachment may contribute to the metastasis potential of malignant tumors.	Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Boston University; Boston University	Yu, Q (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	qyu@sibs.ac.cn			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059678] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59678] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V272, pL28, DOI 10.1152/ajplung.1997.272.1.L28; BJELFMAN C, 1990, CANCER RES, V50, P6908; Bjorge JD, 1996, BIOCHEM CELL BIOL, V74, P477, DOI 10.1139/o96-052; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiang GG, 2000, J BIOL CHEM, V275, P6055, DOI 10.1074/jbc.275.9.6055; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; COLLETT MS, 1979, P NATL ACAD SCI USA, V76, P3159, DOI 10.1073/pnas.76.7.3159; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hisano C, 2003, CELL BIOL INT, V27, P415, DOI 10.1016/S1065-6995(03)00032-5; JACOBS C, 1983, CANCER RES, V43, P1696; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; MAZURENKO NN, 1992, EUR J CANCER, V28A, P372, DOI 10.1016/S0959-8049(05)80056-5; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Ogata Y, 2003, HYPERTENSION, V41, P1156, DOI 10.1161/01.HYP.0000064342.30653.24; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Wei L, 2001, CANCER RES, V61, P2439; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1	53	74	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9052	9061		10.1038/sj.onc.1208091	http://dx.doi.org/10.1038/sj.onc.1208091			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489898				2022-12-28	WOS:000225492800006
J	Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL				Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL			Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						IRF-1; tamoxifen; CBP; breast cancer	CREB-BINDING PROTEIN; GAMMA INHIBITS GROWTH; RETINOIC-ACID; BREAST-CANCER; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; STIMULATED GENES; CARCINOMA-CELLS; UP-REGULATION; BETA	Unlike estrogen receptor-positive (ER(+)) breast cancers, normal human mammary epithelial cells (HMECs) typically express low nuclear levels of ER ( ER poor). We previously demonstrated that 1.0 muM tamoxifen (Tam) promotes apoptosis in acutely damaged ER-poor HMECs through a rapid, 'nonclassic' signaling pathway. Interferon-regulatory factor-1 (IRF-1), a target of signal transducer and activator of transcription-1 transcriptional regulation, has been shown to promote apoptosis following DNA damage. Here we show that 1.0 muM Tam promotes apoptosis in acutely damaged ER-poor HMECs through IRF-1 induction and caspase-1/3 activation. Treatment of acutely damaged HMEC-E6 cells with 1.0 muM Tam resulted in recruitment of CBP to the gamma-IFN-activated sequence element of the IRF-1 promoter, induction of IRF-1, and sequential activation of caspase-1 and -3. The effects of Tam were blocked by expression of siRNA directed against IRF-1 and caspase-1 inhibitors. These data indicate that Tam induces apoptosis in HMEC-E6 cells through a novel IRF-1-mediated signaling pathway that results in activated caspase-1 and -3.	Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98120 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Med Ctr, Div Med Oncol, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA088799, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88799, 2P30CA14236-26, R01CA984441] Funding Source: Medline; NIDDK NIH HHS [2P30DK 35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiba-Masago S, 2001, CELL SIGNAL, V13, P617, DOI 10.1016/S0898-6568(01)00183-8; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aubele MM, 2000, DIAGN MOL PATHOL, V9, P14, DOI 10.1097/00019606-200003000-00003; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Coradini D, 1997, TUMOR BIOL, V18, P22, DOI 10.1159/000218012; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Detjen KM, 2002, INT J ONCOL, V21, P1133; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GIBSON DFC, 1993, BREAST CANCER RES TR, V25, P141, DOI 10.1007/BF00662139; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Gjermandsen IM, 2000, CYTOKINE, V12, P233, DOI 10.1006/cyto.1999.0549; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hoshiya Y, 2003, J BIOL CHEM, V278, P51703, DOI 10.1074/jbc.M307626200; Iacopino F, 1997, INT J CANCER, V71, P1103, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1103::AID-IJC29>3.0.CO;2-C; Jiang B, 2004, TOXICON, V43, P53, DOI 10.1016/j.toxicon.2003.10.017; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Karlsen AE, 2000, J CLIN ENDOCR METAB, V85, P830, DOI 10.1210/jc.85.2.830; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lindner DJ, 1997, MOL CELL BIOCHEM, V167, P169, DOI 10.1023/A:1006854110122; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1994, EMBO J, V16, P406; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, CANCER RES, V61, P616; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAMPFER M, 1985, J TISSUE CULT METHOD, V9, P109; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tsuda H, 1998, JPN J CLIN ONCOL, V28, P5, DOI 10.1093/jjco/28.1.5; Tzoanopoulos D, 2002, BRIT J HAEMATOL, V119, P46, DOI 10.1046/j.1365-2141.2002.03829.x; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Widschwendter M, 1996, ANTICANCER RES, V16, P369; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yim JH, 1997, J IMMUNOL, V158, P1284; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	83	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8743	8755		10.1038/sj.onc.1208120	http://dx.doi.org/10.1038/sj.onc.1208120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467738				2022-12-28	WOS:000225165100004
J	Cheng, PL; Chang, MH; Chao, CH; Lee, YHW				Cheng, PL; Chang, MH; Chao, CH; Lee, YHW			Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation	ONCOGENE			English	Article						HCV; core protein; NS3 protein; TGF-beta; Smad3; hepatocarcinogenesis	GROWTH-FACTOR-BETA; VIRUS CORE PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; RECEPTOR; BINDING; REPLICATION; SUPPRESSION; CELLS	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine implicated as a pathogenic mediator in various liver diseases. Enhanced TGF-beta production and lack of TGF-beta responses are often observed during hepatitis C virus (HCV) infection. In this study, we demonstrate that TGF-beta-mediated transactivation is decreased in cells exogenously expressing the intact HCV polyprotein. Among 16 viral products of HCV, only core and nonstructural protein 3 (NS3) physically interact with the MH1 (Mad homology 1) region of the Smad3 and block TGF-beta/Smad3-mediated transcriptional activation through interference with the DNA-binding ability of Smad3, not the nuclear translocation. However, the interactive domain of NS3 extends to the MH2 (Mad homology 2) region of Smad3 and a distinction is found between effects mediated, respectively, by these two viral proteins. HCV core, in the presence or absence of TGF-beta, has a stronger suppressive effect on the DNA-binding and transactivation ability of Smad3 than NS3. Although HCV core, NS3, and the HCV subgenomic replicon all attenuate TGF-beta/Smad3-mediated apoptosis, only HCV core represses TGF-beta-induced G1 phase arrest through downregulation of the TGF-beta-induced p21 promoter activation. Along with this, HCV core, rather than NS3, exhibits a significant inhibitory effect on the binding of Smad3/Sp1 complex to the proximal p21 promoter in response to TGF-beta. In conclusion, HCV viral proteins interact with the TGF-beta signaling mediator Smad3 and differentially impair TGF-beta/Smad3-mediated transactivation and growth inhibition. This functional counteraction of TGF-beta responses provides insights into possible mechanisms, whereby the HCV oncogenic proteins antagonize the host defenses during hepatocarcinogenesis.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Cheng, Pei-Lin/ABB-2255-2021	Cheng, Pei-Lin/0000-0002-0090-8153; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; Dubourdeau M, 2002, J HEPATOL, V37, P486, DOI 10.1016/S0168-8278(02)00241-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fujita T, 1996, BIOCHEM BIOPH RES CO, V229, P825, DOI 10.1006/bbrc.1996.1887; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; ITO N, 1991, CANCER RES, V51, P4080; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kim DH, 1997, J BIOL CHEM, V272, P688; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lee MN, 2002, J GEN VIROL, V83, P2145, DOI 10.1099/0022-1317-83-9-2145; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matsuzaki K, 2000, CANCER RES, V60, P1394; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Prokova V, 2002, J BIOL CHEM, V277, P9342, DOI 10.1074/jbc.M109099200; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2001, J VIRAL HEPATITIS, V8, P96, DOI 10.1046/j.1365-2893.2001.00283.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	48	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7821	7838		10.1038/sj.onc.1208066	http://dx.doi.org/10.1038/sj.onc.1208066			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334054				2022-12-28	WOS:000224331600008
J	Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A				Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A			FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells	ONCOGENE			English	Article						malignant mesothelioma; Fas; TRAIL; FLIP; caspase-8; apoptosis	LIGAND-INDUCED APOPTOSIS; TUMOR IMMUNE ESCAPE; PLEURAL MESOTHELIOMA; MEDIATED APOPTOSIS; FAS-LIGAND; EXPRESSION; TRAIL; PROTEIN; GROWTH; LINES	Tumors have developed several forms of resistance to receptor-induced cell death. Here, we show that malignant mesothelial (MM) cell lines as well as primary MM cells and normal mesothelial (NM) cells express Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5. We found that, although Fas expression levels are comparable, only MM cells are resistant to cell death. Furthermore, MM cells show resistance to TRAIL-induced apoptosis. Caspase-8 (FLICE) is not activated by death receptors triggering in malignant cells whereas it is well activated by nonreceptor stimuli, such as UV radiation. We found that FLIP (FLICE-Inhibitory Protein) is constitutively expressed in all MM cell lines and is more expressed in primary MM cells than in NM cells. Knockdown of FLIP expression in MM cell lines, by a FLIPsiRNA, re-established the normal response to apoptosis induced by Fas or DR4/DR5, which was blocked by pretreatment with the caspase-8 inhibitor z-IETD-fmk. These results indicate that MM cells develop an intrinsic resistance to apoptosis induced by death receptors upregulating the expression of the antiapoptotic protein c-FLIP.	Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy; Italian Natl Res Ctr Aging, Lab Cytol, I-860124 Ancona, Italy; S Antonio & Biagio Hosp, Dept Anat Pathol, I-15100 Alessandria, Italy; Pediat Hosp G Salesi, I-60100 Ancona, Italy	Marche Polytechnic University; IRCCS INRCA; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo	Rippo, MR (corresponding author), Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy.	m.r.rippo@univpm.it	Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; RIPPO, Maria Rita/0000-0003-3024-3495				Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bradley M, 1998, BLOOD, V92, P4248, DOI 10.1182/blood.V92.11.4248.423k20_4248_4255; CARBONE M, 1994, ONCOGENE, V9, P1781; Catalan MP, 2003, KIDNEY INT, V64, P321, DOI 10.1046/j.1523-1755.2003.00062.x; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frost P, 1997, CELL IMMUNOL, V180, P70, DOI 10.1006/cimm.1997.1169; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaklitsch MT, 2001, WORLD J SURG, V25, P210, DOI 10.1007/s002680020021; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; LEW F, 1986, J CLIN IMMUNOL, V6, P225, DOI 10.1007/BF00918702; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459; Narasimhan SR, 1998, AM J PHYSIOL-LUNG C, V275, pL165, DOI 10.1152/ajplung.1998.275.1.L165; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Roth W, 2001, CANCER RES, V61, P2759; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Stewart JH, 2002, J THORAC CARDIOV SUR, V123, P295, DOI 10.1067/mtc.2002.119882; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Tomasetti M, 2004, BRIT J CANCER, V90, P1644, DOI 10.1038/sj.bjc.6601707; Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058	38	75	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7753	7760		10.1038/sj.onc.1208051	http://dx.doi.org/10.1038/sj.onc.1208051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334061				2022-12-28	WOS:000224331600001
J	Bitomsky, N; Bohm, M; Klempnauer, KH				Bitomsky, N; Bohm, M; Klempnauer, KH			Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun	ONCOGENE			English	Article						Pdcd4; c-Jun; phosphorylation; JNK-signaling; p300	INITIATION-FACTOR 4A; NF-KAPPA-B; ACTIVATION DOMAIN; C/EBP-BETA; HA-RAS; V-MYB; AP-1 TRANSACTIVATION; DELTA-DOMAIN; MIM-1 GENE; IN-VIVO	The transformation suppressor gene Pdcd4 ( programmed cell death gene 4) inhibits the tumor-promoter mediated transformation of mouse keratinocytes and has recently been implicated as a potential tumor suppressor gene in the development of human lung cancer. Biochemical analysis has suggested that the Pdcd4 protein is involved in protein translation as well as in nuclear events. Recent work has shown that Pdcd4 suppresses the transactivation of AP-1 responsive promoters by c-Jun, suggesting that the transformation-suppressor activity of Pdcd4 might be due, at least in part, to the inhibition of c-Jun activity. Here, we have addressed how Pdcd4 inhibits c-Jun. We show that Pdcd4 interferes with the phosphorylation of c-Jun by Jun N-terminal kinase (JNK). The inhibition of c-Jun phosphorylation by Pdcd4 appears not to be due to a general suppression of JNK activity, our data rather suggest that Pdcd4 interacts with c-Jun and thereby blocks phosphorylation of c-Jun. In addition to affecting c-Jun phosphorylation, Pdcd4 blocks the recruitment of the coactivator p300 by c-Jun. Taken together, our results strongly suggest that Pdcd4 is directly involved in the regulation of c-Jun activity.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DAI TN, 1995, ONCOGENE, V10, P849; David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	37	116	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7484	7493		10.1038/sj.onc.1208064	http://dx.doi.org/10.1038/sj.onc.1208064			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334056				2022-12-28	WOS:000224176500005
J	Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Wang, HS; Liang, WY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma	ONCOGENE			English	Article						thymosin beta-4; colorectal carcinoma; beta-catenin; MMP-7; Fas; metastasis	BETA-CATENIN; FAS LIGAND; E-CADHERIN; MATRIX METALLOPROTEINASE-7; CANCER CELLS; MATRILYSIN EXPRESSION; TUMOR PROGRESSION; LIVER METASTASES; IMMUNE PRIVILEGE; BREAST-CANCER	Cell-matrix and cell-cell adhesive interactions play important roles in the normal organization and stabilization of the cell layer in epithelial tissue. Alterations in the expression and function of these adhesion systems that cause a switch to a migratory phenotype in tumor invasion and metastasis are critical for the malignant conversion of epithelial cells. Thymosin beta-4 (Tbeta-4) is the major actin-sequestering protein that has been shown to be upregulated in a wide variety of human carcinomas and has been implicated to be involved in altering the motility of certain tumors. We have recently demonstrated that the growth rate, colony formation in soft agar, and motility, all good indicators for malignant progression, of SW480 colon carcinoma cells are dramatically increased by enforced Tbeta-4 expression. To test the hypothesis that overexpression of this G- actin sequestering peptide also promotes tumor invasion, we examined not only the invasion capability of Tbeta-4-overexpressing SW480 cells, but also the expression levels of Tbeta-4 as well as several proteins that participate in different stages of tumor progression in matched samples of human primary colorectal adenocarcinoma and liver metastases from several patients. A marked increase on the invasiveness in Tbeta-4-overexpressing SW480 cells with increased levels and activity of matrix metalloproteinase-7 (MMP-7) was observed. Furthermore, the levels of Fas as well as the susceptibility to Fas ligand-mediated apoptosis in Tbeta-4-overexpressing cells were significantly decreased. Interestingly, the levels of Tbeta-4 mRNA, beta-catenin, c-Myc, and MMP-7 in metastatic liver lesions were relatively higher, whereas the levels of E-cadherin and Fas were significantly lower than those in the matched primary colorectal tumors. These results suggest that upregulation of Tbeta-4, by promoting the disruption of cell-cell adhesion and a consequential activation of the beta-catenin signaling, could be a key event in the acquisition of growth advantages as well as invasive phenotypes in human colorectal carcinomas.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Taipei Vet Gen Hosp, Div Med Oncol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Califano D, 1998, CANCER RES, V58, P823; Cardi G, 1998, CANCER RES, V58, P2078; Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100; Chopin D, 2003, AM J PATHOL, V162, P1139, DOI 10.1016/S0002-9440(10)63910-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; MORI M, 1995, CANCER, V75, P1516, DOI 10.1002/1097-0142(19950315)75:6+<1516::AID-CNCR2820751522>3.0.CO;2-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; Noe V, 2001, J CELL SCI, V114, P111; O'Connell J, 1998, J PATHOL, V186, P240; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; O'Connell J, 2000, ANN NY ACAD SCI, V910, P178; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xie D, 2002, INT J ONCOL, V21, P499; Yamamoto H, 2003, J PATHOL, V199, P176, DOI 10.1002/path.1277; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	41	98	105	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6666	6671		10.1038/sj.onc.1207888	http://dx.doi.org/10.1038/sj.onc.1207888			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235586				2022-12-28	WOS:000223530800014
J	Lang, G; White, JR; Argent-Katwala, MJG; Allinson, CG; Weston, K				Lang, G; White, JR; Argent-Katwala, MJG; Allinson, CG; Weston, K			Myb proteins regulate the expression of diverse target genes	ONCOGENE			English	Article						c-Myb; B-Myb; transcription; hematopoiesis; T cell	C-MYB; B-MYB; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; A-MYB; V-MYB; APOPTOSIS; DIFFERENTIATION; CELLS; IDENTIFICATION	Hematopoiesis, the process by which mature blood cells arise, is controlled by multiple transcription factors, which act in stage- and lineage-specific complexes. It is a major goal to elucidate the genes regulated by these transcription factors, in order to obtain a full understanding of the process and its malignant counterpart, leukemia. Myb family transcription factors play a central role in hematopoicsis. To identify new Myb family target genes, we have used an inducible dominant-negative protein for a subtraction cloning protocol in a model cell system (FDCP-Mix) with many characteristics of normal hematopoiesis. We present here a novel group of 29 validated Myb family target genes of diverse functions. Published online 20 December 2004.	Ctr Cell & Mol Biol, CRUK, Inst Canc Res, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Ctr Cell & Mol Biol, CRUK, Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.	kathy.weston@icr.ac.uk						ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BIES J, 1995, CANCER RES, V55, P501; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Chan VSF, 2002, EUR J IMMUNOL, V32, P1223, DOI 10.1002/1521-4141(200205)32:5<1223::AID-IMMU1223>3.0.CO;2-5; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Derrien V, 2002, J CELL SCI, V115, P2867; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Iwanaga Y, 2002, CANCER RES, V62, P2618; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; MCMAHON J, 1988, ONCOGENE, V3, P717; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Orkin SH, 2003, IMMUNITY, V19, P633, DOI 10.1016/S1074-7613(03)00302-9; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rantanen A, 2003, MAMM GENOME, V14, P1, DOI 10.1007/s00335-002-2218-z; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Sala A, 1996, CANCER RES, V56, P1991; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki H, 2001, LUNG CANCER-J IASLC, V34, P53, DOI 10.1016/S0169-5002(01)00213-6; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Tewari M, 1997, CANCER RES, V57, P4063; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; Wilkinson JC, 2004, J BIOL CHEM, V279, P51082, DOI 10.1074/jbc.M408655200; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yunta M, 2003, ONCOGENE, V22, P1219, DOI 10.1038/sj.onc.1206183; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	61	37	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1375	1384		10.1038/sj.onc.1208301	http://dx.doi.org/10.1038/sj.onc.1208301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608679				2022-12-28	WOS:000227092600007
J	Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM				Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM			HOXB4 confers a constant rate of in vitro proliferation to transduced bone marrow cells	ONCOGENE			English	Article						HOXB4; bone marrow cells; proliferation; differentiation; cell cycle regulation	HEMATOPOIETIC STEM-CELLS; CELLULAR PROLIFERATION; VIVO EXPANSION; EXPRESSION; JUNB; DIFFERENTIATION; OVEREXPRESSION; PROTEINS; DIVISION; MICE	HOXB4 overexpression mediates increased self-renewal of haematopoietic stem cells (HSCs) ex vivo. Since HOXB4-expanded HSCs retain normal differentiation potential and there is no leukaemia development from transduced HSCs, HOXB 4 represents a promising tool for human HSC therapy. However, the increased proliferation capacity of HOXB4 overexpressing fibroblasts resulting from upregulation of JunB, Fra-1 and cyclin D1 protein levels may indicate a potential risk associated with the HOXB4 overexpression approach. This prompted us to investigate the proliferation rate, differentiation and expression of cell cycle regulators directly in bone marrow cultures overexpressing HOXB4. Here we show that in comparison to neo-transduced control bone marrow cultures, HOXB4-overexpressing cultures had a more homogenous morphology and increased numbers of haematopoietic progenitor cells capable to generate primitive colonies in vitro. In contrast, neo-transduced bone marrow cells in long-term cultures showed hallmarks of myeloid differentiation and a reduced secondary colony forming activity. We further show that multilineage repopulating activity in vivo, which was present only in HOXB4 long-term cultures, declined over time. HOXB4 overexpression in vitro did not result in an increase but in a stabilization of the proliferation rate (1.4 - 1.8 cell divisions per day), while the proliferation rate of control neo-transduced bone marrow cultures gradually declined. Correspondingly, increased HOXB4 expression was paralleled by decreased expression levels of cyclins, CDKs and AP-1 family members. These results suggest that the growth rate of HOXB4- compared to neo-transduced bone marrow cells remains constant in long-term cultures along with a suppression of myeloid differentiation. In contrast to HOXB4 overexpression in fibroblasts, bone marrow cells engineered to overexpress HOXB4 do not upregulate AP-1 complex members or cyclins indicating that HOXB4 acts in a cell type-specific way.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacherstr 5, D-97078 Wurzburg, Germany.	andris@ema-avoti.de; albrecht.mueller@mail.uni-wuerzburg.de						Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Brun ACM, 2003, MOL THER, V8, P618, DOI 10.1016/S1525-0016(03)00237-5; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; Furukawa Y, 2002, LEUKEMIA LYMPHOMA, V43, P225, DOI 10.1080/10428190290005973; Israels ED, 2001, STEM CELLS, V19, P88, DOI 10.1634/stemcells.19-1-88; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Loeffler M, 2002, CELLS TISSUES ORGANS, V171, P8, DOI 10.1159/000057688; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Rowlands TM, 2004, CELL CYCLE, V3, P145; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schiedlmeier B, 2003, BLOOD, V101, P1759, DOI 10.1182/blood-2002-03-0767; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	38	14	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					561	572		10.1038/sj.onc.1208202	http://dx.doi.org/10.1038/sj.onc.1208202			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580301				2022-12-28	WOS:000226420400004
J	Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML				Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML			Tumor suppressive role of a 2.4Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma	ONCOGENE			English	Article						chromosome 9; deleted in esophageal cancer 1; tumor suppressor gene; esophageal carcinoma; microcell-mediated chromosome transfer	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA; HOMOZYGOUS DELETION; CHROMOSOME TRANSFER; FUNCTIONAL EVIDENCE; GENETIC ALTERATIONS; BLADDER-CANCER; ALLELE LOSS; LINES; HETEROZYGOSITY	The key genes involved in the development of esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Previous studies indicate extensive genomic alterations occur on chromosome 9 in ESCC. Using a monochromosome transfer approach, this study provides functional evidence and narrows down the critical region (CR) responsible for chromosome 9 tumor suppressing activity to a 2.4 Mb region mapping to 9q33 - q34 between markers D9S1798 and D9S61. Interestingly, a high prevalence of allelic loss in this CR is also observed in primary ESCC tumors by microsatellite typing. Allelic loss is found in 30/ 34 (88%) tumors and the loss of heterozygosity (LOH) frequency ranges from 67 to 86%. Absent to low expression of a 9q32 candidate tumor suppressor gene (TSG), DEC1 ( deleted in esophageal cancer 1), is detected in four Asian ESCC cell lines. Stably expressing DEC1 transfectants provide functional evidence for inhibition of tumor growth in nude mice and DEC1 expression is decreased in tumor segregants arising after long-term selection in vivo. There is 74% LOH in the DEC1 region of ESCC primary tumors. This study provides the first functional evidence for the presence of critical tumor suppressive regions on 9q33 - q34. DEC1 is a candidate TSG that may be involved in ESCC development.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Tottori Univ, Dept Biomed Sci, Tottori 680, Japan; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Tuen Mun Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; University of Hong Kong; Hong Kong Polytechnic University; Tottori University; University of California System; University of California Irvine; University of Tokyo; Tuen Mun Hospital; Tuen Mun Hospital; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny Cheuk-on/W-7214-2019; Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Lung, Maria Li/C-4495-2009	Tang, Johnny Cheuk-on/0000-0002-4261-3206; Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Daigo, Yataro/0000-0002-0915-3025; Lung, Maria Li/0000-0003-2559-3626				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gorgoulis VG, 1998, MOL MED, V4, P807, DOI 10.1007/BF03401773; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Grady B, 2001, J UROLOGY, V166, P1088, DOI 10.1016/S0022-5347(05)65927-7; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; He CD, 1999, CHINESE MED J-PEKING, V112, P497; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; HUANG Y, 1992, CANCER RES, V52, P6525; Jagasia AA, 1996, CANCER LETT, V105, P91, DOI 10.1016/0304-3835(96)04274-7; Karkera JD, 2000, CLIN CANCER RES, V6, P3565; Kwong FM, 2004, CANCER LETT, V208, P207, DOI 10.1016/j.canlet.2003.11.017; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Miura K, 1996, CANCER RES, V56, P1629; MORI T, 1994, HUM MOL GENET, V3, P1969, DOI 10.1093/hmg/3.11.1969; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; Naidoo R, 1999, DIAGN MOL PATHOL, V8, P131, DOI 10.1097/00019606-199909000-00005; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Parker WL, 2003, J BONE MINER RES, V18, P289, DOI 10.1359/jbmr.2003.18.2.289; Parris CN, 1999, CANCER RES, V59, P516; Qin P, 2004, J CELL BIOCHEM, V92, P147, DOI 10.1002/jcb.20057; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; SAMPSON JR, 1995, J MED GENET, V32, P848, DOI 10.1136/jmg.32.11.848; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; Tada K, 2000, CANCER GENET CYTOGEN, V117, P108, DOI 10.1016/S0165-4608(99)00160-0; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Wang L, 1996, ONCOGENE, V12, P699; Wiest JS, 1997, CANCER RES, V57, P1; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; YAMADA H, 1990, ONCOGENE, V5, P1141; Yang LC, 2004, CANCER LETT, V203, P71, DOI 10.1016/j.canlet.2003.09.027; Yen CC, 2003, INT J ONCOL, V23, P871; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M	45	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					697	705		10.1038/sj.onc.1208179	http://dx.doi.org/10.1038/sj.onc.1208179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580306				2022-12-28	WOS:000226420400017
J	Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C				Rudner, J; Jendrossek, V; Lauber, K; Daniel, PT; Wesselborg, S; Belka, C			Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies	ONCOGENE			English	Article						TRAIL; Bcl-2; apoptosis	TUMOR-NECROSIS-FACTOR; TYROSINE KINASE LCK; CD95 TYPE-I; CYTOCHROME-C; MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; SIGNALING COMPLEX; LIGAND TRAIL; SMAC/DIABLO RELEASE	Death receptor-induced apoptosis is paradigmatically mediated via the recruitment of FADD adapter molecule to the ligand/receptor complex and subsequent activation of caspase-8. However, several observations provided evidence that components of the mitochondrial apoptosis pathway are involved in death receptor-mediated apoptosis. In this regard, caspase-8-mediated activation of Bid induces the release of cytochrome c from the mitochondria, which, in turn, triggers the formation of the apoptosome protein complex, resulting in the activation of caspase-9. Whereas Bax or Bak were shown to be required for the proapoptotic effect of Bid, Bcl-2 was described to interfere with its action. Up to now, contradictory results regarding the role of Bcl-2 in TRAIL-induced apoptosis have been published. In order to study the influence of Bcl-2 on TRAIL-induced cell death more detailed, we utilized a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. After having analysed the dose response for TRAIL-induced activation of caspase-8, -9, -3, breakdown of the mitochondrial membrane potential, and changes in the apoptotic morphology in cells expressing different Bcl-2 levels, we conclude that overexpression of Bcl-2 mediates a partial resistance towards lower doses of TRAIL that can be overcome when higher doses of TRAIL are applied. Thus, the requirement of the mitochondrial pathway for death receptor-induced apoptosis in type II cells should be reconsidered, since the protective effect of Bcl-2 is limited to lower TRAIL doses or early observation time points.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Humboldt Univ, Charite, Dept Mol Hematol & Oncol, D-13125 Berlin, Germany	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Rudner, Justine/ABD-1397-2021; Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 2003, STRAHLENTHER ONKOL, V179, P141, DOI 10.1007/s00066-003-1047-7; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marini P, 2003, RADIOTHER ONCOL, V68, P189, DOI 10.1016/S0167-8140(03)00186-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 2000, NAT MED, V6, P502, DOI 10.1038/74972; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; RUFFOLO SC, 2003, J BIOL CHEM, V29, P29; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; SUN XM, 2002, J BIOL CHEM, V18, P18; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TECCHIO C, 2004, BLOOD, V15, P15; Velthuis JHL, 2002, J BIOL CHEM, V277, P24631, DOI 10.1074/jbc.M111572200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zhang XD, 2001, CANCER RES, V61, P7339	78	72	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					130	140		10.1038/sj.onc.1208191	http://dx.doi.org/10.1038/sj.onc.1208191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531922				2022-12-28	WOS:000226125800015
J	Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K				Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K			BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells	ONCOGENE			English	Article						PC-3; DU-145; p21(CIP1/WAF1); pRb	BONE MORPHOGENETIC PROTEIN; RETINOBLASTOMA PROTEIN; CANCER CELLS; II RECEPTOR; FACTOR-BETA; EXPRESSION; TGF-BETA-1; CYCLE; DIFFERENTIATION; TRANSDUCTION	Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen-insensitive PC-3 and DU-145 prostate cancer cells in a medium containing 1% fetal bovine serum, observed as decreased incorporation of [H-3] thymidine and decreased cell number. Cell cycle analysis by flow cytometry showed an increased fraction of cells in the G1 phase and subsequent decrease in both S and G2/M phase after BMP-7 stimulation. BMP-7 caused an upregulation of the cyclin-dependent kinase inhibitor (CDKI) p21(CIP1/WAF1), and decreased the activity of Cdk2, leading to hypophosphorylation of Rb proteins. Furthermore, in order to evaluate the impact of BMP signals on prostate tumor growth, we generated the PC-3 cell lines expressing a constitutively active BMP type I receptor (constitutively active (c.a.) activin receptor-like kinase (ALK)-6) in a tetracycline (Tet)-regulated manner. Tet/doxycycline-regulated expression of c.a.ALK-6 resulted in the inhibition of in vitro cell proliferation and reduction of the size of tumors derived from the PC-3 cells subcutaneously injected into immune-deficient mice. Collectively, these findings suggest that BMP signals inhibit growth and proliferation of prostate tumor cells through induction of CDKI. Furthermore, this is the first report of a role for BMP signaling in reducing growth kinetics of androgen-insensitive prostate tumors.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	Kitamura, Toshio/AAA-2071-2021					Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Candia AF, 1997, DEVELOPMENT, V124, P4467; CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464-410X.1991.tb15260.x; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ide H, 1997, CANCER RES, V57, P5022; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; ISHIKAWA T, 1995, BIOCHEM BIOPH RES CO, V216, P26, DOI 10.1006/bbrc.1995.2587; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 1996, CANCER RES, V56, P44; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU F, 1995, MOL CELL BIOL, V15, P3479; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Miyazono K, 2000, J CELL SCI, V113, P1101; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Park BJ, 2000, CANCER RES, V60, P3031; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SCHER HI, 1987, AM J MED, V82, P6, DOI 10.1016/0002-9343(87)90483-9; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26	39	83	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9326	9335		10.1038/sj.onc.1208127	http://dx.doi.org/10.1038/sj.onc.1208127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531927				2022-12-28	WOS:000225764100004
J	Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F				Vey, N; Mozziconacci, MJ; Groulet-Martinec, A; Debono, S; Finetti, P; Carbuccia, N; Beillard, E; Devilard, E; Arnoulet, C; Coso, D; Sainty, D; Xerri, L; Stoppa, AM; Lafage-Pochitaloff, M; Nguyen, C; Houlgatte, R; Blaise, D; Maraninchi, D; Birg, F; Birnbaum, D; Bertucci, F			Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling	ONCOGENE			English	Article						acute myelogenous leukaemia; gene expression; DNA microarrays; chemotherapy; normal karyotype; FLT3	ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TOPOISOMERASE-II; NITRIC-OXIDE; AML 10; CANCER; CHEMOTHERAPY; CYTOGENETICS; PREDICTION; SURVIVAL	Conventional cytogenetic analysis currently stratifies acute myelogenous leukaemia (AML) into prognostically relevant groups. However, approximately 50% of adult AMLs have normal cytogenetics (NC-AMLs), and represent a heterogeneous and poorly understood group. We analysed gene expression in 55 AML samples including 53 cases from adult patients with NC-AML (n=36), trisomy 8, t(15;17), t(8;21), t(11;19), 7q deletion, and two cell lines using 9000-gene DNA microarrays. Global hierarchical clustering showed that NC-AMLs are a heterogeneous group. Supervised analysis distinguished two subgroups of NC-AML: one subgroup constituted a homogeneous NC cluster ('pure NC-AML'), and the other NC-AMLs were close to the AML cases with translocations ('translocation like'). Gene expression signatures were also derived for patients with trisomy 8, as well as FLT3 and MLL gene duplications. Importantly, samples from 24 NC-AML patients who could be evaluated for clinical outcome were analysed. In all, 43 genes that discriminated two classes of patients with significantly different prognosis were identified. The poor prognosis class contained a majority of 'pure NC-AMLs', whereas the 'translocation-like' AMLs were in the good prognosis class. Discriminator genes included genes involved in drug resistance (TOP2B), protein transport (MTX2, SLC35A2), and cell signalling (MAPK1, PRKAB2). Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of 'translocation-like' NC-AMLs and of a gene expression signature that may predict response to chemotherapy.	Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Haematol,Marseille Canc Inst, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM, UMR599, Dept Biopathol,Marseille Canc Inst, F-13009 Marseille, France; IPSOGEN SAS, Marseille, France; ERT MEIDIA, Marseille, France; Univ Mediterranee, Marseille, France; ERM206, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, UMR599, Dept Mol Oncol,Marseille Canc Inst, 27 Bd Lei Roure,IFR137, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Blaise, Didier/R-2483-2016; Vey, Norbert/AGE-3573-2022; Carbuccia, Nadine/O-4459-2017; Houlgatte, Remi/P-3020-2017; Nguyen, Catherine/M-4119-2016; Finetti, Pascal/O-8669-2017	Blaise, Didier/0000-0002-5684-9447; Vey, Norbert/0000-0001-7027-040X; Carbuccia, Nadine/0000-0002-3561-4315; Nguyen, Catherine/0000-0001-9376-6360; Finetti, Pascal/0000-0002-2674-3123; Bertucci, Francois/0000-0002-0157-0959; Birnbaum, Daniel/0000-0001-7920-9883				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bonilla E, 2003, BIOCHEM PHARMACOL, V65, P1701, DOI 10.1016/S0006-2952(03)00119-9; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dingemans AMC, 1999, CLIN CANCER RES, V5, P2048; Downing JR, 2002, CANCER CELL, V2, P437, DOI 10.1016/S1535-6108(02)00211-8; GOASGUEN JE, 1992, LEUKEMIA, V6, P520; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Haferlach T, 2003, SEMIN HEMATOL, V40, P281, DOI 10.1016/S0037-1963(03)00193-8; Haferlach T, 2003, J CLIN ONCOL, V21, P256, DOI 10.1200/JCO.2003.08.005; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kaufmann SH, 1998, LEUKEMIA LYMPHOMA, V29, P217, DOI 10.3109/10428199809068560; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; LANOTTE M, 1991, BLOOD, V77, P1080; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Noguera N, 2002, LEUKEMIA, V16, P2185, DOI 10.1038/sj.leu.2402723; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Pinto A, 2001, CRIT REV ONCOL HEMAT, V39, P275, DOI 10.1016/S1040-8428(00)00122-0; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; Reid HM, 2003, J BIOL CHEM, V278, P51190, DOI 10.1074/jbc.M309314200; Reiffers J, 1996, LEUKEMIA, V10, P389; Reiffers J, 1996, LEUKEMIA, V10, P1874; Sabatti C, 2002, MATH BIOSCI, V176, P17, DOI 10.1016/S0025-5564(01)00102-X; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Tanaka K, 2002, BIOCHEM BIOPH RES CO, V292, P776, DOI 10.1006/bbrc.2002.6713; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Wallqvist A, 2003, BIOINFORMATICS, V19, P2212, DOI 10.1093/bioinformatics/btg302; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	39	42	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9381	9391		10.1038/sj.onc.1207910	http://dx.doi.org/10.1038/sj.onc.1207910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543237				2022-12-28	WOS:000225764100009
J	Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD				Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD			The ATM gene is a target for epigenetic silencing in locally advanced breast cancer	ONCOGENE			English	Article						ATM; epigenetics; promoter hypermethylation; breast cancer	PROMOTER; MUTATIONS; RADIATION; HYPERMETHYLATION; METHYLATION; WOMEN	Several epidemiological studies on ataxia-telangiectasia families indicate that obligate ATM heterozygotes display an elevated risk for developing breast cancer. However, a molecular basis for a potential link between diminished ATM function and sporadic breast malignancy remains elusive. Here, we show that 78% (18 out of a panel of 23) of surgically removed breast tumors (stage II or greater) displayed aberrant methylation of the ATM proximal promoter region as judged by methylation-specific PCR. Aberrant methylation of the ATM promoter was independently confirmed in several tumors by bisulfate sequencing. Moreover, bisulfate sequencing indicated that this region of the genome is subject to dense methylation. Further, we found a highly significant correlation (P = 0.0006) between reduced ATM mRNA abundance, as measured by real-time RT-PCR, and aberrant methylation of the ATM gene promoter. These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.	Dept Biochem & Mol Biol, New Orleans, LA USA; LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA; Dept Surg, New Orleans, LA USA; Dept Pathol, New Orleans, LA USA; Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Brown, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245,1600 Archer Rd, Gainesville, FL 32610 USA.	kdbrown1@ufl.edu						Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Angele S, 2000, CLIN CANCER RES, V6, P3536; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Esteller M, 2001, CANCER RES, V61, P3225; Fang ZM, 2001, PATHOLOGY, V33, P30; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Vo QN, 2002, J CLIN PATHOL, V55, P669, DOI 10.1136/jcp.55.9.669	21	80	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9432	9437		10.1038/sj.onc.1208092	http://dx.doi.org/10.1038/sj.onc.1208092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516988				2022-12-28	WOS:000225764100015
J	Sinenko, SA; Mathey-Prevot, B				Sinenko, SA; Mathey-Prevot, B			Increased expression of Drosophila tetraspanin, Tsp68C, suppresses the abnormal proliferation of ytr-deficient and Ras/Raf-activated hemocytes	ONCOGENE			English	Article						tetraspanin; Tsp68C; yantar; Raf; hemocyte; Drosophila	DENDRITIC CELLS; EGF RECEPTOR; SUPERFAMILY; PROTEINS; ORGANIZERS; INTEGRINS; COMPLEXES; MIGRATION; RESPONSES; PATHWAY	Tetraspanins are evolutionary conserved transmembrane proteins thought to facilitate cell proliferation, movement or fusion by acting as organizers of different signaling events. Despite their prevalence and conservation, their specific role and functions remain largely elusive, as their redundancy in various. organisms has hindered loss of function studies. Here, we take a gain of function approach to study Drosophila tetraspanin Tsp68C and its effect on larval hemocytes. We recently characterized a lethal mutation in ytr, a conserved gene that encodes a nuclear arginine-rich protein of unknown function, which is accompanied by abnormal differentiation and proliferation of the larval hematopoietic tissue in flies. A hemolectin (hml)-Gal4 construct carried by hml-Gal4 transgenic flies was sufficient by itself to abrogate the hematopoietic defects in ytr mutant larvae. This rescue correlated with the overexpression of tsp68C, a tetraspanin gene nested in the hml promoter. The suppression of abnormal proliferation by the hml-Gal4 construct was not restricted to ytr-deficient hemocytes, but was also observed in hemocytes expressing the oncogenic forms of Raf or Ras proteins. However, it had no effect on overproliferation mediated by a constitutively active form of Jak. New hml-Gal4 lines, in which the tsp68C gene was silenced or deleted from the promoter, no longer rescued the hematopoietic defect in ytr mutants nor suppressed the activated Raf-induced overproliferation. Therefore, change in tetraspanin Tsp68C expression has a strong suppressor effect on abnormal proliferation and differentiation of hemocytes in the context of specific lesions, such as overactivation of the Ras/Raf/MAPK pathway.	Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Sinenko, SA (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, 621 Charles E Young Dr S,Life Sci Bldg 2204, Los Angeles, CA 90024 USA.	sinenko@mcdb.ucla.edu	Sinenko, Sergey A./C-3703-2016	Sinenko, Sergey A./0000-0001-5517-8218	NHLBI NIH HHS [R01 HL62434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anzai N, 2002, BLOOD, V99, P4413, DOI 10.1182/blood.V99.12.4413; Asha H, 2003, GENETICS, V163, P203; Bach EA, 2003, GENETICS, V165, P1149; Berditchevski F, 2001, J CELL SCI, V114, P4143; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Boucheix C., 2001, EXPERT REV MOL MED, V2001, P1; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRAND AH, 1993, DEVELOPMENT, V118, P401; Callus BA, 2002, ONCOGENE, V21, P4812, DOI 10.1038/sj.onc.1205618; Carloni V, 2004, ONCOGENE, V23, P1566, DOI 10.1038/sj.onc.1207287; Engering A, 2003, EUR J BIOCHEM, V270, P2412, DOI 10.1046/j.1432-1033.2003.03609.x; Fradkin LG, 2002, P NATL ACAD SCI USA, V99, P13663, DOI 10.1073/pnas.212511099; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hubner K, 2002, INT REV CYTOL, V214, P103; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mantegazza AR, 2004, BLOOD, V104, P1183, DOI 10.1182/blood-2004-01-0104; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Scherberich A, 2002, THROMB HAEMOSTASIS, V87, P1043, DOI 10.1055/s-0037-1613130; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Sinenko SA, 2004, DEV BIOL, V273, P48, DOI 10.1016/j.ydbio.2004.05.022; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Sorrentino RP, 2002, DEV BIOL, V243, P65, DOI 10.1006/dbio.2001.0542; Tarrant JA, 2002, MOL CELL BIOL, V22, P5006, DOI 10.1128/MCB.22.14.5006-5018.2002; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Todres E, 2000, INSECT MOL BIOL, V9, P581, DOI 10.1046/j.1365-2583.2000.00222.x; Xu H, 2004, EMBO J, V23, P811, DOI 10.1038/sj.emboj.7600112; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	32	98	98	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9120	9128		10.1038/sj.onc.1208156	http://dx.doi.org/10.1038/sj.onc.1208156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480416				2022-12-28	WOS:000225492800013
J	Tamguney, G; Van Snick, J; Fickenscher, H				Tamguney, G; Van Snick, J; Fickenscher, H			Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309	ONCOGENE			English	Article						autocrine loop; growth transformation; rhadinovirus; suppressive subtractive hybridization T lymphocyte	VIRUS TYPE-I; DEXAMETHASONE-INDUCED APOPTOSIS; SAIMIRI PROTEIN TIP; SUBGROUP-C STRAINS; HERPESVIRUS-SAIMIRI; MOLECULAR-CLONING; RECEPTOR CCR8; MONOCYTE CHEMOATTRACTANT; GROWTH TRANSFORMATION; ONCOPROTEIN STP-C488	The rhadinovirus herpesvirus saimiri transforms human T lymphocytes to stable growth in culture. Besides the viral oncogenes stpC and tip, little is understood about the transformation process at the cellular level. To identify cellular factors that might contribute to growth transformation, we compared cellular gene expression in pairs of herpesvirus saimiri-transformed and nontransformed human T-cell clones. Using cDNA arrays and suppressive subtractive hybridization, we were able to identify the chemokine CCL1/I-309 as one of the few cellular genes that are strongly overexpressed in T cells after growth transformation with herpesvirus saimiri. The transformed T cells expressed CCR8, the receptor for CCL1, which rapidly induced intracellular calcium ion levels. Neutralizing antibodies to CCL1 led to reduced secretion of interferon-gamma and tumor necrosis factor-alpha as well as to reduced proliferation rates in transformed T cells. Thus, we propose that growth transformation of human T cells with herpesvirus saimiri gives rise to an autocrine loop where the proliferation of transformed T cells is supported by the endogenous production of the chemokine CCL1.	Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, B-1200 Brussels, Belgium	Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Fickenscher, H (corresponding author), Univ Heidelberg, Dept Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	helmut.fickenscher@med.uni-heidelberg.de	Fickenscher, Helmut/A-3004-2010; Tamgüney, Gültekin/T-6333-2019; Fickenscher, Helmut/J-9655-2019	Tamgüney, Gültekin/0000-0002-6933-5154; Fickenscher, Helmut/0000-0003-0043-1153				BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BROKER BM, 1993, J IMMUNOL, V151, P1184; BURD PR, 1987, J IMMUNOL, V139, P3126; Colantonio L, 2002, EUR J IMMUNOL, V32, P3506, DOI 10.1002/1521-4141(200212)32:12<3506::AID-IMMU3506>3.0.CO;2-#; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; DECARLI M, 1993, J IMMUNOL, V151, P5022; DELPRETE G, 1994, J IMMUNOL, V153, P4872; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fickenscher H, 2002, METHOD MICROBIOL, V32, P657; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Goya I, 1998, J IMMUNOL, V160, P1975; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; INATSUKI A, 1989, J IMMUNOL, V143, P1327; Inngjerdingen M, 2000, J IMMUNOL, V164, P4048, DOI 10.4049/jimmunol.164.8.4048; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knappe A, 1997, J VIROL, V71, P9124, DOI 10.1128/JVI.71.12.9124-9133.1997; Kraft MS, 1998, J VIROL, V72, P3138, DOI 10.1128/JVI.72.4.3138-3145.1998; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Louahed J, 2003, EUR J IMMUNOL, V33, P494, DOI 10.1002/immu.200310025; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Mackewicz CE, 1997, CLIN IMMUNOL IMMUNOP, V82, P274, DOI 10.1006/clin.1996.4292; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; MURPHY C, 1994, ONCOGENE, V9, P221; Napolitano M, 1996, J IMMUNOL, V157, P2759; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; Schrum S, 1996, J IMMUNOL, V157, P3598; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; VanSnick J, 1996, J IMMUNOL, V157, P2570; Wehner LE, 2001, DNA CELL BIOL, V20, P81, DOI 10.1089/104454901750070283; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YASUKAWA M, 1995, J VIROL, V69, P8114, DOI 10.1128/JVI.69.12.8114-8117.1995; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595; Zingoni A, 1998, J IMMUNOL, V161, P547	56	6	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8475	8485		10.1038/sj.onc.1207903	http://dx.doi.org/10.1038/sj.onc.1207903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378023				2022-12-28	WOS:000224870700008
J	Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA				Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA			Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells	ONCOGENE			English	Article						BMP; BMP receptors; prostate cancer	OSTEOGENIC PROTEIN-1; GROWTH-FACTOR; IB RECEPTOR; PROLIFERATION; DIFFERENTIATION; INSENSITIVITY; PROGRESSION; TISSUES; MOUSE	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily and signal through a number of membrane receptors. We have previously demonstrated that the loss of expression of BMP receptors (BMPRs) type IA, - IB, and - II (BMP-RIA, - RIB, and - RII) correlates with Gleason score in prostate cancer patients. To evaluate the prognostic value of this observation, we used immunohistochemistry to investigate the expression of BMPRs in association with disease progression in 60 patients. The results demonstrated a significant association between the loss of expression of the three BMPRs and Gleason score and clinical stage. However, only the loss of expression of BMP-RII showed a statistically significant association with 5-year survival rate ( P<0.05) and biochemical recurrence-free rate following radical prostatectomy ( P<0.005). To elucidate the effect of an abnormal BMP signaling in prostate cancer cells, we transfected dominant-negative BMP-RII (BMP-RIIDN) into the human prostate cancer cell line, PC3M. When a stable clone overexpressing BMP-RIIDN was inoculated subcutaneously into nude mice, the tumor growth rate was approximately 10 times that of control and parental cell line. These observations, taken together, indicate that the loss of BMP-RII expression as measured by immunohistochemistry may be a prognostic marker in prostate cancer patients, and that the loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells.	Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Ewha Womans Univ, Dept Urol, Seoul, South Korea; Asan Med Ctr, Dept Urol, Seoul, South Korea; Univ Calif Irvine, Dept Urol, Orange, CA 92868 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ewha Womans University; University of Ulsan; Asan Medical Center; University of California System; University of California Irvine	Morton, RA (corresponding author), Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA.	mortonra@umdnj.edu			NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Hamdy FC, 1997, CANCER RES, V57, P4427; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; HOGAN BL, 1996, GENE DEV, V10, P1540; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Ide H, 1997, CANCER RES, V57, P5022; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 2003, CLIN CANCER RES, V9, P6046; Kim IY, 1996, CANCER RES, V56, P44; Lamm MLG, 2001, DEV BIOL, V232, P301, DOI 10.1006/dbio.2001.0187; LIU F, 1995, MOL CELL BIOL, V15, P3479; Masuda H, 2004, PROSTATE, V59, P101, DOI 10.1002/pros.20030; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Pouliot F, 2003, CANCER RES, V63, P277; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Sintich SM, 1999, ENDOCRINOLOGY, V140, P3411, DOI 10.1210/en.140.8.3411; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yonemori K, 1997, AM J PATHOL, V150, P1335; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	33	64	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7651	7659		10.1038/sj.onc.1207924	http://dx.doi.org/10.1038/sj.onc.1207924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15354178				2022-12-28	WOS:000224306700006
J	Fulda, S; Debatin, KM				Fulda, S; Debatin, KM			Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol	ONCOGENE			English	Article						apoptosis; resveratrol; anticancer drugs; cancer	CELL-CYCLE; NEUROBLASTOMA-CELLS; CD95 APO-1/FAS; CANCER; DEATH; CHEMOTHERAPY; SURVIVIN; DEGRADATION; INHIBITION; EXPRESSION	Current attempts to improve the survival of cancer patients largely depend on strategies to target tumor cell resistance. Naturally occurring dietary compounds such as resveratrol have gained considerable attention as cancer chemopreventive agents. Here, we report that resveratrol acts as potent sensitizer for anticancer drug-induced apoptosis by inducing cell cycle arrest, which in turn resulted in survivin depletion. Concomitant analysis of cell cycle and apoptosis revealed that pretreatment with resveratrol resulted in cell cycle arrest in S phase and apoptosis induction preferentially out of S phase upon subsequent drug treatment. Likewise, cell cycle arrest in S phase by cell cycle inhibitors enhanced drug-induced apoptosis. Resveratrol-mediated cell cycle arrest sensitized for apoptosis by downregulating survivin expression through transcriptional and post-transcriptional mechanisms. Similarly, downregulation of survivin expression using survivin antisense oligonucleotides sensitized for drug-induced apoptosis. Importantly, downregulation of survivin and enhanced drug-induced apoptosis by resveratrol occurred in various human tumor cell lines irrespective of p53 status. Thus, this combined sensitizer ( resveratrol)/inducer ( cytotoxic drugs) concept may be a novel strategy to enhance the efficacy of anticancer therapy in a variety of human cancers.	Univ Childrens Hosp, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Debatin, KM (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bierau J, 2003, INT J CANCER, V103, P387, DOI 10.1002/ijc.10858; Cal C., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P77, DOI 10.2174/1568011033353443; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahotka C, 1999, CANCER RES, V59, P6097; Olie RA, 2000, CANCER RES, V60, P2805; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sherr CJ, 2000, CANCER RES, V60, P3689; Smith DM, 2000, INT J MOL MED, V6, P503; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Zhao J, 2000, J CELL SCI, V113, P4363	37	172	181	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6702	6711		10.1038/sj.onc.1207630	http://dx.doi.org/10.1038/sj.onc.1207630			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273734				2022-12-28	WOS:000223653600002
J	Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK				Saidi, SA; Holland, CM; Kreil, DP; MacKay, DJC; Charnock-Jones, DS; Print, CG; Smith, SK			Independent component analysis of microarray data in the study of endometrial cancer	ONCOGENE			English	Article						endometrial cancer; lipid metabolism; principal components analysis; independent component analysis; gene microarrays	GENE-EXPRESSION PROFILES; ENDOGENOUS HORMONES; CLASSIFICATION; HETEROZYGOSITY	Gene microarray technology is highly effective in screening for differential gene expression and has hence become a popular tool in the molecular investigation of cancer. When applied to tumours, molecular characteristics may be correlated with clinical features such as response to chemotherapy. Exploitation of the huge amount of data generated by microarrays is difficult, however, and constitutes a major challenge in the advancement of this methodology. Independent component analysis (ICA), a modern statistical method, allows us to better understand data in such complex and noisy measurement environments. The technique has the potential to significantly increase the quality of the resulting data and improve the biological validity of subsequent analysis. We performed microarray experiments on 31 postmenopausal endometrial biopsies, comprising 11 benign and 20 malignant samples. We compared ICA to the established methods of principal component analysis (PCA), Cyber-T, and SAM. We show that ICA generated patterns that clearly characterized the malignant samples studied, in contrast to PCA. Moreover, ICA improved the biological validity of the genes identified as differentially expressed in endometrial carcinoma, compared to those found by Cyber-T and SAM. In particular, several genes involved in lipid metabolism that are differentially expressed in endometrial carcinoma were only found using this method. This report highlights the potential of ICA in the analysis of microarray data.	Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England; Univ Cambridge, Dept Pathol, Cambridge CB1 1QP, England; Univ Cambridge, Cavendish Lab, Dept Phys, Inference Grp, Cambridge CB3 0HE, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Saidi, SA (corresponding author), Rosie Hosp, Dept Obstet & Gynaecol, Box 223,Robinson Way, Cambridge CB2 2SW, England.	samsaidi@obgyn.cam.ac.uk	Charnock-Jones, D. Stephen/AAE-3391-2020; Kreil, D/O-1783-2013; Charnock-Jones, D. Stephen/B-3743-2009; Smith, Stephen K/F-6938-2012	Charnock-Jones, D. Stephen/0000-0002-2936-4890; Kreil, D/0000-0001-7538-2056; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Saidi, Samir/0000-0001-5165-2461; Print, Cristin/0000-0001-8345-7812; Smith, Stephen/0000-0003-1912-3935				Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Badawi AF, 2002, INT J ONCOL, V20, P1109; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Borthwick JM, 2003, MOL HUM REPROD, V9, P19, DOI 10.1093/molehr/gag004; Burgess JK, 2001, CLIN EXP PHARMACOL P, V28, P321, DOI 10.1046/j.1440-1681.2001.03448.x; Draghici S, 2001, Curr Opin Drug Discov Devel, V4, P332; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans Amanda L., 2003, Angiogenesis, V6, P93, DOI 10.1023/B:AGEN.0000011732.83724.e5; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kreil DP, 2003, COMP FUNCT GENOM, V4, P300, DOI 10.1002/cfg.298; Liebermeister W, 2002, BIOINFORMATICS, V18, P51, DOI 10.1093/bioinformatics/18.1.51; Martoglio AM, 2002, BIOINFORMATICS, V18, P1617, DOI 10.1093/bioinformatics/18.12.1617; Miskin J. W., 2000, THESIS U CAMBRIDGE; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Niederacher D, 1998, EUR J CANCER, V34, P1770, DOI 10.1016/S0959-8049(98)00270-6; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Risinger JI, 2003, CANCER RES, V63, P6; Sirchia SM, 2000, CANCER GENET CYTOGEN, V121, P156, DOI 10.1016/S0165-4608(00)00240-5; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wernisch L, 2003, BIOINFORMATICS, V19, P53, DOI 10.1093/bioinformatics/19.1.53; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Wildsmith SE, 2001, BIOTECHNIQUES, V30, P202, DOI 10.2144/01301dd04	29	71	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6677	6683		10.1038/sj.onc.1207562	http://dx.doi.org/10.1038/sj.onc.1207562			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247901				2022-12-28	WOS:000223530800016
J	Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C				Iwata, S; Souta-Kuribara, A; Yamakawa, A; Sasaki, T; Shimizu, T; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Watanabe, T; Arima, N; Morimoto, C			HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L)	ONCOGENE			English	Article						ATL; Tax; HTLV-I; NF-kappa B; Cas-L; HEF1	T-CELL LEUKEMIA; VIRUS TYPE-I; MEDIATED TYROSINE PHOSPHORYLATION; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEIN; ACTIVATION; TRANSACTIVATION	Crk-associated substrate lymphocyte type (Cas-L) is a docking protein that is heavily tyrosine phosphorylated by the engagement of beta1 integrins in T cells. In the present study, we attempted to evaluate the role of Cas-L in the pathophysiology of adult T-cell leukemia (ATL). Examination of peripheral blood mononuclear cells from ATL patients as well as ATL-derived T cell lines showed an elevation of Cas-L in these cells. We showed that tyrosine phosphorylation as well as expression of Cas-L was markedly elevated through the induction of human T-lymphotropic virus type I ( HTLV-I) Tax in JPX-9 cells, with these cells showing marked motile behavior on the ligands for integrins. We next performed yeast two-hybrid screening of cDNA library from an HTLV-I-transformed T cell line, which resulted in the identification of Tax as a putative binding partner for Cas-L. Co-precipitation experiments revealed that the serine-rich region of Cas-L might serve as the binding site with the highest afinity for Tax. Co-localization study showed that Tax and Cas-L partly merged in the cytoplasm. Finally, we showed that exogenous Cas-L inhibited Tax-mediated transactivation of nuclear factor kappaB ( NF-kappaB), while Tax-independent activation of NF-kappaB remained intact, hence indicating that Cas-L might specically regulate Tax-NF-kappaB pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Keio Univ, Sch Med, Dept Internal Med, Shinjyuku Ku, Tokyo 1608582, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA; Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Host Response, Kagoshima 8908520, Japan	University of Tokyo; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Keio University; University of Texas System; UTMD Anderson Cancer Center; University of Tokyo; Kagoshima University	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					ALBRECHT H, 1992, J VIROL, V66, P6191, DOI 10.1128/JVI.66.10.6191-6193.1992; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHIKAWA T, 1993, BLOOD, V82, P1590; Ishino M, 1995, ONCOGENE, V11, P2331; Iwata S, 2002, EUR J IMMUNOL, V32, P1328, DOI 10.1002/1521-4141(200205)32:5<1328::AID-IMMU1328>3.0.CO;2-6; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SATO T, 1995, J IMMUNOL, V155, P2938; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007/BF01541665; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; YAMASHITA I, 1994, BLOOD, V84, P1573; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Zheng MZ, 2002, J BIOL CHEM, V277, P39599, DOI 10.1074/jbc.M202263200	47	18	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1262	1271		10.1038/sj.onc.1208261	http://dx.doi.org/10.1038/sj.onc.1208261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592516				2022-12-28	WOS:000226898700013
J	Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G				Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G			C-Myc activation by Theileria parasites promotes survival of infected B-lymphocytes	ONCOGENE			English	Article						apoptosis; c-Myc; STAT3; Theileria; transformation	INDUCED APOPTOSIS; CELLS; PARVA; EXPRESSION; KINASE; ANNULATA; STAT3; TRANSFORMATION; PROLIFERATION; LEUKOCYTES	Theileria parasites infect and transform bovine lymphocytes, but host cell immortalization is reversible, as upon parasite death the lymphocytes rapidly die of apoptosis. Infection leads to a marked augmentation in the levels of lymphocyte c-Myc, and the parasite achieves this by inducing increased c-myc transcription and by prolonging the half-life of the transcription factor. Reduction in c-Myc turnover can be ascribed to CK2-mediated phosphorylation of the transcription factor. A parasite-dependent GM-CSF autocrine loop activates a JAK2/ STAT3 signalling pathway that contributes to heightened c-myc transcription, and inhibition of the pathway leads to caspase 9 activation and apoptosis that can be directly ascribed to a reduction in c-Myc. An antiapoptotic role for c-Myc was clearly demonstrated by specific inhibition of c-myc expression with antisense oligonucleotides, and this correlates with loss of the antiapoptotic protein Mcl-1, and, consistently, ectopic expression of c-Myc abrogates B-cell death induced upon JAK2 inhibition. Thus, Theileria parasites ensure the survival of their host lymphocytes via specific activation of c-Myc.	Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, F-75724 Paris 15, France; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Royal Vet Coll, N Mymms AL9 7TA, Herts, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Francisco; University of London; University of London Royal Veterinary College	Langsley, G (corresponding author), Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, Batiment Elie Metchnikoff,25-28 Rue Dr Roux, F-75724 Paris 15, France.	langsley@pasteur.fr	Werling, Dirk/F-5555-2013	Werling, Dirk/0000-0001-5411-4044; Baumgartner, Martin/0000-0001-9539-7204				Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Baumgartner M, 2000, CELL MICROBIOL, V2, P329, DOI 10.1046/j.1462-5822.2000.00062.x; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Chaussepied M, 1996, RES IMMUNOL, V147, P127, DOI 10.1016/0923-2494(96)83165-8; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1990, INFECT IMMUN, V58, P3847, DOI 10.1128/IAI.58.12.3847-3855.1990; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Guergnon J, 2003, BIOCHIMIE, V85, P771, DOI 10.1016/j.biochi.2003.09.013; Guergnon J, 2003, CELL MICROBIOL, V5, P709, DOI 10.1046/j.1462-5822.2003.00314.x; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Heussler VT, 2002, SCIENCE, V298, P1033, DOI 10.1126/science.1075462; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuenzi P, 2003, J IMMUNOL, V171, P1224, DOI 10.4049/jimmunol.171.3.1224; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; McGuire K, 2004, VET IMMUNOL IMMUNOP, V99, P87, DOI 10.1016/j.vetimm.2004.01.003; McKeever DJ, 1997, PARASITE IMMUNOL, V19, P319, DOI 10.1046/j.1365-3024.1997.d01-214.x; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moreau MF, 1999, INFECT IMMUN, V67, P6678; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	35	63	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1075	1083		10.1038/sj.onc.1208314	http://dx.doi.org/10.1038/sj.onc.1208314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15580287				2022-12-28	WOS:000226749200013
J	Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM				Meinhold-Heerlein, I; Bauerschlag, D; Hilpert, F; Dimitrov, P; Sapinoso, LM; Orlowska-Volk, M; Bauknecht, T; Park, TW; Jonat, W; Jacobsen, A; Sehouli, J; Luttges, J; Krajewski, M; Krajewski, S; Reed, JC; Arnold, N; Hampton, GM			Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential	ONCOGENE			English	Article						microarray; cluster; cell cycle	FATTY-ACID SYNTHASE; GENE-EXPRESSION PROFILES; POLO-LIKE KINASE; BREAST-CANCER; CELL-PROLIFERATION; PROSTATE-CANCER; CDNA MICROARRAY; TUMORS; BORDERLINE; P53	Profiles of gene transcription have begun to delineate the molecular basis of ovarian cancer, including distinctions between carcinomas of differing histology, tumor progression and patient outcome. However, the similarities and differences among the most commonly diagnosed noninvasive borderline ( low malignant potential, LMP) lesions and invasive serous carcinomas of varying grade (G1, G2 and G3) have not yet been explored. Here, we used oligonucleotide arrays to pro. le the expression of 12 500 genes in a series of 57 predominantly stage III serous ovarian adenocarcinomas from 52 patients, eight with borderline tumors and 44 with adenocarcinomas of varying grade. Unsupervised and supervised analyses showed that LMP lesions were distinct from high-grade serous adenocarcinomas, as might be expected; however, well-differentiated ( G1) invasive adenocarcinomas showed a strikingly similar pro. le to LMP tumors as compared to cancers with moderate ( G2) or poor ( G3) cellular differentiation, which were also highly similar. Comparative genomic hybridization of an independent cohort of five LMP and 63 invasive carcinomas of varying grade demonstrated LMP and G1 were again similar, exhibiting significantly less chromosomal aberration than G2/G3 carcinomas. A majority of LMP and G1 tumors were characterized by high levels of p21/WAF1, with concomitant expression of cell growth suppressors, gadd34 and BTG-2. In contrast, G2/G3 cancers were characterized by the expression of genes associated with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced gene expression. The distinction between the LMP-G1 and G2 G3 groups of tumors was highly correlated to patient outcome ( v 2 for equivalence of death rates = 7.681189; P = 0.0056, log-rank test). Our results are consistent with the recent demonstration of a poor differentiation molecular 'meta-signature' in human cancer, and underscore a number of cell-cycle- and STAT-associated targets that may prove useful as points of therapeutic intervention for those patients with aggressive disease.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany; Univ Freiburg, Dept Pathol, D-7800 Freiburg, Germany; Lilly Deutschland, Bad Homburg, Germany; Univ Bonn, Dept Gynecol & Obstet, D-5300 Bonn, Germany; Univ Hosp Charite, Dept Gynecol & Obstet, Berlin, Germany; Univ Kiel, Dept Pathol, D-24098 Kiel, Germany; Burnham Inst, La Jolla, CA 92037 USA	Novartis; University of Kiel; Schleswig Holstein University Hospital; University of Freiburg; Eli Lilly; Lilly Deutschland GmbH; University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Sanford Burnham Prebys Medical Discovery Institute	Hampton, GM (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org	Arnold, Norbert/E-3012-2010; Jonat, Walter/E-3024-2010; Bauerschlag, Dirk/H-9393-2015; Meinhold-Heerlein, Ivo/AAK-1240-2021; Bauerschlag, Dirk/B-1958-2013; Meinhold-Heerlein, Dr. Ivo/A-8970-2015	Arnold, Norbert/0000-0003-4523-8808; Meinhold-Heerlein, Dr. Ivo/0000-0002-0331-8781; Bauerschlag, Dirk O./0000-0001-8157-6121				Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Auersperg N, 2002, INT J GYNECOL CANCER, V12, P691, DOI 10.1046/j.1525-1438.2002.01152.x; BEREK JS, 2000, CANC MED, P1687; Broggini M, 2000, ANTICANCER RES, V20, P4835; Caduff RF, 1999, AM J SURG PATHOL, V23, P323, DOI 10.1097/00000478-199903000-00012; Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125; Chan WY, 2000, AM J PATHOL, V156, P409, DOI 10.1016/S0002-9440(10)64744-X; Collins Y, 2004, INT J MOL MED, V14, P43; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Gershenson DM, 2002, BEST PRACT RES CL OB, V16, P513, DOI 10.1053/beog.2002.0308; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HAMILTON SR, 1992, J CELL BIOCHEM, P41; HAMPTON GM, 2003, EXPRESSION PROFILING, P277; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hellstrom I, 2003, CANCER RES, V63, P3695; HENRIKSEN R, 1994, ANTICANCER RES, V14, P603; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Kiechle M, 2001, CANCER, V91, P534, DOI 10.1002/1097-0142(20010201)91:3<534::AID-CNCR1031>3.3.CO;2-K; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kim JH, 2003, CLIN CANCER RES, V9, P4782; Korkolopoulou P, 2002, GYNECOL ONCOL, V85, P404, DOI 10.1006/gyno.2002.6627; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KREIPE H, 1993, AM J PATHOL, V142, P1689; Kuo ML, 2003, CANCER RES, V63, P1046; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luo C, 2004, DRUG DISCOV TODAY, V9, P268, DOI 10.1016/S1359-6446(03)03014-9; Marx D, 1997, ANTICANCER RES, V17, P775; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; Morice P, 2003, ANN ONCOL, V14, P592, DOI 10.1093/annonc/mdg173; Muggia Franco, 2003, Expert Opin Emerg Drugs, V8, P203, DOI 10.1517/eoed.8.1.203.21032; Nijjar T, 1999, CANCER RES, V59, P5112; Okamoto Y, 2003, CANCER RES, V63, P4167; Ortiz BH, 2001, CANCER RES, V61, P7264; Palazzo JP, 2000, HUM PATHOL, V31, P698, DOI 10.1053/hupa.2000.7641; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Seidman JD, 2002, BEST PRACT RES CL OB, V16, P499, DOI 10.1053/beog.2002.0300; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Singer G, 2002, AM J PATHOL, V160, P1223, DOI 10.1016/S0002-9440(10)62549-7; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Su AI, 2001, CANCER RES, V61, P7388; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Terlikowski S, 1999, ARCH GYNECOL OBSTET, V263, P29, DOI 10.1007/s004040050257; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vassilopoulos I, 2003, HISTOL HISTOPATHOL, V18, P761, DOI 10.14670/HH-18.761; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; Wang Y, 2001, CLIN CHIM ACTA, V304, P107, DOI 10.1016/S0009-8981(00)00404-6; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yagi A, 2003, J CELL BIOCHEM, V90, P1242, DOI 10.1002/jcb.10711	76	163	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1053	1065		10.1038/sj.onc.1208298	http://dx.doi.org/10.1038/sj.onc.1208298			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15558012				2022-12-28	WOS:000226749200011
J	Agger, K; Santoni-Rugiu, E; Holmberg, C; Karlstrom, O; Helin, K				Agger, K; Santoni-Rugiu, E; Holmberg, C; Karlstrom, O; Helin, K			Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS	ONCOGENE			English	Article						E2F; retinoblastoma; testis; apoptosis; neoplasia	E2F-INDUCED S-PHASE; GERM-CELL TUMORS; P53-DEPENDENT APOPTOSIS; DEREGULATED EXPRESSION; RETINOBLASTOMA GENE; FAMILY-MEMBER; DNA-SYNTHESIS; TRANSCRIPTION; P53; PROLIFERATION	E2F1 is a crucial downstream effector of the retinoblastoma protein (pRB) pathway. To address the consequences of short-term increase in E2F1 activity in adult tissues, we generated transgenic mice expressing the human E2F1 protein fused to the oestrogen receptor ( ER) ligand-binding domain. The expression of the ER-E2F1 fusion protein, which is inactive in the absence of 4-hydroxy tamoxifen (OHT), was targeted to the testes. We show that short-term activation of E2F1 results in activation of E2F target genes and apoptosis of germ cells. Consistent with our previously published results, the apoptotic response was independent of p53. Persistent E2F1 activation for 3 weeks led to massive apoptosis and severe testicular atrophy with seminiferous tubules containing only Sertoli cells and clusters of undifferentiated spermatogonia. The latter showed high expression of ER-E2F1 and excessive mitotic activity, including atypical mitoses. In addition, gonocyte-like dysplastic germ cells, resembling carcinoma in situ (CIS) cells in humans, appeared. Our results show that a relatively short period of deregulated E2F1 activity in testicles can induce premalignant changes. Moreover, we demonstrate the feasibility of tissue-specific expression of conditional ER-E2F1 in transgenic mice.	Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Copenhagen Hosp, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark	University of Copenhagen; IRCCS European Institute of Oncology (IEO); Rigshospitalet; University of Copenhagen	Helin, K (corresponding author), Biotech Res & Innovat Ctr, Fruebjergvej 3, DK-2100 Copenhagen, Denmark.	kristian.helin@bric.dk	Holmberg, Christian/L-8011-2014; Helin, Kristian/HDM-8306-2022; Santoni-Rugiu, Eric/H-4913-2019; Helin, Kristian/K-2526-2019; Santoni-Rugiu, Eric/AAH-3368-2020	Holmberg, Christian/0000-0001-9224-0543; Helin, Kristian/0000-0003-1975-6097; Santoni-Rugiu, Eric/0000-0002-2283-3535				Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chaganti RSK, 2000, CANCER RES, V60, P1475; Cheville JC, 1998, AM J SURG PATHOL, V22, P1361, DOI 10.1097/00000478-199811000-00006; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MEHTALI M, 1990, GENE, V91, P179, DOI 10.1016/0378-1119(90)90086-7; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Mostofi FK, 1994, IARC SCI PUBL, V111, P407; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; POON GK, 1995, DRUG METAB DISPOS, V23, P377; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	53	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					780	789		10.1038/sj.onc.1208248	http://dx.doi.org/10.1038/sj.onc.1208248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531911				2022-12-28	WOS:000226577100004
J	Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA				Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA			Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1	ONCOGENE			English	Article						cell cycle; Id1; breast cancer	CANCER-CELLS; C-MYC; TRANSCRIPTIONAL REPRESSION; G(1) PROGRESSION; GENE-EXPRESSION; ID-1; ESTROGEN; GROWTH; D1; DIFFERENTIATION	The helix-loop-helix protein Id1 has been implicated in regulating mammary epithelial cell proliferation and differentiation but the underlying molecular mechanisms are not well characterized. Under low serum conditions, ectopic expression of Id1, but not Id2, allowed continued proliferation of immortalized mammary epithelial cells and breast cancer cells. Conversely, downregulation of Id1 impaired proliferation. The effects of short interfering RNA (siRNA)-mediated downregulation of Id1 were the same as those following downregulation of c-Myc: decreased expression of cyclins D1 and E, reduced phosphorylation of pRb at Ser780 ( a site targeted by cyclin D1-Cdk4) and reduced cyclin E-Cdk2 activity. Decreased cyclin D1 expression was an early response to Id1 antisense oligonucleotide treatment. Inhibition of c-Myc function by siRNA, antisense oligonucleotides or a dominant repressor resulted in downregulation of Id1, while ectopic expression of c-Myc resulted in rapid induction of Id1, suggesting that Id1 may be downstream of c-Myc. These data indicate that in mammary epithelial cells, Id1 has cell cycle regulatory functions that are similar to those of c-Myc, and suggest that cyclin D1 may be involved in Id1 regulation of cell cycle progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008; Swarbrick, Alexander/E-6107-2010	Caldon, Liz/0000-0003-1392-3472; Swarbrick, Alexander/0000-0002-3051-5676				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carroll JS, 2002, CANCER RES, V62, P3126; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Desprez PY, 2003, J MAMMARY GLAND BIOL, V8, P225, DOI 10.1023/A:1025957025773; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DUBIK D, 1987, CANCER RES, V47, P6517; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guan XY, 1996, CANCER RES, V56, P3446; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARA E, 1994, J BIOL CHEM, V269, P2139; Holmes ML, 1999, MOL CELL BIOL, V19, P4182; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Itahana Y, 2003, CANCER RES, V63, P7098; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Tanner MM, 1996, CANCER RES, V56, P3441; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON PH, 1991, CANCER RES, V51, P3996; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968	51	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					381	389		10.1038/sj.onc.1208188	http://dx.doi.org/10.1038/sj.onc.1208188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15489884				2022-12-28	WOS:000226279700009
J	Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C				Worch, J; Tickenbrock, L; Schwable, J; Steffen, B; Cauvet, T; Mlody, B; Buerger, H; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C			The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RAR alpha and regulates differentiation of hematopoietic cells	ONCOGENE			English	Article						AML; balanced translocation; myeloid differentiation; MNK1; eIF4E; c-myc	ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA TRANSPORT; P14(ARF) TUMOR-SUPPRESSOR; TRANSLATION INITIATION; CYCLIN D1; MALIGNANT TRANSFORMATION; HISTONE DEACETYLASE	Microarray analyses were performed to identify target genes that are shared by the acute myeloid leukemia (AML) translocation products PML-RARalpha, PLZF-RARalpha and AML1-ETO in inducibly transfected U937 cell lines. The cytoplasmic serine and threonine kinase MNK1 was identified as one of the target genes. At the protein level, MNK1 was significantly induced by each of the three fusion proteins. Protein half-life analyses showed that PML-RARalpha enhanced MNK1 protein stability in U937 cells and ATRA exposure decreased MNK1 half-life in NB4 cells. EIF4E, the main MNK1 substrate, plays a role in the pathogenesis of a variety of cancers. Upon MNK1 overexpression, eIF4E phosphorylation increased as a sign of functional activation. Interestingly, MNK1 protein expression decreased during myeloid differentiation. Inhibition of MNK1 activity by a specific inhibitor (CGP57380) enhanced differentiation of HL60 and 32D cells, further suggesting a role for MNK1 in the myeloid differentiation. In addition, kinase dead mutants of MNK1 significantly impaired proliferation of 32D cells. Immunohistochemistry of primary AML bone marrow biopsies showed strong cytoplasmic MNK1 expression in 25 of 99 AML specimens (25%). MNK1 expression was associated with high levels of c-myc expression. Taken together, we identified MNK1 as a target gene of several leukemogenic fusion proteins in AML. MNK1 plays a role in myeloid differentiation. These data suggest a role for MNK1 in the AML fusion protein-associated differentiation block.	Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-4400 Munster, Germany; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	University of Munster; University of Munster; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Serve, H (corresponding author), Univ Munster, Dept Med Hematol & Oncol, Domagkstr 3, D-48129 Munster, Germany.	muellerc@uni-muenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018	Müller-Tidow, Carsten/0000-0002-7166-5232; Mlody, Barbara/0000-0001-5184-1772				Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Ferrara FF, 2001, CANCER RES, V61, P2; Flynn A, 1996, CANCER SURV, V27, P293; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Muller-Tidow C, 2004, LEUKEMIA, V18, P720, DOI 10.1038/sj.leu.2403296; Muller-Tidow C, 2004, CLIN CANCER RES, V10, P1241, DOI 10.1158/1078-0432.CCR-0954-03; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nathan CAO, 2000, CANCER RES, V60, P3599; Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Tschopp C., 2000, Molecular Cell Biology Research Communications, V3, P205, DOI 10.1006/mcbr.2000.0217; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	44	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9162	9172		10.1038/sj.onc.1208164	http://dx.doi.org/10.1038/sj.onc.1208164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516979				2022-12-28	WOS:000225638000001
J	McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J				McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J			Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones	ONCOGENE			English	Article						TGCT; microarray CGH; regions of imbalance	DIFFERENTIAL EXPRESSION; BREAST-CANCER; HYBRIDIZATION; GENES; KIT; MUTATIONS; PROTEIN; TESTIS; DNA; IDENTIFICATION	Identifying changes in DNA copy number can pinpoint genes that may be involved in tumor development. Here we have defined the smallest overlapping regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has been previously investigated. Definition of the regions was achieved through comparative genomic hybridization (CGH) analysis of a 4559 cDNA clone microarray. A total of 14 SORI were identified, which involved at least five of the 11 samples analysed. Many of these refined regions were previously reported using chromosomal or allelic imbalance studies. The SORI included gain of material from the regions 4q12, 17q21.3, 22q11.23 and Xq22, and loss from 5q33, 11q12.1, 16q22.3 and 22q11. Comparison with parallel chromosomal CGH data supported involvement of most regions. The various SORI span between one and 20 genes and highlight potential oncogenes/tumor suppressor genes to be investigated further (Supplementary material is available at http://www.crukdmf.icr.ac.uk/array/array.html).	Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, Sutton SM2 5NG, Surrey, England; Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Royal Marsden NHS Foundation Trust	Shipley, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	janet.shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; huddart, robert/0000-0003-3604-1990; McIntyre, Alan/0000-0002-4791-7292; Zafarana, Gaetano/0000-0003-1391-4488; Shipley, Janet/0000-0001-6748-8678				Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Chen JZ, 2002, BIOCHEM BIOPH RES CO, V294, P161, DOI 10.1016/S0006-291X(02)00446-1; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Lu YJ, 1999, LUNG CANCER-J IASLC, V23, P61, DOI 10.1016/S0169-5002(98)00093-2; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, CANCER-AM CANCER SOC, V32, P1186, DOI 10.1002/1097-0142(197311)32:5<1186::AID-CNCR2820320527>3.0.CO;2-8; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rapley EA, 2004, BRIT J CANCER, V90, P2397, DOI 10.1038/sj.bjc.6601880; Rapley EA, 2003, APMIS, V111, P128, DOI 10.1034/j.1600-0463.2003.11101171.x; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; SAMBROOK J, 2001, MOL CLONING LA MANUA, V3; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Skotheim RI, 2002, CANCER RES, V62, P2359; Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; WATSON JV, 1986, BRIT J CANCER, V53, P331, DOI 10.1038/bjc.1986.56; Zafarana G, 2003, ONCOGENE, V22, P7695, DOI 10.1038/sj.onc.1207011	36	35	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9142	9147		10.1038/sj.onc.1208115	http://dx.doi.org/10.1038/sj.onc.1208115			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489896				2022-12-28	WOS:000225492800016
J	Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G				Roz, L; Andriani, F; Ferreira, CG; Giaccone, G; Sozzi, G			The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression	ONCOGENE			English	Article						Fhit; lung cancer; apoptosis control	HISTIDINE TRIAD GENE; TUMOR-DEVELOPMENT; DEATH DOMAIN; EXPRESSION; LESIONS; TUMORIGENICITY; MITOCHONDRIA; TRANSDUCTION; CHEMOTHERAPY; INHIBITION	The expression of the tumour suppressor protein fragile histidine triad (Fhit) is often impaired in many human cancers and its restoration in Fhit-negative cancer cell lines suppresses tumorigenicity and induces apoptosis. Although the proapoptotic function of Fhit is well documented, little is known about its precise mechanism of action and further studies are needed in order to elucidate the putative therapeutic properties of this protein. To this end, we have engineered the lung cancer cell line NCI-H460 in order to express different molecules involved in the control of apoptotic pathways. Infection of these cells with an adenoviral vector transducing the Fhit gene (Ad-Fhit) revealed that complete protection from apoptosis was conferred by the inhibitor of caspases Cytokine response modifier A (CrmA) and by a dominant-negative form of the adapter protein Fas-associated death domain (FADD) and partial protection by a dominant-negative form of caspase-8, while cells over expressing mitochondrial mediators of the apoptotic response such as Bcl-2 or Bcl-x(L) that are resistant to treatment with cisplatin, remained highly susceptible to cell death triggered by Fhit gene transfer. In line to what was observed in H460 cells, Ad-Fhit efficacy was not affected by Bcl-2 overexpression also in two other lung cancer cell lines (A549 and Calu-1). Analysis of cytochrome c release also confirmed that in Bcl-2- or Bel-x(L)-expressing cells apoptosis could be detected by terminal deoxynucleotidyltransferase mediated dUTP nick-end labelling (TUNEL) assay before any evidence of mitochondrial membrane perturbation. In conclusion, our analysis indicates that the Fhit protein exerts its oncosuppressor activity through induction of an apoptotic mechanism that seems to be FADD dependent, caspase-8 mediated and independent from mitochondrial amplification.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands	Fondazione IRCCS Istituto Nazionale Tumori Milan; Vrije Universiteit Amsterdam	Roz, L (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	luca.roz@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Ferreira, Carlos Gil/AAD-4104-2020; Giaccone, Giuseppe/E-8297-2017; Roz, Luca/AAB-3889-2019; Andriani, Francesca/D-4898-2017; Ferreira, Carlos Gil/G-4957-2013	sozzi, gabriella/0000-0001-9360-6914; Ferreira, Carlos Gil/0000-0002-7228-7018; Giaccone, Giuseppe/0000-0002-5023-7562; Roz, Luca/0000-0001-5817-7149; Andriani, Francesca/0000-0002-6178-7789; 				Baffa R, 2000, AM J PATHOL, V156, P419, DOI 10.1016/S0002-9440(10)64745-1; Broker LE, 2002, CANCER RES, V62, P4081; CAVAZZONI A, 2004, ONCOGENE        0913; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ferreira CG, 2000, CANCER RES, V60, P7133; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huisman C, 2002, CLIN CANCER RES, V8, P596; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mori M, 2000, CANCER RES, V60, P1177; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sozzi G, 1998, CANCER RES, V58, P5032; van Heerden WFP, 1999, J ORAL PATHOL MED, V28, P433; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	30	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9102	9110		10.1038/sj.onc.1208142	http://dx.doi.org/10.1038/sj.onc.1208142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489891				2022-12-28	WOS:000225492800011
J	Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X				Slee, EA; Gillotin, S; Bergamaschi, D; Royer, C; Llanos, S; Ali, S; Jin, BQ; Trigiante, G; Lu, X			The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization	ONCOGENE			English	Article						p53; iASPP; apoptosis	P53 TUMOR-SUPPRESSOR; APOPTOTIC FUNCTION; DNA-DAMAGE; INHIBITOR; PROTEINS; ANKYRIN; FAMILY; 53BP2; CELLS; DIE	ASPP1 and ASPP2 are both proteins that interact with p53 and enhance its ability to induce apoptosis by selectively elevating the expression of proapoptotic p53-responsive genes. iASPP(RAI) is a third member of the family that is the most conserved inhibitor of p53-mediated apoptosis. Here, we have described iASPP, a longer form of iASPP(RAI), which at 828 amino acids is more than twice the size of iASPP(RAI). Using two antibodies that recognize both iASPP and iASPP(RAI), we report that this longer form of iASPP is the predominant form of the molecule expressed in cells. Like iASPP(RAI), iASPP also binds to p53 and inhibits apoptosis induced by p53 overexpression. However, whereas iASPP(RAI) is predominantly nuclear, the N-terminus of iASPP is entirely cytoplasmic, and the longer iASPP is located in both the cytoplasm and the nucleus. The effect upon subcellular localization of the longer N-terminus of iASPP means that this new, longer form of the molecule may be subject to greater regulation and provides another layer in the control of p53-induced apoptosis.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China	Imperial College London; Ludwig Institute for Cancer Research; Air Force Military Medical University	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	x.lu@imperial.ac.uk	, Susana/AAA-9282-2019	Royer, Christophe/0000-0002-9882-7676; Bergamaschi, Daniele/0000-0002-3955-1091; Llanos, Susana/0000-0002-8555-9326; Gillotin, Sebastien/0000-0002-4129-4936; Lu, Xin/0000-0002-6587-1152				Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yap DBS, 2000, J BIOL CHEM, V275, P37296, DOI 10.1074/jbc.M004359200	18	52	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9007	9016		10.1038/sj.onc.1208088	http://dx.doi.org/10.1038/sj.onc.1208088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489900				2022-12-28	WOS:000225492800001
J	Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I				Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I			Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence	ONCOGENE			English	Article						endometrium; endometrial carcinoma; estrogen; cyclin; AP-1	BREAST-CANCER CELLS; GENE-EXPRESSION; IMMUNOHISTOCHEMICAL ANALYSIS; PROMOTER; PROTEIN; GROWTH; FOS; RECEPTOR; ELEMENT; PROTOONCOGENE	To explore the mechanism of estrogen-induced growth of normal endometrium, the transactivation system of the cyclin D1 gene was analysed using cultured normal endometrial glandular cells. Estradiol (E2) treatment of cultured normal endometrial glandular cells induced upregulation of c-Jun, and then cyclin D1 proteins, followed by serial expressions of cyclins E, A and B1 proteins. Increase in the mRNA expression of cyclin D1 preceded the protein expression of cyclin D1 under E2 treatment. A luciferase assay using deletion constructs of the cyclin D1 promoter indicated that E2-induced increase in transcriptional activity was observed in reporters containing AP-1-binding site sequence, and that in the absence of E2, cotransfection of c-Jun also showed increase of transcriptional activity in the same reporters with AP-1 sequence. A gel shift assay using nuclear extract from E2-treated endometrial glandular cells and AP-1 sequences of the cyclin D1 promoter indicated specific binding between c-Jun protein and the promoter. Transfection of c-jun antisense oligonucleotides to the glandular cells resulted in the suppression of the E2-induced upregulation of cyclin D1 mRNA and protein. These findings suggest that E2-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to the AP-1 sequences.	Shinshu Univ, Sch Med, Dept Obstet & Gynecol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Anat 2, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Organ Regenerat, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Shiozawa, T (corresponding author), Shinshu Univ, Sch Med, Dept Obstet & Gynecol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tanri@hsp.md.shinshu-u.ac.jp	Miyamoto, Tsutomu/ADW-0798-2022	Miyamoto, Tsutomu/0000-0002-1513-9473				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Altucci L, 1996, ONCOGENE, V12, P2315; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; GRONROOS M, 1987, ANN CHIR GYNAECOL FE, V76, P76; HERBER B, 1994, ONCOGENE, V9, P1295; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Kaneuchi M, 2003, INT J ONCOL, V22, P159; Kawasaki S, 1999, BIOCHEM BIOPH RES CO, V263, P560, DOI 10.1006/bbrc.1999.1402; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li SF, 1996, CANCER, V77, P321, DOI 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; LURAIN JR, 2002, UTERINE CANC NOVAKS, P1143; Miao ZH, 2003, CANCER RES, V63, P4527; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Salmi A, 1998, J CLIN ENDOCR METAB, V83, P1788, DOI 10.1210/jc.83.5.1788; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Shiozawa T, 1997, CANCER, V80, P2250, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2250::AID-CNCR5>3.0.CO;2-Y; Shiozawa T, 2001, ENDOCRINOLOGY, V142, P4182, DOI 10.1210/en.142.10.4182; Shiozawa T, 1996, MOL HUM REPROD, V2, P745, DOI 10.1093/molehr/2.10.745; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SPEROFF L, 1999, FEMALE INFERTILITY C, P1014; STRAUSS J, 1999, ENDOMETRIUM MYOMETRI, P218; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; TSENG L, 1980, CYCLIC CHANGE ESTRAD, P211; WEBB DK, 1993, ENDOCRINOLOGY, V133, P20, DOI 10.1210/en.133.1.20; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	44	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8603	8610		10.1038/sj.onc.1207849	http://dx.doi.org/10.1038/sj.onc.1207849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467760	Bronze			2022-12-28	WOS:000224988800006
J	Gauld, SB; Cambier, JC				Gauld, SB; Cambier, JC			Src-family kinases in B-cell development and signaling	ONCOGENE			English	Review						Src kinase; B-lymphocyte; antigen receptor; signaling; development	PROTEIN-TYROSINE KINASE; LYN-DEFICIENT MICE; RECEPTOR-MEDIATED SIGNALS; PHOSPHORYLATED IG-ALPHA; ANTIGEN RECEPTOR; NEGATIVE REGULATION; PROCESSIVE AMPLIFICATION; ADAPTER PROTEIN; CUTTING EDGE; ACTIVATION	The Src-family protein tyrosine kinases (SFKs) are known to play key roles in initiating signal transduction by the B-cell antigen receptor (BCR). In addition, numerous studies have shown that this family of molecules also contributes to signaling by BCR surrogates during B-lymphocyte lineage development and maturation. Paradoxically, ablation of SFKs not only results in obvious defects in B-cell development but also in the onset of autoimmunity. Thus SFKs, most notably Lyn, play both activating and inhibitory roles in B-cell function. Confounding analyses of SFK function in B cells is the varied coexpression of family members that mediate redundant as well as unique functions. In this review, we will focus mainly on the role of Lyn in mediating positive and negative roles in B-cell activation and how these affect immune signaling and disease progression.	Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Cambier, JC (corresponding author), Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	cambierj@njc.org		Cambier, John/0000-0002-7803-242X				Adachi T, 1998, J IMMUNOL, V160, P4662; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; Campbell KS, 1995, MOL IMMUNOL, V32, P1283, DOI 10.1016/0161-5890(95)00088-7; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; Cornall RJ, 1999, CURR TOP MICROBIOL, V244, P57; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Fujimoto M, 2001, J BIOL CHEM, V276, P44820, DOI 10.1074/jbc.M107559200; Fujimoto M, 2000, IMMUNOL RES, V22, P281, DOI 10.1385/IR:22:2-3:281; Gupta N, 2003, MOL BIOL CELL, V14, P432, DOI 10.1091/mbc.02-05-0078; Hasegawa M, 2001, J IMMUNOL, V167, P2469, DOI 10.4049/jimmunol.167.5.2469; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Janas ML, 1999, J IMMUNOL, V163, P4192; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Katagiri T, 1999, J IMMUNOL, V163, P1321; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; Meade J, 2002, EUR J IMMUNOL, V32, P1029, DOI 10.1002/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Otipoby KL, 2001, J BIOL CHEM, V276, P44315, DOI 10.1074/jbc.M105446200; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pao LI, 1998, J IMMUNOL, V160, P3305; Pao LI, 1997, J IMMUNOL, V158, P2663; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Pracht C, 2002, EUR J IMMUNOL, V32, P1614, DOI 10.1002/1521-4141(200206)32:6<1614::AID-IMMU1614>3.0.CO;2-A; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sen G, 1999, EUR J IMMUNOL, V29, P3319; Shrivastava P, 2004, BLOOD, V103, P1425, DOI 10.1182/blood-2003-03-0716; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; WECHSLER RJ, 1995, J IMMUNOL, V154, P1919; WENG WK, 1994, J BIOL CHEM, V269, P32514; Whyburn LR, 2003, J IMMUNOL, V171, P1850, DOI 10.4049/jimmunol.171.4.1850; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Yamanashi Y, 2000, GENE DEV, V14, P11; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487	69	107	109	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8001	8006		10.1038/sj.onc.1208075	http://dx.doi.org/10.1038/sj.onc.1208075			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489917				2022-12-28	WOS:000224558300010
J	Luttrell, DK; Luttrell, LM				Luttrell, DK; Luttrell, LM			Not so strange bedfellows: G-protein-coupled receptors and Src family kinases	ONCOGENE			English	Review						G-protein-coupled receptor; focal adhesion kinase; epidermal growth factor; mitogen-activated protein kinase; receptor crosstalk	GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; DEPENDENT TYROSINE KINASE; C-SRC; EGF RECEPTOR; ANGIOTENSIN-II; MAP KINASE; BETA-ARRESTIN; LYSOPHOSPHATIDIC ACID	Src family nonreceptor tyrosine kinases are an integral component of the signal transduction apparatus employed by growth factor receptor tyrosine kinases. As such, their role in cellular growth control and malignant transformation has been the subject of intensive investigation. In contrast, classical G-protein-coupled receptor ( GPCR) signaling involves activation of second messenger-regulated serine/threonine kinases or ion channels, and is primarily involved in neurotransmission and the short-term regulation of intermediary metabolism. Over the past decade, this strictly dichotomous model of transmembrane signaling has been challenged by the discovery that GPCRs also exert control over cellular growth, proliferation, and differentiation, and do so by stimulating tyrosine phosphorylation cascades. Several mechanisms, from the direct association of Src family kinases with GPCRs or receptor-associated proteins, to the transactivation of receptor tyrosine kinases and focal adhesion complexes by G-protein-mediated signals, permit GPCRs to activate Src family kinases. Conversely, Src activity plays a central role in controlling GPCR trafficking and effects on cell proliferation and cytoskeletal rearrangement. It is now clear that GPCRs and Src family kinases do not belong to separate, exclusive clubs. Rather, these strange bedfellows are intimately involved in multilayered forms of crosstalk that influence a host of cellular processes.	Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Luttrell, LM (corresponding author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,816 CSB,POB 250624, Charleston, SC 29425 USA.	luttrell@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058283, R01DK064353, R01DK055524, R56DK055524] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55524, DK58283, DK64353] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gschwind A, 2002, CANCER RES, V62, P6329; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Liu J, 2004, J BIOL CHEM, V279, P8212, DOI 10.1074/jbc.M312230200; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; LUTTRELL DK, 1992, CELL SIGNAL, V4, P531, DOI 10.1016/0898-6568(92)90022-Z; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898-6568(03)00099-8; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack BE, 1998, P NATL ACAD SCI USA, V95, P7281, DOI 10.1073/pnas.95.13.7281; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VAN BT, 1995, NATURE, V376, P781; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	103	170	174	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7969	7978		10.1038/sj.onc.1208162	http://dx.doi.org/10.1038/sj.onc.1208162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489914				2022-12-28	WOS:000224558300007
J	Parsons, SJ; Parsons, JT				Parsons, SJ; Parsons, JT			Src family kinases, key regulators of signal transduction	ONCOGENE			English	Review						tyrosine kinase; transformation; cancer; cell proliferation	PROTEIN-TYROSINE KINASES	The Src family of protein tyrosine kinases (SFKs) plays key roles in regulating signal transduction by a diverse set of cell surface receptors in the context of a variety of cellular environments. SFKs have evolved many ingenious molecular strategies to couple receptors with the cytoplasmic signaling machinery. The contributions to this issue of ONCOGENE describe how this machinery regulates fundamental cellular processes, including cell growth, differentiation, cell shape, migration and survival, and specialized cell signals. The pleotropic functions of Src and Src family members underscore the importance of these kinases and explain why many of the members of this family have been identified as cellular oncogenes. In this volume, we have attempted to provide the reader with an overview of the current understanding of the function of Src family kinases in the regulation of selected cellular signaling pathways.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	sap@virginia.edu; jtp@virginia.edu						Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RODAN SB, 1997, J ENDOCRINOL, V154, P47; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513	8	665	697	0	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7906	7909		10.1038/sj.onc.1208160	http://dx.doi.org/10.1038/sj.onc.1208160			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489908				2022-12-28	WOS:000224558300001
J	Fulda, S; Jeremias, I; Debatin, KM				Fulda, S; Jeremias, I; Debatin, KM			Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells	ONCOGENE			English	Article						apoptosis; TRAIL; betulinic acid; cancer resistance	IN-VIVO; DECOY RECEPTORS; HUMAN-MELANOMA; LIGAND TRAIL; CANCER; DEATH; SENSITIZATION; CYTOTOXICITY; CHEMOTHERAPY; IRRADIATION	We previously reported that the TRAIL ( tumor necrosis factor (TNF)-related apoptosis-inducinglig and)-induced death signal requires amplification by mitochondria in certain cell types, for example, in type II cells. Here, we provide for the first time evidence that the natural compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells. Through functional complementation, simultaneous stimulation of the death receptor pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of effector caspases, apoptosis and inhibition of clonogenic survival. BetA and TRAIL cooperated to trigger loss of mitochondrial membrane potential and release of cytochrome c and Smac from mitochondria. Also, combination treatment with BetA and TRAIL resulted in increased cleavage of caspase-8 and Bid indicating that activation of effector caspases may feed back in a positive amplification loop. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells, but not in normal human fibroblasts indicating some tumor specificity. Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany; Dr von Haunersches Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Fulda, S (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 1998, KLIN PADIATR, V210, P148, DOI 10.1055/s-2008-1043870; Gliniak B, 1999, CANCER RES, V59, P6153; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Nagane M, 2000, CANCER RES, V60, P847; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Stahnke K, 2003, LEUKEMIA, V17, P2130, DOI 10.1038/sj.leu.2403144; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	31	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7611	7620		10.1038/sj.onc.1207970	http://dx.doi.org/10.1038/sj.onc.1207970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361826				2022-12-28	WOS:000224306700002
J	Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V				Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V			Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells	ONCOGENE			English	Article						TNF alpha; senescence; AML cells; genetic instability	COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; OXIDATIVE DNA-DAMAGE; INDUCED APOPTOSIS; TELOMERASE ACTIVITY; ULCERATIVE-COLITIS; TNF-ALPHA; CERAMIDE; EXPRESSION; LINES	Previous studies have documented that Tumor necrosis factor alpha (TNFalpha) is a potent negative regulator of normal hematopoiesis. However, the mechanism by which TNFalpha acts at the cellular level is not totally understood. Although apoptotic cell killing appears to be the most common cellular effect of TNFalpha, other studies suggest that this cytokine may elicit other cellular responses such as prolonged growth inhibition. In this context, we have investigated whether TNFalpha may induce senescence in hematopoietic cells, which display intrinsic defect in the apoptotic machinery. The present study described that, in the leukemic KG1 cells, TNFalpha induced no apoptosis but a senescence state characterized by prolonged growth arrest, increased beta-galactosidase activity, p21(WAF-1) induction, decreased telomerase activity, telomeric disturbances ( shortening, losses, fusions), and additional chromosomal aberrations. Telomerase inhibition correlated with reduced levels of hTERT transcripts. GM-CSF prevented TNFalpha effects and allowed leukemic cells to recover growth capacity. Finally, our study shows for the first time that, at least in some hematopoietic cells, TNFalpha may induce senescence with important functional consequences, including sustained growth inhibition and genetic instability, and that this cellular response is efficiently regulated by hematopoietic growth factors.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31059 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France; CHU Purpan, Hematol Lab, F-31059 Toulouse, France; CEA, DSV, DRR, LRO, F-92265 Fontenay Aux Roses, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CEA	Mansat-De Mas, V (corresponding author), Hop Purpan, Hematol Lab, Pavillon Caubet,Pl Dr Baylac, F-31059 Toulouse, France.	demas.v@chu-toulouse.fr	De Mas, Véronique/P-2414-2014; Beyne-Rauzy, Odile OBR/G-6560-2013; Beyne-Rauzy, Odile/AAN-1873-2020	Beyne-Rauzy, Odile/0000-0003-0321-6029; Sabatier, Laure/0000-0003-0552-6549				Akiyama M, 2002, CANCER RES, V62, P3876; BALOCH Z, 1990, J IMMUNOL, V145, P2908; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, J ANAT, V197, P529, DOI 10.1046/j.1469-7580.2000.19740529.x; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mathieu N, 2004, CELL MOL LIFE SCI, V61, P641, DOI 10.1007/s00018-003-3296-0; MURASE T, 1987, BLOOD, V69, P467; Nathan I, 2000, CYTOKINE, V12, P881, DOI 10.1006/cyto.1999.0638; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186; Park YM, 1998, J CELL PHYSIOL, V174, P27, DOI 10.1002/(SICI)1097-4652(199801)174:1<27::AID-JCP4>3.0.CO;2-I; Quentmeier H, 2000, EXP HEMATOL, V28, P1008, DOI 10.1016/S0301-472X(00)00516-6; QuilletMary A, 1996, LEUKEMIA, V10, P417; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TOBLER A, 1987, BLOOD, V70, P200; Tsukada Y, 2002, AM J GASTROENTEROL, V97, P2820; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	31	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7507	7516		10.1038/sj.onc.1208024	http://dx.doi.org/10.1038/sj.onc.1208024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326480				2022-12-28	WOS:000224176500007
J	Dominguez-Caceres, MA; Garcia-Martinez, JM; Calcabrini, A; Gonzalez, L; Porque, PG; Leon, J; Martin-Perez, J				Dominguez-Caceres, MA; Garcia-Martinez, JM; Calcabrini, A; Gonzalez, L; Porque, PG; Leon, J; Martin-Perez, J			Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells	ONCOGENE			English	Article						prolactin; cell proliferation and survival; Src kinases; Akt; FKHRL1; GSK3; Myc	GLYCOGEN-SYNTHASE KINASE-3; FORKHEAD TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; S6 KINASE; PROTEIN STABILITY; GENE-EXPRESSION; TARGET GENES; IN-VIVO; APOPTOSIS; PROLIFERATION	Stimulation of resting W53 cells ( lymphoid murine cells expressing prolactin (PRL) receptor) by PRL induced expression of growth-related immediate-early genes (IEG), and proliferation through activation of the Src kinases. Since IEG are essential for cell cycle progression, we have studied how PRL controls expression of c-Myc mRNA and c-Fos. Stimulation of W53 cell proliferation by PRL required activation of MAPK, as the Mek1/2 inhibitor PD184352 eliminated Erk1/2 stimulation, cell proliferation, and expression of c-Fos mRNA. In contrast, PD184352 did not alter PRL activation of c-Myc mRNA expression or stimulation of p70S6K, Akt, and the Jak2/ Stat5 pathway. Activation of the PI3K by PRL was necessary for the expression of c-Myc mRNA and W53 cell proliferation, as the PI3K inhibitor LY294002 abolished them. However, it did not modify PRL stimulation of c-Fos mRNA expression or activation of Erk1/2 and Stat5. Furthermore, rapamycin, an inhibitor of mTOR and consequently of p70S6K, did not alter PRL stimulation of c-Myc and c-Fos mRNA expression and it had a very minor inhibitory effect on PRL stimulation of W53 cell proliferation. In addition, rapamycin did not affect PRL stimulation of Akt or Stat5. However, it reinforced PRL activation of Erk1/2. Overexpression of a constitutively activated Akt ( myristoylated Akt) in W53 cells overcame the inhibitory effect of LY294002 on c-Myc expression, as well as cell death upon PRL deprivation. Consistently, inducible expression of Akt-CAAX Box in W53 cells caused inhibition of c-Myc expression. PRL stimulation of W53 cells resulted in Akt translocation to the nucleus, phosphorylation of FKHRL1 transcription factor, and its nuclear exclusion. In contrast, induced expression of Akt-CAAX Box caused inhibition of FKHRL1 phosphorylation. Furthermore, transient expression of nonphosphorylatable FKHRL1-A3 mutant impaired PRL-induced activation of the c-Myc promoter. Akt activation also resulted in phosphorylation and inhibition of glycogen synthetase kinase 3 (GSK3), which in turn promoted c-Myc stability. Consistently, treatment of W53 with selective inhibitors of GSK3 such as SB415286 and lithium salts resulted in increased levels of c-Myc. Also, overexpression of c-Myc in W53 cells overcame the decrease in cell proliferation induced by LY294002. These findings defined a PRL-signalling cascade in W53 cells, involving Src kinases/PI3K/Akt/ FKHRL1-GSK3, that mediates stimulation of c-Myc expression.	CSIC, Inst Invest Biomed, Madrid 28029, Spain; Ist Super Sanita, I-00161 Rome, Italy; Hosp Univ Ramon & Cajal, Serv Inmunol, Madrid, Spain; Univ Cantabria, Fac Med, Dept Mol Biol, Unidad Biomed,CSIC, E-39005 Santander, Spain; Univ Cantabria, Grp Biol Mol Canc, E-39005 Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Istituto Superiore di Sanita (ISS); Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Universidad de Cantabria	Martin-Perez, J (corresponding author), CSIC, Inst Invest Biomed, Calle Arturo Duperier 4, Madrid 28029, Spain.	jmartin@iib.uam.es	Martin-Perez, Jorge/A-3522-2008; Leon, Javier/K-4615-2014; Calcabrini, Annarica/C-9897-2015; Martínez, José Manuel García/AAB-5909-2019	Martin-Perez, Jorge/0000-0002-2292-0057; Calcabrini, Annarica/0000-0002-9600-1117; Martínez, José Manuel García/0000-0002-6498-5174; Gonzalez, Lorena/0000-0002-0575-7833; Leon, Javier/0000-0001-5803-0112				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Barry FA, 2003, FEBS LETT, V553, P173, DOI 10.1016/S0014-5793(03)01015-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FERRARI S, 1993, J BIOL CHEM, V268, P16091; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Jeay S, 2001, ENDOCRINOLOGY, V142, P147, DOI 10.1210/en.142.1.147; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LUTZ W, 2002, BIOCHIM BIOPHYS ACTA, V14, P61; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mauleon I, 2004, MOL CARCINOGEN, V39, P85, DOI 10.1002/mc.20000; Medh RD, 2001, ONCOGENE, V20, P4629, DOI 10.1038/sj.onc.1204680; Morales P, 1999, CELL GROWTH DIFFER, V10, P583; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu M, 1996, MOL CELL BIOL, V16, P5015; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942	58	65	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7378	7390		10.1038/sj.onc.1208002	http://dx.doi.org/10.1038/sj.onc.1208002			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286700				2022-12-28	WOS:000224021400008
J	Faubert, A; Lessard, J; Sauvageau, G				Faubert, A; Lessard, J; Sauvageau, G			Are genetic determinants of asymmetric stem cell division active in hematopoietic stem cells?	ONCOGENE			English	Review						asymmetric division; hematopoiesis; phylogenic search; self-renewal; stem cell	CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR; DROSOPHILA NEUROBLASTS; MAMMALIAN NUMB; CORTICAL NEUROGENESIS; INTRACELLULAR DOMAIN; MITOTIC NEUROBLASTS; ENDOCYTIC PROTEIN; EPITHELIAL-CELLS; PROGENITOR CELLS	Stem cells have acquired a golden glow in the past few years as they represent possible tools for reversing the damage wreak on organs. These cells are found not only in major regenerative tissues, such as the epithelia, blood and testes, but also in 'static tissues', such as the nervous system and liver, where they play a central role in tissue growth and maintenance. The mechanism by which stem cells maintain populations of highly differentiated, short-lived cells seems to involve a critical balance between alternate fates: daughter cells either maintain stem cell identity or initiate differentiation. Recent studies in lower organisms have unveiled the regulatory mechanisms of asymmetric stem cell divisions. In these models, the surrounding environment likely provides key instructive signals for the cells to choose one fate over another. Our understanding now extends to the intrinsic mechanisms of cell polarity that influence asymmetrical stem cell divisions. This article focuses on the genetic determinants of asymmetric stem cell divisions in lower organisms as a model for studying the process of self-renewal of mammalian hematopoietic stem cells.	Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hematopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ, Canada; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Hosp Maisonneuve Rosemont, Dept Med, Montreal, PQ, Canada; Hosp Maisonneuve Rosemont, Div Hematol, Montreal, PQ, Canada	Universite de Montreal; McGill University; Stanford University; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hematopoiet Stem Cells, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Allman D, 2002, IMMUNOL REV, V187, P75, DOI 10.1034/j.1600-065X.2002.18707.x; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO;2-M; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beatus P, 1999, DEVELOPMENT, V126, P3925; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Brummendorf TH, 1998, J EXP MED, V188, P1117, DOI 10.1084/jem.188.6.1117; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cayouette M, 2003, DEVELOPMENT, V130, P2329, DOI 10.1242/dev.00446; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; Darzacq X, 2003, CURR OPIN MICROBIOL, V6, P614, DOI 10.1016/j.mib.2003.10.005; DELABIE J, 1993, LEUKEMIA LYMPHOMA, V12, P21, DOI 10.3109/10428199309059567; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gonczy P, 1996, DEVELOPMENT, V122, P2437; GONZALEZ C, 2002, SCI STKE, pE48; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Grunicke HH, 2003, ADV ENZYME REGUL, V43, P213, DOI 10.1016/S0065-2571(02)00032-8; HARDY RW, 1979, J ULTRA MOL STRUCT R, V69, P180, DOI 10.1016/S0022-5320(79)90108-4; Hawkins N, 1998, GENE DEV, V12, P3625, DOI 10.1101/gad.12.23.3625; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Ho SM, 2003, ONCOGENE, V22, P4243, DOI 10.1038/sj.onc.1206437; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jablonka S, 2004, J NEUROBIOL, V58, P272, DOI 10.1002/neu.10313; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaltschmidt JA, 2002, J CELL SCI, V115, P2257; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Katoh M, 2003, INT J MOL MED, V11, P111; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Knust E, 2001, CELL, V107, P125, DOI 10.1016/S0092-8674(01)00534-7; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Lin HJ, 2001, J CELL BIOL, V155, P1173, DOI 10.1083/jcb.200108119; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nagai H, 2003, GENE CHROMOSOME CANC, V38, P13, DOI 10.1002/gcc.10248; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; O'Connor-Giles KM, 2003, DEV CELL, V5, P231, DOI 10.1016/S1534-5807(03)00226-0; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; Petritsch C, 2003, DEV CELL, V4, P273, DOI 10.1016/S1534-5807(03)00020-0; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roegiers F, 2001, P NATL ACAD SCI USA, V98, P14469, DOI 10.1073/pnas.261555598; Sahin U, 2002, BLOOD, V100, P4139, DOI 10.1182/blood.V100.12.4139; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaner CE, 2003, DEV CELL, V5, P747, DOI 10.1016/S1534-5807(03)00327-7; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Schweisguth F, 2000, CURR BIOL, V10, pR265, DOI 10.1016/S0960-9822(00)00402-4; Segal M, 2001, TRENDS CELL BIOL, V11, P160, DOI 10.1016/S0962-8924(01)01954-7; Selzer E, 2002, MELANOMA RES, V12, P201, DOI 10.1097/00008390-200206000-00003; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen Q, 2002, DEVELOPMENT, V129, P4843; SHEN Q, 2002, SCI STKE, pE52; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Song XQ, 2002, P NATL ACAD SCI USA, V99, P14813, DOI 10.1073/pnas.232389399; SPANA EP, 1995, DEVELOPMENT, V121, P3187; Tio M, 1999, J CELL SCI, V112, P1541; Torii MA, 1999, DEVELOPMENT, V126, P443; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wai P, 1999, DEVELOPMENT, V126, P2759; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhong WM, 2000, P NATL ACAD SCI USA, V97, P6844, DOI 10.1073/pnas.97.12.6844; Zhu CH, 2003, DEVELOPMENT, V130, P2579, DOI 10.1242/dev.00499	114	16	18	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7247	7255		10.1038/sj.onc.1207944	http://dx.doi.org/10.1038/sj.onc.1207944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378084				2022-12-28	WOS:000223998800010
J	Gomyo, Y; Sasaki, J; Branch, C; Roth, JA; Mukhopadhyay, T				Gomyo, Y; Sasaki, J; Branch, C; Roth, JA; Mukhopadhyay, T			5-aza-2 '-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells	ONCOGENE			English	Article						5-aza-2-deoxycytidine; caspase-9; p53; lung tumor; apoptosis	DNA METHYLATION; P53-DEPENDENT APOPTOSIS; CPG METHYLATION; DOWN-REGULATION; IN-VITRO; GENE; ACTIVATION; GROWTH; INHIBITION; APAF-1	Treating lung cancer cell lines using low-dose 5-aza-2'-deoxycytidine (DAC) caused an accumulation of procaspase-9 through mRNA upregulation, but the cells did not undergo apoptosis. However, when cells were treated with DAC and infected with a low dose of a recombinant wildtype p53 adenovirus vector (Ad-p53), a synergistic growth inhibitory effect was observed. Combination treatment induced Apaf-1 and procaspase-9 expression in which cytochrome c releases by Ad-p53 triggered the mitochondrial pathway of apoptosis. Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. In addition, DAC sensitized lung cancer cells to cisplatin and paclitaxel. Induction of the mitochondrial pathway of apoptosis using a slightly toxic dose of DAC may therefore be a strategy for treating lung cancer, and DAC treatment may have clinical implications when combined with chemotherapy or apoptosis-inducing gene therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 023, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sasaki, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 023, 1515 Holcombe Blvd, Houston, TX 77030 USA.	saji@gpo.kumamoto-u.ac.jp			NCI NIH HHS [P01 CA78778-01A1, P50-CA709007, 2P50-CA70970-04, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Bender CM, 1998, CANCER RES, V58, P95; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Debatin KM, 2000, TOXICOL LETT, V112, P41, DOI 10.1016/S0378-4274(99)00252-0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; HERMAN JG, 1995, CANCER RES, V55, P4525; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kano Y, 1998, CANCER CHEMOTH PHARM, V42, P91, DOI 10.1007/s002800050790; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LENZI R, 1995, INT J ONCOL, V6, P447; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PINTO A, 1984, BLOOD, V64, P922; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	63	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6779	6787		10.1038/sj.onc.1207381	http://dx.doi.org/10.1038/sj.onc.1207381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273730				2022-12-28	WOS:000223653600009
J	McCullough, ML; Giovannucci, EL				McCullough, ML; Giovannucci, EL			Diet and cancer prevention	ONCOGENE			English	Review						diet; nutrition; neoplasms; prevention	VITAMIN-D-RECEPTOR; MAJOR CHRONIC DISEASE; METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; COLORECTAL ADENOMA RECURRENCE; EPITHELIAL-CELL PROLIFERATION; BETA-CAROTENE SUPPLEMENTATION; GUIDELINES-FOR-AMERICANS; INCIDENT BREAST-CANCER; DONE MEAT INTAKE; COLON-CANCER	Dietary effects are presumed to underlie many of the large international differences in incidence seen for most cancers. Apart from alcohol and a few micronutrients, however, the role of specific nutritional factors remains ill-defined. The evidence for a role of energy balance, physical inactivity, and obesity has strengthened, while for dietary fat it has weakened. Phytochemicals such as folate, lycopene and flavonoids are still the subject of active research. As the mechanisms underlying human carcinogenesis are better understood, dietary research will focus increasingly on intermediate markers such as the insulin-like growth factors and potentially carcinogenic metabolites.	Amer Canc Soc, Epidemiol & Surveillance Res Dept, Atlanta, GA 30329 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	American Cancer Society; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	McCullough, ML (corresponding author), Amer Canc Soc, Epidemiol & Surveillance Res Dept, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.	marji.mccullough@cancer.org		McCullough, Marjorie/0000-0003-3025-6341				ALBANES D, 1988, CANCER RES, V48, P1658; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; ALDECRUETZ H, 2003, LANCET ONCOL, V3, P364; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Ambrosone CB, 1998, INT J CANCER, V75, P825, DOI 10.1002/(SICI)1097-0215(19980316)75:6&lt;825::AID-IJC2&gt;3.0.CO;2-X; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Arab L, 2001, EPIDEMIOL REV, V23, P211, DOI 10.1093/oxfordjournals.epirev.a000803; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Augustin LSA, 2001, ANN ONCOL, V12, P1533, DOI 10.1023/A:1013176129380; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; Baron JA, 2003, JNCI-J NATL CANCER I, V95, P717, DOI 10.1093/jnci/95.10.717; Barreto AM, 2000, CANCER EPIDEM BIOMAR, V9, P265; Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; Bingham SA, 2002, J NUTR, V132, p3522S, DOI 10.1093/jn/132.11.3522S; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Bingham SA, 2003, LANCET, V362, P212, DOI 10.1016/S0140-6736(03)13913-X; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bostick RM, 1997, CANCER EPIDEM BIOMAR, V6, P971; Branca F, 2001, BRIT J NUTR, V86, pS55, DOI 10.1079/BJN2001339; Bretherton-Watt D, 2001, BRIT J CANCER, V85, P171, DOI 10.1054/bjoc.2001.1864; Brockton N, 2000, AM J EPIDEMIOL, V151, P846; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Campbell IG, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr457; CARROLL KK, 1975, CANCER RES, V35, P3374; Chan JM, 1999, CANCER EPIDEM BIOMAR, V8, P893; Chan JM, 2001, EPIDEMIOL REV, V23, P87, DOI 10.1093/oxfordjournals.epirev.a000800; Chen J, 1998, CANCER RES, V58, P3307; Chen J, 1996, CANCER RES, V56, P4862; Cho E, 2003, CANCER EPIDEM BIOMAR, V12, P1153; Cho EY, 2003, JNCI-J NATL CANCER I, V95, P1079, DOI 10.1093/jnci/95.14.1079; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Clinton SK, 1998, ANNU REV NUTR, V18, P413, DOI 10.1146/annurev.nutr.18.1.413; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Cotton SC, 2000, AM J EPIDEMIOL, V151, P7, DOI 10.1093/oxfordjournals.aje.a010124; Cramer DW, 2000, CANCER EPIDEM BIOMAR, V9, P95; Crews H, 2001, BRIT J NUTR, V86, pS5, DOI 10.1079/BJN2001337; Cross AJ, 2003, CANCER RES, V63, P2358; Cross HS, 1997, J STEROID BIOCHEM, V62, P21, DOI 10.1016/S0960-0760(97)00020-4; de Lorgeril M, 1998, ARCH INTERN MED, V158, P1181, DOI 10.1001/archinte.158.11.1181; Deitz AC, 2000, CANCER EPIDEM BIOMAR, V9, P905; Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607; *DHHS, 1996, FED REGISTER, V61, P8781; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1992, CANCER RES, V52, pS2024; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; Duthie SJ, 2000, NUTR CANCER, V37, P245, DOI 10.1207/S15327914NC372_18; Eichholzer M, 2001, SWISS MED WKLY, V131, P539; ENNS CW, 1997, FAM EC NUTR REV, V10, P2; FAO/WHO, 2002, HLTH IMPL ACR FOOD, V90; Feigelson HS, 2003, CANCER EPIDEM BIOMAR, V12, P161; Ferguson LR, 2001, NUTR CANCER, V39, P155, DOI 10.1207/S15327914nc392_1; Fitzgerald AL, 2002, NUTR CANCER, V43, P127, DOI 10.1207/S15327914NC432_2; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P66, DOI 10.1097/00001648-199401000-00011; Friedenreich CM, 2001, CANCER EPIDEM BIOMAR, V10, P287; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Fung T, 2003, ARCH INTERN MED, V163, P309, DOI 10.1001/archinte.163.3.309; Fung TT, 2001, AM J CLIN NUTR, V73, P61; Gann PH, 1999, CANCER RES, V59, P1225; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R; Gershoni-Baruch R, 2000, EUR J CANCER, V36, P2313, DOI 10.1016/S0959-8049(00)00306-3; Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Giovannucci E, 2004, INT J EPIDEMIOL, V33, P217, DOI 10.1093/ije/dyh020; Giovannucci E, 1998, CANCER RES, V58, P442; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; Giovannucci E, 2000, JNCI-J NATL CANCER I, V92, P1966, DOI 10.1093/jnci/92.24.1966; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P567, DOI 10.1023/A:1008835903714; Goodlad RA, 2001, GUT, V48, P587, DOI 10.1136/gut.48.5.587; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Harnack L, 2002, AM J CLIN NUTR, V76, P889, DOI 10.1093/ajcn/76.4.889; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HEILBRUN LK, 1985, LANCET, V1, P925; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Helzlsouer KJ, 2000, J NATL CANCER I, V92, P2018, DOI 10.1093/jnci/92.24.2018; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Higginbotham S, 2004, JNCI-J NATL CANCER I, V96, P229, DOI 10.1093/jnci/djh020; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; Holick CN, 2002, AM J EPIDEMIOL, V156, P536, DOI 10.1093/aje/kwf072; Holt PR, 2002, CANCER EPIDEM BIOMAR, V11, P113; Holt PR, 1999, J AM COLL NUTR, V18, p379S, DOI 10.1080/07315724.1999.10718902; Hou MF, 2002, BREAST CANCER RES TR, V74, P1, DOI 10.1023/A:1016048900049; Howe GR, 1997, CANCER CAUSE CONTROL, V8, P215, DOI 10.1023/A:1018476414781; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; *IARC, 2003, FRUIT VEG; *IARC, 1999, MET POL SUSC CANC; Ingles SA, 2000, CANCER CAUSE CONTROL, V11, P25, DOI 10.1023/A:1008979417618; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; IOM, 2000, DIET REF INT VIT C V; Jacob RA., 1999, MODERN NUTR HLTH DIS, V9th edn, P467; Jacobs EJ, 2001, CANCER CAUSE CONTROL, V12, P927, DOI 10.1023/A:1013716323466; John EM, 1999, CANCER EPIDEM BIOMAR, V8, P399; Jonas CR, 2003, CANCER EPIDEM BIOMAR, V12, P573; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; KANT AK, 1995, J AM COLL NUTR, V14, P358; Kant AK, 2000, JAMA-J AM MED ASSOC, V283, P2109, DOI 10.1001/jama.283.16.2109; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KATSOUYANNI K, 1988, CANCER-AM CANCER SOC, V61, P181, DOI 10.1002/1097-0142(19880101)61:1<181::AID-CNCR2820610130>3.0.CO;2-J; Kolonel LN, 2001, EPIDEMIOL REV, V23, P72, DOI 10.1093/oxfordjournals.epirev.a000798; Kolonel LN, 1999, JNCI-J NATL CANCER I, V91, P414, DOI 10.1093/jnci/91.5.414; Krebs-Smith SM, 2001, J NUTR, V131, p487S, DOI 10.1093/jn/131.2.487S; Kushi L, 2002, AM J MED, V113, P63, DOI 10.1016/S0002-9343(01)00994-9; Lampe JW, 2000, CANCER EPIDEM BIOMAR, V9, P787; Lampe JW, 1999, AM J CLIN NUTR, V70, p475S, DOI 10.1093/ajcn/70.3.475s; Lampe JW, 2002, J NUTR, V132, P2991, DOI 10.1093/jn/131.10.2991; Lamprecht SA, 2001, ANN NY ACAD SCI, V952, P73, DOI 10.1111/j.1749-6632.2001.tb02729.x; Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Levi F, 2001, INT J CANCER, V91, P260, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1041&gt;3.3.CO;2-R; Lin HJ, 1998, CANCER EPIDEM BIOMAR, V7, P647; Lipkin M, 1999, J AM COLL NUTR, V18, p392S, DOI 10.1080/07315724.1999.10718903; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; Liu C, 2003, J NUTR, V133, P173, DOI 10.1093/jn/133.1.173; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ma J, 1998, CANCER EPIDEM BIOMAR, V7, P385; Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S; MARTIN GM, 1997, PRINCIPLES PRACTICE, P439; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; McCullough ML, 2000, AM J CLIN NUTR, V72, P1214; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P959, DOI 10.1023/B:CACO.0000007983.16045.a1; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P1, DOI 10.1023/A:1022591007673; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; Michaud DS, 2002, J NATL CANCER I, V94, P1293, DOI 10.1093/jnci/94.17.1293; Michels KB, 2002, INT J EPIDEMIOL, V31, P847, DOI 10.1093/ije/31.4.847; MILLER DK, 1994, J FOOD SCI, V59, P747, DOI 10.1111/j.1365-2621.1994.tb08118.x; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mirvish SS, 2002, J NUTR, V132, p3526S, DOI 10.1093/jn/132.11.3526S; Missmer SA, 2002, INT J EPIDEMIOL, V31, P78, DOI 10.1093/ije/31.1.78; Negri E, 1996, INT J CANCER, V65, P140, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;140::AID-IJC3&gt;3.0.CO;2-Z; Nelson M, 1997, DESIGN CONCEPTS NUTR; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; Nomura AMY, 2000, CANCER EPIDEM BIOMAR, V9, P883; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; OLSON JA, 1999, MODERN NUTR HLTH DIS; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Outwater JL, 1997, MED HYPOTHESES, V48, P453, DOI 10.1016/S0306-9877(97)90110-9; PALMER S, 1983, CANCER RES, V43, P2509; Parodi PW, 1997, J NUTR, V127, P1055, DOI 10.1093/jn/127.6.1055; Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848; Peters U, 2001, CANCER EPIDEM BIOMAR, V10, P1267; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; PLATZ EA, 1999, NUTR ONCOLOGY, P223; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Potischman N, 1999, INT J CANCER, V82, P315, DOI 10.1002/(SICI)1097-0215(19990730)82:3&lt;315::AID-IJC1&gt;3.0.CO;2-N; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; PRASAD MPR, 1992, NUTR CANCER, V18, P85, DOI 10.1080/01635589209514208; Prior RL, 1999, FREE RADICAL BIO MED, V27, P1173, DOI 10.1016/S0891-5849(99)00203-8; Rodriguez C, 2003, CANCER EPIDEM BIOMAR, V12, P597; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rossouw J E, 1995, J Am Med Womens Assoc (1972), V50, P50; Ruggiero M, 1998, ONCOL RES, V10, P43; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012; Semenza JC, 2003, BREAST CANCER RES TR, V77, P217, DOI 10.1023/A:1021843019755; Serafini M, 2002, GASTROENTEROLOGY, V123, P985, DOI 10.1053/gast.2002.35957; Seymour JD, 2003, AM J EPIDEMIOL, V157, P980, DOI 10.1093/aje/kwg077; Sharp L, 2002, CANCER LETT, V181, P65, DOI 10.1016/S0304-3835(02)00030-7; Shin MH, 2002, JNCI-J NATL CANCER I, V94, P1301, DOI 10.1093/jnci/94.17.1301; Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2; Slattery ML, 1997, CANCER EPIDEM BIOMAR, V6, P677; Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a; Slattery ML, 2001, CANCER CAUSE CONTROL, V12, P359, DOI 10.1023/A:1011280518278; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Tangrea J, 1997, CANCER CAUSE CONTROL, V8, P615, DOI 10.1023/A:1018450531136; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; Terry P, 2002, CANCER EPIDEM BIOMAR, V11, P1507; Terry P, 2001, CANCER EPIDEM BIOMAR, V10, P1281; Terry P, 2001, AM J EPIDEMIOL, V154, P1143, DOI 10.1093/aje/154.12.1143; Terry P, 2001, J INTERN MED, V250, P280, DOI 10.1046/j.1365-2796.2001.00886.x; Terry PD, 2003, AM J CLIN NUTR, V77, P532, DOI 10.1093/ajcn/77.3.532; Terry PD, 2003, JNCI-J NATL CANCER I, V95, P914, DOI 10.1093/jnci/95.12.914; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; Tiemersma EW, 2002, CANCER CAUSE CONTROL, V13, P383, DOI 10.1023/A:1015236701054; Toniolo P, 2001, AM J EPIDEMIOL, V153, P1142, DOI 10.1093/aje/153.12.1142; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Vineis P, 2001, Public Health Nutr, V4, P485; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1998, NUTR EPIDEMIOL; WILLETT WC, 1999, MODERN NUTR HLTH DIS, P1243; WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167; Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Wu K, 2002, JNCI-J NATL CANCER I, V94, P437, DOI 10.1093/jnci/94.6.437; Yamagata Z, 1997, AM J HUM GENET, V61, pA388; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang SM, 2003, J NATL CANCER I, V95, P373, DOI 10.1093/jnci/95.5.373; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632; Zhang YQ, 2002, AM J MED, V113, P734, DOI 10.1016/S0002-9343(02)01382-7; Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233; Zmuda JM, 2001, J NATL CANCER I, V93, P930, DOI 10.1093/jnci/93.12.930; Zmuda JM, 2000, EPIDEMIOL REV, V22, P203, DOI 10.1093/oxfordjournals.epirev.a018033	222	119	122	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6349	6364		10.1038/sj.onc.1207716	http://dx.doi.org/10.1038/sj.onc.1207716			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322510				2022-12-28	WOS:000223468800004
J	Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K				Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K			Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB	ONCOGENE			English	Article						sodium butyrate; histone deacetyalse inhibitor; chromatin remodeling; microarray; expression profiling; cytokine signaling; metastasis	HISTONE DEACETYLASE INHIBITOR; KAPPA-B ACTIVATION; CHAIN FATTY-ACIDS; INTERFERON-GAMMA; PROSTATE-CANCER; IFN-GAMMA; IN-VITRO; GROWTH-INHIBITION; EPITHELIAL-CELLS; CROHNS-DISEASE	Histone deacetylase (HDAC) inhibitors induce growth arrest and apoptosis in a variety of human cancer cells. Sodium butyrate (NaB), a short chain fatty acid, is a HDAC inhibitor and is produced in the colonic lumen as a consequence of microbial degradation of dietary fibers. In order to dissect out the mechanism of NaB-induced growth inhibition of cancer cells, we carried out expression pro. ling of a human lung carcinoma cell line (H460) treated with NaB using a cDNA microarray. Of the total 1728 genes analysed, there were 32 genes with a mean expression value of 2.0-fold and higher and 66 genes with a mean expression value 3.0-fold and lower in NaB-treated cells. For a few selected genes, we demonstrate that their expression pattern by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis is matching with the results obtained by microarray analysis. Closer view at the expression pro. le of NaB-treated cells revealed the downregulation of a total of 16 genes associated with cytokine signaling, in particular, interferon gamma (IFNgamma) pathway. In good correlation, NaB-pretreated cells failed to induce interferon regulatory factor 1, an INFgamma target gene, efficiently upon IFNgamma addition. These results suggest that NaB inhibits proinflammatory cytokine signaling pathway, thus providing proof of mechanism for its anti-inflammatory activity. We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis. Upregulation of metastatic suppressor Kangai 1 (KAI1) by NaB in a time-dependent manner was confirmed by RT-PCR analysis. The differential regulation of metastasis-associated genes by NaB provides explanation for the anti-invasive properties of NaB. Therefore, our study presents new evidence for pathways regulated by NaB, thus providing evidence for the mechanism behind anti-inflammatory and antimetastatic activities of NaB.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in						Ailenberg M, 2002, BIOCHEM BIOPH RES CO, V298, P110, DOI 10.1016/S0006-291X(02)02420-8; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; BREESE E, 1993, IMMUNOLOGY, V78, P127; BUGAUT M, 1993, ANNU REV NUTR, V13, P217, DOI 10.1146/annurev.nu.13.070193.001245; Butler LM, 2000, CANCER RES, V60, P5165; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clarke KO, 2001, CANCER LETT, V171, P57, DOI 10.1016/S0304-3835(01)00574-2; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DeRisi J, 1996, NAT GENET, V14, P457; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FAIS S, 1991, GUT, V32, P403, DOI 10.1136/gut.32.4.403; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KAWAMATA H, 1995, INT J CANCER, V63, P680, DOI 10.1002/ijc.2910630513; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Klampfer L, 2003, MOL CANCER RES, V1, P855; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; Lehninger A., 1993, PRINCIPLES BIOCH; Liu LT, 2003, CANCER RES, V63, P3069; Luhrs H, 2002, SCAND J GASTROENTERO, V37, P458, DOI 10.1080/003655202317316105; Luhrs H, 2002, ANTICANCER RES, V22, P1561; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; McIntosh GH, 1996, J GASTROEN HEPATOL, V11, P113, DOI 10.1111/j.1440-1746.1996.tb00046.x; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Medina V, 1997, CANCER RES, V57, P3697; Miele ME, 1997, CLIN EXP METASTAS, V15, P259, DOI 10.1023/A:1018473415458; MORITA A, 1982, CANCER RES, V42, P4540; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Phillips KK, 1998, MOL CARCINOGEN, V21, P111, DOI 10.1002/(SICI)1098-2744(199802)21:2<111::AID-MC5>3.0.CO;2-Q; Ranganna K, 2000, MOL CELL BIOCHEM, V205, P149, DOI 10.1023/A:1007078200482; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saemann MD, 2000, FASEB J, V14, P2380; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Tabuchi Y, 2000, CELL STRUCT FUNCT, V25, P297, DOI 10.1247/csf.25.297; TSAO D, 1982, CANCER RES, V42, P1052; Urnov FD, 2003, J CELL BIOCHEM, V88, P684, DOI 10.1002/jcb.10397; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang JX, 1999, CANCER RES, V59, P2766; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Whiteley LO, 1996, DIGEST DIS SCI, V41, P1458, DOI 10.1007/BF02088573; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200	71	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6304	6315		10.1038/sj.onc.1207852	http://dx.doi.org/10.1038/sj.onc.1207852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15318170	Green Accepted			2022-12-28	WOS:000223399000015
J	Jang, JH				Jang, JH			Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis	ONCOGENE			English	Article						FGFR1; silencing; tumorigenesis; colon cancer; FGFR3	FIBROBLAST-GROWTH-FACTOR; FACTOR-RECEPTOR; MULTIPLE-MYELOMA; HEPARAN-SULFATE; HUMAN BREAST; COMMON	We have previously demonstrated that the expression of FGFR3 is frequently downregulated in colorectal carcinoma cells. Here we have shown that FGFR1 is over-expressed in colorectal carcinoma cells and the gene expressions between FGFR1 and FGFR3 are mutually exclusive. Moreover, we have also shown that the disruption of FGFR1 expression by introducing of FGFR1 siRNA was effective in elevating FGFR3 expression and tumor suppressive activities. Thus, FGFR1 may confer a selectable advantage on clones of cells in colorectal tumorigenesis, favoring proliferation, whereas FGFR3 may have the effect of an unfavorable negative regulation of progression of the carcinomas to malignancy, promoting differentiation. Our results indicate that the reciprocal relationship in gene expression between FGFR1 and FGFR3 in colorectal tissue plays an important role in the progression of the carcinomas to malignancy.	Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Inha University	Jang, JH (corresponding author), Inha Univ, Coll Med, Dept Biochem, 7-241 Shinheung Dong 3 Ga, Inchon 400712, South Korea.	juhjang@seoul.com						BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Feng SJ, 1997, CANCER RES, V57, P5369; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; Jang JH, 2000, CANCER RES, V60, P4049; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanai M, 1997, AM J PHYSIOL-GASTR L, V272, pG885, DOI 10.1152/ajpgi.1997.272.4.G885; Kornmann M, 2002, GASTROENTEROLOGY, V123, P301, DOI 10.1053/gast.2002.34174; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Oh LYS, 2003, J NEUROSCI, V23, P883; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	28	21	23	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					945	948		10.1038/sj.onc.1208254	http://dx.doi.org/10.1038/sj.onc.1208254			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558020				2022-12-28	WOS:000226577100020
J	Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR				Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR			Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells	ONCOGENE			English	Article						superoxide dismutase; prostate cancer; reactive oxygen species; cell cycle; overexpression; hydrogen peroxide	NORMAL HUMAN FIBROBLASTS; NF-KAPPA-B; ANTIOXIDANT ENZYMES; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; MALIGNANT PHENOTYPE; OXIDATIVE STRESS; FREE-RADICALS; GENE-TRANSFER; H2O2 RELEASE	This study investigates the role of the antioxidant enzyme manganese superoxide dismutase (MnSOD) in androgen-independent human prostate cancer (PC-3) cells' growth rate in vitro and in vivo. MnSOD levels were found to be lower in parental PC-3 cells compared to nonmalignant, immortalized human prostate epithelial cells (P69SV40T). To unravel the role of MnSOD in the prostate cancer phenotype, PC-3 cells were stably transfected with MnSOD cDNA plasmid. The MnSOD protein and activity levels in clones overexpressing MnSOD were increased seven- to eightfold. These cell lines showed elongated cell doubling time, reduced anchorage-independent growth in soft agar compared to parental PC-3 (Wt) cells, and reduced growth rate of PC-3 tumor xenografts in athymic nude mice. Flow cytometric studies showed an increase in membrane potential in the MnSOD-overexpressing clone (Mn32) compared to Wt and Neo cells. Also, production of extracellular H2O2 was increased in the MnSOD-overexpressing clones. As determined by DNA cell cycle analysis, the proportion of cells in G(1) phase was enhanced by MnSOD overexpression. Therefore, MnSOD not only regulates cell survival but also affects PC-3 cell proliferation by retarding G(1) to S transition. Our results are consistent with MnSOD being a tumor suppressor gene in human prostate cancer.	Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Buettner, GR (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, EMRB 68, Iowa City, IA 52242 USA.	garry-buettner@uiowa.edu		Buettner, Garry/0000-0002-5594-1903; Goswami, Prabhat/0000-0002-5700-2096	NCI NIH HHS [CA 66081, CA 81090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066081, R01CA081090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEERS RF, 1952, J BIOL CHEM, V195, P133; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chin CWS, 2003, J PATHOL, V200, P308, DOI 10.1002/path.1363; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; da Silva MM, 2003, AM J PHYSIOL-HEART C, V285, pH154, DOI 10.1152/ajpheart.00955.2002; Foster CS, 1999, BJU INT, V83, P171; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Jung K, 1997, FREE RADICAL BIO MED, V23, P127, DOI 10.1016/S0891-5849(96)00613-2; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 2000, J DENT RES, V79, P1410, DOI 10.1177/00220345000790061001; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liochev SI, 1997, FREE RADICAL BIO MED, V23, P668, DOI 10.1016/S0891-5849(97)00060-9; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Menon SG, 2003, CANCER RES, V63, P2109; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1985, CRC HDB METHODS OXYG, P217; OBERLEY LW, 1986, MODERN AGING RES, V8, P352; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Palazzotti B, 1999, INT J CANCER, V82, P145, DOI 10.1002/(SICI)1097-0215(19990702)82:1<145::AID-IJC24>3.3.CO;2-2; Palmeira CM, 1996, J PHARMACOL TOX MET, V35, P35, DOI 10.1016/1056-8719(95)00131-X; PANUS PC, 1993, FREE RADICAL BIO MED, V14, P217, DOI 10.1016/0891-5849(93)90013-K; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SAS Institute, 2001, SAS SYST WIND VERS 8; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Wang D, 1997, Chin Med Sci J, V12, P76; Weydert C, 2003, MOL CANCER THER, V2, P361; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhang Y, 2002, CANCER RES, V62, P1205; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	56	127	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					77	89		10.1038/sj.onc.1208145	http://dx.doi.org/10.1038/sj.onc.1208145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15543233				2022-12-28	WOS:000226125800010
J	Li, J; Sahagian, GG				Li, J; Sahagian, GG			Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor	ONCOGENE			English	Article						breast cancer; apoptosis; lysosomal trafficking; TGF-beta; uPAR; retinoic acid	GROWTH-FACTOR-II; SQUAMOUS-CELL CARCINOMA; LYSINE-BASED STRUCTURE; MOUSE MAMMARY-TUMOR; BREAST-CANCER CELLS; TGF-BETA-RII; 6-PHOSPHATE RECEPTOR; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROSATELLITE INSTABILITY	The mannose 6-phosphate/IGF-2 receptor has been proposed to be a tumor suppressor gene on the basis of loss of heterozygosity and mutations in tumors from cancer patients. To test this hypothesis, the receptor was expressed in 66cl4, a mouse mammary tumor cell line deficient in the receptor. Expression of the receptor corrected the abnormal lysosomal trafficking phenotype displayed by these cells. Receptor expression had no apparent effect on growth or invasiveness of the cells in vitro but effectively inhibited formation of mammary tumors in BALB/c mice. Analysis of cell proliferation and apoptosis in tumors indicated that the primary effect of the receptor was to inhibit cell proliferation. Proliferation indices for receptor-deficient and receptor-expressing tumors, as determined by BrdU incorporation, were 24.6 and 7.6%, respectively. No significant effect of receptor expression on apoptosis was observed. Receptor expression similarly inhibited tumor growth in BALB/c scid mice indicating that cytotoxic T cells and other components of the immune system missing in scid mice are not involved in the receptor's tumor suppressing effect. These findings establish a role for the receptor as a bona. de tumor suppressor gene and together with previous studies, suggest an important role for the receptor in human and rodent cancers.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	gary.sahagian@tufts.edu			NCI NIH HHS [R01-CA66575] Funding Source: Medline; NIDDK NIH HHS [P30DK34928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; Caligo MA, 2000, ONCOL REP, V7, P1371; Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.3.CO;2-A; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cuozzo JW, 1998, J BIOL CHEM, V273, P21067, DOI 10.1074/jbc.273.33.21067; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DOLE M, 1994, CANCER RES, V54, P3253; FILSON AJ, 1993, DEVELOPMENT, V118, P731; Gamma A, 2000, LUNG CANCER-J IASLC, V30, P91, DOI 10.1016/S0169-5002(00)00130-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghahary A, 1999, J CELL PHYSIOL, V180, P61, DOI 10.1002/(SICI)1097-4652(199907)180:1<61::AID-JCP7>3.0.CO;2-R; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hale AJ, 1996, EUR J BIOCHEM, V237, P884; Hankins GR, 1996, ONCOGENE, V12, P2003; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; KIESS W, 1988, J BIOL CHEM, V263, P9339; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Leboulleux S, 2001, EUR J ENDOCRINOL, V144, P163, DOI 10.1530/eje.0.1440163; Lee JS, 2003, INT J CANCER, V107, P564, DOI 10.1002/ijc.11453; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P7523; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; McKinnon T, 2001, J CLIN ENDOCR METAB, V86, P3665, DOI 10.1210/jc.86.8.3665; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; O'Gorman DB, 2002, ENDOCRINOLOGY, V143, P4287, DOI 10.1210/en.2002-220548; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; SAHAGIAN GG, 1981, P NATL ACAD SCI-BIOL, V78, P4289, DOI 10.1073/pnas.78.7.4289; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Tao K, 2001, INT J ONCOL, V19, P1333; TONG PY, 1988, J BIOL CHEM, V263, P2585; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Zavras AI, 2003, CANCER RES, V63, P296	47	28	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9359	9368		10.1038/sj.onc.1208039	http://dx.doi.org/10.1038/sj.onc.1208039			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543235				2022-12-28	WOS:000225764100007
J	Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H				Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H			Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models	ONCOGENE			English	Article						Aurora-A; mitosis; mammary gland; p53; Cre-loxP	SPINDLE ASSEMBLY CHECKPOINT; CENTROSOME AMPLIFICATION; TETRAPLOIDY CHECKPOINT; CHROMOSOME SEGREGATION; PROTEIN-KINASE; BREAST-CANCER; APOPTOSIS; CELLS; GENE; P53	Aurora-A, a serine/threonine mitotic kinase, was reported to be overexpressed in various human cancers, and its overexpression induces aneuploidy, centrosome amplification and tumorigenic transformation in cultured human and rodent cells. However, the underlying mechanisms and pathological settings by which Aurora-A promotes tumorigenesis are largely unknown. Here, we created a transgenic mouse model to investigate the involvement of Aurora-A overexpression in the development of mammary glands and tumorigenesis using a Cre-loxP system. The conditional expression of Aurora-A resulted in significantly increased binucleated cell formation and apoptosis in the mammary epithelium. The surviving mammary epithelial cells composed hyperplastic areas after a short latency. Induction of Aurora-A overexpression in mouse embryonic fibroblasts prepared from the transgenic mice also led to aberrant mitosis and binucleated cell formation followed by apoptosis. The levels of p53 protein were remarkably increased in these Aurora-A-overexpressing cells, and the apoptosis was significantly suppressed by deletion of p53. Given that no malignant tumor formation was found in the Aurora-A-overexpressing mouse model after a long latency, additional factors, such as p53 inactivation, are required for the tumorigenesis of Aurora-A-overexpressing mammary epithelium. Our findings indicated that this mouse model is a useful system to study the physiological roles of Aurora-A and the genetic pathways of Aurora-A-induced carcinogenesis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Saitama Med Sch, Dept Pathol, Omiya, Japan; Kumamoto Univ, Inst Resource Dev & Anal, Ctr Anim Resources & Dev, Div Transgen Technol, Kumamoto, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Saitama Medical University; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Arima, Yoshimi/J-8057-2013	Arima, Yoshimi/0000-0002-2384-1406; Sasayama, Takashi/0000-0002-5593-9045				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; FRANCISCO L, 1994, CELL MOL BIOL RES, V40, P207; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hogan B, 1994, MANIPULATING MOUSE E; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li DH, 2003, CLIN CANCER RES, V9, P991; Lund LR, 1996, DEVELOPMENT, V122, P181; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tanaka T, 1999, CANCER RES, V59, P2041; TSUKADA T, 1993, ONCOGENE, V8, P3313; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	123	126	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8720	8730		10.1038/sj.onc.1208153	http://dx.doi.org/10.1038/sj.onc.1208153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480417				2022-12-28	WOS:000225165100002
J	Poole, AJ; Heap, D; Carroll, RE; Tyner, AL				Poole, AJ; Heap, D; Carroll, RE; Tyner, AL			Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon	ONCOGENE			English	Article						p21; Waf1; azoxymethane; aberrant crypt foci; colon	ABERRANT CRYPT FOCI; CELL-CYCLE; COLORECTAL-CANCER; INDUCED APOPTOSIS; GENE-TRANSFER; LARGE-BOWEL; DNA-DAMAGE; P21(WAF1/CIP1); CARCINOMA; MICE	The Cdk inhibitor p21 regulates p53-mediated growth arrest following DNA damage. It is expressed during epithelial differentiation in a variety of organs including colon. We investigated susceptibility of p21-deficient mice to the colon carcinogen azoxymethane (AOM). After AOM injections, rodents develop putative premalignant lesions called aberrant crypt foci (ACF) that are localized to the distal three centimeters of the colon. p21-deficient mice developed significantly higher numbers of ACF than wild-type mice in response to AOM, and these were not restricted to distal colon. After AOM treatment, increased numbers of lymphoid aggregates were detected in p21-deficient colon. Proliferation was similar in wild type and p21-deficient colon before and after AOM injection, but AOM-induced apoptosis was detected only in wild-type crypt epithelial cells, and not in the p21-deficient colon. The proapoptotic function uncovered for p21 was unexpected, because p21 acts as an inhibitor of apoptosis in many systems, and is not required for p53-dependent apoptosis. Enhanced formation of ACF in p21-deficient mice supports a tumor suppressor function for p21 in the colon. Reduced apoptosis of colon epithelial cells with deleterious mutations may be an initiating event in the formation of ACF, with inflammatory cell cytokine expression contributing to their further expansion.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NCI NIH HHS [CA-80360] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283, R01 DK056283-05, DK07788, DK56283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA080360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BIRD RP, 1989, CANCER SURV, V8, P189; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARTER JW, 1994, CANCER RES, V54, P4304; Cheng JD, 1999, CLIN CANCER RES, V5, P1057; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FEINBERG A, 1980, CANCER RES, V40, P4446; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; Jackson RJ, 2003, CANCER RES, V63, P3021; Kadowaki Y, 1999, CLIN CANCER RES, V5, P4233; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; Kwon YH, 2003, J BIOL CHEM, V278, P30348, DOI 10.1074/jbc.M300996200; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Lincet H, 2000, CANCER LETT, V161, P17, DOI 10.1016/S0304-3835(00)00586-3; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Paulsen JE, 2001, CANCER RES, V61, P5010; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wataru AA, 2003, TOXICOL LETT, V144, P213, DOI 10.1016/S0378-4274(03)00221-2; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200	39	71	74	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8128	8134		10.1038/sj.onc.1207994	http://dx.doi.org/10.1038/sj.onc.1207994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377995				2022-12-28	WOS:000224692500010
J	Wu, JH; Lingrel, JB				Wu, JH; Lingrel, JB			KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21(WAF1/CIP1)	ONCOGENE			English	Article						Kruppel-like factor; KLF2; Jurkat leukemia cells; cell proliferation; p21(WAF1/CIP1)	KRUPPEL-LIKE FACTOR; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; GENE PROMOTER; SP1 SITES; IN-VIVO; CANCER; LKLF; P53; SUPPRESSION	Kruppel-like factor 2 (KLF2) is a member of the KLF family of zinc-finger transcription factors and is involved in maintaining T-cell quiescence, regulating preadipocyte differentiation, endothelial cell function and lung development. We used a tetracycline-inducible system in Jurkat T leukemia cells to study the biological role of KLF2 in cellular growth and differentiation. Our results show that expression of KLF2 inhibits cell growth in autonomously proliferating Jurkat cells. Further, 3H-thymidine uptake assays indicate that KLF2 inhibits DNA synthesis in these cells. Moreover, both activation and inhibitory domains are required for KLF2 to suppress Jurkat cell proliferation. In addition, KLF2 upregulates p21(WAF1/CIP1) expression. Additionally, we found that KLF2 upregulates p21(WAF1/CIP1) promoter activity in Jurkat, HepG2 and SW480 cells. Our analysis shows that the potential KLF2 responsive elements are located between -124 and -60 of the p21(WAF1/CIP1) promoter. The sole CACCC site, a sequence recognized by KLF2, in this region is not the element responsive to KLF2. Finally, we determined that the Sp1-3-binding site is the functional responsive element of KLF2 in the p21(WAF1/CIP1) promoter, and we conclude that KLF2 directly regulates p21(WAF1/CIP1) expression.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 57281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V278, P788; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Omotehara F, 2002, BRIT J CANCER, V87, P1042, DOI 10.1038/sj.bjc.6600592; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	39	102	104	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8088	8096		10.1038/sj.onc.1207996	http://dx.doi.org/10.1038/sj.onc.1207996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361832				2022-12-28	WOS:000224692500006
J	Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP				Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP			RAR beta 2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia	ONCOGENE			English	Article						myelofibrosis; CD34+; RAR beta	ACID RECEPTOR-BETA; RETINOIC ACID; LUNG-CANCER; BREAST-CANCER; EPIGENETIC INACTIVATION; BRONCHIAL EPITHELIUM; COLORECTAL-CARCINOMA; PROMOTER METHYLATION; TRANSCRIPTION FACTOR; HOMOZYGOUS DELETION	Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem-cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular mechanisms underlying the development of this myeloproliferative syndrome are currently unknown. In order to identify tumor suppressor genes that may be involved in the disease process, we performed an analysis for loss of heterozygosity (LOH) in CD34 + cells from 29 patients with MMM. We observed a frequency of allelic loss on chromosomal arm 3p in 24% of cases. Detailed mapping of 3p revealed a distinct region of deletion at 3p24. Among the genes known to map within this region is the retinoic acid receptor-beta (RARbeta2) gene. To determine whether RARbeta2 gene activity is diminished in this disease, we analysed its expression in CD34 + cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARbeta2 is significantly decreased in 100% of patient samples compared to that in CD34+ cells from 10 normal individuals. Since allelic loss at 3p24 occurs in <25% of patients, we investigated the contribution of epigenetic modifications to RAR&beta;2 inactivity. Using methylation-specific PCR, we found hypermethylation of RAR&beta;2 in 16 of 18 patients (89%), while the methylated form of the gene was absent in CD34 + cells from nine normal individuals. Our results suggest that RAR&beta;2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RAR&beta;2 gene activity in these patients.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA; Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Jones, LC (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.	letetiajones@yahoo.com			NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA-75956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Batova A, 1997, CANCER RES, V57, P832; Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153; Breems-de Ridder MC, 2000, MOL CELL ENDOCRINOL, V165, P1, DOI 10.1016/S0303-7207(00)00255-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kuroki T, 2003, CANCER RES, V63, P3724; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lin F, 2000, CANCER RES, V60, P3271; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MARTYRE MC, 1994, BRIT J HAEMATOL, V88, P9, DOI 10.1111/j.1365-2141.1994.tb04970.x; Mesa RA, 2000, BLOOD, V96, P3374; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Prowse AH, 1997, AM J HUM GENET, V60, P765; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shimizu T, 2000, CANCER RES, V60, P4544; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2001, BRIT J HAEMATOL, V113, P763, DOI 10.1046/j.1365-2141.2001.02796.x; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 1997, CANCER RES, V57, P4158; Wistuba II, 2000, CANCER RES, V60, P1949; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xie D, 2000, LEUKEMIA, V14, P805, DOI 10.1038/sj.leu.2401717; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	54	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7846	7853		10.1038/sj.onc.1207510	http://dx.doi.org/10.1038/sj.onc.1207510			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361842				2022-12-28	WOS:000224331600010
J	Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T				Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T			Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner	ONCOGENE			English	Article						beta-catenin; Siah-1; Siah-1L; p53; hepatocellular carcinoma	HUMAN HEPATOCELLULAR CARCINOMAS; CANCER-CELLS; P53; MUTATIONS; IDENTIFICATION; SUPPRESSION; APOPTOSIS; HOMOLOGS; PATHWAY; GENE	beta-Catenin is a potent oncogenic protein whose cytoplasmic accumulation is a frequent event in cancer cells. The level of beta-catenin is regulated by two mechanisms: the adenomatous polyposis coli/Axin/glycogen synthase kinase 3beta-dependent degradation pathway and the Siah-1/ Siah interacting protein/Ebi-mediated degradation pathway. In this study, we have investigated the functional significance of p53-inducible human Siah-family protein expression in the regulation of beta-catenin activity. We show here by reverse-transcriptase polymerase chain reaction that two mRNA transcripts, designated human Siah-1 and Siah-1L, are generated from the human Siah-1 locus. Interestingly, the expression of Siah-1L was upregulated by p53, whereas human Siah-1 expression was constant. Furthermore, introduction of exogenous Siah-1L protein downregulated beta-catenin protein and promoted apoptosis induced by anticancer drugs in cancer cells that lack endogenous p53. Thus, Siah-1L represents a new member of the human Siah family that is induced in response to p53 and plays an important role in the regulation of beta-catenin activity in tumor cells. These findings also suggest new strategies for restoring tumor suppressive pathways lost in cancer cells that have suffered p53 inactivation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Med, Div Gastroenterol & Hepatol, Kyoto, Japan; Burnham Inst, La Jolla, CA 92037 USA	Kyoto University; Kyoto University; Sanford Burnham Prebys Medical Discovery Institute	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		Marusawa, Hiroyuki/0000-0002-4286-2712				Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maeda A, 2002, FEBS LETT, V512, P223, DOI 10.1016/S0014-5793(02)02265-2; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Park WS, 2001, J PATHOL, V193, P483; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	28	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7593	7600		10.1038/sj.onc.1208016	http://dx.doi.org/10.1038/sj.onc.1208016			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326481	Green Submitted			2022-12-28	WOS:000224176500017
J	Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK				Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK			Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro	ONCOGENE			English	Article						FLIP; caspases; chemoresistance; cisplatin; ovarian cancer	X-LINKED INHIBITOR; APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; DOWN-REGULATION; CELLULAR FLIP; UP-REGULATION; C-FLIP; CISPLATIN; EXPRESSION; RESISTANCE	Chemoresistance is a major therapeutic problem and the current knowledge on cellular mechanisms involved is incomplete. In the present study, we have investigated the possible involvement of Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein ( FLIP) in ovarian cancer resistance by comparing chemosensitive (OV2008) and chemoresistant (C13*) ovarian cancer cells treated with cisplatin in vitro, and/ or transfected with FLIP sense cDNA or FLIP small interfering RNA ( siRNA) and determining FLIP protein content, cleavage of caspase-8 and caspase-3 and apoptosis. Cisplatin significantly decreased FLIP protein level, induced cleavage of caspase-8 and caspase-3 and apoptosis in a concentration-dependent manner in cisplatin-sensitive but not - resistant cells. While overexpression of FLIP-attenuated cisplatin-induced cleavage of caspase-8 and caspase-3 and apoptosis in chemosensitive cells, downregulation of FLIP in chemoresistant cells by siRNA increased apoptosis induced by cisplatin. These results suggest that FLIP plays a significant role in the regulation of apoptosis in human ovarian cancer cells and their sensitivity to cisplatin. This cell survival factor may be an important determinant in chemoresistance in ovarian cancer and may serve as a molecular target for the development of novel therapy for chemoresistant ovarian cancer.	Univ Ottawa, Dept Obstet, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Gynaecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular Med, Ottawa, ON, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Tsang, BK (corresponding author), 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Arts HJG, 2000, INT J GYNECOL CANCER, V10, P47, DOI 10.1046/j.1525-1438.2000.99511.x; Asselin E, 2001, CANCER RES, V61, P1862; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fraser M, 2003, CANCER RES, V63, P7081; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Hu LM, 2002, CANCER RES, V62, P1087; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kim JH, 2003, CLIN CANCER RES, V9, P3134; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Sasaki H, 2000, CANCER RES, V60, P5659; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Song JH, 2003, CLIN CANCER RES, V9, P4255; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant Harald, 2003, Mol Interv, V3, P124, DOI 10.1124/mi.3.3.124; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yoshikawa H, 2000, J IMMUNOL, V165, P6262, DOI 10.4049/jimmunol.165.11.6262; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	31	103	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					6997	7004		10.1038/sj.onc.1207925	http://dx.doi.org/10.1038/sj.onc.1207925			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258564				2022-12-28	WOS:000223885100001
J	Bocchetta, M; Carbone, M				Bocchetta, M; Carbone, M			Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation	ONCOGENE			English	Article						tumor suppressor genes; senoscence; cell cycle checkpoints; cell immortalization; inflammation	TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; TELOMERE DYSFUNCTION; DROSOPHILA NOTCH; MYELOID-LEUKEMIA; MICE DEFICIENT; HUMAN HOMOLOG; HUMAN CANCER; CELL-GROWTH; IN-VIVO	Epidemiology is a very reliable science for the identification of carcinogens. Epidemiological studies require that the effect, cancer in this case, has already occurred, when of course it would be more desirable to identify potential carcinogenic substances at an earlier stage before they have caused a large number of malignancies and thus become identifiable by epidemiological studies. In the past 30 years, molecular pathology (which includes chemistry, biochemistry, molecular biology, molecular virology, molecular genetics, epigenetics, genomics, proteomics, and other molecular-based approaches) has identified some key alterations that are required for cellular transformation and malignancy. Agents that specifically interfere with some of these mechanisms are suspected human carcinogens. It can be stated that tumor formation requires the following steps: (1) inactivation of Rb and p53 cellular pathways; (2) activation of Ras and/or other growth promoting pathways; (3) inactivation of phosphatase 2A that causes changes in the phosphorylation and activity of several cellular proteins; (4) evasion of apoptosis; (5) telomerase activation or alternative mechanisms of cellular immortalization; (6) angiogenic activity; and (7) the ability to invade surrounding tissues and to metastasize. Here, we review the molecular mechanisms of cellular transformation. The integration of this knowledge with classical epidemiology and animal studies should permit a more rapid and accurate identification of human carcinogens.	Loyola Univ, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Loyola University Chicago	Bocchetta, M (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, 2160 South 1st Ave, Maywood, IL 60153 USA.	mbocche@lumc.edu			NCI NIH HHS [R01CA92657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CARBONE M, IN PRESS CANC RES; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dammann R, 2001, CANCER RES, V61, P3105; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; Diefenbach A, 2003, CURR OPIN IMMUNOL, V15, P37, DOI 10.1016/S0952-7915(02)00007-9; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; Goytisolo FA, 2002, ONCOGENE, V21, P584, DOI 10.1038/sj.onc.1205085; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karre K, 2002, SCAND J IMMUNOL, V55, P221, DOI 10.1046/j.1365-3083.2002.01053.x; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LEE JH, 1991, ONCOGENE, V6, P665; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McLaughlin ME, 2002, CANCER CELL, V1, P408, DOI 10.1016/S1535-6108(02)00078-8; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Myohanen SK, 1998, CANCER RES, V58, P591; Naito Y, 1998, CANCER RES, V58, P3491; Nauts H, 1953, ACTA MED SCAND, V144, pS1; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Parkin D, 1999, INFECT HUMAN CANC; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; SCHREIBER H, IN PRESS SEMIN CANC; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smyth MJ, 2000, J IMMUNOL, V165, P2665, DOI 10.4049/jimmunol.165.5.2665; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.3.CO;2-D; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WOGAN GN, IN PRESS SEM CANC BI	74	17	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6484	6491		10.1038/sj.onc.1207855	http://dx.doi.org/10.1038/sj.onc.1207855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322519				2022-12-28	WOS:000223468800013
J	Nagy, R; Sweet, K; Eng, C				Nagy, R; Sweet, K; Eng, C			Highly penetrant hereditary cancer syndromes	ONCOGENE			English	Review						inherited cancer susceptibility; familial cancer syndromes; breast cancer; colon cancer; endocrine neoplasia	NONPOLYPOSIS COLORECTAL-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; ENDOCRINE NEOPLASIA TYPE-1; GERM-LINE MUTATIONS; MEDULLARY-THYROID CARCINOMA; VONHIPPEL-LINDAU DISEASE; PEUTZ-JEGHERS-SYNDROME; GENOTYPE-PHENOTYPE CORRELATIONS; CELL-CYCLE ARREST	The past two decades have brought many important advances in our understanding of the hereditary susceptibility to cancer. Approximately 5-10% of all cancers are inherited, the majority in an autosomal dominant manner with incomplete penetrance. While this is a small fraction of the overall cancer burden worldwide, the molecular genetic discoveries that have resulted from the study of families with heritable cancer have not only changed the way these families are counselled and managed, but have shed light on molecular regulatory pathways important in sporadic tumour development as well. In this review, we consider 10 of the more highly penetrant cancer syndromes, with emphasis on those predisposing to breast, colon, and/or endocrine neoplasia. We discuss the prevalence, penetrance, and tumour spectrum associated with these syndromes, as well as their underlying genetic defects.	Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43221 USA; Ohio State Univ, Human Genet Program, Ctr Comprehens Canc, Div Human Genet,Dept Internal Med, Columbus, OH 43221 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Nagy, R (corresponding author), Ohio State Univ, Clin Canc Genet Program, 2050 Kenny Rd,8th Floor Tower, Columbus, OH 43221 USA.	nagy-1@medctr.osu.edu	Nagy, Rebecca Shrigley/E-4088-2011; Sweet, Kevin/E-4172-2011; Pinheiro, Maísa/E-7424-2012	Eng, Charis/0000-0002-3693-5145				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; AALTONEN LA, 2000, PATHOLOGY GENETICS T, P74; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Anderson TI, 1996, AM J HUM GENET, V59, P486; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Avizienyte E, 1998, CANCER RES, V58, P2087; BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BARDRAM L, 1985, SCAND J GASTROENTERO, V20, P233; BENSON L, 1987, AM J MED, V82, P731, DOI 10.1016/0002-9343(87)90008-8; Bertario L, 2001, INT J CANCER, V95, P102, DOI 10.1002/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO;2-8; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bevan S, 1999, GUT, V45, P406, DOI 10.1136/gut.45.3.406; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, CANCER RES, V54, P1298; Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621; Bisgaard ML, 2002, HUM MUTAT, V20, P20, DOI 10.1002/humu.10083; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BORRESEN AL, 1992, CANCER RES, V52, P3234; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Brandi ML, 2001, J CLIN ENDOCR METAB, V86, P5658, DOI 10.1210/jc.86.12.5658; BRANDI ML, 1987, ENDOCR REV, V8, P391, DOI 10.1210/edrv-8-4-391; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BULOW S, 1995, INT J COLORECTAL DIS, V10, P43, DOI 10.1007/BF00337586; Burgess JR, 1996, ARCH SURG-CHICAGO, V131, P699; BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CANTU JM, 1980, CANCER, V46, P223, DOI 10.1002/1097-0142(19800701)46:1<223::AID-CNCR2820460137>3.0.CO;2-8; Carlomagno F, 1997, CANCER RES, V57, P391; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Carty SE, 1998, SURGERY, V124, P1106, DOI 10.1067/msy.1998.93107; Cetta F, 2000, J CLIN ENDOCR METAB, V85, P286, DOI 10.1210/jc.85.1.286; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376; Chandrasekharappa SC, 2001, FRONT HORM RES, V28, P50; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chrousos GP, 1998, J INTERN MED, V243, P573; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; Corbetta S, 1997, CLIN ENDOCRINOL, V47, P507, DOI 10.1046/j.1365-2265.1997.3311122.x; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; Dackiw APB, 1999, SURGERY, V126, P1097, DOI 10.1067/msy.2099.101376; Darling TN, 1997, ARCH DERMATOL, V133, P853, DOI 10.1001/archderm.133.7.853; DECKER RA, 1995, SURGERY, V118, P257, DOI 10.1016/S0039-6060(05)80332-0; Desai DC, 1998, J MED GENET, V35, P476, DOI 10.1136/jmg.35.6.476; DESAI DC, 1995, BRIT J SURG, V82, P14, DOI 10.1002/bjs.1800820106; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EASTON DF, 1989, AM J HUM GENET, V44, P208; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eeles RA, 1995, CANCER SURV, V25, P101; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; Eng C, 2000, Rev Endocr Metab Disord, V1, P283, DOI 10.1023/A:1026514301172; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Eng C, 2001, NAT GENET, V28, P105, DOI 10.1038/88802; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; ENG C, 2001, MOL GENETICS CANC, P171; Enholm S, 2003, AM J PATHOL, V163, P827, DOI 10.1016/S0002-9440(10)63443-8; Entius MM, 2001, J CLIN PATHOL, V54, P126, DOI 10.1136/jcp.54.2.126; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Evans DGR, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.012104; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FORD D, 1995, AM J HUM GENET, V57, P1457; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foulkes WD, 2002, AM J HUM GENET, V71, P1395, DOI 10.1086/345075; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Friedl W, 1996, HUM GENET, V97, P579; Friedl W, 2002, HUM GENET, V111, P108, DOI 10.1007/s00439-002-0748-9; Friedl W, 2001, GUT, V48, P515, DOI 10.1136/gut.48.4.515; Furnari FB, 1998, CANCER RES, V58, P5002; Gao Q, 1997, AM J HUM GENET, V60, P1233; GARBER JE, 1991, CANCER RES, V51, P6094; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; Gayther SA, 1997, AM J HUM GENET, V60, P1239; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gimm O, 2001, FRONT HORM RES, V28, P103; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GORLIN RJ, 1968, CANCER, V22, P293, DOI 10.1002/1097-0142(196808)22:2<293::AID-CNCR2820220206>3.0.CO;2-R; Gorski B, 2000, AM J HUM GENET, V66, P1963, DOI 10.1086/302922; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gruber SB, 1998, CANCER RES, V58, P5267; Guillem JG, 1999, CURR PROB SURG, V36, P222; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; He LS, 1998, CANCER RES, V58, P4238; Heiskanen I, 1999, ENDOSCOPY, V31, P412; HELWIG EB, 1946, AM J DIS CHILD, V72, P289; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hisada M, 1998, JNCI-J NATL CANCER I, V90, P606, DOI 10.1093/jnci/90.8.606; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hopper JL, 1999, CANCER EPIDEM BIOMAR, V8, P741; HORRILLENO EG, 1957, CANCER, V10, P1210, DOI 10.1002/1097-0142(195711/12)10:6<1210::AID-CNCR2820100619>3.0.CO;2-2; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hutter P, 1996, J MED GENET, V33, P636, DOI 10.1136/jmg.33.8.636; Hwang SJ, 2003, AM J HUM GENET, V72, P975, DOI 10.1086/374567; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Ito S, 1997, CANCER RES, V57, P2870; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; JARVINEN HJ, 1992, GUT, V33, P357, DOI 10.1136/gut.33.3.357; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; JASS JR, 1988, HISTOPATHOLOGY, V13, P619; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johannsson O, 1996, AM J HUM GENET, V58, P441; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kadmon M, 2001, INT J COLORECTAL DIS, V16, P63, DOI 10.1007/s003840100290; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kolodner RD, 1999, CANCER RES, V59, P5068; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; Kuismanen SA, 2002, AM J PATHOL, V160, P1953, DOI 10.1016/S0002-9440(10)61144-3; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lalloo F, 2003, LANCET, V361, P1101, DOI 10.1016/S0140-6736(03)12856-5; LAMIELL JM, 1989, MEDICINE, V68, P1; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li DM, 1997, CANCER RES, V57, P2124; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1988, CANCER RES, V51, P6094; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liede A, 2000, BRIT J CANCER, V82, P705; Lipton L, 2003, CANCER RES, V63, P7595; Longy M, 1996, ANN GENET-PARIS, V39, P35; Lynch HT, 1996, GASTROENTEROLOGY, V110, P943, DOI 10.1053/gast.1996.v110.agast960943; Lynch HT, 2004, JAMA-J AM MED ASSOC, V291, P718, DOI 10.1001/jama.291.6.718; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; LYNCH HT, 1988, GASTROENTEROL CLIN N, V17, P679; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; LYNCH HT, 1971, CANCER, V27, P1505, DOI 10.1002/1097-0142(197106)27:6<1505::AID-CNCR2820270635>3.0.CO;2-L; Maddock IR, 1996, J MED GENET, V33, P120, DOI 10.1136/jmg.33.2.120; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marra G, 2003, NEW ENGL J MED, V348, P845, DOI 10.1056/NEJMe030002; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Marx SJ, 2002, GENETIC BASIS HUMAN, P475; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MCCOLL I, 1964, P ROY SOC MED, V57, P896; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; MEGERIAN CA, 1995, LARYNGOSCOPE, V105, P801, DOI 10.1288/00005537-199508000-00006; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; Miedlich S, 2001, EUR J ENDOCRINOL, V145, P155, DOI 10.1530/eje.0.1450155; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Millar AL, 1999, HUM MOL GENET, V8, P823, DOI 10.1093/hmg/8.5.823; Miyaki M, 2000, CANCER RES, V60, P6311; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Moisio AL, 2002, GUT, V50, P845, DOI 10.1136/gut.50.6.845; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Murphy GP, 1995, AM CANC SOC TXB CLIN; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakagawa H, 2002, CANCER RES, V62, P4579; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Neuhausen S, 1996, NAT GENET, V13, P126, DOI 10.1038/ng0596-126; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; Nilsson O, 1999, JAMA-J AM MED ASSOC, V281, P1587, DOI 10.1001/jama.281.17.1587; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Norton JA, 1999, NEW ENGL J MED, V341, P635, DOI 10.1056/NEJM199908263410902; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Olivier M, 2003, CANCER RES, V63, P6643; Olschwang S, 1998, J MED GENET, V35, P42, DOI 10.1136/jmg.35.1.42; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pannett AAJ, 2003, CLIN ENDOCRINOL, V58, P639, DOI 10.1046/j.1365-2265.2003.01765.x; Parc Y, 2003, J MED GENET, V40, P208, DOI 10.1136/jmg.40.3.208; Park YJ, 2000, CLIN CANCER RES, V6, P2994; PASINI B, 1995, ONCOGENE, V11, P1737; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Piao Z, 2000, CANCER RES, V60, P4701; PIPELEERSMARICHAL M, 1990, NEW ENGL J MED, V322, P723, DOI 10.1056/NEJM199003153221103; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; PONDER BAJ, 1988, LANCET, V1, P397; Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; ROTH SI, 1963, CANCER, V16, P468, DOI 10.1002/1097-0142(196304)16:4<468::AID-CNCR2820160408>3.0.CO;2-F; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Roy PK, 2000, MEDICINE, V79, P379, DOI 10.1097/00005792-200011000-00004; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sampson JR, 2003, LANCET, V362, P39, DOI 10.1016/S0140-6736(03)13805-6; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sayed MG, 2002, ANN SURG ONCOL, V9, P901, DOI 10.1007/BF02557528; SCHEITHAUER BW, 1987, SEMIN DIAGN PATHOL, V4, P205; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schuffenecker I, 1998, J CLIN ENDOCR METAB, V83, P487, DOI 10.1210/jc.83.2.487; Schuffenecker I, 1997, AM J HUM GENET, V60, P233; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHANNON KE, 1999, J ENDOCR GENET, V1, P39; SHEPHERD NA, 1987, AM J SURG PATHOL, V11, P743, DOI 10.1097/00000478-198710000-00001; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SKOGSEID B, 1994, ENDOCRIN METAB CLIN, V23, P1; SKOGSEID B, 1992, J CLIN ENDOCR METAB, V75, P76, DOI 10.1210/jc.75.1.76; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sodha N, 2002, HUM MUTAT, V20, P460, DOI 10.1002/humu.10136; SOLOMAN C, GENEREVIEWS GENE TES; Somasundaram K, 2003, J CELL BIOCHEM, V88, P1084, DOI 10.1002/jcb.10469; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Syngal S, 2000, J MED GENET, V37, P641, DOI 10.1136/jmg.37.9.641; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Teh BT, 1998, ANN SURG, V228, P99, DOI 10.1097/00000658-199807000-00015; Thakker RV, 1995, ENDOCRINOLOGY; Thompson D, 2002, CANCER EPIDEM BIOMAR, V11, P329; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thorlacius S, 1998, LANCET, V352, P1337, DOI 10.1016/S0140-6736(98)03300-5; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; TOCCALIN.H, 1973, ACTA PAEDIATR SCAND, V62, P337, DOI 10.1111/j.1651-2227.1973.tb08117.x; TOMLINSON MJ, 1987, BRIT J RADIOL, V60, P89, DOI 10.1259/0007-1285-60-709-89; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Tonin PN, 1999, CLIN GENET, V55, P318, DOI 10.1034/j.1399-0004.1999.550504.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trump D, 1996, QJM-INT J MED, V89, P653; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Uchino S, 2000, CANCER RES, V60, P5553; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; VANDERLUIJT RB, 1995, HUM GENET, V96, P705, DOI 10.1007/BF00210303; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Varley JM, 2003, HUM MUTAT, V21, P313, DOI 10.1002/humu.10185; Varley JM, 1997, CANCER RES, V57, P3245; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; VERALDI S, 1991, J AM ACAD DERMATOL, V25, P632, DOI 10.1016/0190-9622(91)70244-V; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wagner A, 2003, AM J HUM GENET, V72, P1088, DOI 10.1086/373963; Wagner A, 2002, GENE CHROMOSOME CANC, V35, P49, DOI 10.1002/gcc.10094; Wagner A, 2001, J MED GENET, V38, P318, DOI 10.1136/jmg.38.5.318; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wallis YL, 1999, J MED GENET, V36, P14; Walon C, 1997, HUM GENET, V100, P601, DOI 10.1007/s004390050560; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Warthin AS, 1931, ANN INTERN MED, V4, P681, DOI 10.7326/0003-4819-4-7-681; Watson P, 1998, CANCER, V83, P259, DOI 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L; Wautot V, 2002, HUM MUTAT, V20, P35, DOI 10.1002/humu.10092; WEBER HC, 1995, GASTROENTEROLOGY, V108, P1637, DOI 10.1016/0016-5085(95)90124-8; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wiench M, 2001, J CLIN ONCOL, V19, P1374, DOI 10.1200/JCO.2001.19.5.1374; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wohllk N, 1996, J CLIN ENDOCR METAB, V81, P3740, DOI 10.1210/jc.81.10.3740; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wynford-Thomas D, 1999, J PATHOL, V187, P100; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445; Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	354	216	221	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6445	6470		10.1038/sj.onc.1207714	http://dx.doi.org/10.1038/sj.onc.1207714			26	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322516				2022-12-28	WOS:000223468800010
J	Rodway, H; Llanos, S; Rowe, J; Peters, G				Rodway, H; Llanos, S; Rowe, J; Peters, G			Stability of nucleolar versus non-nucleolar forms of human p14(ARF)	ONCOGENE			English	Article						ARF; MDM; p53; proteasome; ubiquitylation	UBIQUITIN-PROTEIN LIGASE; TUMOR SUPPRESSORS; CELL-CYCLE; P53; MDM2; ARF; LOCUS; E2F1; STABILIZATION; P19(ARF)	Fusion proteins containing the amino-terminal domain of human p14(ARF) linked to green fluorescent protein are able to bind MDM2 and stabilize p53 without localization in the nucleolus. However, these fusion proteins are inherently unstable, with half-lives considerably shorter than either authentic ARF or chimaeras containing the entire coding domain, both of which are predominantly nucleolar. We present evidence that the unstable fusion proteins are significantly stabilized if redirected to the nucleolus by addition of a basic motif based on the nuclear localization signal of SV40 T-antigen. Moreover, the stability of these proteins can be enhanced by modulating the functions of MDM2 and p53. These data are consistent with a model in which ARF interacts with MDM2 in the nucleoplasm but is consequently subject to proteasomal degradation. Nucleolar localization may serve to store or stabilize ARF.	London Res Inst, Canc Res UK, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Lincolns Inn Fields, London WC2A 3PX, England.	gordon.peters@cancer.org.uk	, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; David-Pfeuty T, 2002, ONCOGENE, V21, P6779, DOI 10.1038/sj.onc.1205871; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	46	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6186	6192		10.1038/sj.onc.1207854	http://dx.doi.org/10.1038/sj.onc.1207854			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15286709				2022-12-28	WOS:000223399000002
J	Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM				Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM			Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells	ONCOGENE			English	Article						apoptosis; Bcl-2; CD95; cytosine deaminase; p53; thymidine kinase	INDUCED APOPTOSIS; MALIGNANT GLIOMAS; KINASE GENE; BRAIN-TUMOR; P53 GENE; VIRUS; BCL-2; ACTIVATION; GANCICLOVIR; GLIOBLASTOMA	Suicide gene transfer using thymidine kinase (TK) and ganciclovir (GCV) treatment or the cytosine deaminase (CD)/5-fluorocytosine (5-FC) system represents the most widely used approach for gene therapy of cancer. However, molecular pathways and resistance mechanisms remain controversial for GCV-mediated cytotoxicity, and are virtually unknown for the CD/5-FC system. Here, we elucidated some of the cellular pathways in glioma cell lines that were transduced to express the TK or CD gene. In wild-type p53-expressing U87 cells, exposure to GCV and 5-FC resulted in a weak p53 response, although apoptosis was efficiently induced. Cell death triggered by GCV and 5-FC was independent of death receptors, but accompanied by mitochondrial alterations. Whereas expression of Bax remained unaffected, in particular, GCV and also 5-FC caused a decline in the level of Bcl-2. Similar findings were obtained in 9L and T98G glioma cells that express mutant p53, and also underwent mitochondrial apoptosis in both the TK/GCV and CD/5-FC system. Upon treatment of 9L cells with 5-FC, Bcl-x(L) expression slowly declined, whereas exposure to GCV resulted in the rapid proapoptotic phosphorylation of Bcl-x(L). These data suggest that TK/GCV- and CD/5-FC-induced apoptosis does neither require p53 nor death receptors, but converges at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Pediat Hematol Oncol & Immunol, D-40225 Dusseldorf, Germany; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England; Walton Ctr Neurol & Neurosurg, NHS Trust, Liverpool, Merseyside, England	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Liverpool; Walton Centre	Schulze-Osthoff, KS (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Steffens, Sabine/AAV-4551-2020; Schulze-Osthoff, Klaus/N-9025-2013	Steffens, Sabine/0000-0002-6892-9751; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FREEMAN SM, 1993, CANCER RES, V53, P5274; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Glaser T, 2001, GENE THER, V8, P469, DOI 10.1038/sj.gt.3301415; Hamel W, 1996, CANCER RES, V56, P2697; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ichikawa T, 2000, CANCER GENE THER, V7, P74, DOI 10.1038/sj.cgt.7700086; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Kramm Christof M, 2003, Methods Mol Biol, V215, P137; KRAMM CM, 1995, BRAIN PATHOL, V5, P345, DOI 10.1111/j.1750-3639.1995.tb00615.x; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Milosevic J, 2003, ONCOGENE, V22, P6852, DOI 10.1038/sj.onc.1206716; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; Nanda D, 2001, CANCER RES, V61, P8743; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499; Rainov Nikolai G., 2001, Current Gene Therapy, V1, P367, DOI 10.2174/1566523013348445; Schilsky RL, 1998, ONCOLOGY-NY, V12, P13; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace H, 1996, ONCOGENE, V13, P55; Wei JW, 2004, CANCER CELL, V5, P477, DOI 10.1016/S1535-6108(04)00116-3; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xie YJ, 1999, CLIN CANCER RES, V5, P4224; Zimmer C, 1997, EXP NEUROL, V143, P61, DOI 10.1006/exnr.1996.6350	59	83	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1231	1243		10.1038/sj.onc.1208290	http://dx.doi.org/10.1038/sj.onc.1208290			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592511				2022-12-28	WOS:000226898700010
J	Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R				Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R			Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappa B: implications for angioprevention and antiangiogenic therapy	ONCOGENE			English	Article						endothelial cells; cell cycle arrest; apoptosis; Akt; NF-kappa B; silibinin	DEPENDENT KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; PROSTATE-CANCER; INDUCED APOPTOSIS; BCL-2 FAMILY; ANGIOGENESIS; ACTIVATION; EXPRESSION; PROLIFERATION; MITOCHONDRIA	Recently, we observed that suppression of tumor xenograft growth by silibinin was associated with reduction in tumor vasculature and an increased apoptosis. Here, we provide evidence for molecular events associated with antiangiogenic efficacy of pharmacologically achievable doses of silibinin in endothelial cell culture system. Our data show that silibinin almost completely (P<0.001) inhibits growth of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC-dermal origin) together with induction of cell death in a dose- and time-dependent manner. Growth inhibition was associated with a strong induction of G1 arrest accompanied by an increase in Kip1/p27, Cip1/p21 and p53. Apoptosis induction (up to 14- to 17-fold in both cell lines, P<0.001) was an underlying mechanism in silibinin-induced death of endothelial cells. In the studies elucidating the molecular events involved in apoptosis, silibinin caused loss of mitochondrial membrane potential and an increase in cytochrome c release from mitochondria. An increase in Bax and a decrease in Mcl-1 proteins were also observed. Silibinin-induced apoptosis involved both caspase-dependent and -independent mechanisms. Silibinin also decreased survivin level and inhibited Akt and NF-kappaB signaling. Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-kappaB. Further, silibinin showed a concentration-dependent strong inhibition of capillary tube formation on matrigel, retraction and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC. Together, these findings identify pleiotropic mechanisms for antiangiogenic efficacy of silibinin, and suggest its usefulness in angioprevention and antiangiogenic therapy.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	rajesh.agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R01CA091883, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA102514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Brawer MK, 1996, CANCER, V78, P345, DOI 10.1002/(SICI)1097-0142(19960715)78:2<345::AID-CNCR25>3.0.CO;2-V; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 2004, BIOCHEM PHARMACOL, V67, P1337, DOI 10.1016/j.bcp.2003.12.015; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Fotsis T, 1997, CANCER RES, V57, P2916; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; GRANA X, 1995, ONCOGENE, V11, P211; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu QY, 2004, RADIAT RES, V161, P692, DOI 10.1667/RR3158; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jiang C, 2000, BIOCHEM BIOPH RES CO, V276, P371, DOI 10.1006/bbrc.2000.3474; Jiang C, 2000, MOL CARCINOGEN, V29, P236, DOI 10.1002/1098-2744(200012)29:4<236::AID-MC1006>3.0.CO;2-E; Jones MK, 1999, NAT MED, V5, P1418; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YW, 2002, CLIN CANCER RES, V8, P2369; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ozes ON, 1999, NATURE, V401, P82; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Qi J H, 1999, Angiogenesis, V3, P371, DOI 10.1023/A:1026565908445; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Singh RP, 2003, CURR CANCER DRUG TAR, V3, P205, DOI 10.2174/1568009033481985; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2002, CANCER RES, V62, P3063; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yoo HY, 2004, INT J MOL MED, V13, P81; Zandi E, 1999, MOL CELL BIOL, V19, P4547	67	126	129	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1188	1202		10.1038/sj.onc.1208276	http://dx.doi.org/10.1038/sj.onc.1208276			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558015				2022-12-28	WOS:000226898700006
J	Ivanov, VN; Hei, TK				Ivanov, VN; Hei, TK			Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway	ONCOGENE			English	Article						melanoma; EGFR; arsenite; ERK; AKT; TRAIL	NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; HEME OXYGENASE-1 GENE; HYPOXIA-INDUCIBLE FACTOR; TRAIL-INDUCED APOPTOSIS; CELL LUNG-CANCER; THERAPEUTIC TARGET; TRANSCRIPTION FACTOR; MEDIATED APOPTOSIS; TYROSINE KINASES	Epidermal growth factor receptor (EGFR) is expressed, albeit at low or intermediate levels, in human melanomas at the different stages of tumor progression. Coexpression of EGFR with its ligand TGFalpha indicates their role in paracrine and autocrine growth regulation of melanomas. As it was previously observed for several types of cancer, specific inhibitors of EGFR-mediated signaling may reduce antiapoptotic properties of cancer cells and sensitize them to cytotoxic drugs. We recently reported that arsenite, particularly in combination with inhibitors of the PI3K-AKT and mitogen-activated protein kinase (MAPK) kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways, induces high levels of apoptosis in different melanomas. Since EGFR signaling operates via activation of the PI3K-AKTand MEK-ERK pathways, we suggested that the combination of arsenite and EGFR inhibitors might also effectively induce apoptosis in melanoma. Here, we demonstrate that a moderate concentration of arsenite (5 - 10 muM) indeed upregulates apoptosis induced by EGFR inhibitors in EGFR-positive melanomas. In contrast, induction of apoptosis in melanomas with negligible surface expression of EGFR or with defective EGFR signaling requires direct suppression of the PI3K-AKTand MAPK pathways by specific pharmacological inhibitors in the presence of arsenite. Under these conditions, metastatic melanoma cell lines undergo TNF-related apoptosis-inducing ligand ( TRAIL)and tumor necrosis factor alpha (TNFalpha)- mediated apoptosis. Taken together, these data provide additional approaches in sensitizing melanomas to the cytotoxic effects of specific inhibitors of survival pathways.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA	Columbia University; Columbia University	Ivanov, VN (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St,VC11-218, New York, NY 10032 USA.	vni3@columbia.edu	Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NIEHS NIH HHS [P42 ES010349, P30 ES 09089, R01 ES011804, P30 ES009089, ES 05786, ES 11804, F32 ES005786, P42 ES 10349, R01 ES005786] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011804, R01ES005786, P42ES010349, P30ES009089, F32ES005786] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1992, J BIOL CHEM, V267, P21894; Amit S, 2003, SEMIN CANCER BIOL, V13, P15, DOI 10.1016/S1044-579X(02)00096-2; Berking C, 2001, CANCER RES, V61, P8306; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blackledge G, 2004, BRIT J CANCER, V90, P566, DOI 10.1038/sj.bjc.6601550; Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cheng HYY, 2004, ONCOGENE, V23, P3603, DOI 10.1038/sj.onc.1207466; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; Dancey JE, 2004, CANCER CELL, V5, P411, DOI 10.1016/S1535-6108(04)00122-9; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Durante W, 2003, J CELL PHYSIOL, V195, P373, DOI 10.1002/jcp.10274; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hayashi T, 2003, BRIT J HAEMATOL, V120, P10, DOI 10.1046/j.1365-2141.2003.03929.x; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hershko DD, 2002, J CELL BIOCHEM, V84, P687, DOI 10.1002/jcb.10083; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; IVANOV V, 1994, J IMMUNOL, V153, P2394; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2004, J BIOL CHEM, V279, P22747, DOI 10.1074/jbc.M314131200; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li G, 2003, ONCOGENE, V22, P6891, DOI 10.1038/sj.onc.1206819; Li G, 2001, CANCER RES, V61, P3819; Li MY, 2002, J CELL BIOCHEM, V87, P29, DOI 10.1002/jcb.10269; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; MYKLEBUST AT, 1994, J NEURO-ONCOL, V21, P215, DOI 10.1007/BF01063770; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Rea MA, 2003, CARCINOGENESIS, V24, P747, DOI 10.1093/carcin/bgg010; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Satyamoorthy K, 2003, CANCER RES, V63, P756; SATYAMOORTHY K, 1997, MELANOMA RES S2, V7, P35; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; von Willebrand M, 2003, CANCER RES, V63, P1420; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yih LH, 2002, CARCINOGENESIS, V23, P867, DOI 10.1093/carcin/23.5.867; Zhang XC, 2003, J BIOL CHEM, V278, P22061, DOI 10.1074/jbc.M301858200; Zhang XD, 2003, ONCOGENE, V22, P2869, DOI 10.1038/sj.onc.1206427; Zheng XH, 2003, TOXICOLOGY, V187, P39, DOI 10.1016/S0300-483X(03)00025-8	82	53	55	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					616	626		10.1038/sj.onc.1208125	http://dx.doi.org/10.1038/sj.onc.1208125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580309	Green Published, Green Accepted			2022-12-28	WOS:000226420400009
J	Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK				Jun, JI; Chung, CW; Lee, HJ; Pyo, JO; Lee, KN; Kim, NS; Kim, YS; Yoo, HS; Lee, TH; Kim, E; Jung, YK			Role of FLASH in caspase-8-mediated activation of NF-kappa B: dominant-negative function of FLASH mutant in NF-kappa B signaling pathway	ONCOGENE			English	Article						caspase-8; FLASH; NF-kappa B; siRNA; dominant negative	TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; INTERFERING MUTANT; IKK-ALPHA; APOPTOSIS; PROTEIN; INDUCTION; TRANSDUCTION; FADD	Caspase-8 is the most receptor-proximal, upstream caspase in the caspase cascade and plays a key role in cell death triggered by various death receptors. Here, we addressed the role of endogenous caspase-8 in tumor necrosis factor (TNF)-alpha-induced activation of NF-kappaB. Direct targeting of caspase-8 with siRNA and antisense (AS) approaches abolished TNF-alpha-induced activation of NF-kappaB in NIH3T3, HeLa, and HEK293 cells as determined with luciferase reporter gene and cell fractionation assays. Reconstitution of caspase-8-deficient C33A cells with processing-defective (P/D) mutant of caspase-8 sensitized the cells to TNF-alpha for NF-kappaB activation. In contrast to wild-type caspase-8, death effector domain mutant replacing Asp73 with Ala (caspase-8 (D73A)) failed to activate NF-kappaB and to bind FLICE-associated huge protein ( FLASH) in vitro and in vivo. Instead, caspase-8 (D73A) mutant bound to caspase-8 and blocked NF-kappaB activation triggered by TNF-alpha and caspase-8. In addition, expression of an NF-kappaB-activating domain-deletion mutant of FLASH or transfection of FLASH AS oligonucleotides abolished TNF-alpha and caspase-8, but not phorbol 12-myristate 13-acetate, - induced activation of NF-kappaB. Further, immunoprecipitation assays showed that caspase-8 formed triple complex with TRAF2 and FLASH. Taken together, these results suggest that endogenous caspase-8 mediates TNF-alpha-induced activation of NF-kappaB via FLASH.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Yonsei Univ, Dept Biol, Seoul 120749, South Korea; PaiChai Univ, Dept Life Sci, Taejon 302735, South Korea	Gwangju Institute of Science & Technology (GIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University; Pai Chai University	Jung, YK (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	ykjung@kjist.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533				Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Guiet C, 2002, CELL DEATH DIFFER, V9, P138, DOI 10.1038/sj/cdd/4400947; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 2000, J BIOL CHEM, V275, P27823; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	25	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					688	696		10.1038/sj.onc.1208186	http://dx.doi.org/10.1038/sj.onc.1208186			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592525				2022-12-28	WOS:000226420400016
J	Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F				Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F			The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation	ONCOGENE			English	Review						tax; HTLV-I; Rb; proteasome; cell cycle; tumorigenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; TUMOR-SUPPRESSOR PROTEIN; ONCOGENE PRODUCT TAX; KAPPA-B-ALPHA; CYCLE PROGRESSION; ADENOVIRUS E1A; RB FAMILY; TRANSCRIPTIONAL ACTIVATION; HUMAN-LYMPHOCYTES	Human T-cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T-cell leukemia (ATL), is estimated to affect 10 - 20 million people worldwide. The transforming ability of HTLV-I has been largely attributed to the viral protein Tax, which modulates the activity of several well-known cell cycle regulators. An important cell cycle regulator, the retinoblastoma (Rb) protein, is often inactivated in many cancers including virally induced cancers. Upon examination of Rb status, we observed a decrease in Rb protein expression in HTLV-1-infected cell lines as well as in ex vivo ATL patient samples. Transient transfection assays indicated that decreased Rb protein levels were Tax dependent. Here, we demonstrate for the first time that Tax directly associates with Rb. This interaction was localized within the B pocket of Rb and the C-terminus of Tax (aa 245 - 353). Within the C-terminus of Tax, we have identified an LXCXE-like motif, that when mutated resulted in the loss of Tax/Rb interaction. Furthermore, through the use of proteasome inhibitors, such as MG-132, in vivo and proteasome degradation assays in vitro, we found that Tax destabilizes the hypo-phosphorylated( active) form of Rb via the proteasome pathway. Therefore, we propose a model whereby Tax targets Rb to the proteasome by acting as a molecular bridge bringing Rb into contact with the proteasome for degradation.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; NCI, Virus Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Inst Pasteur, Dept SIDA & Retrovirus, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; George Washington Univ, Med Ctr, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Inst Genom Res TIGR, Rockville, MD 20850 USA	George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013	Bottazzi, Maria Elena/0000-0002-8429-0476; mahieux, renaud/0000-0002-5129-6804	NIAID NIH HHS [AI061560, AI44357, AI43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI061560, R01AI043894, R29AI044357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Akagi T, 1996, ONCOGENE, V12, P1645; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Antelman D, 1997, ONCOGENE, V15, P2855, DOI 10.1038/sj.onc.1201465; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Boyer SN, 1996, CANCER RES, V56, P4620; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen WJ, 2004, J BIOL CHEM, V279, P13496, DOI 10.1074/jbc.M212390200; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Dunaief JL, 2002, CURR EYE RES, V24, P392, DOI 10.1076/ceyr.24.5.392.8524; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FUJII M, 1991, ONCOGENE, V6, P1023; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grossman WJ, 1996, J ACQ IMMUN DEF SYND, V13, pS162, DOI 10.1097/00042560-199600001-00025; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; ISHIDA S, 1995, CELL GROWTH DIFFER, V6, P229; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kalejta RF, 2003, MOL CELL BIOL, V23, P1885, DOI 10.1128/MCB.23.6.1885-1895.2003; Kashanchi F, 1996, J VIROL, V70, P5503, DOI 10.1128/JVI.70.8.5503-5510.1996; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mori N, 1997, EUR J HAEMATOL, V58, P114; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2; Pan WJ, 2001, CANCER RES, V61, P2885; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; Plath T, 2002, J NATL CANCER I, V94, P129, DOI 10.1093/jnci/94.2.129; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Salcedo M, 1995, ARCH MED RES, V26, pS157; Sambrook J., 2001, MOL CLONING LAB MANU; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Suzuki Takeshi, 1997, Leukemia (Basingstoke), V11, P14; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	101	85	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					525	540		10.1038/sj.onc.1208105	http://dx.doi.org/10.1038/sj.onc.1208105			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580311				2022-12-28	WOS:000226420400001
J	Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Magrini, R; Moorthy, D; Muller, A; Sausville, EA; Kohno, K; Wiegand, P; Daniel, PT; Zeitz, M; Hanski, C			The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein	ONCOGENE			English	Article						colon carcinoma; chemotherapy; UCN-01; apoptosis; cell cycle arrest	LUNG-CANCER CELLS; 7-HYDROXYSTAUROSPORINE UCN-01; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; UP-REGULATION; CONSTITUTIVE ACTIVATION; CHECKPOINT FUNCTION; GROWTH-INHIBITION; LEUKEMIA-CELLS; BCL-X	The broad-range cyclin-dependent kinase inhibitor 7-hydroxystaurosporine (UCN-01) is known to induce both a G1 cell cycle arrest and apoptosis. The mechanism of UCN-01-induced apoptosis is largely unknown. We analysed the mechanism of cytotoxicity of UCN-01 in four established colon carcinoma cell lines. The cell lines SW48 and LS513 responded to UCN-01 treatment by undergoing apoptosis in a concentration-dependent manner while the cell lines HT-29 and WiDr were completely resistant. Apoptosis in LS513 and SW48 cell lines was concomitant with the suppression of Bcl-x(L) on mRNA and protein level. In contrast, in the apoptosis-resistant cell lines, Bcl-x(L) expression was not affected by UCN-01. Stable overexpression of the Bcl-x(L) protein abrogated UCN-01-triggered apoptosis, but only partially restored growth, indicating that both cell cycle arrest and apoptosis exert the anticancer effect in a coordinated manner. The inhibition of Akt phosphorylation did not correlate with the apoptotic phenotype. UCN-01 inhibited the activating STAT3 phosphorylations on Ser727 and, notably, on Tyr705, but STAT3 did not contribute to Bcl-x(L) expression in colon carcinoma cells. Moreover, we show for the first time that UCN-01 induces apoptosis by suppression of Bcl-x(L) expression. The inhibition of this pathway is a new aspect of cytotoxic and modulatory potential of UCN-01.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Dept Clin & Mol Oncol, Berlin, Germany; NCI, Rockville, MD USA; Univ Occupat & Environm Hlth, Sch Med, Kitakyushu, Fukuoka 807, Japan; Inst Forens Med, Ulm, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Occupational & Environmental Health - Japan	Hanski, C (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de	Moorthy, Dhatchana/AAD-7680-2019	Moorthy, Dhatchana/0000-0002-0071-4762				Abe S, 2000, JPN J CANCER RES, V91, P1192, DOI 10.1111/j.1349-7006.2000.tb00904.x; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43; AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1991, CANCER RES, V51, P4888; Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; Akiyama T, 1999, JPN J CANCER RES, V90, P1364, DOI 10.1111/j.1349-7006.1999.tb00721.x; Alas S, 2003, CLIN CANCER RES, V9, P316; Amundson SA, 2000, CANCER RES, V60, P6101; Bredel M, 1999, J NEURO-ONCOL, V41, P9, DOI 10.1023/A:1006047025425; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Byrd JC, 2001, EXP HEMATOL, V29, P703, DOI 10.1016/S0301-472X(01)00649-X; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan UPF, 2003, ANTI-CANCER DRUG, V14, P761, DOI 10.1097/01.cad.0000094782.62385.7a; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Dai Y, 2001, CANCER RES, V61, P5106; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; HANSKI C, 1992, INT J CANCER, V50, P924, DOI 10.1002/ijc.2910500618; Hirose Y, 2001, CANCER RES, V61, P5843; Husain A, 1997, CLIN CANCER RES, V3, P2089; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Koh Junichi, 2002, Breast Cancer, V9, P50, DOI 10.1007/BF02967547; Kruger EA, 1999, INVAS METAST, V18, P209, DOI 10.1159/000024514; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Mack PC, 1999, CLIN CANCER RES, V5, P2596; Mora LB, 2002, CANCER RES, V62, P6659; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; Patel V, 2002, CLIN CANCER RES, V8, P3549; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POWELL SN, 1995, CANCER RES, V55, P1643; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; SEYNAEVE CM, 1993, CANCER RES, V53, P2081; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Sugiyama K, 1999, CANCER RES, V59, P4406; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; Usuda J, 2000, INT J CANCER, V85, P275, DOI 10.1002/(SICI)1097-0215(20000115)85:2<275::AID-IJC20>3.0.CO;2-5; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yu Q, 2002, CANCER RES, V62, P5743	51	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					148	156		10.1038/sj.onc.1207842	http://dx.doi.org/10.1038/sj.onc.1207842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15467762				2022-12-28	WOS:000226125800017
J	Nagata, KI; Inagaki, M				Nagata, KI; Inagaki, M			Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin	ONCOGENE			English	Article						septin; sept9; RhoGEF; actin	ACUTE MYELOID-LEUKEMIA; CHROMOSOME 17Q; ALLELIC LOSS; FAMILY; GENE; OVARIAN; BREAST; EXPRESSION; REGION; MSF	Small GTPase Rho and septin family proteins are thought to be related to tumorigenesis. We have identified a Rho-guanine nucleotide exchange factor (GEF) as a binding partner for a mammalian septin Sept9b using yeast two-hybrid screening. We termed this molecule septin-associated RhoGEF (SA-RhoGEF). Molecular dissection analyses indicated that the C-terminal area of SA-RhoGEF exhibited binding to the N-terminal variable region of Sept9b. SA-RhoGEF was found by immunoprecipitation analysis to associate with septin complexes in REF52 fibroblast cells, maybe through direct interaction with Sept9b. Immunofluorescence analyses revealed the colocalization of SA-RhoGEF and Sept9b along with actin stress fibers in REF52 cells, and their colocalization along stress fibers was most likely to depend on their mutual interaction. In transient expression analyses, Sept9b inhibited SA-RhoGEF-dependent Rho activation in COS7 and HeLa cells. SA-RhoGEF and its fragments expressed in REF52 cells altered endogenous septin. lament structures. To our knowledge, SA-RhoGEF is the first molecule providing a link between septins and Rho signaling.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Inagaki, M (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Mol Neurobiol, 713-8 Kamiya Cho, Kasugai, Aichi 4800392, Japan.	knagata@inst-hsc.jp; minagaki@aichi-cc.jp	Inagaki, Masaki/B-9920-2016					Burrows JF, 2003, J PATHOL, V201, P581, DOI 10.1002/path.1484; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; Hanai N, 2004, FEBS LETT, V568, P83, DOI 10.1016/j.febslet.2004.05.030; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1992, J BIOL CHEM, V267, P19600; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Phelan CM, 1998, CANCER RES, V58, P1004; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1993, CANCER RES, V53, P3382; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; THEILE M, 1995, ONCOGENE, V10, P439; Togashi H, 2000, J BIOL CHEM, V275, P29570, DOI 10.1074/jbc.M003726200; TOKSOZ D, 1994, ONCOGENE, V9, P621; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5	38	73	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					65	76		10.1038/sj.onc.1208101	http://dx.doi.org/10.1038/sj.onc.1208101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558029				2022-12-28	WOS:000226125800009
J	Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS				Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS			Ras-dependent induction of HIF-1a(785) via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion	ONCOGENE			English	Article						HIF-1 alpha isoform; Ras signaling; phobol ester; EGF	INDUCIBLE FACTOR 1-ALPHA; OVEREXPRESSION; STABILIZATION; HIF-1-ALPHA; EXPRESSION; PROTEIN; TARGET; CELLS	Hypoxia-inducible factor-1alpha (HIF-1alpha) plays crucial roles in tumor promotion by transactivating approximately 60 kinds of its target genes. Recently, we reported a novel splice variant HIF-1alpha(785), which is regulated primarily by phorbol ester. This variant can be stabilized under normoxic conditions because it loses an acetylation site Lys532. Its expression was found to promote xenografted tumor growth in nude mice. We here found that the Ras oncogene regulates HIF-1alpha(785) expression via the Raf/MEK/ERK pathway, and that both phorbol ester and epidermal growth factor also induced HIF-1alpha(785) via the same pathway. We also identified the nonhypoxic regulatory domain responsible for phorbol ester-induced HIF-1alpha(785) expression. These results imply that HIF-1alpha(785) may play an important role in tumor promotion mediated by the Ras oncogene, phorbol ester or tumor growth factors.	Seoul Natl Univ, Coll Med, Human Genome Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Chosun Univ, Coll Med, Dept Pharmacol, Kwangju 501759, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chosun University; Seoul National University (SNU)	Chun, YS (corresponding author), Seoul Natl Univ, Coll Med, Human Genome Res Inst, 28 Yongon Dong, Seoul 110799, South Korea.	chunys@snu.ac.kr	Park, Jong-Wan/J-2758-2012; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020; Chun, Yang Sook/J-2789-2012	Lee, Jung Weon/0000-0003-2722-8200; 				Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Birner P, 2000, CANCER RES, V60, P4693; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Chun YS, 2003, CANCER RES, V63, P8700; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Chun YS, 2001, J CELL SCI, V114, P4051; Feldser D, 1999, CANCER RES, V59, P3915; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	20	85	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9427	9431		10.1038/sj.onc.1208003	http://dx.doi.org/10.1038/sj.onc.1208003			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543236				2022-12-28	WOS:000225764100014
J	Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH				Yoo, MH; Song, HW; Woo, CH; Kim, HG; Kim, JH			Role of the BLT2, a leukotriene B-4 receptor, in Ras transformation	ONCOGENE			English	Article						BLT2; cancer; leukotriene B-4; Ras transformation	CELL LUNG-CANCER; COLLAGEN-INDUCED ARTHRITIS; TERNARY COMPLEX-FORMATION; SIGNAL-REGULATED KINASE; SERUM RESPONSE ELEMENT; CYCLOOXYGENASE-2 COX-2; TRANSCRIPTION FACTOR; MEDIATES CHEMOTAXIS; PHOSPHOLIPASE A(2); GENE-EXPRESSION	Oncogenic Ras is known to drive both the Rac and Raf-MAP-kinase pathways, which act in concert to cause cell transformation. Unlike the Raf-MAP-kinase cascade, however, the downstream elements of Rac pathway are not fully understood. Previously, we showed that cytosolic phospholipase A(2) (cPLA(2)) and subsequent metabolism of arachidonic acid act downstream of Rac to mediate the transformation signaling induced by Ha-Ras(V12). In the present study, we observed that leukotriene B-4 (LTB4) and its synthetic enzymes as well as BLT2, the low-affinity LTB4 receptor, are all elevated in Ha-Ras(V12)-transformed cells. In addition, the malignant phenotypes of Ras-transformed cells were markedly inhibited by BLT2 blockade, as was their tumorigenicity in vivo. Finally, in situ hybridization analysis revealed that expression of BLT2 is significantly upregulated in a variety of human cancers. Taken together, our results suggest that an LTB4-BLT2-linked cascade plays a crucial mediatory role in the cell transformation induced by oncogenic Ha-Ras(V12), possibly acting downstream of Rac-cPLA(2).	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Abou-Issa HM, 2001, ANTICANCER RES, V21, P3425; Bae SH, 2001, CLIN CANCER RES, V7, P1410; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bauer AK, 2000, CARCINOGENESIS, V21, P543, DOI 10.1093/carcin/21.4.543; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; COROMINAS M, 1991, ONCOGENE, V6, P645; Dang CT, 2002, ONCOLOGY-NY, V16, P30; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Fournier DB, 2000, J CELL BIOCHEM, P97; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDMAN DW, 1991, J IMMUNOL, V146, P2671; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Gunning WT, 2002, CANCER RES, V62, P4199; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Izumi T, 2002, J BIOCHEM, V132, P1; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1998, MOL CELLS, V8, P90; KOCH K, 1994, J MED CHEM, V37, P3197, DOI 10.1021/jm00046a001; Kreimer-Erlacher H, 2001, PHOTOCHEM PHOTOBIOL, V74, P323, DOI 10.1562/0031-8655(2001)074<0323:HMFAHR>2.0.CO;2; KUJUBU DA, 1991, J BIOL CHEM, V274, P24372; KUMAR CC, 1992, CANCER RES, V52, P6877; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVERS SJ, 1996, SIGNAL TRANSDUCTION; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Patti R, 2002, CANCER LETT, V180, P13, DOI 10.1016/S0304-3835(02)00003-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Showell HJ, 1996, BRIT J PHARMACOL, V117, P1127, DOI 10.1111/j.1476-5381.1996.tb16706.x; Shureiqi I, 2001, CANCER RES, V61, P6307; Tong WG, 2002, CLIN CANCER RES, V8, P3232; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200	55	44	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9259	9268		10.1038/sj.onc.1208151	http://dx.doi.org/10.1038/sj.onc.1208151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489890				2022-12-28	WOS:000225638000011
J	Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL				Ekberg, J; Landberg, G; Holm, C; Richter, J; Wolgemuth, DJ; Persson, JL			Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells	ONCOGENE			English	Article						cyclin A1; AML; subcellular localization; CDK1; RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; PML-RAR-ALPHA; FUSION PROTEINS; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DEPENDENT KINASES; HUMAN CANCER	An important role of the cell cycle regulatory protein cyclin A1 in the development of acute myeloid leukemia (AML) was previously demonstrated in a transgenic mouse model. We have now turned our attention to study specific aspects of the activity and subcellular distribution of cyclin A1 using bone marrow samples from normal donors and patients with AML, as well as leukemic cell lines. We show that the localization of cyclin A1 in normal hematopoietic cells is nuclear, whereas in leukemic cells from AML patients and cell lines, it is predominantly cytoplasmic. In leukemic cell lines treated with all-trans retinoic acid (ATRA), cyclin A1 localized to the nucleus. Further, there was a direct interaction between cyclin A1 and cyclin-dependent kinase 1, as well as a major ATRA receptor, RARalpha, in ATRA-treated cells but not in untreated leukemic cells. Our results indicate that the altered intracellular distribution of cyclin A1 in leukemic cells correlates with the status of the leukemic phenotype.	Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; BMC, Div Mol Med & Gene Therapy, S-22184 Lund, Sweden; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ, Med Ctr, Ctr Reprod Sci, Dept Obstet & Gynecol, New York, NY 10032 USA	Lund University; Skane University Hospital; Columbia University; Columbia University; Columbia University	Persson, JL (corresponding author), Lund Univ, Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	jenny.persson@pat.mas.lu.se		Persson, Jenny/0000-0001-7682-7678	NATIONAL CANCER INSTITUTE [T32CA009363, R21CA095362] Funding Source: NIH RePORTER; NCI NIH HHS [CA09363, CA95362] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, BLOOD, V96, P475; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Dao MA, 1999, LEUKEMIA, V13, P1473, DOI 10.1038/sj.leu.2401537; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Furukawa Y, 1997, Hum Cell, V10, P159; Furukawa Y, 1998, Hum Cell, V11, P81; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MARIDOR G, 1993, J CELL SCI, V106, P535; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Palmqvist R, 2000, AM J PATHOL, V157, P1947, DOI 10.1016/S0002-9440(10)64833-X; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Singh SP, 1998, CANCER RES, V58, P1730; Stein GS, 2000, J CELL SCI, V113, P2527; Sweeney C, 1996, DEVELOPMENT, V122, P53; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yaroslavskiy B, 2001, J CELL BIOCHEM, V83, P380, DOI 10.1002/jcb.1243; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	40	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9082	9089		10.1038/sj.onc.1208090	http://dx.doi.org/10.1038/sj.onc.1208090			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489899	Green Published			2022-12-28	WOS:000225492800009
J	Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS				Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS			Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1	ONCOGENE			English	Article						tumor progression; redox signaling; transcription coactivator; cell cycle	DOMAIN-BINDING PROTEIN-1; NF-KAPPA-B; COP9 SIGNALOSOME; TRANSCRIPTION FACTORS; INHIBITOR P27(KIP1); DIRECT ASSOCIATION; OXIDATIVE STRESS; REDOX REGULATION; CELL-CYCLE; EXPRESSION	Thioredoxin (Trx) is a cellular redox enzyme that plays multiple roles in regulating cell growth and apoptosis. Jun activation domain-binding protein 1 (Jab1) was originally identified as a coactivator of activator protein 1 (AP-1) transcription and was also shown to promote degradation of the cyclin-dependent kinase inhibitor, p27Kip1. Recently, Jab1 expression was associated with the progression and poor prognosis of pituitary, epithelial ovarian, and breast cancers, suggesting that it plays a role in oncogenesis. Here, we report that Trx specifically interacts with and modulates the function of Jab1. Fluorescence resonance energy transfer and co-immunoprecipitation studies revealed that Trx and Jab1 colocalize and directly interact with each other. Further, Trx negatively regulates two important Jab1-controlled signaling pathways, activation of AP-1 transcription and degradation of p27Kip1, probably through a direct interaction between Trx and C-terminal of Jab1. The negative effect of Trx on AP-1 activity is Jab1-dependent, as it disappears when Jab1 levels are suppressed by an antisense approach. In addition, Trx competes with p27Kip1 for Jab1 binding. Taken together, our results suggest that Trx may regulate cell cycle and growth through a novel modulation of Jab1-mediated proliferation signals, further indicating that Trx may have the ability to control tumor progression.	Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea; PaiChai Univ, Div Life Sci, Taejon 302735, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pai Chai University; Chonnam National University	Kwon, KS (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, 52 Oun Dong, Taejon 305333, South Korea.	kwonks@kribb.re.kr		Chae, Suhn-Kee/0000-0003-2164-1053				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen XX, 2003, J BIOL CHEM, V278, P49022, DOI 10.1074/jbc.M304057200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ito Y, 2003, ANTICANCER RES, V23, P4121; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lu CR, 2002, FASEB J, V16, P90, DOI 10.1096/fj.01-0506fje; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yodoi J, 2001, BIOFACTORS, V15, P107, DOI 10.1002/biof.5520150212	40	58	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8868	8875		10.1038/sj.onc.1208116	http://dx.doi.org/10.1038/sj.onc.1208116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480426				2022-12-28	WOS:000225354600002
J	Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A				Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A			Unliganded thyroid hormone receptor beta 1 inhibits proliferation of murine broblasts by delaying the onset of the G1 cell-cycle signals	ONCOGENE			English	Article						thyroid hormone; thyroid hormone receptors; TR beta 1; cell cycle; cell proliferation; E2F transcription factor	OLIGODENDROCYTE DIFFERENTIATION; NEURONAL DIFFERENTIATION; GENE-EXPRESSION; MOLECULAR-BASIS; REPRESSION; MICE; RESISTANCE; REGULATOR; CARCINOMA; ALPHA	Thyroid hormone receptors (TRs) are members of the ligand-inducible transcription factor superfamily. The two major functional TRs (alpha1 and beta1) have different spatial and temporal expression patterns and specific physiological functions for these isoforms are now starting to emerge. By expressing these TR isoforms individually in Swiss 3T3 fibroblasts, we found that TRbeta1 expression, in the absence of hormone, provokes a proliferation arrest in G0/G1, lengthening the cycling time. Upon serum stimulation TRbeta1-expressing cells showed a marked delay in the induction of cyclins D and E, in the phosphorylation of retinoblastoma protein, and in the activation of cyclin-dependent kinase 2, accompanied by increased levels of cyclin-dependent kinase inhibitor p27(Kip1). Accordingly, serum-stimulated E2F-1 transcriptional activity was repressed by TRbeta1 in transient transfection experiments. Analysis of the receptor domains required for this effect confirmed that there is no need for a functional ligand-binding domain while the DNA-binding domain is essential. In this work, we demonstrate for the first time that TRbeta1 participates in the molecular mechanisms that control cell proliferation. The unliganded TRbeta1 impairs the normal induction of the G1/S cycle regulators preventing progression into the S phase.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Rodriguez-Pena, A (corresponding author), CSIC, Inst Cajal, Dr Arce 37, E-28002 Madrid, Spain.	arodriguez@iib.uam.es	Vacas, Teresa Iglesias/ABF-8663-2020; porlan, Eva/AAE-6561-2022; Vega, Sonia/R-1883-2018	Vacas, Teresa Iglesias/0000-0002-4326-9005; porlan, Eva/0000-0003-0934-9711; Vega, Sonia/0000-0002-3895-6265; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Billon N, 2001, DEV BIOL, V235, P110, DOI 10.1006/dbio.2001.0293; BROWN DD, 1995, RECENT PROG HORM RES, V50, P309; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Carre JL, 1998, J NEUROSCI RES, V54, P584; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Durand B, 2000, BIOESSAYS, V22, P64; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; HAYASHI Y, 1994, J CLIN INVEST, V94, P607, DOI 10.1172/JCI117376; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PAAVONEN T, 1982, SCAND J IMMUNOL, V15, P211, DOI 10.1111/j.1365-3083.1982.tb00640.x; PASTOR R, 1994, ONCOGENE, V9, P1081; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SHERR CJ, 1994, COLD SPRING HARB SYM, V59, P11, DOI 10.1101/SQB.1994.059.01.004; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0	39	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8756	8765		10.1038/sj.onc.1208126	http://dx.doi.org/10.1038/sj.onc.1208126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467737	Bronze			2022-12-28	WOS:000225165100005
J	Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT				Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT			Integrin signaling links protein kinase C epsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells	ONCOGENE			English	Article						PI3K; Src kinase; integrin-linked kinase; beta-catenin; fibronectin	GLYCOGEN-SYNTHASE KINASE; BETA-CATENIN; ANDROGEN RECEPTOR; CYCLIN D1; INTRAEPITHELIAL NEOPLASIA; PKC-EPSILON; INHIBITION; ACTIVATION; EXPRESSION; APOPTOSIS	Failure of hormone therapy often involves an outgrowth of protein kinase Cepsilon (PKCepsilon)-positive cells in recurrent prostate cancer. Our previous investigations have uncovered evidence of a complex signaling network operating downstream of this oncogenic protein kinase to actively advance the survival and proliferation of prostate cancer cells. In this study, we present evidence of a functional interplay among integrin receptors, PKCe, and protein kinase B (PKB/Akt) in recurrent CWR-R1 prostate cancer cells. Flow cytometry and confocal microscopy provided evidence that PKCepsilon signaling promoted the assembly of matrix adhesions containing an abundance of colocalized actin filaments and beta1 integrins that exhibited an exposed activation epitope on the surface of live CWR-R1 cells. Reciprocal coimmunoprecipitations provided evidence of signaling complexes containing PKCepsilon, beta1 integrins, Src, and PKB/Akt in CWR-R1 cell cultures. An investigation into the functional significance of these interactions, and of their positive influence on beta1 integrins, demonstrated that PKCepsilon and several key components of the PKB/Akt signaling pathway remain constitutively phosphorylated/activated in adherent but not suspension cultures of PTEN-positive CWR-R1 cells. Gene transfer, antisense and pharmacological experiments provided additional support for the hypothesis that a mutually reinforcing signaling loop sustains the activation of beta1 integrins, PKCepsilon, and PKB/Akt in adherent prostate cancer cells.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	David, MT (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.	terriand@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA256058, R01 CA98195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bernard D, 2003, J CLIN INVEST, V112, P1724; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FONARO M, 2001, CANCER METAST REV, V20, P321; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Gregory CW, 2001, CANCER RES, V61, P2892; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Koren R, 2004, ONCOL REP, V11, P321; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Linja MJ, 2001, CANCER RES, V61, P3550; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Mackay HJ, 2003, ENDOCR-RELAT CANCER, V10, P389, DOI 10.1677/erc.0.0100389; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; McMenamin ME, 1999, CANCER RES, V59, P4291; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; Moro L, 2004, J BIOL CHEM, V279, P1692, DOI 10.1074/jbc.M307857200; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Orchard S, 2002, CURR OPIN DRUG DI DE, V5, P713; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tucker GC, 2002, CURR OPIN PHARMACOL, V2, P394, DOI 10.1016/S1471-4892(02)00175-3; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wescott G G, 1999, Methods Mol Med, V22, P125, DOI 10.1385/0-89603-612-X:125; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wu Daqing, 2003, Methods Mol Biol, V218, P143; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; Xie ZH, 2003, CANCER RES, V63, P5370; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	71	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8659	8672		10.1038/sj.onc.1207900	http://dx.doi.org/10.1038/sj.onc.1207900			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467757				2022-12-28	WOS:000224988800012
J	Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G				Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G			Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line	ONCOGENE			English	Article						FHIT; inducible expression system; proliferation; lung cancer; p21	HISTIDINE TRIAD GENE; SUPPRESSES TUMORIGENICITY; GLUTAMINE DEPRIVATION; TUMOR-SUPPRESSOR; APOPTOSIS; SUSCEPTIBILITY; SURVIVAL; PROTEIN	Abnormalities in the expression of the tumour suppressor fragile histidine triad ( FHIT) gene have been reported in a variety of human tumours, including lung cancer and restoration of its expression in cancer cell lines resulted in the inhibition of proliferation and apoptosis induction. Most of the studies that have assigned a proapoptotic role to the FHIT gene were performed in adenoviral-FHIT-transduced cancer cells expressing high levels of the Fhit protein. The present work was the first study designed to investigate the effects of FHIT gene replacement in a human FHIT-negative non-small-cell lung cancer (NSCLC) cell line (Calu-1) by using a hormone-inducible expression system that allows tight modulation of the transgene expression. Through this approach, we demonstrated that a prolonged induction was required to accumulate the Fhit protein at levels adequate to promote a significant decrease of cell proliferation. Analysis of cell-cycle phase distribution showed an accumulation of cells in the G(0)/G(1) phase and a concomitant decrease in the S phase. Moreover, an upregulation of p21(waf1) transcript was found, which could account for the alteration of the cycling properties of the cells. The growth-inhibitory effects observed were not associated with apoptosis appearance, and although in these conditions the Fhit protein content was higher than in normal bronchial human epithelial cells (NHBE), it was still significantly lower than the level capable of inducing apoptosis in Calu-1 cells after adenoviral-mediated FHIT gene transfer. These results indicate that the tumour suppressor properties of Fhit are strictly related to its expression level and show that the Fhit protein has a dose-dependent antiproliferative effect on the Fhit-negative Calu-1 lung cancer cell line.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Parma, Dept Expt Med, I-43100 Parma, Italy; Univ Parma, Dept Surg, Thorac Surg Unit, I-43100 Parma, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Parma; University of Parma	Sozzi, G (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	gabriella.sozzi@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Andriani, Francesca/D-4898-2017; Galetti, Maricla/AAJ-8927-2020; Alfieri, Roberta R/G-6350-2012; Cavazzoni, Andrea/J-8079-2019; Carbognani, Paolo/AAC-2610-2019; Roz, Luca/AAB-3889-2019; Galetti, Maricla/CAG-4178-2022	sozzi, gabriella/0000-0001-9360-6914; Andriani, Francesca/0000-0002-6178-7789; Galetti, Maricla/0000-0002-8061-8649; Cavazzoni, Andrea/0000-0002-3752-1868; Roz, Luca/0000-0001-5817-7149; Galetti, Maricla/0000-0002-8061-8649				Alfieri RR, 2002, J PHYSIOL-LONDON, V540, P499, DOI 10.1113/jphysiol.2001.013395; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Dumon KR, 2001, CANCER RES, V61, P4827; FAIRCHILD CR, 2000, P 91 AACR ANN M S FR, V41, P227; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; PETRONINI PG, 1993, BRIT J CANCER, V67, P493, DOI 10.1038/bjc.1993.92; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Roz Luca, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1129; Roz Luca, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1206; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Werner NS, 2000, CANCER RES, V60, P2780; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	21	32	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8439	8446		10.1038/sj.onc.1207847	http://dx.doi.org/10.1038/sj.onc.1207847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361849				2022-12-28	WOS:000224870700004
J	Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ				Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ			Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways	ONCOGENE			English	Article						ovarian cancer; microarray; signaling pathways	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; TYPE-1 MATRIX-METALLOPROTEINASE; PROTEIN-TYROSINE KINASE; INTEGRIN-ASSOCIATED PROTEIN; SURFACE EPITHELIAL-CELLS; CARCINOMA-CELLS; CYCLIN D1; BREAST-CARCINOMA; CDNA MICROARRAY	Ovarian cancer is the most lethal type of gynecologic cancer in the Western world. The high case fatality rate is due in part because most ovarian cancer patients present with advanced stage disease which is essentially incurable. In order to obtain a whole genome assessment of aberrant gene expression in advanced ovarian cancer, we used oligonucleotide microarrays comprising over 40000 features to profile 37 advanced stage papillary serous primary carcinomas. We identified 1191 genes that were significantly (P<0.001) differentially regulated between the ovarian cancer specimens and normal ovarian surface epithelium. The microarray data were validated using real time RT-PCR on 14 randomly selected differentially regulated genes. The list of differentially expressed genes includes ones that are involved in cell growth, differentiation, adhesion, apoptosis and migration. In addition, numerous genes whose function remains to be elucidated were also identified. The microarray data were imported into PathwayAssist software to identify signaling pathways involved in ovarian cancer tumorigenesis. Based on our expression results, a signaling pathway associated with tumor cell migration, spread and invasion was identified as being activated in advanced ovarian cancer. The data generated in this study represent a comprehensive list of genes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identification of potentially new and novel markers and therapeutic targets for ovarian cancer.	NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA; NCI, Cellular Oncol Lab, Virus Tumor Biol Sect, Rockville, MD 20850 USA; NCI, Biometr Res Branch, Rockville, MD 20852 USA; NCI, Lab Biosyst & Canc, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov	Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baciu PC, 2003, EXP CELL RES, V291, P167, DOI 10.1016/S0014-4827(03)00387-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1997, CANCER RES, V57, P1306; Bao JJ, 2002, CANCER RES, V62, P7264; Barbieri F, 1999, CLIN CANCER RES, V5, P1837; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; CAMPBELL IG, 1992, CANCER RES, V52, P5416; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Cary LA, 1996, J CELL SCI, V109, P1787; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Dhar KK, 1999, BRIT J CANCER, V81, P1174, DOI 10.1038/sj.bjc.6690826; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Etienne W, 2004, BIOTECHNIQUES, V36, P618, DOI 10.2144/04364ST02; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Fashena SJ, 2002, J CELL SCI, V115, P99; Fishman DA, 1996, INVAS METAST, V16, P150; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hough CD, 2000, CANCER RES, V60, P6281; Hu J, 2003, GYNECOL ONCOL, V89, P369, DOI 10.1016/S0090-8258(03)00056-8; Imai K, 1996, CANCER RES, V56, P2707; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ismail RS, 2000, CANCER RES, V60, P6744; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kreuzer KA, 1999, CLIN CHEM, V45, P297; Kurochkin IV, 2001, BIOCHEM BIOPH RES CO, V280, P340, DOI 10.1006/bbrc.2000.4125; Law SF, 1996, MOL CELL BIOL, V16, P3327; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molino M, 1997, J BIOL CHEM, V272, P11133; Nap M, 1996, TUMOR BIOL, V17, P325; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ono K, 2000, CANCER RES, V60, P5007; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8; Rosano L, 2003, AM J PATHOL, V163, P753, DOI 10.1016/S0002-9440(10)63702-9; Rosano L, 2001, CANCER RES, V61, P8340; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; Sasaki H, 2000, CANCER RES, V60, P5659; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Scully RE, 1998, TUMORS OVARY MALDEVE, V23; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TESTA JR, 1994, CANCER RES, V54, P2778; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang L, 2003, CLIN CANCER RES, V9, P3660; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com; Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	92	102	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8065	8077		10.1038/sj.onc.1207959	http://dx.doi.org/10.1038/sj.onc.1207959			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361855				2022-12-28	WOS:000224692500004
J	Martin, GS				Martin, GS			The road to Src	ONCOGENE			English	Review						Src; Rous sarcoma virus; oncogene; cancer; tyrosine kinase	ROUS-SARCOMA-VIRUS; TEMPERATURE-SENSITIVE MUTANTS; DEPENDENT DNA-POLYMERASE; PP60C-SRC PROTEIN-KINASE; AMINO-ACID-SEQUENCE; C-SRC; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; TYROSINE KINASE; V-SRC	More than a quarter of a century has elapsed since the identification of the c-src proto-oncogene. During that period, we have learned that cancer arises as the result of mutations in proto-oncogenes and tumor suppressor genes, and we are now seeing the first fruits of these discoveries, in the form of targeted therapies directed against activated tyrosine kinases such as Bcr-Abl, c-Kit and the EGF receptor. But the discovery of the c-src proto-oncogene was in turn based on decades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV). Here I review the work that led up to the identification of the RSV transforming gene and its protein product, and how this information in turn led to the discovery of cellular Src.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Martin, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall 3204, Berkeley, CA 94720 USA.	smartin@socrates.berkeley.edu	Martin, Greg/B-4085-2009	Martin, Greg/0000-0002-9684-7593	NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NCI NIH HHS [CA17542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrewes C H, 1971, Biogr Mem Fellows R Soc, V17, P643, DOI 10.1098/rsbm.1971.0025; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BEEMON K, 1977, P NATL ACAD SCI USA, V74, P3302, DOI 10.1073/pnas.74.8.3302; BERNSTEIN A, 1976, VIROLOGY, V70, P206, DOI 10.1016/0042-6822(76)90254-3; BISHOP JM, 2003, WIN NOBEL PRIZE; BLACK PH, 1963, P NATL ACAD SCI USA, V50, P1148, DOI 10.1073/pnas.50.6.1148; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYAN WR, 1955, JNCI-J NATL CANCER I, V16, P317; Cairns J., 1992, PHAGE ORIGINS MOL BI; Coffin J, 1997, RETROVIRUSES; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CRAWFORD LV, 1960, VIROLOGY, V12, P143, DOI 10.1016/0042-6822(60)90190-2; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DOUGHERTY RM, 1965, VIROLOGY, V27, P351, DOI 10.1016/0042-6822(65)90115-7; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; DUESBERG PH, 1968, P NATL ACAD SCI USA, V60, P1511, DOI 10.1073/pnas.60.4.1511; DULBECCO R, 1953, COLD SPRING HARB SYM, V18, P273, DOI 10.1101/SQB.1953.018.01.039; DUTTA A, 1985, J VIROL, V55, P728, DOI 10.1128/JVI.55.3.728-735.1985; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; EDGAR RS, 1964, GENETICS, V49, P649; Ellerman V., 1908, ZBL BAKT, V46, P595; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; FRIED M, 1965, P NATL ACAD SCI USA, V53, P486, DOI 10.1073/pnas.53.3.486; Fujinami A, 1914, Z KREBSFORSCH, V14, P94, DOI DOI 10.1007/BF02137232; GOLDE A, 1966, CR ACAD SCI D NAT, V262, P329; GOLDE A, 1966, CR ACAD SCI D NAT, V262, P420; GOLDE A, 1970, VIROLOGY, V40, P1022, DOI 10.1016/0042-6822(70)90148-0; Gross L., 1983, ONCOGENIC VIRUSES; Halberstaedter L, 1941, BRIT J EXP PATHOL, V22, P179; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P572, DOI 10.1073/pnas.49.4.572; HANAFUSA H, 1965, VIROLOGY, V25, P248, DOI 10.1016/0042-6822(65)90203-5; HUEBNER RJ, 1969, P NATL ACAD SCI USA, V64, P1087, DOI 10.1073/pnas.64.3.1087; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JACOBS C, 1983, CANCER RES, V43, P1696; KAMINE J, 1977, P NATL ACAD SCI USA, V74, P2011, DOI 10.1073/pnas.74.5.2011; Keogh EV, 1938, BRIT J EXP PATHOL, V19, P1; LERNER TL, 1984, J VIROL, V49, P549, DOI 10.1128/JVI.49.2.549-556.1984; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MANAKER RA, 1956, VIROLOGY, V2, P838, DOI 10.1016/0042-6822(56)90064-2; MARTIN GS, 1972, VIROLOGY, V47, P494, DOI 10.1016/0042-6822(72)90287-5; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; ROBINSON WS, 1965, P NATL ACAD SCI USA, V54, P137, DOI 10.1073/pnas.54.1.137; ROBINSON WS, 1967, P NATL ACAD SCI USA, V58, P825, DOI 10.1073/pnas.58.3.825; Rous P, 1911, J AMER MED ASSOC, V56, P741; Rous P, 1914, J EXP MED, V19, P52, DOI 10.1084/jem.19.1.52; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; RUBIN H, 1960, P NATL ACAD SCI USA, V46, P1105, DOI 10.1073/pnas.46.8.1105; RUBIN H, 1961, VIROLOGY, V13, P200, DOI 10.1016/0042-6822(61)90054-X; RUBIN H, 1955, VIROLOGY, V1, P445, DOI 10.1016/0042-6822(55)90037-4; RUBIN H, 1962, VIROLOGY, V17, P184, DOI 10.1016/0042-6822(62)90096-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHMIDTRUPPIN KH, 1959, SONDERBAND STRAHLENT, V41, P26; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHALLOWAY D, 1981, CELL, V24, P531, DOI 10.1016/0092-8674(81)90344-5; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMONS PJ, 1963, JNCI-J NATL CANCER I, V31, P1275; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; SVETMOLDAVSKY GJ, 1958, NATURE, V182, P1452, DOI 10.1038/1821452b0; SVETMOLDAVSKY GJ, 1957, NATURE, V180, P1299, DOI 10.1038/1801299a0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TEMIN HM, 1962, COLD SPRING HARB SYM, V27, P407, DOI 10.1101/SQB.1962.027.001.038; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOYOSHIMA K, 1969, VIROLOGY, V39, P930, DOI 10.1016/0042-6822(69)90030-0; TOYOSHIMA K, 1970, VIROLOGY, V42, P163, DOI 10.1016/0042-6822(70)90249-7; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGT PK, 1967, P NATL ACAD SCI USA, V58, P801, DOI 10.1073/pnas.58.3.801; VOGT PK, 1971, VIROLOGY, V46, P939, DOI 10.1016/0042-6822(71)90092-4; WANG LH, 1976, P NATL ACAD SCI USA, V73, P447, DOI 10.1073/pnas.73.2.447; Waterson A. P., 1978, INTRO HIST VIROLOGY; WEISS SR, 1977, CELL, V12, P983, DOI 10.1016/0092-8674(77)90163-5; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; ZIL'BER L A, 1958, Vopr Virusol, V3, P166; ZILBER L A, 1957, Acta Virol, V1, P156	100	121	132	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7910	7917		10.1038/sj.onc.1208077	http://dx.doi.org/10.1038/sj.onc.1208077			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489909				2022-12-28	WOS:000224558300002
J	McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M				McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M			Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells	ONCOGENE			English	Article						ErbB; EGF-R; Raf/MEK/ERK; PI3K/Akt; signal transduction; apoptosis	CYCLE PROGRESSION; SIGNAL-TRANSDUCTION; PREVENT APOPTOSIS; PROTEIN-KINASE; GM-CSF; RAS/RAF/MEK/ERK PATHWAY; DIFFERENTIAL ABILITIES; PI3K/AKT PATHWAY; PRECURSOR CELLS; BETA-SUBUNIT	Epidermal growth factor (EGF) and its cognate receptor (EGF-R) are often dysregulated in human neoplasia. Moreover, EGF-R-transformed cell lines have constitutive EGF-R activity, which makes elucidation of its effects difficult to determine. In the following studies, the effects of a novel conditionally activated form of EGF-R, v-ErbB:ER, on the morphological transformation of NIH-3T3 cells and the abrogation of hematopoietic cell cytokine dependence were investigated. The v-ErbB ES-4 oncogene was fused to the hormone binding domain of the estrogen receptor (ER). This construct, v-ErbB:ER, requires beta-estradiol or 4-OH tamoxifen for activation. v-ErbB:ER conditionally transformed NIH-3T3 cells and abrogated cytokine dependence of hematopoietic cells. Stimulation of v-ErbB:ER activity resulted in the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and Raf/MEK/ERK kinase cascades. To determine the importance of these signal transduction pathways, the conditionally transformed hematopoietic cells were treated with EGF-R, PI3K and MEK inhibitors. The EGF-R inhibitor AG1478 effectively inhibited MEK, ERK and Akt activation, and induced apoptosis when the cells were grown in response to v-ErbB:ER. Apoptosis was observed at 100- to 1000-fold lower concentrations of AG1478 when the cells were grown in response to v-ErbB:ER as opposed to IL-3. Furthermore, the parental, BCR-ABL- and Raf-transformed cells were only susceptible to the apoptosis-inducing effects of AG1478 at the highest concentrations demonstrating the specificity of these inhibitors. MEK or PI3K inhibitors suppressed ERK or Akt activation, respectively, and induced apoptosis in the v-ErbB:ER-responsive cells. However, MEK and PI3K inhibitors only induced apoptosis at 1000-fold higher concentrations than the EGFR inhibitor. This novel v-ErbB:ER construct and these conditionally transformed cell lines will be useful to further elucidate ErbB-mediated signal transduction and to determine the effectiveness of various inhibitors in targeting different aspects of EGFR-mediated signal transduction and malignant transformation.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA; UCSF Mt Zion Canc Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Georgetown University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; McCubrey, James/0000-0001-6027-3156; Franklin, Richard A./0000-0003-0299-9578	NCI NIH HHS [R01CA98185, R01CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025, R01CA098185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn NG, 2001, METHOD ENZYMOL, V332, P417; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUSKIN A, 1990, ONCOGENE, V5, P15; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang FM, 2003, INT J ONCOL, V22, P469; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KUAN CT, 2001, BRAIN TUMOR PATHOL, V17, P71; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Larson RA, 2003, LEUKEMIA, V17, P2358, DOI 10.1038/sj.leu.2403156; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MCCUBREY JA, 1995, INT J ONCOL, V7, P573; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCMAHON M, 1991, MOL CELL BIOL, V11, P4760, DOI 10.1128/MCB.11.9.4760; McMahon M, 2001, METHOD ENZYMOL, V332, P401; MILLER M, 1990, ONCOGENE, V5, P1125; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Navolanic PM, 2003, INT J ONCOL, V22, P237; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shelton JG, 2004, CELL CYCLE, V3, P189; Shelton JG, 2004, CELL CYCLE, V3, P372; Shelton JG, 2004, CELL CYCLE, V3, P503; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; Steelman LS, 1996, LEUKEMIA, V10, P528; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WEISS R, 1984, RNA TUMOR VIRUSES	50	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7810	7820		10.1038/sj.onc.1208055	http://dx.doi.org/10.1038/sj.onc.1208055			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361836				2022-12-28	WOS:000224331600007
J	Al-Hajj, M; Clarke, MF				Al-Hajj, M; Clarke, MF			Self-renewal and solid tumor stem cells	ONCOGENE			English	Review						stem cells; cancer; self-renewal; solid tumors	ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BLADDER-CARCINOMA ONCOGENE; HUMAN HEMATOPOIETIC-CELLS; BONE-MARROW; PROGENITOR CELLS; BREAST-CANCER; BRAIN-TUMORS; PROMYELOCYTIC LEUKEMIA; IN-VITRO	Solid tumors arise in organs that contain stem cell populations. The tumors in these tissues consist of heterogeneous populations of cancer cells that differ markedly in their ability to proliferate and form new tumors. In both breast cancers and central nervous system tumors, cancer cells differ in their ability to form tumors. While the majority of the cancer cells have a limited ability to divide, a population of cancer stem cells that has the exclusive ability to extensively proliferate and form new tumors can be identified based on marker expression. Growing evidence suggests that pathways that regulate the self-renewal of normal stem cells are deregulated in cancer stem cells resulting in the continuous expansion of self-renewing cancer cells and tumor formation. This suggests that agents that target the defective self-renewal pathways in cancer cells might lead to improved outcomes in the treatment of these diseases.	Univ Michigan, Sch Med, CCGC, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Sch Med, CCGC, Room 4410,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mclarke@umich.edu						Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; AKASHI K, 2001, DEV BIOL HEMATOPOIES; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alvi AJ, 2003, BREAST CANCER RES, V5, DOI 10.1186/bcr563; Aubele M, 1999, ANAL CELL PATHOL, V19, P53, DOI 10.1155/1999/960923; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; BERGSAGEL DE, 1968, CANCER RES, V28, P2187; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Braun S, 1998, BREAST CANCER RES TR, V52, P201, DOI 10.1023/A:1006164914610; BREITMAN TR, 1981, BLOOD CELLS, V7, P79; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chepko G, 1999, J MAMMARY GLAND BIOL, V4, P35, DOI 10.1023/A:1018752519356; Costello RT, 2000, CANCER RES, V60, P4403; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; DISTEFANO A, 1979, CANCER, V44, P196, DOI 10.1002/1097-0142(197907)44:1<196::AID-CNCR2820440132>3.0.CO;2-H; DONOHUE JP, 1994, WORLD J UROL, V12, P190; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; DOUER D, 1981, BRIT J HAEMATOL, V49, P615, DOI 10.1111/j.1365-2141.1981.tb07271.x; DRASGA RE, 1983, J CLIN ONCOL, V1, P179, DOI 10.1200/JCO.1983.1.3.179; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fialkow P J, 1976, Birth Defects Orig Artic Ser, V12, P123; FIALKOW PJ, 1990, VERH DEUT G, V74, P43; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; George AA, 2001, BLOOD, V97, P3925, DOI 10.1182/blood.V97.12.3925; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; HEPPNER GH, 1984, CANCER RES, V44, P2259; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kesler KA, 1999, J THORAC CARDIOV SUR, V118, P692, DOI 10.1016/S0022-5223(99)70015-2; KNUDSON AG, 1973, PROG MED GENET, V9, P113; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lemischka IR, 2003, NATURE, V425, P778, DOI 10.1038/425778a; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li L, 2003, CANCER RES, V63, P2733; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; MCBRIDE OW, 1982, NATURE, V300, P773, DOI 10.1038/300773a0; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Morrison SJ, 2002, J IMMUNOL, V168, P635, DOI 10.4049/jimmunol.168.2.635; NOWELL PC, 1986, CANCER RES, V46, P2203; Ohno R, 2003, LEUKEMIA, V17, P1454, DOI 10.1038/sj.leu.2403031; OZOLS RF, 1980, CANCER RES, V40, P4109; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Paterson SC, 2003, BRIT J CANCER, V88, P983, DOI 10.1038/sj.bjc.6600828; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; PHILLIPS RL, 1992, P NATL ACAD SCI USA, V89, P11607, DOI 10.1073/pnas.89.23.11607; Ravandi F, 2004, CANCER-AM CANCER SOC, V100, P441, DOI 10.1002/cncr.11935; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; SALSBURY AJ, 1975, CANCER TREAT REV, V2, P55, DOI 10.1016/S0305-7372(75)80015-6; Setoguchi T, 2004, CELL CYCLE, V3, P414; Singh SK, 2003, CANCER RES, V63, P5821; Smith GH, 2003, CELL PROLIFERAT, V36, P3, DOI 10.1046/j.1365-2184.36.s.1.2.x; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; ULBRIGHT TM, 1985, HUM PATHOL, V16, P268, DOI 10.1016/S0046-8177(85)80013-7; ULBRIGHT TM, 1984, CANCER-AM CANCER SOC, V54, P1824, DOI 10.1002/1097-0142(19841101)54:9<1824::AID-CNCR2820540910>3.0.CO;2-J; VARMUS H, 1986, CANCER SURV, V5, P153; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEISENTHAL LM, 1985, CANCER TREAT REP, V69, P615; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; WODINSKY ISIDORE, 1967, CANCER CHEMOTHER REP, V51, P415; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	91	672	774	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7274	7282		10.1038/sj.onc.1207947	http://dx.doi.org/10.1038/sj.onc.1207947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378087				2022-12-28	WOS:000223998800013
J	Ramakrishnan, R; Fujimura, Y; Zou, JP; Liu, F; Lee, L; Rao, VN; Reddy, ESP				Ramakrishnan, R; Fujimura, Y; Zou, JP; Liu, F; Lee, L; Rao, VN; Reddy, ESP			Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1	ONCOGENE			English	Article						EWS-Fli-1; Ewing's sarcoma; Fli-1; CBP; RXR	CREB-BINDING-PROTEIN; EWINGS-SARCOMA CELLS; RUBINSTEIN-TAYBI SYNDROME; ACUTE MYELOID-LEUKEMIA; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; CHIMERIC PROTEIN; TUMOR-CELLS; HISTONE ACETYLTRANSFERASE	In the majority of Ewing's family tumors, chromosomal translocation t(11; 22) leads to aberrant fusion of RNA-binding protein EWS with DNA-binding ETS transcriptional factor Fli-1. EWS-Fli-1 has altered the transcriptional activity and modulating its downstream target genes through this transcriptional activity is thought to be responsible for this tumor. We have previously shown that both EWS-Fli-1 and Fli-1 have antiapoptotic activity against several apoptotic inducers. Here, we show that the transcriptional activity of EWS-Fli-1 and Fli-1 is not essential for its antiapoptotic activity. We also demonstrate that EWS-Fli-1 and Fli-1 interact with CBP through its amino-terminal region and inhibit the CBP-dependent transcriptional activity of RXR. This activity appears to be independent of DNA-binding activity of EWS-Fli-1. Introduction of the dominant-negative form of CBP into Ewing's sarcoma cells sensitizes these cells against genotoxic or retinoic-acid induced apoptosis. These results suggest that the ability of EWS-Fli-1/Fli-1 to target transcriptional cofactor(s) and modulate apoptotic pathways may be responsible for its antiapoptotic and tumorigenic activities.	Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Med, Canc Biol Program, Atlanta, GA 30303 USA; Drexel Univ, Philadelphia, PA 19102 USA; SAIC, Frederick, MD 21702 USA	Morehouse School of Medicine; Drexel University; Science Applications International Corporation (SAIC); SAIC-Frederick	Reddy, ESP (corresponding author), Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Med, Canc Biol Program, 80 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.	ereddy@msm.edu			NATIONAL CANCER INSTITUTE [R01CA057322, R01CA085343, P50CA083591] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85642, CA 83591, R01 CA 85343, CA 57322] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; Deneen B, 2003, MOL CELL BIOL, V23, P3897, DOI 10.1128/MCB.23.11.3897-3908.2003; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Fujimura Y, 2001, ONCOGENE, V20, P6653, DOI 10.1038/sj.onc.1204684; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kung AL, 2000, GENE DEV, V14, P272; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Martini A, 2002, CANCER RES, V62, P5408; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Rossow KL, 2001, CANCER RES, V61, P2690; Sargiannidou I, 2004, SEMIN THROMB HEMOST, V30, P127; Sarrazin S, 2002, BBA-MOL CELL RES, V1592, P123, DOI 10.1016/S0167-4889(02)00290-2; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Soldatenkov VA, 2002, ONCOGENE, V21, P2890, DOI 10.1038/sj.onc.1205393; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WELFORD SM, 2001, J BIOL CHEM, V11, P11; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930; Zhao F, 2003, MOL CELL BIOL, V23, P3837, DOI 10.1128/MCB.23.11.3837-3846.2003; Zhou RR, 2002, CANCER GENE THER, V9, P407, DOI 10.1038/sj.cgt.7700449; Zhou ZC, 2001, CANCER RES, V61, P3394	56	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7087	7094		10.1038/sj.onc.1207927	http://dx.doi.org/10.1038/sj.onc.1207927			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273724				2022-12-28	WOS:000223885100009
J	Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL				Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL			Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12	ONCOGENE			English	Article						proteomics; 14-3-3 sigma; androgen receptor; epidermal growth factor receptor; prostate	GLUCOCORTICOID-RECEPTOR; CANCER; ASSOCIATION; PROTEINS	The epidermal growth factor receptor and androgen receptor (AR) bot h play major roles in the control of prostate growth. Our hypothesis is that shared downstream components of these two signaling pathways are significant participants in androgen-independent growth. Our first objective was to identify proteins whose activation and/or expression in AR-positive prostate epithelial cells are induced by both epidermal growth factor (EGF) and dihydrotestosterone (DHT). AR expression was induced in a tumorigenic, metastatic subline of the SV40 large T-antigen immortalized human prostate epithelial subline M12 by stable transfection with human wild-type AR cDNA. These M12AR (+) cells with functional AR were treated in parallel with EGF (10 ng/ml) or DHT (10(-8) M) for 24 h before 2D gel electrophoresis and Western immunoblotting with antiphosphotyrosine monoclonal antibody. Coomassie blue-stained spots on a 2D gel run in parallel were aligned with the phosphoproteins on the Western immunoblot, and identified by matrix-assisted laser desorption ionization/time-of-flight mass spectroscopy. The most interesting of the seven proteins that appeared to be phosphorylated by these criteria was 14-3-3 protein sigma. Protein extracted after either EGF or DHT treatment, immunoprecipitated with antiphosphotyrosine monoclonal antibody, and immunoblotted by anti-14-3-3 sigma confirmed phosphorylation of 14-3-3 sigma. Addition of either DHT or EGF to the M12AR(+) cells induced subcellular migration of 14-3-3 sigma and activated a 14-3-3 sigma reporter construct. Immunohistochemical analysis revealed nuclear localization of 14-3-3 sigma in higher Gleason grade prostate cancers relative to benign glands. These findings implicate 14-3-3 sigma in the development of human prostate cancer cells and could provide a new target for intervention in prostate cancer.	Virginia Commonwealth Univ, Med Ctr, Dept Pathol, Richmond, VA 23298 USA; Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; Virginia Commonwealth Univ, Med Ctr, Dept Biostat, Richmond, VA 23298 USA	Virginia Commonwealth University; University of Washington; University of Washington Seattle; Virginia Commonwealth University	Ware, JL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Pathol, 1101 E Marshall St,Sanger Hall Rm 5-014,POB 98066, Richmond, VA 23298 USA.	jlware@vcu.edu	Best, Al/F-6425-2012	Idowu, Michael/0000-0002-7416-5444; Best, Al/0000-0002-6300-3925; Ketchum, Jessica/0000-0002-5566-3691	NIDDK NIH HHS [R01 DK52683] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CULIG Z, 1994, CANCER RES, V54, P5474; El Sheikh SS, 2003, NEOPLASIA, V5, P99, DOI 10.1016/S1476-5586(03)80001-5; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Haendler B, 2001, MOL CELL ENDOCRINOL, V173, P63, DOI 10.1016/S0303-7207(00)00434-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Martel CL, 2003, CANCER TREAT REV, V29, P171, DOI 10.1016/S0305-7372(02)00090-7; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PLYMATE SR, 2004, IN PRESS PROSTATE; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/mend.15.4.0624	28	14	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6881	6889		10.1038/sj.onc.1207788	http://dx.doi.org/10.1038/sj.onc.1207788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15300238				2022-12-28	WOS:000223750700005
J	Bennett, RA; Izumi, H; Fukasawa, K				Bennett, RA; Izumi, H; Fukasawa, K			Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs	ONCOGENE			English	Article						centrosome amplification; chromosome instability; p53; DNA synthesis; anticancer drug	TUMOR-SUPPRESSOR GENE; P53; CANCER; HYPERAMPLIFICATION; OVEREXPRESSION; DUPLICATION; INHIBITOR; KINASES; CYCLE; P21	Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will re-enter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521,3125 Eden Ave, Cincinnati, OH 45267 USA.	kenji.fukasawa@uc.edu			NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Izumi H, 2002, NEOPLASIA, V4, P103, DOI 10.1038/sj.neo.7900205; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; OAKLEY A, 1996, EFFECTIVE HLTH CARE, V2, P1; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	21	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6823	6829		10.1038/sj.onc.1207561	http://dx.doi.org/10.1038/sj.onc.1207561			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273731				2022-12-28	WOS:000223653600015
J	Kim, CJ; Cho, YG; Park, CH; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Kim, CJ; Cho, YG; Park, CH; Kim, SY; Nam, SW; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Genetic alterations of the MYH gene in gastric cancer	ONCOGENE			English	Article						somatic mutation; stomach cancer; loss of heterozygosity; DNA repair	OXIDATIVE DNA-DAMAGE; SOMATIC G-C->T-A MUTATIONS; HELICOBACTER-PYLORI; ESCHERICHIA-COLI; MUTY GENE; ADENOMATOUS POLYPOSIS; GERMLINE MUTATIONS; TRANSVERSIONS; REPAIR; HOMOLOG	Increased oxygen free radicals produced in gastric mucosa by H. pylori induce DNA damage and lead to dyspalsia and gastric cancers. However, only a small percentage of individuals that carry H. pylori develop gastric cancer, indicating that other factors are involved. We have screened a set of 95 sporadic gastric cancers for mutations and allele loss of the DNA glycosylase MYH gene, which excises adenine misincorporated opposite unrepaired 8-oxoG. Two of 95 cancers had bi-allelic mutations of the MYH gene with somatic missense mutation of one allele and loss of the remaining allele. The mutations were missense mutations, P391S and Q400R, in exon 13 encoding NUDIX hydrolase domain of the gene. The patients were H. pylori-positive and the tumors were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 4 (17.4%) of 23 informative cases showed allele loss at MYH locus. Therefore, our data suggest that somatic mutations of base excision repair gene MYH contribute to the development of a sub-set of sporadic gastric cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Baik SC, 1996, CANCER RES, V56, P1279; Cheadle JP, 2003, HUM MOL GENET, V12, pR159, DOI 10.1093/hmg/ddg259; Danese S, 2001, SCAND J GASTROENTERO, V36, P247, DOI 10.1080/003655201750074474; Farinati F, 1998, GUT, V42, P351, DOI 10.1136/gut.42.3.351; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Maaroos HI, 1999, SCAND J GASTROENTERO, V34, P864, DOI 10.1080/003655299750025318; MALINS DC, 1991, CANCER RES, V51, P5430; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; MORIYA M, 1993, MOL GEN GENET, V239, P72, DOI 10.1007/BF00281603; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Noguchi K, 2002, PATHOL INT, V52, P110, DOI 10.1046/j.1440-1827.2002.01331.x; OKAMOTO K, 1994, INT J CANCER, V58, P825, DOI 10.1002/ijc.2910580613; Sampson JR, 2003, LANCET, V362, P39, DOI 10.1016/S0140-6736(03)13805-6; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Smoot DT, 2000, CARCINOGENESIS, V21, P2091, DOI 10.1093/carcin/21.11.2091; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405	25	26	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6820	6822		10.1038/sj.onc.1207574	http://dx.doi.org/10.1038/sj.onc.1207574			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273732				2022-12-28	WOS:000223653600014
J	Malavaud, B; Pedron, S; Sordello, S; Mazerolles, C; Billottet, C; Thiery, JP; Jouanneau, J; Plouet, J				Malavaud, B; Pedron, S; Sordello, S; Mazerolles, C; Billottet, C; Thiery, JP; Jouanneau, J; Plouet, J			Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells	ONCOGENE			English	Article						anti-idiotypic antibodies; fibroblast growth factor; angiogenesis; tumor proliferation	FIBROBLAST-GROWTH-FACTOR; ENDOTHELIAL-CELLS; FACTOR-2; SUFFICIENT; RELEASE	The hypothesis that tumor growth is angiogenesis-dependent has been documented by a considerable body of direct and indirect experimental data. Since the discovery of the vascular endothelial growth factor ( VEGF), most attention has been focused on the VEGF system. Although fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) can exert a strong angiogenic activity when they are supplied as a single pharmacological agent, their role in pathological angiogenesis in preclinical models remains controversial. To decipher the contribution of FGF receptors in various models of angiogenesis, we took advantage of the anti-idiotypic strategy to obtain circulating agonists specific for FGFR-1 and FGFR-2 (AIdF-1 and AIdF-2). They mimicked FGF-1 and FGF-2 for receptor binding, signal transduction, proliferation of endothelial cells and differentiation of the bladder carcinoma cell NBT-II which expresses FGFR-2b but not FGFR-1. The constitutive expression of FGFR-1 allowed binding of FGF-2 and AIdF-2 and inhibition of the proliferation of NBT-II cells. AIdF-1 and AIdF-2 induced angiogenesis in the corneal pocket assay. Although FGFR-1 dimerization achieved by AIdF-2 injection led to highly differentiated and smaller NBT-II tumors, no sign of reduction of tumor angiogenesis was observed, thus suggesting that endothelial cells are resistant to FGF.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Univ Toulouse 3, CHU Toulouse Rangueil, Clin Univ Urol, F-31062 Toulouse, France; CHU Toulouse Purpan, Lab Anatomopathol, F-31059 Toulouse, France; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Plouet, J (corresponding author), Hop Lariboisiere, Inst Vaisseaux & Sang, 8 Rue Guy Patin, F-75010 Paris, France.	jean.plouet@idf.inserm.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Billottet C, 2002, ONCOGENE, V21, P8128, DOI 10.1038/sj.onc.1205935; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COURAUD PO, 1991, BIOCHEM SOC T, V19, P147, DOI 10.1042/bst0190147; GOSPODAROWICZ D, 1987, NUCL MED BIOL, V14, P421, DOI 10.1016/0883-2897(87)90019-5; Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; Jouanneau J, 1999, ONCOGENE, V18, P327, DOI 10.1038/sj.onc.1202285; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; Ortega N, 1997, AM J PATHOL, V151, P1215; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; PLOUET J, 1990, EXP EYE RES, V51, P519, DOI 10.1016/0014-4835(90)90082-6; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QUARTO N, 1994, J CELL SCI, V107, P3201; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	30	3	3	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6769	6778		10.1038/sj.onc.1207135	http://dx.doi.org/10.1038/sj.onc.1207135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273729				2022-12-28	WOS:000223653600008
J	Schwarzbach, MHM; Koesters, R; Germann, A; Mechtersheimer, G; Geisbill, J; Winkler, S; Niedergethmann, M; Ridder, R; Buechler, MW; Doeberitz, MVK; Willeke, F				Schwarzbach, MHM; Koesters, R; Germann, A; Mechtersheimer, G; Geisbill, J; Winkler, S; Niedergethmann, M; Ridder, R; Buechler, MW; Doeberitz, MVK; Willeke, F			Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas	ONCOGENE			English	Article						liposarcoma; FUS/CHOP; fusion transcript; transformation	RNA-BINDING PROTEIN; MYXOID LIPOSARCOMA; TLS-CHOP; ONCOGENIC TRANSFORMATION; TRANSLOCATIONS; IDENTIFICATION; BREAKPOINTS; INHIBITION; INDUCTION; T(12-16)	The chromosomal translocation t(12; 16)(q13; p11) is a common genetic alteration in myxoid and round-cell liposarcomas. It results in transcription of various chimeric FUS/CHOP fusion transcripts that encode different oncogenic proteins. Recent reports suggest that these may have different neoplastic transformation activities. To audit this hypothesis, we transfected expression plasmids for the two major variant FUS/ CHOP transcripts I and II in NIH 3T3 cells and determined the number of outgrowing foci as well as their growth potential in soft agar. In addition, we compared tumour growth in nude mice upon subcutaneous injection of the respective transfectants. No significant differences in transformation assays in vitro and in vivo were observed, suggesting that both variant transcripts confer comparable transforming activities. The histopathological picture of tumours derived from both cell populations resembles high-grade spindle cell sarcomas. This suggests that both FUS/ CHOP variants cause similar patterns of differential gene expression. This hypothesis was confirmed by mRNA-expression profiles of the respective cell clones. Strong overexpression of the pentaxin-related gene (PTX), the osteoblast-specific factor 2 (osf-2), the basic Kruppel-like factor (bklf), the leucoprotease inhibitor, and the cyclophilin B were observed in both types of FUS/ CHOP-transfected cell clones. Taken together, our data suggest that different FUS/ CHOP variants cause transformation of mesenchymal cells via the same pathways with comparable efficacy.	Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Surg, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Pathol, D-69120 Heidelberg, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Heidelberg Univ, Mannheim Univ Clin, Dept Surg, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Doeberitz, MVK (corresponding author), Heidelberg Univ, Inst Mol Pathol, INF 220-221, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de	von Knebel Doeberitz, Magnus/D-2372-2016	von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Antonescu CR, 2001, CLIN CANCER RES, V7, P3977; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; BUTTERWITH SC, 1994, PHARMACOL THERAPEUT, V61, P399, DOI 10.1016/0163-7258(94)90018-3; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Domoto H, 2002, PATHOL INT, V52, P497, DOI 10.1046/j.1440-1827.2002.01391.x; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Genini M, 1996, INT J CANCER, V66, P571; Gohara R, 2002, J IMMUNOTHER, V25, P439, DOI 10.1097/00002371-200209000-00008; Gomi S, 1999, J IMMUNOL, V163, P4994; Ito T, 2002, KIDNEY INT, V62, P763, DOI 10.1046/j.1523-1755.2002.00533.x; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; KURODA M, 1995, AM J PATHOL, V147, P1221; Kuroda M, 1997, AM J PATHOL, V151, P735; Kuroda M, 1999, P NATL ACAD SCI USA, V96, P5025, DOI 10.1073/pnas.96.9.5025; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schneider-Stock R, 1999, CANCER GENET CYTOGEN, V111, P130, DOI 10.1016/S0165-4608(98)00197-6; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Willeke F, 1998, CLIN CANCER RES, V4, P1779; YOSHIKAWA H, 1994, CANCER, V73, P85, DOI 10.1002/1097-0142(19940101)73:1<85::AID-CNCR2820730116>3.0.CO;2-8; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	32	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6798	6805		10.1038/sj.onc.1207840	http://dx.doi.org/10.1038/sj.onc.1207840			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15286712				2022-12-28	WOS:000223653600011
J	An, JB; Fisher, M; Rettig, MB				An, JB; Fisher, M; Rettig, MB			VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappa B-dependent mechanism	ONCOGENE			English	Article						bortezomib; renal cell carcinoma; von Hippel-Lindau tumor suppressor gene; NF-kappa B; RNA interference	PROTEASOME INHIBITOR PS-341; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; DRUG-RESISTANCE; CANCER; APOPTOSIS; ACTIVATION; PRODUCT; PATHWAY; MYELOMA	In renal cell carcinomas (RCC), NF-kappaB blockade is required for maximal bortezomib-induced apoptosis, and expression of the von Hippel-Lindau (VHL) tumor suppressor protein downregulates NF-kappaB. Thus, we hypothesized that expression of wild-type (wt) VHL sensitizes RCC cells to bortezomib by reducing constitutive NF-kappaB activity. Using isogenic paired cell lines with and without expression of wtVHL, we have confirmed that VHL expression reduces constitutive NF-kappaB activity. Moreover, VHL expression confers markedly heightened sensitivity to the growth inhibitory effects of bortezomib in vitro. The bortezomib IC50 values were greater than two logs lower in the VHL-expressing cell lines compared to the VHL-deficient counterparts. By manipulating the level of constitutive NF-kappaB activity in an isogenic pair of RCC cell lines independently of VHL expression, we were able to demonstrate that the VHL sensitization effect is due to downregulation of NF-kappaB activity. These findings offer the enticing possibility of using VHL status as a molecular marker to identify RCC patients who may be sensitive to bortezomib. In particular, RCC patients who have non-clear-cell histologies as well as approximately 25% of clear-cell RCCs manifest expression of wtVHL and represent a subpopulation of patients that is apt to respond to bortezomib.	VAGLAHS, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), VAGLAHS, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA.	matthew.rettig@med.va.gov						Adams J, 1999, CANCER RES, V59, P2615; An JB, 2004, MOL CANCER THER, V3, P727; An JB, 2003, CLIN CANCER RES, V9, P4537; ATKINS MB, 2004, UP TO DATE; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; CHEN F, 1995, CANCER RES, V55, P4804; Cusack JC, 2001, CANCER RES, V61, P3535; Davis NB, 2004, J CLIN ONCOL, V22, P115, DOI 10.1200/JCO.2004.07.165; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Glaspy JA, 2002, SEMIN ONCOL, V29, P41, DOI 10.1053/sonc.2002.33083; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Godley P, 2002, CURR OPIN ONCOL, V14, P280, DOI 10.1097/00001622-200205000-00005; Gunaratnam L, 2003, J BIOL CHEM, V278, P44966, DOI 10.1074/jbc.M305502200; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Nathan PD, 2002, LANCET ONCOL, V3, P89, DOI 10.1016/S1470-2045(02)00650-2; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pavlovich CP, 2003, UROL CLIN N AM, V30, P437, DOI 10.1016/S0094-0143(03)00023-5; Qi H, 2003, CANCER RES, V63, P7076; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288	25	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1563	1570		10.1038/sj.onc.1208348	http://dx.doi.org/10.1038/sj.onc.1208348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608669				2022-12-28	WOS:000227218200009
J	Belguise, K; Kersual, N; Galtier, F; Chalbos, D				Belguise, K; Kersual, N; Galtier, F; Chalbos, D			FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells	ONCOGENE			English	Article						FRA-1; cell proliferation; in vitro invasion; gene expression; breast cancer cells	ENDOTHELIAL GROWTH-FACTOR; ACTIVATOR PROTEIN-1 ACTIVITY; FOS-RELATED ANTIGEN-1; TISSUE INHIBITOR; C-FOS; METALLOPROTEINASES-1 TIMP-1; MATRIX METALLOPROTEINASES; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; BINDING-ACTIVITY	Breast cancer progression is likely a multistep process involving the activation and inactivation of a number of genes. Previously, we showed that the mRNA coding for Fra-1, a FOS family member and an AP-1 transcription factor component, was highly expressed in the more invasive estrogen receptor negative (ER-) breast cancer cell lines. We used a tet-off system to stably overexpress Fra-1 in MCF7 ER + cells and evaluate the impact of Fra-1 on this aggressive phenotype. Conversely, Fra-1 was silenced in highly invasive ER-MDA-MB231 cells using RNA interference. We report that in both systems the Fra-1 expression level was positively associated with cell proliferation, cell motility and invasiveness assessed in vitro. In addition, Fra-1 inhibition in fibroblastoid ER-cells, which formed colonies with large stellate projections in Matrigel, resulted in morphological changes. Cells acquired an epithelioid shape and had a spherical appearance in Matrigel. Fra-1 regulated several genes, implicated in invasion, angiogenesis and cell proliferation independently of beta1-integrin activation, and directly induced MMP-1 and MMP-9 promoter activity. These overall results show that high Fra-1 expression is associated with a more malignant cell phenotype and suggest that Fra-1 could have a pivotal role in breast cancer progression.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Chalbos, D (corresponding author), INSERM, U540, 60 Reu Navacelles, F-34090 Montpellier, France.	chalbos@u540.montp.inserm.fr		Belguise, Karine/0000-0003-3426-8040				Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Bamberger AM, 2000, HORM RES, V54, P32; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; Gasparini G, 2000, Oncologist, V5 Suppl 1, P37; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hua J, 1996, CANCER RES, V56, P5279; Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li GY, 1999, CANCER RES, V59, P6267; Luo YP, 2003, P NATL ACAD SCI USA, V100, P8850, DOI 10.1073/pnas.1033132100; MATSUI M, 1990, ONCOGENE, V5, P249; MCGUIRE WL, 1975, ANNU REV MED, V26, P353, DOI 10.1146/annurev.me.26.020175.002033; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ramos-Nino ME, 2002, CANCER RES, V62, P6065; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Yoshiji H, 1996, CANCER RES, V56, P2013; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zajchowski DA, 2001, CANCER RES, V61, P5168	59	172	182	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1434	1444		10.1038/sj.onc.1208312	http://dx.doi.org/10.1038/sj.onc.1208312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608675	Bronze			2022-12-28	WOS:000227092600013
J	von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T				von Wichert, T; Haeussler, U; Greten, FR; Kliche, S; Dralle, H; Bohm, BO; Adler, G; Seufferlein, T			Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells	ONCOGENE			English	Article						IGF-I; cyclin D1; PI3-kinase; neuroendocrine tumours; NF kappa B	GROWTH-FACTOR-I; NF-KAPPA-B; CARCINOID-TUMORS; CANCER-CELLS; ANTISENSE; PATHWAYS; PROMOTER; KINASE	Constitutive expression of cyclin D1 is a frequent abnormality in human cancer and sustains the transformed phenotype. We have previously demonstrated that cyclin D1 is constitutively expressed in human BON neuroendocrine tumour cells due to an autocrine insulin-like growth factor-I (IGF-I) loop. Here we examine the regulation of cyclin D1 expression by endogenously released IGF-I in BON cells. Cyclin D1 expression in these cells was found to be dependent on phosphatidylinositol 3-kinase (PI3-K), but independent of the extracellular signal-regulated kinase cascade. Ras- and Rac-GTPases were found to be upstream activators of cyclin D1 expression, whereas protein kinase B/AKT and nuclear factor kappa B (NFkappaB) could be established as downstream mediators of cyclin D1 transcription in response to endogenously released IGF-I in these cells. In addition, the Ras/PI3-K/AKT/Rac/NFkappaB/ cyclin D1 signaling cascade triggered by endogenously released IGF-I is sufficient to sustain Rb phosphorylation and cdk4 kinase activity in BON cells. In conclusion, our data provide the first comprehensive map of the signaling events elicited by endogenously released IGF-I leading to constitutive cyclin D1 expression in human neuroendocrine tumour cells.	Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg, D-06099 Halle Saale, Germany	Ulm University; Ulm University; Martin Luther University Halle Wittenberg	Seufferlein, T (corresponding author), Univ Ulm, Med Klin, Innere Med Abt 1, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.seufferlein@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Greten, Florian R/AAF-5196-2020; Boehm, Bernhard Otto/F-8750-2015	Greten, Florian R/0000-0002-3928-6080; 				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Oberg K, 2002, CURR OPIN ONCOL, V14, P38, DOI 10.1097/00001622-200201000-00008; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; von Wichert G, 2000, CANCER RES, V60, P4573; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023; ZHOU P, 1995, ONCOGENE, V11, P571	20	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1284	1289		10.1038/sj.onc.1208264	http://dx.doi.org/10.1038/sj.onc.1208264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580291				2022-12-28	WOS:000226898700016
J	Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K				Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K			HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein	ONCOGENE			English	Article						HTLV-1; ATL; HBZ; AP-1; c-jun; transcription	VIRUS TYPE-I; HUMAN-PAPILLOMAVIRUS TYPE-16; CELL LEUKEMIA-CELLS; FACTOR-KAPPA-B; TAX PROTEIN; T-CELLS; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE EXPRESSION; INTERLEUKIN-8 GENE; E6 ONCOPROTEIN	Disruption of transcriptional control of cellular genes by human T-cell leukemia virus type-1 (HTLV-1) is thought to be associated, at least in part, with the development of adult T-cell leukemia. It has been reported that activating protein-1 (AP-1) is dysregulated by HTLV-1 infection. HTLV-1-encoded Tax elevates AP-1 activity through the induction of AP-1 family member gene expression, including c-Jun, JunD, c-Fos, and Fra-1. However, the precise mechanism by which HTLV-1 regulates AP-1 activity remains to be addressed. Recently, a novel viral protein named HTLV-1 basic leucine-zipper factor, HBZ, has been shown to interact with c-Jun and repress c-Jun-mediated transcription by abrogating its DNA-binding activity. In the course of investigating HBZ function, we found that HBZ reduced the steady-state levels of c-Jun, and the levels were restored by treatment with a proteasome inhibitor. Together, this indicates that HBZ promotes c-Jun degradation through a proteasome-dependent pathway. Furthermore, HBZ deletion mutants revealed that both the N-terminal and leucine-zipper region of HBZ were required for the elimination of c-Jun. These results suggest dual effects of HBZ on the suppression of AP-1 activity by inhibiting c-Jun function, which may contribute to the dysregulation of cell proliferation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan.	tohshima@virus.kyoto-u.ac.jp; kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu W, 1997, J NEUROVIROL, V3, P16, DOI 10.3109/13550289709015789; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOOPER WC, 1991, BIOCHEM BIOPH RES CO, V181, P976, DOI 10.1016/0006-291X(91)92032-F; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2000, BLOOD, V95, P3915; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	30	104	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1001	1010		10.1038/sj.onc.1208297	http://dx.doi.org/10.1038/sj.onc.1208297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592508				2022-12-28	WOS:000226749200006
J	Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ				Daly, NL; Arvanitis, DA; Fairley, JA; Gomez-Roman, N; Morton, JP; Graham, SV; Spandidos, DA; White, RJ			Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus	ONCOGENE			English	Article						cervical cancer; human papillomavirus (HPV); RNA polymerase III (pol III); TFIIIB; transcription	TATA-BINDING-PROTEIN; GENE; EXPRESSION; ACTIVATION; CANCER; INTEGRATION; SEQUENCES; TYPE-16; HPV; REPRESSION	RNA polymerase (pol) III transcription is a major determinant of biosynthetic capacity, providing essential products such as tRNA and 5S rRNA. It is controlled directly by the tumour suppressors RB and p53. High-risk types of human papillomavirus (HPV), such as HPV16, express the oncoproteins E6 and E7 that can inactivate p53 and RB, respectively. Accordingly, both E6 and E7 stimulate pol III transcription in cultured cells. HPV16-positive cervical biopsies express elevated levels of tRNA and 5S rRNA when compared to biopsies that test negative for HPV or are infected with the lower risk HPV11. Integration of viral DNA into the host cell genome stimulates expression of E6 and E7 and correlates with induction of tRNA and 5S rRNA. Expression of mRNA encoding the pol III-specific transcription factor Brf1 also correlates with the presence of integrated HPV16. Brf1 levels are limiting for tRNA and 5S rRNA synthesis in cervical cells. Furthermore, pol III-transcribed genes that do not use Brf1 are not induced in HPV16-positive biopsies. Three complementary mechanisms may therefore allow high-risk HPV to stimulate production of tRNA and 5S rRNA: E6-mediated removal of p53; E7-mediated neutralization of RB; and induction of Brf1. The resultant increase in biosynthetic capacity may contribute to deregulated cell growth.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Greece	University of Glasgow; University of Crete	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk	Morton, Jennifer P/E-1633-2011; Arvanitis, Demetrios A/J-6434-2017; Morton, Jennifer/AAJ-5113-2021	Morton, Jennifer P/0000-0001-5766-9141; Arvanitis, Demetrios A/0000-0003-1231-320X; Morton, Jennifer/0000-0001-5766-9141; Graham, Sheila/0000-0002-7140-8279; Spandidos, Demetrios/0000-0002-1146-931X; Gomez-Roman, Natividad/0000-0002-2325-7517				Aasen T, 2003, ONCOGENE, V22, P7969, DOI 10.1038/sj.onc.1206709; Alazawi W, 2002, CANCER RES, V62, P6959; ARENDS MJ, 1991, J PATHOL, V165, P301, DOI 10.1002/path.1711650405; BALDWIN P, 2003, NAT REV CANCER, V3, P1; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Clayton DA, 2001, NATURE, V410, P29, DOI 10.1038/35065191; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GEY GO, 1952, CANCER RES, V12, P264; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; KOFFA M, 1994, INT J ONCOL, V5, P189; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; White RJ, 2004, EUR J CANCER, V40, P21, DOI 10.1016/j.ejca.2003.09.027; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; YEE C, 1985, AM J PATHOL, V119, P361; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	49	33	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					880	888		10.1038/sj.onc.1208031	http://dx.doi.org/10.1038/sj.onc.1208031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592529				2022-12-28	WOS:000226577100014
J	Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P				Yoon, T; Chakrabortty, A; Franks, R; Valli, T; Kiyokawa, H; Raychaudhuri, P			Tumor-prone phenotype of the DDB2-deficient mice	ONCOGENE			English	Article						DDB2; DNA repair; XP-E; UV-induced tumor; DDB2 knockout mice	DNA-BINDING-PROTEIN; PIGMENTOSUM GROUP-E; NUCLEOTIDE EXCISION-REPAIR; GLOBAL GENOMIC REPAIR; GROUP-E CELLS; XERODERMA-PIGMENTOSUM; DAMAGED-DNA; UBIQUITIN LIGASE; UV-IRRADIATION; ULTRAVIOLET-B	DDB2 is an essential subunit of the damaged-DNA recognition factor DDB, which is involved in global genomic repair in human cells. Moreover, DDB2 is mutated in the repair-deficiency disease xeroderma pigmentosum ( Group E). Expression of DDB2 in human cells is induced by P53, BRCA1 and by ionizing radiation. The DDB2 protein associates with transcriptional activator and coactivator proteins. In addition, DDB2 in conjunction with DDB1 associates with cullin 4A and the Cop9/signalosome. We generated a mouse strain deficient for DDB2 (DDB2-/-). Consistent with the human disease (XP-E), the DDB2-/- mice were susceptible to UV-induced skin carcinogenesis. We observed a significant difference in the initial rate of cyclobutane pyrimidine dimer (CPD)-removal from the skin following UV irradiation. Also, the DDB2-deficient mice exhibited a significantly reduced life span compared to their wild-type littermates. Moreover, unlike other XP-deficient mice, the DDB2-deficient mice developed spontaneous malignant tumors at a high rate between the ages of 20 and 25 months. The observations suggest that, in addition to DNA repair, the other interactions of DDB2 are significant in its tumor suppression function.	Univ Illinois, Dept Biochem & Mol Genet MC 669, Chicago, IL 60607 USA; Univ Illinois, Coll Vet Med, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [1R01CA100204, R01 CA088863, R01 CA100204, CA 88863, R01 CA088863-05, R01 CA077637-06A1, R01 CA077637, CA 77637] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100204, R01CA088863, R01CA077637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22439; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Inoki T, 2004, BIOCHEM BIOPH RES CO, V314, P1036, DOI 10.1016/j.bbrc.2004.01.003; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Itoh T, 2003, MOL CELL BIOL, V23, P7540, DOI 10.1128/MCB.23.21.7540-7553.2003; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lu YP, 1999, CANCER RES, V59, P4591; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	43	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					469	478		10.1038/sj.onc.1208211	http://dx.doi.org/10.1038/sj.onc.1208211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558025	Green Accepted			2022-12-28	WOS:000226279700017
J	Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F				Bernard-Pierrot, I; Ricol, D; Cassidy, A; Graham, A; Elvin, P; Caillault, A; Lair, S; Broet, P; Thiery, JP; Radvanyi, F			Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; urothelial cell carcinoma; IGF-II; tumour suppressor gene; DNA array		The b isoform of fibroblast growth factor receptor 2, FGFR2b/FGFR2-IIIb/Ksam-IIC1/KGFR, a tyrosine kinase receptor, is expressed in a wide variety of epithelia and is downregulated in several human carcinomas including prostate, salivary and urothelial cell carcinomas. FGFR2b has been shown to inhibit growth in tumour cell lines derived from these carcinomas. Here, we investigated the molecular mechanisms underlying the inhibition of human urothelial carcinoma cell growth following FGFR2b expression. Using a nylon DNA array, we analysed the gene expression pro. le of the T24 bladder tumour cell line, transfected or not with a construct encoding FGFR2b. The expression of FGFR2b in T24 cells decreased insulin-like growth factor (IGF)-II mRNA levels. This decrease was correlated with a decrease in IGF-II secretion and may have been responsible for the observed inhibition of cell growth because the addition of exogenous IGF-II restored growth rates to normal levels. Using SU5402, an inhibitor of FGFR tyrosine kinase activity, and a kinase dead mutant of the receptor, FGFR2b Y659F/Y660F, we also demonstrated that the growth inhibition and decrease in IGF-II secretion induced by FGFR2b did not require tyrosine kinase activity. Finally, we demonstrated the involvement of the distal carboxy-terminal domain of the receptor in decreasing IGF-II expression and inhibiting T24 cell growth, as Ksam-IIC3, a variant of FGFR2b carrying a short carboxy-terminus, neither downregulated IGF-II nor inhibited cell proliferation. Our data suggest that FGFR2b inhibits the growth of bladder carcinoma cells by reducing IGF-II levels via its carboxy-terminal domain, independent of its tyrosine kinase activity.	Inst Curie, Sect Rech, CNRS, UMR144, F-75248 Paris, France; AstraZeneca, Canc & Infect Res Area, Macclesfield SK10 4TG, Cheshire, England; Hop Paul Brousse, F-94807 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; AstraZeneca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP	Radvanyi, F (corresponding author), Inst Curie, Sect Rech, CNRS, UMR144, 26 Rue Ulm, F-75248 Paris, France.	francois.radvanyi@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020; BROET, PHILIPPE/0000-0001-9122-2810				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Berger W, 1999, INT J CANCER, V83, P415, DOI 10.1002/(SICI)1097-0215(19991029)83:3<415::AID-IJC19>3.0.CO;2-Y; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Broet P, 2002, J COMPUT BIOL, V9, P671, DOI 10.1089/106652702760277381; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; FENG S, 1997, CANCER RES, V23, P5369; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Freeman KW, 2003, CANCER RES, V63, P6237; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; Matsubara A, 1998, CANCER RES, V58, P1509; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; Myoken Y, 1996, INT J CANCER, V65, P650, DOI 10.1002/(SICI)1097-0215(19960301)65:5<650::AID-IJC15>3.0.CO;2-B; Naimi B, 2002, PROSTATE, V52, P245, DOI 10.1002/pros.10104; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sakaguchi K, 1999, ONCOGENE, V18, P5497, DOI 10.1038/sj.onc.1202947; Volm M, 1997, EUR J CANCER, V33, P691, DOI 10.1016/S0959-8049(96)00411-X; WARE LB, 2002, AM J PHYSIOL-LUNG C, V5, P924; WILKIE AOM, 1995, CURR BIOL, V5, P500; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	46	33	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9201	9211		10.1038/sj.onc.1208150	http://dx.doi.org/10.1038/sj.onc.1208150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516981				2022-12-28	WOS:000225638000005
J	Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M				Pajonk, F; Weil, A; Sommer, A; Suwinski, R; Henke, M			The erythropoietin-receptor pathway modulates survival of cancer cells	ONCOGENE			English	Article						cancer; Epo; EpoR; NF-kappa B; radiation response	NF-KAPPA-B; QUALITY-OF-LIFE; EPOETIN-ALPHA; DOUBLE-BLIND; TUMOR-CELLS; ANEMIA; RADIOSENSITIVITY; CHEMOTHERAPY; RADIOTHERAPY; SENSITIVITY	Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-kappaB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-kappaB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-kappaB did not require degradation of IkappaBalpha and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.	Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, D-79106 Freiburg, Germany; Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Radiat Oncol, Gliwice, Poland	University of Freiburg; Maria Sklodowska-Curie National Research Institute of Oncology	Pajonk, F (corresponding author), Radiol Univ Clin, Dept Radiat Therapy, Clin & Expt Radiat Biol Res Sect, Robert Koch Str 3, D-79106 Freiburg, Germany.	pajonk@uni-freiburg.de	Pajonk, Frank/E-4247-2010	Suwinski, Rafal/0000-0002-3895-7938				Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Batra S, 2003, LAB INVEST, V83, P1477, DOI 10.1097/01.LAB.0000090156.94795.48; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Damen JE, 1996, EXP HEMATOL, V24, P1455; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dunst J, 2003, INT J RADIAT ONCOL, V56, P778, DOI 10.1016/S0360-3016(03)00123-8; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Frommhold H, 1998, STRAHLENTHER ONKOL, V174, P31; Gabrilove JL, 2001, J CLIN ONCOL, V19, P2875, DOI 10.1200/JCO.2001.19.11.2875; Harrison LB, 2002, ONCOLOGY-BASEL, V63, P11, DOI 10.1159/000067147; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HIRST DG, 1984, INT J RADIAT BIOL, V46, P345, DOI 10.1080/09553008414551521; HIRST DG, 1987, INT J RADIAT BIOL, V51, P597, DOI 10.1080/09553008414552131; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JOINER B, 1993, BRIT J CANCER, V68, P720, DOI 10.1038/bjc.1993.417; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; POSKITT TR, 1987, CANCER INVEST, V5, P231, DOI 10.3109/07357908709011739; Ribatti D, 2003, HISTOPATHOLOGY, V42, P246, DOI 10.1046/j.1365-2559.2003.01581.x; SANTUCCI MA, 1994, STEM CELLS, V12, P506, DOI 10.1002/stem.5530120506; Suwinski R, 1999, RADIOTHER ONCOL, V50, P57, DOI 10.1016/S0167-8140(99)00014-6; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214	29	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8987	8991		10.1038/sj.onc.1208140	http://dx.doi.org/10.1038/sj.onc.1208140			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480420				2022-12-28	WOS:000225354600014
J	Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J				Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J			Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy	ONCOGENE			English	Article						NF-kappa B; pyropheophorbide; photodynamic therapy; endothelial cells; oxidative stress; adhesion molecules	NF-KAPPA-B; PYROPHEOPHORBIDE-A; OXIDATIVE STRESS; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; TUMOR; MATRIX-METALLOPROTEINASE-9; ACTIVATION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a treatment for cancer and several noncancerous proliferating cell diseases that depends on the uptake of a photosensitizing compound followed by selective irradiation with visible light. In the presence of oxygen, irradiation leads to the production of reactive oxygen species (ROS). A large production of ROS induces the death of cancer cells by apoptosis or necrosis. A small ROS production can activate various cellular pathways. Here, we show that PDT by pyropheophorbide-a methyl ester (PPME) induces the activation of nuclear factor kappa B (NF-kappaB) in HMEC-1 cells. NF-kappaB is active since it binds to the NF-kappaB sites of both ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) promoters and induces the transcription of several NF-kappaB target genes such as those of IL-6, ICAM-1, VCAM-I. In contrast, expression of ICAM-1 and VCAM-I at the protein level was not observed, although we measured an IL-6 secretion. Using specific chemical inhibitors, we showed that the lack of ICAM-1 and VCAM-I expression is the consequence of their degradation by lysosomal proteases. The proteasome and calpain pathways were not involved. All these observations were consistent with the fact that no adhesion of granulocytes was observed in these conditions.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Dept Immunol & Vaccinol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19; Arkell J, 2003, CELL BIOCHEM FUNCT, V21, P381, DOI 10.1002/cbf.1037; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; deVree WJA, 1996, CANCER RES, V56, P2908; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gollnick SO, 1997, CANCER RES, V57, P3904; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HENDERSON BW, 1995, PHOTOCHEM PHOTOBIOL, V62, P780, DOI 10.1111/j.1751-1097.1995.tb08730.x; Henderson BW, 1997, CANCER RES, V57, P4000; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Krammer B, 2001, ANTICANCER RES, V21, P4271; KROSL G, 1995, BRIT J CANCER, V71, P549, DOI 10.1038/bjc.1995.108; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Marcinkowska A, 2001, FOLIA HISTOCHEM CYTO, V39, P177; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Niziolek M, 2003, PHOTOCHEM PHOTOBIOL, V78, P262, DOI 10.1562/0031-8655(2003)078<0262:CAACAO>2.0.CO;2; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Rousset N, 1999, J PHOTOCH PHOTOBIO B, V52, P65, DOI 10.1016/S1011-1344(99)00104-9; Santos CF, 2003, AM J PHYSIOL-HEART C, V285, pH775, DOI 10.1152/ajpheart.00818.2002; Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	40	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8649	8658		10.1038/sj.onc.1207871	http://dx.doi.org/10.1038/sj.onc.1207871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467759				2022-12-28	WOS:000224988800011
J	Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T				Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T			Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors	ONCOGENE			English	Article						Aggrus; seminoma; embryonal carcinoma; germ cell tumor	EUROPEAN COUNTRIES; EXPRESSION; T1-ALPHA; CANCER; IDENTIFICATION; ANTIGENS; PROTEIN; BIRTH; RAT	Aggrus ( also known as T1alpha/podoplanin) is a membrane sialoglycoprotein whose function in tumors is unknown. We recently determined that Aggrus possessed the ability of inducing platelet aggregation and that its expression was frequently upregulated in colorectal tumors. Thus, Aggrus expression might be associated with tumor-induced platelet aggregation and tumor metastasis. Here we show, by means of cancer pro. ling array and real-time PCR, that aggrus mRNA expression is frequently upregulated in testicular germ cell tumors when compared with the surrounding normal tissue. Immunohistochemical staining revealed that Aggrus protein expression was detected in 10 of 11 seminomas (90.9%), but its expression was not observed in embryonal carcinomas (0/4; 0%). Specific markers for seminomas have not been reported, and Aggrus is a potential diagnostic marker for seminomas and may be associated with malignancies of the testis.	Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Yamagata Univ, Sch Med, Dept Expt & Forens Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Urol, Yamagata 9909585, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Yamagata University; Yamagata University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; K. Kaneko, Mika/0000-0002-4158-9208; Kato, Yukinari/0000-0001-5385-8201				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Cheville JC, 1999, MODERN PATHOL, V12, P974; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; Ma TH, 1998, AM J RESP CELL MOL, V19, P143, DOI 10.1165/ajrcmb.19.1.2953; MOLLER H, 1993, EUR UROL, V23, P8; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; RICHIE JP, 2003, UROL ONCOL, V21, P91; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; WATANABE M, 1988, CANCER RES, V48, P6411; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186	16	100	137	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8552	8556		10.1038/sj.onc.1207869	http://dx.doi.org/10.1038/sj.onc.1207869			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361850				2022-12-28	WOS:000224870700016
J	Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE				Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE			Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA	ONCOGENE			English	Article						STAT3-C; Src; transformation	MAP KINASE KINASE; MAMMALIAN-CELLS; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN; P53; IDENTIFICATION; SYSTEM; SIGNAL	Induced transformation of mouse fibroblasts was carried out by releasing tetracycline-repressed expression of an oncogenic mutant of STAT3, STAT3-C, or of v-Src or Ha-Ras. At 15 days after derepression of each oncogene, DNA microarrays showed elevation (> 3-fold) of a similar group of similar to25 mRNAs compared to untransformed cells. RT - PCR confirmed a number of these mRNA elevations. RNA samples were then analysed at intervals during the first 24 h after doxycycline removal to determine the time of early changes. Extensive changes were not observed by array analysis, except in v-Src-expressing cells where about 10 mRNAs were elevated threefold or more. However, RT - PCR did uncover changes in each derepressed cell type that included some of the changes observed after the 15-day transformation period. In addition, STAT3-C target genes such as BclXI and cyclin D1, which were not observed on array analysis, were elevated by RT - PCR analysis. We conclude, therefore, that early after oncogene induction, transcriptional changes, including those initiated by STAT3-C, may occur only in scarce mRNA and/or to a limited extent. However, with additional time and probably additional cell division, a new epigenetic state is established that is mirrored by a changed transcriptional pro. le emblematic of transformation by each of three oncogenes.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	darnell@rockefeller.edu	van Nimwegen, Erik/ABF-1085-2021	van Nimwegen, Erik/0000-0001-6338-1312	NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R01AI034420, R37AI034420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BOYNTON AL, 1984, CANCER LETT, V21, P293, DOI 10.1016/0304-3835(84)90008-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; GEIGER B, 1979, P NATL ACAD SCI USA, V76, P2833, DOI 10.1073/pnas.76.6.2833; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Naef F, 2003, BIOINFORMATICS, V19, P178, DOI 10.1093/bioinformatics/19.2.178; Naef F, 2002, GENOME BIOL, V3; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; STJOHNSTON D, 1992, CELL, V68, P201; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8455	8463		10.1038/sj.onc.1207803	http://dx.doi.org/10.1038/sj.onc.1207803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378015				2022-12-28	WOS:000224870700006
J	Downward, J				Downward, J			RNA interference-based functional genomics in cancer research - an introduction	ONCOGENE			English	Editorial Material									Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Baum B, 2004, ONCOGENE, V23, P8336, DOI 10.1038/sj.onc.1208009; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Fraser A, 2004, ONCOGENE, V23, P8346, DOI 10.1038/sj.onc.1208044; Poulin G, 2004, ONCOGENE, V23, P8340, DOI 10.1038/sj.onc.1208010; Sachse C, 2004, ONCOGENE, V23, P8384, DOI 10.1038/sj.onc.1208072; Silva J, 2004, ONCOGENE, V23, P8401, DOI 10.1038/sj.onc.1208176; van Haaften G, 2004, ONCOGENE, V23, P8366, DOI 10.1038/sj.onc.1208011; Vanhecke D, 2004, ONCOGENE, V23, P8353, DOI 10.1038/sj.onc.1208027; Willingham AT, 2004, ONCOGENE, V23, P8392, DOI 10.1038/sj.onc.1208217	10	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8334	8335		10.1038/sj.onc.1208121	http://dx.doi.org/10.1038/sj.onc.1208121			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517012				2022-12-28	WOS:000224815900001
J	Willingham, AT; Deveraux, QL; Hampton, GM; Aza-Blanc, P				Willingham, AT; Deveraux, QL; Hampton, GM; Aza-Blanc, P			RNAi and HTS: exploring cancer by systematic loss-of-function	ONCOGENE			English	Article						RNA interference; RNAi; siRNA; high throughput screen	GENOME-WIDE RNAI; RETRACTED ARTICLE. SEE; SHORT-INTERFERING RNAS; HUMAN TUMOR-CELLS; CAENORHABDITIS-ELEGANS; MAMMALIAN-CELLS; LUNG-CANCER; INDUCED APOPTOSIS; GENE-EXPRESSION; EGFR MUTATIONS	Cancer develops through the successive accumulation and selection of genetic and epigenetic alterations, enabling cells to survive, replicate and evade homeostatic control mechanisms such as apoptosis and antiproliferative signals. This transformation process, however, may create vulnerabilities since the accumulation of mutations can expose synthetic lethal gene interactions and oncogene-driven cellular reprogramming ('addiction'), giving rise to new therapeutic avenues. With the completion of the human genome project, it is anticipated that the identification and characterization of genetic networks that regulate cell growth, differentiation, apoptosis and transformation will be fundamental to decoding the complexity of these processes, and ultimately, cancer itself. Genomic methodologies, such as large-scale mRNA profiling using microarrays, have already begun to reveal the molecular basis of cancer heterogeneity and the clinical behavior of tumors. The combination of traditional cell culture techniques with high-throughput screening approaches has given rise to new cellular-genomics methodologies that enable the simultaneous interrogation of thousands of genes in live cells, facilitating true functional pro. ling of biological processes. Among these, RNA interference (RNAi) has the potential to enable rapid genome-wide loss-of-function (LOF) screens in mammalian systems, which until recently has been the sole domain of lower organisms. Here, we present a broad overview of this maturing technology and explore how, within current technical constraints, large-scale LOF use of RNAi can be exploited to uncover the molecular basis of cancer - from the genetics of synthetic lethality and oncogene-dependent cellular addiction to the acquisition of cancer-associated cellular phenotypes.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92093 USA	Novartis; Scripps Research Institute	Aza-Blanc, P (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John J Hopkins Dr, San Diego, CA 92121 USA.	pazabla@gnf.org						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baghdoyan S, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh074; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Deveraux QL, 2003, SEMIN CANCER BIOL, V13, P293, DOI 10.1016/S1044-579X(03)00043-9; Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P981, DOI 10.1093/nar/gkg184; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mittal V, 2004, NAT REV GENET, V5, P355, DOI 10.1038/nrg1323; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Reddy A, 2002, CURR OPIN PHARMACOL, V2, P366, DOI 10.1016/S1471-4892(02)00178-9; REN YG, 2004, MOL CELL BIOL   0908; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305; Snove O, 2004, BIOCHEM BIOPH RES CO, V319, P256, DOI 10.1016/j.bbrc.2004.04.175; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Yanagawa S, 1998, J BIOL CHEM, V273, P32353, DOI 10.1074/jbc.273.48.32353; Yoshikawa T, 2004, J CONTROL RELEASE, V96, P227, DOI 10.1016/j.jconrel.2004.01.024; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	62	48	53	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8392	8400		10.1038/sj.onc.1208217	http://dx.doi.org/10.1038/sj.onc.1208217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517021				2022-12-28	WOS:000224815900010
J	Barbera, MJ; Puig, I; Dominguez, D; Julien-Grille, S; Guaita-Esteruelas, S; Peiro, S; Baulida, J; Franci, C; Dedhar, S; Larue, L; de Herreros, AG				Barbera, MJ; Puig, I; Dominguez, D; Julien-Grille, S; Guaita-Esteruelas, S; Peiro, S; Baulida, J; Franci, C; Dedhar, S; Larue, L; de Herreros, AG			Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells	ONCOGENE			English	Article						snail; promoter; transcription; EMT; MEK; NF-kappa B	E-CADHERIN EXPRESSION; TGF-BETA; GROWTH; REPRESSOR; MESODERM; DIFFERENTIATION; INHIBITION; LOCATION; ADHESION; SLUG	Expression of Snail transcriptional factor is a determinant in the acquisition of a mesenchymal phenotype by epithelial tumor cells. However, the regulation of the transcription of this gene is still unknown. We describe here the characterization of a human SNAIL promoter that contains the initiation of transcription and regulates the expression of this gene in tumor cells. This promoter was activated in cell lines in response to agents that induce Snail transcription and the mesenchymal phenotype, as addition of the phorbol ester PMA or overexpression of integrin-linked kinase (ILK) or oncogenes such as Ha-ras or v-Akt. Although other regions of the promoter were required for a complete stimulation by Akt or ILK, a minimal fragment ( - 78/ +59) was sufficient to maintain the mesenchymal specificity. Activity of this minimal promoter and SNAIL RNA levels were dependent on ERK signaling pathway. NFkappaB/p65 also stimulated SNAIL transcription through a region located immediately upstream the minimal promoter, between - 194 and - 78. These results indicate that Snail transcription is driven by signaling pathways known to induce epithelial to mesenchymal transition, reinforcing the role of Snail in this process.	Univ Pompeu Fabra, Unitat Bio Celluar & Mol, Inst Municipal Invest Med, Barcelona 08003, Spain; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada	Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of British Columbia	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Unitat Bio Celluar & Mol, Inst Municipal Invest Med, C Doctor Aiguader 80, Barcelona 08003, Spain.	agarcia@imim.es	Larue, Lionel/I-6532-2016; Larue, Lionel/F-7355-2013; de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Dedhar, Shoukat/0000-0003-4355-1657; Puig Borreil, Isabel/0000-0001-5614-4298; Dominguez-Sola, David/0000-0001-9569-8402				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Christen B, 1999, DEVELOPMENT, V126, P119; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grille SJ, 2003, CANCER RES, V63, P2172; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, CANCER RES, V62, P1613; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; MAYOR R, 1993, DEVELOPMENT, V119, P661; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Paznekas WA, 1999, GENOMICS, V62, P42, DOI 10.1006/geno.1999.6010; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Spagnoli FM, 2000, J CELL SCI, V113, P3639; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100	37	269	279	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7345	7354		10.1038/sj.onc.1207990	http://dx.doi.org/10.1038/sj.onc.1207990			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286702				2022-12-28	WOS:000224021400005
J	Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK				Yordy, JS; Li, RZ; Sementchenko, VI; Pei, HP; Muise-Helmericks, RC; Watson, DK			SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion	ONCOGENE			English	Article						Ets; transcription; invasion; SP100; MMP; UPA	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; MATRIX METALLOPROTEINASE-1; PROTEIN INTERACTIONS; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; ANDROGEN RECEPTOR	The ETS1 transcription factor is a member of the Ets family of conserved sequence-specific DNA-binding proteins. ETS1 has been shown to play important roles in various cellular processes such as proliferation, differentiation, lymphoid development, motility, invasion and angiogenesis. These diverse roles of ETS1 are likely to be dependent on specific protein interactions. To identify proteins that interact with ETS1, a yeast two-hybrid screen was conducted. Here, we describe the functional interaction between SP100 and ETS1. SP100 protein interacts with ETS1 both in vitro and in vivo. SP100 is localized to nuclear bodies and ETS1 expression alters the nuclear body morphology in living cells. SP100 negatively modulates ETS1 transcriptional activation of the MMP1 and uPA promoters in a dose-dependent manner, decreases the expression of these endogenous genes, and reduces ETS1 DNA binding. Expression of SP100 inhibits the invasion of breast cancer cells and is induced by Interferon-alpha, which has been shown to inhibit the invasion of cancer cells. These data demonstrate that SP100 modulates ETS1-dependent biological processes.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Watson, DK (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu			NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGERON D, 1995, CELL MOL BIOL RES, V41, P155; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; Chen ZQ, 1997, CANCER RES, V57, P2013; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FISHER RJ, 1991, ONCOGENE, V6, P2249; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GULDNER HH, 1992, J IMMUNOL, V149, P4067; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kita D, 2001, CANCER RES, V61, P7985; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Negorev D, 2001, J CELL SCI, V114, P59; Obika S, 2003, J MOL BIOL, V331, P345, DOI 10.1016/S0022-2836(03)00726-5; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pei HP, 2003, ONCOGENE, V22, P2699, DOI 10.1038/sj.onc.1206374; Quaranta V, 2003, TUMORI J, V89, P343, DOI 10.1177/030089160308900401; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Rutter JL, 1998, CANCER RES, V58, P5321; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	67	34	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6654	6665		10.1038/sj.onc.1207891	http://dx.doi.org/10.1038/sj.onc.1207891			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247905				2022-12-28	WOS:000223530800013
J	Wu, XF; Zhao, H; Suk, R; Christiani, DC				Wu, XF; Zhao, H; Suk, R; Christiani, DC			Genetic susceptibility to tobacco-related cancer	ONCOGENE			English	Review						genetic susceptibility; tobacco-related cancer; polymorphism; phenotype; risk assessment; clinical outcome	GLUTATHIONE-S-TRANSFERASE; MICROSOMAL EPOXIDE HYDROLASE; SQUAMOUS-CELL CARCINOMA; SINGLE-NUCLEOTIDE POLYMORPHISM; DNA-REPAIR GENES; GROWTH-FACTOR-I; CUMULATIVE CIGARETTE-SMOKING; MATRIX METALLOPROTEINASE-1 PROMOTER; HOGG1 SER326CYS POLYMORPHISM; FACTOR-BINDING PROTEIN-3	Although cigarette smoking is the dominant risk factor for several epithelial cancers, only a small fraction of individuals with tobacco exposure develop cancer. The underlying hypothesis is that genetic factors may render certain smokers more susceptible to cancer than others. Genetic alterations in critical regulatory pathways may predispose cells to carcinogenesis. These pathways include regulation of xenobiotic metabolism; control of genomic stability, including DNA repair mechanisms, cell-cycle checkpoints, apoptosis and telomere length; and control of microenvironmental factors, such as matrix metalloproteinases, inflammation and growth factors. In addition, epigenetic events, such as promoter hypermethylation and loss of imprinting, are also involved in carcinogenesis. In this review, we will summarize recent advances in genetic susceptibility to tobacco-related cancer. Emphasizing on risk assessment, we will describe how genetic variations in the above-mentioned genetic pathways modify the tobacco-related cancer risk. In addition, we will discuss how genetic variations may assist in predicting clinical outcome, such as the natural history of cancer and treatment response. The measurements of genetic susceptibility by both genotypic and phenotypic assays are covered in the text. Finally, we present a number of current concerns that need to be addressed as the exciting field of molecular cancer epidemiology advances rapidly.	Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Wu, XF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Box 189,1515 Holcombe Blvd, Houston, TX 77030 USA.	xwu@mdanderson.org						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abdel-Rahman SZ, 1998, CANCER DETECT PREV, V22, P129; ALEXANDRIE AK, 1994, CARCINOGENESIS, V15, P1785, DOI 10.1093/carcin/15.9.1785; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; ANTTILA S, 1994, CARCINOGENESIS, V15, P1133, DOI 10.1093/carcin/15.6.1133; Anwar WA, 1996, CARCINOGENESIS, V17, P1923, DOI 10.1093/carcin/17.9.1923; AUSTIN GE, 1993, LEUKEMIA, V7, P1445; BADAWI AF, 1995, EUR J CANCER PREV, V4, P45, DOI 10.1097/00008469-199502000-00004; Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343; Benhamou S, 1998, CANCER RES, V58, P5291; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Biros E, 2002, LUNG CANCER-J IASLC, V35, P231, DOI 10.1016/S0169-5002(01)00446-9; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BONASSI S, 1995, CANCER GENET CYTOGEN, V79, P133, DOI 10.1016/0165-4608(94)00131-T; Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091; Bouchardy C, 1998, PHARMACOGENETICS, V8, P291, DOI 10.1097/00008571-199808000-00002; Brockmoller J, 1996, CANCER RES, V56, P3915; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Cajas-Salazar N, 2003, CANCER GENET CYTOGEN, V145, P97, DOI 10.1016/S0165-4608(03)00058-X; Camps Carlos, 2003, Clin Lung Cancer, V4, P237, DOI 10.3816/CLC.2003.n.004; Cascorbi I, 1996, CANCER RES, V56, P3961; Cascorbi I, 2000, CANCER RES, V60, P644; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chen HW, 1999, CANCER RES, V59, P3045; Chen WC, 2002, UROL ONCOL, V7, P63, DOI 10.1016/S1078-1439(01)00152-1; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choi JY, 2003, PHARMACOGENETICS, V13, P349, DOI 10.1097/00008571-200306000-00006; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Cortessis VK, 2003, CARCINOGENESIS, V24, P1645, DOI 10.1093/carcin/bgg128; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Curigliano G, 1996, CARCINOGENESIS, V17, P911, DOI 10.1093/carcin/17.5.911; David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2; David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; Dunn SE, 1997, CANCER RES, V57, P2687; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Farker K, 1998, EXP TOXICOL PATHOL, V50, P425, DOI 10.1016/S0940-2993(98)80029-8; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gao CM, 2002, CANCER LETT, V188, P95, DOI 10.1016/S0304-3835(02)00115-5; GarciaClosas M, 1997, CANCER CAUSE CONTROL, V8, P544, DOI 10.1023/A:1018481910663; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Ghilardi G, 2002, CLIN CANCER RES, V8, P3820; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Goto I, 1996, CANCER RES, V56, P3725; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HAGMAR L, 1994, CANCER RES, V54, P2919; HAMADA GS, 1995, CANCER EPIDEM BIOMAR, V4, P63; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Harris MJ, 1998, PHARMACOGENETICS, V8, P27, DOI 10.1097/00008571-199802000-00004; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P407, DOI 10.1093/oxfordjournals.jbchem.a123594; HAYASHI S, 1992, JPN J CANCER RES, V83, P866, DOI 10.1111/j.1349-7006.1992.tb01992.x; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hazra A, 2003, CANCER RES, V63, P1157; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hinoda Y, 2002, INT J CANCER, V102, P526, DOI 10.1002/ijc.10750; Hirata H, 2003, INT J CANCER, V106, P372, DOI 10.1002/ijc.11229; HIRVONEN A, 1993, CARCINOGENESIS, V14, P1479, DOI 10.1093/carcin/14.7.1479; HIRVONEN A, 1992, CANCER EPIDEM BIOMAR, V1, P485; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Hong YL, 1996, J CLIN ENDOCR METAB, V81, P1791, DOI 10.1210/jc.81.5.1791; Houlston RS, 2000, PHARMACOGENETICS, V10, P105, DOI 10.1097/00008571-200003000-00002; HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310; HSU TC, 1987, IN VITRO CELL DEV B, V23, P591; Hu JJ, 1996, CANCER EPIDEM BIOMAR, V5, P263; Huang QR, 1997, MOL IMMUNOL, V34, P577, DOI 10.1016/S0161-5890(97)00081-3; Hung HC, 1997, CANCER EPIDEM BIOMAR, V6, P901; Hung RJ, 2003, CARCINOGENESIS, V24, P875, DOI 10.1093/carcin/bgg026; Inatomi H, 1999, INT J UROL, V6, P446, DOI 10.1046/j.1442-2042.1999.00096.x; Ishibe N, 1997, CANCER EPIDEM BIOMAR, V6, P1075; Jeng YL, 2003, ANTICANCER RES, V23, P5149; JENSEN RA, 1993, HUM PATHOL, V24, P455, DOI 10.1016/0046-8177(93)90155-A; Jeon HS, 2003, CARCINOGENESIS, V24, P1677, DOI 10.1093/carcin/bgg120; Jernstrom H, 2001, MOL GENET METAB, V72, P144, DOI 10.1006/mgme.2000.3130; Johns LE, 2000, ENVIRON MOL MUTAGEN, V36, P221, DOI 10.1002/1098-2280(2000)36:3<221::AID-EM5>3.0.CO;2-Q; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Kanayama H, 1998, CANCER, V82, P1359, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1359::AID-CNCR20>3.0.CO;2-4; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Katoh T, 1999, PHARMACOGENETICS, V9, P165; KATOH T, 1995, CARCINOGENESIS, V16, P655, DOI 10.1093/carcin/16.3.655; KAWAJIRI K, 1990, FEBS LETT, V263, P131, DOI 10.1016/0014-5793(90)80721-T; Kiemeney LALM, 1996, J UROLOGY, V156, P867, DOI 10.1016/S0022-5347(01)65644-1; KIHARA M, 1993, CANCER LETT, V71, P151, DOI 10.1016/0304-3835(93)90110-U; Kihara M, 1999, CANCER LETT, V137, P53, DOI 10.1016/S0304-3835(98)00337-1; KIHARA M, 1995, CARCINOGENESIS, V16, P2331, DOI 10.1093/carcin/16.10.2331; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Landi S, 2003, CANCER RES, V63, P3560; Le Marchand L, 1998, CANCER RES, V58, P4858; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lewis SJ, 2001, LUNG CANCER-J IASLC, V34, P177, DOI 10.1016/S0169-5002(01)00243-4; Lin DX, 1998, CANCER EPIDEM BIOMAR, V7, P1013; Lin P, 2000, BRIT J CANCER, V82, P852, DOI 10.1054/bjoc.1999.1011; Lin PP, 1999, J TOXICOL ENV HEAL A, V58, P187, DOI 10.1080/009841099157287; London SJ, 1997, CANCER RES, V57, P5001; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551; Mabrouk I, 2003, ANN NY ACAD SCI, V1010, P764, DOI 10.1196/annals.1299.137; Malats N, 2000, CANCER EPIDEM BIOMAR, V9, P827; Malkinson AM, 2000, CHEST, V117, p228S, DOI 10.1378/chest.117.5_suppl_1.228S; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Marcus PM, 2000, CANCER EPIDEM BIOMAR, V9, P461; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Marsh HP, 2003, BRIT J CANCER, V89, P1096, DOI 10.1038/sj.bjc.6601165; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MARTINEZ C, 1995, PHARMACOGENETICS, V5, P207, DOI 10.1097/00008571-199508000-00004; Matakidou A, 2003, MUTAGENESIS, V18, P377, DOI 10.1093/mutage/geg008; Matthias C, 1998, CLIN CANCER RES, V4, P2411; Matthias C, 1999, CANCER EPIDEM BIOMAR, V8, P815; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; McCann J, 1999, J NATL CANCER I, V91, P497, DOI 10.1093/jnci/91.6.497; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; Miao XP, 2003, CANCER RES, V63, P3987; Miller DG, 1998, CANCER EPIDEM BIOMAR, V7, P321; Miller DP, 2003, EPIDEMIOLOGY, V14, P545, DOI 10.1097/01.ede.0000073120.46981.24; Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989; Miller DP, 2002, CANCER RES, V62, P2819; Minematsu N, 2001, BIOCHEM BIOPH RES CO, V289, P116, DOI 10.1006/bbrc.2001.5936; Morita S, 1999, INT J CANCER, V80, P685, DOI 10.1002/(SICI)1097-0215(19990301)80:5<685::AID-IJC9>3.0.CO;2-W; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Myohanen SK, 1998, CANCER RES, V58, P591; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; Nazar-Stewart V, 2003, LUNG CANCER-J IASLC, V40, P247, DOI 10.1016/S0169-5002(03)00076-X; Nia AB, 2000, CARCINOGENESIS, V21, P1335, DOI 10.1093/carcin/21.7.1335; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; Nimura Y, 1997, CANCER, V80, P852, DOI 10.1002/(SICI)1097-0142(19970901)80:5<852::AID-CNCR4>3.0.CO;2-N; OKADA T, 1994, PHARMACOGENETICS, V4, P333, DOI 10.1097/00008571-199412000-00006; Oyama T, 1997, ANTICANCER RES, V17, P577; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P993; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23; Park JY, 1997, CANCER EPIDEM BIOMAR, V6, P791; Park SJ, 2003, MUTAT RES-GEN TOX EN, V536, P131, DOI 10.1016/S1383-5718(03)00041-X; Peluso M, 2000, CARCINOGENESIS, V21, P183, DOI 10.1093/carcin/21.2.183; Perera FP, 2002, CARCINOGENESIS, V23, P1641, DOI 10.1093/carcin/23.10.1641; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Pfeifer K, 2000, AM J HUM GENET, V67, P777, DOI 10.1086/303101; PHILIP PA, 1988, CARCINOGENESIS, V9, P491, DOI 10.1093/carcin/9.3.491; Phillips DH, 2002, CARCINOGENESIS, V23, P1979, DOI 10.1093/carcin/23.12.1979; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; Pinarbasi H, 2003, CANCER GENET CYTOGEN, V146, P125, DOI 10.1016/S0165-4608(03)00059-1; Qiao YW, 2002, CARCINOGENESIS, V23, P295, DOI 10.1093/carcin/23.2.295; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rojas E, 1999, J CHROMATOGR B, V722, P225, DOI 10.1016/S0378-4347(98)00313-2; Rosell R, 2003, LUNG CANCER-J IASLC, V41, pS97, DOI 10.1016/S0169-5002(03)00151-X; Rosen CJ, 1998, J CLIN ENDOCR METAB, V83, P2286, DOI 10.1210/jc.83.7.2286; Ross D, 1996, BRIT J CANCER, V74, P995, DOI 10.1038/bjc.1996.477; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Ruano-Ravina A, 2003, ANTICANCER RES, V23, P4333; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Saarikoski ST, 2000, PHARMACOGENETICS, V10, P183, DOI 10.1097/00008571-200003000-00010; Santella RM, 1999, CANCER EPIDEM BIOMAR, V8, P733; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; Schabath MB, 2003, J NATL CANCER I, V95, P540, DOI 10.1093/jnci/95.7.540; Schabath MB, 2002, LUNG CANCER-J IASLC, V37, P35, DOI 10.1016/S0169-5002(02)00034-X; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SELLERS TA, 1994, AM J MED GENET, V52, P308, DOI 10.1002/ajmg.1320520311; Seow A, 1999, CARCINOGENESIS, V20, P1877, DOI 10.1093/carcin/20.9.1877; Shen HB, 2001, CANCER RES, V61, P3321; Shen HB, 2002, CANCER RES, V62, P4992; Shen HB, 2001, CANCER EPIDEM BIOMAR, V10, P397; Shi QL, 2003, CARCINOGENESIS, V24, P1499, DOI 10.1093/carcin/bgg035; Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309; Shih CM, 2000, JPN J CANCER RES, V91, P9, DOI 10.1111/j.1349-7006.2000.tb00854.x; SHIMA I, 1992, CANCER, V70, P2747, DOI 10.1002/1097-0142(19921215)70:12<2747::AID-CNCR2820701204>3.0.CO;2-5; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Sjalander A, 1996, HUM HERED, V46, P221, DOI 10.1159/000154357; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Song CY, 2001, CANCER RES, V61, P3272; Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689; Spitz MR, 2001, CANCER RES, V61, P1354; Stolzenberg-Solomon RZ, 2003, CANCER EPIDEM BIOMAR, V12, P1222; Stucker I, 2002, CARCINOGENESIS, V23, P1475, DOI 10.1093/carcin/23.9.1475; Su L, 2003, CANCER EPIDEM BIOMAR, V12, P174; Su T, 2000, CANCER RES, V60, P5074; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Sweeney C, 2003, CANCER EPIDEM BIOMAR, V12, P527; TEFRE T, 1991, PHARMACOGENETICS, V1, P20, DOI 10.1097/00008571-199110000-00004; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; To-Figueras J, 1999, CANCER CAUSE CONTROL, V10, P65, DOI 10.1023/A:1008811824890; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Tsai FJ, 2001, UROL RES, V29, P412, DOI 10.1007/s002400100219; Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637; Veglia F, 2003, CANCER EPIDEM BIOMAR, V12, P157; Vineis P, 2003, INT J CANCER, V104, P650, DOI 10.1002/ijc.10995; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vulimiri SV, 2000, MOL CARCINOGEN, V27, P34, DOI 10.1002/(SICI)1098-2744(200001)27:1<34::AID-MC6>3.3.CO;2-7; Wang AH, 2004, WORLD J GASTROENTERO, V10, P940; Wang HJ, 2003, CANCER RES, V63, P8057; Wang LE, 2003, LUNG CANCER-J IASLC, V42, P1, DOI 10.1016/S0169-5002(03)00276-9; Wang LI, 2001, J NATL CANCER I, V93, P1818, DOI 10.1093/jnci/93.23.1818; Wang LZ, 2002, CARCINOGENESIS, V23, P257, DOI 10.1093/carcin/23.2.257; Wang YC, 1999, EUR J CANCER, V35, P226, DOI 10.1016/S0959-8049(98)00369-4; Wang YC, 2001, J MEMBRANE SCI, V185, P193, DOI 10.1016/S0376-7388(00)00655-4; Wang YF, 2003, CANCER, V98, P1701, DOI 10.1002/cncr.11692; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; Wang YF, 2002, LUNG CANCER, V35, P137, DOI 10.1016/S0169-5002(01)00406-8; Warren AJ, 1997, P SOC EXP BIOL MED, V216, P172; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Williams JA, 1998, PHARMACOGENETICS, V8, P519, DOI 10.1097/00008571-199812000-00009; Williams MP, 1999, AM J GASTROENTEROL, V94, pS11, DOI 10.1016/S0002-9270(99)00657-7; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Wu XF, 1998, J NATL CANCER I, V90, P1393, DOI 10.1093/jnci/90.18.1393; Wu XF, 1998, CANCER-AM CANCER SOC, V83, P1118, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1118::AID-CNCR10>3.3.CO;2-1; Wu XF, 2003, J NATL CANCER I, V95, P1211, DOI 10.1093/jnci/djg011; Wu XF, 2003, CARCINOGENESIS, V24, P505, DOI 10.1093/carcin/24.3.505; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Wu XF, 1997, CARCINOGENESIS, V18, P967, DOI 10.1093/carcin/18.5.967; Wu XF, 1998, CANCER EPIDEM BIOMAR, V7, P13; Wu XF, 2001, CARCINOGENESIS, V22, P923, DOI 10.1093/carcin/22.6.923; Xing DY, 2001, INT J CANCER, V95, P140, DOI 10.1002/1097-0215(20010520)95:3&lt;140::AID-IJC1024&gt;3.0.CO;2-2; Xu LL, 2001, CANCER EPIDEM BIOMAR, V10, P303; Yu CY, 2003, CANCER EPIDEM BIOMAR, V12, P176; Yu CY, 2002, CANCER RES, V62, P6430; Zambon CF, 2004, GASTROENTEROLOGY, V126, P382, DOI 10.1053/j.gastro.2003.08.042; Zhang XL, 2002, J PHARMACOL EXP THER, V302, P416, DOI 10.1124/jpet.302.2.416; Zhao H, 2002, MOL CARCINOGEN, V33, P99, DOI 10.1002/mc.10023; Zhao H, 2001, CANCER RES, V61, P7819; Zheng YX, 2001, CARCINOGENESIS, V22, P1195, DOI 10.1093/carcin/22.8.1195; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533; Zhou W, 2002, CANCER RES, V62, P1377; Zhou W, 2002, CANCER EPIDEM BIOMAR, V11, P15; Zhou W, 2001, CANCER EPIDEM BIOMAR, V10, P461; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359; Zhu Y, 2001, CANCER RES, V61, P7825; Zhu Y, 2004, CANCER RES, V64, P2251, DOI 10.1158/0008-5472.CAN-03-2800	275	116	125	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6500	6523		10.1038/sj.onc.1207811	http://dx.doi.org/10.1038/sj.onc.1207811			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322521				2022-12-28	WOS:000223468800015
J	Tagawa, H; Karnan, S; Suzuki, R; Matsuo, K; Zhang, XH; Ota, A; Morishima, Y; Nakamura, S; Seto, M				Tagawa, H; Karnan, S; Suzuki, R; Matsuo, K; Zhang, XH; Ota, A; Morishima, Y; Nakamura, S; Seto, M			Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM	ONCOGENE			English	Article						mantle cell lymphoma; array CGH; BIM; 2q 13; chromosome alteration	IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; FAMILY-MEMBER BIM; BCL-2 FAMILY; AGGRESSIVE VARIANTS; CHROMOSOME 17P13.3; TISSUE-TYPE; ATM GENE; APOPTOSIS; OVEREXPRESSION	Mantle cell lymphoma (MCL) is characterized by 11q13 chromosomal translocation and CCND1 overexpression, but additional genomic changes are also important for lymphomagenesis. To identify the genomic aberrations of MCL at higher resolutions, we analysed 29 patient samples and seven cell lines using array-based comparative genomic hybridization (array CGH) consisting of 2348 artificial chromosome clones, which cover the whole genome at a 1.3 mega base resolution. The incidence of identified genomic aberrations was generally higher than that determined with chromosomal CGH. The most frequent imbalances detected by array CGH were gains of chromosomes 3q26 (48%), 7p21 (34%), 6p25 (24%), 8q24 (24 %), 10p12 (21 %) and 17q23 (17 %), and losses of chromosomes 2p11 (83%), 11q22 (59%), 13q21 (55%), 1p21-p22 (52%), 13q34 (52%), 9q22 (45%), 17p13 (45%), 9p21 (41%), 9p24 (41%), 6q23-q24 (38%), 1p36 (31%), 8p23 (34%), 10p14 (31%), 19p13 (28%), 5q21 (21%), 22q12 (21%), 1q42 (17%) and 2q13 (17%). Our analyses also detected several novel recurrent regions of loss located at 1p36, 1q42.2-q43, 2p11.2, 2q13, 17p13.3 and 19p13.2-p13.3, as well as recurrent regions of homozygous loss such as 2p11 (IgK), 2q13 and 9p21.3-p24.1 (INK4a/ARF). Of the latter, we investigated the 2q13 loss, which led to identification of homozygous deletions of the proapoptotic gene BIM. The high-resolution array CGH technology allowed for the precise identification of genomic aberrations and identification of BIM as a novel candidate tumor suppressor gene in MCL.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Epidemiol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan; Yan An Univ, Sch Med, Dept Pathol, Yan An 716000, Peoples R China; Immunol Biol Labs Co Ltd, Gunma 3750005, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Yanan University	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp	Nakamura, Shigeo/I-1571-2012; Matsuo, Keitaro/H-6758-2019; Ota, Akinobu/H-4510-2019; Ota, Akinobu/AAI-9396-2020; Ota, Akinobu/CAC-5999-2022	Matsuo, Keitaro/0000-0003-1761-6314; Ota, Akinobu/0000-0002-6296-2921; Suzuki, Ritsuro/0000-0002-5974-7614				Allen JE, 2002, BRIT J HAEMATOL, V116, P291, DOI 10.1046/j.1365-2141.2002.03260.x; Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Bea S, 1999, BLOOD, V93, P4365; Bea S, 2001, CANCER RES, V61, P2409; Bentz M, 2000, GENE CHROMOSOME CANC, V27, P285, DOI 10.1002/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.3.CO;2-D; Bigoni R, 2001, LEUKEMIA LYMPHOMA, V40, P581, DOI 10.3109/10428190109097656; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; COGEN PH, 1992, AM J HUM GENET, V50, P584; Cuneo A, 1999, BLOOD, V93, P1372, DOI 10.1182/blood.V93.4.1372.404k21_1372_1380; Dreyling MH, 1997, CANCER RES, V57, P4608; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; FUJIMORI M, 1991, CANCER RES, V51, P89; Greiner TC, 1996, BLOOD, V87, P4302, DOI 10.1182/blood.V87.10.4302.bloodjournal87104302; Hernandez L, 1996, BLOOD, V87, P3351, DOI 10.1182/blood.V87.8.3351.bloodjournal8783351; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; JAFFE E, 2001, WORLD HLTH CLASSIFIC; Jeon HJ, 1998, BRIT J HAEMATOL, V102, P1323, DOI 10.1046/j.1365-2141.1998.00911.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohlhammer H, 2004, BLOOD, V104, P795, DOI 10.1182/blood-2003-12-4175; Konishi H, 2002, CANCER RES, V62, P271; Liu JW, 2002, CANCER RES, V62, P2976; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Martinez N, 2003, CANCER RES, V63, P8226; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Monni O, 1998, GENE CHROMOSOME CANC, V21, P298, DOI 10.1002/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO;2-U; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; NACHEVA E, 1993, BLOOD, V82, P231, DOI 10.1182/blood.V82.1.231.bloodjournal821231; Nomura K, 2003, CANCER GENET CYTOGEN, V140, P49, DOI 10.1016/S0165-4608(02)00632-5; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Phillips NJ, 1996, CANCER RES, V56, P606; PINKEL D, 1998, NAT GENET, V23, P41; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SALTMAN DL, 1988, BLOOD, V72, P2026, DOI 10.1182/blood.V72.6.2026.2026; SAXENA A, 1992, CANCER RES, V52, P6716; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schultz DC, 1996, CANCER RES, V56, P1997; SETO M, 1992, ONCOGENE, V7, P1401; Stilgenbauer S, 1999, BLOOD, V94, P3262, DOI 10.1182/blood.V94.9.3262.421a33_3262_3264; Suzuki R, 1999, LEUKEMIA, V13, P1335, DOI 10.1038/sj.leu.2401485; Zhang XH, 2004, CANCER SCI, V95, P809, DOI 10.1111/j.1349-7006.2004.tb02186.x	45	243	252	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1348	1358		10.1038/sj.onc.1208300	http://dx.doi.org/10.1038/sj.onc.1208300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608680				2022-12-28	WOS:000227092600005
J	May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E				May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E			Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer	ONCOGENE			English	Article						ero1-l alpha; VEGF; HIF1; hypoxia; disulfide bond formation	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MESSENGER-RNA STABILITY; INDUCIBLE FACTOR-I; ENDOPLASMIC-RETICULUM; HIF-ALPHA; PROTEIN; EXPRESSION; FACTOR-1; GENES	Oxygen is the ultimate source of oxidizing power for disulfide bond formation, suggesting that under limiting oxygen proper protein folding might be compromised. We show that secretion of vascular endothelial growth factor ( VEGF), a protein with multiple disulfide bonds, was indeed impeded under hypoxia and was partially restored by artificial increase of oxidizing equivalents with diamide. Physiologically, the oxireductase endoplasmic reticulum oxidoreductin-1 (Ero1)-Lalpha, but not other proteins in the relay of disulfide formation, was strongly upregulated by hypoxia and independently by hypoglycemia, two known accompaniments of tumors. Further, we provide genetic evidence that induction of Ero1-Lalpha by hypoxia and hypoglycemia is mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) but is independent of p53. In natural human tumors, Ero1-Lalpha mRNA was specifically induced in hypoxic microenvironments coinciding with that of upregulated VEGF expression. To establish a physiological relevance to modulations in Ero1-Lalpha levels, we showed that even a modest, two- to three-fold reduction in Ero1-Lalpha production via siRNA leads to significant inhibition of VEGF secretion, a compromised proliferation capacity and enhanced apoptosis. Together, these findings demonstrate that hypoxic induction of Ero1-Lalpha is the key adaptive response in a previously unrecognized HIF-1-mediated pathway that operates to improve protein secretion under hypoxia and might be harnessed for inhibiting tumor growth via inhibiting VEGF-driven angiogenesis.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel	Hebrew University of Jerusalem	Keshet, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.	keshet@cc.huji.ac.il	Keshet, Eli/GQR-0445-2022					An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARASH Y, 2004, BIOINFORMATICS  0928; BENDA P, 1968, SCIENCE, V161, P371; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; CzyzykKrzeska MF, 1997, RESP PHYSIOL, V110, P99, DOI 10.1016/S0034-5687(97)00076-5; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Endoh H, 2004, J CLIN ONCOL, V22, P811, DOI 10.1200/JCO.2004.04.109; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryan HE, 2000, CANCER RES, V60, P4010; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P845; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Walter DH, 1996, LAB INVEST, V74, P546; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	113	122	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1011	1020		10.1038/sj.onc.1208325	http://dx.doi.org/10.1038/sj.onc.1208325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592500				2022-12-28	WOS:000226749200007
J	Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP				Ingley, E; McCarthy, DJ; Pore, JR; Sarna, MK; Adenan, AS; Wright, MJ; Erber, W; Tilbrook, PA; Klinken, SP			Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis	ONCOGENE			English	Article						erythropoiesis; erythropoietin; Lyn; STAT5; GATA-1; EKLF	TRANSCRIPTION FACTOR; DNA-BINDING; ERYTHROID-DIFFERENTIATION; TYROSINE PHOSPHORYLATION; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; STAT5A(-/-)5B(-/-) MICE; RECEPTOR; PROLIFERATION; ACTIVATION	In vitro studies have implicated the Lyn tyrosine kinase in erythropoietin signaling. In this study, we show that J2E erythroid cells lacking Lyn have impaired signaling and reduced levels of transcription factors STAT5a, EKLF and GATA-1. Since mice lacking STAT5, EKLF or GATA-1 have red cell abnormalities, this study also examined the erythroid compartment of Lyn(-/-) mice. Significantly, STAT5, EKLF and GATA-1 levels were appreciably lower in Lyn(-/-) erythroblasts, and the phenotype of Lyn(-/-) animals was remarkably similar to GATA-1(low) animals. Although young adult Lyn-deficient mice had normal hematocrits, older mice developed anemia. Grossly enlarged erythroblasts and florid erythrophagocytosis were detected in the bone marrow of mice lacking Lyn. Markedly elevated erythroid progenitors and precursor levels were observed in the spleens, but not bone marrow, of Lyn(-/-) animals indicating that extramedullary erythropoiesis was occurring. These data indicate that Lyn(-/-) mice display extramedullary stress erythropoiesis to compensate for intrinsic and extrinsic erythroid defects.	Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, PathCtr, Nedlands, WA, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Univ Western Australia, Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134				Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; BUSFIELD SJ, 1992, BLOOD, V80, P412; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Chin H, 1998, BLOOD, V91, P3734; Coghill E, 2001, BLOOD, V97, P1861, DOI 10.1182/blood.V97.6.1861; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Harashima A, 2002, BLOOD, V100, P4440, DOI 10.1182/blood-2002-03-0864; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1987, J IMMUNOL, V139, P3091; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; Kubota Y, 2001, EMBO J, V20, P5666, DOI 10.1093/emboj/20.20.5666; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MCLEOD DL, 1974, BLOOD, V44, P517, DOI 10.1182/blood.V44.4.517.517; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V28, P175; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Vannucchi AM, 2001, BLOOD, V97, P3040, DOI 10.1182/blood.V97.10.3040; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Whyatt D, 2000, NATURE, V406, P519, DOI 10.1038/35020086; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457	64	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					336	343		10.1038/sj.onc.1208199	http://dx.doi.org/10.1038/sj.onc.1208199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516974				2022-12-28	WOS:000226279700005
J	Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA				Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA			c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK)	ONCOGENE			English	Article						VRK1; c-Jun; JNK; transcription	CELL LUNG CARCINOMAS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; ACTIVATION; FAMILY; CANCER; ATF2; PROLIFERATION; AP-1	The VRK1 kinase is a novel Ser-Thr kinase in the human kinome that diverged from the casein kinase 1 branch. These kinases phosphorylate transcription factors related to stress responses, such as p53. In this report we have studied the phosphorylation of the transcription factor c-Jun in its N-terminal region. The VRK1 protein phosphorylates c-Jun with a Km of 0.4 muM, and is not inhibited by SP600125. VRK1 phosphorylates c-Jun in Ser63 and Ser73 in vitro, the same residues targeted by the N-terminal kinase of c-Jun (JNK). This phosphorylation induces the stabilization and accumulation of the c-Jun protein. VRK1 phosphorylates the endogenous c-Jun in Ser63. VRK1 activates c-Jun dependent transcription, which is dependent on phosphorylation of Ser63 and Ser73. The c-Jun with Ser63Ala and Ser73Ala substitutions is not transcriptionally active when cotransfected with VRK1. VRK1 interacts with c-Jun but not with JNK. The cotransfection of VRK1 and JNK has an additive effect on the transcriptional activation of c-Jun indicating that they can cooperate when both are at suboptimal dose; otherwise, maximum effect by one of them prevents the effect of the other. The VRK1-c-Jun connection represents a component of a new signaling pathway whose upstream elements remain to be identified.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Sevilla, Ana/N-8579-2017; Vega, Francisco M./C-4678-2008; Lazo, Pedro A./M-6435-2014	Sevilla, Ana/0000-0002-9251-4759; Vega, Francisco M./0000-0002-9015-864X; Lazo, Pedro A./0000-0001-8997-3025				ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Aoyagi K, 1998, CLIN CANCER RES, V4, P2153; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meggiato T, 2003, PANCREAS, V26, P65, DOI 10.1097/00006676-200301000-00011; Neyns B, 1996, ONCOGENE, V12, P1247; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Szabo E, 1996, CANCER RES, V56, P305; TINIAKOS DG, 1994, BRIT J UROL, V74, P757, DOI 10.1111/j.1464-410X.1994.tb07121.x; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Volm M, 2002, CLIN CANCER RES, V8, P1843; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x	38	84	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8950	8958		10.1038/sj.onc.1208015	http://dx.doi.org/10.1038/sj.onc.1208015			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15378002	Bronze, Green Submitted			2022-12-28	WOS:000225354600010
J	Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD				Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD			Involvement of p53 and Fas/CD95 in murine neural progenitor cell response to ionizing irradiation	ONCOGENE			English	Article						p53; Fas/CD95; neural progenitor; apoptosis; radiation	RADIATION-INDUCED APOPTOSIS; CENTRAL-NERVOUS-SYSTEM; CD95 APO-1/FAS; DNA-DAMAGE; WILD-TYPE; IN-VIVO; TUMOR-SUPPRESSOR; DEATH RECEPTOR; DENTATE GYRUS; STEM-CELLS	We investigated the role of tumor suppressor p53 and Fas (CD95/APO-1), a member of the tumor necrosis factor receptor family, in neural progenitors response to gamma-irradiation exposure. Telencephalic cells were obtained from wild-type C57Bl/6, or p53 -/- or fas -/-, 15-day-old mouse embryos. They were cultured in conditions allowing neural progenitors to form proliferating clusters ( neurospheres). A 2 Gy gamma-irradiation induced a G1 cell cycle arrest and triggered apoptosis in wild-type neural progenitor cultures in correlation with an enhanced expression of p53 and of its downstream target p21(WAF1), both of them acquiring a nuclear localization. These effects did not occur in p53 -/- neural progenitors demonstrating the central role played by p53 in their response to ionizing radiation. Furthermore, the monoclonal antibody Jo2 directed against Fas induced apoptosis of wild type but not of fas -/- neural progenitors, indicating the existence of a functional Fas signaling pathway in neural progenitors. Ionizing radiation induced an increase of Fas membrane expression related to a p53-dependent increase of fas mRNA expression in wild-type neural progenitors. Moreover, fas -/- neural progenitors exhibited delayed radiation-induced apoptosis compared to wild-type cells. Therefore, these findings establish a role for Fas/CD95 related to p53 in the response of neural progenitors to gamma-radiation exposure. Similar mechanisms could be triggered in neural progenitors in case of different stresses during brain development or in the course of various diseases affecting the adult brain.	CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France; CEA, CNRS,UMR 217, DRR DSV, Lab Cancerol Mol, Fontenay Aux Roses, France; CEA, IPSC, SEGG DRR DSV, Lab Radiosensibil Cellules Germinales, Fontenay Aux Roses, France	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Boussin, FD (corresponding author), CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France.	boussin@cea.fr		Boussin, francois/0000-0003-3778-4403; Mouthon, Marc-Andre/0000-0003-2633-9179; allemand, isabelle/0000-0002-8861-7632; MILLET, Pascal/0000-0001-8877-8455				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chow BM, 2000, CELL DEATH DIFFER, V7, P712, DOI 10.1038/sj.cdd.4400704; Craig CG, 1996, J NEUROSCI, V16, P2649; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DANIEL PT, 1994, J IMMUNOL, V152, P5624; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; DHEIN J, 1992, J IMMUNOL, V149, P3166; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROSCI, V17, P1397; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kovac AD, 2002, EUR J NEUROSCI, V16, P159, DOI 10.1046/j.1460-9568.2002.02060.x; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu X, 1999, NEUROREPORT, V10, P3087, DOI 10.1097/00001756-199909290-00039; Maecker HL, 2000, CANCER RES, V60, P4638; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsui Y, 2001, AM J CLIN ONCOL-CANC, V24, P486, DOI 10.1097/00000421-200110000-00014; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nat R, 2001, J CELL MOL MED, V5, P417, DOI 10.1111/j.1582-4934.2001.tb00177.x; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; O'Connor L, 2000, CANCER RES, V60, P1217; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Rao MS, 1999, ANAT RECORD, V257, P137; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sheard MA, 2001, INT J CANCER, V96, P213, DOI 10.1002/ijc.1020; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Unger C, 1998, CELL DEATH DIFFER, V5, P87, DOI 10.1038/sj.cdd.4400321; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiang H, 1998, J NEUROSCI, V18, P1363	81	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8497	8508		10.1038/sj.onc.1207821	http://dx.doi.org/10.1038/sj.onc.1207821			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361846				2022-12-28	WOS:000224870700010
J	Oh, SM; Pyo, CW; Kim, Y; Choi, SY				Oh, SM; Pyo, CW; Kim, Y; Choi, SY			Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappa B activation cascade	ONCOGENE			English	Article						lactoferrin; p53; NF-kappa B	TUMOR-NECROSIS-FACTOR; NUCLEAR-FACTOR; KINASE CASCADES; BINDING; TRANSCRIPTION; EXPRESSION; ALPHA; GRANULOPOIESIS; LOCALIZATION; SEQUENCE	Neutrophil lactoferrin (Lf) was previously shown to act as a transcriptional activator in various mammalian cells. Here, we describe that Lf specifically transactivates the p53 tumor suppressor gene through the activation of nuclear factor-kappaB (NF-kappaB) and consequently regulates p53-responsive oncogenes. In HeLa cervical carcinoma cells stably expressing Lf (HeLa-Lf), expression of mdm2 and p21(waf1/cip1) as well as p53 was greatly enhanced. Transient expression of Lf also markedly transactivates transcription of a p53 promoter-driven reporter and NF-kappaB-driven reporters in various mammalian cells. However, mutation of the NF-kappaB site or treatment with an NF-kappaB inhibitor abrogated the transactivation, suggesting that NF-kappaB should play an essential role in the Lf-induced transactivation. Increased binding activity and nuclear translocation of p65 in response to Lf strongly support these findings. Furthermore, Lf-mediated NF-kappaB activation is diminished in IKKalpha- or IKKbeta-deficient mouse embryonic fibroblast cells. The activation of both IKKs and NF-kappaB by Lf is over-ridden by the expression of dominant-negative mutants of NIK, MEKK 1, IKKalpha and IKKbeta. Collectively, we conclude that overexpressed Lf directly relays signals to upstream components responsible for NF-kappaB activation, thereby leading to the activation of NF-kappaB target genes.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Univ Ulsan, Coll Med, Genome Res Ctr Birth Defects & Genet Disorders, Seoul 138736, South Korea	Korea University; University of Ulsan	Choi, SY (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	sychoi@korea.ac.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGBY GC, 1989, BLOOD CELLS, V15, P386; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GALBRAITH PR, 1986, CLIN INVEST MED, V9, P1; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GINSBERG D, 1990, ONCOGENE, V5, P1285; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG308, DOI 10.1152/ajpgi.1994.267.2.G308; Oh SM, 2001, J BIOL CHEM, V276, P42575, DOI 10.1074/jbc.M107724200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Suzuki YA, 2002, BIOCHEM CELL BIOL, V80, P75, DOI 10.1139/o01-228; WENG HQ, 1995, J BIOL CHEM, V270, P13637, DOI 10.1074/jbc.270.23.13637; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	28	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8282	8291		10.1038/sj.onc.1208021	http://dx.doi.org/10.1038/sj.onc.1208021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378004				2022-12-28	WOS:000224749500010
J	Song, H; Jin, XH; Lin, JY				Song, H; Jin, XH; Lin, JY			Stat3 upregulates MEK5 expression in human breast cancer cells	ONCOGENE			English	Article						MEK5; Stat3; breast carcinoma; siRNA	GENE-EXPRESSION; SIGNAL TRANSDUCER; TRANSCRIPTION FACTORS; ACTIVATION; KINASE; OVEREXPRESSION; GROWTH; ADRENOMEDULLIN; RESISTANCE; PATHWAYS	The constitutive activation of signal transducer and activator of transcription 3 (Stat3) is frequently detected in breast cancer cell lines but not in normal breast epithelial cells. Stat3 has been classified as an oncogene, because constitutively active Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice. Since Stat3 appears to play an important role in breast cancer, it is of interest to investigate Stat3-regulated genes and elucidate Stat3-mediated oncogenesis. In this study, we investigated the Stat3-regulated genes in human breast epithelial cells. Upon overexpression of Stat3-C, a constitutively active Stat3 form, in nonmalignant telomerase immortalized breast (TERT) cells, the total mRNA was extracted and subjected to Affymetrix microarray analysis. Our results showed that mitogen-activated protein kinase kinase 5 (MEK5) was markedly induced (more than 22-fold increase, P < 0.001) by Stat3-C expression. RT-PCR result also demonstrated that MEK5 mRNA was significantly induced by Stat3-C in TERT cells. The upregulation of MEK5 by Stat3-C was further confirmed by Western blot in MCF10A breast epithelial cells. Further more, in MDA-MB-435s breast carcinoma cells, which express high levels of activated Stat3 and MEK5, MEK5 protein was significantly reduced by using Stat3 short interfering RNA. The reduction of MEK5 was consistent with Stat3 knockdown in this breast carcinoma cell line. We also investigated MEK5 expression in different breast carcinoma cell lines and breast cancer tissues using tissue array analysis. Compared with nonmalignant breast epithelial cells or normal tissues without constitutively active Stat3 signaling, MEK5 protein levels are remarkably higher in breast carcinoma cell lines and cancer tissues with constitutively activated Stat3. Taken together, our findings suggest that constitutively active Stat3 upregulates MEK5 in the breast epithelial cells. MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies.	Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lin, JY (corresponding author), Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	linjia@umich.edu	Lin, Jiayuh/E-3515-2011		NCI NIH HHS [R01 CA096714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alas S, 2001, CANCER RES, V61, P5137; Atsumi T, 2002, CANCER RES, V62, P5881; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Dalton WS, 1999, SEMIN ONCOL, V26, P23; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Martinez A, 2002, J NATL CANCER I, V94, P1226; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pollett JB, 2002, BLOOD, V100, P3819, DOI 10.1182/blood-2002-02-0608; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Song H, 2004, INT J ONCOL, V24, P1017; Song H, 2004, BIOCHEM BIOPH RES CO, V314, P143, DOI 10.1016/j.bbrc.2003.12.048; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tan KB, 2004, HISTOPATHOLOGY, V44, P24, DOI 10.1111/j.1365-2559.2004.01774.x; Ueno H, 1997, CANCER RES, V57, P2055; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yoshizumi M, 2003, J PHARMACOL SCI, V91, P172; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	54	44	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8301	8309		10.1038/sj.onc.1208026	http://dx.doi.org/10.1038/sj.onc.1208026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378007				2022-12-28	WOS:000224749500012
J	Sloan, EK; Stanley, KL; Anderson, RL				Sloan, EK; Stanley, KL; Anderson, RL			Caveolin-1 inhibits breast cancer growth and metastasis	ONCOGENE			English	Article						caveolin-1; breast cancer; invasion; metastasis; bone metastases	TUMOR-SUPPRESSOR GENE; ENDOPLASMIC-RETICULUM; PROSTATE-CANCER; NULL MICE; EXPRESSION; CHOLESTEROL; D7S522; REGION; 7Q31.1	Caveolin-1 was identified in a screen for genes involved in breast cancer progression. Caveolin-1 is the major protein component of caveolae, flask-shaped invaginations found in a number of different cell types. Using an orthotopic model of spontaneous breast cancer metastasis, caveolin-1 was found to be expressed in low and non-metastatic primary tumors, but at much lower levels in highly metastatic 4T1.2 and 4T1.13 tumors. Exogenous expression of caveolin-1 at moderate levels in 4T1.2 cells was sufficient to suppress primary tumor growth after inoculation of cells into the mammary gland. Expression of high levels of caveolin-1 also inhibited subsequent metastasis to distant organs. Cells expressing high levels of caveolin-1 showed reduced capacity to invade Matrigel, diminished response to laminin-1 stimulation and decreased metastasis to lung and bone. This study provides the first functional evidence that caveolin-1 regulates primary breast tumor growth and spontaneous metastasis of breast cancer.	Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Anderson, RL (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	robin.anderson@petermac.org	Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Sloan, Erica/0000-0002-2355-1433; Anderson, Robin/0000-0002-6841-7422	NCI NIH HHS [R01 CA 90291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bender FC, 2000, CANCER RES, V60, P5870; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hayashi K, 2001, CANCER RES, V61, P2361; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Li LK, 2001, CANCER RES, V61, P4386; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Parker BS, 2004, CAN META BIO TREAT, V6, P1; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Razani B, 2001, J BIOL CHEM, V276, P38121; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Tester AM, 2002, CLIN EXP METASTAS, V19, P377, DOI 10.1023/A:1016381416463; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	35	131	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7893	7897		10.1038/sj.onc.1208062	http://dx.doi.org/10.1038/sj.onc.1208062			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334058				2022-12-28	WOS:000224331600015
J	Suzuki, A; Kusakai, G; Kishimoto, A; Shimojo, Y; Miyamoto, S; Ogura, T; Ochiai, A; Esumi, H				Suzuki, A; Kusakai, G; Kishimoto, A; Shimojo, Y; Miyamoto, S; Ogura, T; Ochiai, A; Esumi, H			Regulation of caspase-6 and FLIP by the AMPK family member ARK5	ONCOGENE			English	Article						ARK5; caspase-6; FLIP; Fas ligand/Fas system; colorectal cancer	ACTIVATED PROTEIN-KINASE; TRAIL-INDUCED APOPTOSIS; HUMAN COLON-CANCER; FAS LIGAND; CELL-DEATH; NUTRIENT DEPRIVATION; GLUCOSE STARVATION; LIVER METASTASES; TUMOR-CELLS; EXPRESSION	Colorectal cancer cells are unique in that they escape Fas-mediated cell death in the presence of Fas ligand, and we recently reported that AMP-activated protein kinase-related kinase 5 (ARK5) suppresses cell death signaling mediated by cell death receptor in Akt-dependent manner. In the current study, therefore, we examined whether ARK5 is involved in the escape from Fas-mediated cell death of colorectal cancer cells. Among 10 cell lines, ARK5 mRNA expression was observed in LoVo, SW480, and SW1116 cell lines. Interestingly, SW480 and SW1116 cell lines, but not LoVo cell line, showed expressions of both Fas ligand ( FasL) and Fas mRNAs. SW620 cell line also showed FasL mRNA; however, Fas and ARK5 mRNAs were not detected. Furthermore, well-coincided expression among ARK5, FasL, and Fas mRNAs was observed in tumor tissues from patients with colorectal cancer, suggesting the suppression of FasL/Fas system-induced cell death by ARK5 in colorectal cancer cell lines. Intensive cell death, which was dependent on the FasL/Fas system was encountered when ARK5 antisense RNA (ARK5/AS) was introduced into SW480 cells. FLIP was expressed in only ARK5 mRNA-expressing cell lines, and ARK5/AS induced FLIP cleavage in a caspase-6-dependent manner. Amino-acid sequence analysis of caspase-6 revealed two putative sites of phosphorylation by ARK5 at Ser(80) and Ser(257). Although active caspase-6 overexpression induced cell death in SW480 and DLD-1 cell lines, SW480 cells, but not DLD-1 cells, exhibited strong resistance to procaspase-6 overexpression. Moreover, mutant caspase-6, in which the Ser257 was substituted by Ala ( caspase-6/SA), induced cell death and FLIP degradation, even in SW480 cells. Active ARK5 was found to phosphorylate wild-type caspase-6 in vitro, but not caspase-6/SA, and the prevented activation of caspase-6 was promoted due to its phosphorylation by active ARK5 in vitro. On the basis of the results of this study, we propose that ARK5 negatively regulates procaspase-6 by phosphorylation at Ser(257), leading to resistance to the FasL/Fas system.	Natl Canc Ctr, Res Inst E, Invest Treatment Div, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Chiba 2778562, Japan; Natl Canc Ctr, Res Inst E, Div Pathol, Chiba 2778577, Japan	National Cancer Center - Japan; University of Tokyo; National Cancer Center - Japan	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp						Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598; Berman R S, 2001, Cancer Treat Res, V109, P183; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ding EX, 1998, RES COMMUN MOL PATH, V101, P13; Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hashimoto K, 2002, BIOCHEM BIOPH RES CO, V290, P263, DOI 10.1006/bbrc.2001.6193; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Izuishi K, 2000, CANCER RES, V60, P6201; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakanishi K, 2002, CANCER RES, V62, P2971; O'Connell J, 1998, J PATHOL, V186, P240; PESO LD, 1997, SCIENCE, V278, P687; PEUDOEBERL L, 1999, INT J CANCER, V81, P772; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; Wyllie A H, 1980, Int Rev Cytol, V68, P251	36	69	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7067	7075		10.1038/sj.onc.1207963	http://dx.doi.org/10.1038/sj.onc.1207963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273717				2022-12-28	WOS:000223885100007
J	Iwakiri, D; Sheen, TS; Chen, JY; Huang, DP; Takada, K				Iwakiri, D; Sheen, TS; Chen, JY; Huang, DP; Takada, K			Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines	ONCOGENE			English	Article						EBV; IGF-1; nasopharyngeal carcinoma; EBER	BURKITTS-LYMPHOMA; INFECTION; CANCER	To assess the role of insulin-like growth factor 1 (IGF-1) in the growth of nasopharyngeal carcinoma (NPC), three NPC-derived cell lines, C666-1, CNE1 and HONE1, were examined. C666-1 cells maintained NPC phenotype of Epstein-Barr virus (EBV) expression and were positive for IGF-1 secretion, and their growth was strikingly inhibited by treatment with an anti-IGF-1 antibody under low serum condition. On the other hand, CNE1 and HONE1 cells were EBV-negative and did not secrete IGF-1. Although they could not grow under low serum condition, addition of recombinant IGF-1 made them grow. EBV conversion of CNE1 and HONE1 cells reproduced NPC phenotype of EBV expression and accompanied IGF-1 expression. Although they could grow under low serum condition, their growth was strikingly inhibited by treatment with the anti-IGF-1 antibody. These results suggest that EBV infection induces IGF-1 in NPC cell lines, and that the secreted IGF-1 acts as an autocrine growth factor. These findings seem to be operative in vivo, as NPC biopsies consistently express IGF-1. Further studies demonstrated that increased IGF-1 expression reflected transcriptional activation, and EBV-encoded small RNA ( EBER) was responsible for IGF-1 induction. EBER is invariably expressed in EBV-associated malignancies, including NPC. The present findings strongly suggest that EBER directly affects the pathogenesis of NPC.	Hokkaido Univ, Inst Med Genet, Dept Tumor Virol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Natl Taiwan Univ, Coll Med, Dept Otolaryngol, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Med, Dept Microbiol, Taipei 10764, Taiwan; Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Hokkaido University; National Taiwan University; National Taiwan University; Chinese University of Hong Kong	Takada, K (corresponding author), Hokkaido Univ, Inst Med Genet, Dept Tumor Virol, Kita Ku, N15 W7, Sapporo, Hokkaido 0600815, Japan.	kentaka@igm.hokudai.ac.jp	Takada, Kenzo/A-6666-2012; Chen, Jen-Yang/D-2085-2010					Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3; Imai S, 1998, J VIROL, V72, P4371, DOI 10.1128/JVI.72.5.4371-4378.1998; Iwakiri D, 2003, CANCER RES, V63, P7062; KIEFF E, 2002, FIELDS VIROLOGY, P2511; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; RICKINSON AB, 2002, FIELDS VIROLOGY, P2575; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; ZHANG S, 1982, HEREDITAS, V97, P23, DOI 10.1111/j.1601-5223.1982.tb00706.x	15	96	104	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1767	1773		10.1038/sj.onc.1208357	http://dx.doi.org/10.1038/sj.onc.1208357			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608666				2022-12-28	WOS:000227345100012
J	Abu-Amero, KK; Alzahrani, AS; Zou, MJ; Shi, YF				Abu-Amero, KK; Alzahrani, AS; Zou, MJ; Shi, YF			High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines	ONCOGENE			English	Article						mitochondria; mutation; thyroid neoplasm; respiratory function	TUMORS; NUCLEAR; GENOME; CHAIN; VARIANTS; DISEASE; MELAS	Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression. However, most investigations have mainly focused on the genetic alterations of nuclear DNA. The potential role of mitochondrial DNA (mtDNA) mutations in thyroid tumorigenesis is not well defined. In the present study, we investigated the frequency of mtDNA mutations in 24 thyroid tumor specimens (19 primary papillary thyroid carcinomas (PTC), one follicular thyroid carcinoma, and four multinodular hyperplasias) and four thyroid cancer cell lines by sequencing the entire coding regions of mitochondrial genome. Among the 19 PTC samples tested, seven (36.8%) had somatic mutations. Somatic mtDNA mutations were also detected in one of four multinodular hyperplasias examined. All the thyroid tumor cell lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants. Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines revealed a severe defect in mitochondrial complex I activity. The majority of the mutations was involved in genes located in the complex I of the mitochondrial genome. The mutations were either A-->G or C-->T transitions, often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. These data suggest that mtDNA mutations may play an important role in the thyroid tumorigenesis. Given that mtDNA mutation is present in the benign multinodular hyperplasia, it might be involved in the early stage of tumor development.	King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC 03, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center	Shi, YF (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Genet MBC 03, POB 3354, Riyadh 11211, Saudi Arabia.	yufei@kfshrc.edu.sa	Shi, Yufei/ABG-5228-2020; Alzahrani, Ali S/L-3664-2017	Shi, Yufei/0000-0002-6999-0191; Alzahrani, Ali S/0000-0003-4294-3624				Abu-Amero K, 2004, CLIN GENET, V66, P569, DOI 10.1111/j.1399-0004.2004.00365.x; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bosley TM, 2004, NEUROLOGY, V63, P1305, DOI 10.1212/01.WNL.0000140696.34117.95; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K; Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Hartman P, 2004, MECH AGEING DEV, V125, P417, DOI 10.1016/j.mad.2004.02.007; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jones JB, 2001, CANCER RES, V61, P1299; Liu VWS, 2001, CANCER RES, V61, P5998; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; Parrella P, 2001, CANCER RES, V61, P7623; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967; Schmutzler C, 2000, EUR J ENDOCRINOL, V143, P15, DOI 10.1530/eje.0.1430015; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; Setterfield K, 2002, MITOCHONDRION, V1, P437, DOI 10.1016/S1567-7249(02)00008-9; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043; Stefaneanu L, 1979, Endocrinologie, V17, P233; Takano T, 2000, BRIT J CANCER, V83, P1495, DOI 10.1054/bjoc.2000.1483; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Williams AJ, 1999, J CHILD NEUROL, V14, P518, DOI 10.1177/088307389901400807; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537	30	49	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1455	1460		10.1038/sj.onc.1208292	http://dx.doi.org/10.1038/sj.onc.1208292			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608681				2022-12-28	WOS:000227092600015
J	Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A				Kramer, S; Ozaki, T; Miyazaki, K; Kato, C; Hanamoto, T; Nakagawara, A			Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells	ONCOGENE			English	Article						p53; p73; RanBPM; two-hybrid; ubiquitination	KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; BINDING-PROTEIN; P53-RELATED PROTEIN; INDUCE APOPTOSIS; NUCLEAR-PROTEIN; P53; DEGRADATION; NEUROBLASTOMA	Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73alpha by yeast-based two-hybrid screening, and also found that RanBPM has an ability to stabilize p73alpha. GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73alpha, whereas it failed to interact with p53. Co-expression of RanBPM with p73alpha resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73alpha, and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73alpha was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp						Agami R, 1999, NATURE, V399, P809; Bai D, 2003, BIOCHEM BIOPH RES CO, V309, P552, DOI 10.1016/j.bbrc.2003.08.033; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Gong JG, 1999, NATURE, V399, P806; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lutz W, 2003, BIOCHEM BIOPH RES CO, V303, P1186, DOI 10.1016/S0006-291X(03)00499-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Stiewe T, 2002, CANCER RES, V62, P3598; Umeda M, 2003, GENE, V303, P47, DOI 10.1016/S0378-1119(02)01153-8; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang Y, 2002, BIOCHEM BIOPH RES CO, V297, P148, DOI 10.1016/S0006-291X(02)02020-X; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	33	60	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					938	944		10.1038/sj.onc.1208257	http://dx.doi.org/10.1038/sj.onc.1208257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558019				2022-12-28	WOS:000226577100019
J	Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M				Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M			Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						methylation; pancreatic cancer; invasion; protease inhibitor	FACTOR PATHWAY INHIBITOR-2; METHYLATION-SPECIFIC PCR; MATRIX-METALLOPROTEINASE EXPRESSION; HUMAN CANCER-CELLS; HUMAN GLIOMAS; CHORIOCARCINOMA CELLS; PROTEASE INHIBITOR; MOLECULAR-CLONING; CPG-ISLANDS; IN-VITRO	Using microarrays, we have screened for genes reactivated by drugs that modify epigenetic mechanisms in pancreatic cancer cells. One of the genes identified was tissue factor pathway inhibitor 2 (TFPI-2), which encodes for a broad-spectrum serine proteinase inhibitor that negatively regulates the extracellular matrix degradation, an essential step in tumor invasion and metastasis. We therefore investigated the expression and methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tumor growth and invasion. In contrast to its abundant expression in normal pancreas, TFPI-2 mRNA was undetectable in a high fraction of pancreatic cancer cell lines and in primary pancreatic ductal neoplasms (IPMNs). Loss of TFPI-2 expression was associated with aberrant hypermethylation of its promoter CpG island. Treatment with the phorbol ester (PMA), known to stimulate the TFPI-2 promoter activity, augmented the TFPI-2 expression in cell lines with unmethylated or partially methylated TFPI-2, but failed to induce the expression in cell lines that harbored fully methylated TFPI-2. Aberrant methylation of TFPI-2 was also detected in 73% (102/140) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older patients with pancreatic cancer, and significantly correlated with progression of IPMNs (P = 0.0002). Restored expression of the TFPI-2 gene in nonexpressing pancreatic cancer cells resulted in marked suppression in their proliferation, migration, and invasive potential in vitro. We thus conclude that epigenetic inactivation of TFPI-2 is a common mechanism that contributes to the aggressive phenotype of pancreatic ductal adenocarcinoma.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Kanagawa Canc Ctr, Div Tumor Pathol, Yokohama, Kanagawa 2410815, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Prefectural Cancer Center	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave,241-0815, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NCI NIH HHS [CA90709, CA62924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090709, P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fukushima N, 2003, CANCER BIOL THER, V2, P78; HAHN SA, 1995, CANCER RES, V55, P4670; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hube F, 2003, BIOL CHEM, V384, P1029, DOI 10.1515/BC.2003.115; Iacobuzio-Donahue CA, 2004, CANCER RES, V64, P871, DOI 10.1158/0008-5472.CAN-03-2756; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 2003, INT J ONCOL, V22, P843; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka Y, 2004, INVEST OPHTH VIS SCI, V45, P245, DOI 10.1167/iovs.03-0230; Tasiou A, 2001, INT J ONCOL, V19, P591; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140	41	121	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					850	858		10.1038/sj.onc.1208050	http://dx.doi.org/10.1038/sj.onc.1208050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592528				2022-12-28	WOS:000226577100011
J	Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE				Chan, EL; Peace, BE; Collins, MH; Toney-Earley, K; Waltz, SE			Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis	ONCOGENE			English	Article						tyrosine kinase; Ras; hepatocyte growth factor-like protein (HGFL); macrophage-stimulating protein (MSP); Met; stem cell-derived tyrosine kinase (stk)	MACROPHAGE-STIMULATING PROTEIN; RAS GENE MUTATION; TRANSGENIC MOUSE; SPLICING VARIANT; POINT MUTATIONS; RETINOIC ACID; ACTIVATED RAS; MET; TRANSFORMATION; CARCINOMA	Recent studies demonstrate that the receptor tyrosine kinase (TK) Ron is tumorigenic when overexpressed and plays a role in regulating skin homeostasis. We hypothesized that Ron signaling promotes skin carcinogenesis. To test this hypothesis, mice deficient in the TK domain of Ron (TK-/- mice) were crossed with v-Ha-ras (Tg.AC) transgenic mice; the resulting TK-/- Tg.AC(+/-) mice, and their controls, we re utilized in a model of chemically induced Ras-mediated skin carcinogenesis. The mice were treated with 2.5 mug of 12-O-tetradecanoylphorbol-13-acetate applied weekly to the shaved back of 36 control (TK+/+ Tg.AC(+/-)) and 35 experimental (TK-/- Tg.AC(+/-)) mice. In an analysis of the resulting papillomas, a reduction in cellular proliferation and papilloma volume was found in the TK-/- Tg.AC(+/-) mice compared to controls. Further, Ron protein expression was upregulated during papilloma formation. Ablation of Ron signaling resulted in partial defects in MAPK and Akt signaling that may account for the decreased papilloma growth in the TK-/- Tg.AC(+/-) mice. The papilloma-bearing mice were monitored for the occurrence of malignant skin tumors and other malignant tumor types for a period of 48 weeks. Loss of Ron receptor signaling significantly reduced the percent of papillomas that underwent malignant conversion as well as the number of mice developing other malignant tumor types. In conclusion, these studies demonstrate that Ron signaling augments papilloma growth and malignant conversion in vivo.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Waltz, SE (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, SRU-MSB G482,ML 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu		Waltz, Susan/0000-0003-3572-4642	NCI NIH HHS [R01 CA100002-02, R01 CA100002-01A1, R01 CA100002, R01 CA100002-03] Funding Source: Medline; NICHD NIH HHS [T32 HD43005-01, HD-36888, T32 HD043005, R01 HD036888-04, R01 HD036888, R01 HD036888-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036888, T32HD043005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Bohle RM, 1996, AM J PATHOL, V148, P731; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chen QY, 1997, HEPATOLOGY, V26, P59; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HENNINGS H, 1990, CANCER RES, V50, P653; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; KULESZMARTIN MF, 1991, CANCER RES, V51, P4701; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Leonis NA, 2002, HEPATOLOGY, V36, P1053, DOI 10.1053/jhep.2002.36822; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; McDowell SA, 2002, AM J RESP CELL MOL, V26, P99, DOI 10.1165/ajrcmb.26.1.4621; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakamoto A, 2001, HUM PATHOL, V32, P1225, DOI 10.1053/hupa.2001.28953; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spalding JW, 1999, TOXICOL SCI, V49, P241, DOI 10.1093/toxsci/49.2.241; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, ONCOGENE, V13, P2167; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; Webb CP, 1998, ONCOGENE, V17, P2019, DOI 10.1038/sj.onc.1202135; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	36	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					479	488		10.1038/sj.onc.1208231	http://dx.doi.org/10.1038/sj.onc.1208231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531916				2022-12-28	WOS:000226279700018
J	Du, LH; Lyle, CS; Chambers, TC				Du, LH; Lyle, CS; Chambers, TC			Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction	ONCOGENE			English	Article						vinblastine; Bcl-xL; Bcl-2; phosphorylation; apoptosis; protein kinase	N-TERMINAL KINASE; CELL-DEATH; SIGNALING PATHWAYS; CYTOCHROME-C; LOOP DOMAIN; MITOCHONDRIA; BCL-X(L); FAMILY; JNK; IDENTIFICATION	Bcl-xL and Bcl-2 are phosphorylated in response to microtubule inhibitors, but the kinase(s) responsible and the functional significance have remained unclear. In this study, we investigated the characteristics of Bcl-xL and Bcl-2 phosphorylation in KB-3 carcinoma cells treated with vinblastine. In both asynchronous and synchronous cell cultures, Bcl-xL and Bcl-2 underwent a well-defined and coordinated cycle of phosphorylation and dephosphorylation, with a lengthy period of phosphorylation preceding apoptosis induction, and with dephosphorylation closely correlated with initiation of apoptosis. Internally, validated inhibitors of JNK, ERK, p38(MAPK), or CDK1 failed to inhibit vinblastine-induced phosphorylation of Bcl-xL or Bcl-2. In vitro, Bcl-xL and Bcl-2 were poor substrates relative to c-Jun and ATF2 for active recombinant JNK1. Both Bcl-xL and Bcl-2 were localized primarily to the mitochondrial fraction in both control and vinblastine-treated cells, indicating that phosphorylation did not promote subcellular redistribution. Bcl-xL kinase activity was demonstrated in mitochondrial extracts from vinblastine-treated, but not control, cells. These findings suggest that phosphorylation of these key antiapoptotic proteins may be catalysed by a novel or unsuspected kinase that is activated or induced in response to microtubule damage. Furthermore, the same kinase and phosphatase system may be operating in tandem on both proteins, and phosphorylation appears to maintain their antiapoptotic function, whereas dephosphorylation may trigger apoptosis. These results provide evidence for a novel signaling pathway connecting microtubule damage to apoptosis induction, and help to clarify some of the controversy concerning the role of Bcl-2 phosphorylation in microtubule inhibitor-induced apoptosis.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.	chamberstimothyc@.uams.edu			NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER; NCI NIH HHS [CA10982, CA75577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 2000, CANCER RES, V60, P6101; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blagosklonny MV, 1997, CANCER RES, V57, P130; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Fan MY, 2000, CANCER RES, V60, P6403; Fang GF, 1998, CANCER RES, V58, P3202; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Osborn MT, 1999, ONCOGENE, V18, P5756, DOI 10.1038/sj.onc.1202943; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	33	68	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					107	117		10.1038/sj.onc.1208189	http://dx.doi.org/10.1038/sj.onc.1208189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531923				2022-12-28	WOS:000226125800013
J	Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F				Lim, MA; Yang, L; Zheng, Y; Wu, H; Dong, LQ; Liu, F			Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation of PTEN-knockout cells	ONCOGENE			English	Article						PTEN; cortical actin; Rho; Rac; PKN; PDK-1; cell migration	TUMOR-SUPPRESSOR GENE; PROTEIN-KINASE-C; ZIPPER-LIKE SEQUENCES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CATALYTIC DOMAIN; PUTATIVE TARGET; PROSTATE-CANCER; HUMAN BRAIN; ACTIVATION	Mutations in the tumor suppressor protein PTEN (phosphatase and tensin homologue deleted on chromosome 10) enhance cell migration, yet the underlying molecular mechanisms remain largely uncharacterized. Loss of PTEN in mouse embryonic fibroblasts (MEFs) correlates with striking cortical actin accumulation. However, how loss of PTEN leads to cortical actin formation and whether the presence of cortical actin contributes to the increased cell migration are unclear. Here we show that overexpression of dominant-negative forms of (DN) PTEN, RhoA or its kinase-dead (KD) effector, PKN, inhibited cortical actin formation, indicating that cortical actin of Pten(-/-) MEFs is mediated by the PTEN/Rho/PKN pathway. However, neither DN RhoA nor KD PKN inhibited the enhanced migration of Pten(-/-) cells, in contrast to the inhibitory effect of DN Rac. In agreement with the previous observation that DN Akt inhibits migration of Pten(-/-) cells, we demonstrate here that overexpression of KD PDK-1, the Akt kinase, reduces Pten(-/-) cell migration. Furthermore, overexpression of DN forms of Akt, Rac, or PDK-1, all of which inhibit migration of Pten(-/-) cells, had no effect on cortical actin accumulation. Our findings suggest that PDK-1/Akt signaling pathway plays a major role in regulating cell migration induced by PTEN deficiency.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Celebi JT, 2000, J MED GENET, V37, P653, DOI 10.1136/jmg.37.9.653; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hahn M, 1999, CLIN CANCER RES, V5, P2431; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Mertens F, 1997, CANCER RES, V57, P2765; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NOBES CD, 1995, J CELL SCI, V108, P225; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; RIJKEN PJ, 1991, J CELL SCI, V100, P491; Risinger JI, 1997, CANCER RES, V57, P4736; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang SI, 1997, CANCER RES, V57, P4183; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zeng X, 2002, CANCER RES, V62, P3538; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	60	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9348	9358		10.1038/sj.onc.1208147	http://dx.doi.org/10.1038/sj.onc.1208147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531926				2022-12-28	WOS:000225764100006
J	Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM				Rocchi, P; Muracciole, X; Fina, F; Mulholland, DJ; Karsenty, G; Palmari, J; Ouafik, L; Bladou, F; Martin, PM			Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft	ONCOGENE			English	Article						prostate cancer; androgen-independence; molecular expression analysis; LuCaP 23.1 xenograft	HUMAN-PROSTATE-CANCER; EPIDERMAL-GROWTH-FACTOR; CELL-LINES; RECEPTOR GENE; PLASMINOGEN-ACTIVATOR; FACTOR-ALPHA; TUMOR-MODEL; IN-VIVO; EXPRESSION; CASTRATION	After therapeutic hormone deprivation, most prostate cancer (PrCa) cells develop androgen-independent (AI) growth. PrCa is highly heterogeneous and multifocal, suggesting that several molecular processes or pathways may be contributing to AI. The human LuCaP 23.1 xenograft model retains clinical hallmarks of PrCa, including heterogeneous growth, PSA production, androgen-responsiveness and progression to AI. In this work, we studied the effect of androgen depletion (castration) on the growth of LuCaP 23.1 xenografts. A total of 100 nude mice were implanted and analysed for their growth profiles before and after castration. By 11 and 15 weeks, tumours were harvested and assessed for molecular marker expression specific for PrCa. Prior to castration we found 37 fast growing (FG) tumours (948.9 +/- 76.9 mm(3)) and 63 slow growing (SG) tumours (229.6 +/- 18.4 mm(3)), a previously undescribed result for this PrCa model. Quantitative RT-PCR showed that in comparison to SGs, FGs contained high HER1, uPA and thymidilate synthetase (TS) expression with low levels of 5alpha-reductase 2 mRNA. All FG tumours progressed rapidly to AI growth 5 weeks after castration (FG-P). In SG castrated tumours, 66% of tumours (SG-P) showed retarded progression (by 12 weeks) to AI, whereas 34% responded to castration (SG-R). Molecular analysis permitted us to define distinct molecular profiles integrating different pathways associated with AI progression. FG-P, and a subgroup of SG-P tumours, presented significantly high levels of peptidylglycine alpha-amidating monooxygenase (PAM), HER1, HER2, TS, and uPA mRNA, all of which correlated with AR expression. The second subgroup of SG-P tumours showed overexpression of the antiapoptotic gene Bcl-2. A third subgroup of SG-P tumours showed significant expression of hypoxia-related gene (adrenomedullin) after castration. This work permitted to define distinct molecular profiles related to different AI growth in the LuCaP 23.1 xenograft.	Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France; CHU Timone, APHM, Marseille, France; Hop Salvator, APHM, Serv Urol, Marseille, France; Jack Bell Res Ctr, Prostate Ctr, Vancouver, BC, Canada	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of British Columbia	Rocchi, P (corresponding author), Fac Med Marseille, IFR Jean Roche, APHM,Lab Transfert Oncol Biol, Lab Cancerol Expt EMI 0359, Marseille, France.	procchi@vanhosp.bc.ca	Rocchi, Palma/P-5455-2014; Muracciole, Xavier/P-5640-2016	Rocchi, Palma/0000-0002-4383-4684; Karsenty, Gilles/0000-0002-9047-3332; Ouafik, L'Houcine/0000-0002-4848-1232				Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Bladou F, 1996, INT J CANCER, V67, P785, DOI 10.1002/(SICI)1097-0215(19960917)67:6<785::AID-IJC6>3.0.CO;2-N; Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dahiya R, 1996, UROLOGY, V48, P963, DOI 10.1016/S0090-4295(96)00376-7; Delos S, 1998, INT J CANCER, V75, P840; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Ellis WJ, 1996, CLIN CANCER RES, V2, P1039; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GAYLIS FD, 1989, J UROLOGY, V142, P193, DOI 10.1016/S0022-5347(17)38709-8; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Helenius MA, 2001, CANCER RES, V61, P5340; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; Huss WJ, 2001, CANCER RES, V61, P2736; JANIK P, 1975, CANCER RES, V35, P3698; Jenster G, 1999, SEMIN ONCOL, V26, P407; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; Koivisto P, 1997, CANCER RES, V57, P314; LANDSTROM M, 1994, CANCER RES, V54, P4281; Liu AY, 1996, INT J CANCER, V65, P85, DOI 10.1002/(SICI)1097-0215(19960103)65:1<85::AID-IJC15>3.3.CO;2-E; LYON PB, 1995, PROSTATE, V27, P179, DOI 10.1002/pros.2990270402; McGowen R, 2000, CANCER RES, V60, P4771; McLeod DG, 2003, UROLOGY, V61, P3, DOI 10.1016/S0090-4295(02)02393-2; Miyake H, 1999, CANCER RES, V59, P4030; Negri-Cesi P, 1999, PROSTATE, V41, P224, DOI 10.1002/(SICI)1097-0045(19991201)41:4<224::AID-PROS2>3.0.CO;2-Q; Nelson JB, 2000, CANCER INVEST, V18, P87, DOI 10.3109/07357900009023066; Nelson JB, 2000, BJU INT, V85, P45, DOI 10.1046/j.1464-410X.2000.00063.x; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Rocchi P, 2001, CANCER RES, V61, P1196; Ross RK, 1998, CANCER RES, V58, P4497; Scher HI, 1995, CLIN CANCER RES, V1, P545; Scher HI, 2000, J NATL CANCER I, V92, P1866, DOI 10.1093/jnci/92.23.1866; Solit DB, 2002, CLIN CANCER RES, V8, P986; TURKERI LN, 1994, PROSTATE, V25, P199, DOI 10.1002/pros.2990250405; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wen Y, 2000, CANCER RES, V60, P6841; Xing RHM, 1999, ENDOCRINOLOGY, V140, P4056, DOI 10.1210/en.140.9.4056; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zhang LQ, 2003, CANCER RES, V63, P4552; Zudaire E, 2003, REGUL PEPTIDES, V112, P175, DOI 10.1016/S0167-0115(03)00037-5	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	2004	23	56					9111	9119		10.1038/sj.onc.1208154	http://dx.doi.org/10.1038/sj.onc.1208154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489889				2022-12-28	WOS:000225492800012
J	Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C				Michod, D; Yang, JY; Chen, JH; Bonny, C; Widmann, C			A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells	ONCOGENE			English	Article						cancer; RasGAP; cell permeable peptides; TAT; genotoxins	NF-KAPPA-B; APOPTOSIS; TRANSDUCTION; INHIBITOR; DELIVERY; PROTECTS; CLEAVAGE	Treatment of many cancers relies on the combined action of several genotoxins, but the detrimental effect of these drugs on normal cells can cause severe side effects. One major challenge in anticancer therapy is therefore to increase the selectivity of current treatments toward cancer cells in order to spare normal cells. We have recently demonstrated that a RasGAP caspase cleavage fragment is able to sensitize HeLa cells towards cisplatin-induced apoptosis. Here, we extend this observation by showing that this fragment also enhances cell death induced by adriamycin and mitoxantrone, two other widely used genotoxins. Furthermore, we have delineated a short sequence within this fragment that still bears the genotoxin-sensitization property. The peptide encoded by this sequence, when fused to the TAT cell permeation sequence, potently sensitized a number of tumors cells, but not normal cells, towards apoptosis induced by cisplatin, adriamycin and mitoxantrone. This sensitization effect was not mediated through modulation of NFkappaB activity or activation of the JNK and p38 MAPK pathways. Our results demonstrate the feasibility in enhancing the efficacy of currently used drugs to selectively kill cancer cells using peptides derived from pro-apoptotic caspase substrate fragments.	Univ Lausanne, DBCM, CH-1005 Lausanne, Switzerland; CHU Vaudois, Med Genet Unit, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Widmann, C (corresponding author), Univ Lausanne, DBCM, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@ibcm.unil.ch	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Michod, David/0000-0002-4187-405X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yang JY, 2002, EUR CYTOKINE NETW, V13, P404; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	18	46	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8971	8978		10.1038/sj.onc.1207999	http://dx.doi.org/10.1038/sj.onc.1207999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467750				2022-12-28	WOS:000225354600012
J	Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ				Rong, R; Surace, EI; Haipek, CA; Gutmann, DH; Ye, KQ			Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression	ONCOGENE			English	Article						neurofibromatosis; NF2; merlin; phosphorylation; PAK2	CELL EXTENSION ACTIVITY; N-TERMINAL DOMAIN; TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; ERM PROTEINS; FERM DOMAIN; EZRIN; MEMBRANE	The neurofibromatosis 2 (NF2) tumor suppressor protein, merlin, functions as a negative growth regulator; however, the molecular mechanisms that underlie merlin regulation remain elusive. Recent studies have implicated merlin phosphorylation in regulating merlin subcellular localization and growth suppression. P21-activated kinase (PAK), a downstream target of Rac1/Cdc42, directly phosphorylates merlin at Serine 518. In this report, we show that PAK2 directly phosphorylates wild-type merlin, whereas merlin truncation mutants with impaired GST-amino-terminal domain ( N-term or NTD)/GST-carboxy-terminal domain ( C-term or CTD) intramolecular association exhibit impaired S518 phosphorylation. We directly demonstrate that PAK2 phosphorylation impairs merlin N-term/C-term binding in vitro and in vivo. Lastly, we show that PAK2 phosphorylation impairs the ability of merlin to bind to two interacting proteins, CD44 and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), both critical for merlin growth suppression. These observations suggest that merlin S518 phosphorylation directly modulates merlin intramolecular and intermolecular associations important for the ability of merlin to function as a tumor suppressor.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Emory University; Washington University (WUSTL)	Ye, KQ (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35848] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533; Brault E, 2001, J CELL SCI, V114, P1901; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Neill GW, 2001, BIOCHEM J, V358, P727, DOI 10.1042/0264-6021:3580727; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7	36	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8447	8454		10.1038/sj.onc.1207794	http://dx.doi.org/10.1038/sj.onc.1207794			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378014				2022-12-28	WOS:000224870700005
J	Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T				Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T			Loss of c-abl facilitates anchorage-independent growth of p53- and RB-deficient primary mouse embryonic fibroblasts	ONCOGENE			English	Article						anchorage-independent growth; SV40 T antigen; c-Abl; p53; RB	CHRONIC MYELOGENOUS LEUKEMIA; LARGE TUMOR-ANTIGEN; T-ANTIGEN; TYROSINE KINASE; CELL-TRANSFORMATION; PHOSPHORYLATION; METHYLATION; MICE; P53; SUPPRESSOR	The c-abl tyrosine kinase is the proto-oncogene of the v-abl oncogene of the Abelson murine leukemia virus. Although mutational variants of c-Abl can exhibit gain of function and can produce a transformed phenotype, the function of c-Abl in transformation remained unclear. Here, we report that the loss of c-abl facilitates transformation. c-abl-knockout mouse embryonic fibroblasts (MEFs) immortalized by SV40 T antigen acquired anchorage-independent growth, and by constructing mutational variants of T antigen we showed that binding of large T antigen to p53 and RB was necessary to induce anchorage-independent growth. Although c-abl/p53 double-knockout MEFs did not undergo anchorage-independent growth, those expressing human papilloma virus 16 E7, which mainly inactivates RB, did. Our results show that the loss of c-abl facilitates anchorage-independent growth in the context of p53 and RB deficiency, and suggest that loss of function of c-abl facilitates some types of transformation.	Nara Inst Sci & Technol, Oncol Mol Lab, Nara 6300101, Japan; Osaka Biosci Inst, Oncol Mol Lab, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Shiga Univ Med Sci, Sch Med, Dept Microbiol, Shiga 5202192, Japan; Ludwig Inst Canc Res, London W1W 7BS, England; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Nara Institute of Science & Technology; Osaka University; University of Texas System; UTMD Anderson Cancer Center; Shiga University of Medical Science; Ludwig Institute for Cancer Research; Columbia University	Shishido, T (corresponding author), Nara Inst Sci & Technol, Oncol Mol Lab, 8916-5 Takayama, Nara 6300101, Japan.	shishid@bs.naist.jp	Georgescu, Maria-Magdalena/AAJ-6359-2020; Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Shishido, Tomoyuki/0000-0002-8944-2088				ABELSON HT, 1970, CANCER RES, V30, P2213; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Asimakopoulos FA, 1999, BLOOD, V94, P1141, DOI 10.1182/blood.V94.3.1141.415a35d_1141_1142; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hardin JD, 1996, ONCOGENE, V12, P2669; Issa JPJ, 1999, BLOOD, V93, P2075, DOI 10.1182/blood.V93.6.2075.406k29_2075_2080; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Miyoshi-Akiyama T, 2001, ONCOGENE, V20, P4058, DOI 10.1038/sj.onc.1204528; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JM, 2002, FRONT BIOSCI, V7, pD31; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; Whang YE, 2000, P NATL ACAD SCI USA, V97, P5486, DOI 10.1073/pnas.97.10.5486; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	44	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8527	8534		10.1038/sj.onc.1207894	http://dx.doi.org/10.1038/sj.onc.1207894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378021				2022-12-28	WOS:000224870700013
J	Downward, J				Downward, J			Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells	ONCOGENE			English	Article						RNA interference; screening; transformation; library; oncogenesis	GENE-EXPRESSION; STABLE SUPPRESSION; CANCER; DESIGN; VECTOR; INHIBITION; APOPTOSIS; SIRNAS; SYSTEM; P53	Over the past decade, 'RNA interference' has emerged as a natural mechanism of silencing of gene expression. This ancient cellular antiviral response can be manipulated to provide an effective research tool to knock down the level of expression of selected target genes, providing a very powerful new method for the analysis of cell signalling pathways. Systematic silencing of genes on a genome-wide scale using large rationally designed libraries targeting many thousands of genes provides a novel functional genomics approach to the investigation of many aspects of mammalian cell behaviour, including oncogenic transformation. Here, the different approaches taken to use RNA interference libraries to study the cancer phenotype will be considered, including both selective and high throughput screens and the use of both vector-based and synthetic oligonucleotide-based methods for inducing RNA interference. The advantages and drawbacks of the competing methodologies will be discussed. RNA interference library technology holds great promise for enabling somatic cell genetics in tissue culture systems. Whether it can provide significant new insights into cancer will be its greatest challenge.	Canc Res UK London Res Inst, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Arts GJ, 2003, GENOME RES, V13, P2325, DOI 10.1101/gr.1332603; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen YC, 2003, CANCER RES, V63, P4801; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cui WW, 2004, COMPUT METH PROG BIO, V75, P67, DOI 10.1016/j.cmpb.2003.09.002; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Downward J, 2004, BRIT MED J, V328, P1245, DOI 10.1136/bmj.328.7450.1245; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gupta S, 2004, P NATL ACAD SCI USA, V101, P1927, DOI 10.1073/pnas.0306111101; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang LQ, 2004, BIOINFORMATICS, V20, P1818, DOI 10.1093/bioinformatics/bth164; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Zhao LJ, 2003, GENE, V316, P137, DOI 10.1016/S0378-1119(03)00750-9	37	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8376	8383		10.1038/sj.onc.1208073	http://dx.doi.org/10.1038/sj.onc.1208073			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517019				2022-12-28	WOS:000224815900008
J	Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A				Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A			Identification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen	ONCOGENE			English	Article						genetic suppressor element (GSE); cancer therapeutic target; tumor cell; apoptosis; essential gene; xenograft	FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODY; CANCER-CELLS; EXPRESSION SELECTION; RETROVIRAL VECTORS; INDUCED APOPTOSIS; RNA INTERFERENCE; CARCINOMA CELLS; MAMMALIAN-CELLS; CDNA LIBRARIES	Survival factors play critical roles in regulating cell growth in normal and cancer cells. We designed a genetic screen to identify survival factors which protect tumor cells from apoptosis. A retroviral expression library of random cDNA fragments was constructed from cancer cells and used to transduce the colon carcinoma cell line HCT116. Recipient cells were functionally selected for induction of caspase 3-mediated apoptosis. Analyses of over 10000 putative genetic suppression elements (GSEs) sequences revealed cognate gene candidates that are implicated in apoptosis. We further analysed 26 genes encoding cell surface and secreted proteins that can potentially serve as targets for therapeutic antibodies. Tetracycline-inducible GSEs from several gene candidates induced apoptosis in stable HCT 116 cell lines. Similar phenotypes were caused by RNAi derived from the same genes. Our data suggest requirement for the cell surface targets IGF2R, L1CAM and SLC31A1 in tumor cell growth in vitro, and suggests that IGF2R is required for xenograft tumor growth in a mouse model.	PPD Discovery Inc, Menlo Pk, CA 94025 USA; PPD Discovery Inc, Piedmont Res Ctr, Morrisville, NC 27560 USA		Axenovich, SA (corresponding author), 1018 4th Av,Suite 119, Oakland, CA 94606 USA.	sergey.axenovich@gmail.com; arieabo@yahoo.com						Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Dunn SJ, 1999, GENE THER, V6, P130, DOI 10.1038/sj.gt.3300791; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gallagher WM, 1997, ONCOGENE, V14, P185; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gros L, 2003, CANCER RES, V63, P164; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Gudkov A V, 1997, Methods Mol Biol, V69, P221; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFMANN MA, 1991, BIOTECHNIQUES, V11, P30; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Levenson VV, 2000, CANCER RES, V60, P5027; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; Neznanov N, 2003, J BIOL CHEM, V278, P3809, DOI 10.1074/jbc.M210698200; Ouyang H, 1997, CANCER RES, V57, P1851; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; RONINSON IB, 1995, CANCER RES, V55, P4023; Schaffer BS, 2003, ENDOCRINOLOGY, V144, P955, DOI 10.1210/en.2002-220751; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Yang XD, 1999, CANCER RES, V59, P1236; Zhou GY, 2002, J VIROL, V76, P6197, DOI 10.1128/JVI.76.12.6197-6204.2002	42	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8158	8170		10.1038/sj.onc.1208054	http://dx.doi.org/10.1038/sj.onc.1208054			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361835				2022-12-28	WOS:000224692500014
J	Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R				Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R			Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase	ONCOGENE			English	Article						signaling; PGM; glycolysis; cancer metabolism	BREAST-CANCER CELLS; P21-ACTIVATED KINASES; SACCHAROMYCES-CEREVISIAE; ESTROGEN-RECEPTOR; REORGANIZATION; EXPRESSION; APOPTOSIS; TARGETS; COMPLEX; GROWTH	We have identified a novel mechanism of cross-talk between cell signaling and metabolic pathways, whereby the signaling kinase p21-activated kinase 1 (Pak1) binds to, phosphorylates and enhances the enzymatic activity of phosphoglucomutase 1 (PGM), an important regulatory enzyme in cellular glucose utilization and energy homeostasis. Pak1 and PGM were colocalized in model cell systems and showed functional interactions in a physiological setting. Strong direct interaction of PGM with Pak1 but not Pak2, Pak3, or Pak4 was observed. PGM binding was within 75-149 amino acids (aa) of Pak1, while Pak1 binding to PGM was in the N-terminal 96 aa. Pak1-mediated phosphorylation of PGM selectively on threonine 466 significantly increased PGM enzymatic activity and could be blocked by transfection with a dominant-negative Pak1 expression vector and by Pak1-specific small inhibitory RNA. Stable transfection of PGM into PGM-deficient K-562 leukemia cells further demonstrated the role of Pak1 in regulating PGM activity. The results presented here provide new evidence that the cell signaling kinase Pak1 is a novel regulator of glucose metabolism through its phosphorylation and regulation of PGM activity. These findings suggest a new mechanism whereby growth factor signaling may coordinately integrate metabolic regulation with established signaling functions of cell cycle regulation and cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Barnes, Christopher/B-1545-2015	Barnes, Christopher/0000-0001-9682-0748	NATIONAL CANCER INSTITUTE [R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Barnes CJ, 2002, CANCER RES, V62, P1251; BARNES CJ, 2003, NAT STRUCT BIOL, V3, P30; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Boros LG, 2002, PANCREAS, V24, P26, DOI 10.1097/00006676-200201000-00004; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DEY NB, 1994, J BIOL CHEM, V269, P27143; Gao H, 2004, ANAL BIOCHEM, V329, P269, DOI 10.1016/j.ab.2004.03.011; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; PUTT W, 1993, BIOCHEM J, V296, P417, DOI 10.1042/bj2960417; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Takahashi N, 2001, HUM BIOL, V73, P755, DOI 10.1353/hub.2001.0076; Tomkins J, 1997, ANN HUM GENET, V61, P99; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Zhai WG, 1999, MOL CELL BIOL, V19, P2791	27	75	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8118	8127		10.1038/sj.onc.1207969	http://dx.doi.org/10.1038/sj.onc.1207969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378030				2022-12-28	WOS:000224692500009
J	Boggon, TJ; Eck, MJ				Boggon, TJ; Eck, MJ			Structure and regulation of Src family kinases	ONCOGENE			English	Review						Src regulation; modular signaling; CD4/CD8 alpha	TYROSINE-PROTEIN-KINASE; N-TERMINAL REGION; AFFINITY PHOSPHOTYROSYL PEPTIDE; FOCAL ADHESION KINASE; CRYSTAL-STRUCTURE; SH3 DOMAIN; C-SRC; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT	Src family kinases are prototypical modular signaling proteins. Their conserved domain organization includes a myristoylated N-terminal segment followed by SH3, SH2, and tyrosine kinase domains, and a short C-terminal tail. Structural dissection of Src kinases has elucidated the canonical mechanisms of phosphotyrosine recognition by the SH2 domain and proline-motif recognition by the SH3 domain. Crystallographic analysis of nearly intact Src kinases in the autoinhibited state has shown that these protein interaction motifs turn inward and lock the kinase in an inactive conformation via intramolecular interactions. The autoinhibited Src kinase structures reveal a mode of domain assembly used by other tyrosine kinases outside the Src family, including Abl and likely Tec family kinases. Furthermore, they illustrate the underlying regulatory principles that have proven to be general among diverse modular signaling proteins. Although there is considerable structural information available for the autoinhibited conformation of Src kinases, how they may assemble into active signaling complexes with substrates and regulators remains largely unexplored.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Eck, MJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, 44 Binney St, Boston, MA 02115 USA.	eck@red.dfci.harvard.edu						ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Arold ST, 2001, J BIOL CHEM, V276, P17199, DOI 10.1074/jbc.M011185200; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Berry DM, 2002, CURR BIOL, V12, P1336, DOI 10.1016/S0960-9822(02)01038-2; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; Hamaguchi I, 1996, BIOCHEM BIOPH RES CO, V224, P172, DOI 10.1006/bbrc.1996.1003; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Huse M, 1998, J BIOL CHEM, V273, P18729, DOI 10.1074/jbc.273.30.18729; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kesavan KP, 2002, J BIOL CHEM, V277, P14666, DOI 10.1074/jbc.M111911200; Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin RS, 1998, J BIOL CHEM, V273, P32878, DOI 10.1074/jbc.273.49.32878; Liu Q, 2003, MOL CELL, V11, P471, DOI 10.1016/S1097-2765(03)00046-7; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; SHALLOWAY D, 1992, CIBA F SYMP, V170, P248; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sieg DJ, 1999, J CELL SCI, V112, P2677; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; Summy JM, 2003, J CELL SCI, V116, P2585, DOI 10.1242/jcs.00466; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WAKSMAN G, 2004, CELL, V116, pS48; Waksman Gabriel, 2004, Cell, VS116, pS45, DOI 10.1016/S0092-8674(04)00043-1; WATTS JD, 1993, J IMMUNOL, V151, P6862; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	94	494	506	3	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7918	7927		10.1038/sj.onc.1208081	http://dx.doi.org/10.1038/sj.onc.1208081			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489910				2022-12-28	WOS:000224558300003
J	Sutherland, KD; Lindeman, GJ; Choong, DYH; Wittlin, S; Brentzell, L; Phillips, W; Campbell, IG; Visvader, JE				Sutherland, KD; Lindeman, GJ; Choong, DYH; Wittlin, S; Brentzell, L; Phillips, W; Campbell, IG; Visvader, JE			Differential hypermethylation of SOCS genes in ovarian and breast carcinomas	ONCOGENE			English	Article						suppressor of cytokine signaling (SOCS); ovary; breast; carcinoma; tumor suppressor	CONSTITUTIVE EXPRESSION; NEGATIVE REGULATOR; METHYLATION; PROTEIN; GROWTH; SUPPRESSOR; BINDING; KINASE; BOX	Suppressor of cytokine signaling ( SOCS) proteins have emerged as critical attenuators of cytokine-mediated processes, suggesting a role in the suppression of tumorigenesis. In the ovary and mammary gland, cytokines such as prolactin and IL-6 are important regulators of growth and differentiation. We have investigated whether silencing or inactivation of SOCS genes occurs in ovarian and breast carcinomas. The SOCS1 and SOCS2 CpG islands were found to be hypermethylated in 23 and 14% of primary ovarian cancers, respectively, whereas only SOCS1 was methylated in breast cancers (9%). Methylation of these genes did not occur in normal tissues. No correlation was apparent between methylation and loss of heterozygosity, and no somatic mutations were found in a large panel of carcinomas. Aberrant methylation of these SOCS genes correlated with transcriptional silencing in ovarian and breast cancer cell lines, since expression was induced by the demethylating agent 5-azadeoxycytidine. SOCS3 was not hypermethylated in either cancer type. Consistent with this data, SOCS1 and SOCS2 but not SOCS3 suppressed the growth of ovarian and breast cancer cells. Hypermethylation and silencing of specific SOCS genes in the ovary, and to a lesser extent in breast, may augment cytokine responsiveness in these tissues, thereby contributing to oncogenesis.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Peter Maccallum Cancer Center	Visvader, JE (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au	campbell, Ian G/F-6006-2011; Phillips, Wayne A/H-8070-2013	Phillips, Wayne A/0000-0002-7961-638X; Sutherland, Kate/0000-0002-7453-3366; Lindeman, Geoffrey/0000-0001-9386-2416; Campbell, Ian/0000-0002-7773-4155				Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; CHAUBERT P, 1993, BIOTECHNIQUES, V15, P586; Chen CY, 2003, GENE CHROMOSOME CANC, V37, P300, DOI 10.1002/gcc.10222; Dobrovic A, 2002, METHODS, V27, P134, DOI 10.1016/S1046-2023(02)00065-8; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; GRAFF JR, 1995, CANCER RES, V55, P5195; Grosdemouge Isabelle, 2003, Reprod Biol Endocrinol, V1, P12, DOI 10.1186/1477-7827-1-12; Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Herman JG, 1996, CANCER RES, V56, P722; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; MACHELON V, 1994, CELL MOL BIOL, V40, P373; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nash MA, 1999, ENDOCR-RELAT CANCER, V6, P93, DOI 10.1677/erc.0.0060093; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; SILBERSTEIN GB, 1987, J DAIRY SCI, V70, P1981, DOI 10.3168/jds.S0022-0302(87)80240-0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tam SP, 2001, ENDOCRINOLOGY, V142, P5015, DOI 10.1210/en.142.11.5015; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhao L, 2002, MOL ENDOCRINOL, V16, P2902, DOI 10.1210/me.2001-0330	38	177	192	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7726	7733		10.1038/sj.onc.1207787	http://dx.doi.org/10.1038/sj.onc.1207787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361843				2022-12-28	WOS:000224306700014
J	Cao, C; Mu, Y; Hallahan, DE; Lu, B				Cao, C; Mu, Y; Hallahan, DE; Lu, B			XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer	ONCOGENE			English	Article						XIAP; survivin; lung cancer; radio therapy	X-LINKED INHIBITOR; ENDOTHELIAL-CELLS; IAP PROTEINS; APOPTOSIS; EXPRESSION; MARKER; GENE; ANGIOPOIETIN-1; ANGIOGENESIS; SUPPRESSION	Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs ( P = 0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI NIH HHS [R01-CA89674, R01-CA88076, R01-CA58508, P50-CA90949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090949, R01CA058508, R01CA088076, R01CA089674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Bao RD, 2002, J NATL CANCER I, V94, P522; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Edwards E, 2002, CANCER RES, V62, P4671; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Geng L, 2001, CANCER RES, V61, P2413; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ikehara M, 2002, ONCOL REP, V9, P835; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7	28	147	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7047	7052		10.1038/sj.onc.1207929	http://dx.doi.org/10.1038/sj.onc.1207929			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258565				2022-12-28	WOS:000223885100005
J	Wu, M; Xu, LG; Su, T; Tian, Y; Zhai, ZH; Shu, HB				Wu, M; Xu, LG; Su, T; Tian, Y; Zhai, ZH; Shu, HB			AMID is a p53-inducible gene downregulated in tumors	ONCOGENE			English	Article						AMID; p53; promoter; tumor; apoptosis	APOPTOSIS-INDUCING FACTOR; SUPPRESSOR PROTEIN P53; PROGRAMMED CELL-DEATH; CASPASE 9; IN-VIVO; PATHWAYS; TRANSCRIPTION; MITOCHONDRIA; ACTIVATION; LETHALITY	AMID, also called PRG3, is an AIF-homologous and mitochondria-associated protein that has been implicated in caspase-independent apoptosis. In this report, we demonstrated that human AMID gene promoter was activated by p53 in reporter gene assays. Chromatin immunoprecipitation experiments indicated that p53 could bind to human AMID promoter. Deletion mutagenesis indicated that human AMID promoter contains two p53-responsive elements. Furthermore, expression array analysis indicated that human AMID mRNA expression was downregulated in a majority of human tumors. Our findings point to the possibility that AMID is a p53-downstream gene involved in tumorigenesis.	Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA	Peking University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Shu, HB (corresponding author), Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China.	shuh@njc.org		Wu, Min/0000-0003-1372-4764; Xu, Liangguo/0000-0003-1991-2889				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XD, 2001, GENE DEV, V15, P2922; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	33	36	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6815	6819		10.1038/sj.onc.1207909	http://dx.doi.org/10.1038/sj.onc.1207909			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273740				2022-12-28	WOS:000223653600013
J	Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T				Kawamura-Tsuzuku, J; Suzuki, T; Yoshida, Y; Yamamoto, T			Nuclear localization of Tob is important for regulation of its antiproliferative activity	ONCOGENE			English	Article						Tob; NLS; NES; antiproliferative activity; subcellular localization	EXPORT SIGNALS; NUCLEOCYTOPLASMIC TRANSPORT; PC3/BTG/TOB FAMILY; TOB/BTG1 FAMILY; PROTEIN BTG1; MICE LACKING; REV PROTEIN; IDENTIFICATION; MEMBER; GENE	tob is a member of an antiproliferative gene family that includes btg1, pc3/tis21/btg2, pc3b, ana/btg3, and tob2. Exogenous overexpression of the family proteins suppresses cell proliferation. These proteins participate in transcriptional regulation of several genes. Here, we show that Tob is a nuclear protein that is imported into the nucleus through a nuclear localization signal (NLS)mediated mechanism. Mutation in the NLS sequence of Tob affects its nuclear localization and impairs antiproliferative activity. Additionally, Tob contains a nuclear export signal (NES). In oncogenic ErbB2-transformed cells, nuclear export of Tob is facilitated by NES-mediated mechanism, resulting in decrease of its antiproliferative activity. These results indicate that regulation of nuclear localization of Tob is important for its antiproliferative activity.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp						ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Bear J, 1999, MOL CELL BIOL, V19, P6306; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Luo JC, 2001, ONCOGENE, V20, P1435, DOI 10.1038/sj.onc.1204228; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Matsuda S, 1996, ONCOGENE, V12, P705; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakamura T, 2004, NAT GENET, V36, P528, DOI 10.1038/ng1344; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	45	46	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6630	6638		10.1038/sj.onc.1207890	http://dx.doi.org/10.1038/sj.onc.1207890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235587				2022-12-28	WOS:000223530800010
J	Houlston, RS; Peto, J				Houlston, RS; Peto, J			The search for low-penetrance cancer susceptibility alleles	ONCOGENE			English	Article						low-penetrance genes; cancer; risk	COMPLEX HUMAN-DISEASES; BREAST-CANCER; LINKAGE DISEQUILIBRIUM; LUNG-CANCER; BRCA2 MUTATIONS; RISK; ASSOCIATION; POLYMORPHISMS; GENE; LOCALIZATION	Much of the familial aggregation of common cancer results from inherited susceptibility, but highly penetrant mutations in known genes cannot account for most of the excess. Some of the unexplained familial risk is presumably due to high-penetrance mutations in as yet unidentified genes, but polygenic mechanisms are likely to account for a greater proportion, particularly in breast cancer. This inference, coupled with technological developments, has led to a renaissance in association studies. Most such studies have evaluated small numbers of single-nucleotide polymorphisms (SNPs) in a few candidate genes, but reliable high-density oligonucleotide arrays and other novel techniques will allow genome-wide allelic association studies to be conducted. High-density genome-wide SNP analysis will include targets identified by structural considerations, as well as the growing list of candidate genes. In the longer term, high-throughput resequencing will be required to identify the rare pathogenic variants that may constitute the majority of low-penetrance alleles. The detection of low-penetrance cancer susceptibility genes will then be restricted mainly by the availability of large numbers of well-characterized cases and controls. Cancer patients with affected relatives are considerably more informative than unselected cases for such studies.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Inst Canc Res, Canc Res UK Epidemiol & Genet Unit, Sutton SMZ 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; University of London; Institute of Cancer Research - UK	Houlston, RS (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.	richard.houlston@icr.ac.uk; julian.peto@lshtm.ac.uk		Houlston, Richard/0000-0002-5268-0242				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Collins A, 2001, HUM MUTAT, V17, P255, DOI 10.1002/humu.21; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DeMille MMC, 2002, HUM GENET, V111, P521, DOI 10.1007/s00439-002-0809-0; Dunning AM, 2000, AM J HUM GENET, V67, P1544, DOI 10.1086/316906; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Feyler A, 2002, CANCER EPIDEM BIOMAR, V11, P1550; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Heijmans BT, 2003, CANCER RES, V63, P1249; Houlston RS, 2001, GASTROENTEROLOGY, V121, P282, DOI 10.1053/gast.2001.26265; Houlston RS, 2003, HUM GENET, V112, P434, DOI 10.1007/s00439-002-0902-4; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Morton NE, 2001, P NATL ACAD SCI USA, V98, P5217, DOI 10.1073/pnas.091062198; NTAIS C, 2003, CANCER EPIDEM BIOMAR, V12, P20; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Peto J, 2002, CANCER CELL, V1, P411, DOI 10.1016/S1535-6108(02)00079-X; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; PETO J, 1980, BANBURY REPORT, V4, P203; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rostami-Hodjegan A, 1998, PHARMACOGENETICS, V8, P227, DOI 10.1097/00008571-199806000-00005; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	42	144	146	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6471	6476		10.1038/sj.onc.1207951	http://dx.doi.org/10.1038/sj.onc.1207951			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322517				2022-12-28	WOS:000223468800011
J	Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T				Iwatsuki, K; Tanaka, K; Kaneko, T; Kazama, R; Okamoto, S; Nakayama, Y; Ito, Y; Satake, M; Takahashi, S; Miyajima, A; Watanabe, T; Hara, T			Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3	ONCOGENE			English	Article						angiogenesis; endothelial cell; IGFBP-3; Runx1; transcriptional repression	GONAD-MESONEPHROS REGION; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID-LEUKEMIA; ENDOTHELIAL-CELLS; GENE-TRANSCRIPTION; CORPUS-LUTEUM; MOUSE EMBRYO; STEM-CELLS; EXPRESSION; AML1	Mouse embryos lacking the Runx1 transcription factor exhibit an angiogenic defect accompanied by the absence of hematopoietic stem cells ( HSCs). To ask whether Runx1 plays a direct role in angiogenesis, we established a novel endothelial progenitor cell line, designated AEL-DeltaR1, from the aorta-gonad-mesonephros ( AGM) region of Runx1-null mouse. We introduced Runx1 cDNA into AEL-DeltaR1 cells under the doxycycline-inducible promoter. The ability of AEL-DeltaR1 cells to form vascular networks on matrigel was highly enhanced by the restored expression of Runx1. By molecular comparison of mRNAs in AEL-DeltaR1 cells before and after the induction of Runx1, we found that mRNA expression of insulin-like growth factor-binding protein 3 (IGFBP-3) is downregulated by Runx1. Gel retardation and reporter assays revealed that Runx1 binds to the promoter region of mouse IGFBP-3 gene and represses its transcription. When IGFBP-3 was exogenously added in the matrigel assay, the angiogenesis-enhancing activity of Runx1 was suppressed in a dose-dependent manner. These results demonstrate that Runx1 is directly involved in angiogenesis by repression of IGFBP-3 mRNA expression.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, Tokyo 1138613, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Tokyo Metropolitan Institute of Medical Science; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Tohoku University; University of Tokyo; University of Tokyo	Hara, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Biochem, Tokyo Metropolitan Org Med Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527; Takahashi, Shin-Ichiro/0000-0002-2323-2010				BAE SC, 1993, ONCOGENE, V8, P809; Bertrand-Philippe M, 2004, J BIOL CHEM, V279, P24530, DOI 10.1074/jbc.M311804200; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Erondu NE, 1997, ENDOCRINOLOGY, V138, P2856, DOI 10.1210/en.138.7.2856; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Gucev ZS, 1996, CANCER RES, V56, P1545; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Iwatsuki K, 2000, BIOL REPROD, V62, P1352, DOI 10.1095/biolreprod62.5.1352; Javed A, 2000, J CELL SCI, V113, P2221; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; LEE GH, 1995, AM J PATHOL, V147, P1811; Lee WH, 1999, ENDOCRINE, V11, P181, DOI 10.1385/ENDO:11:2:181; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; North T, 1999, DEVELOPMENT, V126, P2563; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; Ongeri EM, 2004, ENDOCRINOLOGY, V145, P1776, DOI 10.1210/en.2003-1552; Schmid MC, 2003, INT J CANCER, V103, P577, DOI 10.1002/ijc.10874; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tamura H, 2002, EXP HEMATOL, V30, P957, DOI 10.1016/S0301-472X(02)00822-6; Tanaka K, 2002, DEV BIOL, V246, P466, DOI 10.1006/dbio.2002.0671; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	53	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1129	1137		10.1038/sj.onc.1208287	http://dx.doi.org/10.1038/sj.onc.1208287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592512				2022-12-28	WOS:000226898700001
J	Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R				Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R			A novel CYR61-triggered 'CYR61-alpha(v)beta(3) integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway	ONCOGENE			English	Article						CYR61; CCN1; heregulin; alpha(v)beta(3); paclitaxel; taxol; ERK1/ERK2 MAPK; chemotherapy; breast cancer	TISSUE GROWTH-FACTOR; TAXOL-INDUCED APOPTOSIS; IMMEDIATE-EARLY GENE; PACLITAXEL-INDUCED CYTOTOXICITY; INTESTINAL EPITHELIAL-CELLS; KINASE KINASE INHIBITION; VEIN ENDOTHELIAL-CELLS; HUMAN SKIN FIBROBLASTS; CCN FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE	The angiogenic inducer CYR61 is differentially over-expressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor alpha(v)beta(3) (>200 times). Small peptidomimetic alpha(v)beta(3) integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of alpha(v)beta(3) specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, alpha(v)beta(3) inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of alpha(v)beta(3) antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nick-end labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of alpha(v)beta(3), similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G(2) phase of the cell cycle and the appearance of sub-G(1) hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alpha(v)beta(3) or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a alpha(v)beta(3)-activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-alpha(v)beta(3) autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alpha(v)beta(3) may simultaneously prevent breast cancer angiogenesis, growth, and chemo resistance.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Pharmacia Corp, Discovery Res, Oncol Pharmacol, St Louis, MO USA	Northwestern University; Feinberg School of Medicine; Pfizer	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Atlas E, 2003, MOL CANCER RES, V1, P165; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Hortobagyi GN, 1997, SEMIN ONCOL, V24, pS30; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MacKeigan JP, 2002, CLIN CANCER RES, V8, P2091; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OKELLY J, 2002, P AM ASS CANC RES, V42; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perez, 1998, Oncologist, V3, P373; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; Torres K, 1998, CANCER RES, V58, P3620; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; VELLON L, 2004, P AM ASSOC CANC RES, V45, P74; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 2001, SEMIN ONCOL, V28, P12; Yu DH, 1996, ONCOGENE, V13, P1359; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	126	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					761	779		10.1038/sj.onc.1208238	http://dx.doi.org/10.1038/sj.onc.1208238			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592521				2022-12-28	WOS:000226577100003
J	Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH				Teramoto, H; Castellone, MD; Malek, RL; Letwin, N; Frank, B; Gutkind, JS; Lee, NH			Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12	ONCOGENE			English	Article						Ras; NIH3T3; RNAi; siRNA; microarray; osteopontin	DOWNSTREAM-REGULATED GENE-2; FAMILY SMALL GTPASES; CELL-MIGRATION; RAS; EXPRESSION; BINDING; CD44; IDENTIFICATION; PROTEIN; RAC1	Activated forms of Ras family members are prevalent in many cancers where Ras mutants transduce signals essential for transformation, angiogenesis, invasion and metastasis. As a cancer progression model, we used NIH3T3 cells to explore the mechanism of Ras-induced tumorigenesis. Ras family mutants H-RasV12 and Rit79L strongly induced foci formation, while Rho family mutants RhoA-QL, Rac1-QL and Cdc42-QL were less effective. A comparison of downstream transcriptional targets of Ras and Rho family members using a 26 383 element cDNA microarray revealed that the osteopontin (OPN) gene exhibited the best correlation between magnitude of gene expression change and level of foci formation (r=0.96, P<0.001). In association with H-RasV12- and Rit79L-mediated transformation, foci secreted OPN protein and upregulated the OPN receptor CD44, suggesting the novel initiation of an aberrant OPN-CD44-Rac autocrine pathway. In support of this were the following observations. First, RGD-deficient OPN protein-binding activity was present in H-RasV12- transformed cells but not in control cells, and binding activity was inhibited by the CD44 blocking antibody. Second, foci formation, cell invasion and Rac activity were induced by H-RasV12 and inhibited by the CD44 blocking antibody. Third, foci formation by H-RasV12 was substantially reduced by a short interfering RNA ( siRNA) specifically targeting OPN expression for knockdown. Fourth, H-RasV12- mediated transformation was not blocked by the GRGDS peptide, suggesting that OPN effects were not mediated by the integrins. Lastly, OPN knockdown affected the downstream expression of 160 '2nd tier' genes, and at least a subset of these genes appears to be involved in transformation. Indeed, four genes were selected for knockdown, each resulting in a disruption of foci formation and/or invasion. These results underscore the role of aberrant autocrine signaling and transcriptional networking during tumorigenesis.	Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); George Washington University	Gutkind, JS (corresponding author), Inst Genom Res, Dept Funct Genom, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	sg39v@nih.gov; nhlee@tigr.org	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bachelder RE, 2003, CANCER RES, V63, P5230; Berken A, 2003, ONCOGENE, V22, P8524, DOI 10.1038/sj.onc.1207195; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Breen EC, 2003, J CELL BIOCHEM, V88, P848, DOI 10.1002/jcb.10398; Bug G, 2002, J LEUKOCYTE BIOL, V72, P837; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Choi SC, 2003, FEBS LETT, V553, P413, DOI 10.1016/S0014-5793(03)01030-5; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Crowe DL, 2004, ANTICANCER RES, V24, P593; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Feng F, 2000, BREAST CANCER RES TR, V63, P71, DOI 10.1023/A:1006466516192; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Katagiri YU, 1996, J CELL BIOCHEM, V62, P123, DOI 10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O; Katagiri YU, 1999, CANCER RES, V59, P219; Mahabeleshwar GH, 2004, J BIOL CHEM, V279, P9733, DOI 10.1074/jbc.M311400200; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Oates AJ, 1997, INVAS METAST, V17, P1; Oates AJ, 1996, ONCOGENE, V13, P97; Ownby SE, 2002, LIPIDS, V37, P185, DOI 10.1007/s11745-002-0879-1; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Qu XH, 2002, J BIOL CHEM, V277, P35574, DOI 10.1074/jbc.M206451200; Rozsnyay Z, 1999, IMMUNOL LETT, V68, P101, DOI 10.1016/S0165-2478(99)00037-1; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sehgal A, 1999, ANTICANCER RES, V19, P4947; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Singh R. P., 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P75, DOI 10.1615/JEnvPathToxOncol.v22.i2.10; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Wu Y, 2000, BRIT J CANCER, V83, P156; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	55	71	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					489	501		10.1038/sj.onc.1208209	http://dx.doi.org/10.1038/sj.onc.1208209			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516973				2022-12-28	WOS:000226279700019
J	Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT				Mourtada-Maarabouni, M; Kirkham, L; Farzaneh, F; Williams, GT			Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression	ONCOGENE			English	Article						fau; functional expression cloning; Finkel-Biskis-Reilly osteosarcoma virus; apoptosis	CHROMOSOMAL LOCALIZATION; DEPENDENT DEGRADATION; GENOMIC STRUCTURE; GENE-EXPRESSION; UBIQUITIN; PROTEIN; CDNA; SUPPRESSOR; CANCER; INVOLVEMENT	Functional expression cloning is a powerful strategy for identifying critical steps in biological pathways independently of prior assumptions. It is particularly suitable for the identification of molecules crucial to the control of apoptosis. Our screen for sequences suppressing T-cell apoptosis isolated a sequence antisense to fau (Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV)-associated ubiquitously expressed gene). The fox gene in FBR murine osteosarcoma virus is also antisense to fau and several reports have indicated that fau displays tumour suppressor and oncogenic properties in different contexts. Our observations indicate that the fau antisense sequence suppresses expression of endogenous fau mRNA and produces resistance to apoptosis induced both by the glucocorticoid analogue dexamethasone' by ultraviolet radiation, and by the anticancer drug cisplatin. In all cases, colony-forming ability is protected, indicating that fau affects the critical events prior to commitment to cell death. Overexpression of fau in the sense orientation induces cell death, which is inhibited both by Bcl-2 and by inhibition of caspases, in line with its proposed role in apoptosis.	Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England; GKT Sch Med, Rayne Inst, London SE21 7AN, England	Keele University; University of London; King's College London	Williams, GT (corresponding author), Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England.	bia19@biol.keele.ac.uk; g.t.williams@keele.ac.uk	Farzaneh, Farzin/B-4902-2009; Williams, Gwyn/GQY-7555-2022	Farzaneh, Farzin/0000-0002-9275-2415; /0000-0001-8324-1325; Williams, Gwyn/0000-0003-4556-9930				Anderson Claire L, 2003, ScientificWorldJournal, V3, P51; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; CASTEELS D, 1995, GENOMICS, V25, P291, DOI 10.1016/0888-7543(95)80140-H; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DENHARDT DT, 1992, NEW BIOL, V4, P473; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Finkel M P, 1976, Recent Results Cancer Res, P92; Gabig TG, 1998, MAMM GENOME, V9, P660, DOI 10.1007/s003359900840; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KAS K, 1993, HUM MOL GENET, V2, P349, DOI 10.1093/hmg/2.4.349; Katoh M, 2003, INT J ONCOL, V22, P1375; Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lock RB, 1996, INT J ONCOL, V8, P305; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MICHIELS L, 1993, ONCOGENE, V8, P2537; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; MONIA BP, 1990, J BIOL CHEM, V265, P19356; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 2003, EUR J BIOCHEM, V270, P4052, DOI 10.1046/j.1432-1033.2003.03790.x; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; RATHMELL JC, 2002, CELL S, V109, P97; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Rossman TG, 2003, ONCOGENE, V22, P1817, DOI 10.1038/sj.onc.1206283; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Seraj MJ, 2000, CANCER RES, V60, P2764; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WLODARSKA I, 1993, GENE CHROMOSOME CANC, V8, P224, DOI 10.1002/gcc.2870080404; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zannettino ACW, 1996, J IMMUNOL, V156, P611	58	26	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9419	9426		10.1038/sj.onc.1208048	http://dx.doi.org/10.1038/sj.onc.1208048			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543234				2022-12-28	WOS:000225764100013
J	Raafat, A; Bargo, S; Anver, MR; Callahan, R				Raafat, A; Bargo, S; Anver, MR; Callahan, R			Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh)	ONCOGENE			English	Article						Notch4/Int3 signaling; mammary tumorigenesis; mammary gland development	NEOPLASTIC TRANSFORMATION; GLAND TUMORIGENESIS; EPITHELIAL-CELLS; FVB/N MICE; INT3 GENE; NOTCH; DIFFERENTIATION; HYPERPLASIA; INTEGRATION; MEMBER	Recently, we have identified a novel 1.8 kb human Notch4/Int3 RNA species (designated h-Int3sh). The h-Int3sh RNA encodes a protein that is missing the CBF1-binding region (RAM23) of the Notch 4/Int3 intracellular domain (ICD). Expression of h-Int3sh in the MCF10A 'normal' human mammary epithelial cell line has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth in soft agar. To study the consequences of h-Int3sh expression in vivo on mammary gland development and tumorigenesis, three transgenic mouse lines were established, in which the transgene is the Whey acidic protein (WAP) promoter linked to h-Int3sh. Expression of WAP-Int3sh was detectable in the mammary gland at day 15 of pregnancy in each transgenic line. Mammary gland development in all founder lines is normal and the females can lactate. WAP-h-Int3sh females from each of the founder lines develop mammary tumors, but with a long latency (average age of 18 months). Tumor development was associated with activation of Notch pathway, as evidenced by upregulation of Hes-1. The long latency of mammary tumors in WAP-h-Int3sh mice could be due in part to the subcellular localization of h-Int3sh. Immuno. fluorescence analysis of transfected COS-1 cells showed that h-Int3sh is localized in the cytoplasm and nucleus, while Int3-ICD is detected only in the nucleus. We speculate that the Notch4/Int3 ICD-induced block to mammary gland development and tumorigenesis are consequences of an increasing gradient of CBF1-dependent Notch4/Int3 signaling.	NCI, Mammary Biol & Tumorignesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Pathol & Histotechnol Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorignesis Lab, NIH, Bldg 10 Room 5B50, Bethesda, MD 20892 USA.	rc54d@nih.gov			PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Nieto AI, 2003, COMPARATIVE MED, V53, P433; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Wakefield LM, 2003, COMPARATIVE MED, V53, P424; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910	22	43	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9401	9407		10.1038/sj.onc.1208187	http://dx.doi.org/10.1038/sj.onc.1208187			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531924				2022-12-28	WOS:000225764100011
J	Shively, JE				Shively, JE			CEACAM1 and hyperplastic polyps: new links in the chain of events leading to colon cancer	ONCOGENE			English	Editorial Material							CELL ADHESION MOLECULE; TUMORIGENESIS; MORPHOGENESIS; MODEL		City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org						BATTS KP, 2004, PATHOL CASE REV, V9, P173; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Huang J, 1999, J CELL SCI, V112, P4193; Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Phan D, 2004, CANCER RES, V64, P3072, DOI 10.1158/0008-5472.CAN-03-3730; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398	8	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9303	9305		10.1038/sj.onc.1208266	http://dx.doi.org/10.1038/sj.onc.1208266			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602572				2022-12-28	WOS:000225764100001
J	Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP				Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP			ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)	ONCOGENE			English	Article						mitogen-activated protein kinase (MAPK); Ras; natural killer cells	NATURAL-KILLER-CELLS; GERANYLGERANYLTRANSFERASE-I; CHROMOSOMAL-ABNORMALITIES; PERIPHERAL-BLOOD; RECEPTOR; KINASE; PROTEIN; EXPRESSION; APOPTOSIS; LEUKEMIA	Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3(-), CD16(+) or CD56(+) lymphocytes. The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation. There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy. We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease). Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells. Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas. Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL. These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.	James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Penn State Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Epling-Burnett, PK (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,Res Bldg 2,Room 115, Tampa, FL 33612 USA.	burnetpk@moffitt.usf.edu			NCI NIH HHS [R01 CA098472, CA83146, CA94872, CA90633, CA83947] Funding Source: Medline; NIAID NIH HHS [AI052613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083146, K24CA083947, R01CA090633, R01CA098472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI052613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Epling-Burnette PK, 2004, BLOOD, V103, P3431, DOI 10.1182/blood-2003-02-0400; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Husain Z, 2002, IMMUNOLOGY, V106, P373, DOI 10.1046/j.1365-2567.2002.01444.x; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Lamy T, 1998, BLOOD, V92, P4771, DOI 10.1182/blood.V92.12.4771.424k32_4771_4777; LANIER LL, 1986, J EXP MED, V163, P209, DOI 10.1084/jem.163.1.209; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lima M, 2002, BLOOD CELL MOL DIS, V28, P181, DOI 10.1006/bcmd.2002.0506; Loughran TP, 1997, BLOOD, V90, P1977, DOI 10.1182/blood.V90.5.1977; LOUGHRAN TP, 1994, LEUKEMIA RES, V18, P423, DOI 10.1016/0145-2126(94)90078-7; LOUGHRAN TP, 1985, ANN INTERN MED, V102, P169, DOI 10.7326/0003-4819-102-2-169; LOUGHRAN TP, 1993, BLOOD, V82, P1; MCVICAR DW, 2001, SCI STKE, pRE1, DOI DOI 10.1126/STKE.2001.75.RE1; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MONTAGNA D, 1992, BIOL NEONATE, V62, P385; OHNO T, 1988, CANCER-AM CANCER SOC, V62, P1918, DOI 10.1002/1097-0142(19881101)62:9<1918::AID-CNCR2820620909>3.0.CO;2-8; ORTALDO JR, 1995, J EXP MED, V181, P339, DOI 10.1084/jem.181.1.339; Perzova RN, 2000, BRIT J HAEMATOL, V109, P64, DOI 10.1046/j.1365-2141.2000.01972.x; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEMENZATO G, 1987, CANCER-AM CANCER SOC, V60, P2971, DOI 10.1002/1097-0142(19871215)60:12<2971::AID-CNCR2820601220>3.0.CO;2-O; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Sun JZ, 1999, CANCER RES, V59, P4919; Takahashi A, 2001, J IMMUNOL, V166, P6771, DOI 10.4049/jimmunol.166.11.6771; TANIWAKI M, 1990, AM J HEMATOL, V33, P32, DOI 10.1002/ajh.2830330107; TEFFERI A, 1994, BLOOD, V84, P2721; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; Zingoni A, 2000, EUR J IMMUNOL, V30, P644, DOI 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H	41	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9220	9229		10.1038/sj.onc.1208122	http://dx.doi.org/10.1038/sj.onc.1208122			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516985	Bronze			2022-12-28	WOS:000225638000007
J	Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA				Shao, CS; Deng, L; Chen, YP; Kucherlapati, R; Stambrook, PJ; Tischfield, JA			Mlh1 mediates tissue-specific regulation of mitotic recombination	ONCOGENE			English	Article						Mlh1; mismatch repair; mitotic recombination; point mutation; mouse model	DNA MISMATCH REPAIR; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; MUTATOR PHENOTYPE; APC MUTATIONS; MOUSE GENOME; MICE; CELLS; DEFICIENT; HETEROZYGOSITY	Mitotic recombination (MR) between chromosome homologs in somatic cells is a major pathway to the loss of heterozygosity (LOH), which may cause cancer if tumor suppressor genes are involved. MR can be suppressed by DNA sequence heterology (homeology) in hybrid mice from matings between species or between subspecies. We now report that MR is relatively suppressed in F1 hybrids between inbred strains C57BL/6 and 129S2. The frequency of MR in fibroblasts is lower in F1 hybrid mice than in either of the two parental strains. However, MR in T cells is not affected by strain background. Thus, relatively small genetic differences are capable of restricting MR in a tissue-specific manner. Using Mlh1-deficient mice, we tested the role of mismatch repair in MR in two isogenic cell types. In fibroblasts of C57BL/6 x 129S2 F1 mice, the suppression of MR is alleviated in the absence of MLH1. In contrast, MR is not affected by Mlh1 status in T cells. The frequency of point mutations at the reporter gene loci Aprt and Hprt, on the other hand, is significantly increased in both T cells and fibroblasts of Mlh1(-/-) mice. Thus, different cell types respond differently to MLH1 deficiency, and the contribution of MR to tumorigenesis may be tissue-dependent in the absence of mismatch repair.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	Rutgers State University New Brunswick; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; University System of Ohio; University of Cincinnati	Shao, CS (corresponding author), Rutgers State Univ, Dept Genet, 604 Allison Rd, Piscataway, NJ 08854 USA.	shao@biology.rutgers.edu; jay@biology.rutgers.edu	Kucherlapati, Raju/ABC-8807-2021; Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342; Tischfield, Jay/0000-0003-3217-8287	NIEHS NIH HHS [R01ES011633] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011633] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cervantes RB, 2002, P NATL ACAD SCI USA, V99, P3586, DOI 10.1073/pnas.062527199; Datta A, 1996, MOL CELL BIOL, V16, P1085; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hall MC, 2003, NUCLEIC ACIDS RES, V31, P2025, DOI 10.1093/nar/gkg324; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Kuraguchi M, 2000, ONCOGENE, V19, P5755, DOI 10.1038/sj.onc.1203962; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; LOEB LA, 1991, CANCER RES, V51, P3075; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; Shao CS, 2002, ONCOGENE, V21, P2840, DOI 10.1038/sj.onc.1205358; Shao CS, 2001, NAT GENET, V28, P169, DOI 10.1038/88897; Shin CY, 2002, DNA REPAIR, V1, P995, DOI 10.1016/S1568-7864(02)00149-0; Shin CY, 2002, ONCOGENE, V21, P1768, DOI 10.1038/sj.onc.1205241; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wijnhoven SWP, 2003, CARCINOGENESIS, V24, P139, DOI 10.1093/carcin/24.1.139; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9017	9024		10.1038/sj.onc.1208148	http://dx.doi.org/10.1038/sj.onc.1208148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15480418				2022-12-28	WOS:000225492800002
J	Eischen, CM; Alt, JR; Wang, P				Eischen, CM; Alt, JR; Wang, P			Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development	ONCOGENE			English	Article						Mdm2; ARF; lymphoma; apoptosis; Myc; p53	MYC-INDUCED LYMPHOMAGENESIS; TUMOR-SUPPRESSOR P53; WILD-TYPE P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TRANSGENIC MICE; CANCER-THERAPY; MAMMARY-GLAND; FEEDBACK LOOP; IN-VIVO	The tumor suppressor p19(ARF) inhibits Mdm2, which restricts the activity of p53. Complicated feedback and control mechanisms regulate ARF, Mdm2, and p53 interactions. Here we report that ARF haploinsufficiency completely rescued the p53-dependent effects of Mdm2 haploinsufficiency on B-cell development, survival, and transformation. In contrast to Mdm2(+/-) B cells, Mdm2(+/-) B cells deficient in ARF were similar to wild-type B cells in their rates of growth and apoptosis and activation of p53. Consequently, the profoundly reduced numbers of B cells in Mdm2(+/-) Emu-myc transgenic mice were restored to normal levels in ARF(+/-)Mdm(2+/-) Emu-myc transgenics. Additionally, ARF(+/-)Mdm2(+/-) Emu-myc transgenics developed lymphomas at rates analogous to those observed for wild-type Emu-myc transgenics, demonstrating that loss of one allele of ARF rescued the protracted lymphoma latency in Mdm2(+/-) Emu-myc transgenics. Importantly, in ARF(+/-)Mdm2(+/-) Emu-myc transgenic lymphomas, p53 was inactivated at the frequency observed in lymphomas of wild-type Emu-myc transgenics. Collectively, these results support a model whereby the stoichiometry of Mdm2 and ARF controls apoptosis and tumor development, which should have significant implications in the treatment of malignancies that have inactivated ARF.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Eischen, CM (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA.	ceischen@unmc.edu			NCI NIH HHS [CA098139, T32 CA09476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098139, T32CA009476] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang H, 2001, CURR CANCER DRUG TAR, V1, P177, DOI 10.2174/1568009013334133; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	2004	23	55					8931	8940		10.1038/sj.onc.1208052	http://dx.doi.org/10.1038/sj.onc.1208052			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467748				2022-12-28	WOS:000225354600008
J	Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM				Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM			Inactivation of the RRB1-Pescadillo pathway involved in ribosome biogenesis induces chromosomal instability	ONCOGENE			English	Article						cell cycle; chromosomal instability; mitosis; ribosome; yeast	CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; DNA-REPLICATION; HUMAN CANCERS; PROTEIN; GENE; CHECKPOINT; PROLIFERATION; MUTATIONS	Since chromosomal instability (CIN) is a hallmark of most cancer cells, it is essential to identify genes whose alteration results into this genetic instability. Using a yeast CIN indicator strain, we show that inactivation of the YMR131c/RRB1 gene, which is involved in early ribosome assembly and whose expression is induced when the spindle checkpoint is activated, alters chromosome segregation and blocks mitosis at the metaphase/anaphase transition. We demonstrate that RRB1 interacts with YPH1 (yeast pescadillo homologue 1) and other members of the Yph1 complex, RPL3, ERB1 and ORC6, involved in ribosome biogenesis and DNA replication. Transient depletion of the human homologues GRWD, Pescadillo, Rp13, Bop1 and Orc6L resulted in an increase of abnormal mitoses with appearance of binucleate or hyperploid cells, of cells with multipolar spindles and of aberrant metaphase plates. If deregulation of proteins involved in ribosome biogenesis, commonly observed in malignant tumors, could contribute to cancer through an aberrant protein synthesis, our study demonstrates that alteration of proteins linking ribosome biogenesis and DNA replication may directly cause CIN.	INSERM, U614, IFRMP, Fac Med, F-76183 Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Frebourg, T (corresponding author), INSERM, U614, IFRMP, Fac Med, 22 Blvd Gambetta, F-76183 Rouen, France.	Thierry.Frebourg@chu-rouen.fr	Flaman, Jean-Michel/K-8415-2018; BOUGEARD, Gaëlle/ABI-6642-2020; Frebourg, Thierry/AAK-8390-2020	Flaman, Jean-Michel/0000-0003-3544-0199; BOUGEARD, Gaëlle/0000-0002-1475-0254; 				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bergoglio V, 2002, CANCER RES, V62, P3511; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DOKAL I, 1994, LEUKEMIA LYMPHOMA, V15, P1, DOI 10.3109/10428199409051671; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	34	57	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8597	8602		10.1038/sj.onc.1207845	http://dx.doi.org/10.1038/sj.onc.1207845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467761				2022-12-28	WOS:000224988800005
J	Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E				Nagy, N; Takahara, M; Nishikawa, J; Bourdon, JC; Kis, LL; Klein, G; Klein, E			Wild-type p53 activates SAP expression in lymphoid cells	ONCOGENE			English	Article						SAP; XLP; p53; lymphoma	LINKED LYMPHOPROLIFERATIVE-DISEASE; BARR-VIRUS INFECTION; NF-KAPPA-B; MICE DEFICIENT; ENCODING GENE; SH2 DOMAIN; EBV; MUTATIONS; MUTANT; SLAM	SAP is an adaptor molecule with one SH2 domain and it is expressed in activated T and NK cells, where it is required for the appropriate signaling from the SLAM family of surface receptors. Deleted or mutated SAP genes that encode functionally defective protein are associated with the X-linked lymphoproliferative disease(XLP). This primary immunodeficiency is characterized by extreme sensitivity to Epstein-Barr virus (EBV) infection, dysgammaglobulinemia and a high rate of lymphoma development. The vigorous T- and B-cell proliferation that follows EBV infection and the high incidence of lymphomas (30%) in XLP patients might reflect functional defects in cell cycle and/or apoptosis control. Our experiments show that SAP is a target of p53. In Burkitt lymphoma (BL) lines transfected with a temperatur-sensitive (ts) p53, SAP mRNA and protein expression was dependent on wild-type (wt) p53. Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-a. Cell lines that carried mutant p53 did not express SAP under similar conditions. Moreover, we have shown binding of wt p53 to the promoter region of SAP by ChIP assay. Our results suggest that SAP contributes to the execution of some p53 functions.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	Karolinska Institutet; University of Dundee	Nagy, N (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	Noemi.Nagy@mtc.ki.se	Nagy, Noemi/J-2936-2012; JC, Bourdon/A-4439-2008; Nishikawa, Jun/AAE-5355-2020	JC, Bourdon/0000-0003-4623-9386; Nagy, Noemi/0000-0002-7800-3493				Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Chan B, 2003, NAT CELL BIOL, V5, P155, DOI 10.1038/ncb920; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Czar MJ, 2001, P NATL ACAD SCI USA, V98, P7449, DOI 10.1073/pnas.131193098; Fei PW, 2002, CANCER RES, V62, P7316; Gorgoulis VG, 2003, EMBO J, V22, P1567, DOI 10.1093/emboj/cdg157; GRIERSON H, 1987, ANN INTERN MED, V106, P538, DOI 10.7326/0003-4819-106-4-538; HARADA S, 1982, INT J CANCER, V30, P739, DOI 10.1002/ijc.2910300610; HARRINGTON DS, 1987, CANCER-AM CANCER SOC, V59, P1419, DOI 10.1002/1097-0142(19870415)59:8<1419::AID-CNCR2820590807>3.0.CO;2-P; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Latour S, 2003, NAT CELL BIOL, V5, P149, DOI 10.1038/ncb919; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nagy N, 2002, INT J CANCER, V100, P433, DOI 10.1002/ijc.10498; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; OKAN I, 1995, ONCOGENE, V11, P1027; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Shlapatska LM, 2001, J IMMUNOL, V166, P5480, DOI 10.4049/jimmunol.166.9.5480; Strahm B, 2000, BRIT J HAEMATOL, V108, P377; Sumegi J, 2000, BLOOD, V96, P3118; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; VOELKERDING KV, 1995, ONCOGENE, V10, P515; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Yin L, 2003, J MED VIROL, V71, P446, DOI 10.1002/jmv.10504; Zhou XZ, 1999, J IMMUNOL, V162, P3957	30	15	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	2004	23	53					8563	8570		10.1038/sj.onc.1207908	http://dx.doi.org/10.1038/sj.onc.1207908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378026				2022-12-28	WOS:000224988800001
J	Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE				Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE			Alternative splicing and mutation status of CHEK2 in stage III breast cancer	ONCOGENE			English	Article						breast cancer; CHEK2; mutation; splicing; p53	DNA-DAMAGE CHECKPOINT; MDM2 TRANSCRIPTS; TUMOR-SUPPRESSOR; HEREDITARY BREAST; KINASE CHK2; P53; PHOSPHORYLATION; EXPRESSION; PROTEIN; GENE	The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.	Univ Bergen, Dept Mol Biol, Bergen, Norway; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Haukeland Hosp, Inst Med, Sect Oncol, N-5021 Bergen, Norway; Norwegian Radium Hosp, Dept Genet, Oslo, Norway	University of Bergen; Danish Cancer Society; University of Bergen; Haukeland University Hospital; University of Oslo	Lonning, PE (corresponding author), Univ Bergen, Dept Mol Biol, Bergen, Norway.	per.lonning@helse-bergen.no	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Lonning, Per Eystein/0000-0002-8890-6303				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartel F, 2004, INT J ONCOL, V24, P143; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Evdokiou A, 2001, INT J ONCOL, V19, P625; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Frebourg T, 2001, B CANCER, V88, P581; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Ishimoto O, 2002, CANCER RES, V62, P636; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2000, Science, V289, P359; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zheng YX, 2001, CARCINOGENESIS, V22, P2005, DOI 10.1093/carcin/22.12.2005; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	52	63	64	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8535	8544		10.1038/sj.onc.1207928	http://dx.doi.org/10.1038/sj.onc.1207928			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361853				2022-12-28	WOS:000224870700014
J	Dasgupta, R; Perrimon, N				Dasgupta, R; Perrimon, N			Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research	ONCOGENE			English	Article						functional genomics; proteomics; RNA interference; chemical genetics; high-throughput screens; network; genome-wide	SMALL-MOLECULE INHIBITOR; SMALL INTERFERING RNAS; SIGNAL-TRANSDUCTION; SCREENS; GENOME; NETWORKS; SEQUENCE; PATHWAY; COMPLEX; BIOLOGY	The completion of whole-genome sequencing of various model organisms and the recent explosion of new technologies in the field of Functional Genomics and Proteomics is poised to revolutionize the way scientists identify and characterize gene function. One of the most significant advances in recent years has been the application of RNA interference (RNAi) as a means of assaying gene function. In the post-genomic era, advances in the field of cancer biology will rely upon the rapid identification and characterization of genes that regulate cell growth, proliferation, and apoptosis. Significant efforts are being directed towards cancer therapy and devising efficient means of selectively delivering drugs to cancerous cells. In this review, we discuss the promise of integrating genome-wide RNAi screens with proteomic approaches and small-molecule chemical genetic screens, towards improving our ability to understand and treat cancer.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	perrimon@receptor.med.harvard.edu		Perrimon, Norbert/0000-0001-7542-472X; Dasgupta, Ramanuj/0000-0001-9015-3729				Adams MD, 2002, NAT REV GENET, V3, P189, DOI 10.1038/nrg752; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Auerbach D, 2002, PROTEOMICS, V2, P611, DOI 10.1002/1615-9861(200206)2:6<611::AID-PROT611>3.0.CO;2-Y; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bak M, 2003, PHARMACOGENOMICS, V4, P411, DOI 10.1517/phgs.4.4.411.22751; Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billadeau DD, 2002, J GASTROINTEST CANC, V31, P5, DOI 10.1385/IJGC:31:1-3:5; BOS JL, 1989, CANCER RES, V49, P4682; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; Buckholz Richard G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P135; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Diaz-Camino C, 2003, ANAL BIOCHEM, V316, P171, DOI 10.1016/S0003-2697(02)00706-6; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hild M, 2004, GENOME BIOL, V5; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Li H, 2003, CURR OPIN GENET DEV, V13, P611, DOI 10.1016/j.gde.2003.10.012; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mercurio A M, 2001, Surg Oncol Clin N Am, V10, P313; MICHELSON AM, 2003, SCI STKE; Milhavet O, 2003, PHARMACOL REV, V55, P629, DOI 10.1124/pr.55.4.1; Milo R, 2004, SCIENCE, V303, P1538, DOI 10.1126/science.1089167; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; Montell DJ, 1999, CELL BIOCHEM BIOPHYS, V31, P219, DOI 10.1007/BF02738240; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Nagy A, 2003, NAT GENET, V33, P276, DOI 10.1038/ng1115; Oldak M, 2001, INT J MOL MED, V8, P445; Oliver B, 2004, GENOME BIOL, V5; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rosamond L, 2000, SCIENCE, V287, P1973, DOI 10.1126/science.287.5460.1973; Rubin G M, 2000, Novartis Found Symp, V229, P79; Rubin G. M., 2000, NOVART FDN SYMP, p[229, 82]; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sanchez-Carbayo M, 2003, BRIT J CANCER, V89, P2172, DOI 10.1038/sj.bjc.6601406; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; TAKAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P338; Tewari M, 2004, MOL CELL, V13, P469, DOI 10.1016/S1097-2765(04)00033-4; van Duin M, 2003, BIOCHEM SOC T, V31, P429, DOI 10.1042/BST0310429; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wajant H, 2004, PROG MOLEC, V34, P47; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100	77	37	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8359	8365		10.1038/sj.onc.1208028	http://dx.doi.org/10.1038/sj.onc.1208028			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517017				2022-12-28	WOS:000224815900006
J	Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K				Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K			Cyclin-dependent kinase inhibitor indirubin-3 '-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies	ONCOGENE			English	Article						cancer; cell cycle; centrosome anomalies; chromosomal instability; human papillomavirus	RETINOBLASTOMA TUMOR-SUPPRESSOR; E7 ONCOPROTEIN; CELL-DIVISION; DNA-SYNTHESIS; DUPLICATION; CDK2; DEGRADATION; INDUCTION; PROTEIN; DIFFERENTIATION	Dysregulation of the centrosome duplication cycle has been implicated in tumorigenesis. Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rapidly induces aberrant centrosome and centriole duplication in normal human cells. We report here that HPVE7-induced abnormal centriole duplication is specifically abrogated by a small molecule CDK inhibitor, indirubin-3'-oxime (IO), but not a kinase-inactive derivative. Importantly, normal centriole duplication was not markedly affected by IO, and the inhibitory effects were observed at concentrations that did not affect the G1/S transition of the cell division cycle. Depletion of CDK2 by siRNA similarly abrogated HPV E7-induced abnormal centrosome duplication and ectopic expression of CDK2 in combination with cyclin E or cyclin A could rescue the inhibitory effect of IO. IO treatment also reduced the steady-state level of aneuploid cells in HPV-16 E7-expressing cell populations. Our results suggest that cyclin/CDK2 activity is critically involved in abnormal centrosome duplication induced by HPV-16 E7 oncoprotein expression, but may be dispensable for normal centrosome duplication and cell cycle progression.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece; CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, Bretagne, France	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; National & Kapodistrian University of Athens; Centre National de la Recherche Scientifique (CNRS)	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu; karl_munger@hms.harvard.edu	skaltsounis, alexios leandros/AAE-9617-2019; MEIJER, Laurent/ABE-7465-2021	Manuel, Edwin/0000-0002-4602-7060; , laurent/0000-0003-3511-4916; Duensing, Anette/0000-0002-0168-4067; Munger, Karl/0000-0003-3288-9935				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Boyer SN, 1996, CANCER RES, V56, P4620; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Klausner RD, 2002, CANCER CELL, V1, P3, DOI 10.1016/S1535-6108(02)00020-X; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Paoletti A, 1996, J CELL SCI, V109, P3089; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pihan GA, 1998, CANCER RES, V58, P3974; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	61	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8206	8215		10.1038/sj.onc.1208012	http://dx.doi.org/10.1038/sj.onc.1208012			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378001				2022-12-28	WOS:000224749500003
J	Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND				Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND			The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression	ONCOGENE			English	Article						forkhead-associated domain; p300; AP-1; Swi/Snf; BRG1	NF-KAPPA-B; DNA-DAMAGE CHECKPOINT; REPLICATION FACTOR-C; SWI/SNF COMPLEX; LARGE SUBUNIT; P53; BINDING; TRANSACTIVATION; TRANSCRIPTION; SPECIFICITY	Smad nuclear interacting protein 1 (SNIP1) is an evolutionarily conserved protein containing a forkhead-associated (FHA) domain that regulates gene expression through interactions with multiple transcriptional regulators. Here, we have used short interfering RNAs (siRNAs) to knockdown SNIP1 expression in human cell lines. Surprisingly, we found that reduction in SNIP1 levels resulted in significantly reduced cell proliferation and accumulation of cells in the G1 phase of the cell cycle. Consistent with this result, we observed that cyclin D1 protein and mRNA levels were reduced. Moreover, SNIP1 depletion results in inhibition of cyclin D1 promoter activity in a manner dependent upon a previously characterized binding site for the AP-1 transcription factor family. SNIP1 itself is induced upon serum stimulation immediately prior to cyclin D1 expression. These effects were independent of the tumour suppressors p53 and retinoblastoma (Rb), but were consistent with an interaction with BRG1, a component of the ATP-dependent chromatin remodelling complex, Swi/Snf. These results define both a new function for SNIP1 and identify a previously unrecognized regulator of the cell cycle and cyclin D1 expression.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Owen-Hughes, Tom/0000-0002-0618-8185				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003; Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Beadling C, 2001, ONCOGENE, V20, P1771, DOI 10.1038/sj.onc.1204212; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chehab NH, 2000, GENE DEV, V14, P278; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; RADNEY C, 2003, J BIOL CHEM, V278, P2370; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2000, CELL GROWTH DIFFER, V11, P491; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhou MM, 2000, NAT STRUCT BIOL, V7, P1085, DOI 10.1038/81919	30	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8185	8195		10.1038/sj.onc.1208025	http://dx.doi.org/10.1038/sj.onc.1208025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378006				2022-12-28	WOS:000224749500001
J	McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC				McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC			Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics	ONCOGENE			English	Article						XIAP; RNAi; antisense; apoptosis; IAPs	X-LINKED INHIBITOR; LIGAND-INDUCED APOPTOSIS; STRUCTURAL BASIS; SERINE-PROTEASE; DOWN-REGULATION; CYTOCHROME-C; IN-VITRO; CASPASE INHIBITION; GENE-TRANSFER; BCL-2 GENE	Stable expression of short-hairpin RNAs (shRNAs) directed against the X-linked inhibitor of apoptosis (XIAP) resulted in the generation of three MDA-MB-231 cell lines (XIAP shRNA cells) with reductions in XIAP mRNA and protein levels >85% relative to MDA-MB-231 cells stably transfected with the U6 RNA polymerase III promoter alone (U6 cells). This RNA interference (RNAi) approach dramatically sensitized these cells to killing by the (t) under bar umor necrosis factor-(r) under bar elated (a) under bar poptosis-(i) under bar nducing (l) under bar igand (TRAIL). Importantly, loss of XIAP also sensitized the cells to killing by taxanes but had no additional effects on killing by carboplatin and doxorubicin. The increased sensitivity of the XIAP shRNA cells to killing by TRAIL and taxanes correlated with enhanced caspase cleavage and activation, including caspase-8, and robust processing of poly(ADP-ribose) polymerase and BID compared to U6 cells. Additionally, increasing XIAP levels by adenovirus-mediated expression protected both XIAP shRNA and U6 cells from TRAIL killing in a dose-dependent manner. The effects observed by stable RNAi with respect to TRAIL sensitization were also achieved following downregulation of XIAP in Panc-1 cells treated with a second-generation, mixed-backbone antisense oligonucleotide, AEG 35156/GEM640. These data indicate that reducing XIAP protein expression by either RNAi or antisense approaches increases cancer cell susceptibility to functionally diverse chemotherapeutic agents and supports the notion that downregulation of XIAP in vivo may synergize with disease-relevant chemotherapeutic regimes, including TRAIL and taxanes, to increase the effectiveness of antineoplastic agents.	Univ Ottawa, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; Hybridon Inc, Cambridge, MA 02139 USA; Aegera Therapeut Inc, Verdun, PQ H3E 1A8, Canada	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	LaCasse, EC (corresponding author), Univ Ottawa, Aegera Oncol Inc, Rm 306,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	eric.lacasse@aegera.com		Agrawal, Sudhir/0000-0003-4275-2510				Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CHAWLASARKAR M, 2004, CELL DEATH DIFFER, V30, P1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummings BS, 2004, J PHARMACOL EXP THER, V310, P126, DOI 10.1124/jpet.104.065862; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Giodini A, 2002, CANCER RES, V62, P2462; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1997, APOPTOSIS, V2, P423, DOI 10.1023/A:1026465926478; Lo YMD, 1999, CANCER RES, V59, P3899; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sasaki H, 2000, CANCER RES, V60, P5659; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi J, 2003, CURR MOL MED, V3, P727, DOI 10.2174/1566524033479401; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tillman DM, 2003, CANCER RES, V63, P5118; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vilenchik M, 2002, CANCER RES, V62, P2175; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang L, 2003, CANCER RES, V63, P6815; Zhang XD, 2001, CANCER RES, V61, P7339	58	151	162	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8105	8117		10.1038/sj.onc.1207967	http://dx.doi.org/10.1038/sj.onc.1207967			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378029				2022-12-28	WOS:000224692500008
J	Davidson, AJ; Zon, LI				Davidson, AJ; Zon, LI			The 'definitive' (and 'primitive') guide to zebrafish hematopoiesis	ONCOGENE			English	Review						zebrafish; blood; hematopoietic stem cell; embryo; leukemia; hematopoiesis	HOMEOBOX GENE CDX2; T-CELL LEUKEMIA; IN-VIVO; EXPRESSION PATTERN; POSITIONAL CLONING; EARLY MACROPHAGES; BINDING-PROTEIN; TAIL MESODERM; BLOOD; MODEL	Progressive advances using zebrafish as a model organism have provided hematologists with an additional genetic system to study blood cell formation and hematological malignancies. Despite extensive evolutionary divergence between bony fish (teleosts) and mammals, the molecular pathways governing hematopoiesis have been highly conserved. As a result, most (if not all) of the critical hematopoietic transcription factor genes identified in mammals have orthologues in zebrafish. As in other vertebrates, all of the teleost blood lineages are believed to originate from a pool of pluripotent, self-renewing hematopoietic stem cells. Here, we provide a detailed review of the timing, anatomical location, and transcriptional regulation of zebrafish 'primitive' and 'definitive' hematopoiesis as well as discuss a model of T-cell leukemia and recent advances in blood cell transplantation. Given that many of the regulatory genes that control embryonic hematopoiesis have been implicated in oncogenic pathways in adults, an understanding of blood cell ontogeny is likely to provide insights into the pathophysiology of human leukemias.	Childrens Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Zon, LI (corresponding author), Childrens Hosp, Div Hematol Oncol, Dept Med, KARP7,1 Blackfan Circle, Boston, MA 02115 USA.	zon@enders.tch.harvard.edu						ALADHAMI MA, 1976, ROUX ARCH DEV BIOL, V179, P393, DOI 10.1007/BF00848245; ALADHAMI MA, 1977, DEV GROWTH DIFFER, V19, P171; Amacher SL, 2002, DEVELOPMENT, V129, P3311; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; BRECHER G, 1993, P NATL ACAD SCI USA, V90, P6028, DOI 10.1073/pnas.90.13.6028; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Brownlie A, 2003, DEV BIOL, V255, P48, DOI 10.1016/S0012-1606(02)00041-6; Brownlie A, 1998, NAT GENET, V20, P244, DOI 10.1038/3049; Burns CE, 2002, EXP HEMATOL, V30, P1381, DOI 10.1016/S0301-472X(02)00955-4; CATTON WT, 1951, BLOOD, V6, P39, DOI 10.1182/blood.V6.1.39.39; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CHEN XD, 1995, J IMMUNOL, V154, P2557; Childs S, 2000, CURR BIOL, V10, P1001, DOI 10.1016/S0960-9822(00)00653-9; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Danilova N, 2002, P NATL ACAD SCI USA, V99, P13711, DOI 10.1073/pnas.212515999; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DIETERLENLIEVRE F, 2001, HEMATOPOIESIS DEV AP; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; DOOLEY KA, 2004, IN PRESS DEV BIOL; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Fisher RC, 2004, LEUKEMIA RES, V28, P83, DOI 10.1016/S0145-2126(03)00178-4; Galloway JL, 2003, CURR TOP DEV BIOL, V53, P139, DOI 10.1016/S0070-2153(03)53004-6; Gering M, 2003, DEVELOPMENT, V130, P6187, DOI 10.1242/dev.00875; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Gregory M, 2002, BLOOD CELL MOL DIS, V28, P418, DOI 10.1006/bcmd.2002.0527; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Haffter P, 1996, DEVELOPMENT, V123, P1; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Harshbarger JC, 2001, MAR BIOTECHNOL, V3, pS115; HAWKINS WE, 1985, J APPL TOXICOL, V5, P261, DOI 10.1002/jat.2550050408; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Herbomel P, 2001, DEV BIOL, V238, P274, DOI 10.1006/dbio.2001.0393; Hill DJ, 1996, BRIT J HAEMATOL, V92, P200, DOI 10.1046/j.1365-2141.1996.280814.x; Jagadeeswaran P, 1999, BRIT J HAEMATOL, V107, P731, DOI 10.1046/j.1365-2141.1999.01763.x; Jessen JR, 1998, P NATL ACAD SCI USA, V95, P5121, DOI 10.1073/pnas.95.9.5121; Jessen JR, 2001, GENESIS, V29, P156, DOI 10.1002/gene.1019; Kalev-Zylinska ML, 2003, DEV DYNAM, V228, P323, DOI 10.1002/dvdy.10388; Kalev-Zylinska ML, 2002, DEVELOPMENT, V129, P2015; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lam SH, 2002, DEV DYNAM, V225, P87, DOI 10.1002/dvdy.10127; Lane MC, 2002, DEV DYNAM, V225, P434, DOI 10.1002/dvdy.10182; Lane MC, 2000, DEV BIOL, V225, P37, DOI 10.1006/dbio.2000.9803; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Liao EC, 1998, GENE DEV, V12, P621, DOI 10.1101/gad.12.5.621; Liao EC, 2002, DEVELOPMENT, V129, P649; Liao EC, 2000, DEVELOPMENT, V127, P5123; Liao W, 1997, DEVELOPMENT, V124, P381; Liao W, 2000, DEVELOPMENT, V127, P4303; Lieschke GJ, 2002, DEV BIOL, V246, P274, DOI 10.1006/dbio.2002.0657; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lin HF, 2001, BLOOD, V98, p514A; Lin HF, 2000, BLOOD, V96, p36A; Liu F, 2002, MECH DEVELOP, V113, P69, DOI 10.1016/S0925-4773(01)00658-X; LLOYDEVANS P, 1994, BBA-LIPID LIPID MET, V1215, P291, DOI 10.1016/0005-2760(94)90056-6; Lohnes D, 2003, BIOESSAYS, V25, P971, DOI 10.1002/bies.10340; Long QM, 1997, DEVELOPMENT, V124, P4105; Lyons SE, 2002, P NATL ACAD SCI USA, V99, P5454, DOI 10.1073/pnas.082695299; Lyons SE, 2001, BLOOD, V97, P2611, DOI 10.1182/blood.V97.9.2611; Majumdar A, 2000, DEVELOPMENT, V127, P2089; MESEGUER J, 1991, ARCH HISTOL CYTOL, V54, P299, DOI 10.1679/aohc.54.299; Munoz-Sanjuan I, 2001, DEV BIOL, V237, P1, DOI 10.1006/dbio.2001.0350; Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295-8305.2003; Oates AC, 1999, BLOOD, V94, P2622, DOI 10.1182/blood.V94.8.2622.420k39_2622_2636; Oates AC, 2001, BLOOD, V98, P1792, DOI 10.1182/blood.V98.6.1792; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Parker L, 1999, DEVELOPMENT, V126, P2643; Paw BH, 2003, NAT GENET, V34, P59, DOI 10.1038/ng1137; Pfeffer PL, 1998, DEVELOPMENT, V125, P3063; Pratt SJ, 2002, PHYSIOL GENOMICS, V11, P91, DOI 10.1152/physiolgenomics.00112.2001; Ransom DG, 1996, DEVELOPMENT, V123, P311; RANSOM DG, 2004, IN PRESS PLOS BIOL; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; RIEB J-P, 1973, Annales d'Embryologie et de Morphogenese, V6, P43; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Ruvinsky I, 1998, DEV GENES EVOL, V208, P94, DOI 10.1007/s004270050158; Schorpp M, 2002, MECH DEVELOP, V118, P179, DOI 10.1016/S0925-4773(02)00241-1; Shafizadeh E, 2002, DEVELOPMENT, V129, P4359; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; STANTON MF, 1965, JNCI-J NATL CANCER I, V34, P117, DOI 10.1093/jnci/34.1.117; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stockard CR, 1915, AM J ANAT, V18, P227, DOI 10.1002/aja.1000180205; Sumoy L, 1997, MECH DEVELOP, V63, P15, DOI 10.1016/S0925-4773(97)00671-0; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Toyama R, 1998, MECH DEVELOP, V71, P197, DOI 10.1016/S0925-4773(97)00202-5; Traver D, 2003, NAT IMMUNOL, V4, P1238, DOI 10.1038/ni1007; TRAVER D, 2004, IN PRESS BLOOD; Traver D, 2003, ADV IMMUNOL, V81, P253; Trede NS, 2001, TRENDS IMMUNOL, V22, P302, DOI 10.1016/S1471-4906(01)01939-1; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Walmsley M, 2002, DEVELOPMENT, V129, P5683, DOI 10.1242/dev.00169; Wang H, 1998, NAT GENET, V20, P239, DOI 10.1038/3041; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Ward AC, 2003, BLOOD, V102, P3238, DOI 10.1182/blood-2003-03-0966; Warga RM, 1999, DEVELOPMENT, V126, P827; Weinstein BM, 1996, DEVELOPMENT, V123, P303; Wellbrock C, 2002, MICROSC RES TECHNIQ, V58, P456, DOI 10.1002/jemt.10163; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Willett CE, 1999, DEV DYNAM, V214, P323, DOI 10.1002/(SICI)1097-0177(199904)214:4<323::AID-AJA5>3.3.CO;2-V; Willett CE, 1997, IMMUNOGENETICS, V45, P394, DOI 10.1007/s002510050221; Willett CE, 2001, DEV DYNAM, V222, P694, DOI 10.1002/dvdy.1223; WINGERT RA, 2003, HEMATOPOIETIC STEM C; YODER MC, 2001, HEMATOPOIESIS DEV AP; ZAPATA A, 1979, DEV COMP IMMUNOL, V3, P55, DOI 10.1016/S0145-305X(79)80006-3	115	314	339	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7233	7246		10.1038/sj.onc.1207943	http://dx.doi.org/10.1038/sj.onc.1207943			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378083				2022-12-28	WOS:000223998800009
J	Vineis, P				Vineis, P			Individual susceptibility to carcinogens	ONCOGENE			English	Article						SNP; carcinogen metabolism; DNA repair; dose-response; public health	DNA-REPAIR; POLYMORPHISMS; CANCER; LUNG; POPULATIONS; CYP1A1; MEAT	The contribution of polymorphisms in carcinogen metabolizing genes to overall cancer rates may vary widely between groups with differing allele frequencies and with varying levels of carcinogenic exposure. Their effects are modified by interactions with each other and with other genes, particularly those involved in DNA repair. Studies on the combined effects of particular polymorphisms on colorectal and other cancers, and also on intermediate markers such as DNA adduct formation, are discussed. Such susceptibility genes are of considerable scientific interest, but do not confer high enough risks to be clinically relevant.	Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Canc Epidemiol Unit, Turin, Italy	Imperial College London; University of Turin	Vineis, P (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England.	p.vineis@imperial.ac.uk						Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; BERWICK M, 2002, BIOMARKERS ENV ASS D; Burnet NG, 1998, INT J CANCER, V79, P606, DOI 10.1002/(SICI)1097-0215(19981218)79:6<606::AID-IJC9>3.0.CO;2-Y; Dybdahl M, 1999, CANCER EPIDEM BIOMAR, V8, P77; EYFJORD JE, 2000, P WORKSH MOL EP NEW; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; Garte S, 1998, CARCINOGENESIS, V19, P1329, DOI 10.1093/carcin/19.8.1329; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; Le Marchand L, 2002, MUTAT RES-FUND MOL M, V506, P205, DOI 10.1016/S0027-5107(02)00167-7; Matullo G, 2003, CANCER EPIDEM BIOMAR, V12, P674; Nicas M, 1999, J OCCUP ENVIRON MED, V41, P535, DOI 10.1097/00043764-199907000-00002; Riboli E, 2002, IARC SCI PUBLICATION, V156; Taioli E, 1999, CANCER EPIDEM BIOMAR, V8, P727; Vineis P, 2004, INT J CANCER, V108, P2, DOI 10.1002/ijc.11467; Vineis P, 2003, INT J CANCER, V104, P650, DOI 10.1002/ijc.10995; Vineis P, 1996, CANCER CAUSE CONTROL, V7, P479, DOI 10.1007/BF00052675; Vineis P, 1999, IARC SCI PUBLICATION, V148; Vogelstein B., 1998, GENETIC BASIS HUMAN; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Weber WW, 1999, MOL DIAGN, V4, P299, DOI 10.1016/S1084-8592(99)80006-X; Ye Zheng, 2002, Med Sci Monit, V8, pCR558	21	50	51	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6477	6483		10.1038/sj.onc.1207897	http://dx.doi.org/10.1038/sj.onc.1207897			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322518				2022-12-28	WOS:000223468800012
J	Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ				Hentges, KE; Weiser, KC; Schountz, T; Woodward, LS; Morse, HC; Justice, MJ			Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia	ONCOGENE			English	Article						Evi3; EBF; Pax-5; mb-1; B29; B-cell leukemia	ANTIGEN RECEPTOR; FUNCTIONAL-CHARACTERIZATION; RETROVIRAL INTEGRATION; LYMPHOCYTE DEVELOPMENT; TARGET GENES; MOUSE; CD19; IDENTIFICATION; CLONING; TRANSCRIPTION	Retroviral insertions that activate proto-oncogenes are a primary cause of tumors in certain strains of mice. The AKXD recombinant inbred mice are predisposed to a variety of leukemias and lymphomas as a result of viral integration. One common insertion site, the ecotropic viral insertion site 3 ( Evi3), has been implicated in most B-cell tumors in the AKXD-27 strain. The Evi3 gene encodes a zinc-finger protein with sequence similarity to the Early B-cell Factor-Associated Zinc-finger gene (EBFAZ). We show that the Evi3 gene is overexpressed in several tumors with viral insertions at Evi3, which results in the upregulation of Early B-cell Factor (EBF)-target gene expression, suggesting that Evi3 modulates EBF activity. Reconstitution of primary leukemia cells showed that these tumors express high densities of the B-cell surface proteins CD19 and CD38, which are EBF targets. Using a transactivation assay, we show that the terminal six zinc-fingers of Evi3 are required for modi. cation of EBF activity. This is the first evidence that Evi3 expression in tumors alters the level of EBF target genes, and the first characterization of the Evi3 protein domains required for modulation of EBF activity. Further, these data imply that Evi3 misexpression initiates tumorigenesis by perturbing B-cell development via an interaction with EBF.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; NIAID, Immunopathol Lab, NIH, Rockville, MD USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Room S413,1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu	Schountz, Tony/I-2161-2017	Hentges, Kathryn/0000-0001-8917-3765; Morse, Herbert/0000-0002-9331-3705	NCI NIH HHS [R01 CA63229] Funding Source: Medline; NICHD NIH HHS [F32 HD42436] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD042436] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerblad P, 1999, MOL CELL BIOL, V19, P392; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; Donis-Hernandez FR, 2001, EUR J IMMUNOL, V31, P1261, DOI 10.1002/1521-4141(200104)31:4<1261::AID-IMMU1261>3.0.CO;2-H; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Gisler R, 2000, BLOOD, V96, P1457, DOI 10.1182/blood.V96.4.1457.h8001457_1457_1464; Gisler R, 1999, MOL IMMUNOL, V36, P1067, DOI 10.1016/S0161-5890(99)00092-9; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hase H, 2004, BLOOD, V103, P2257, DOI 10.1182/blood-2003-08-2694; Hasegawa M, 2001, J IMMUNOL, V167, P3190, DOI 10.4049/jimmunol.167.6.3190; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; JUSTICE MJ, 1994, J VIROL, V68, P1293, DOI 10.1128/JVI.68.3.1293-1300.1994; KRONENBERG M, 1985, NATURE, V313, P647, DOI 10.1038/313647a0; Lund FE, 1999, J IMMUNOL, V162, P2693; Lund FE, 1996, J IMMUNOL, V157, P1455; Maier H, 2002, SEMIN IMMUNOL, V14, P415, DOI 10.1016/S1044532302000763; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schountz T, 1996, J IMMUNOL, V157, P3893; Shim S, 2002, NUCLEIC ACIDS RES, V30, P3107, DOI 10.1093/nar/gkf437; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Smith EMK, 2002, J IMMUNOL, V169, P261, DOI 10.4049/jimmunol.169.1.261; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Wang SS, 1997, J NEUROSCI, V17, P4149; Warming S, 2003, BLOOD, V101, P1934, DOI 10.1182/blood-2002-08-2652; Xu YK, 2002, J IMMUNOL, V169, P6910, DOI 10.4049/jimmunol.169.12.6910; ZHOU LJ, 1991, J IMMUNOL, V147, P1424	39	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1220	1230		10.1038/sj.onc.1208243	http://dx.doi.org/10.1038/sj.onc.1208243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580294				2022-12-28	WOS:000226898700009
J	Kim, H; Kim, YN; Kim, H; Kim, CW				Kim, H; Kim, YN; Kim, H; Kim, CW			Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction	ONCOGENE			English	Article						hydrogen peroxide; apoptosis; Bfl-1; NF-kappa B	NF-KAPPA-B; HYDROGEN-PEROXIDE; REDOX REGULATION; HUMAN A1; GROWTH ARREST; UP-REGULATION; BCL-X; ACTIVATION; EXPRESSION; PROMOTER	Many types of mammalian cells produce ROS in response to many different stimuli to modulate a number of cellular functions, including apoptosis. However, the correlation between ROS and apoptosis remains controversial, and the mechanisms whereby ROS-induced signals are propagated to critical downstream targets remain largely undefined. Here, we demonstrate that hydrogen peroxide ( H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. When Jurkat, human leukemic T cells, were pretreated with 100 muM H2O2 and then treated with anti-Fas antibody, apoptosis was impaired without change of cell surface Fas expression. An investigation of the expression patterns of Bcl-2 family genes revealed that H2O2 treatment induced Bfl-1 gene expression, but left other genes unchanged, and this Bfl-1 expression and H2O2-induced antiapoptotic effect was inhibited by antioxidants or NF-kappaB inhibitor. In addition, an electromobility shift assay revealed that the p65/p50 subunits of NF-kappaB activated by H2O2 bound to a bfl-1 promoter. Neither the induction of Bfl-1 nor the antiapoptotic effect of H2O2 was detected in Bfl-1-knockdown Jurkat cell line containing Bfl-1 antisense (Bfl-1AS). These data indicate that oxidative stress induces the expression of Bfl-1 via NF-kappaB activation, and this early-response gene protects cells from Fas-mediated apoptosis. This may be a cellular survival mechanism of cells exposed to phagocytes-derived ROS.	Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Biochem & Mol Biol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, 28 Yongon Dong, Seoul 110799, South Korea.	cwkim@plaza.snu.ac.kr	Kim, Chul-Woo/F-7008-2011	Kim, Hyungsoo/0000-0002-8189-5939				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilston V, 2001, FREE RADICAL RES, V35, P681, DOI 10.1080/10715760100301201; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee KM, 2001, CELL SIGNAL, V13, P645, DOI 10.1016/S0898-6568(01)00178-4; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Malmberg KJ, 2001, J IMMUNOL, V167, P2595, DOI 10.4049/jimmunol.167.5.2595; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Moreb JS, 1997, LEUKEMIA, V11, P998, DOI 10.1038/sj.leu.2400719; Moreb JS, 2001, BLOOD, V97, P578, DOI 10.1182/blood.V97.2.578; Otsuji M, 1996, P NATL ACAD SCI USA, V93, P13119, DOI 10.1073/pnas.93.23.13119; Preston TJ, 2003, EXP CELL RES, V285, P146, DOI 10.1016/S0014-4827(03)00015-6; Pugazhenthi S, 2003, J NEUROCHEM, V84, P982, DOI 10.1046/j.1471-4159.2003.01606.x; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmielau J, 2001, CANCER RES, V61, P4756; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1252	1261		10.1038/sj.onc.1208282	http://dx.doi.org/10.1038/sj.onc.1208282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592513				2022-12-28	WOS:000226898700012
J	Morris, C; Jalinot, P				Morris, C; Jalinot, P			Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation	ONCOGENE			English	Article						Int-6; mitosis; chromosome segregation; Cdk1; Wee1	MAMMARY-TUMOR VIRUS; FISSION YEAST HOMOLOG; TRANSLATION INITIATION; CELL-DIVISION; SUBUNIT; KINASES; PROTEIN; GENE; SITE; PHOSPHORYLATION	The Int-6 protein has been originally identified as the product of a mouse gene being a frequent integration site of the mouse mammary tumour virus. Here, we show that reducing Int-6 expression by RNA interference in HeLa cells markedly alters mitosis progression. Defects in spindle formation, chromosome segregation and cytokinesis were observed. These abnormalities of mitosis completion are correlated with an inhibition of cyclin B Cdk1 kinase activity, due to a prolonged inhibitory phosphorylated state of Cdk1. In line with this observation, the Wee1 tyrosine kinase that negatively controls Cdk1 was less efficiently inactivated during G2 in Int-6-depleted cells. These findings support the notion that the oncogenic properties associated with alteration of Int-6 originate from chromosomal instability.	Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, F-69364 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, UMR5161, Lab Biol Mol Cellule,IFR 128, 46 Allee Italie, F-69364 Lyon, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; ALVES K, 2004, THESIS ECOLE NORMALE; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; DANIELS MJ, 2004, SCIENCE, V16, P16; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HOAREAU AK, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Kawasaki H, 2003, ONCOGENE, V22, P6839, DOI 10.1038/sj.onc.1206903; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1999, NATL CELL BIOL, V1, P73; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Secchiero P, 1998, BLOOD, V92, P1685, DOI 10.1182/blood.V92.5.1685.417k30_1685_1696; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Stock RP, 2003, NAT BIOTECHNOL, V21, P13, DOI 10.1038/nbt0103-13; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watkins SJ, 2004, CELL PROLIFERAT, V37, P149, DOI 10.1111/j.1365-2184.2004.00305.x; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370	39	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1203	1211		10.1038/sj.onc.1208268	http://dx.doi.org/10.1038/sj.onc.1208268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558017				2022-12-28	WOS:000226898700007
J	Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J				Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J			REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase	ONCOGENE			English	Article						apoptosis; hypoxia; phosphoinositide; 3-kinase; prostate cancer; gene silencing; RNA interference	INDUCIBLE FACTOR-I; CELL-GROWTH DOWNSTREAM; PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; PERICELLULAR HYPOXIA; TUMOR SUPPRESSION; CANCER-THERAPY; EXPRESSION; HIF-1-ALPHA; TARGET	Cancer cells frequently evade apoptosis during tumorigenesis by acquiring mutations in apoptotic regulators. Chronic activation of the PI 3-kinase-Akt pathway through loss of the tumor suppressor PTEN is one mechanism by which these cells can gain increased protection against apoptosis. W e report here that REDD1 ( RTP801) can act as a transcriptional downstream target of PI 3-kinase signaling in human prostate cancer cells (PC-3). REDD1 expression is markedly reduced in PC-3 cells treated with LY294002 (LY) or Rapamycin and strongly induced under hypoxic conditions in a hypoxia-inducible factor-1 (HIF-1)-dependent manner. Loss of function studies employing antisense molecules or RNA interference indicate that REDD1 is essential for invasive growth of prostate cancer cells in vitro and in vivo. Reduced REDD1 levels can sensitize cells towards apoptosis, whereas elevated levels of REDD1 induced by hypoxia or overexpression desensitize cells to apoptotic stimuli. Taken together our data designate REDD1 as a novel target for therapeutic intervention in prostate cancer.	Atugen AG, D-13125 Berlin, Germany		Kaufmann, J (corresponding author), Atugen AG, Otto Warburg Haus Nr 80,Robert Roessle Str 10, D-13125 Berlin, Germany.	kaufmann@atugen.com		Schwarzer, Rolf/0000-0002-8934-8788				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Anastasiadis AG, 2003, CURR DRUG TARGETS, V4, P191, DOI 10.2174/1389450033491136; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chrastina A, 2003, NEOPLASMA, V50, P251; Chun YS, 2000, EUR J BIOCHEM, V267, P4198, DOI 10.1046/j.1432-1327.2000.01453.x; Coffer PJ, 1998, BIOCHEM J, V335, P1; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kaufmann J, 2004, BIOCHEM SOC T, V32, P355, DOI 10.1042/BST0320355; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Paul SAM, 2004, J CELL PHYSIOL, V200, P20, DOI 10.1002/jcp.10479; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Salnikow K, 2000, CANCER RES, V60, P3375; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	58	103	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1138	1149		10.1038/sj.onc.1208236	http://dx.doi.org/10.1038/sj.onc.1208236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592522				2022-12-28	WOS:000226898700002
J	Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L				Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L			High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome	ONCOGENE			English	Article						neuroblastoma; activin A; angiogenesis; outcome	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; CELL-PROLIFERATION; DOWN-REGULATION; IN-VITRO; INDUCTION; DIFFERENTIATION; ANGIOGENESIS; FOLLISTATIN; INHIBITORS	Amplification of the MYCN oncogene contributes to the malignant progression of human neuroblastomas, but the mechanisms have remained unclear. We have previously demonstrated that N-Myc facilitates angiogenesis by downregulating an angiogenesis inhibitor identified as the inhibin betaA homodimer activin A. Here, we have sought to define the molecular, biological and clinical consequences of activin A expression in human neuroblastoma. We report that enhanced activin A expression suppresses proliferation and colony formation of human neuroblastoma cells with amplified MYCN in vitro; that it inhibits neuroblastoma growth and angiogenesis in vivo; that it is highly expressed in differentiated, but not undifferentiated human neuroblastomas; and that it correlates with favourable outcome of neuroblastoma patients. Our results indicate that high activin A expression plays an important beneficial role in human neuroblastoma.	Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, D-37075 Gottingen, Germany; Univ Kinderklin Essen, Abt Hamatol Onkol & Endokrinol, Essen, Germany; Univ Kinderklin Marburg, Marburg, Germany	University of Gottingen; University of Duisburg Essen	Schweigerer, L (corresponding author), Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, Robert Koch Str 40, D-37075 Gottingen, Germany.	lothar.schweigerer@med.uni-goettingen.de	Schramm, Alexander/G-5688-2010	Schramm, Alexander/0000-0001-7670-7529				ALTABA AR, 1989, NATURE, V341, P33; ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cantero R, 1999, WORLD J SURG, V23, P1294, DOI 10.1007/s002689900665; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cinatl J, 2002, INT J ONCOL, V20, P97; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Giusti AF, 2000, EVOL DEV, V2, P294, DOI 10.1046/j.1525-142x.2000.00071.x; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; Rossler J, 1999, INT J CANCER, V81, P113; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Tuuri T, 1996, MOL CELL ENDOCRINOL, V121, P1, DOI 10.1016/0303-7207(96)03842-7; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wai DH, 2002, INT J ONCOL, V20, P441; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Woodruff TK, 1997, J ENDOCRINOL, V152, P167, DOI 10.1677/joe.0.1520167; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8	25	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					680	687		10.1038/sj.onc.1208087	http://dx.doi.org/10.1038/sj.onc.1208087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580313				2022-12-28	WOS:000226420400015
J	Chalitchagorn, K; Shuangshoti, S; Hourpai, N; Kongruttanachok, N; Tangkijvanich, P; Thong-ngam, D; Voravud, N; Sriuranpong, V; Mutirangura, A				Chalitchagorn, K; Shuangshoti, S; Hourpai, N; Kongruttanachok, N; Tangkijvanich, P; Thong-ngam, D; Voravud, N; Sriuranpong, V; Mutirangura, A			Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis	ONCOGENE			English	Article						LINE-1 methylation; global hypomethylation; COBRA PCR; microdissection; cellular differentiation; multistep carcinogenesis	DNA METHYLATION; L1 RETROTRANSPOSONS; COLORECTAL-CANCER; CPG ISLANDS; HYPOMETHYLATION; CARCINOMAS; SEQUENCES; ASSAY; SERUM	Genome-wide losses of DNA methylation have been regarded as a common epigenetic event in malignancies and may play crucial roles in carcinogenesis. Limited information is available on the global methylation status in normal tissues and other cancer types beyond colonic carcinoma. Here we applied the combined bisulfite restriction analysis PCR to evaluate the methylation status of LINE-1 repetitive sequences in genomic DNA derived from microdissected samples from several human normal and neoplastic tissues. We found that methylation of LINE-1 in leukocytes was independent of age and gender. In contrast, normal tissues from different organs showed tissue-specific levels of methylated LINE-1. Globally, most carcinomas including breast, colon, lung, head and neck, bladder, esophagus, liver, prostate, and stomach, revealed a greater percentage of hypomethylation than their normal tissue counterparts. Furthermore, DNA derived from sera of patients with carcinoma displayed more LINE-1 hypomethylation than those of noncarcinoma individuals. Finally, in a colonic carcinogenesis model, we detected significantly greater hypomethylation in carcinoma than those of dysplastic polyp and histological normal colonic epithelium. Thus, the methylation status is a unique feature of a specific tissue type and the global hypomethylation is a common epigenetic process in cancer, which may progressively evolve during multistage carcinogenesis.	Chulalongkorn Univ, Fac Med, Dept Anat, Genet Unit, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Grad Sch, Interdept Program Biomed Sci, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Biochem, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Physiol, Bangkok 10330, Thailand; Chulalongkorn Univ, Fac Med, Dept Med, Med Oncol Unit, Bangkok 10330, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Mutirangura, A (corresponding author), Chulalongkorn Univ, Fac Med, Dept Anat, Genet Unit, Bangkok 10330, Thailand.	mapiwat@chula.ac.th	Werawatganon, Duangporn/X-2507-2019; Mutirangura, Apiwat/C-8197-2009	Werawatganon, Duangporn/0000-0001-8847-9690; 				Anker P, 2000, MEDICINA-BUENOS AIRE, V60, P699; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jurgens B, 1996, CANCER RES, V56, P5698; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lyon Mary F., 1994, European Journal of Human Genetics, V2, P255; Mutirangura A, 1999, INT J CANCER, V83, P210, DOI 10.1002/(SICI)1097-0215(19991008)83:2<210::AID-IJC11>3.3.CO;2-P; Mutirangura A, 1998, CLIN CANCER RES, V4, P665; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Santourlidis S, 1999, PROSTATE, V39, P166; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3; Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yang AS, 2003, SCIENCE, V302	23	331	349	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8841	8846		10.1038/sj.onc.1208137	http://dx.doi.org/10.1038/sj.onc.1208137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480421				2022-12-28	WOS:000225165100014
J	Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y				Dai, JL; Wang, L; Sahin, AA; Broemeling, LD; Schutte, M; Pan, Y			NHERF (Na+/H+ Exchanger Regulatory Factor) gene mutations in human breast cancer	ONCOGENE			English	Article						spleen tyrosine kinase; NHERF; breast cancer; mutation; merlin; haploinsufficiency	TYROSINE KINASE; ALLELIC IMBALANCE; TUMOR; HAPLOINSUFFICIENCY; EZRIN; SYK; CARCINOGENESIS; SUPPRESSES; DELETION; REGIONS	Yeast two-hybrid screening was used to explore novel proteins that interact with a breast tumor or metastasis suppressor, SYK (spleen tyrosine kinase). The screening yielded NHERF (Na+/H+ exchanger regulatory factor, also known as NHERF1 or EBP-50) that binds to the interdomain B of SYK. NHERF is an estrogen-responsive gene that encodes an inhibitory factor for epithelial Na+/H+ exchanger isoform 3 (NHE3). We found intragenic mutation of the NHERF gene accompanied by loss of heterzygosity (LOH) in similar to3% (3/85) of breast cancer cell lines and primary breast tumors. Mutations occurred at the conserved PDZ domains at NHERF NH2-terminus that bound to SYK, or at its COOH-terminus motif that binds to MERLIN, the product of Neurofibromatosis 2 (NF2) tumor suppressor gene. NHERF tumorigenic mutations decreased or abolished its interaction with SYK or MERLIN, suggesting a pathway link among these three molecules that may play a critical role in mammary neoplastic progression. Primary breast tumors with LOH at the NHERF locus had clinical presentations of higher aggressiveness, indicating that deregulated NHERF signaling may be associated with disease progression. Moreover, the LOH was inversely correlated with SYK promoter methylation, suggesting that NHERF and SYK may transduce a common suppressive signal. Taken together, the results indicated NHERF to be a candidate tumor suppressor gene in human breast carcinoma that may be interconnected to the SYK and MERLIN suppressors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Erasmus MC, Josephine Nefkens Inst, Dept Med Oncol, Rotterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org			NCI NIH HHS [R01 CA100278] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bartkova J, 1996, CANCER RES, V56, P5475; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; COUCH FJ, 2002, GENETIC BASIS HUMAN, P549; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harkes IC, 2003, BRIT J CANCER, V89, P2289, DOI 10.1038/sj.bjc.6601448; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LUPULESCU A, 1993, EXP CLIN ENDOCRINOL, V101, P204, DOI 10.1055/s-0029-1211234; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; RADFORD DM, 1995, CANCER RES, V55, P3399; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REIFENBERGER G, 1993, CANCER RES, V53, P2736; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Srivastava M, 2003, P NATL ACAD SCI USA, V100, P14287, DOI 10.1073/pnas.2235927100; Staff S, 2003, CANCER RES, V63, P4978; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Wang L, 2003, CANCER RES, V63, P4724; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2003, FEBS LETT, V536, P141, DOI 10.1016/S0014-5793(03)00043-7; YAEGASHI S, 1995, JPN J CANCER RES, V86, P929, DOI 10.1111/j.1349-7006.1995.tb03003.x; Yuan YF, 2001, CANCER RES, V61, P5558	38	74	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8681	8687		10.1038/sj.onc.1207962	http://dx.doi.org/10.1038/sj.onc.1207962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467753				2022-12-28	WOS:000224988800014
J	Wang, H; Zhang, Y; Toratani, S; Okamoto, T				Wang, H; Zhang, Y; Toratani, S; Okamoto, T			Transformation of vascular endothelial cells by a point mutation in the Tie2 gene from human intramuscular haemangioma	ONCOGENE			English	Article						Tie2; VEGF; haemangioma; angiosarcoma; endothelial cell	GROWTH-FACTOR; MOUSE; ACTIVATION; INHIBITION; EXPRESSION; ONCOGENE; DELIVERY; PROTEIN; DOMAIN	Tie2, an endothelial-cell-specific receptor tyrosine kinase, collaborates with vascular endothelial growth factor (VEGF) in regulating angiogenesis and vascular maturation. Here, we report a mutation of glycine to aspartic acid at the second glycine of the GXGXXG motif of Tie2 ((G833D)Tie2) in human intramuscular haemangiomas (IMHs) of the capillary type. Murine endothelial cells (ECs) overexpressing this (G833D)Tie2 receptor exhibited an increase in cell proliferation at low serum concentrations and angiosarcomas developed in nude mice, whereas cells overexpressing either wild-type Tie2 or (Q837H)Tie2 failed to elicit these responses. Furthermore, the (G833D)Tie2 receptor increased VEGF expression in ECs. These findings provide molecular mechanisms for pathogenesis of IMH.	Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan; Second Mil Med Univ, Shanghai Changhai Hosp, Dept Oral Med & Maxillofacial Surg, Shanghai 200433, Peoples R China	Hiroshima University; Naval Medical University	Okamoto, T (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan.	tetsuok@hiroshima-u.ac.jp						Akada T, 2002, J CELL PHYSIOL, V193, P253, DOI 10.1002/jcp.10169; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Brown LF, 2000, AM J PATHOL, V156, P2179, DOI 10.1016/S0002-9440(10)65088-2; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1879; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P512; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Holliday R, 1996, CANCER SURV, V28, P103; Lee RJ, 2000, CIRCULATION, V102, P898; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	19	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8700	8704		10.1038/sj.onc.1208006	http://dx.doi.org/10.1038/sj.onc.1208006			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15377998				2022-12-28	WOS:000224988800017
J	Shi, RX; Ong, CN; Shen, HM				Shi, RX; Ong, CN; Shen, HM			Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells	ONCOGENE			English	Article						luteolin; TNF alpha; NF-kappa B; JNK; apoptosis	NF-KAPPA-B; ZINC-FINGER PROTEIN; TNF-INDUCED APOPTOSIS; DOMAIN KINASE RIP; DEATH DOMAIN; INDUCED ACTIVATION; TERMINAL KINASE; JNK ACTIVATION; CANCER; INDUCTION	Tumor necrosis factor-alpha (TNFalpha) activates both cell death and cell survival pathways, which render most cancer cells resistant to its cytotoxicity. In this study, we found that pretreatment with luteolin, a plant flavonoid, greatly sensitized TNFalpha-induced apoptotic cell death in a number of human cancer cell lines; including colorectal cancer COLO205, HCT116 cells and cervical cancer HeLa cells. In the search of the molecular mechanisms responsible for the sensitization effect of luteolin, we discovered that luteolin inhibited TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB), the main survival factor in TNFa signaling. As a result, luteolin suppressed the expression of NF-kappaB-targeted antiapoptotic genes, including A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1). The role of A20 and c-IAP1 was further confirmed by ectopic expression of these two genes, which significantly protected cell death induced by luteolin followed by TNFalpha. In addition, inhibition of NF-kappaB by luteolin led to augmentation and prolongation of c-Jun N-terminal kinase (JNK) activation induced by TNFalpha. Suppression of JNK activation, either by a synthetic JNK inhibitor ( SP600125) or by overexpression of the dominant negative forms of JNK kinase 1 (JNKK1) and JNK kinase 2 (JNKK2), conferred significant protection against apoptotic cell death induced by luteolin and TNFalpha, suggesting that NF-kappaB and JNK are closely associated with the sensitization effect of luteolin. Data from this study reveal a novel function of luteolin and enhance the value of luteolin as an anticancer agent.	Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, Singapore 117597, Singapore	National University of Singapore	Shen, HM (corresponding author), Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, 16 Med Dr, Singapore 117597, Singapore.	cofshm@nus.edu.sg	Shi, Ranxin/F-9817-2012; SHEN, Han-Ming/B-5942-2011; Shi, Ranxin/E-5934-2012; Ong, Choon Nam/E-8638-2010	SHEN, Han-Ming/0000-0001-7369-5227; 				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Farah M, 2003, AM J PHYSIOL-GASTR L, V285, pG919, DOI 10.1152/ajpgi.00205.2003; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Huang YT, 1999, BRIT J PHARMACOL, V128, P999, DOI 10.1038/sj.bjp.0702879; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim DM, 2003, CANCER RES, V63, P621; Kim SH, 2003, BIOCHEM PHARMACOL, V66, P955, DOI 10.1016/S0006-2952(03)00465-9; Ko WG, 2002, PHYTOTHER RES, V16, P295, DOI 10.1002/ptr.871; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mafune K, 1999, CLIN CANCER RES, V5, P4073; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Petak I, 2000, CLIN CANCER RES, V6, P4119; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shen HM, 2000, FREE RADICAL BIO MED, V28, P1115, DOI 10.1016/S0891-5849(00)00206-9; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Ueda H, 2003, BIOL PHARM BULL, V26, P560, DOI 10.1248/bpb.26.560; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xagorari A, 2001, J PHARMACOL EXP THER, V296, P181; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	55	81	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7712	7721		10.1038/sj.onc.1208046	http://dx.doi.org/10.1038/sj.onc.1208046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334063				2022-12-28	WOS:000224306700012
J	Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX				Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX			An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy	ONCOGENE			English	Article						survivin variant; p53; apoptosis; leukemia	PRE-MESSENGER-RNA; ANTI-APOPTOSIS GENE; WILD-TYPE P53; BCL-X; EXPRESSION; IDENTIFICATION; CHECKPOINT; INHIBITOR; INDUCTION; CASPASE-9	Survivin is a unique member of the inhibitor of apoptosis protein family, and its expression is regulated by p53. Recent identification of several functionally divergent survivin variants augments the complexity of survivin action as well as its regulation. Here we report that survivin-2B ( retaining a part of intron 2 as a cryptic exon) is positively regulated by p53, and its overexpression plays a role in sensitizing leukemia cells to chemotherapeutic drug doxorubicin. Doxorubicin treatment activated p53, downregulated survivin and survivin-DeltaEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-type (wt)-p53 phenotype. In contrast, doxorubicin treatment failed to induce these alterations in EU-6 cells, a mutant-p53 ALL cell line. To specify the role of wt-p53 in regulating survivin and its variants, a temperature-sensitive p53 mutant plasmid p53-143 was transfected into EU-4, a p53-null ALL cell line, to establish a subline EU-4/p53-143. When EU-4/p53-143 cell culture was shifted from 37.5 degreesC to the wt-p53-permissive temperature (32.5 degreesC), the expression of survivin and survivin-DEx3 was decreased whereas survivin-2B expression was increased, confirming the distinct regulatory effect of p53 on survivin and its variants. To clarify the role of survivin-2B in the process of apoptosis, survivin-2B cDNA was cloned into pcDNA3HA vector and transfected into EU-4 cells. Enforced expression of survivin-2B in EU-4 cells inhibited cell growth and sensitized these cells to doxorubicin-induced apoptosis. These results suggest that survivin-2B variant is a proapoptotic factor and its expression is upregulated by p53.	Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, Atlanta, GA 30322 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Emory University; Roswell Park Cancer Institute	Zhou, MX (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [R01 CA82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 2000, BLOOD, V96, P1921; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HU H, 2003, ONCOL RES, V13, P429; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kato J, 2001, INT J CANCER, V95, P92; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tu SP, 2003, CANCER RES, V63, P7724; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	31	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7545	7551		10.1038/sj.onc.1208038	http://dx.doi.org/10.1038/sj.onc.1208038			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334064				2022-12-28	WOS:000224176500011
J	Brabek, J; Constancio, BS; Shin, NY; Pozzi, A; Weaver, AM; Hanks, SK				Brabek, J; Constancio, BS; Shin, NY; Pozzi, A; Weaver, AM; Hanks, SK			CAS promotes invasiveness of Src-transformed cells	ONCOGENE			English	Article						p130CAS; Src; cortactin; MMP-2; invasion; podosome	SPECIALIZED SURFACE PROTRUSIONS; CRK-ASSOCIATED SUBSTRATE; TYROSINE PHOSPHORYLATION; V-SRC; KINASE-ACTIVITY; DIFFERENTIAL REGULATION; EXTRACELLULAR-MATRIX; PODOSOME FORMATION; FAMILY KINASES; P130(CAS)	CAS ('Crk-associated substrate') is an Src substrate found at sites of integrin-mediated cell adhesion and linked to cell motility and survival. In this study, the involvement of CAS in oncogenic transformation was evaluated through analysis of mouse embryo fibroblast populations expressing an activated Src mutant, either in the presence or absence of CAS expression. CAS was not found to be a critical determinant of either Src-mediated morphologic transformation or anchorage-independent growth. However, CAS had a profound effect on other aspects of oncogenic Src function. CAS expression led to a substantial increase in the phosphotyrosine content of FAK and paxillin, supporting a role for CAS as a positive regulator of Src activity at integrin adhesion sites. Importantly, CAS expression resulted in a striking enhancement of the capacity of Src-transformed cells to invade through Matrigel. The increased invasiveness was associated with increased activation of matrix metalloproteinase MMP-2 and formation of large actin-rich podosomal aggregates appearing as ring and belt structures. Thus, elevated CAS-associated tyrosine phosphorylation signaling events occurring at sites of integrin-mediated cell adhesion can have a major role in the development of an invasive cell phenotype.	Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med Nephrol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Hanks, SK (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA.	steve.hanks@vanderbilt.edu	Brábek, Jan/J-9836-2017	Brábek, Jan/0000-0001-7754-7299; Lund, Sabata/0000-0002-6092-5131	NATIONAL CANCER INSTITUTE [R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056018, P50DK039261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049882] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA94849-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK56018, P50 DK39261-16] Funding Source: Medline; NIGMS NIH HHS [R01 GM49882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Brabek J, 2002, BIOCHEM BIOPH RES CO, V296, P664, DOI 10.1016/S0006-291X(02)00884-7; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kaverina I, 2003, J CELL SCI, V116, P4915, DOI 10.1242/jcs.00818; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mizutani K, 2002, CANCER RES, V62, P669; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; MONSKY WL, 1993, CANCER RES, V53, P3159; MUELLER SC, 1991, J CELL SCI, V99, P213; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200	44	74	75	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7406	7415		10.1038/sj.onc.1207965	http://dx.doi.org/10.1038/sj.onc.1207965			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15273716				2022-12-28	WOS:000224021400011
J	Truong, AHL; Cervi, D; Lee, J; Ben-David, Y				Truong, AHL; Cervi, D; Lee, J; Ben-David, Y			Direct transcriptional regulation of MDM2 by Fli-1	ONCOGENE			English	Article						erythroleukemia; Fli-1; MDM2; Friend Disease; p53	MULV-INDUCED-ERYTHROLEUKEMIAS; MURINE LEUKEMIA-VIRUS; DNA-BINDING; F-MULV; ERYTHROID PROLIFERATION; P53 PROTEIN; ETS FAMILY; DIFFERENTIATION; CELLS; GENE	The Ets transcription factor, Fli-1, has been shown to play a pivotal role in the induction and progression of Friend Murine Leukemia Virus (F-MuLV)-induced erythroleukemia, with its overexpression leading to erythroblast survival, proliferation, and inhibition of terminal differentiation. P53 inactivation is an additional genetic alteration that occurs in late-stage leukemic progression associated with in vivo and in vitro immortalization. Since p53 protein expression levels are low, to undetectable, in primary erythroleukemic cells that express elevated levels of Fli-1, we investigated the potential regulation of p53 by Fli-1. We assessed whether the overexpression of Fli-1 could partially regulate p53 via modulation of its well-established regulator, MDM2. In this paper, we demonstrate that the promoter of MDM2 contains a consensus binding site for Fli-1that is bound by this transcription factor in vitro and in vivo, resulting in MDM2 transcriptional regulation. We further substantiate these observations in vivo by demonstrating a positive correlation in the expression of Fli-1and MDM2, and a negative correlation with p53 in leukemic tissues obtained from mice with Friend Disease. These observations depict a significant function of Fli-1 overexpression in the indirect control of p53, evidently capable of leading to an increasingly aggressive erythroleukemic clone in vivo.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Mol & Cellular Biol, Res Bldg,Room S-216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; CordonCardo C, 1997, CANCER RES, V57, P1217; Datta NS, 2002, EXP HEMATOL, V30, P158, DOI 10.1016/S0301-472X(01)00780-9; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Kawada H, 2001, INT J HEMATOL, V73, P463, DOI 10.1007/BF02994008; Lee CR, 2003, ANTICANCER RES, V23, P2159; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAO XH, 1994, J BIOL CHEM, V269, P18216; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; RAO VN, 1993, ONCOGENE, V8, P2167; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	29	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					962	969		10.1038/sj.onc.1208323	http://dx.doi.org/10.1038/sj.onc.1208323			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592502				2022-12-28	WOS:000226749200002
J	Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE				Huh, JI; Calvo, A; Stafford, J; Cheung, M; Kumar, R; Philp, D; Kleinman, HK; Green, JE			Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and nonantiangiogenic mechanisms	ONCOGENE			English	Article						antiangiogenesis; VEGFR tyrosine kinase inhibitor; mammary cancer; C3(1)/Tag transgenic mice	BONE-MARROW MICROENVIRONMENT; MULTIPLE-MYELOMA CELLS; TYROSINE KINASE; MOUSE MODEL; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; BREAST-CANCER; THERAPY; ANTIGEN; ENDOSTATIN	Cancer growth and progression is often critically influenced by the production of vascular endothelial growth factor ( VEGF), a key mediator of angiogenesis. VEGF produced by tumor cells stimulates endothelial cell growth through the binding and activation of the KDR/Flk-1 receptor (VEGFR-2) on endothelial cells. Recently, some human breast cancer epithelial cells have been shown to express VEGF receptors, suggesting a potential autocrine-mediated growth stimulation of a subset of cancers by VEGF. We demonstrate that mammary tumors in the C3(1)/Tag transgenic model express VEGF and VEGF receptors and tumor growth is stimulated by this autocrine mechanism. GW654652, an indazolylpyrimidine, is a VEGFRs tyrosine kinase inhibitor that dramatically reduces both angiogenesis and tumor cell growth in this model, as demonstrated using both in vitro and in vivo assays. GW654652 significantly decreased cell proliferation and induced apoptosis in human umbilical vein endothelial cells and M6 mammary tumor cells derived from C3(1)/Tag ( Tag: simian virus 40 T-antigen) transgenic mice. A 75% reduction in VEGF-induced angiogenesis was observed with GW654652 using the chick chorioallantoic membrane assay, whereas GW654652 produced an approximately 85% reduction in angiogenesis as assessed by the Matrigel(TM) plug assay. A profound inhibitory effect on tumor growth in the C3(1)/Tag transgenic model of human breast cancer was observed with oral administration of GW654652 as measured by delayed tumor onset, decreased multiplicity, reduced tumor volume, and extended animal survival. The antitumor effects of GW654652 were associated with reduced tumor vascularization and no apparent toxicity. Tumor growth, however, rapidly advanced following cessation of treatment. This is the first demonstration that a VEGF receptor inhibitor, GW654652, has a strong inhibitory effect on angiogenesis and tumor progression in a transgenic model of mammary cancer, suggesting that this is a useful approach for preclinical testing of such agents.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cell Biol Sect, NIH, Bethesda, MD USA; GlaxoSmithKline, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); GlaxoSmithKline	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room C629,41 Medlars Dr, Bethesda, MD 20892 USA.	jegreen@nih.gov	Calvo, Alfonso/V-7945-2017	Calvo, Alfonso/0000-0003-4074-4242	NATIONAL CANCER INSTITUTE [Z01BC005740, ZIABC005740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000482] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Calvo A, 2002, CANCER RES, V62, P3934; Calvo A, 2002, INT J CANCER, V101, P224, DOI 10.1002/ijc.10589; Chen YL, 2003, ACTA BOT SIN, V45, P40; Ciardiello F, 2002, EXPERT OPIN INV DRUG, V11, P755; DEV I, 2003, P AM ASSOC CANC RES, V45, P4695; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Heer K, 2001, CLIN CANCER RES, V7, P3491; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Itokawa T, 2002, MOL CANCER THER, V1, P295; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KUMAR R, 2003, P AM ASSOC CANC RES, V45, P39; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lin B, 2002, CANCER RES, V62, P5019; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Nakopoulou L, 2002, HUM PATHOL, V33, P863, DOI 10.1053/hupa.2002.126879; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; Presta LG, 1997, CANCER RES, V57, P4593; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Reich S, 2003, MOL VIS, V9, P210; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shibata MA, 1996, CANCER RES, V56, P2998; Spiekermann K, 2002, EXP HEMATOL, V30, P767, DOI 10.1016/S0301-472X(02)00837-8; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/14728222.7.2.215; Xie B, 1999, BRIT J CANCER, V81, P1335, DOI 10.1038/sj.bjc.6692206; Yokoyama Y, 2000, CANCER RES, V60, P4362; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	38	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					790	800		10.1038/sj.onc.1208221	http://dx.doi.org/10.1038/sj.onc.1208221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592523				2022-12-28	WOS:000226577100005
J	Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT				Kim, Y; McBride, J; Zhang, R; Zhou, XF; Wong, DT			p12(CDK2-AP1) mediates DNA damage responses induced by cisplatin	ONCOGENE			English	Article						p12(CDK2-AP1); DNA-damaging agent; cisplatin; cell cycle; human oral cancer	HUMAN OVARIAN-CANCER; SQUAMOUS-CELL CARCINOMA; NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR GENE; MISMATCH REPAIR; ACQUIRED-RESISTANCE; DRUG ACCUMULATION; GROWTH SUPPRESSOR; CYCLE ARREST; NECK-CANCER	We examined the biological role of p12(CDK2-AP1) in cisplatin-mediated responses by using murine ES p12(CDK2-AP1) knockout clones generated by a targeted disruption of murine p12(CDK2-AP1). Homozygous knockout clones showed an increased cellular proliferation along with an increase in Sand a decrease in G2/M phase populations. Interestingly, ES p12(CDK2-AP1) knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12(CDK2-AP1) short interfering RNA ( siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12(CDK2-AP1) resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12(CDK2-AP1) knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12(CDK2-AP1) plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12(CDK2-AP1) is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.	Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Wong, DT (corresponding author), Univ Calif Los Angeles, Sch Dent, Dent Res Inst, 10833 Le Conte Ave,73-017 CHS, Los Angeles, CA 90095 USA.	dtww@ucla.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014857, T32DE007296] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 14857, T32 DE 007296-08] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aebi S, 1996, CANCER RES, V56, P3087; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Andreadis C, 2003, ORAL ONCOL, V39, P380, DOI 10.1016/S1368-8375(02)00141-0; ANDREWS PA, 1990, CANCER COMMUN-US, V2, P93, DOI 10.3727/095535490820874641; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; Anthoney DA, 1996, CANCER RES, V56, P1374; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Boulikas T, 2004, ONCOL REP, V11, P559; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Cwikla SJ, 2000, J ORAL MAXIL SURG, V58, P406, DOI 10.1016/S0278-2391(00)90924-8; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FOSSA SD, 1995, ONCOLOGY-BASEL, V52, P300; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Higuchi E, 2003, HEAD NECK-J SCI SPEC, V25, P187, DOI 10.1002/hed.10204; Hoffmann TK, 2002, ANTI-CANCER DRUG, V13, P93, DOI 10.1097/00001813-200201000-00011; Hu MG, 2004, CANCER RES, V64, P490, DOI 10.1158/0008-5472.CAN-03-2284; Johnson SW, 1997, CANCER RES, V57, P850; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Khuri FR, 2000, SEMIN ONCOL, V27, P25; Kim ES, 2003, CANC TREAT, V114, P295; Kim Y, 2001, INT J ORAL BIOL  DEC, V2001, P87; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kohno Y, 2002, ORAL ONCOL, V38, P274, DOI 10.1016/S1368-8375(01)00055-0; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Li QD, 2000, ANTICANCER RES, V20, P645; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MASUDA H, 1988, CANCER RES, V48, P5713; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Milas L, 2003, HEAD NECK-J SCI SPEC, V25, P152, DOI 10.1002/hed.10232; MISTRY P, 1993, INT J CANCER, V55, P848, DOI 10.1002/ijc.2910550526; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Mukai M, 2002, ONCOL REP, V9, P839; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; OZOLS RF, 1989, CURR PROB CANCER, V13, P287; OZOLS RF, 1992, CURR PROB CANCER, V16, pU63; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Pendyala L, 1997, CLIN CANCER RES, V3, P793; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; RUBIN E, 1992, CANCER RES, V52, P878; Runger TM, 2000, J INVEST DERMATOL, V114, P34, DOI 10.1046/j.1523-1747.2000.00844.x; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; Song H, 2004, INT J ONCOL, V24, P1017; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Tsutsumi T, 1991, Gan To Kagaku Ryoho, V18, P1003; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148	69	15	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					407	418		10.1038/sj.onc.1208222	http://dx.doi.org/10.1038/sj.onc.1208222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543230				2022-12-28	WOS:000226279700012
J	Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A				Nasr, R; El-Sabban, ME; Karam, JA; Dbaibo, G; Kfoury, Y; Arnulf, B; Lepelletier, Y; Bex, F; de The, H; Hermine, O; Bazarbachi, A			Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma	ONCOGENE			English	Article						HTLV-I; leukemia; lymphoma; treatment; proteasome inhibitors; PS-341	VIRUS TYPE-I; NF-KAPPA-B; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA; INDUCED APOPTOSIS; CYCLE ARREST; TAX PROTEIN; ACTIVATION; GROWTH; INDUCTION	HTLV-I associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis. Using pharmacological concentrations of the proteasome inhibitor PS-341, we demonstrate inhibition of cell proliferation and induction of apoptosis in fresh ATL cells, HTLV-I transformed and HTLV-I-negative malignant T cells, while normal resting or activated T lymphocytes were resistant. Combination of PS-341 and doxorubicin or etoposide resulted in an additive growth inhibition. In HTLV-I-negative malignant cells, PS-341 treatment significantly downregulated the antiapoptotic protein X-IAP and to a lesser extent c-IAP-1 and bcl-XL and resulted in caspase-dependent apoptosis. In HTLV-I transformed cells, the inhibition of the proteasomal degradation of Tax by PS-341 likely explains the relative protection of HTLV-I infected cells against caspase-dependent apoptosis. PS-341 treatment of these cells stabilized IkappaBalpha, IkappaBbeta, IkappaBepsilon, p21, p27 and p53 proteins and selectively inhibited Rel-A DNA binding NF-kappaB complexes. In both HTLV-I-positive and -negative cells, PS-341 treatment induced ceramide accumulation that correlated with apoptosis. We conclude that PS-341 affects multiple pathways critical for the survival of HTLV-I-positive and -negative malignant T cells supporting a potential therapeutic role for PS-341 in both ATL and HTLV-I-negative T-cell lymphomas, whether alone or in combination with chemotherapy.	Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Human Morphol, Beirut, Lebanon; Amer Univ Beirut, Fac Med, Dept Pediat, Beirut, Lebanon; Hop Necker Enfants Malad, CNRS, UMR 8603, F-75743 Paris 15, France; Hop Necker Enfants Malad, Dept Hematol, F-75743 Paris 15, France; Free Univ Brussels, Dept Mol Biol, Brussels, Belgium; Com Paris Ligue Canc, Lab Associe, CNRS, UPR 9051, Paris, France	American University of Beirut; American University of Beirut; American University of Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS)	Hermine, O (corresponding author), Amer Univ Beirut, Fac Med, Dept Internal Med, POB 113-6044, Beirut, Lebanon.	hermine@necker.fr; bazarbac@aub.edu.lb	Karam, Jose A/A-9006-2009; Dbaibo, Ghassan S./X-2978-2019; Nasr, Rihab/AAF-1606-2020; Hermine, Olivier/Q-7072-2018; lepelletier, yves/AAF-1546-2020	lepelletier, yves/0000-0001-7746-5170; Hermine, Olivier/0000-0003-2574-3874; Bazarbachi, Ali/0000-0002-7171-4997; Nasr, Rihab/0000-0003-1166-4999				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016/S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097/00042560-199600001-00028; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016/S0168-1702(01)00286-6; Bielawska A, 2001, ANAL BIOCHEM, V298, P141, DOI 10.1006/abio.2001.5342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; El-Sabban ME, 2000, BLOOD, V96, P2849; Gatto S, 2003, HAEMATOLOGICA, V88, P853; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Gisselbrecht C, 1998, BLOOD, V92, P76; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056/NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038/sj.thj.6200195; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Huang Y, 2000, CANCER RES, V60, P4426; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002/(SICI)1097-0215(19990812)82:4<599::AID-IJC21>3.0.CO;2-R; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kawakami A, 1999, BLOOD, V94, P3847, DOI 10.1182/blood.V94.11.3847.423a24_3847_3854; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lau A, 1998, BLOOD, V91, P2467, DOI 10.1182/blood.V91.7.2467.2467_2467_2474; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Lomas M, 2002, J GEN VIROL, V83, P641, DOI 10.1099/0022-1317-83-3-641; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mitra-Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood-2003-11-3967; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Tamiya S, 1998, BLOOD, V91, P3935; Tan C, 2002, CANCER RES, V62, P1083; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zar JH., 1999, BIOSTAT ANAL, V663rd	51	70	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					419	430		10.1038/sj.onc.1208212	http://dx.doi.org/10.1038/sj.onc.1208212			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543232				2022-12-28	WOS:000226279700013
J	Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D				Schlosser, I; Holzel, M; Hoffmann, R; Burtscher, H; Kohlhuber, F; Schuhmacher, M; Chapman, R; Weidle, UH; Eick, D			Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line	ONCOGENE			English	Article						Myc; serum; target genes; B-cells	GENE-EXPRESSION; GENOMIC TARGETS; GROWTH-FACTOR; LYMPHOCYTES; PROTEIN; FIBROBLASTS; CHROMATIN; CYCLE	Proliferation of higher eukaryotic cells is triggered by the proto-oncogene c-myc (myc), which is induced downstream of a large number of growth factor receptors. Myc, a basic helix-loop-helix leucine zipper transcription factor, transmits growth signals by up- and downregulation of target genes. The importance of Myc in growth control is well established. However, the number of growth control genes requiring Myc as an essential factor for regulation after mitogenic stimulation of cells is not yet clear. Here, we have studied the transcriptional programme of a human B-cell line, P493-6, in response to Myc and serum. P493-6 cells do not express the endogenous myc, nor is it induced by serum stimulation. Proliferation of the cells is dependent upon both the expression of a tetracycline-regulated myc gene and serum stimulation. Using DNA microarrays, expression pro. ling was performed following stimulation of cells with serum, with Myc, or with both. We observed serum regulation of > 1000 genes. A number of these genes were synergistically or antagonistically regulated by Myc. Moreover, we identified > 300 Myc-regulated genes that were almost unresponsive to serum. Gene ontology analysis revealed that a high proportion of Myc target genes are involved in ribosome biogenesis and tRNA metabolism. The data support our current notion that Myc is essential for the regulation of a large number of growth-related genes in B cells, and cannot be replaced by other serum-induced factors.	GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Max von Pettenkofer Inst, D-80336 Munich, Germany; Roche Diagnost GmbH, Roche Pharma Res Penzberg, Dept TR ON, D-82372 Penzberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Roche Holding	Eick, D (corresponding author), GSF Res Ctr, Inst Clin Mol Biol & Tumour Genet, Marchioninistr 25, D-81377 Munich, Germany.	eick@gsf.de	Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Newton JS, 1996, BIOCHEM SOC T, V24, pS7, DOI 10.1042/bst024007s; NORVELL A, 1995, J IMMUNOL, V154, P4404; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	25	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					520	524		10.1038/sj.onc.1208198	http://dx.doi.org/10.1038/sj.onc.1208198			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15516975				2022-12-28	WOS:000226279700022
J	Portis, T; Longnecker, R				Portis, T; Longnecker, R			Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway	ONCOGENE			English	Article						EBV; LMP2A; ras; PI3K; akt; apoptosis	MEMBRANE-PROTEIN 2A; REED-STERNBERG CELLS; GENE-TRANSCRIPTION; DEVELOPMENTAL PROGRESSION; IN-VIVO; KINASE; APOPTOSIS; EXPRESSION; 3-KINASE; SIGNALS	Epstein-Barr virus (EBV) establishes a lifelong latent infection in host B cells and is associated with the development of a variety of malignancies. The viral LMP2A protein mediates viral latency by mimicking a constitutively activated B-cell receptor (BCR). In vivo LMP2A provides developmental and survival signals to BCR-negative B cells, allowing them to survive in peripheral lymphoid organs. In this study, we have demonstrated that Ras is constitutively active in peripheral, BCR-negative B cells from LMP2A transgenic mice. Furthermore, increased expression of activated Ras correlated with elevated levels of Bcl-xL expression and a slower migrating, band-shifted form of Bcl-2. B cells from LMP2A transgenic mice were sensitive to apoptosis induction in the presence of specific inhibitors of Ras, phosphatidylinositol 3-kinase (PI3K), and Akt, indicating that LMP2A activates the Ras/PI3K/Akt pathway to mediate B-cell survival. Increased B-cell apoptosis correlated with reduced expression of Bcl-xL, suggesting that this Bcl-2 family member may be involved in apoptosis inhibition mediated by LMP2A. The ability of LMP2A to activate constitutively the Ras pathway, a common event during tumorigenesis, suggests that this viral protein plays an active role in the development of EBV-associated malignancies.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Longnecker, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Ward 6-231,303 E Chicago Ave, Chicago, IL 60611 USA.	r-longnecker@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA073507, R01CA093444, R01CA062234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013127] Funding Source: NIH RePORTER; NCI NIH HHS [CA62234, CA93444, CA73507] Funding Source: Medline; NIDCR NIH HHS [DE13127] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bairey O, 1999, CLIN CANCER RES, V5, P2860; Blank N, 2002, CYTOMETRY, V48, P179, DOI 10.1002/cyto.10127; Brinkmann MM, 2003, J VIROL, V77, P9346, DOI 10.1128/JVI.77.17.9346-9358.2003; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Fang W, 1996, IMMUNITY, V4, P291, DOI 10.1016/S1074-7613(00)80437-9; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuppers R, 2002, ANN ONCOL, V13, P11, DOI 10.1093/annonc/13.S1.11; Longnecker R, 1998, HUMAN TUMOR VIRUSES, P133; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Merchant M, 2001, VIROLOGY, V291, P46, DOI 10.1006/viro.2001.1187; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; Milne CD, 2004, IMMUNOL REV, V197, P75, DOI 10.1111/j.0105-2896.2004.0103.x; Nagaoka H, 2000, J EXP MED, V192, P171, DOI 10.1084/jem.192.2.171; Niedobitek G, 1997, BLOOD, V90, P1664, DOI 10.1182/blood.V90.4.1664.1664_1664_1672; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Portis T, 2003, BLOOD, V102, P4166, DOI 10.1182/blood-2003-04-1018; Portis T, 2003, J VIROL, V77, P105, DOI 10.1128/JVI.77.1.105-114.2003; Portis T, 2002, FRONT BIOSCI-LANDMRK, V7, pD414, DOI 10.2741/portis; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlaifer D, 1996, AM J PATHOL, V149, P177; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shaw AC, 1999, P NATL ACAD SCI USA, V96, P2239, DOI 10.1073/pnas.96.5.2239; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556	56	148	155	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8619	8628		10.1038/sj.onc.1207905	http://dx.doi.org/10.1038/sj.onc.1207905			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15361852				2022-12-28	WOS:000224988800008
J	Silva, J; Chang, K; Hannon, GJ; Rivas, FV				Silva, J; Chang, K; Hannon, GJ; Rivas, FV			RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age	ONCOGENE			English	Article						RNAi; high throughput screening; functional genomics; cancer; apoptosis; synthetic lethality	DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; PROTEIN-KINASE; SCREENS; DESIGN; ART; IDENTIFICATION; MICROARRAYS; GENES	Sequencing of complete genomes has provided researchers with a wealth of information to study genome organization, genetic instability, and polymorphisms, as well as a knowledge of all potentially expressed genes. The identification of all genes encoded in the human genome opens the door for large-scale systematic gene silencing using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs). With the recent development of siRNA and shRNA expression libraries, the application of RNAi technology to assign function to cancer genes and to delineate molecular pathways in which these genes affect in normal and transformed cells, will contribute significantly to the knowledge necessary to develop new and also improve existing cancer therapy.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.edu	Hannon, Gregory/AAB-3568-2019					Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; BASSON ME, 1987, GENETICS, V117, P645; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen Z, 2000, BIOESSAYS, V22, P503, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;503::AID-BIES2&gt;3.0.CO;2-7; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Forster T, 2003, J ENDOCRINOL, V178, P195, DOI 10.1677/joe.0.1780195; GLASS B, 1954, ADV GENET, V6, P95, DOI 10.1016/S0065-2660(08)60128-5; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Harborth J, 2001, J CELL SCI, V114, P4557; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; MINKS MA, 1979, J BIOL CHEM, V254, P180; Montgomery Mary K, 2004, Methods Mol Biol, V265, P3; Mousses S, 2003, GENOME RES, V13, P2341, DOI 10.1101/gr.1478703; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Shuman HA, 2003, NAT REV GENET, V4, P419, DOI 10.1038/nrg1087; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	42	84	101	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8401	8409		10.1038/sj.onc.1208176	http://dx.doi.org/10.1038/sj.onc.1208176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517022				2022-12-28	WOS:000224815900011
J	Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY				Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY			Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats	ONCOGENE			English	Article						esophagus; apoptosis; gene expression analysis; zinc replenishment	CELL-PROLIFERATION; N-NITROSOMETHYLBENZYLAMINE; CANCER; INDUCTION; CARCINOGENESIS; PROGRESSION; METABOLISM; ALCOHOL; DEATH; LINE	Zinc deficiency (ZD) in rats increases esophageal cell proliferation and the incidence of N-nitrosomethylbenzylamine-induced esophageal tumors. Conversely, zinc replenishment (ZR) rapidly induces apoptosis in esophageal epithelia and reverses cancer development. We investigated gene expression changes in ZR versus ZD esophageal epithelia to identify differentially expressed genes associated with the antitumor effect of ZR. Weanling rats were fed a ZD diet for 6 weeks to establish esophageal cell proliferation or a zinc-sufficient (ZS) diet. Then, 10 ZD rats were treated with zinc gluconate intragastrically and switched to ZS diet; the remaining 10 ZD and ZS animals were treated with saline. All animals were killed 26-28 h later. Using cDNA microarrays, real-time polymerase chain reaction amplification and RNA hybridization techniques, we identified novel differentially expressed genes, including a RNA-binding protein with two RNA recognition motifs and a zinc knuckle (ZD7), and a DNA/RNA helicase with a DEAD box (ZD10) with two splice variants, ZD10a and ZD10b. In situ hybridization detected increased mRNA expression of ZD7, ZD10a and ZD10b in ZR esophageal epithelia, which displayed markedly increased occurrence of apoptotic cells, relative to ZD epithelia. Overexpression of ZD7 in human esophageal cancer cells resulted in induction of apoptosis and activation of caspase-3 and -7, activities that were inhibited by caspase-specific inhibitors. In addition, ZD7 mRNA levels and zinc-induced apoptosis in rat squamous carcinoma cells were reduced by specific small interfering ribonucleic acids. Thus, ZR rapidly induces ZD7 and ZD10 expression, which in turn stimulates apoptosis. These results provide the beginnings of a molecular pathway for zinc-induced apoptosis under conditions that reverse esophageal tumor initiation.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Jichi Med Sch, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan	Jefferson University; Jichi Medical University	Fong, LYY (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, 1020 Locust St, Philadelphia, PA 19107 USA.	L_Fong@mail.jci.tju.edu	Furukawa, Yusuke/Y-1342-2018; Young, Richard A/F-6495-2012	Furukawa, Yusuke/0000-0002-7249-6418; Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856; Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [CA56036, CA77738] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel FM, 1988, MOL REPROD DEV; BARCH DH, 1984, CANCER RES, V44, P5629; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Cintorino M, 2001, ANTICANCER RES, V21, P4195; COIA LR, 1994, CURR PROB CANCER, V18, P189; Cousins RJ, 2003, J NUTR, V133, p1521S, DOI 10.1093/jn/133.5.1521S; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Didenko Vladimir V, 2002, Methods Mol Biol, V203, P143; Didenko VV, 1998, AM J PATHOL, V152, P897; Dieck HT, 2003, J NUTR, V133, P1004, DOI 10.1093/jn/133.4.1004; Fong LYY, 1999, CANCER LETT, V143, P63, DOI 10.1016/S0304-3835(99)00191-3; Fong LYY, 2003, CANCER RES, V63, P186; Fong LYY, 2001, JNCI-J NATL CANCER I, V93, P1525, DOI 10.1093/jnci/93.20.1525; Fong LYY, 1996, CARCINOGENESIS, V17, P1841, DOI 10.1093/carcin/17.9.1841; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; Fong LYY, 2000, CANCER RES, V60, P4589; Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132; GABRIAL GN, 1982, J NATL CANCER I, V68, P785; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Ishii H, 2001, CANCER RES, V61, P1578; Kadkol Shrihari, 2003, Methods Mol Biol, V223, P51; Kindermann B, 2004, J NUTR, V134, P57, DOI 10.1093/jn/134.1.57; Lu S H, 1991, IARC Sci Publ, P11; LU SH, 1986, J CELL PHYSIOL, P51; MAGEE PN, 1989, CANCER SURV, V8, P207; Moore JB, 2003, P NATL ACAD SCI USA, V100, P3883, DOI 10.1073/pnas.0330670100; Newberne PM, 1997, PATHOBIOLOGY, V65, P39, DOI 10.1159/000164101; Nodera M, 2001, LIFE SCI, V69, P1639, DOI 10.1016/S0024-3205(01)01252-8; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134; Truong-Tran AQ, 2000, J NUTR, V130, p1459S, DOI 10.1093/jn/130.5.1459S; VANRENSBURG SJ, 1981, J NATL CANCER I, V67, P243; YANG CS, 1980, CANCER RES, V40, P2633	33	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8040	8048		10.1038/sj.onc.1207974	http://dx.doi.org/10.1038/sj.onc.1207974			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361827				2022-12-28	WOS:000224692500002
J	Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C				Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C			Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; cell death; glutathion-S-transferase; mitochondrion; permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY PROTEINS; BENZODIAZEPINE-RECEPTOR; SIGNALING PATHWAY; BAX TRANSLOCATION; OXIDATIVE STRESS; PORE COMPLEX; BH4 DOMAIN	The mitochondrial permeability transition pore complex (PTPC) is involved in the control of the mitochondrial membrane permeabilization during apoptosis, necrosis and autophagy. Indeed, the adenine nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC), two major components of PTPC, are the targets of a variety of proapoptotic inducers. Using co-immunoprecipitation and proteomic analysis, we identified some of the interacting partners of ANT in several normal tissues and human cancer cell lines. During chemotherapy-induced apoptosis, some of these interactions were constant (e g. ANT-VDAC), whereas others changed strongly concomitantly with the dissipation of the mitochondrial transmembrane potential and until nuclear degradation occurred (e.g. Bax, Bcl-2, subunits of the respiratory chain, a subunit of the phosphatase PP2A, phospholipase PLC beta 4 and IP3 receptor). In addition, a glutathione-S-transferase (GST) interacts with ANT in normal tissue, in colon carcinoma cells and in vitro. This interaction is lost during apoptosis induction, suggesting that GST behaves as an endogenous repressor of PTPC and ANT pore opening. Thus, ANT is connected to mitochondrial proteins as well as to proteins from other organelles such as the endoplasmic reticulum forming a dynamic polyprotein complex. Changes within this ANT interactome coordinate the lethal response of cells to apoptosis induction.	Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France; Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; INRA, UR 121, Rech Technol Laitiere Lab, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; INRAE	Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Mignotte, Bernard/A-3499-2009; Kroemer, Guido/AAY-9859-2020; Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Jan, Gwenael/K-6767-2014	Mignotte, Bernard/0000-0002-8512-8518; KROEMER, Guido/0000-0002-9334-4405; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ARMSTRONG JS, 2002, FASEB J, V7, P7; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Bribes E, 2003, IMMUNOL LETT, V85, P13, DOI 10.1016/S0165-2478(02)00177-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dorner A, 1997, MOL CELL BIOCHEM, V174, P261, DOI 10.1023/A:1006825028170; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yin ZM, 2000, CANCER RES, V60, P4053; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	74	78	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8049	8064		10.1038/sj.onc.1208001	http://dx.doi.org/10.1038/sj.onc.1208001			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377997				2022-12-28	WOS:000224692500003
J	Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L				Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L			Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor	ONCOGENE			English	Article						prostate cancer; androgen receptor; PLZF; gene expression	ACID RECEPTOR-ALPHA; DNA-BINDING DOMAIN; HISTONE DEACETYLASE; PROSTATE-CANCER; RAR-ALPHA; NUCLEAR RECEPTORS; PROMYELOCYTIC LEUKEMIA; CELL-LINE; EXPRESSION; ESTROGEN	The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and plays a key role in the development and progression of prostate cancer. Current therapies include the use of antiandrogens aimed at inhibiting the transcriptional activation of AR-regulated genes by AR. Here, we explore a strategy aimed at obtaining silencing of AR-regulated genes, based on the properties of the transcriptional repressor promyelocytic leukamia zinc-finger protein ( PLZF). In order to do this, we have made a fusion protein between PLZF and AR, named PLZF-AR, and show that PLZF-AR is able to bring about silencing of genomically encoded AR-regulated genes and inhibit the androgen-regulated growth of LNCaP prostate cancer cells. Together, our results show that this strategy is able to bring about potent repression of AR-regulated responses and, therefore, could be of value in the development of new therapies for prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England	Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Du Cane Rd, London W12 0NN, England.	simak.ali@imperial.ac.uk; l.buluwela@imperial.ac.uk	Zelent, Arthur/B-3532-2009; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816; Zelent, Arthur/0000-0002-7968-9888; Holmes, David/0000-0002-4560-3572; Davies, Derek/0000-0002-6977-4181				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Blankvoort BMG, 2001, ANAL BIOCHEM, V298, P93, DOI 10.1006/abio.2001.5352; Bramlett KS, 2001, MOL CELL ENDOCRINOL, V183, P19, DOI 10.1016/S0303-7207(01)00636-0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heemers H, 2000, BIOCHEM BIOPH RES CO, V269, P209, DOI 10.1006/bbrc.2000.2262; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsieh ML, 1997, CANCER RES, V57, P2651; HUGGINS C, 1967, CANCER RES, V27, P1925; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LABRIE F, 1986, ENDOCR REV, V7, P67, DOI 10.1210/edrv-7-1-67; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu QY, 1996, CANCER RES, V56, P1155; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MONNE M, 1994, CANCER RES, V54, P6344; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	59	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7561	7570		10.1038/sj.onc.1208030	http://dx.doi.org/10.1038/sj.onc.1208030			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334066				2022-12-28	WOS:000224176500013
J	Veuger, SJ; Curtin, NJ; Smith, GCM; Durkacz, BW				Veuger, SJ; Curtin, NJ; Smith, GCM; Durkacz, BW			Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair	ONCOGENE			English	Article						DNA-dependent protein kinase; poly(ADP-ribose) polymerase-1	DOUBLE-STRAND BREAK; BIOCHEMICAL-CHARACTERIZATION; IONIZING-RADIATION; MAMMALIAN-CELLS; COMPLEX; PARP-1; DAMAGE; RECOMBINATION; ASSOCIATION; SUPPRESSION	DNA-dependent protein kinase (DNA-PK) and poly (ADP-ribose) polymerase-1 (PARP-1) participate in nonhomologous end joining and base excision repair, respectively, and are key determinants of radio- and chemo-resistance. Both PARP-1 and DNA-PK have been identified as therapeutic targets for anticancer drug development. Here we investigate the effects of specific inhibitors on enzyme activities and DNA double-strand break (DSB) repair. The enzyme activities were investigated using purified enzymes and in permeabilized cells. Inhibition, or loss of activity, was compared using potent inhibitors of DNA-PK (NU7026) and PARP-1 (AG14361), and cell lines proficient or deficient for DNA-PK or PARP-1. Inactive DNA-PK suppressed the activity of PARP-1 and vice versa. This was not the consequence of simple substrate competition, since DNA ends were provided in excess. The inhibitory effect of DNA-PK on PARP activity was confirmed in permeabilized cells. Both inhibitors prevented ionizing radiation-induced DSB repair, but only AG14361 prevented single-strand break repair. An increase in DSB levels caused by inhibition of PARP-1 was shown to be caused by a decrease in DSB repair, and not by the formation of additional DSBs. These data point to combined inhibition of PARP-1 and DNA-PK as a powerful strategy for tumor radiosensitization.	Newcastle Univ, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; KuDOS Pharmaceut, Cambridge CB4 4WG, England	Newcastle University - UK; AstraZeneca	Durkacz, BW (corresponding author), Newcastle Univ, No Inst Canc Res, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	b.w.durkacz@newcastle.ac.uk		Curtin, Nicola/0000-0003-1369-1843	NCI NIH HHS [F31 CA260794] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton S, 1999, CARCINOGENESIS, V20, P199, DOI 10.1093/carcin/20.2.199; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dibiase SJ, 2000, CANCER RES, V60, P1245; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FORNACE AJ, 1977, BIOCHIM BIOPHYS ACTA, V477, P343, DOI 10.1016/0005-2787(77)90253-2; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALLDORSSON H, 1978, FEBS LETT, V85, P349, DOI 10.1016/0014-5793(78)80489-X; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505; KOHN KW, 1981, DNA REPAIR LAB MAN B, V2, P379; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Peng YL, 2002, CANCER RES, V62, P6400; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rudat V, 2001, INT J RADIAT BIOL, V77, P303, DOI 10.1080/09553000010009026; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sak A, 2002, CANCER RES, V62, P6621; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Skalitzky DJ, 2003, J MED CHEM, V46, P210, DOI 10.1021/jm0255769; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smulson ME, 1998, CANCER RES, V58, P3495; Susse S, 2004, NUCLEIC ACIDS RES, V32, P669, DOI 10.1093/nar/gkh227; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; Veuger SJ, 2003, CANCER RES, V63, P6008; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491	45	99	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7322	7329		10.1038/sj.onc.1207984	http://dx.doi.org/10.1038/sj.onc.1207984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286704				2022-12-28	WOS:000224021400003
J	Cheng, T				Cheng, T			Cell cycle inhibitors in normal and tumor stem cells	ONCOGENE			English	Review						adult stem cell; hematopoietic stem cell; tumor stem cell; tissue regeneration; self-renewal; cell cycle; cyclin-dependent kinase inhibitor; p21; p27; p18; p16; Rb protein	DEPENDENT KINASE INHIBITORS; STAGE-SPECIFIC REGULATION; GROWTH-FACTOR-BETA; CDK-INHIBITORS; IN-VIVO; PROGENITOR CELLS; SELF-RENEWAL; HEMATOPOIETIC PROGENITORS; TRANSFORMING GROWTH-FACTOR-BETA-1; CORD BLOOD	Emerging data suggest that stem cells may be one of the key elements in normal tissue regeneration and cancer development, although they are not necessarily the same entity in both scenarios. As extensively demonstrated in the hematopoietic system, stem cell repopulation is hierarchically organized and is intrinsically limited by the intracellular cell cycle inhibitors. Their inhibitory effects appear to be highly associated with the differentiation stage in stem/progenitor pools. While this negative regulation is important for maintaining homeostasis, especially at the stem cell level under physiological cues or pathological insults, it constrains the therapeutic use of adult stem cells in vitro and restricts endogenous tissue repair after injury. On the other hand, disruption of cell cycle inhibition may contribute to the formation of the so-called 'tumor stem cells' (TSCs) that are currently hypothesized to be partially responsible for tumorigenesis and recurrence of cancer after conventional therapies. Therefore, understanding how cell cycle inhibitors control stem cells may offer new strategies not only for therapeutic manipulations of normal stem cells but also for novel therapies selectively targeting TSCs.	Univ Pittsburgh, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cheng, T (corresponding author), Hillman Canc Ctr, Res Pavil,Off Suite 2-42E,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	chengt@msx.upmc.edu		Cheng, Tao/0000-0002-5925-2769	NHLBI NIH HHS [HL70561] Funding Source: Medline; NIDDK NIH HHS [DK02761] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002761] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bonfanti L, 2001, CONT NEUROS, P49; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bradford GB, 1997, EXP HEMATOL, V25, P445; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burton PBJ, 1999, DEV BIOL, V216, P659, DOI 10.1006/dbio.1999.9524; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CARDOSO AA, 1993, P NATL ACAD SCI USA, V90, P8707, DOI 10.1073/pnas.90.18.8707; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 2001, BLOOD, V98, P3643, DOI 10.1182/blood.V98.13.3643; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; D'Urso G, 2001, COLD SPRING HARBOR M, P61; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dunnwald M, 2003, J CELL PHYSIOL, V195, P194, DOI 10.1002/jcp.10311; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Gao FB, 1997, CURR BIOL, V7, P152, DOI 10.1016/S0960-9822(06)00060-1; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1991, BLOOD, V78, P1237; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hirabayashi Y, 2002, EXP BIOL MED, V227, P474, DOI 10.1177/153537020222700711; Horner PJ, 2000, J NEUROSCI, V20, P2218; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Karnezis AN, 2001, J CLIN INVEST, V108, P383, DOI 10.1172/JCI11933; KAY HEM, 1965, LANCET, V2, P418; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Legrier ME, 2001, CELL GROWTH DIFFER, V12, P591; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liu Y, 1996, CANCER RES, V56, P31; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marone M, 2000, BRIT J HAEMATOL, V110, P654, DOI 10.1046/j.1365-2141.2000.02227.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POTTEN MLA, 1997, STEM CELLS CELLULAR; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Qiu JH, 2004, J EXP MED, V199, P937, DOI 10.1084/jem.20031385; Quesenberry PJ, 2002, BLOOD, V100, P4266, DOI 10.1182/blood-2002-04-1246; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Roy V, 1999, EXP HEMATOL, V27, P302, DOI 10.1016/S0301-472X(98)00031-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Shen HM, 1999, J VIROL, V73, P728, DOI 10.1128/JVI.73.1.728-737.1999; Sherr CJ, 2000, CANCER RES, V60, P3689; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tong X, 1998, EXP HEMATOL, V26, P684; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; Uchida N, 1997, BLOOD, V90, P4354; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Verfaillie CM, 2002, NAT IMMUNOL, V3, P314, DOI 10.1038/ni0402-314; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yuan YZ, 2003, BLOOD, V102, p855A; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	135	80	90	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7256	7266		10.1038/sj.onc.1207945	http://dx.doi.org/10.1038/sj.onc.1207945			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378085				2022-12-28	WOS:000223998800011
J	Rozier, L; El-Achkar, E; Apiou, F; Debatisse, M				Rozier, L; El-Achkar, E; Apiou, F; Debatisse, M			Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer	ONCOGENE			English	Article						common fragile site; hepatic carcinogenesis; inherited disease, chromosome rearrangement; grid2; aphidicolin	DELTA-2 GLUTAMATE-RECEPTOR; MAMMALIAN GENE AMPLIFICATION; BONE-MARROW CELLS; HEPATOCELLULAR-CARCINOMA; OVARIAN-CANCER; MORTALITY GENE(S); TUMOR PROGRESSION; HUMAN-CHROMOSOMES; POTENTIAL ROLE; BREAST-CANCER	Fragile sites are classified as common or rare depending on their occurrence in the populations. While rare sites are mainly associated with inherited diseases, common sites have been involved in somatic rearrangements found in the chromosomes of cancer cells. Here we study a mouse locus containing the ionotropic glutamate receptor delta 2 (grid2) gene in which spontaneous chromosome rearrangements occur frequently, giving rise to mutant animals in inbred populations. We identify and clone common fragile sites overlapping the mouse grid2 gene and its human ortholog GRID2, lying respectively at bands 6C1 and 4q22 in a 7-Mb-long region of synteny. These results show a third example of orthologous common sites conserved at the molecular level, and reveal an unexpected link between an inherited disease and an aphidicolin-sensitive region. Recurrent deletions of subregions of band 4q22 have been previously described in human hepatocellular carcinomas. This 15-Mb-long region appears precisely centered on the site described here, which strongly suggests that it also plays a specific role in hepatic carcinogenesis.	Inst Curie, CNRS, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Debatisse, M (corresponding author), Inst Curie, CNRS, FRE2584,26 Rue Ulm, F-75248 Paris 05, France.	michelle.debatisse@curie.fr						Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Bryce SD, 2002, NEOPLASIA, V4, P544, DOI 10.1038/sj.neo.7900268; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Callahan G, 2003, ONCOGENE, V22, P590, DOI 10.1038/sj.onc.1206171; CAPOROSSI D, 1995, HUM GENET, V96, P269; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Coquelle A, 2002, ONCOGENE, V21, P7671, DOI 10.1038/sj.onc.1205880; DeJager PL, 1997, GENOME RES, V7, P736, DOI 10.1101/gr.7.7.736; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Denison SR, 2002, GENE CHROMOSOME CANC, V34, P406, DOI 10.1002/gcc.10084; ELDER FFB, 1989, CHROMOSOMA, V97, P459, DOI 10.1007/BF00295030; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Forsyth NR, 2002, ONCOGENE, V21, P5135, DOI 10.1038/sj.onc.1205688; FURUYA T, 1989, CANCER GENET CYTOGEN, V43, P131, DOI 10.1016/0165-4608(89)90136-2; Gericke GS, 1996, AM J MED GENET, V67, P25, DOI 10.1002/(SICI)1096-8628(19960216)67:1<25::AID-AJMG4>3.0.CO;2-R; Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462; Glover TW, 1998, CANCER RES, V58, P3409; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; HSU YY, 2002, J BIOL CHEM, V5, P5; Hu W, 1998, GENOMICS, V47, P143, DOI 10.1006/geno.1997.5108; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Jones C, 2000, HUM MOL GENET, V9, P1201, DOI 10.1093/hmg/9.8.1201; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Lalouette A, 2001, NEUROSCIENCE, V105, P443, DOI 10.1016/S0306-4522(01)00193-2; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; MITRA AB, 1994, CANCER RES, V54, P4481; MURANO I, 1989, HUM GENET, V84, P71, DOI 10.1007/BF00210675; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nowaczyk MJM, 1997, AM J MED GENET, V69, P400, DOI 10.1002/(SICI)1096-8628(19970414)69:4<400::AID-AJMG12>3.3.CO;2-3; Pekarsky Y, 1998, CANCER RES, V58, P3401; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Simonic I, 1997, AM J MED GENET, V74, P331, DOI 10.1002/(SICI)1096-8628(19970531)74:3<331::AID-AJMG16>3.3.CO;2-1; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Smith DI, 1998, INT J ONCOL, V12, P187; Sutherland GR, 2000, CLIN GENET, V58, P157, DOI 10.1034/j.1399-0004.2000.580301.x; Terada Y, 2001, AM J MED GENET, V103, P176, DOI 10.1002/ajmg.1521; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Wang Y, 2003, EUR J NEUROSCI, V17, P1581, DOI 10.1046/j.1460-9568.2003.02595.x; Wong N, 2000, CLIN CANCER RES, V6, P4000; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1	56	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6872	6880		10.1038/sj.onc.1207809	http://dx.doi.org/10.1038/sj.onc.1207809			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286716				2022-12-28	WOS:000223750700004
J	Calle, EE; Thun, MJ				Calle, EE; Thun, MJ			Obesity and cancer	ONCOGENE			English	Review						anthropometry; body mass index; cancer; epidemiology; obesity; overweight	BODY-MASS-INDEX; GROWTH-FACTOR-I; IGF-BINDING-PROTEINS; EARLY-ONSET OBESITY; BREAST-CANCER; PHYSICAL-ACTIVITY; PROSPECTIVE COHORT; PANCREATIC-CANCER; RISK-FACTORS; DIABETES-MELLITUS	Large prospective studies show a significant association with obesity for several cancers, and the International Agency for Research on Cancer has classified the evidence of a causal link as 'sufficient' for cancers of the colon, female breast (postmenopausal), endometrium, kidney (renal cell), and esophagus (adenocarcinoma). These data, and the rising worldwide trend in obesity, suggest that overeating may be the largest avoidable cause of cancer in nonsmokers. Few obese people are successful in long-term weight reduction, and thus there is little direct evidence regarding the impact of weight reduction on cancer risk. If the correlation between obesity and cancer mortality is entirely causal, we estimate that overweight and obesity now account for one in seven of cancer deaths in men and one in five in women in the US.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Calle, EE (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA.	jcalle@cancer.org						Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Allison DB, 1996, INT J OBESITY, V20, P501; Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385; Austin MA, 1997, OBES RES, V5, P326, DOI 10.1002/j.1550-8528.1997.tb00559.x; Ballard-Barbash Rachel, 1996, American Journal of Clinical Nutrition, V63, p437S, DOI 10.1093/ajcn/63.3.437; BARNESJOSIAH D, 1995, CANCER CAUSE CONTROL, V6, P112, DOI 10.1007/BF00052771; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Bjorntorp P, 1997, LANCET, V350, P423, DOI 10.1016/S0140-6736(97)04503-0; BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673; Boutin P, 2001, BEST PRACT RES CL EN, V15, P391, DOI 10.1053/beem.2001.0153; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; BRUNING PF, 1992, INT J CANCER, V52, P511, DOI 10.1002/ijc.2910520402; Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Calle EE, 1998, CANCER CAUSE CONTROL, V9, P403, DOI 10.1023/A:1008819701485; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Calle EE, 2000, AM J EPIDEMIOL, V151, P550, DOI 10.1093/oxfordjournals.aje.a010242; Chagnon YC, 2003, OBES RES, V11, P313, DOI 10.1038/oby.2003.47; Chow WH, 2000, NEW ENGL J MED, V343, P1305, DOI 10.1056/NEJM200011023431804; Chow WH, 1996, CANCER EPIDEM BIOMAR, V5, P17; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Clement Karine, 2002, Am J Pharmacogenomics, V2, P177, DOI 10.2165/00129785-200202030-00003; Coady SA, 2002, OBES RES, V10, P675, DOI 10.1038/oby.2002.91; COATES RJ, 1990, J NATL CANCER I, V82, P1684, DOI 10.1093/jnci/82.21.1684; CRAMER DW, 1984, OBSTET GYNECOL, V63, P833; Del Giudice ME, 1998, BREAST CANCER RES TR, V47, P111, DOI 10.1023/A:1005831013718; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dunn SE, 1997, CANCER RES, V57, P4667; EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605; FABSITZ RR, 1994, AM J EPIDEMIOL, V140, P711, DOI 10.1093/oxfordjournals.aje.a117319; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fogelholm M, 2000, Obes Rev, V1, P95, DOI 10.1046/j.1467-789x.2000.00016.x; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; Galanis DJ, 1998, CANCER CAUSE CONTROL, V9, P217, DOI 10.1023/A:1008842613331; Gapstur SM, 2000, JAMA-J AM MED ASSOC, V283, P2552, DOI 10.1001/jama.283.19.2552; Giovannucci E, 2000, CANCER EPIDEM BIOMAR, V9, P345; GIOVANNUCCI E, 1995, ANN INTERN MED, V122, P327, DOI 10.7326/0003-4819-122-5-199503010-00002; Giovannucci E, 1996, CANCER CAUSE CONTROL, V7, P253, DOI 10.1007/BF00051301; Giovannucci E, 1997, CANCER EPIDEM BIOMAR, V6, P557; Glenny AM, 1997, INT J OBESITY, V21, P715, DOI 10.1038/sj.ijo.0800495; GREENBERG ER, 1985, BRIT J CANCER, V51, P691, DOI 10.1038/bjc.1985.104; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Henley SJ, 2002, EPIDEMIOLOGY, V13, P268, DOI 10.1097/00001648-200205000-00006; Hill HA, 1996, CANCER CAUSE CONTROL, V7, P19, DOI 10.1007/BF00115635; Holly EA, 1999, AM J EPIDEMIOL, V150, P375, DOI 10.1093/oxfordjournals.aje.a010017; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; Hursting SD, 1997, CANCER RES, V57, P2843; IARC, 2002, IARC HDB CANC PREV W; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; James P T, 2001, Obes Res, V9 Suppl 4, p228S, DOI 10.1038/oby.2001.123; Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481; Kaaks R, 1998, INT J CANCER, V76, P647, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;647::AID-IJC6&gt;3.0.CO;2-Q; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Kaaks R, 1996, CANCER CAUSE CONTROL, V7, P605, DOI 10.1007/BF00051703; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; Komninou D, 2003, EXP BIOL MED, V228, P396, DOI 10.1177/153537020322800410; Kritchevsky D, 1999, TOXICOL SCI, V52, P13, DOI 10.1093/toxsci/52.suppl_1.13; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Kuczmarski RJ, 2000, AM J CLIN NUTR, V72, P1074; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lee AV, 1999, CONT ENDOCRINOL, V11, P187; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lindblad P, 1999, DIABETOLOGIA, V42, P107, DOI 10.1007/s001250051122; Lindsted KD, 1998, INT J OBESITY, V22, P544, DOI 10.1038/sj.ijo.0800623; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Madigan MP, 1998, CANCER CAUSE CONTROL, V9, P199, DOI 10.1023/A:1008838412423; Maehle BO, 1996, BREAST CANCER RES TR, V41, P123, DOI 10.1007/BF01807157; Mann JI, 2000, BRIT J NUTR, V83, pS169; Manousos O, 1999, INT J CANCER, V83, P15, DOI 10.1002/(SICI)1097-0215(19990924)83:1<15::AID-IJC4>3.0.CO;2-Y; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; McGuire MT, 1999, OBES RES, V7, P334, DOI 10.1002/j.1550-8528.1999.tb00416.x; MCLAUGHLIN JK, 1992, INT J CANCER, V52, P562, DOI 10.1002/ijc.2910520411; MCLAUGHLIN JK, 1984, JNCI-J NATL CANCER I, V72, P275; MELLEMGAARD A, 1994, INT J CANCER, V56, P66; Metropolitan Life Foundation New weight standards for men and women, 1959, STAT B, V40, P1; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; Mink PJ, 1996, EPIDEMIOLOGY, V7, P38, DOI 10.1097/00001648-199601000-00008; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; PAPA V, 1993, CANCER RES, V53, P3736; Petrelli JM, 2002, CANCER CAUSE CONTROL, V13, P325, DOI 10.1023/A:1015288615472; PEYRAT JP, 1993, EUR J CANCER, V29A, P492, DOI 10.1016/S0959-8049(05)80137-6; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Potischman N, 1996, JNCI-J NATL CANCER I, V88, P756, DOI 10.1093/jnci/88.11.756; Purdie DM, 2001, CANCER CAUSE CONTROL, V12, P855, DOI 10.1023/A:1012267619561; Reeves MJ, 1996, CANCER, V77, P301, DOI 10.1002/(SICI)1097-0142(19960115)77:2<301::AID-CNCR12>3.0.CO;2-5; Renehan AG, 2000, BRIT J CANCER, V83, P1344, DOI 10.1054/bjoc.2000.1462; Rice T, 1999, GENET EPIDEMIOL, V16, P316; Rodriguez C, 2001, CANCER EPIDEM BIOMAR, V10, P345; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147; SEIDELL JC, 2003, PROGR OBESITY RES, V9, P571; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353; Silverman DT, 1998, JNCI-J NATL CANCER I, V90, P1710, DOI 10.1093/jnci/90.22.1710; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P497, DOI 10.1093/oxfordjournals.aje.a115363; Stephenson GD, 2003, NUTR CANCER, V45, P1, DOI 10.1207/S15327914NC4501_1; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STROM BL, 1995, CANCER, V76, P1747, DOI 10.1002/1097-0142(19951115)76:10<1747::AID-CNCR2820761011>3.0.CO;2-L; STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; Toniolo P, 2000, INT J CANCER, V88, P828, DOI 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8; TrenthamDietz A, 1997, AM J EPIDEMIOL, V145, P1011, DOI 10.1093/oxfordjournals.aje.a009057; TRETLI S, 1990, BRIT J CANCER, V62, P299, DOI 10.1038/bjc.1990.282; Tretli S, 1999, EUR J CANCER PREV, V8, P115, DOI 10.1097/00008469-199904000-00005; *USDA, 2000, NUTR YOUR HLTH DIET; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; Wee CC, 2000, ANN INTERN MED, V132, P697, DOI 10.7326/0003-4819-132-9-200005020-00003; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323; Wolk A, 1996, CANCER CAUSE CONTROL, V7, P5, DOI 10.1007/BF00115634; Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; World Cancer Research Fund, 1997, FOOD NUTR PREV CANC, P371; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; Zatonski WA, 1997, JNCI-J NATL CANCER I, V89, P1132, DOI 10.1093/jnci/89.15.1132; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	140	471	489	3	36	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6365	6378		10.1038/sj.onc.1207751	http://dx.doi.org/10.1038/sj.onc.1207751			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322511				2022-12-28	WOS:000223468800005
J	Farias, EF; Marzan, C; Mira-y-Lopez, R				Farias, EF; Marzan, C; Mira-y-Lopez, R			Cellular retinol-binding protein-I inhibits PI3K/Akt signaling through a retinoic acid receptor-dependent mechanism that regulates p85-p110 heterodimerization	ONCOGENE			English	Article						breast cancer; vitamin A; differentiation; anoikis; SV40; T47D	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; ACTIVATION; KINASE; PROLIFERATION; APOPTOSIS; PATHWAYS	Downregulation of the cellular retinol-binding protein-I (CRBP-I) occurs in breast and other human cancers, but its significance is not well understood. Recently, we showed that restoration of CRBP-I expression in transformed MTSV1-7 breast epithelial cells increased retinoic receptor activity, inhibited anoikis, promoted acinar differentiation and inhibited tumorigenicity, suggesting that CRBP-I suppresses tumor progression. However, the mechanism underlying these effects of CRBP-I was not elucidated. Here we demonstrate, using genetic and pharmacological approaches, that CRBP-I inhibits, in a retinoic acid receptor-dependent manner, the PI3K/Akt survival pathway. Inhibition of PI3K/Akt was necessary and sufficient to explain the antitumor effects of CRBP-I and was mediated by decreased p85 regulatory and p110 catalytic subunit heterodimerization. We present evidence consistent with the idea that this effect is due to CRBP-I inhibition of p85 phosphorylation at Y688. To our knowledge, this is the first demonstration of PI3K regulation at the level of p85-p110 heterodimerization. These findings lead us to hypothesize that CRBP-I downregulation in cancer promotes tumor progression through inhibition of retinoic acid receptor activity and derepression of PI3K/Akt signaling via a novel mechanism.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mira-y-Lopez, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, 1 Gustave Levy Pl,Annenberg Bldg,Room 24-74,Box 1, New York, NY 10029 USA.	eduardo.farias@mssm.edu; rafael.mira@mssm.edu			NCI NIH HHS [R01 CA119018, R24 CA88302, R01 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054273, R24CA088302, R01CA119018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Dirami G, 2004, AM J PHYSIOL-LUNG C, V286, pL249, DOI 10.1152/ajplung.00140.2003; Esteller M, 2002, CANCER RES, V62, P5902; FARIAS EF, 2005, IN PRESS J NATL CANC, V97; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Kuppumbatti YS, 2001, ONCOGENE, V20, P7413, DOI 10.1038/sj.onc.1204749; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Lango M, 2003, CLIN CANCER RES, V9, P4205; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Nilsson A, 1997, INT J BIOCHEM CELL B, V29, P381, DOI 10.1016/S1357-2725(96)00068-4; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	39	42	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1598	1606		10.1038/sj.onc.1208347	http://dx.doi.org/10.1038/sj.onc.1208347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608670				2022-12-28	WOS:000227218200013
J	Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N				Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N			The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin	ONCOGENE			English	Article						AKT; PTEN; I kappa B kinase; nuclear factor-kappa B; beta-catenin; colorectal cancer	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; IKK-BETA; SUPPRESSOR PTEN; NEMO/IKK-GAMMA; COLON-CANCER; P65 SUBUNIT; TRANSCRIPTIONAL ACTIVATION	Our laboratory has delineated that the phosphatidylinositol 30 kinase (PI3K)/AKT/IkappaB kinase (IKK) pathway positively regulates NFkappaB and beta-catenin, both important transcriptional regulators in colorectal cancer (CRC). Therefore, we investigated the effect of inhibiting the PI3K/AKT/IKKalpha pathway in regulating the inappropriate constitutive activation of NFkappaB and beta-catenin in CRC cell lines. SW480 and RKO CRC cell lines demonstrate constitutive activation of AKT as well as both NFkappaB- and beta-catenin-dependent transcription. The constitutive activation of NFkappaB- and beta-catenin-dependent transcription is inhibited by transiently transfecting either kinase dead (KD) IKKalpha, which blocks IKKalpha kinase activity, KD AKT, which blocks AKT activity, or wildtype (WT) PTEN, which inhibits PI3K and AKT activity. The ability of KD IKKalpha, KD AKT or WT PTEN to decrease beta-catenin-dependent transcription is independent of their effects on NFkappaB. Inducible expression of either KD IKKalpha or WT PTEN strongly inhibits both the constitutive NFkappaB- and beta-catenin-dependent promoter and endogenous gene activation. Targeted array-based gene expression analysis of this inducible system reveals that many of the genes downregulated upon inhibition of this pathway are involved in tumor angiogenesis and metastasis. The activation of this pathway and the expression of the three most repressed genes was further analysed in samples of CRC. These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis.	Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sizemore, N (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sizemon@ccf.org			NCI NIH HHS [R01 CA100748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 2003, CR BIOL, V326, P1041, DOI 10.1016/j.crvi.2003.09.007; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 2000, CIRC RES, V86, P251, DOI 10.1161/01.RES.86.3.251; Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006; Easwaran V, 2003, CANCER RES, V63, P3145; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Haefner B, 2002, DRUG DISCOV TODAY, V7, P653, DOI 10.1016/S1359-6446(02)02309-7; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Haraguchi M, 2002, ONCOL REP, V9, P159; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Polakis P, 2000, GENE DEV, V14, P1837; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROTHWARF DM, 1999, SCI STKE, P5; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wigmore SJ, 2001, INT J ONCOL, V18, P467; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	67	149	157	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1021	1031		10.1038/sj.onc.1208296	http://dx.doi.org/10.1038/sj.onc.1208296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592509				2022-12-28	WOS:000226749200008
J	Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M				Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M			Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal	ONCOGENE			English	Article						cyclin D1; cell cycle; message stability; single-cell analysis; mitogenic signaling	SMOOTH-MUSCLE-CELLS; BREAST-CANCER CELLS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RESTRICTION POINT; DEPENDENT KINASES; PROMOTER ACTIVITY; HUMAN FIBROBLASTS; GENE-EXPRESSION	Cyclin D1 is critical for entry into, continuation of, and exit from the cell division cycle. Mitogen stimulation of quiescent cells induces cyclin D1 expression in a transcription-dependent manner. In actively cycling cells, on the other hand, fluctuation of cyclin D1 protein levels through the cell cycle is post-transcriptionally regulated. Cyclin D1 is expressed at low levels during S phase to allow efficient DNA synthesis, and induced to high levels in G2 phase through Ras activity to commit the cells to continuing cell cycle progression. Once induced in G2 phase, cyclin D1 expression becomes Ras independent through the next G1 phase, where it promotes G1/S transition. When mitogenic signaling is abrogated, however, cyclin D1 fails to increase during G2 phase and the cell becomes arrested in the next G1 phase. In this way, the expression levels of cyclin D1 in G2 phase determine the fate of the next cell cycle. Despite its importance of the mechanism of cyclin D1 suppression upon mitogen withdrawal is unknown. Using both quantitative fluorescence microscopy and biochemical analyses, we have found that, upon serum deprivation, cyclin D1 mRNA is downmodulated without any decline in its rate of transcription. Furthermore, cyclin D1 mRNA half-life becomes shorter when serum is removed. These results demonstrate that cyclin D1 message destabilization plays a critical role in cyclin D1 suppression during G2 phase of serum-deprived cultures, and therefore in the withdrawal from the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.	hitomim@ccf.org			NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER; NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gouble A, 2002, CANCER RES, V62, P1489; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Musa NL, 1999, AM J RESP CELL MOL, V20, P352, DOI 10.1165/ajrcmb.20.2.3160; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RIMOKH R, 1994, BLOOD, V83, P3689; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stacey D W, 1981, Methods Enzymol, V79, P76; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winston JT, 1996, ONCOGENE, V12, P127	59	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1032	1042		10.1038/sj.onc.1208299	http://dx.doi.org/10.1038/sj.onc.1208299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592507				2022-12-28	WOS:000226749200009
J	Xi, SC; Gooding, WE; Grandis, JR				Xi, SC; Gooding, WE; Grandis, JR			In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy	ONCOGENE			English	Article						signal transducers and activators of transcription; head and neck cancer; epidermal growth factor receptor; STAT3 decoy; cisplatin	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; TUMOR ANGIOGENESIS; TYROSINE KINASE; SRC ONCOPROTEIN; NECK-CANCER; KAPPA-B	The development of more effective prevention and treatment strategies for solid tumors is limited by an incomplete understanding of the critical growth pathways that are activated in carcinogenesis. Signal transducers and activators of transcription ( STAT) proteins have been linked to transformation and tumor progression. Several approaches have been used to block STAT3 in cancer cells resulting in reduced proliferation and apoptosis. We tested the hypothesis that blocking STAT3 activation using a transcription factor decoy approach would decrease tumor growth and STAT3 target gene expression in vivo. In a xenograft model of squamous cell carcinoma of the head and neck (SCCHN), daily administration of the STAT3 decoy ( 25 mug) resulted in decreased tumor volumes, abrogation of STAT3 activation, and decreased expression of STAT3 target genes ( VEGF, Bcl-xL, and cyclin D1) compared to treatment with a mutant control decoy. Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. These results suggest that a transcription factor decoy approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NCI NIH HHS [R01CA 101840-01, 1 P50 CA097190-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097190, R01CA101840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lim R, 2000, J NEUROCHEM, V74, P596, DOI 10.1046/j.1471-4159.2000.740596.x; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Mayer F, 2003, ANN ONCOL, V14, P825, DOI 10.1093/annonc/mdg242; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rak J, 2000, CANCER RES, V60, P490; Takeda T, 1997, J ENDOCRINOL, V153, pR1, DOI 10.1677/joe.0.153R001; Takeuchi S, 1999, MOL BRAIN RES, V74, P208, DOI 10.1016/S0169-328X(99)00298-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	134	148	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					970	979		10.1038/sj.onc.1208316	http://dx.doi.org/10.1038/sj.onc.1208316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592503	Bronze			2022-12-28	WOS:000226749200003
J	Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N				Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N			Characterization of VIK-1: a new Vav-interacting Kruppel-like protein	ONCOGENE			English	Article						Vav-1 proto-oncogene; Kruppel genes; cell-cycle control	ZINC-FINGER PROTEINS; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; BINDING PROTEINS; CELLS; GENE; RECEPTOR; DOMAINS; RNA; ASSOCIATION	Binding partners of the Src homology domains of Vav-1 were characterized by a two-hybrid screening of a Jurkat cell cDNA library. One of the isolated clones encoded a new protein named VIK that belongs to the Kruppel-like zinc-finger gene family. Genome mapping showed that a single gene positioned at chromosome 7q22.1 generated three possible isoforms containing alternative domains such as proline-rich and Kruppel-associated box A or B repressor domains. The isolated isoform, VIK-1, did not contain such motifs but presented six tandemly arranged zinc-fingers and consensus Kruppel H-C links. VIK-1 interacted both with Vav-1 and cyclin-dependent kinase 4 through two independent domains and corresponded to a Vav C-Src homology domain (SH)3 partner able to shuttle between the nucleus and the cytoplasm exhibiting functional nuclear addressing and export sequences. The results indicated a restricted expression of the protein during the G1 phase and its overexpression resulted in an inhibition of the cell-cycle progression that was reversed in the presence of Vav 1. Thus, this ubiquitous factor provides a first link between Vav-1 and the cell-cycle machinery.	Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, Batiment G Roussy,27 Rue Faubourg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr	Varin-Blank, Nadine/G-4396-2013; Romero, Francisco/K-2101-2014	Romero, Francisco/0000-0002-9588-6881; VARIN-BLANK, Nadine/0000-0003-2769-018X				Bertagnolo V, 1998, FEBS LETT, V441, P480, DOI 10.1016/S0014-5793(98)01593-2; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Millot GA, 2002, J CELL SCI, V115, P2329; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PANDYA K, 2002, J BIOL CHEM, V13, P13; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	12	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					28	38		10.1038/sj.onc.1208043	http://dx.doi.org/10.1038/sj.onc.1208043			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558030				2022-12-28	WOS:000226125800005
J	Li, C; Lin, MH; Liu, JW				Li, C; Lin, MH; Liu, JW			Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis	ONCOGENE			English	Article						p53; PRC1; ptsp53; cell cycle; cytokinesis; transcriptional regulation	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE ARREST; TRANSCRIPTIONAL REGULATION; GROWTH ARREST; BINDING; PROTEIN; INHIBITION; MECHANISMS; SENESCENCE	Our previous studies conducted in MCF7-ptsp53 cells have demonstrated that overexpression of the wild-type (wt) p53 at permissive temperature 32degreesC leads to growth arrest at the G2/M phase of the cell cycle. To identify novel p53-regulated genes that are responsible for the p53-induced G2/M arrest, we conducted cDNA microarray analyses. The array results indicated that the mRNA level of protein regulator of cytokinesis (PRC1) was significantly decreased when the p53 transactivation activity was turned on, suggesting that PRC1 transcription could be downregulated by p53. In this study, we have extensively examined the functional role of p53 in the regulation of PRC1, a cell cycle protein that plays important roles during cytokinesis. We demonstrate that increased expression of the wt p53 either by exogenous transfection or chemical induction results in reduced mRNA and protein expression of PRC1 in HCT116 p53(+/+), HCT116 p53(-/-), MCF-7, T47D, and HeLa cells. Importantly, we show that the decreased PRC1 expression is accompanied by the appearance of binucleated cells, indicating the process of cell division after mitosis being inhibited. By isolation and characterization of a 3 kb genomic fragment containing the 5'-flanking region and part of exon 1 of PRC1 gene, we demonstrate that p53 directly suppresses PRC1 gene transcription. We further locate the p53-responsive sequence to the proximal promoter region -214 to -163, relative to the transcriptional start site. The in vivo interaction of p53 with PRC1 gene promoter is further demonstrated by chromatin immunoprecipitation assay. Taken together, these new findings suggest that p53 may have important roles in the regulation of cytokinesis through controlling the transcription of PRC1.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; CHENG KC, 1993, ADV CANCER RES, V60, P121; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Dubrez L, 2001, GENE THER, V8, P1705, DOI 10.1038/sj.gt.3301592; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Harris LC, 1996, CANCER RES, V56, P2029; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li C, 2003, BREAST CANCER RES TR, V80, P23, DOI 10.1023/A:1024483017549; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Nakamura S, 2002, ONCOGENE, V21, P2102, DOI 10.1038/sj.onc.1205251; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wesierska-Gadek J, 2000, J CELL BIOCHEM, V80, P85; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; YIN XY, 2001, CANCER RES, V61, P6493	35	48	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9336	9347		10.1038/sj.onc.1208114	http://dx.doi.org/10.1038/sj.onc.1208114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531928				2022-12-28	WOS:000225764100005
J	Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB				Takada, Y; Bhardwaj, A; Potdar, P; Aggarwal, BB			Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappa B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation	ONCOGENE			English	Article						NSAID; NF-kappa B; I kappa B alpha; COX-2; cyclin D1; proliferation	NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RANDOMIZED-TRIAL; PHORBOL ESTER; IN-VITRO; ASPIRIN; KINASE	Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin have been shown to suppress transcription factor NF-kappaB, which controls the expression of genes such as cyclooxygenase (COX)-2 and cyclin D1, leading to inhibition of proliferation of tumor cells. There is no systematic study as to how these drugs differ in their ability to suppress NF-kappaB activation and NF-kappaB-regulated gene expression or cell proliferation. In the present study, we investigated the effect of almost a dozen different commonly used NSAIDs on tumor necrosis factor (TNF)-induced NF-kappaB activation and NF-kappaB-regulated gene products, and on cell proliferation. Dexamethasone, an anti-inflammatory steroid, was included for comparison with NSAIDs. As indicated by DNA binding, none of the drugs alone activated NF-kappaB. All compounds inhibited TNF-induced NF-kappaB activation, but with highly variable efficacy. The 50% inhibitory concentration required was 5.67, 3.49, 3.03, 1.25, 0.94, 0.60, 0.38, 0.084, 0.043, 0.027, 0.024, and 0.010 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. All drugs inhibited IkappaBalpha kinase and suppressed IkappaBalpha degradation and NF-kappaB-regulated reporter gene expression. They also suppressed NF-kappaB-regulated COX-2 and cyclin D1 protein expression in a dose-dependent manner. All compounds inhibited the proliferation of tumor cells, with 50% inhibitory concentrations of 6.09, 1.12, 0.65, 0.49, 1.01, 0.19, 0.36, 0.012, 0.016, 0.047, 0.013, and 0.008 mM for aspirin, ibuprofen, sulindac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celecoxib, and tamoxifen, respectively. Overall these results indicate that aspirin and ibuprofen are least potent, while resveratrol, curcumin, celecoxib, and tamoxifen are the most potent anti-inflammatory and antiproliferative agents of those we studied.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Botting JH, 1999, DRUG TODAY, V35, P225, DOI 10.1358/dot.1999.35.4-5.552199; Bryant CE, 2003, AM J VET RES, V64, P211, DOI 10.2460/ajvr.2003.64.211; Callejas NA, 2002, HEPATOLOGY, V35, P341, DOI 10.1053/jhep.2002.31163; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Arriba AF, 1999, MOL PHARMACOL, V55, P753; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giercksky KE, 2001, BEST PRACT RES CL GA, V15, P821, DOI 10.1053/bega.2001.0237; Goel A, 2003, CLIN CANCER RES, V9, P383; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; Hinz M, 1999, MOL CELL BIOL, V19, P2690; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jack DB, 1997, LANCET, V350, P437, DOI 10.1016/S0140-6736(97)07087-6; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kisley LR, 2002, CARCINOGENESIS, V23, P1653, DOI 10.1093/carcin/23.10.1653; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Moysich KB, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-31; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; O'Neill EA, 1998, NATURE, V396, P15, DOI 10.1038/23810; ROTH GJ, 1994, BLOOD, V83, P885; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Scheuren N, 1998, BRIT J PHARMACOL, V123, P645, DOI 10.1038/sj.bjp.0701652; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Williams CS, 2000, CANCER RES, V60, P6045; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	47	245	257	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9247	9258		10.1038/sj.onc.1208169	http://dx.doi.org/10.1038/sj.onc.1208169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489888				2022-12-28	WOS:000225638000010
J	Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K				Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K			Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells	ONCOGENE			English	Article						DNA methylation; chromatin; gene expression	CPG ISLAND HYPERMETHYLATION; GENE-EXPRESSION; DNA METHYLATION; TUMOR-CELLS; HISTONE MODIFICATIONS; GOOD PROGNOSIS; PROMOTER-IV; LARGE-BOWEL; CARCINOMAS; PROTEIN	Tightly regulated at the level of transcription, expression of MHC class II molecules varies significantly among gastrointestinal cancers. High levels of MHC class II expression are often associated with a better prognosis, which is indicative of the involvement of CD4(+) lymphocytes in tumor suppression, but the molecular mechanism by which MHC class II expression is regulated remains unclear. In the present study, we investigated the expression of one inducible MHC class II molecule, HLA-DR, and its coactivators in a panel of colorectal and gastric cancer cell lines. Interferon-gamma induced expression of HLA-DR in 14 of 20 cell lines tested; the remaining six cell lines did not express HLA-DR. Analysis of the expression of transcription factors and coactivators associated with HLA-DR revealed that the loss of CIITA expression was closely associated with the absence of HLA-DR induction. Moreover, DNA methylation of the 50 CpG island of CIITA-PIV was detected in all cancer cells that lacked CIITA. The methylation and resultant silencing of CIITA-PIV depended on the activities of two DNA methyltransferases, DNMT1 and DNMT3B, and their genetic inactivation restored CIITA-PIV expression. It thus appears that CIITA methylation is a key mechanism that enables some gastrointestinal cancer cells to escape immune surveillance.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Sapporo, Hokkaido 0608543, Japan; PRESTO JST, Kawaguchi 3320012, Japan; Sapporo Med Univ, Dept Pathol, Sapporo, Hokkaido 0608556, Japan; Saga Med Sch, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Yamaguchi Univ, Sch Med, Dept Clin Lab Sci, Yamaguchi 7558505, Japan; Keiyukai Sapporo Hosp, Sapporo, Hokkaido 0030027, Japan	Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Sapporo Medical University; Saga University; Nagoya University; National Cancer Center - Japan; Yamaguchi University	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	mtoyota@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554; Kanaseki, Takayuki/0000-0001-7294-6880				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANDERSEN SN, 1993, BRIT J CANCER, V68, P80, DOI 10.1038/bjc.1993.290; Armstrong TD, 1998, J IMMUNOL, V160, P661; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054; Fahrner JA, 2002, CANCER RES, V62, P7213; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAKLAMANIS L, 1992, CANCER SURV, V13, P155; Kanaseki T, 2003, J IMMUNOL, V170, P4980, DOI 10.4049/jimmunol.170.10.4980; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Liang GN, 2000, CANCER RES, V60, P4907; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MCDOUGALL CJ, 1990, CANCER RES, V50, P8023; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Nguyen CT, 2002, CANCER RES, V62, P6456; Ossendorp F, 2000, IMMUNOL LETT, V74, P75, DOI 10.1016/S0165-2478(00)00252-2; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sengupta PK, 2003, CANCER RES, V63, P1789; Suzuki H, 2000, CANCER RES, V60, P4353; Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; van den Elsen PJ, 2001, J REPROD IMMUNOL, V52, P129, DOI 10.1016/S0165-0378(01)00115-2; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8	39	84	92	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8876	8886		10.1038/sj.onc.1208144	http://dx.doi.org/10.1038/sj.onc.1208144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467734				2022-12-28	WOS:000225354600003
J	Esufali, S; Bapat, B				Esufali, S; Bapat, B			Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation	ONCOGENE			English	Article						Rac1; beta-catenin; TCF-mediated transcription; Wnt signaling; PBR	ADENOMATOUS POLYPOSIS-COLI; FACTOR-KAPPA-B; RHO-GTPASES; CARCINOMA-CELLS; CYCLIN D1; PROTEIN; CANCER; CDC42; TCF; ADHESION	Aberrant activation of the Wnt pathway is observed in numerous cancers, and is particularly important in colon cancer. We demonstrate that Rac1 GTPase can significantly increase the signaling activity of beta-catenin in cells with inherent dysregulation of the canonical Wnt signaling pathway. Expression of dominant-negative (N17)Rac1 mutant in colon cancer cells caused a marked inhibition of Wnt signaling, as determined by the TCF/LEF-responsive (TOPFLASH) transcription assay. Expression of a constitutively active (V12)Rac1 mutant caused up to 40-fold induction from the TOPFLASH promoter, and this was dependent on the presence of stabilized beta-catenin. This induction was completely blocked by the expression of dominant-negative TCF-4, suggesting that beta-catenin and TCF-4 complex formation is required for Rac1-mediated transcription. Furthermore, we show that Cyclin D1, an important biological Wnt target gene, is regulated by Rac1 in a beta-catenin/TCF-dependent manner. We observed that Rac1 co-immunoprecipitates with beta-catenin and TCF-4 only in its active GTP-bound form. Both cell fractionation studies and fluorescence microscopy indicate that overexpression of V12Rac1 results in increased cytosolic and nuclear expression of beta-catenin. Interestingly, mutation of the polybasic region of Rac1, which prevents its nuclear localization, also caused an appreciable decrease in nuclear localization of beta-catenin, and effectively abolished its beta-catenin-dependent transcription co-activator function. Taken together, our data demonstrate a novel mechanism of Wnt pathway regulation whereby activation of Rac1 amplifies the signaling activity of stabilized/mutated beta-catenin by promoting its accumulation in the nucleus, and synergizing with beta-catenin to augment TCF/LEF-dependent gene transcription.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Bapat, B (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, 9th Floor,Room 992B,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	bapat@mshri.on.ca	Bapat, Bharati/B-5839-2014					Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8260	8271		10.1038/sj.onc.1208007	http://dx.doi.org/10.1038/sj.onc.1208007			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15377999				2022-12-28	WOS:000224749500008
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC			Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action	ONCOGENE			English	Article						choline kinase; drug design; MN58b; apoptosis; cell cycle arrest; phospholipid metabolism	HAMSTER OVARY CELLS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; CDP-CHOLINE; GLUTATHIONE-PEROXIDASE; INDUCED APOPTOSIS; IN-VIVO; PHOSPHATIDYLETHANOLAMINE	Choline kinase (ChoK, E. C. 2.7.1.32) is involved in the synthesis of phosphatidylcholine ( PC), and has been found to be increased in human tumors and tumor-derived cell lines. Furthermore, ChoK inhibitors have been reported to show a potent and selective antitumoral activity both in vitro and in vivo. Here, we provide the basis for a rational understanding of the antitumoral activity of ChoK inhibitors. In normal cells, blockage of de novo phosphorylcholine (PCho) synthesis by inhibition of ChoK promotes the dephosphorylation of pRb, resulting in a reversible cell cycle arrest at G0/G1 phase. In contrast, ChoK inhibition in tumor cells renders cells unable to arrest in G0/G1 as manifested by a lack of pRb dephosphorylation. Furthermore, tumor cells specifically suffer a drastic wobble in the metabolism of main membrane lipids PC and sphingomyelin (SM). This lipid disruption results in the enlargement of the intracellular levels of ceramides. As a consequence, normal cells remain unaffected, but tumor cells are promoted to apoptosis. Thus, we provide in this study the rationale for the potential clinical use of ChoK inhibitors.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brindley DN, 1996, BIOCHEM CELL BIOL, V74, P469, DOI 10.1139/o96-051; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DEMOLINA AR, IN PRESS CANC RES; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; Fernandez-Tome MD, 2002, BBA-MOL CELL BIOL L, V1583, P185, DOI 10.1016/S1388-1981(02)00208-1; Finney RE, 2000, CANCER RES, V60, P5204; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1998, J IMMUNOL, V160, P3528; Foster DA, 2003, MOL CANCER RES, V1, P789; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; Hundertmark S, 1999, HORM METAB RES, V31, P8, DOI 10.1055/s-2007-978688; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; KUGE O, 1986, J BIOL CHEM, V261, P5795; Lacal J C, 2001, IDrugs, V4, P419; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MAN AS, 1994, LIPIDS, V29, P15, DOI 10.1007/BF02537085; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; RUIZRUIZ CAL, 2002, BIOCHEM J, P825; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sillence DJ, 1998, BIOCHEM J, V331, P251, DOI 10.1042/bj3310251; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Wang XD, 2001, GENE DEV, V15, P2922; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	66	70	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8247	8259		10.1038/sj.onc.1208045	http://dx.doi.org/10.1038/sj.onc.1208045			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378008				2022-12-28	WOS:000224749500007
J	Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL				Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL			A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function	ONCOGENE			English	Article						Kruppel-like; c-Jun; proliferation; TPA/ionomycin	TUMOR-SUPPRESSOR GENE; PROMOTER-BINDING PROTEIN; ZINC-FINGER PROTEIN; CELL-GROWTH; HA-RAS; ACTIVATION; EXPRESSION; KINASE; SP1; PROGRESSION	Kruppel-like transcription factors (KLFs) represent one of the most diverse set of regulators in vertebrate organisms. KLF family members are involved in cell proliferation and differentiation control in normal as well as in pathological situations. Here, we demonstrate that KLF6 behaves as a functional antagonist of the c-Jun proto-oncoprotein. Thus, KLF6 overexpression downregulated c-Jun-dependent transcription and a physical interaction between c-Jun and KLF6 was detected. Moreover, cell proliferation induced by c-Jun was significantly decreased by KLF6. The inhibition of c-Jun functions correlates directly with c-Jun protein degradation induced by KLF6. We also show that all KLF6 effects on c-Jun were largely dependent on phorbol ester (TPA/ionomycin) extracellular stimulation, which enhanced KLF6 nuclear translocation and transcriptional activity and modified its phosphorylation status. Our data are consistent with a novel mechanism of KLF6's role as an inhibitor of cell proliferation by counteracting the function of the c-Jun proto-oncoprotein involving enhanced c-Jun degradation by the proteasome-dependent pathway, and further reinforces KLF6 as a potential tumor suppressor gene product.	Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, RA-5016 Cordoba, Argentina; Univ Strasbourg, Ecole Super Biotechnol Strasbourg, Strasbourg, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bocco, JL (corresponding author), Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, Haya Torre & Medina Allende,Ciudad Univ, RA-5016 Cordoba, Argentina.	jbocco@fcq.unc.edu.ar	CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; BISHOP JM, 1996, MOL ONCOLOGY; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Bocco JL, 1996, ONCOGENE, V12, P1971; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Cook T, 2000, AM J PHYSIOL-GASTR L, V278, pG513, DOI 10.1152/ajpgi.2000.278.4.G513; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laub F, 2001, MECH DEVELOP, V106, P167, DOI 10.1016/S0925-4773(01)00419-1; Lei L, 2001, DEVELOPMENT, V128, P1147; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Muhlbauer KR, 2003, BRIT J CANCER, V89, P687, DOI 10.1038/sj.bjc.6601164; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	44	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8196	8205		10.1038/sj.onc.1208020	http://dx.doi.org/10.1038/sj.onc.1208020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378003				2022-12-28	WOS:000224749500002
J	Wodarz, D				Wodarz, D			Checkpoint genes, ageing, and the development of cancer	ONCOGENE			English	Article						mathematical; computational; p53	STROMAL CELLS; TUMOR-GROWTH; P53; APOPTOSIS; PROGRESSION; SENESCENCE; DEATH; LIFE; MICE	Mathematical models are used to examine the relationship between checkpoint competence, ageing, and the development of cancer. The models take into account the dynamics of healthy tissue, the dynamics of initial tumor growth, and the interactions between healthy tissue and tumor cells. Two types of behavior are found. (i) A reduction of checkpoint competence results in reduced ageing of tissue, but in faster development and progression of tumors. (ii) Reduced checkpoint competence results both in reduced ageing of tissue, and in a reduced incidence of tumors. The tumors which do become established, however, are predicted to progress at an accelerated rate. The models define the conditions under which this counter-intuitive finding is observed. One reason could be the relationship between checkpoint activity and the ability of the tissue environment to exert inhibitory effects on tumor cells. Checkpoints induce senescence in tissue cells, and this compromises their ability to suppress tumor growth. Reduced checkpoint competence leads to reduced tissue senescence, and this results in higher amounts of tumor inhibition. The theoretical work is discussed with respect to data from p53 mutant mice, which show both types of relationships suggested by the models. The models help to identify differences in the experimental protocols which could explain the seemingly contradictory observations.	Univ Calif Irvine, Dept Ecol & Evolut, Irvine, CA 92697 USA; Inst Adv Study, Princeton, NJ 08540 USA	University of California System; University of California Irvine; Institute for Advanced Study - USA	Wodarz, D (corresponding author), Univ Calif Irvine, Dept Ecol & Evolut, Steinhaus Hall, Irvine, CA 92697 USA.	dwodarz@uci.edu						Bayko L, 1998, Angiogenesis, V2, P203, DOI 10.1023/A:1009275307663; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Camplejohn RS, 2003, BRIT J CANCER, V88, P487, DOI 10.1038/sj.bjc.6600767; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Cunha GR, 2002, DIFFERENTIATION, V70, P469, DOI 10.1046/j.1432-0436.2002.700901.x; Donehower LA, 2002, J CELL PHYSIOL, V192, P23, DOI 10.1002/jcp.10104; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Gilhar A, 2004, BRIT J DERMATOL, V150, P56, DOI 10.1111/j.1365-2133.2004.05715.x; Guba M, 2001, CANCER RES, V61, P5575; Hahnfeldt P, 1999, CANCER RES, V59, P4770; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jansen-Durr Pidder, 2002, TheScientificWorldJOURNAL, V2, P943; Kahlem P, 2004, J CLIN INVEST, V113, P169, DOI 10.1172/JCI200420784; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kirkwood TBL, 2002, BIOESSAYS, V24, P577, DOI 10.1002/bies.10111; Komarova NL, 2003, CANCER RES, V63, P6635; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	34	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7799	7809		10.1038/sj.onc.1207833	http://dx.doi.org/10.1038/sj.onc.1207833			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361848				2022-12-28	WOS:000224331600006
J	Warner, JK; Wang, JCY; Hope, KJ; Jin, LQ; Dick, JE				Warner, JK; Wang, JCY; Hope, KJ; Jin, LQ; Dick, JE			Concepts of human leukemic development	ONCOGENE			English	Review						stem cell; NOD/SCID; leukemic stem cell; cancer stem cell; SCID-repopulating cell; SRC; SL-IC	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; ABILITY IN-VITRO; INTERNAL TANDEM DUPLICATION; ACUTE MYELOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; BONE-MARROW-CELLS; PML-RAR-ALPHA; SELF-RENEWAL	Two fundamental problems in cancer research are identification of the normal cell within which cancer initiates and identification of the cell type capable of sustaining the growth of the neoplastic clone. There is overwhelming evidence that virtually all cancers are clonal and represent the progeny of a single cell. What is less clear for most cancers is which cells within the tumor clone possess tumorigenic or 'cancer stem cell' (CSC) properties and are capable of maintaining tumor growth. The concept that only a subpopulation of rare CSC is responsible for maintenance of the neoplasm emerged nearly 50 years ago. Testing of this hypothesis is most advanced for the hematopoietic system due to the establishment of functional in vitro and in vivo assays for stem and progenitor cells at all stages of development. This body of work led to conclusive proof for CSC with the identification and purification of leukemic stem cells capable of repopulating NOD/SCID mice. This review will focus on the historical development of the CSC hypothesis, the mechanisms necessary to subvert normal developmental programs, and the identification of the cell in which these leukemogenic events first occur.	Univ Toronto, Dept Mol Genet & Microbiol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Div Cell & Mol Biol, Univ Hlth Network, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Dick, JE (corresponding author), Univ Toronto, Toronto Gen Res Inst, Univ Hlth Network, Princess Margaret Hosp, Suite 7-700,620 Univ Ave, Toronto, ON M5G 2C1, Canada.	jdick@uhnres.utoronto.ca		Hope, Kristin/0000-0003-1449-4948; Wang, Jean/0000-0001-7543-3917; Dick, John/0000-0002-9527-8317				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albitar M, 2002, BLOOD, V100, P791, DOI 10.1182/blood.V100.3.791; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERNSTEIN ID, 1992, BLOOD, V79, P1811, DOI 10.1182/blood.V79.7.1811.1811; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; BIRG F, 1992, BLOOD, V80, P2584; BLACKSTOCK AM, 1974, LANCET, V2, P1178; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bonnet D, 2001, Rev Clin Exp Hematol, V5, P42, DOI 10.1046/j.1468-0734.2001.00028.x; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; Brendel C, 1999, LEUKEMIA, V13, P1770, DOI 10.1038/sj.leu.2401543; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; BUDEL LM, 1989, BLOOD, V74, P565; BUICK RN, 1979, BLOOD, V54, P95; BUICK RN, 1981, BRIT J CANCER, V44, P349, DOI 10.1038/bjc.1981.191; BUICK RN, 1984, CANCER RES, V44, P4909; Busque L, 1996, BLOOD, V88, P59; CAMPOS L, 1993, BLOOD, V81, P3091; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; CLARKSON B, 1970, CANCER, V25, P1237, DOI 10.1002/1097-0142(197006)25:6<1237::AID-CNCR2820250602>3.0.CO;2-7; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Davis RE, 1998, LEUKEMIA RES, V22, P767, DOI 10.1016/S0145-2126(98)00051-4; Dehmel U, 1996, LEUKEMIA, V10, P261; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dick JE, 2003, NATURE, V423, P231, DOI 10.1038/423231a; Drexler HG, 1999, LEUKEMIA LYMPHOMA, V33, P83, DOI 10.3109/10428199909093728; Edwards RH, 1999, AM J CLIN PATHOL, V112, P819; Engelhardt M, 1997, BLOOD, V90, P182; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; FERRARIS AM, 1985, BLOOD, V66, P342; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FIALKOW PJ, 1981, BLOOD, V57, P1068; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; Gale RE, 1998, LEUKEMIA, V12, P117, DOI 10.1038/sj.leu.2400935; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; GREAVES MF, 1986, BLOOD, V67, P1; GRIFFIN JD, 1986, BLOOD, V68, P1185; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 2002, CANCER RES, V62, P4730; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guan Y, 2000, LEUKEMIA, V14, P2135, DOI 10.1038/sj.leu.2401975; Guenechea G, 2000, MOL THER, V1, P566, DOI 10.1006/mthe.2000.0077; Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood-2003-06-1999; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; HAASE D, 1995, BLOOD, V86, P2906; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Haughn L, 2003, J BIOL CHEM, V278, P25158, DOI 10.1074/jbc.M212849200; Hayflick L, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1180; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; HEPPNER GH, 1984, CANCER RES, V44, P2259; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HOPE K, 2004, NAT IMMUNOL     0530; ICHIKAWA Y, 1969, J CELL PHYSIOL, V73, P43, DOI 10.1002/jcp.1040730107; IKEDA H, 1991, BLOOD, V78, P2962; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Konopleva M, 2000, BLOOD, V95, P3929; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu Y, 2002, P NATL ACAD SCI USA, V99, P3597, DOI 10.1073/pnas.062549199; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MACKILLOP WJ, 1983, J NATL CANCER I, V70, P9; Matas D, 2004, CELL DEATH DIFFER, V11, P458, DOI 10.1038/sj.cdd.4401379; MCCULLOCH EA, 1979, BLOOD CELLS, V5, P261; MCCULLOCH EA, 1983, BLOOD, V62, P1; MEHROTRA B, 1995, BLOOD, V86, P1139; MENDELSOHN ML, 1962, SCIENCE, V135, P213, DOI 10.1126/science.135.3499.213; METCALF D, 1973, BRIT J CANCER, V27, P191, DOI 10.1038/bjc.1973.24; METCALF D, 1969, J NATL CANCER I, V43, P983; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Miller WH, 2002, ONCOGENE, V21, P3496, DOI 10.1038/sj/onc/1205328; MINDEN MD, 1979, BLOOD, V54, P186; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MOORE MAS, 1973, J NATL CANCER I, V50, P603, DOI 10.1093/jnci/50.3.603; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Nakao M, 1996, LEUKEMIA, V10, P1911; NARA N, 1985, BLOOD, V65, P1484, DOI 10.1182/blood.V65.6.1484.bloodjournal6561484; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Pereira DS, 1998, P NATL ACAD SCI USA, V95, P8239, DOI 10.1073/pnas.95.14.8239; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; RAYMAKERS R, 1995, LEUKEMIA, V9, P450; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Rufer N, 2001, BLOOD, V97, P575, DOI 10.1182/blood.V97.2.575; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Schwieger M, 2004, BLOOD, V103, P2744, DOI 10.1182/blood-2003-07-2280; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SINGH S, 2003, CANCER RES, V63, P5281; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Terpstra W, 1996, BLOOD, V88, P1944, DOI 10.1182/blood.V88.6.1944.bloodjournal8861944; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; Testa U, 2002, BLOOD, V100, P2980, DOI 10.1182/blood-2002-03-0852; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; WANTZIN GL, 1977, EUR J CANCER, V13, P647, DOI 10.1016/0014-2964(77)90050-0; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zanjani ED, 1998, EXP HEMATOL, V26, P353; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969	153	172	176	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7164	7177		10.1038/sj.onc.1207933	http://dx.doi.org/10.1038/sj.onc.1207933			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378077				2022-12-28	WOS:000223998800003
J	Takaoka, M; Harada, H; Deramaudt, TB; Oyama, K; Andl, CD; Johnstone, CN; Rhoades, B; Enders, GH; Opitz, OG; Nakagawa, H				Takaoka, M; Harada, H; Deramaudt, TB; Oyama, K; Andl, CD; Johnstone, CN; Rhoades, B; Enders, GH; Opitz, OG; Nakagawa, H			Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction	ONCOGENE			English	Article						Ras; p53; telomerase; esophagus; keratinocytes; senescence	GROWTH-FACTOR RECEPTOR; HUMAN-DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR; ONCOGENIC RAS; PREMATURE SENESCENCE; P53-INDEPENDENT PATHWAY; CELL-PROLIFERATION; P16(INK4A); MOUSE; TRANSFORMATION	Oncogenic Ras induces premature senescence in primary cells. Such an oncogene-induced senescence involves activation of tumor suppressor genes that provide a checkpoint mechanism against malignant transformation. In mouse, the ARF-p53 pathway mediates Ha-Ras(G12V) - induced senescence, and p19(ARF-/-) and p53(-/-) cells undergo transformation upon Ras activation. In addition, mouse cells, unlike human cells, express constitutively active telomerase and have long telomeres. However, it is unclear how Ras activation affects human cells of epithelial origin with p53 mutation and/or telomerase activation. In order to address this question, Ha-Ras(G12V) was expressed ectopically in primary as well as hTERT-immortalized human esophageal keratinocytes stably expressing dominant- negative p53 mutants. In human esophageal keratinocytes, we found that Ha-Ras(G12V) induced senescence regardless of p53 status and telomerase activation. Ras activation resulted in changes of cellular morphology, activation of senescence-associated beta-galactosidase, and suppression of cell proliferation, all coupled with reduction in the hyperphosphorylated form of the retinoblastoma protein (pRb). Furthermore, Ha-Ras(G12V) upregulated p16(INK4a) and downregulated cyclin-dependent kinase Cdk4 in human esophageal keratinocytes. Thus, Ras-mediated senescence may involve distinct mechanisms between human and mouse cells. Inactivation of the pRb pathway may be necessary for Ras to overcome senescence and transform human esophageal epithelial cells.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Freiburg, Dept Med, D-7800 Freiburg, Germany	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Freiburg	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, 638B CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu			NCI NIH HHS [P01-CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306, R21 DK64249] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064249, P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Concin N, 2003, INT J ONCOL, V22, P51; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gadducci A, 2002, EUR J GYNAECOL ONCOL, V23, P390; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Harada H, 2003, MOL CANCER RES, V1, P729; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagawa H, 2003, GASTROINTESTINAL CAN, P241; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Opitz OG, 2002, J CLIN INVEST, V110, P761, DOI 10.1172/JCI200215324; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sigal A, 2000, CANCER RES, V60, P6788; Suliman Y, 2001, CANCER RES, V61, P6467; Suzuki H, 2003, BIOCHEM BIOPH RES CO, V312, P1273, DOI 10.1016/j.bbrc.2003.11.071; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG WC, 1994, CANCER RES, V54, P5584; YANO H, 1991, CANCER, V67, P91, DOI 10.1002/1097-0142(19910101)67:1<91::AID-CNCR2820670118>3.0.CO;2-A; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	52	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6760	6768		10.1038/sj.onc.1207923	http://dx.doi.org/10.1038/sj.onc.1207923			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273725				2022-12-28	WOS:000223653600007
J	Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY				Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY			Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; methyl-CpG-binding protein; non-small-cell lung cancer	HISTONE DEACETYLASE INHIBITOR; BRONCHIAL EPITHELIAL-CELLS; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CPG METHYLATION; RETINOIC ACID; HEPATOCELLULAR-CARCINOMA; CHROMOSOMAL PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION	Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferation of non-small-cell lung cancer (NSCLC) cells by inducing apoptosis, is lost in about half of stage I NSCLC cases. Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in loss of IGFBP-3 expression in NSCLC. We found the IGFBP-3 promoter to be methylated in seven of 13 NSCLC cell lines and in 16 of 23, seven of 9, eight of 11, and six of six tumor specimens from patients with stage I, II, III, and IV NSCLC, respectively. Methylation status correlated with IGFBP-3 mRNA and protein levels in a subset of NSCLC cell lines tested in our study. However, treatment with 5'-aza-2'-deoxycytidine (5'-aza- dC) restored IGFBP-3 expression in four of seven NSCLC cell lines with the methylated promoter, suggesting that multiple mechanisms regulate IGFBP-3 expression in NSCLC. Gel shift and chromatin immunoprecipitation assays showed that methylation of the Sp-1/ Sp-3-binding element in the IGFBP-3 promoter influenced the binding of Sp-1, methyl-CpG-binding protein-2 (MeCP2), and histone deacetylase ( HDAC). A luciferase construct expressing IGFBP-3 promoter in which the Sp1/ Sp-3-binding element was methylated showed significantly reduced transcriptional activity. The reduction in promoter activity was further suppressed by overexpression of MeCP2, which was rescued by 5'-aza- dC. Thus interference with Sp-1 transactivation by MeCP2 may contribute to the transcriptional defect of IGFBP-3 expression in NSCLC cells with methylated promoter.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Texas Childrens Liver Ctr, Houston, TX 77030 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Emory University	Lee, HY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	hlee@mdanderson.org	Mao, Li/C-7570-2011; Khuri, Fadlo R./AAU-4942-2020	Mao, Li/0000-0001-7263-3358; Khuri, Fadlo R./0000-0002-8638-7618; Chang, Yoon Soo/0000-0003-3340-4223; Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [1R01 CA10081-01A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; DEAR C, 2001, J CLIN ENDOCR METAB, V86, P1274; Fowler CA, 2000, INT J CANCER, V88, P448, DOI 10.1002/1097-0215(20001101)88:3<448::AID-IJC18>3.3.CO;2-M; Graessmann M, 1993, EXS, V64, P404; Gray SG, 2000, INT J MOL MED, V5, P33; Gucev ZS, 1996, CANCER RES, V56, P1545; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kim SK, 1997, CANCER RES, V57, P400; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee HY, 2002, CANCER RES, V62, P3530; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nakao M, 2001, BRAIN DEV-JPN, V23, pS174, DOI 10.1016/S0387-7604(01)00348-5; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zi XL, 2000, CANCER RES, V60, P5617	50	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6569	6580		10.1038/sj.onc.1207882	http://dx.doi.org/10.1038/sj.onc.1207882			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247904				2022-12-28	WOS:000223530800004
J	Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A				Mezquita, P; Parghi, SS; Brandvold, KA; Ruddell, A			Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation	ONCOGENE			English	Article						Myc; VEGF; translational control; mammalian target of rapamycin; protein synthesis	ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITES; C-MYC; VASCULAR-PERMEABILITY; FACTOR 4E; PROTEIN-SYNTHESIS; EXPRESSION; PHOSPHORYLATION; ANGIOGENESIS; VIRUS	Deregulated c-myc gene expression is associated with many human and animal cancers. Myc overexpression promotes the growth of blood and lymphatic vessels, which is due in part to induction of growth factors including vascular endothelial growth factor (VEGF). We determined that the P493-6 human B-cell line increases VEGF production 10-fold upon Myc overexpression. Myc overexpression in avian B cells similarly resulted in high level VEGF production. Real-time RT-PCR analyses showed that Myc did not alter the VEGF mRNA content of these cell lines, indicating that a post-transcriptional mechanism regulates VEGF production. VEGF mRNA translation was examined by RT-PCR analysis of monosome and polysome sucrose gradient fractions from Myc-on and Myc-off P493-6 cells. Myc increased VEGF mRNA translation initiation, as VEGF mRNA loading onto polysomes increased 14-fold in Myc-on cells, and the number of ribosomes loaded per VEGF mRNA increased threefold. This translational regulation is specific to VEGF mRNA, as total polysomes show the same sucrose gradient pro. le in Myc-on and Myc-off cells, with no change in the percent ribosomes in polysomes, or in the number of ribosomes per polysomal mRNA. Myc stimulates VEGF production by a rapamycin- and LY294002-sensitive pathway, which does not involve alteration of eIF4E activity.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,POB 19024,MS C2-023, Seattle, WA 98109 USA.	aruddell@fhcrc.org	Mezquita, Pau/AGN-4799-2022	Ruddell, Alanna/0000-0002-0195-5576	NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER; NCI NIH HHS [CA68328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Barr LF, 2000, CANCER RES, V60, P143; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bellamy WT, 1999, CANCER RES, V59, P728; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; HUMPHRIES EH, 1984, CURR TOP MICROBIOL, V113, P47; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Satake S, 1998, BIOL CELL, V90, P161, DOI 10.1016/S0248-4900(98)80337-7; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DR, 1985, J VIROL, V56, P969, DOI 10.1128/JVI.56.3.969-977.1985; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tuxworth WJ, 2004, BIOCHEM J, V378, P73, DOI 10.1042/BJ20031027; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269	52	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					889	901		10.1038/sj.onc.1208251	http://dx.doi.org/10.1038/sj.onc.1208251			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580293	Green Accepted			2022-12-28	WOS:000226577100015
J	Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI				Chang, NS; Schultz, L; Hsu, LJ; Lewis, J; Su, M; Sze, CI			17 beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo	ONCOGENE			English	Article						WWOX; FOR2; WOX1; WOX2; estrogen; androgen	DOMAIN-CONTAINING OXIDOREDUCTASE; WILD-TYPE P53; SHORT-CHAIN DEHYDROGENASES/REDUCTASES; NECROSIS-FACTOR CYTOTOXICITY; ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR; NEUROBLASTOMA-CELLS; EPITHELIAL-CELLS; DELETED REGIONS; HYALURONIC-ACID	Human WWOX gene encodes a proapoptotic WW domain-containing oxidoreductase WOX1 ( also named WWOX, FOR2 or WWOXv1). Apoptotic and stress stimuli activate WOX1 via Tyr33 phosphorylation and nuclear translocation. WOX1 possesses a tetrad NSYK motif in the C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, which may bind estrogen and androgen. Here, we determined that 17beta-estradiol (E-2) activated WOX1, p53 and ERK in COS7 fibroblasts, primary lung epithelial cells, and androgen receptor (AR)-negative prostate DU145 cells, but not in estrogen receptor ( ER)positive breast MCF7 cells. Androgen also activated WOX1 in the AR-negative DU145 cells. These observations suggest that sex hormone-mediated Tyr33 phosphorylation and nuclear translocation of WOX1 is independent of ER and AR. Stress stimuli increase physical binding of p53 with WOX1 in vivo. We determined here that E2 increased the formation of p53/WOX1 complex and their nuclear translocation in COS7 cells; however, nuclear translocation of this complex could not occur in MCF7 cells. By immunohistochemistry, we determined that progression of prostate from normal to hyperplasia, cancerous and metastatic stages positively correlate with upregulation and activation of WOX1 and WOX2 (FOR1/WWOXv2). In contrast, breast cancer development to a premetastatic state is associated with upregulation and Tyr33 phosphorylation of cytosolic WOX1 and WOX2, followed by significant downregulation or absent expression during metastasis. These Tyr33-phosphorylated proteins are mostly located in the mitochondria without translocating to the nuclei, which is comparable to those findings in cultured breast cancer cells. Together, sex steroid hormone-induced activation of WOX1 and WOX2 is independent of ER and AR, and this activation positively correlates with cancerous progression of prostate and breast to a premetastatic state.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, 1 Guthrie Sq, Sayre, PA 18840 USA.	chang_nanshan@guthrie.org	Hsu, Li-Jin/G-7822-2011					Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bednarek AK, 2000, CANCER RES, V60, P2140; BRONZERT DA, 1982, ENDOCRINOLOGY, V110, P2177, DOI 10.1210/endo-110-6-2177; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; Caligo MA, 1998, INT J ONCOL, V13, P177; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Chen ST, 2004, NEUROSCIENCE, V124, P831, DOI 10.1016/j.neuroscience.2003.12.036; CHEN ST, 2004, IN PRESS NEUROSCIENC; COEZY E, 1982, CANCER RES, V42, P317; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Filling C, 2001, MOL CELL ENDOCRINOL, V171, P99, DOI 10.1016/S0303-7207(00)00419-6; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Gangolli EA, 1997, J STEROID BIOCHEM, V61, P1, DOI 10.1016/S0960-0760(97)00003-4; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gartel AL, 2003, ONCOL RES, V13, P405; Gompel A, 2000, STEROIDS, V65, P593, DOI 10.1016/S0039-128X(00)00172-0; Green PS, 1997, J NEUROSCI, V17, P511; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; He XY, 2001, EUR J BIOCHEM, V268, P4899, DOI 10.1046/j.0014-2956.2001.02421.2421.x; ISAACS WB, 1991, CANCER RES, V51, P4716; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Lau KM, 2000, CANCER RES, V60, P3175; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; Linja MJ, 2003, PROSTATE, V55, P180, DOI 10.1002/pros.10242; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Marker PC, 2003, DEV BIOL, V253, P165, DOI 10.1016/S0012-1606(02)00031-3; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Setalo G, 2002, J NEUROBIOL, V50, P1, DOI 10.1002/neu.10000; Song RXD, 2003, APOPTOSIS, V8, P55, DOI 10.1023/A:1021649019025; Sze CI, 2004, J BIOL CHEM, V279, P30498, DOI 10.1074/jbc.M401399200; Toillon RA, 2002, BREAST CANCER RES TR, V71, P269, DOI 10.1023/A:1014422101452; Watanabe A, 2003, CANCER RES, V63, P8629; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; WOLLIN M, 1989, RADIOTHER ONCOL, V15, P285, DOI 10.1016/0167-8140(89)90097-2; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634	50	72	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					714	723		10.1038/sj.onc.1208124	http://dx.doi.org/10.1038/sj.onc.1208124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580310				2022-12-28	WOS:000226420400019
J	Chen, YH; Rodrik, V; Foster, DA				Chen, YH; Rodrik, V; Foster, DA			Alternative phospholipase D/mTOR survival signal in human breast cancer cells	ONCOGENE			English	Article						phospholipase D; survival signals; rapamycin; phosphatidylinositol-3-kinase; Akt; breast cancer	GROWTH-FACTOR RECEPTOR; MAMMALIAN TARGET; V-SRC; DEPENDENT ACTIVATION; TRANSFORMED-CELLS; RAT FIBROBLASTS; RAPAMYCIN; MTOR; PATHWAY; PROTEIN	Cancer cells generate survival signals to suppress default apoptotic programs that protect from cancer. Phosphatidylinositol-3-kinase (PI3K) generates a survival signal that is frequently dysregulated in human cancers. Phospholipase D (PLD) has also been implicated in signals that promote survival. One of the targets of PLD signaling is mTOR ( mammalian target of rapamycin), a critical regulator of cell cycle progression and cell growth. We report here that elevated PLD activity in the MDA-MB-231 human breast cancer cell line generates an mTOR-dependent survival signal that is independent of PI3K. In contrast, MDA-MB-435S breast cancer cells, which have very low levels of PLD activity, are dependent on PI3K for survival signals. The data presented here identify an alternative survival signal that is dependent on PLD and mTOR and is active in a breast cancer cell line where the PI3K survival pathway is not active.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster DA, 2003, MOL CANCER RES, V1, P789; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yamada Y, 2003, J MOL MED, V81, P126, DOI 10.1007/s00109-002-0411-x; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	52	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					672	679		10.1038/sj.onc.1208099	http://dx.doi.org/10.1038/sj.onc.1208099			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580312				2022-12-28	WOS:000226420400014
J	Li, WL; Kessler, P; Williams, BRG				Li, WL; Kessler, P; Williams, BRG			Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia	ONCOGENE			English	Article						Wilms tumor; pro. ling; kidney morphogenesis; anaplasia	WOLF-HIRSCHHORN-SYNDROME; P53 GENE-MUTATIONS; N-MYC; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINE; METANEPHRIC MESENCHYME; ONCOGENE EXPRESSION; EMBRYONIC LETHALITY; MULTIPLE-MYELOMA	Anaplasia (unfavorable histology) is associated with therapy resistance and poor prognosis of Wilms tumor, but the molecular basis for this phenotype is unclear. Here, we used a cDNA array with 9240 clones relevant to cancer biology and/or kidney development to examine the expression profiles of 54 Wilms tumors, five normal kidneys and fetal kidney. By linking genes differentially expressed between fetal kidney and Wilms tumors to kidney morphogenesis, we found that genes expressed at a higher level in Wilms tumors tend to be expressed more in uninduced metanephrogenic mesenchyme or blastema than in their differentiated structures. Conversely, genes expressed at a lower level in Wilms tumors tend to be expressed less in uninduced metanephrogenic mesenchyme or blastema. We also identified 97 clones representing 76 Unigenes or unclustered ESTs that clearly separate anaplastic Wilms tumors from tumors with favorable histology. Genes in this set provide insight into the nature of the abnormal nuclear morphology of anaplastic tumors and may facilitate identification of molecular targets to improve their responsiveness to treatment.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Li, Wenliang/A-1022-2010; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alli E, 2002, CANCER RES, V62, P6864; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Bard JBL, 2002, BIOESSAYS, V24, P72, DOI 10.1002/bies.10024; BARDEESY N, 1995, CANCER RES, V55, P215; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Bates CM, 2000, DEV BIOL, V222, P317, DOI 10.1006/dbio.2000.9716; BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BONADIO JF, 1985, J CLIN ONCOL, V3, P513, DOI 10.1200/JCO.1985.3.4.513; Cabello OA, 2001, MOL BIOL CELL, V12, P3527, DOI 10.1091/mbc.12.11.3527; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cook DM, 1996, ONCOGENE, V13, P1789; DIAZRUIZ C, 1993, CELL TISSUE RES, V271, P3, DOI 10.1007/BF00297536; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; Gow KW, 2002, J PEDIATR SURG, V37, P823, DOI 10.1053/jpsu.2002.32880; Grisaru S, 2000, PEDIATR NEPHROL, V14, P146, DOI 10.1007/s004670050031; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Higinbotham KG, 1998, MOL CARCINOGEN, V23, P53, DOI 10.1002/(SICI)1098-2744(199810)23:2<53::AID-MC1>3.0.CO;2-T; Hippo Y, 2001, CANCER RES, V61, P889; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2002, CANCER RES, V62, P6756; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kang DH, 2001, AM J KIDNEY DIS, V37, P601, DOI 10.1053/ajkd.2001.22087; Karavanov AA, 1998, INT J DEV BIOL, V42, P61; Kim IG, 1997, BBA-MOL CELL RES, V1359, P181, DOI 10.1016/S0167-4889(97)00103-1; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; Kooistra R, 1999, MOL CELL BIOL, V19, P6269; Korkola JE, 2003, CANCER RES, V63, P7167; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; Lahoti C, 1996, AM J PATHOL, V148, P1577; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Malgeri U, 2000, CANCER RES, V60, P4058; MALKIN D, 1994, CANCER RES, V54, P2077; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Niimura F, 1997, AM J PHYSIOL-REG I, V272, pR142, DOI 10.1152/ajpregu.1997.272.1.R142; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1989, VERH DEUT G, V73, P372; Sato N, 2003, CANCER RES, V63, P3735; SAWAI S, 1991, NEW BIOL, V3, P861; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Skacel M, 2002, APPL IMMUNOHISTO M M, V10, P1, DOI 10.1097/00022744-200203000-00001; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; STANTON BR, 1992, BRAIN PATHOL, V2, P71; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stuart RO, 2003, KIDNEY INT, V64, P1997, DOI 10.1046/j.1523-1755.2003.00383.x; Stuart RO, 2001, P NATL ACAD SCI USA, V98, P5649, DOI 10.1073/pnas.091110798; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Tanaka K, 1999, PEDIATR SURG INT, V15, P243, DOI 10.1007/s003830050567; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; WANG YQ, 1995, MECH DEVELOP, V52, P275, DOI 10.1016/0925-4773(95)00408-S; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Zhang Hui-Zhong, 2004, Ai Zheng, V23, P493; Zhang XH, 1999, ANTICANCER RES, V19, P1641; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	86	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					457	468		10.1038/sj.onc.1208228	http://dx.doi.org/10.1038/sj.onc.1208228			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531917				2022-12-28	WOS:000226279700016
J	Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM				Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM			Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma	ONCOGENE			English	Article						colorectal cancer; CGH; microsatellite; chromosomal instability; genetic pathways	COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PTEN MUTATIONS; AMPLIFICATION; INSTABILITY; MALIGNANCIES; MICROARRAYS; PHENOTYPE; DISTINCT; PATHWAY	Microsatellite-stable, near-diploid (MSI-CIN-) colorectal carcinomas have been reported, but it is not clear as to whether these tumours form a discrete group or represent one end of the distribution of MSI-CIN+ cancers. In order to address this question, we screened 23 MSI-CIN- colorectal cancers for gains and losses using array-based comparative genomic hybridization (aCGH) based on large-insert clones at about 1 Mb density. We compared our findings with those from a small set of MSI+CIN+ cancers, and with our reported data from MSI-CIN+ and MSI+CIN- cancers. We found no evidence of any form of genomic instability in MSI-CIN- cancers. At the level of the chromosome arm, the MSI-CIN- cancers had significantly fewer gains and losses than MSI-CIN+ tumours, but more than the MSI+CIN- and MSI+CIN+ lesions. The chromosomal-scale changes found in MSI-CIN- cancers generally involved the same sites as those in MSI-CIN+ tumours, and in both cancer groups, the best predictor of a specific change was the total number of such changes in that tumour. A few chromosomal-scale changes did, however, differ between the MSI-CIN- and MSI-CIN+ pathways. MSI-CIN- cancers showed: low frequencies of gain of 9p and 19p; infrequent loss of 5q and a high frequency of 20p gain. Overall, our data suggested that the MSI-CIN- group is heterogeneous, one type of MSI-CIN- cancer having few (less than or equal to6) chromosomal-scale changes and the other with more (greater than or equal to10) changes resembling MSI-CIN+ cancers. At the level of individual clones, frequent and/or discrete gains or losses were generally located within regions of chromosomal-scale changes in both MSI-CIN- and MSI-CIN+ cancers, and fewer losses and gains were present in MSI-CIN- than MSI-CIN+ tumours. No changes by clone, which were specific to the MSI-CIN- cancers, were found. In addition to indicating differences among the cancer groups, our results also detected over 50 sites (amplifications, potential homozygous deletion and gains or losses which extended over only a few megabases) which might harbour uncharacterized oncogenes or tumour suppressor loci. In conclusion, our data support the suggestion that some MSI-CIN- carcinomas form a qualitatively different group from the other cancer types, and also suggest that the MSI-CIN- group is itself heterogeneous.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; St Marks Hosp, Canc Res UK, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Wellcome Trust Sanger Institute; Cancer Research UK; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	ian.tomlinson@cancer.org.uk		Davison, Ellie/0000-0003-0927-932X				Curtis LJ, 2000, J PATHOL, V192, P440; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giaretti W, 2003, GENE CHROMOSOME CANC, V37, P207, DOI 10.1002/gcc.10203; Gill N, 2002, GASTROENTEROLOGY, V122, P248, DOI 10.1053/gast.2002.30917; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Hawkins NJ, 2001, BRIT J CANCER, V84, P232, DOI 10.1054/bjoc.2000.1554; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; LEACH FS, 1993, CANCER RES, V53, P1986; Lipton L, 2003, CANCER RES, V63, P7595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Pedowitz SD, 2003, GASTROENTEROLOGY, V125, P1915, DOI 10.1053/j.gastro.2003.04.016; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9	20	84	85	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					118	129		10.1038/sj.onc.1208194	http://dx.doi.org/10.1038/sj.onc.1208194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531920				2022-12-28	WOS:000226125800014
J	Fliegauf, M; Stock, M; Berg, T; Lubbert, M				Fliegauf, M; Stock, M; Berg, T; Lubbert, M			Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO	ONCOGENE			English	Article						chromosomal translocation (8;21); acute myeloid leukemia; transcription factor; gene regulation; representational difference analysis	ACUTE MYELOID-LEUKEMIA; REPRESENTATIONAL DIFFERENCE ANALYSIS; CORE-BINDING-FACTOR; T-CELL-RECEPTOR; PROTEIN-PROTEIN INTERACTIONS; STIMULATING FACTOR-RECEPTOR; T(8/21) FUSION PROTEIN; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; DNA-BINDING	The chromosomal translocation t(8;21) fuses the AML1 (RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8 in human acute myeloid leukemias (AMLs), resulting in expression of the chimeric transcription factor AML1/ETO. AML1/ETO-mediated dysregulation of target genes critical for hematopoietic differentiation and proliferation is thought to contribute to the leukemic phenotype. Several mechanisms, including recruitment of histone deacetylases (HDACs) to AML1 target genes, may be responsible for altered gene expression. We used an ecdysone-inducible expression system in the human monoblastic U-937 cell line to isolate genes that were differentially expressed upon induction of AML1/ETO expression. By representational difference analysis (cDNA-RDA), we identified 26 genes whose expression levels were significantly modulated following AML1/ETO induction for 48 h. None of these genes has previously been described as a target of AML1, ETO or AML1/ETO. One gene downregulated by AML1/ETO in vitro, Williams Beuren syndrome critical region 5 (WBSCR5), was expressed in primary t(8;21)-negative AML blasts but not in primary t(8;21)-positive AML blasts, strongly implying a role of this gene in the phenotype of t(8;21)-positive AML. Four upregulated and four downregulated genes were further studied with all-trans-retinoic acid (ATRA), an inducer of differentiation of U-937 cells, and Trichostatin A (TSA), an HDAC inhibitor. Three out of eight genes including WBSCR5 were regulated during ATRA-induced monocytic differentiation of U-937 cells, however, none of them antagonistically, upon both ATRA treatment and AML1/ETO induction. AML1/ETO-associated dysregulation of gene expression was not mediated by a TSA-sensitive mechanism. The identified genes provide a useful model to study the mechanism by which the AML1/ETO fusion protein exerts its function in transcriptional dysregulation in AML. The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study.	Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Depb Biol 3, D-79104 Freiburg, Germany; Univ Freiburg, Depb Biol 1, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	luebbert@mm11.ukl.uni-freiburg.de	Stock, Michael/B-9829-2009; Berg, Tobias/AAT-5094-2021	Berg, Tobias/0000-0003-2668-0449; Stock, Michael/0000-0002-3322-0961				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burger JA, 2000, BLOOD, V96, P2655; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Doyle JL, 2000, CYTOGENET CELL GENET, V90, P285, DOI 10.1159/000056790; ERICKSON P, 1992, BLOOD, V80, P1825; FLIEGAUF M, 2003, HEMAT BLOOD, V41, P28; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Frank R, 1995, ONCOGENE, V11, P2667; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRIMM T, 1980, Z KARDIOL, V69, P168; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Koonpaew S, 2004, J BIOL CHEM, V279, P11229, DOI 10.1074/jbc.M311394200; Kozu T, 1996, J CANCER RES CLIN, V122, P254, DOI 10.1007/BF01209655; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LISITSYN N, 1995, METHOD ENZYMOL, V254, P291; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; RICCIO ML, 1993, DNA SEQUENCE, V4, P129, DOI 10.3109/10425179309020152; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SCHUTTE M, 1995, NUCLEIC ACIDS RES, V23, P4127, DOI 10.1093/nar/23.20.4127; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TKACZYK C, 2004, BLOOD; Uchida H, 1997, J IMMUNOL, V158, P2251; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	71	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9070	9081		10.1038/sj.onc.1208042	http://dx.doi.org/10.1038/sj.onc.1208042			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489901				2022-12-28	WOS:000225492800008
J	Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H				Kappler, R; Bauer, R; Calzada-Wack, J; Rosemann, M; Hemmerlein, B; Hahn, H			Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; patched; p53; microarrays; mouse	ALVEOLAR RHABDOMYOSARCOMA; MYOGENIC DIFFERENTIATION; P53 MUTATIONS; MOUSE MODEL; STEM-CELLS; MICE; EXPRESSION; SARCOMAS; TUMORS; MUSCLE	Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarco-magenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclin-dependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation- and expression-specific therapy.	Univ Gottingen, Inst Human Genet, Gottingen, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Pathol, Neuherberg, Germany; Univ Gottingen, Dept Pathol, D-3400 Gottingen, Germany	University of Gottingen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Hahn, H (corresponding author), Univ Gottingen, Inst Human Genet, Heinrich Duker Weg 12, Gottingen, Germany.	hhahn@gwdg.de	Rosemann, Michael/AAX-8082-2020; Rosemann, Michael/O-2449-2015	Rosemann, Michael/0000-0002-5855-065X; Rosemann, Michael/0000-0002-5855-065X; Calzada, Julia/0000-0003-0816-9305; Kappler, Roland/0000-0002-8581-2803				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Amthor H, 2002, DEV BIOL, V243, P115, DOI 10.1006/dbio.2001.0555; Armand AS, 2003, DEV DYNAM, V227, P256, DOI 10.1002/dvdy.10306; Astolfi A, 2001, GENE, V274, P139, DOI 10.1016/S0378-1119(01)00619-9; Boman F, 1997, PEDIATR PATHOL LAB M, V17, P233, DOI 10.1080/107710497174886; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; Coindre JM, 2003, HISTOPATHOLOGY, V43, P1, DOI 10.1046/j.1365-2559.2003.01639.x; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; Doyle DD, 2003, BIOCHEM BIOPH RES CO, V304, P22, DOI 10.1016/S0006-291X(03)00528-X; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; Kappler R, 2004, INT J ONCOL, V25, P113; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Moretti A, 2002, EUR J CANCER, V38, P2290, DOI 10.1016/S0959-8049(02)00454-9; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Ragazzini P, 2004, HISTOL HISTOPATHOL, V19, P401, DOI 10.14670/HH-19.401; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; STRATTON MR, 1990, ONCOGENE, V5, P1297; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wada MR, 2002, DEVELOPMENT, V129, P2987; Wetmore C, 2001, CANCER RES, V61, P513; WEXLER LH, 1997, RHABDOMYOSARCOMA UND; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	46	29	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8785	8795		10.1038/sj.onc.1208133	http://dx.doi.org/10.1038/sj.onc.1208133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480423				2022-12-28	WOS:000225165100008
J	Demuth, I; Digweed, M; Concannon, P				Demuth, I; Digweed, M; Concannon, P			Human SNM1B is required for normal cellular response to both DNA interstrand crosslink-inducing agents and ionizing radiation	ONCOGENE			English	Article						hSNM1B; DNA doublestrand break; Fanconi anemia; DNA interstrand crosslinks; PSO2; DCLRE1B	FANCONI-ANEMIA GENE; SACCHAROMYCES-CEREVISIAE; POSITIONAL CLONING; GENOME INSTABILITY; MAMMALIAN-CELLS; REPAIR GENE; MITOMYCIN-C; PSO GENES; PATHWAY; PROTEIN	DNA interstrand crosslinks (ICLs) are critical lesions for the mammalian cell since they affect both DNA strands and block transcription and replication. The repair of ICLs in the mammalian cell involves components of different repair pathways such as nucleotide-excision repair and the double-strand break/homologous recombination repair pathways. However, the mechanistic details of mammalian ICL repair have not been fully delineated. We describe here the complete coding sequence and the genomic organization of hSNM1B, one of at least three human homologs of the Saccharomyces cerevisiae PSO2 gene. Depletion of hSNM1B by RNA interference rendered cells hypersensitive to ICL-inducing agents. This requirement for hSNM1B in the cellular response to ICL has been hypothesized before but never experimentally verified. In addition, siRNA knockdown of hSNM1B rendered cells sensitive to ionizing radiation, suggesting the possibility of hSNM1B involvement in homologous recombination repair of double-strand breaks arising as intermediates of ICL repair. Monoubiquitination of FANCD2, a key step in the FANG/BRCA pathway, is not affected in hSNM1B-depleted HeLa cells, indicating that hSNM1B is probably not a part of the Fanconi anemia core complex. Nonetheless, similarities in the phenotype of hSNM1B-depleted cells and cultured cells from patients suffering from Fanconi anemia make hSNM1B a candidate for one of the as yet unidentified Fanconi anemia genes not involved in monoubiquitination of FANCD2.	Benaroya Res Inst, Mol Genet Program, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Humboldt Univ, Inst Humangenet, D-13353 Berlin, Germany	Benaroya Research Institute; University of Washington; University of Washington Seattle; Humboldt University of Berlin	Concannon, P (corresponding author), Benaroya Res Inst, Mol Genet Program, 1201 9th Ave, Seattle, WA 98101 USA.	patcon@benaroyaresearch.org	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523; Concannon, Patrick/0000-0002-5801-1859	NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER; NCI NIH HHS [CA57569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; CASSIER C, 1980, GENETICS, V96, P841; CASSIERCHAUVAT C, 1988, CURR GENET, V13, P37, DOI 10.1007/BF00365754; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Demuth I, 1998, MUTAT RES-DNA REPAIR, V409, P11, DOI 10.1016/S0921-8777(98)00037-8; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Foe J R, 1996, Nat Genet, V14, P488; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatti RA, 2001, ACTA ONCOL, V40, P702, DOI 10.1080/02841860152619115; HENRIQUES JAP, 1980, GENETICS, V95, P273; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; LEVITUS M, 2003, BLOOD, V103, P298; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moynahan ME, 2001, CANCER RES, V61, P4842; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; RICHTER D, 1992, MOL GEN GENET, V231, P194, DOI 10.1007/BF00279791; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711	47	65	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8611	8618		10.1038/sj.onc.1207895	http://dx.doi.org/10.1038/sj.onc.1207895			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467758				2022-12-28	WOS:000224988800007
J	Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK				Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK			Loss of E-cadherin leads to upregulation of NF kappa B activity in malignant melanoma	ONCOGENE			English	Article						melanoma; E-cadherin; p-p38; NF kappa B	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; LOBULAR BREAST CANCERS; CELL-CELL-ADHESION; BETA-CATENIN; EXPRESSION; P38; PATHWAY; GROWTH; GENE	Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here, we show that loss of E-cadherin leads to induction of nuclear factor kappa B (NFkappaB) activity in melanoma cell lines. Melanoma cells show constitutively active NFkappaB, whereas no activity is found in primary melanocytes. After reexpression of E-cadherin in melanoma cells, strong downregulation of NFkappaB activity was found. Consistently, NFkappaB activity was induced in primary human melanocytes after inhibition of E-cadherin activity by functionally blocking anti-E-cadherin antibodies. Interestingly, reexpression of E-cadherin-blocked p38 MAPK activity and the p38 MAPK inhibitors SB203580 and SB202190 almost completely prevented NFkappaB activation in melanoma cells. Furthermore, cytoplasmatic beta-catenin induced p38 and NFkappaB activation in malignant melanoma. To our knowledge, this is the first report suggesting a correlation between E-cadherin and NFkappaB activity in melanocytes and melanoma cells. In summary, we conclude that loss of E-cadherin and cytoplasmatic beta-catenin induces p38-mediated NFkappaB activation, potentially revealing an important mechanism of tumorigenesis in malignant melanomas.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA	University of Regensburg; University of North Carolina; University of North Carolina Chapel Hill	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Li G, 2001, CANCER RES, V61, P3819; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; McNulty SE, 2001, PIGM CELL RES, V14, P456, DOI 10.1034/j.1600-0749.2001.140606.x; Melki JR, 2000, BLOOD, V95, P3208; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Orsulic S, 1999, J CELL SCI, V112, P1237; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Tamura S, 1996, BRIT J SURG, V83, P1608, DOI 10.1002/bjs.1800831138; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Yang JM, 2001, CANCER RES, V61, P4901	41	108	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8509	8519		10.1038/sj.onc.1207831	http://dx.doi.org/10.1038/sj.onc.1207831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378016				2022-12-28	WOS:000224870700011
J	Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D				Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D			Mutant Ras-induced proliferation of human thyroid epithelial cells requires three effector pathways	ONCOGENE			English	Article						Ras; Ral; thyroid; epithelial; signalling; tumour	ADP-RIBOSYLATION FACTOR; ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-D; EXOCYST COMPLEX; TRANSFORMATION; GTPASE; SUFFICIENT; DIFFERENTIATION; STIMULATION; CONTRIBUTE	Ras mutations occur as an early event in many human tumours of epithelial origin, including thyroid. Using primary human thyroid epithelial cells to model tumour initiation by Ras, we have shown previously that activation of both the MAP kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) effector pathways are necessary, but even when activated together are not sufficient, for Ras-induced proliferation. Here, we show that a third effector, RalGEF, is also activated by Ras in these cells, that this activation is necessary for Ras-induced proliferation, and furthermore that in combination with the MAPK and PI3K effectors, it is able to reproduce the proliferative effect of activated Ras. The requirement for three effector pathways indicates a more robust control of cell proliferation in this normal human epithelial cell type than has been displayed in previous similar studies using rodent and human cell lines. Our findings highlight the importance of the appropriate cellular context in models of Ras-induced tumour development.	Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	52	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7839	7845		10.1038/sj.onc.1208085	http://dx.doi.org/10.1038/sj.onc.1208085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361839				2022-12-28	WOS:000224331600009
J	Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G				Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G			Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice	ONCOGENE			English	Article						p53; phosphorylation; mdm2; mdm4; embryogenesis	DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; CRYSTAL-STRUCTURE; MDM4-NULL MICE; GROWTH ARREST; MURINE P53; CELL-DEATH; ACTIVATION	Mdm2 and its homolog Mdm4 inhibit the function of the tumor suppressor p53. Targeted disruption of either mdm2 or mdm4 genes in mice results in embryonic lethality that is completely rescued by concomitant deletion of p53, suggesting that deletion of negative regulators of p53 results in a constitutively active p53. Thus, these mouse models offer a unique in vivo system to assay the functional significance of different p53 modi. cations. Phosphorylation of serine 389 in murine p53 occurs specifically after ultraviolet-light-induced DNA damage, and phosphorylation of this site enhances p53 activity both in vitro and in vivo. Recently, mice with a serine to alanine substitution at serine 389 (p53(S389A)) in the endogenous p53 locus were generated. To examine the in vivo significance of serine 389 phosphorylation during embryogenesis, we crossed these mutant mice to mice lacking mdm2 or mdm4. The p53S389A allele did not alter the embryonic lethality of mdm2 or mdm4. Additional crosses to assay the effect of one p53S389A allele with a p53 null allele also did not rescue the lethal phenotypes. In conclusion, the phenotypes due to loss of mdm2 or mdm4 were not even partially rescued by p53S389A, suggesting that p53S389A is functionally wild type during embryogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; Natl Inst Publ Hlth & Environm, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	University of Texas System; UTMD Anderson Cancer Center; Netherlands National Institute for Public Health & the Environment; Massachusetts Institute of Technology (MIT)	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA.	gglozano@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; BRUINS W, 2004, IN PRESS MOL CELL BI; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Finch RA, 2002, CANCER RES, V62, P3221; FISCELLA M, 1994, ONCOGENE, V9, P3249; Furihata M, 2002, J PATHOL, V197, P82, DOI 10.1002/path.1082; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARVEY M, 1993, ONCOGENE, V8, P2457; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LUNA RMD, 1995, NATURE, V378, P203; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	54	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7644	7650		10.1038/sj.onc.1207793	http://dx.doi.org/10.1038/sj.onc.1207793			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361844				2022-12-28	WOS:000224306700005
J	Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J				Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J			Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms	ONCOGENE			English	Article						Survivin; radiation resistance; primary human glioblastoma	ANTI-APOPTOSIS GENE; MALIGNANT GLIOMA; BRAIN-TUMORS; EXPRESSION; CANCER; PROTEIN; INHIBITOR; PROGNOSIS; PROLIFERATION; NEUROBLASTOMA	The observed radioresistance of human glioblastoma multiforme (GBM) poses a major challenge, which, if overcome, may lead to significant advances in the management of this patient population. There is accumulating evidence from correlative studies that Survivin expression is associated with increased malignant potential of human gliomas. The purpose of this study was to investigate whether Survivin plays a direct role in mediating radiation resistance in primary human glioma cell lines, and, if so, investigating the underlying mechanisms. Our panel of GBM cell lines included two that were relatively radiation resistant (GM20 and GM21) and two that were more radiation sensitive (GM22 and GM23), which demonstrated differential levels of Survivin expression between the two groups. Through the use of adenoviral vectors containing either dominant-negative (pAd-S(T34A)) or wild-type Suvrivin (pAd-S(WT)), we were able to inactivate or overexpress Survivin, respectively. Our findings suggest that Survivin plays a critical role in mediating radiation resistance in primary GBM cells, in part through suppression of apoptotic cell death via a caspase-independent manner. We have identified novel mechanisms by which Survivin may enhance tumor cell survival upon radiation exposure such as regulation of double-strand DNA break repair and tumor cell metabolism, which were most evident in the radiation-resistant cell lines. These differences in Survivin function both in radiation-resistant vs radiation-sensitive cell lines and in the presence vs absence of radiation exposure warrant further investigation and highlight potentially important mechanisms of radiation resistance in these tumors.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA; Univ Giessen, Dept Neurosurg, Giessen, Germany	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Justus Liebig University Giessen	Chakravarti, A (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org	Nestler, Ulf/D-6503-2014; Nestler, Ulf/AHD-3675-2022	Nestler, Ulf/0000-0002-2963-4344; Nestler, Ulf/0000-0002-2963-4344; Malhotra, Rajeev/0000-0003-0120-4630	NCI NIH HHS [KO882163CA] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 2000, BLOOD, V96, P1921; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.3.CO;2-C; Fortugno P, 2002, J CELL SCI, V115, P575; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall E, 2000, RADIOBIOLOGY RADIOLO; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Katoh M, 2003, J NEURO-ONCOL, V64, P71, DOI 10.1007/BF02700022; Kawasaki H, 1998, CANCER RES, V58, P5071; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Lu CD, 1998, CANCER RES, V58, P1808; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MANGIARDI J, 2001, BRAIN TUMORS, P105; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Olie RA, 2000, CANCER RES, V60, P2805; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; TAN EC, 1993, J BIOL CHEM, V268, P27291; Tanaka K, 2000, CLIN CANCER RES, V6, P127; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WESTPHAL M, 1990, CULTURE HUMAN BRAIN, V5; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1	38	176	186	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7494	7506		10.1038/sj.onc.1208049	http://dx.doi.org/10.1038/sj.onc.1208049			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326475				2022-12-28	WOS:000224176500006
J	Haverkos, HW				Haverkos, HW			Viruses, chemicals and co-carcinogenesis	ONCOGENE			English	Article						co-carcinogenesis; oncogenic viruses; chemical carcinogens; cervical cancer; hepatocellular cancer; Kaposi's sarcoma	INVASIVE CERVICAL-CANCER; HERPES-SIMPLEX-VIRUS; HEPATITIS-B-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; HUMAN-PAPILLOMAVIRUS; HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; CIGARETTE-SMOKING; INFECTED WOMEN	The etiology of cancers appears to be complex and multifactorial. Peyton Rous and others demonstrated the process of co-carcinogenesis by exposing rabbits to a virus and tars. Epidemiologists have proposed virus-chemical interactions to cause several cancers. For example, one might propose that the etiology of cervical cancer results from a complex interplay between oncogenic viruses and cervical tar exposures through tar-based vaginal douching, cigarette smoking, and/or long-term cooking over wood-burning stoves in poorly ventilated kitchens. Hepatocellular carcinoma may result from the joint effects of viruses and hepatotoxic chemical carcinogens. Kaposi's sarcoma might happen following reciprocal actions of human herpes virus-8 infection, immunosuppression, and chemical exposures, such as nitrite radicals and alumino-silicates. Use of Koch's postulates will not help one prove or disprove a multifactorial causation of disease; new criteria are needed. Delineating the web of causation may lead to additional strategies for prevention and treatment of several cancers.	Walter Reed Army Med Ctr, Dept Med, Infect Dis Serv, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Haverkos, HW (corresponding author), 5600 Fishers Lane, Rockville, MD 20857 USA.	haverkosh@cder.fda.gov						ARMSTRONG B, 1992, EPIDEMIOLOGY CANC CE, P11; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BEASLEY RP, 1981, LANCET, V2, P1129; BEERS FG, 1973, BRIT J CANCER, V27, P473; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Cannon MJ, 2003, AIDS, V17, P215, DOI 10.1097/00002030-200301240-00012; Carbone M, 2003, ONCOGENE, V22, P5173, DOI 10.1038/sj.onc.1206552; Castle PE, 2002, JNCI-J NATL CANCER I, V94, P1406, DOI 10.1093/jnci/94.18.1406; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Dal Maso L, 2001, EUR J CANCER, V37, P1188, DOI 10.1016/S0959-8049(01)00120-4; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DAY GL, 1994, INT J CANCER, V59, P319, DOI 10.1002/ijc.2910590305; DROTMAN DP, 1995, DERMATOL CLIN, V13, P575, DOI 10.1016/S0733-8635(18)30063-9; DURANREYNALS F, 1957, TEX REP BIOL MED, V15, P306; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; EVANS AS, 1982, YALE J BIOL MED, V55, P193; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Ferrera A, 2000, INT J EPIDEMIOL, V29, P817, DOI 10.1093/ije/29.5.817; FRENKEL N, 1972, P NATL ACAD SCI USA, V69, P3784, DOI 10.1073/pnas.69.12.3784; FRIEDMANKIEN AE, 1989, COLOR ATLAS AIDS; Galloway DA, 2003, LANCET INFECT DIS, V3, P469, DOI 10.1016/S1473-3099(03)00720-5; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GILLISON N, 2003, J NCI MONOGR, V31, P57; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; HAUSEN HZ, 1975, BIOCHIM BIOPHYS ACTA, V417, P25, DOI 10.1016/0304-419X(75)90007-4; Haverkos H, 2000, BIOMED PHARMACOTHER, V54, P54, DOI 10.1016/S0753-3322(00)88642-4; HAVERKOS HW, 1994, ENVIRON HEALTH PERSP, V102, P858, DOI 10.2307/3432118; HAVERKOS HW, 1985, SEX TRANSM DIS, V12, P203, DOI 10.1097/00007435-198510000-00007; Haverkos HW, 1996, BIOMED PHARMACOTHER, V50, P318, DOI 10.1016/0753-3322(96)84834-7; Haverkos HW, 2003, BIOMED PHARMACOTHER, V57, P67, DOI 10.1016/S0753-3322(03)00196-3; HAVERKOS HW, 1982, CA-CANCER J CLIN, V32, P330, DOI 10.3322/canjclin.32.6.330; HAVERKOS HW, 1995, GENETICA, V95, P157, DOI 10.1007/BF01435007; HILDESHEIM A, 1991, INT J CANCER, V49, P335, DOI 10.1002/ijc.2910490304; Hildesheim A, 2001, BRIT J CANCER, V84, P1219, DOI 10.1054/bjoc.2001.1779; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holly EA, 1998, AM J PUBLIC HEALTH, V88, P1767, DOI 10.2105/AJPH.88.12.1767; HUANG MH, 1997, NEW ENGL J MED, V336, P1855; Kew MC, 2002, TOXICOLOGY, V181, P35, DOI 10.1016/S0300-483X(02)00251-2; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LOMBARD HL, 1950, CANCER, V3, P960, DOI 10.1002/1097-0142(1950)3:6<960::AID-CNCR2820030603>3.0.CO;2-G; MARTIN CM, 1961, SCIENCE, V134, P1985, DOI 10.1126/science.134.3494.1985; MENDIS LN, 1981, INT J CANCER, V27, P669, DOI 10.1002/ijc.2910270514; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; MIRVISH SS, 1993, ENVIRON MOL MUTAGEN, V21, P247, DOI 10.1002/em.2850210307; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Osmond DH, 2002, JAMA-J AM MED ASSOC, V287, P221, DOI 10.1001/jama.287.2.221; Papanicolaou GN, 1941, AM J OBSTET GYNECOL, V42, P193; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Prokopczyk B, 1997, J NATL CANCER I, V89, P868, DOI 10.1093/jnci/89.12.868; ROGERS S, 1951, J EXP MED, V93, P459, DOI 10.1084/jem.93.5.459; ROOTBERNSTEIN RS, 1993, RETHINKING AIDS TRAG, P104; Rothman N, 1997, LANCET, V350, P240, DOI 10.1016/S0140-6736(97)02088-6; ROTKIN ID, 1967, AM J PUBLIC HEALTH N, V57, P815, DOI 10.2105/AJPH.57.5.815; Rous P, 1934, J EXP MED, V60, P741, DOI 10.1084/jem.60.6.741; ROUS P, 1965, NATURE, V207, P457, DOI 10.1038/207457a0; Rous P, 1911, J AMER MED ASSOC, V56, P198; Rous P, 1938, J EXP MED, V67, P399, DOI 10.1084/jem.67.3.399; ROWE PC, 1988, JAMA-J AM MED ASSOC, V260, P3167, DOI 10.1001/jama.260.21.3167; ROWSON KE, 1961, NATURE, V191, P893, DOI 10.1038/191893a0; SALAMAN MH, 1964, BRIT MED BULL, V20, P139, DOI 10.1093/oxfordjournals.bmb.a070307; Smith FR, 1931, AM J OBSTET GYNECOL, V21, P18, DOI 10.1016/S0002-9378(31)90837-5; Smith JS, 2002, JNCI-J NATL CANCER I, V94, P1604, DOI 10.1093/jnci/94.21.1604; SOUTHAM CM, 1963, CANCER RES, V23, P1105; Steckley SL, 2003, BIOMED PHARMACOTHER, V57, P78, DOI 10.1016/S0753-3322(02)00342-6; STOKER M, 1963, NATURE, V200, P756, DOI 10.1038/200756a0; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0; TANAKA S, 1962, JNCI-J NATL CANCER I, V29, P711; TANAKA S, 1965, J NATL CANCER I, V34, P441; Tran-Thanh D, 2003, AM J OBSTET GYNECOL, V188, P129, DOI 10.1067/mob.2003.66; Uetake S, 2003, ALCOHOL CLIN EXP RES, V27, p47S, DOI 10.1097/01.ALC.0000079449.47468.B0; Velema JP, 2002, INT J CANCER, V97, P536, DOI 10.1002/ijc.1622; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V106, P257, DOI 10.1093/oxfordjournals.aje.a112460; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V105, P407, DOI 10.1093/oxfordjournals.aje.a112399; ZHURHAUSEN JH, 1975, BIBL HAEMATOL, V43, P569; ZIEGLER JL, 1993, LANCET, V342, P1348, DOI 10.1016/0140-6736(93)92252-O; Ziegler JL, 1997, AIDS, V11, P1619, DOI 10.1097/00002030-199713000-00011; Ziegler JL, 2001, J CLIN VIROL, V20, P127, DOI 10.1016/S1386-6532(00)00137-2; zur Hausen H, 1974, Int J Cancer, V13, P650; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9; ZURHAUSEN H, 1976, CANCER RES, V36, P794; 1996, NIH CONS C APR 1 3, V14, P1	92	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6492	6499		10.1038/sj.onc.1207822	http://dx.doi.org/10.1038/sj.onc.1207822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322520				2022-12-28	WOS:000223468800014
J	Lee, JW; Soung, YH; Kim, SY; Lee, HW; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Lee, JW; Soung, YH; Kim, SY; Lee, HW; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas	ONCOGENE			English	Article						PIK3CA; mutation; cancer; oncogene	TYROSINE KINASE; OVARIAN-CANCER; PATHWAY; ACTIVATION; INHIBITOR; MUTATIONS; ONCOGENE; AKT2; DNA	A recent report revealed that phosphoinositide-3-kinase, catalytic, alpha (PIK3CA) gene is somatically mutated in several types of human cancer, suggesting the mutated PIK3CA gene as an oncogene in human cancers. However, because the previous report focused the mutational search primarily on colon cancers, the data on PIK3CA mutations in other types of human cancers have been largely unknown. Here, we performed mutational analysis of the PIK3CA gene by polymerase chain reaction-single-strand conformation polymorphism assay in 668 cases of common human cancers, including hepatocellular carcinomas, acute leukemias, gastric carcinomas, breast carcinomas, and non-small-cell lung cancers. We detected PIK3CA somatic mutations in 26 of 73 hepatocellular carcinomas (35.6%), 25 of 93 breast carcinomas (26.9%), 12 of 185 gastric carcinomas (6.5%), one of 88 acute leukemias (1.1%), and three of 229 non-small-cell lung cancers (1.3%). Some of the PIK3CA mutations were detected in the early lesions of breast cancer carcinoma, hepatocellular carcinoma, and gastric carcinomas, suggesting that PIK3CA mutation may occur independent of stage of the tumors. The high incidence and wide distribution of PIK3CA gene mutation in the common human cancers suggest that alterations of lipid kinase pathway by PIK3CA mutations contribute to the development of human cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 550 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Arteaga CL, 2002, SEMIN ONCOL, V29, P4, DOI 10.1053/sonc.2002.34047; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; BOGOMOLETZ WV, 1984, AM J SURG PATHOL, V8, P381, DOI 10.1097/00000478-198405000-00007; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakeling AE, 2002, CANCER RES, V62, P5749; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	22	440	473	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1477	1480		10.1038/sj.onc.1208304	http://dx.doi.org/10.1038/sj.onc.1208304			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608678				2022-12-28	WOS:000227092600018
J	Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M				Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M			B-Raf and Ha-ras mutations in chemically induced mouse liver tumors	ONCOGENE			English	Article						mouse hepatocarcinogenesis; B-Raf; Ha-ras; mutation analysis; pyrosequencing	SIGNALING PATHWAY; BRAF GENE; APOPTOSIS; HEPATOCARCINOGENESIS; CANCER; KINASE; MICE; MITOCHONDRIA; DOWNSTREAM; ACTIVATION	The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors. In about 30-50% of cases this effect can be related to activation of the Ha-ras gene by point mutations, whereas in the remaining cases mutations may occur in other members within this pathway, such as Raf kinases. Recently, B-raf has been shown to be frequently mutated in human melanomas and certain other cancers, with a V599E amino-acid change representing the most predominant mutation type. We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes. About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors (similar to20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf. None of the tumors was mutated in both Ha-ras and B-raf. The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes. These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.	Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, D-72074 Tubingen, Germany; Univ Tubingen, Inst Humangenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Schwarz, M (corresponding author), Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, Wilhelmstr 56, D-72074 Tubingen, Germany.	michael.schwarz@uni-tuebingen.de						BAUERHOFMANN R, 1992, MOL CARCINOGEN, V6, P60, DOI 10.1002/mc.2940060110; Berg Lars M, 2002, Expert Rev Mol Diagn, V2, P361, DOI 10.1586/14737159.2.4.361; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; Chang FM, 2003, INT J ONCOL, V22, P469; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRAGANI TA, 1991, ONCOGENE, V6, P333; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Frey S, 2000, CARCINOGENESIS, V21, P161, DOI 10.1093/carcin/21.2.161; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Schwarz M, 1995, MUTAT RES-FUND MOL M, V333, P69, DOI 10.1016/0027-5107(95)00133-6; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yuen ST, 2002, CANCER RES, V62, P6451	26	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1290	1295		10.1038/sj.onc.1208265	http://dx.doi.org/10.1038/sj.onc.1208265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592514				2022-12-28	WOS:000226898700017
J	Feinstein, E				Feinstein, E			Ral-GTPases: good chances for a long-lasting fame	ONCOGENE			English	Editorial Material							REQUIREMENT; INVASION		Quark Biotech Inc, Ness Ziona, Israel		Feinstein, E (corresponding author), Quark Biotech Inc, Ness Ziona, Israel.	elenaf@qbi.co.il						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Malumbres M, 2003, NAT REV CANCER, V3, P708, DOI 10.1038/nrc1193; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	9	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					326	328		10.1038/sj.onc.1208252	http://dx.doi.org/10.1038/sj.onc.1208252			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531910				2022-12-28	WOS:000226279700003
J	Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY				Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY			Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappa B	ONCOGENE			English	Article						arsenic trioxide; irradiation; matrix metalloproteinase-9; metastasis; nuclear factor kappa B	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN CERVICAL-CANCER; CELL LUNG-CANCER; MATRIX METALLOPROTEINASES; IONIZING-RADIATION; HUMAN GLIOBLASTOMA; INDUCED APOPTOSIS; CLINICAL-TRIALS; GLIOMA-CELLS; IN-VITRO	Arsenic trioxide (ATO) has been implicated as a promising anticancer agent by inhibiting cell growth and inducing apoptosis in certain types of cancer cells. This study explored the antimetastasis property of arsenic, drew potential link between arsenic use and radiotherapy, and uncovered the specific mechanisms underlying these remarkable responses. Using gelatin invasion assay and intravasation assay, we report the novel finding that low-dose ATO (1 muM) reduced the intrinsic migration ability of HeLa cells and significantly inhibited radiation-promoted tumor invasive potential of CaSki cells without inducing apoptotic cell death. Using the murine Lewis lung carcinoma model, the control animals and ATO treatment animals (1 mg/kg i.p., twice weekly) displayed similar in vivo growth kinetics, where as the radiation (30 Gy in one fraction) and concurrent treatment groups showed considerable growth inhibition. Importantly, although concurrent treatment did not enhance the effectiveness of radiation therapy to the primary tumor, further examination of the lungs revealed that all animals succumbed to radiation-accelerated lung metastases could be effectively treated by combination of ATO and radiation. Radiation-induced matrix metalloproteinase-9 (MMP-9) expression was significantly inhibited by ATO using sequential analysis of the expression of MMPs in xenografts. Supporting this observation, ATO directly downregulates radiation-induced MMP-9 mRNA expression by inhibiting nuclear factor kappaB activity in human cervical cancer cells. In sum, concurrent arsenic radiation therapy not only achieves local tumor control but also inhibits distant metastasis. Experimental results of this study highlight a novel strategy in cancer treatment.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cyhsieh@ha.mc.ntu.edu.tw	Wei, Lin-Hung/B-1188-2008; Huang, Ruby Yun-Ju/AAE-8854-2019; Kuo, Min-Liang/C-4872-2009	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Achanzar WE, 2002, JNCI-J NATL CANCER I, V94, P1888, DOI 10.1093/jnci/94.24.1888; Azria D, 2003, B CANCER, V90, pS202; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Camphausen K, 2001, CANCER RES, V61, P2207; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Choy H, 1998, J CLIN ONCOL, V16, P3316, DOI 10.1200/JCO.1998.16.10.3316; Choy H, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00268-9; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chun YJ, 2002, FEBS LETT, V519, P195, DOI 10.1016/S0014-5793(02)02765-5; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Didelot C, 2001, INT J RADIAT ONCOL, V51, P1354, DOI 10.1016/S0360-3016(01)02608-6; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eichholtz-Wirth H, 2000, APOPTOSIS, V5, P255, DOI 10.1023/A:1009656513307; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorski DH, 2003, CANCER RES, V63, P308; Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X; Inanami O, 2002, INT J RADIAT BIOL, V78, P267, DOI 10.1080/09553000110105695; Isaac N, 2002, CANCER, V95, P696, DOI 10.1002/cncr.10744; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kondraganti S, 2000, CANCER RES, V60, P6851; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lew YS, 2002, CANCER RES, V62, P4202; LIEBMANN J, 1994, J NATL CANCER I, V86, P441, DOI 10.1093/jnci/86.6.441; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; McGinn CJ, 1996, J NATL CANCER I, V88, P1193, DOI 10.1093/jnci/88.17.1193; Miller WH, 2002, CANCER RES, V62, P3893; Miyamoto S, 2004, CANCER RES, V64, P665, DOI 10.1158/0008-5472.CAN-03-1916; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Qian LW, 2002, CLIN CANCER RES, V8, P1223; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sienel W, 2003, INT J CANCER, V103, P647, DOI 10.1002/ijc.10841; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; Tanioka Y, 2003, BRIT J CANCER, V89, P2116, DOI 10.1038/sj.bjc.6601372; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Wick W, 2002, CANCER RES, V62, P1915; Wild-Bode C, 2001, CANCER RES, V61, P2744; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	56	58	62	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					390	398		10.1038/sj.onc.1208192	http://dx.doi.org/10.1038/sj.onc.1208192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531921				2022-12-28	WOS:000226279700010
J	Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M				Nittka, S; Gunther, J; Ebisch, C; Erbersdobler, A; Neumaier, M			The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis	ONCOGENE			English	Article						CEACAM1; apoptosis; ACF; APC; beta-catenin; carcinogenesis	ABERRANT CRYPT FOCI; CARCINOEMBRYONIC ANTIGEN FAMILY; PROTEIN TRUNCATION TEST; CELL-ADHESION MOLECULE; COLI APC GENE; BILIARY GLYCOPROTEIN; ADENOMATOUS-POLYPOSIS; HYPERPLASTIC POLYPOSIS; CYTOPLASMIC DOMAIN; CANCER-CELLS	Defects in the adenomatous polyposis coli (APC) tumor suppressor pathway are sufficient for neoplastic transformation as the initiating step in colorectal carcinogenesis. In contrast, hyperplastic tumors possess normal APC function, and it is unclear whether they represent significant precursor lesion in cancer development. CEA-CAM1 is a tumor suppressor whose expression is known to be lost in the great majority of early adenomas and carcinomas. We found that loss of CEACAM1 expression is more common in neoplastic tumors than APC mutations. While APC function was normal in hyperplastic aberrant cypt foci and hyperplastic polyps, loss of CEACAM1 was observed as frequently as in the neoplasias. Moreover, the presence or absence of CEACAM1 expression in the hyperplastic tumors correlates with normal or reduced apoptosis, respectively. In vitro, CEACAM1 acts as a regulator of apoptosis in CEA-CAM1-transfected Jurkat cells. Finally, in human HT29 colon cancer cells, apoptosis can be specifically restored by induction of CEACAM1 expression. These data suggest an oncodevelopmental link between neoplasia and hyperplasia and demonstrate that CEACAM1 acts as a regulator of apoptosis in the colonic epithelium. Thus, failure of the maturing colon cell to express CEACAM1 is likely to contribute to the development of hyperplastic lesions, which may eventually pave the way to neoplastic transformation and colon cancer development.	Heidelberg Univ, Med Fac Mannheim, Inst Clin Chem, D-6800 Mannheim, Germany; Univ Hamburg, Hosp Eppendorf, Dept Pathol, D-20246 Hamburg, Germany	Ruprecht Karls University Heidelberg; University of Hamburg	Neumaier, M (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; Battu S, 1998, ANTICANCER RES, V18, P3579; Beauchemin N, 1999, EXP CELL RES, V252, P243; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Blau DM, 2001, J VIROL, V75, P8173, DOI 10.1128/JVI.75.17.8173-8186.2001; BRUMMER J, 1995, ONCOGENE, V11, P1649; Esteller M, 2000, CANCER RES, V60, P4366; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hawkins NJ, 2000, AM J PATHOL, V157, P385, DOI 10.1016/S0002-9440(10)64551-8; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herter P, 1999, J CANCER RES CLIN, V125, P297, DOI 10.1007/s004320050277; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Jass JR, 2001, DIS COLON RECTUM, V44, P163, DOI 10.1007/BF02234287; JEN J, 1994, CANCER RES, V54, P5523; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirchgesser M, 1998, CLIN CHEM LAB MED, V36, P567, DOI 10.1515/CCLM.1998.097; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Launonen V, 2000, CANCER RES, V60, P546; Laurent-Puig P, 1999, EUR J CANCER PREV, V8, pS39; Michor F, 2004, CELL CYCLE, V3, P358; Mori H, 2004, MUTAT RES-REV MUTAT, V566, P191, DOI 10.1016/j.mrrev.2003.08.002; NAP M, 1992, CANCER RES, V52, P2329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Otori K, 1998, CANCER, V83, P896, DOI 10.1002/(SICI)1097-0142(19980901)83:5<896::AID-CNCR14>3.0.CO;2-Q; OTORI K, 1995, CANCER RES, V55, P4743; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Robitaille J, 1999, EUR J BIOCHEM, V264, P534, DOI 10.1046/j.1432-1327.1999.00660.x; Roncucci L, 2000, CELL PROLIFERAT, V33, P1, DOI 10.1046/j.1365-2184.2000.00159.x; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Shpitz B, 1996, DIS COLON RECTUM, V39, P763, DOI 10.1007/BF02054441; Singer BB, 2002, J IMMUNOL, V168, P5139, DOI 10.4049/jimmunol.168.10.5139; SMITH AJ, 1994, CANCER RES, V54, P5527; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; TAKAHASHI H, 1993, CANCER RES, V53, P1612; Tan S, 2002, INT J CANCER, V98, P523, DOI 10.1002/ijc.10236; Turbide C, 1997, CANCER RES, V57, P2781; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	67	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9306	9313		10.1038/sj.onc.1208259	http://dx.doi.org/10.1038/sj.onc.1208259			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15568039				2022-12-28	WOS:000225764100002
J	Mason, DX; Jackson, TJ; Lin, AW				Mason, DX; Jackson, TJ; Lin, AW			Molecular signature of oncogenic ras-induced senescence	ONCOGENE			English	Article						Ras oncogene; G(1) tetraploidy; senescence biomarker; HDAC; topoisomerase; quiescence	DNA TOPOISOMERASE-II; HISTONE DEACETYLASE; HUMAN FIBROBLASTS; GENE-EXPRESSION; GROWTH ARREST; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HUMAN-CELLS; CANCER; P53	Senescence irreversibly arrests the proliferation of cells that have sustained significant cellular stress. Replicative senescence, due to the shortening and dysfunction of telomeres, appears to provide a barrier to the immortalization of cells and development of cancer. In normal human fibroblasts, senescence induced by oncogenic H-ras displays a nearly identical cellular phenotype to that of replicative senescence, suggesting the activation of a common senescence mechanism. In this study, we investigated the gene expression profile of oncogenic H-ras-induced senescent human diploid fibroblasts. We found altered gene expression of various cell cycle regulators in both oncogenic H-ras-induced senescent cells and replicative senescent cells. Similar to replicative senescent cells, H-ras-induced senescent cells exhibited specific downregulation of genes involved in G(2)/M checkpoint control and contained tetraploid cells that were arrested in a G(1) state. This observation suggests that the inactivation of G(2)/M checkpoints may be involved in senescence and may play a role in the generation of senescent G(1) tetraploid cells. Lastly, we have identified two genes, topoisomerase IIalpha and HDAC9, whose expression was specifically altered under several conditions associated with senescence, suggesting that these two molecules may be novel biomarkers for senescent human fibroblasts.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Lin, AW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	Athena.lin@roswellpark.org			NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Benanti JA, 2004, CELL CYCLE, V3, P715; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAMPISI J, 1992, ANN NY ACAD SCI, V663, P195, DOI 10.1111/j.1749-6632.1992.tb38663.x; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Castro ME, 2004, J CELL BIOCHEM, V92, P514, DOI 10.1002/jcb.20079; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Greider C W, 2000, Harvey Lect, V96, P33; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kramer DL, 2001, CANCER RES, V61, P7754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen Annette K, 2003, Prog Cell Cycle Res, V5, P295; Larsson O, 2004, CANCER RES, V64, P482, DOI 10.1158/0008-5472.CAN-03-1872; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Roninson IB, 2003, CANCER RES, V63, P2705; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEEBADDA WKC, 2004, IN PRESS; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	62	87	91	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9238	9246		10.1038/sj.onc.1208172	http://dx.doi.org/10.1038/sj.onc.1208172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489886				2022-12-28	WOS:000225638000009
J	Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR				Reed, KR; Sansom, OJ; Hayes, AJ; Gescher, AJ; Winton, DJ; Peters, JM; Clarke, AR			PPAR delta status and Apc-mediated tumourigenesis in the mouse intestine	ONCOGENE			English	Article						PPARdelta; tumourigenesis; Apc; intestine; PPARbeta	ACTIVATED RECEPTOR-DELTA; COLORECTAL-CANCER CELLS; GENE-EXPRESSION; BETA-CATENIN; TARGETED DISRUPTION; ADENOMA; GROWTH; BRAIN; MICE	Based on recent reports that peroxisome proliferator-activated receptor delta (PPARdelta) activation promotes tumourigenesis, we have investigated the role of this protein in Apc-mediated intestinal tumourigenesis. We demonstrate that the inactivation of Apc in the adult small intestine, while causing the expected nuclear accumulation of beta-catenin, does not cause the expected increase in PPARdelta mRNA or protein but conversely, the levels of PPARdelta mRNA and protein are lowered. Furthermore, we find that Apc(Min)PPARdelta-null mice exhibit an increased predisposition to intestinal tumourigenesis. Our data suggest that PPARdelta is not directly regulated by beta-catenin, and that inhibition of PPARdelta activity is unlikely to be an appropriate strategy for the chemoprevention or chemotherapy of intestinal malignancies.	Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Leicester, Dept Canc Studies, Leicester LE2 7LX, Leics, England; Cambridge Inst Med Res, Canc Res UK Dept Oncol, Cambridge CB2 2XY, England; Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol, Fenske Lab 226, University Pk, PA 16802 USA	Cardiff University; University of Leicester; Cancer Research UK; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Clarke, AR (corresponding author), Univ Wales Coll Cardiff, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.	clarkear@cf.ac.uk	Hayes, Anthony/F-2658-2012; Peters, Jeffrey/D-8847-2011; Reed, Karen/B-8813-2011; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Reed, Karen/0000-0002-7467-1718; Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Peters, Jeffrey/0000-0003-2782-2998				Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Notterman DA, 2001, CANCER RES, V61, P3124; Orner GA, 2003, CARCINOGENESIS, V24, P263, DOI 10.1093/carcin/24.2.263; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Rosenberger TA, 2002, LIPIDS, V37, P495, DOI 10.1007/s11745-002-0923-1; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	20	100	102	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8992	8996		10.1038/sj.onc.1208143	http://dx.doi.org/10.1038/sj.onc.1208143			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480419				2022-12-28	WOS:000225354600015
J	Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY				Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY			Rho/rhotekin-mediated NF-kappa B activation confers resistance to apoptosis	ONCOGENE			English	Article						Rho GTPases; rhotekin; nuclear factor-kappa B; antiapoptosis; gastric cancer	RHO EFFECTOR RHOTEKIN; ACTIN STRESS FIBERS; LUNG-CANCER CELLS; BREAST-CANCER; PROTEIN-KINASE; CYCLIN D1; EXPRESSION; GTPASES; GENE; BINDING	Rhotekin ( RTKN), the gene coding for the Rho effector, RTKN, was shown to be overexpressed in human gastric cancer ( GC). In this study, we further showed that RTKN is expressed at a low level in normal cells and is overexpressed in many cancer-derived cell lines. The function of RTKN as an effector protein in Rho GTPase-mediated pathways regulating apoptosis was investigated. By transfection and expression of RTKN in cells that expressed endogenous RTKN at a low basal level, we showed that RTKN overexpression conferred cell resistance to apoptosis induced by serum deprivation or treatment with sodium butyrate, and the increased resistance correlated to the level of RTKN. Conversely, reducing RTKN expression by small interfering RNAs greatly sensitized cells to apoptosis. The RTKN-mediated antiapoptotic effect was blocked by the nuclear factor-kappaB (NF-kappaB) inhibitors, curcumin or parthenolide, but not by the phosphatidylinositol 3'-OH-kinase inhibitor, LY294002, or the MAP kinase inhibitor, PD98059. Reporter gene assays and electrophoretic mobility shift assay confirmed that RTKN overexpression led to constitutive activation of NF-kappaB through the phosphorylation of IkappaB by IKKbeta. By using the RTKN truncation mutants, we showed that RTKN mediated Rho activity eliciting signaling pathway to activate NF-kappaB, with a concomitant induction of expression of the NF-kappaB antiapoptotic genes, cIAP-2, BCl-xL, A1, and A20. Consistent with these data, RTKN-expressing cells showed increased chemoresistance to 5-fluorouracil and paclitaxol, and the resistance was greatly attenuated by NF-kappaB inhibitor. In conclusion, overactivated Rho/RTKN/NF-kappaB signaling pathway through overexpression of RTKN may play a key role in gastric tumorigenesis by conferring cells resistance to apoptosis, and this signaling pathway may serve as an important target for novel therapeutic approaches to the treatment of human GC.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2 Acad Rd, Taipei 11529, Taiwan.	bmchen@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018					Arlt A, 2002, CANCER RES, V62, P910; Asin S, 1999, J VIROL, V73, P3893, DOI 10.1128/JVI.73.5.3893-3903.1999; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHEN JY, 1993, ONCOGENE, V8, P2159; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gildea JJ, 2002, CANCER RES, V62, P6418; IKEDA H, 2003, AM J PHYSL GASTROINT; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053/gast.2001.25544; Kaneko K, 2002, PANCREAS, V24, P251, DOI 10.1097/00006676-200204000-00007; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim JY, 2000, BIOCHEM BIOPH RES CO, V273, P140, DOI 10.1006/bbrc.2000.2909; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lai JM, 2001, BIOCHEM J, V359, P227, DOI 10.1042/0264-6021:3590227; Liu CA, 2004, J BIOMED SCI, V11, P661, DOI 10.1159/000079679; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sanlioglu S, 2001, CANCER GENE THER, V8, P897, DOI 10.1038/sj.cgt.7700394; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tu H, 1999, MOL CELL BIOL, V19, P602; van Golen KL, 2000, CANCER RES, V60, P5832; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zhou J, 2003, WORLD J GASTROENTERO, V9, P9, DOI 10.3748/wjg.v9.i1.9	56	64	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8731	8742		10.1038/sj.onc.1208106	http://dx.doi.org/10.1038/sj.onc.1208106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480428				2022-12-28	WOS:000225165100003
J	Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG				Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG			The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; PI 3-kinase; Akt; NF-kappa B; c-Myc; PTEN	TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; DEPENDENT PHOSPHORYLATION; DUCTAL ADENOCARCINOMA; CARCINOMA CELLS; PROSTATE-CANCER; AKT ACTIVATION; GROWTH-FACTOR; INHIBITION	The persistent activation of signaling cascades results in dramatic consequences that include loss of cellular growth control and neoplastic transformation. We show here that phosphoinositide 3-kinase (PI 3-kinase) and its mediator Akt were constitutively activated in pancreatic cancer and that this might be due to the aberrant expression of their natural antagonist MMAC/PTEN. Indeed, our results show that MMAC/PTEN expression was either lost or significantly reduced in five of eight cell lines and in twelve of seventeen tumor specimens examined. That the poor expression of MMAC/PTEN in pancreatic cancer cells could be due to promoter methylation was indicated by methylation-specific PCR analysis. Our studies also indicated that PI 3-kinase targeted two important transcription factors in pancreatic cancer cells. The ability of constitutively activated NF-kappaB to induce gene expression and the stabilization of c-MYC protein by decreased phosphorylation of Thr58 were both dependent on PI 3-kinase activity. When pancreatic cancer cells were treated with a peptide antagonist of NF-kappaB nuclear translocation, or stably transfected with a dominant-negative mutant of MYC, their proliferation was markedly inhibited. Taken together, these data indicate that the aberrant expression of MMAC/PTEN contributes to the activation of the PI 3-kinase/Akt pathway and its transcription factor mediators in pancreatic cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Reddy, SAG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	sa08366@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adsay NV, 1999, PANCREAS, V18, P111, DOI 10.1097/00006676-199903000-00001; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bondar VM, 2002, MOL CANCER THER, V1, P989; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Evans D B, 1997, Cancer Treat Res, V90, P109; Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037; Friess H, 1999, DIGEST SURG, V16, P281, DOI 10.1159/000018737; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Grewe M, 1999, CANCER RES, V59, P3581; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; Kolenko V, 1999, J IMMUNOL, V163, P590; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LILLEMOE KD, 1995, ANN SURG, V221, P133, DOI 10.1097/00000658-199502000-00003; Longnecker DS, 1999, ANN NY ACAD SCI, V880, P74, DOI 10.1111/j.1749-6632.1999.tb09511.x; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagy A, 2001, ANTICANCER RES, V21, P1321; Ng SSW, 2000, CANCER RES, V60, P5451; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Okami K, 1998, CANCER RES, V58, P509; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reddy SAG, 2001, CANCER J, V7, P274; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shah SA, 2001, J GASTROINTEST SURG, V5, P603, DOI 10.1016/S1091-255X(01)80102-5; Shi Q, 2001, CANCER RES, V61, P4143; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tanno S, 2001, CANCER RES, V61, P589; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006	56	252	268	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8571	8580		10.1038/sj.onc.1207902	http://dx.doi.org/10.1038/sj.onc.1207902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467756				2022-12-28	WOS:000224988800002
J	Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Inactivating mutations of the Siah-1 gene in gastric cancer	ONCOGENE			English	Article						stomach; beta-catenin; p53; cyclin D1; expression	BETA-CATENIN; TUMOR SUPPRESSION; POLYPOSIS-COLI; HUMAN HOMOLOG; SINA GENE; P53; APOPTOSIS; ABSENTIA; PATHWAY; PROTEIN	Siah-1 is the mammalian homolog of Drosophila seven in absentia (sina) and has been identified as a p53-inducible gene. Siah-1 can induce cell cycle arrests, tumor suppression, and apoptosis through a novel beta-catenin degradation pathway. To determine whether genetic alterations of Siah-1 gene are involved in the development and/or progression of gastric cancer, we searched for mutation of the Siah-1 gene in 95 gastric cancers by single-strand conformational polymorphism and sequencing. The effect of Siah-1 on beta-catenin degradation was further examined in wild- and mutant-type Siah-1-transfected HEK 293T cells. We found two missense mutations of the Siah-1 gene. The cases with Siah-1 mutation showed nuclear translocation and cytoplasmic staining of beta-catenin. Interestingly, two mutants of Siah-1 stabilized cytoplasmic levels of beta-catenin, even after treatment of adriamycin. Furthermore, both mutants failed to suppress cyclin D1 expression and to induce apoptosis. These data suggest that inactivating mutations of the Siah-1 may contribute to the development of gastric cancer through beta-catenin stabilization and apoptosis block.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Park WS, 1999, CANCER RES, V59, P4257; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Shtutman Michael, 2002, Cancer Research, V62, P5947; SIVAK MV, 1984, GASTROINTEST ENDOSC, V30, P102, DOI 10.1016/S0016-5107(84)72333-9; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	25	39	42	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8591	8596		10.1038/sj.onc.1208113	http://dx.doi.org/10.1038/sj.onc.1208113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467739				2022-12-28	WOS:000224988800004
J	Bromann, PA; Korkaya, H; Courtneidge, SA				Bromann, PA; Korkaya, H; Courtneidge, SA			The interplay between Src family kinases and receptor tyrosine kinases	ONCOGENE			English	Review						Src; phosphotyrosine; mitogenesis; ubiquitination; survival	EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; FACTOR-BETA-RECEPTOR; STIMULATING FACTOR-I; MESSENGER-RNA STABILITY; C-MYC EXPRESSION; INDUCED TRANSFORMATION; CELL-PROLIFERATION; INDUCED ACTIVATION; HEPATOCYTE GROWTH	Src family tyrosine kinases (SFKs) are involved in a diverse array of physiological processes, as highlighted in this review. An overview of how SFKs interact with, and participate in signaling from, receptor tyrosine kinases (RTKs) is discussed. And also, how SFKs are activated by RTKs, and how SFKs, in turn, can activate RTKs, as well as how SFKs can promote signaling from growth factor receptors in a number of ways including participation in signaling pathways required for DNA synthesis, control of receptor turnover, actin cytoskeleton rearrangements and motility, and survival are discussed.	Van Andel Res Inst, Grand Rapids, MI 49503 USA	Van Andel Institute	Courtneidge, SA (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	sara.courtneidge@vai.org	Korkaya, Hasan/GRY-1016-2022; Korkaya, Hasan/C-2201-2009					Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Avrov K, 2003, EXP CELL RES, V291, P426, DOI 10.1016/j.yexcr.2003.08.001; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Broudy VC, 1999, BLOOD, V94, P1979; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DEAN M, 1986, J BIOL CHEM, V261, P9161; DECKER SJ, 1989, J BIOL CHEM, V264, P9204; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Guren TK, 2003, J CELL PHYSIOL, V196, P113, DOI 10.1002/jcp.10282; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; Kilkenny DM, 2003, J BIOL CHEM, V278, P17448, DOI 10.1074/jbc.M209698200; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Krystal GW, 1998, CANCER RES, V58, P4660; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANDGREN E, 1995, ONCOGENE, V10, P2027; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lennartsson J, 2003, EXP CELL RES, V288, P110, DOI 10.1016/S0014-4827(03)00206-4; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951; Li WQ, 1996, ONCOGENE, V13, P731; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maejima Y, 2003, ATHEROSCLEROSIS, V167, P89, DOI 10.1016/S0021-9150(02)00384-2; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; Melillo RM, 1999, CANCER RES, V59, P1120; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORI S, 1994, J BIOL CHEM, V269, P4917; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; RHODES CH, 1989, ARCH BIOCHEM BIOPHYS, V272, P175, DOI 10.1016/0003-9861(89)90208-7; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Shi CS, 2004, J BIOL CHEM, V279, P17224, DOI 10.1074/jbc.M311875200; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; Smith CL, 2001, J NEUROSCI, V21, P3151, DOI 10.1523/JNEUROSCI.21-09-03151.2001; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	162	359	365	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7957	7968		10.1038/sj.onc.1208079	http://dx.doi.org/10.1038/sj.onc.1208079			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489913	Green Accepted			2022-12-28	WOS:000224558300006
J	Reynolds, AB; Roczniak-Ferguson, A				Reynolds, AB; Roczniak-Ferguson, A			Emerging roles for p120-catenin in cell adhesion and cancer	ONCOGENE			English	Review						cell adhesion; p120 catenin; cadherin; Rho; Rac; tumor suppressor	PROTEIN-KINASE-C; E-CADHERIN; P120 CATENIN; TYROSINE-KINASE; BETA-CATENIN; GROWTH-FACTOR; BINDING-PROTEIN; ALPHA-CATENIN; PARTNER KAISO; SMALL GTPASES	Although originally identified as a Src substrate, p120-catenin (p120) is now known to regulate cell-cell adhesion through its interaction with the cytoplasmic tail of classical and type II cadherins. New evidence indicates that p120 regulates cadherin turnover at the cell surface, thereby controlling the amount of cadherin available for cell-cell adhesion. This function is necessary but not sufficient to promote strong adhesion, which is further controlled by signals acting on the amino-terminal p120 regulatory domain. p120 also modulates the activities of RhoA, Rac, and Cdc42, suggesting that along with other Src substrates, p120 regulates actin dynamics. Thus, p120 is a master regulator of cadherin abundance and activity, and likely participates in regulating the balance between adhesive and motile cellular phenotypes. This review summarizes recent progress in understanding mechanisms of p120 action, and discusses new implications with respect to roles for p120 in disease and cancer.	Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University	Reynolds, AB (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	al.reynolds@vanderbilt.edu						Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; DOWNING JR, 1991, ONCOGENE, V6, P607; Fang X, 2004, J CELL BIOL, V165, P87, DOI 10.1083/jcb.200307109; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grosheva I, 2001, J CELL SCI, V114, P695; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kallakury BVS, 2001, HUM PATHOL, V32, P849, DOI 10.1053/hupa.2001.26463; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Karayiannakis AJ, 1998, J PATHOL, V185, P413; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KIM L, 1995, MOL CELL BIOL, V15, P4553; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Konstantoulaki M, 2003, AM J PHYSIOL-LUNG C, V285, pL434, DOI 10.1152/ajplung.00075.2003; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pettitt J, 2003, J CELL BIOL, V162, P15, DOI 10.1083/jcb.200212136; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wong EYM, 2000, BIOCHEM J, V346, P209, DOI 10.1042/0264-6021:3460209; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Xu G, 2004, J CELL SCI, V117, P3207, DOI 10.1242/jcs.01174; Yanagisawa M, 2004, J BIOL CHEM, V279, P9512, DOI 10.1074/jbc.M310895200; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zhu AJ, 1996, J CELL SCI, V109, P3013; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	84	217	231	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7947	7956		10.1038/sj.onc.1208161	http://dx.doi.org/10.1038/sj.onc.1208161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489912				2022-12-28	WOS:000224558300005
J	Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T				Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T			Identification of SCN3B as a novel p53-inducible proapoptotic gene	ONCOGENE			English	Article						p53; SCN3B; apoptosis; ER	ADENOVIRUS-MEDIATED TRANSFER; KINASE C-ABL; DNA-DAMAGE; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; SODIUM-CHANNELS; DIRECT TARGET; CANCER-CELLS; P53; P73	Tumor suppressor p53 is a transcription factor that induces growth arrest and/or apoptosis in response to cellular stress. To identify novel p53-inducible genes, we compared the expression of genes in normal mouse embryo fibroblasts (MEFs) to p53-null cells by cDNA representational difference analysis. We report here that expression of endogenous sodium channel subunit beta 3 (SCN3B) is upregulated in mouse embryonic fibroblasts by DNA damage in a p53-dependent manner. In addition, we found that SCN3B levels are upregulated in human cancer cell lines by DNA damaging agents, as well as by overexpression of p53, but not significantly by p63 or p73. Furthermore, we identified two putative p53-binding sites upstream of the first exon (RE1) and in the third intron (RE2). The p53 protein can directly interact with the putative p53-binding sites in vivo, as assessed by chromatin immunoprecipitation. A reporter gene assay revealed that these two p53-binding sites are functional response elements. The SCN3B protein appears to be localized to the endoplasmic reticulum (ER). Introduction of the SCN3B gene into T98G and Saos2 cells potently suppressed colony formation. Furthermore, we found that adenovirus-mediated transfer of SCN3B induced apoptosis when combined with anticancer agents. The results presented here suggest that SCN3B mediates a p53-dependent apoptotic pathway and may be a candidate for gene therapy combined with anticancer drugs.	Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Obstet & Gynecol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Yamaguchi Univ, Sch Med, Div Clin Lab, Ube, Yamaguchi 7558505, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Yamaguchi University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Sasaki Y, 2000, J CLIN LAB ANAL, V14, P314, DOI 10.1002/1098-2825(20001212)14:6<314::AID-JCLA11>3.0.CO;2-O; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	29	51	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7791	7798		10.1038/sj.onc.1208067	http://dx.doi.org/10.1038/sj.onc.1208067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334053				2022-12-28	WOS:000224331600005
J	Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P				Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P			Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis	ONCOGENE			English	Article						Mcl-1; Bim; caspases; cleavage; mitochondria	HUMAN MYELOMA CELLS; FAS-MEDIATED APOPTOSIS; PROTEIN-KINASE-C; BCL-2 FAMILY; INTERFERON-ALPHA; T-LYMPHOCYTES; GENE-PRODUCT; EXPRESSION; SURVIVAL; DEATH	Mcl-1 is an antiapoptotic member of the Bcl-2 family that can promote cell viability. We report here that Mcl-1 is a new substrate for caspases during induction of apoptosis. Mcl-1 cleavage occurs after Asp127 and Asp157 and generates four fragments of 24, 19, 17 and 12 kDa in both intact cells and in vitro, an effect prevented by selective caspase inhibitors. As a consequence, the resulting protein that lacks the first 127 or 157 amino acids contains only the BH1-BH3 domains of Bcl-2 family members. Mutation of Asp127 and Asp157 abolishes the generation of the 24 and 12 kDa fragments and that of the 19 and 17 kDa fragments, respectively. Interestingly, when expressed in HeLa cells Mcl-1 wt and Mcl-1 Delta127 showed a markedly different intracellular distribution. Mcl-1 wt colocalized with a-Tubulin near the internal face of the plasma membrane, while Mcl-1 Delta127 coassociated with Bim-EL at the mitochondrial level. Coinamunoprecipitation experiments also demonstrated that Mcl1 Delta127 exhibited increased binding to Bim when compared to Mcl-1 wt. Finally, Mcl-1 wt unlike Mcl-1 Delta127 inhibited Bim-EL-induced caspase activation. Altogether, our findings demonstrate that cleavage of Mcl-1 by caspases modifies its subcellular localization, increases its association with Bim and inhibits its antiapoptotic function.	Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; Burnham Inst, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Sanford Burnham Prebys Medical Discovery Institute	Auberger, P (corresponding author), Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Jacquel, Arnaud/O-1928-2017; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; AUBERGER, Patrick/G-1491-2013; Marchetti, Sandrine/P-6479-2016; luciano, frederic/P-6264-2016	Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Marchetti, Sandrine/0000-0001-8326-5730; luciano, frederic/0000-0001-9253-4998				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; HAN J, 2004, J BIOL CHEM, V10, P10; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; JACQUEL A, 2003, FASEB J, V4, P4; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Luciano F, 2003, FASEB J, V17, P711, DOI 10.1096/fj.02-0716fje; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rinkenberger JL, 2000, GENE DEV, V14, P23; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHU Y, 2004, P NATL ACAD SCI USA, V10, P10; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	150	151	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7863	7873		10.1038/sj.onc.1208069	http://dx.doi.org/10.1038/sj.onc.1208069			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378010				2022-12-28	WOS:000224331600012
J	Chen, CM; Chang, JL; Behringer, RR				Chen, CM; Chang, JL; Behringer, RR			Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts	ONCOGENE			English	Article						ovarian cancer; tumor suppressor; p53; ovary transplantation; hemangiosarcoma	MICE; ANGIOSARCOMA; INDUCTION; SPECTRUM; CANCER; MODEL; GENE	p53 gene alterations correlate highly with advanced ovarian carcinoma in women. In mice, p53 deficiency predominantly results in the formation of lymphomas and sarcomas. However, ovarian epithelial tumors have not been documented in p53 homozygous mutant (p53(-/-)) mice, probably because they die before other tumors can form. To determine whether p53(-/-) ovaries can develop epithelial tumors, they were transplanted into the ovarian bursae of histocompatible wild-type recipient females. The p53(-/-) ovarian grafts formed tumors similar to1 year posttransplantation. The tumor type was angiosarcoma, suggesting that vascular tissues are predisposed to tumor formation in p53(-/-) ovaries. These findings suggest that p53 deficiency alone is not sufficient for ovarian epithelial tumorigenesis in mice. Thus, other genetic lesions are likely required to develop mouse models of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Armed Forced Taoyuan Gen Hosp, Dept Pathol, Taoyuan, Taiwan	University of Texas System; UTMD Anderson Cancer Center	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Chen, Chun-Ming/0000-0001-8873-7602	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA83639] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; ONCHIT HHS [OC20187] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ONCHIT HHS		Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bast RC, 2000, METH MOLEC MED, V39, P37; Blackburn AC, 2003, CANCER RES, V63, P2364; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jylling A M, 1999, Pathol Oncol Res, V5, P318, DOI 10.1053/paor.1999.0213; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Mohr U., 2001, INT CLASSIFICATION R; Nagy A., 2003, MANIPULATING MOUSE E; Naka N, 1997, INT J CANCER, V71, P952, DOI 10.1002/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.3.CO;2-N; Nucci MR, 1998, AM J SURG PATHOL, V22, P620, DOI 10.1097/00000478-199805000-00014; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Platt JS, 1999, GYNECOL ONCOL, V73, P443, DOI 10.1006/gyno.1998.5335; PURDIE CA, 1994, ONCOGENE, V9, P603; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TURUSOV V, 1994, IARC SCI PUBLICATION, V111; Venkatachalam Sundaresan, 2002, P247; Zietz C, 1998, AM J PATHOL, V153, P1425, DOI 10.1016/S0002-9440(10)65729-X	22	16	16	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7722	7725		10.1038/sj.onc.1208037	http://dx.doi.org/10.1038/sj.onc.1208037			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334065				2022-12-28	WOS:000224306700013
J	Scott, KA; Arnott, CH; Robinson, SC; Moore, RJ; Thompson, RG; Marshall, JF; Balkwill, FR				Scott, KA; Arnott, CH; Robinson, SC; Moore, RJ; Thompson, RG; Marshall, JF; Balkwill, FR			TNF-alpha regulates epithelial expression of MMP-9 and integrin alpha v beta 6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?	ONCOGENE			English	Article						skin carcinogenesis; wound healing; epidermis; matrix metalloproteinase; TPA	NECROSIS-FACTOR-ALPHA; MOUSE SKIN CARCINOGENESIS; SQUAMOUS CARCINOMA-CELLS; GELATINASE-B; GENE-EXPRESSION; FACTOR RECEPTOR; HAIR-FOLLICLES; MESSENGER-RNA; MATRIX-METALLOPROTEINASE-9; GROWTH	Mice deficient in TNF-alpha (TNF-alpha(-/-) mice) are resistant to skin carcinogenesis and expression of MMP-9 is inhibited in TNF-alpha(-/-) mice during skin tumour development. In the early stages of tumour promotion, MMP-9 protein initially localized to the follicular epidermis but subsequently began to accumulate in the interfollicular epidermis of wild-type but not TNF-alpha(-/-) mice. Inhibition of TNF-alpha or MMP-9 function reduced keratinocyte migration in vitro. In addition, a deficiency of TNF-alpha delayed re-epithelialization in vivo and this correlated with reduced MMP-9 expression. Collectively, these data suggest that MMP-9 regulates keratinocyte migration in a TNF-alpha-dependent manner. Expression pro. ling of genes that control cell adhesion and migration revealed markedly lower levels of the integrin subunits alphav and beta6 in TNF-alpha(-/-) compared with wild-type keratinocytes in vitro. alphavbeta6 expression was upregulated by keratinocytes in vitro and during tumour promotion in vivo in a TNF-alpha-dependent manner. Furthermore, alphavbeta6 blockade significantly inhibited keratinocyte migration and TNF-alpha-stimulated MMP-9 expression in vitro. These data illustrate a novel TNF-alpha-dependent mechanism for the control of alphavbeta6 expression and suggest one pathway for TNF-alpha regulation of MMP-9. Increased MMP-9 and alphavbeta6 expression may stimulate epithelial cell migration during tumour formation and may be one mechanism whereby TNF-alpha acts as an endogenous tumour promoter.	Canc Res UK Canc Ctr, John Vane Sci Ctr, Dept Tumor Biol, London EC1M 6BQ, England; Canc Res UK Canc Ctr, John Vane Sci Ctr, Translat Oncol Lab, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London	Scott, KA (corresponding author), Canc Res UK Canc Ctr, John Vane Sci Ctr, Dept Tumor Biol, Charterhouse Sq, London EC1M 6BQ, England.	kate.scott@cancer.org.uk		Balkwill, Frances/0000-0002-5587-9759; Marshall, John/0000-0002-0494-2295				Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Binder RL, 1997, MOL CARCINOGEN, V20, P151, DOI 10.1002/(SICI)1098-2744(199709)20:1<151::AID-MC17>3.0.CO;2-0; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; Buck M, 1996, AM J PATHOL, V149, P195; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Kobayashi T, 2001, EMBO REP, V2, P604, DOI 10.1093/embo-reports/kve129; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Lee RH, 2000, WOUND REPAIR REGEN, V8, P547, DOI 10.1046/j.1524-475x.2000.00547.x; Liabakk NB, 1996, CANCER RES, V56, P190; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Milner R, 2003, J IMMUNOL, V170, P3850, DOI 10.4049/jimmunol.170.7.3850; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Morris RJ, 2000, CANCER RES, V60, P226; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Murphy JE, 2003, J IMMUNOL, V170, P5697, DOI 10.4049/jimmunol.170.11.5697; Nakao S, 2003, J IMMUNOL, V170, P5704, DOI 10.4049/jimmunol.170.11.5704; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; Nielsen BS, 1996, INT J CANCER, V65, P57, DOI 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F; Papathoma AS, 2001, MOL CARCINOGEN, V31, P74, DOI 10.1002/mc.1042; Scott KA, 2000, BRIT J CANCER, V83, P1538, DOI 10.1054/bjoc.2000.1487; Scott KA, 2003, MOL CANCER THER, V2, P445; Steel JH, 1998, EUR J HISTOCHEM, V42, P143; Suganuma M, 1999, CANCER RES, V59, P4516; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V116, P898, DOI 10.1046/j.1523-1747.2001.01352.x; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Weeks BH, 2001, CANCER RES, V61, P7435; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	74	77	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2004	23	41					6954	6966		10.1038/sj.onc.1207915	http://dx.doi.org/10.1038/sj.onc.1207915			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273742				2022-12-28	WOS:000223750700012
J	Jinawath, N; Furukawa, Y; Hasegawa, S; Li, MH; Tsunoda, T; Satoh, S; Yamaguchi, T; Imamura, H; Inoue, M; Shiozaki, H; Nakamura, Y				Jinawath, N; Furukawa, Y; Hasegawa, S; Li, MH; Tsunoda, T; Satoh, S; Yamaguchi, T; Imamura, H; Inoue, M; Shiozaki, H; Nakamura, Y			Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray	ONCOGENE			English	Article						diffuse-type gastric cancer; cDNA microarray; laser-microbeam microdissection; expression profile	E-CADHERIN; SOMATIC MUTATIONS; LIVER METASTASES; BREAST-CANCER; PATTERNS; CELLS; BETA; ADENOCARCINOMA; CARCINOMA; METALLOPROTEINASES	Gastric cancer is the fourth leading cause of cancer-related death in the world. Two histologically distinct types of gastric carcinoma, 'intestinal' and 'diffuse', have different epidemiological and pathophysiological features that suggest different mechanisms of carcinogenesis. A number of studies have investigated intestinal-type gastric cancers at the molecular level, but little is known about mechanisms involved in the diffuse type, which has a more invasive phenotype and poorer prognosis. To clarify the mechanisms that underlie its development and/or progression, we compared the expression profiles of 20 laser-microbeam-microdissected diffuse-type gastric-cancer tissues with corresponding noncancerous mucosae by means of a cDNA microarray containing 23 040 genes. We identified 153 genes that were commonly upregulated and more than 1500 that were commonly downregulated in the tumors. We also identified a number of genes related to tumor progression. Furthermore, comparison of the expression profiles of diffuse-type with those of intestinal-type gastric cancers identified 46 genes that may represent distinct molecular signatures of each histological type. The putative signature of diffuse-type cancer exhibited altered expression of genes related to cell matrix interaction and extracellular-matrix (ECM) components, whereas that of intestinal-type cancer represented enhancement of cell growth. These data provide insight into different mechanisms underlying gastric carcinogenesis and may also serve as a starting point for identifying novel diagnostic markers and/or therapeutic targets for diffuse-type gastric cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; RIKEN, SNP Res Ctr, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Kyoto, Japan; Canc Inst Hosp, Dept Surg, Tokyo, Japan; Sakai City Hosp, Dept Surg, Osaka, Japan; Kinki Univ, Sch Med, Nara Hosp, Dept Surg, Nara, Japan; Kinki Univ, Sch Med, Sayama Hosp, Dept Surg, Osaka 589, Japan	University of Tokyo; RIKEN; Kyoto University; Japanese Foundation for Cancer Research; Kindai University (Kinki University); Kindai University (Kinki University)	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Balkwill F, 2003, SEMIN IMMUNOL, V15, P49, DOI 10.1016/S1044-5323(02)00127-6; BECKER KF, 1994, CANCER RES, V54, P3845; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boussioutas A, 2003, CANCER RES, V63, P2569; Campbell DJ, 2002, J CLIN INVEST, V110, P1079, DOI 10.1172/JCI200216946; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; Couldrey C, 2000, BREAST CANCER RES, V2, P321, DOI 10.1186/bcr75; CRAANEN ME, 1995, GUT, V36, P848, DOI 10.1136/gut.36.6.848; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Dan S, 2002, CANCER RES, V62, P1139; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hasegawa S, 2002, CANCER RES, V62, P7012; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kim B, 2003, CANCER RES, V63, P8248; Kitahara O, 2001, CANCER RES, V61, P3544; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Maehara Y, 1999, J CLIN ONCOL, V17, P607, DOI 10.1200/JCO.1999.17.2.607; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200; Ming Si-Chun, 1998, Gastric Cancer, V1, P31, DOI 10.1007/s101200050053; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Padovan E, 2002, CANCER RES, V62, P3453; Park WS, 1999, CANCER RES, V59, P4257; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Peddanna N, 1995, ANTICANCER RES, V15, P2055; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schwartz DR, 2003, CANCER RES, V63, P2913; SIPPONEN P, 1995, AM J SURG PATHOL, V19, pS30; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; St Croix B, 2000, SCIENCE, V289, P1197; Sumi T, 2003, ONCOL REP, V10, P345; Takemoto H, 2001, INT J CANCER, V91, P783, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1121>3.0.CO;2-Z; Tay ST, 2003, CANCER RES, V63, P3309; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; Yanagawa R, 2001, NEOPLASIA, V3, P395, DOI 10.1038/sj.neo.7900185; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	43	93	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6830	6844		10.1038/sj.onc.1207886	http://dx.doi.org/10.1038/sj.onc.1207886			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273739				2022-12-28	WOS:000223653600016
J	Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J				Vetter, M; Blumenthal, SG; Lindemann, RK; Manns, J; Wesselborg, S; Dittmer, J			Ets1 is an effector of protein kinase Ca in cancer cells	ONCOGENE			English	Article						Ets transcription factors; protein kinase C; breast cancer; RNA interference	HORMONE-RELATED PROTEIN; BREAST-CARCINOMA CELLS; TRANSCRIPTION FACTOR; PKC-ALPHA; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; GROWTH; PHOSPHORYLATION; INVOLVEMENT	PKCalpha and Ets1 are both associated with breast cancer progression. Our previous studies suggested that these proteins are likely to functionally interact with one another. Here, we show that attenuation of endogenous PKCalpha expression (siPalpha) by RNA interference leads to reduced Ets1 protein expression in a variety of cancer cells. Pulse-chase experiments and treatment with proteasome inhibitor MG-132 revealed that siPa interferes with both Ets1 protein synthesis and stability. The effect of siPalpha on Ets1 expression could be partially prevented by KN-93, suggesting that calcium/calmodulin-dependent kinase II ( CaMKII), a modulator of Ets1 activity, may play a role in PKCalpha-dependent Ets1 regulation. In contrast, Ets1-regulating kinases ERK1/ 2 were not found to be involved in this process. To assess the importance of the PKCalpha/Ets1 interaction, we compared the biological responses of MDA-MB-231 cells to PKCalpha- and Ets1-specific siRNAs (siE1). While only siPalpha induced changes in cellular morphology and anchorage-independent growth, both siRNAs similarly affected cellular responses to the antitumor drug mithramycin A and to UV light. Microarray analyses further showed that the expression of a certain set of genes was equally affected by siPa and siE1. The data suggest that Ets1 serves as an effector for PKCalpha to fulfil certain functions in cancer cells.	Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, D-06097 Halle Saale, Saale, Germany; Univ Tubingen, Innere Med Abt 1, Med Klin, D-72076 Tubingen, Germany	Martin Luther University Halle Wittenberg; Eberhard Karls University of Tubingen	Dittmer, J (corresponding author), Univ Halle Wittenberg, Univ Klin & Poliklin Gynakol, Ernst Grube Str 40, D-06097 Halle Saale, Saale, Germany.	dittmer@medizin.uni-halle.de	Dittmer, Juergen/G-1160-2011; Manns, J/AAA-4986-2020	Wesselborg, Sebastian/0000-0002-5236-942X				Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Ballschmieter P, 2003, INT J ONCOL, V22, P849; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; Budworth J, 1997, BRIT J CANCER, V75, P1330, DOI 10.1038/bjc.1997.225; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Cowley DO, 2000, GENE DEV, V14, P366; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Foos G, 2004, HANDB EXP PHARM, V166, P259; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Goldstein AS, 2002, J BIOMED MATER RES, V59, P665, DOI 10.1002/jbm.1276; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Jiang Y, 2002, CANCER RES, V62, P1910; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; Lee MP, 1998, CANCER RES, V58, P1052; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Lindemann RK, 2003, INT J ONCOL, V22, P799; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Okabe H, 2003, CANCER RES, V63, P3043; Orlandi L, 2003, PROSTATE, V54, P133, DOI 10.1002/pros.10181; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Samatar AA, 2002, J BIOL CHEM, V277, P28118, DOI 10.1074/jbc.M203686200; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sioud M, 1998, NAT BIOTECHNOL, V16, P556, DOI 10.1038/nbt0698-556; Soh Jae-Won, 2003, J Exp Ther Oncol, V3, P115, DOI 10.1046/j.1359-4117.2003.01087.x; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song JC, 2002, AM J PHYSIOL-CELL PH, V283, pC1548, DOI 10.1152/ajpcell.00105.2002; Sunaga N, 2002, CANCER EPIDEM BIOMAR, V11, P730; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					650	661		10.1038/sj.onc.1208234	http://dx.doi.org/10.1038/sj.onc.1208234			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15531915				2022-12-28	WOS:000226420400012
J	Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP				Yin, D; Zhou, H; Kumagai, T; Liu, GT; Ong, JM; Black, KL; Koeffler, HP			Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)	ONCOGENE			English	Article						proteasome inhibitor; glioblastoma multiforme; PS-341; apoptosis; NF-kappa B	FACTOR-KAPPA-B; HUMAN GLIOMA-CELLS; MULTIPLE-MYELOMA CELLS; DRUG-RESISTANCE; C-MYC; CANCER; INDUCTION; P53; ANGIOGENESIS; ACTIVATION	The proteasome plays a pivotal role in controlling cell proliferation, apoptosis, and differentiation in a variety of normal and tumor cells. PS-341, a novel boronic acid dipeptide that inhibits 26S proteasome activity, has prominent effects in vitro and in vivo against several solid tumors. We examined its antiproliferation, proapoptotic effects using three human glioblastoma multiforme (GBM) cell lines and five primary GBM explants. PS-341 markedly inhibited proliferation of GBM cell lines and explants in liquid and soft agar culture. These cells developed a G2/M cell cycle arrest with a concomitant decreased percentage of cells in S phase (approximate to2-fold), associated with an increased expression of p21(WAF1), p27(KIP1), as well as cyclin B1 and decreased levels of CDK2, CDK4, and E2F4. About 35-40% of the cells became apoptotic when exposed to PS-341 (10(-7) M, 24-48 h) as shown by Annexin V analysis; in concert with these findings, immunobloting showed a C-terminal 85 kDa apoptotic fragment of poly ADP-ribose polymerase (PARP), and a decreased level of Bcl2 and Bcl-xl. PS-341 downregulated the expression of Bcl-2 and Bcl-xl in protein levels at an early time of treatment. These changes occurred irrespective of the p53 mutational status of the cells. PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition. PS-341 (10(-7) M, 24 h) decreased nuclear NF-kappaB levels as shown by Western blot, and reduced transcriptional activity of NF-kappaB as measured by reporter assays in these transformed cells. Also, PS-341 enhanced TRAIL (TNF-related apoptosis-inducing ligand) and TNFalpha (tumor necrosis factor alpha) induced cell death and apoptosis (two-to-five-fold) in GBM cells. In summary, PS-341 has profound effects on growth and apoptosis of GBM cells, suggesting that PS-341 maybe an effective therapy for patients with gliomas.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, 8700 Beverly Blvd,Davis Bldg 5022 Room, Los Angeles, CA 90048 USA.	Dong.Yin@cshs.org		Black, Keith/0000-0002-0546-4934				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; An JB, 2003, CLIN CANCER RES, V9, P4537; Cusack JC, 2001, CANCER RES, V61, P3535; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; IMAI Y, 1994, MODERN PATHOL, V7, P766; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LeBlanc R, 2002, CANCER RES, V62, P4996; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2002, MOL CANCER THER, V1, P841; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tani E, 2001, FEBS LETT, V504, P53, DOI 10.1016/S0014-5793(01)02770-3; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x	33	205	211	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2005	24	3					344	354		10.1038/sj.onc.1208225	http://dx.doi.org/10.1038/sj.onc.1208225			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531918				2022-12-28	WOS:000226279700006
J	Koutsodontis, G; Kardassis, D				Koutsodontis, G; Kardassis, D			Inhibition of p53-mediated transcriptional responses by mithramycin A	ONCOGENE			English	Article						p53; mithramycin A; 5-fluorouracil; genotoxic stress; p21(Cip1); PUMA; Sp1	COLORECTAL-CANCER CELLS; DEPENDENT KINASES; PAGETS-DISEASE; CDK INHIBITORS; FAMILY-MEMBERS; SMAD PROTEINS; IN-VIVO; P53; PROMOTER; SP1	In the present work, we show that mithramycin A, a drug that is currently used for the treatment of patients with Paget's disease of the bone as well as with several forms of cancer, is a strong activator of the tumor suppressor p53 protein in human hepatoma cells. The time course of p53 activation by mithramycin A was similar to the known chemotherapeutic compound 5-fluorouracil (5-FU). Both 5-FU and mithramycin A induced site-specific phosphorylation of p53 at serine 15. However, in contrast to 5-FU, mithramycin A failed to activate p53 target genes including the cell cycle inhibitor p21(Cip1) gene as well as the proapoptotic genes PUMA (p53-upregulated mediator of apotosis) and BAK (bcl2-homologous antagonist/killer) and blocked the induction of the above genes by 5-FU. Using transactivation assays in Sp1-deficient cells, we showed that mithramycin A inhibited the transcriptional activation of the p21(Cip1) and PUMA promoters by Sp1 and p53. Using chromatin immunoprecipitation assays and a novel protein-protein interaction assay based on biotinylation in vivo, we established that 5-FU enhanced the formation of p53-Sp1 complexes in solution and the subsequent recruitment of both factors to the p21(Cip1) promoter. Mithramycin A also enhanced the recruitment of p53 to the distal p21(Cip1) promoter but totally blocked the recruitment of Sp1 to the proximal p21(Cip1) promoter. Our findings suggest that inhibition of Sp1 binding to the promoters of several p53 target genes, such as the p21(Cip1) gene as well as certain proapoptotic genes, by mithramycin A, prevents the transcriptional induction of these genes by p53 and propose a mechanism that could account for some of the tumor suppressing and antiapoptotic effects of mithramycin A.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	kardasis@imbb.forth.gr						AICH P, 1995, BIOCHEMISTRY-US, V34, P1376, DOI 10.1021/bi00004a032; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELIAS EG, 1972, J BONE JOINT SURG AM, VA 54, P1730, DOI 10.2106/00004623-197254080-00013; Gartel AL, 2002, MOL CANCER THER, V1, P639; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HALL TJ, 1993, BIOCHEM BIOPH RES CO, V195, P1245, DOI 10.1006/bbrc.1993.2178; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jayasuriya H, 2002, J NAT PROD, V65, P1091, DOI 10.1021/np010642f; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Majee S, 1999, BIOCHEM PHARMACOL, V57, P981, DOI 10.1016/S0006-2952(98)00374-8; Majee S, 1999, EUR J BIOCHEM, V260, P619, DOI 10.1046/j.1432-1327.1999.00159.x; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z; RYAN WG, 1970, J AMER MED ASSOC, V213, P1153, DOI 10.1001/jama.213.7.1153; Schavinsky-Khrapunsky Y, 2003, ONCOGENE, V22, P5315, DOI 10.1038/sj.onc.1206782; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005	47	62	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9190	9200		10.1038/sj.onc.1208141	http://dx.doi.org/10.1038/sj.onc.1208141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489892				2022-12-28	WOS:000225638000004
J	Geahlen, RL; Handley, MD; Harrison, ML				Geahlen, RL; Handley, MD; Harrison, ML			Molecular interdiction of Src-family kinase signaling in hematopoietic cells	ONCOGENE			English	Review						Src-family kinase; kinase inhibitor; protein palmitoylation; protein myristoylation; lipid raft; SH2 domain	PROTEIN-TYROSINE KINASE; GPI-ANCHORED PROTEINS; FC-EPSILON-RI; AFFINITY PHOSPHOTYROSYL PEPTIDE; TRANSMEMBRANE ADAPTER PROTEIN; HETEROGENEOUS FATTY ACYLATION; CBL PROTOONCOGENE PRODUCT; LIPID RAFTS; N-MYRISTOYLTRANSFERASE; ANTIGEN RECEPTOR	The ability of Src-family kinases (SFKs) to mediate signaling from cell surface receptors in hematopoietic cells is a function of their catalytic activity, location and binding partners. Kinase activity is regulated in the cell by kinases and phosphatases that alter the state of phosphorylation of key tyrosine residues and by protein binding partners that stabilize the kinase in active or inactive conformations or localize the enzyme to specific subcellular or submembrane domains. Kinase activity and function can be modulated experimentally through the use of small molecule inhibitors designed to directly target catalytic or binding domains or regulate the location of the protein by altering its state of acylation.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Harrison, ML (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	harrison@pharmacy.purdue.edu		Geahlen, Robert/0000-0001-8400-2924	NCI NIH HHS [T32CA09634, CA37372] Funding Source: Medline; NIGMS NIH HHS [GM48099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372, T32CA009634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Arnold LD, 2000, BIOORG MED CHEM LETT, V10, P2167, DOI 10.1016/S0960-894X(00)00441-8; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bi K, 2001, SEMIN IMMUNOL, V13, P139, DOI 10.1006/smim.2000.0305; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2003, J EXP MED, V198, P1453, DOI 10.1084/jem.20031484; Burchat AF, 2002, BIOORG MED CHEM LETT, V12, P1687, DOI 10.1016/S0960-894X(02)00196-8; Burke TR, 2003, ACCOUNTS CHEM RES, V36, P426, DOI 10.1021/ar020127o; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Das J, 2003, BIOORG MED CHEM LETT, V13, P2145, DOI 10.1016/S0960-894X(03)00380-9; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; De Vos ML, 2001, BIOCHEM PHARMACOL, V62, P985, DOI 10.1016/S0006-2952(01)00739-0; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Filipp D, 2003, J EXP MED, V197, P1221, DOI 10.1084/jem.20022112; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; GILMER T, 1994, J BIOL CHEM, V269, P31711; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 2004, TRAFFIC, V5, P265, DOI 10.1111/j.1600-0854.2003.00163.x; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Hawash IY, 2002, BBA-MOL CELL RES, V1589, P140, DOI 10.1016/S0167-4889(02)00165-9; Heerklotz H, 2002, BIOPHYS J, V83, P2693, DOI 10.1016/S0006-3495(02)75278-8; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; HOOEJSI V, 2003, IMMUNOL REV, V191, P148; Hur EM, 2003, J EXP MED, V198, P1463, DOI 10.1084/jem.20030232; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; Kabouridis PS, 2003, BIOCHEM J, V371, P907, DOI 10.1042/BJ20021578; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Kwiatkowska K, 2003, J CELL SCI, V116, P537, DOI 10.1242/jcs.00254; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lawrence DS, 2003, ACCOUNTS CHEM RES, V36, P401, DOI 10.1021/ar020132s; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Lee TR, 1999, J MED CHEM, V42, P784, DOI 10.1021/jm980663f; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Maly DJ, 2000, P NATL ACAD SCI USA, V97, P2419, DOI 10.1073/pnas.97.6.2419; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pierce SK, 2004, NAT CELL BIOL, V6, P180, DOI 10.1038/ncb0304-180; Pizzo P, 2003, CURR OPIN IMMUNOL, V15, P255, DOI 10.1016/S0952-7915(03)00038-4; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Profit AA, 2001, J BIOL CHEM, V276, P9446, DOI 10.1074/jbc.M009262200; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rickles RJ, 1998, CHEM BIOL, V5, P529, DOI 10.1016/S1074-5521(98)90112-0; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sawyer TK, 2002, MINI-REV MED CHEM, V2, P475, DOI 10.2174/1389557023405765; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SCHLESINGER MJ, 1982, J BIOL CHEM, V257, P9887; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stankovic CJ, 1997, BIOORG MED CHEM LETT, V7, P1909, DOI 10.1016/S0960-894X(97)00334-X; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sundaramoorthi R, 2003, BIOPOLYMERS, V71, P717, DOI 10.1002/bip.10600; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Vrljic M, 2002, BIOPHYS J, V83, P2681, DOI 10.1016/S0006-3495(02)75277-6; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Waltenberger J, 1999, CIRC RES, V85, P12; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wilson BS, 2000, J CELL BIOL, V149, P1131, DOI 10.1083/jcb.149.5.1131; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813; Yeh RH, 2001, J BIOL CHEM, V276, P12235, DOI 10.1074/jbc.M011232200; Young RM, 2003, J BIOL CHEM, V278, P20746, DOI 10.1074/jbc.M211402200; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	117	21	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8024	8032		10.1038/sj.onc.1208078	http://dx.doi.org/10.1038/sj.onc.1208078			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489920				2022-12-28	WOS:000224558300013
J	Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M				Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M			Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning	ONCOGENE			English	Article						glioma; RLGS; RFX1; methylation; epigenetics	HUMAN PROSTATE-CANCER; DNA-BINDING; CPG ISLANDS; EXPRESSION; METHYLATION; PROTEIN; HYPERMETHYLATION; INACTIVATION; PROGRESSION; SEQUENCES	To identify the CpG islands differentially methylated in human glioma, we performed restriction landmark genomic scanning with a CpG methylation-sensitive enzyme. We found 12 spots, the intensity of which was entirely lost or decreased in both the human glioma tissues examined as compared with that in matched normal lymphocytes, indicating aberrant methylation of these CpG islands in gliomas. The expression of RFX1, one of the genes associated with the methylated CpG islands, was frequently decreased in human glioma cell lines and tissues. We also demonstrated that the isolated CpG island located in the seventh intron of the RFX1 gene had enhancer activity and was hypermethylated in all of the glioma tissues and cell lines analysed, but not in normal brains or lymphocytes. Treatment of glioma cells with a demethylating agent, 5-azacytidine, resulted in the expression of RFX1, indicating that the silencing of the RFX1 gene may be attributable to its methylation. RFX1 has been implicated in transcriptional downregulation of the proto-oncogene c-myc. By expression of the RFX1 gene, the cellular proliferative activity of glioma cells was suppressed. Taken together, these results suggest that the RFX1 gene may be epigenetically silenced in human gliomas and involved in glioma tumorigenesis.	Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan; Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan; Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Toda, Masahiro/L-2268-2013; nakamura, asuka/S-7235-2016	Kawakami, Yutaka/0000-0003-4836-2855; 				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FULTS D, 1992, CANCER RES, V52, P674; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Melki JR, 1999, CANCER RES, V59, P3730; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yamada KM, 2001, J CELL SCI, V114, P2375; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	28	25	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7772	7779		10.1038/sj.onc.1208058	http://dx.doi.org/10.1038/sj.onc.1208058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334059				2022-12-28	WOS:000224331600003
J	Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF				Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF			DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo	ONCOGENE			English	Article						PRMT3; DAL-1/4.1B; tumor suppressor; protein methylation	N-METHYLTRANSFERASE; SUBCELLULAR-LOCALIZATION; BINDING; DOMAIN; SPECIFICITY; GROWTH; CD44; TRANSCRIPTION; MEMBRANE; RECEPTOR	DAL-1 (differentially expressed in adenocarcinoma of the lung)/4.1B is a tumor suppress-or gene on human chromosome 18p11.3 whose expression is lost in >50% of primary non-small-cell lung carcinomas. Based on sequence similarity, DAL-1/4.1B has been assigned to the Protein 4.1 superfamily whose members interact with plasma membrane proteins through their N-terminal FERM (4.1/Ezrin/Radixin/Moesin) domain, and cytoskeletal components via their C-terminal SAB (spectrin-actin binding) region. Using the DAL-1/4.1B FERM domain as bait for yeast two-hybrid interaction cloning, we identified protein arginine N-methyltransferase 3 (PRMT3) as a specific DAL-1/4.1B-interacting protein. PRMT3 catalyses the post-translational transfer of methyl groups from S-adenosyl-L-methionine to arginine residues of proteins. Coimmunoprecipitation experiments using lung and breast cancer cell lines confirmed this interaction in mammalian cells in vivo. In vitro binding assays demonstrated that this was an interaction occurring via the C-terminal catalytic core domain of PRMT3. DAL-1/4.1B was determined not to be a substrate for PRMT3-mediated methylation but its presence inhibits the in vitro methylation of a glycine-rich and arginine-rich methyl-accepting protein, GST (glutathione-S-transferase-GAR (glycine- and arginine-rich), which contains 14 'RGG' consensus methylation sites. In addition, induced expression of DAL-1/4.1B in MCF-7 breast cancer cells showed that the DAL-1/4.1B protein significantly inhibits PRMT3 methylation of cellular substrates. These findings suggest that modulation of post-translational methylation may be an important mechanism through which DAL-1/ 4.1B affects tumor cell growth.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Henry Ford Health System; Henry Ford Hospital; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Washington University (WUSTL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Newsham, IF (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	irene@bogler.net		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [F32-CA-097816-01, CA77030] Funding Source: Medline; NIGMS NIH HHS [GM26020, T32 GM07185] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, T32GM007185, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; Trofatter J A, 1993, Cell, V75, P826; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060	45	85	104	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7761	7771		10.1038/sj.onc.1208057	http://dx.doi.org/10.1038/sj.onc.1208057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334060	Bronze			2022-12-28	WOS:000224331600002
J	Giraud, S; Hurlstone, A; Avril, S; Coqueret, O				Giraud, S; Hurlstone, A; Avril, S; Coqueret, O			Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene	ONCOGENE			English	Article						STAT3; chromatin; acetylation; p21waf1	RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION; COMPLEX; STAT3; PHOSPHORYLATION; RECRUITMENT; ACETYLATION; INTERACTS; PROMOTER; PROTEIN	STAT transcription factors ( signal transducers and activators of transcription) are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation. Following tyrosine phosphorylation, STAT proteins translocate into the nucleus and activate specific target genes. We have previously reported that STAT3 activates the expression of the p21waf1 gene through its association with the NcoA/SRC1a and CBP coactivators. In this study, we explore the role of BRG1, a component of the SWI/SNF chromatin-remodeling complex, and the role of cdk9, a component of the elongation factor P-TEFb, in the STAT3-mediated expression of p21waf1. We found using pull-down experiments and co-immunoprecipitation assays that both proteins associate with STAT3. Chromatin immunoprecipitation (ChIP) experiments indicate that STAT3 DNA binding results in histone H3 acetylation and BRG1 recruitment. Using Southern blot analysis, we found that the loading of BRG1 is followed by an increased accessibility of the proximal p21waf1 promoter and by the association of RNA polymerase II. As a next step, STAT3 then recruits the cdk9 kinase to phosphorylate the carboxy-terminal domain of the RNA polymerase at serine 2. Accordingly, the elongating form of the polymerase can be detected by ChIP experiments on the coding region of the gene, probably initiating mRNA synthesis. Therefore, STAT3 not only promotes the initiation of transcription but also regulates chromatin remodeling and transcription elongation through its interaction with BRG1 and cdk9.	CHU Angers, INSERM, U564, F-49033 Angers, France; Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Coqueret, O (corresponding author), CHU Angers, INSERM, U564, 4 Rue Larrey, F-49033 Angers, France.	olivier.coqueret@univ-angers.fr	AVRIL, sylvie/K-6024-2015; Coqueret, Olivier/K-9660-2015	Coqueret, Olivier/0000-0002-2843-7867; Hurlstone, Adam/0000-0001-5260-9457; Avril, Sylvie/0000-0003-0574-6752				Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000	22	85	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7391	7398		10.1038/sj.onc.1207972	http://dx.doi.org/10.1038/sj.onc.1207972			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286705				2022-12-28	WOS:000224021400009
J	Chambers, I; Smith, A				Chambers, I; Smith, A			Self-renewal of teratocarcinoma and embryonic stem cells	ONCOGENE			English	Review						pluripotency; teratocarcinoma; Nanog; Oct4; STAT3; GATA6	LEUKEMIA INHIBITORY FACTOR; INTRATESTICULAR GRAFTS; TRANSCRIPTION FACTOR; PLURIPOTENT CELLS; GENE-EXPRESSION; ID PROTEINS; MOUSE; DIFFERENTIATION; ACTIVATION; NANOG	Pluripotent stem cells derived from preimplantation embryos, primordial germ cells or teratocarcinomas are currently unique in undergoing prolonged symmetrical self-renewal in culture. For mouse embryonic stem (ES) cells, self-renewal is dependent on signals from the cytokine leukaemia inhibitory factor (LIF) and from either serum or bone morphogenetic proteins (BMPs). In addition to the extrinsic regulation of gene expression, intrinsic transcriptional determinants are also required for maintenance of the undifferentiated state. These include Oct4, a member of the POU family of homeodomain proteins and a second recently identified homeodomain protein, Nanog. When overexpressed, Nanog allows ES cells to self-renew in the absence of the otherwise obligatory LIF and BMP signals. Although Nanog can act independent of the LIF signal, a contribution of both pathways provides maximal self-renewal efficiency. Nanog function also requires Oct4. Here, we review recent progress in ES cell self-renewal, relate this to the biology of teratocarcinomas and offer testable hypotheses to expose the mechanics of ES cell self-renewal.	Univ Edinburgh, MRC, Ctr Dev Stem Cell Biol, Inst Stem Cell Res, Edinburgh EH9 3JQ, Midlothian, Scotland	University of Edinburgh	Chambers, I (corresponding author), Univ Edinburgh, MRC, Ctr Dev Stem Cell Biol, Inst Stem Cell Res, Kings Bldg,E Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	ichambers@ed.ac.uk; austin.smith@ed.ac.uk	Chambers, Ian/H-5416-2011	Chambers, Ian/0000-0003-2605-1597; Smith, Austin/0000-0002-3029-4682				Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147; Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Buehr M, 2003, PHILOS T R SOC B, V358, P1397, DOI 10.1098/rstb.2003.1327; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Burdon T, 1999, CELLS TISSUES ORGANS, V165, P131, DOI 10.1159/000016693; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FINCH BW, 1967, P NATL ACAD SCI USA, V57, P615, DOI 10.1073/pnas.57.3.615; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Guo Y, 2002, P NATL ACAD SCI USA, V99, P3663, DOI 10.1073/pnas.062041099; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Hart AH, 2004, DEV DYNAM, V230, P187, DOI 10.1002/dvdy.20034; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KAWASE E, 1994, INT J DEV BIOL, V38, P385; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Lako M, 2001, MECH DEVELOP, V103, P49, DOI 10.1016/S0925-4773(01)00331-8; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; Lloyd S, 2003, GENE EXPR PATTERNS, V3, P309, DOI 10.1016/S1567-133X(03)00046-2; Looijenga LHJ, 2003, CANCER RES, V63, P2244; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN GR, 1975, TERATOMAS DIFFERENTI, P169; MATIN MM, 2004, IN PRESS STEM CELLS; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; Nichols J, 2001, DEVELOPMENT, V128, P2333; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Norton JD, 2000, J CELL SCI, V113, P3897; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Payer B, 2003, CURR BIOL, V13, P2110, DOI 10.1016/j.cub.2003.11.026; Pera MF, 2003, METHOD ENZYMOL, V365, P429; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Pierce G B, 1967, Curr Top Dev Biol, V2, P223; Qu CK, 1998, ONCOGENE, V17, P433, DOI 10.1038/sj.onc.1201920; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Skotheim RI, 2003, APMIS, V111, P136, DOI 10.1034/j.1600-0463.2003.11101181.x; Skotheim RI, 2002, CANCER RES, V62, P2359; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITH TA, 1983, EXP CELL RES, V145, P458, DOI 10.1016/0014-4827(83)90025-3; SOLTER D, 1970, NATURE, V227, P503, DOI 10.1038/227503a0; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2; STEVENS LC, 1968, J EMBRYOL EXP MORPH, V20, P329; STEVENS LC, 1983, TERATOCARCINOMA STEM, P23; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tu Z, 2001, BLOOD, V98, P2028, DOI 10.1182/blood.V98.7.2028; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693	97	410	450	2	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7150	7160		10.1038/sj.onc.1207930	http://dx.doi.org/10.1038/sj.onc.1207930			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378075	Green Published			2022-12-28	WOS:000223998800001
J	Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M				Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M			Paired-like homeodomain protein ESXR1 possesses a cleavable C-terminal region that inhibits cyclin degradation	ONCOGENE			English	Article						ESXR1; cyclin; paired-like homeodomain; processing; M-phase arrest	MITOSIS UNTIL; DNA-BINDING; KINASE; PHOSPHORYLATION; PROTEOLYSIS; CELLS; G1; PROGRESSION; ACTIVATION; ONSET	The eukaryotic cell cycle is regulated by sequential activation and inactivation of cyclin-cyclin-dependent kinase (Cdk) complexes. In this work, we screened human cDNAs that can rescue yeast Saccharomyces cerevisiae from lethality caused by ectopic expression of human cyclin E and isolated a cDNA encoding ESXR1, a paired-like homeodomain-containing protein with a unique C-terminal proline-rich repeat region. In adult tissues, ESXR1 is primarily expressed in the testis. We demonstrate that ESXR1 prevents degradation of ubiquitinated cyclins in human cells. Accordingly, elevation of ESXR1 level results in accumulation of cyclin A and cyclin B1 and thereby provokes M-phase arrest. In human cells, the 65-kDa full-length ESXR1 protein is capable of proteolytically processing into N-terminal 45-kDa and C-terminal 20-kDa fragments. The C-terminal fragment, containing a proline-rich repeat region, is localized to the cytoplasm and displays the ability to inhibit cyclin degradation. In contrast, the N-terminal fragment, containing a paired-like homeodomain, is localized exclusively in the nucleus, suggesting that it plays a role in transcription. Our results indicate that proteolytic processing of ESXR1 plays a role in concerted regulation of the cell cycle and transcription in human cells.	Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600815, Japan; Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Supramol Struct, Tokyo 1130032, Japan; Hokkaido Univ, Ctr Adv Sci & Technol, Lab Anim Cytogenet, Sapporo, Hokkaido 0600810, Japan; Kawasaki Med Sch, Dept Urol, Kurashiki, Okayama 7010192, Japan	Hokkaido University; Hokkaido University; Kitasato University; University of Tokyo; Hokkaido University; Kawasaki Medical School	Hatakeyama, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Maeda, Tatsuya/L-5540-2019; Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012	OHNISHI, Naomi/0000-0002-2382-3152				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Branford WW, 1997, MECH DEVELOP, V65, P87, DOI 10.1016/S0925-4773(97)00058-0; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAUMANN M, 1993, ONCOGENE, V8, P2275; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Sette C, 1999, J BIOL CHEM, V274, P33571, DOI 10.1074/jbc.274.47.33571; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Su TT, 2001, CURR BIOL, V11, pR467, DOI 10.1016/S0960-9822(01)00283-4; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000	32	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6590	6602		10.1038/sj.onc.1207884	http://dx.doi.org/10.1038/sj.onc.1207884			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235584				2022-12-28	WOS:000223530800006
J	Pike, MC; Pearce, CL; Wu, AH				Pike, MC; Pearce, CL; Wu, AH			Prevention of cancers of the breast, endometrium and ovary	ONCOGENE			English	Review						prevention; breast cancer; endometrial cancer; ovarian cancer	HORMONE REPLACEMENT THERAPY; BODY-MASS INDEX; RISK-FACTORS; POSTMENOPAUSAL WOMEN; REPRODUCTIVE FACTORS; MAMMOGRAPHIC DENSITIES; CHORIONIC-GONADOTROPIN; EPITHELIAL TUMORS; ESTROGEN-LEVELS; UNITED-STATES	A central epidemiological feature of cancers of the breast, endometrium and ovary is the sharp slowing down in their rate of increase with age around the time of menopause. The incidence of these tumors by the age of 70 years would be between fourfold and eightfold increased if the rapid increase with age seen in young women continued into old age. These phenomena can be explained by the different effects of ovarian hormones on cell division rates in the relevant tissues. Models of these effects provide a plausible explanation of most of the known epidemiology of each of the cancers, including the increase in breast cancer risk from menopausal estrogen-progestin therapy. Some recent epidemiological findings in endometrial and ovarian cancer suggest new avenues for possible chemoprevention of these cancers.	USC, Norris Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California	Pike, MC (corresponding author), USC, Norris Canc Ctr, Los Angeles, CA 90089 USA.	mcpike@usc.edu						ALBREKTSEN G, 1995, INT J CANCER, V61, P485, DOI 10.1002/ijc.2910610410; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ANDERSON TJ, 1982, BRIT J CANCER, V46, P376, DOI 10.1038/bjc.1982.213; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERNSTEIN L, 1990, CANCER CAUSE CONTROL, V1, P51, DOI 10.1007/BF00053183; BERNSTEIN L, 1995, CANCER EPIDEM BIOMAR, V4, P437; Blankenstein MA, 1999, J STEROID BIOCHEM, V69, P293, DOI 10.1016/S0960-0760(99)00048-5; Boyd NF, 2002, NEW ENGL J MED, V347, P886, DOI 10.1056/NEJMoa013390; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; BRINTON LA, 1992, AM J OBSTET GYNECOL, V167, P1317, DOI 10.1016/S0002-9378(11)91709-8; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650; CASAGRANDE JT, 1979, LANCET, V2, P170; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Cerin A, 1996, NEW ENGL J MED, V334, P668, DOI 10.1056/NEJM199603073341018; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Colditz GA, 2000, AM J EPIDEMIOL, V152, P950, DOI 10.1093/aje/152.10.950; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUTLER SJ, 1975, NATL CANC I MONOGR, V41; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; El-Bastawissi AY, 2001, ANN EPIDEMIOL, V11, P257, DOI 10.1016/S1047-2797(00)00225-8; Engeland A, 2003, JNCI-J NATL CANCER I, V95, P1244, DOI 10.1093/jnci/djg010; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; Fairfield KM, 2002, OBSTET GYNECOL, V100, P288, DOI 10.1016/S0029-7844(02)02053-7; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; FLOWERS CE, 1983, OBSTET GYNECOL, V61, P135; FUJIMOTO I, 1979, NATL CANCER I MONOGR, V53, P5; Gapstur SM, 2003, CANCER EPIDEM BIOMAR, V12, P1074; GOLDIN BR, 1986, AM J CLIN NUTR, V44, P945, DOI 10.1093/ajcn/44.6.945; Gram IT, 2001, CANCER EPIDEM BIOMAR, V10, P1117; Greendale GA, 2003, J NATL CANCER I, V95, P30, DOI 10.1093/jnci/95.1.30; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1981, LANCET, V2, P363; HENDERSON BE, 1981, HORMONES BREAST CANC, P115; HOEL DG, 1983, AM J EPIDEMIOL, V118, P78, DOI 10.1093/oxfordjournals.aje.a113619; Jakes RW, 2002, CANCER EPIDEM BIOMAR, V11, P608; JANERICH DT, 1979, LANCET, V1, P1240; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; KEY TJA, 1990, BRIT J CANCER, V62, P631, DOI 10.1038/bjc.1990.344; KING RJB, 1984, MED MANAGEMENT ENDOM, P67; Kuper H, 2002, CANCER CAUSE CONTROL, V13, P455, DOI 10.1023/A:1015751105039; KVALE G, 1988, CANCER RES, V48, P6217; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Lambe M, 1999, CANCER CAUSE CONTROL, V10, P43, DOI 10.1023/A:1008860615584; LANE G, 1986, FERTIL STERIL, V45, P345; LEE NC, 1987, JAMA-J AM MED ASSOC, V257, P796; LEE NC, 1986, AGING REPROD CLIMACT; Lippman SM, 1999, JNCI-J NATL CANCER I, V91, P1809, DOI 10.1093/jnci/91.21.1809; Lubin F, 2003, AM J EPIDEMIOL, V157, P113, DOI 10.1093/aje/kwf184; Lukanova A, 2002, INT J CANCER, V99, P603, DOI 10.1002/ijc.10374; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; McPherson CP, 1996, AM J EPIDEMIOL, V143, P1195, DOI 10.1093/oxfordjournals.aje.a008707; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Ness RB, 2002, AM J EPIDEMIOL, V155, P217, DOI 10.1093/aje/155.3.217; NEWHOUSE ML, 1977, BRIT J PREV SOC MED, V31, P148; *OFF POP CENS SURV, 1978, DEC SUPPL OCC MORT 1, V1; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PEARCE CL, 2004, UNPUB; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PETTERSSON B, 1986, ACTA OBSTET GYN SCAN, V65, P247, DOI 10.3109/00016348609155179; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Pike MC, 2004, FERTIL STERIL, V82, P186, DOI 10.1016/j.fertnstert.2004.03.013; Pike MC, 2002, CANCER EPIDEM BIOMAR, V11, P795; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PIKE MC, 1989, BRIT J CANCER, V60, P142, DOI 10.1038/bjc.1989.237; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Purdie DM, 2001, CANCER CAUSE CONTROL, V12, P855, DOI 10.1023/A:1012267619561; Riman T, 2002, AM J EPIDEMIOL, V156, P363, DOI 10.1093/aje/kwf048; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; RISCH HA, 1994, AM J EPIDEMIOL, V140, P585, DOI 10.1093/oxfordjournals.aje.a117296; Rodriguez C, 2002, CANCER EPIDEM BIOMAR, V11, P822; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Royar J, 2001, INT J CANCER, V95, P370, DOI 10.1002/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T; RUSSO IH, 1991, BRIT J CANCER, V64, P481, DOI 10.1038/bjc.1991.335; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; Schairer C, 2000, JAMA-J AM MED ASSOC, V284, P693; Schildkraut JM, 2001, OBSTET GYNECOL, V98, P85, DOI 10.1016/S0029-7844(01)01388-6; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32; Schouten LJ, 2003, AM J EPIDEMIOL, V157, P424, DOI 10.1093/aje/kwf224; SHIMIZU H, 1990, BRIT J CANCER, V62, P451, DOI 10.1038/bjc.1990.316; SIITERI PK, 1981, HORMONES BREAST CANC, P87; Siiteri PK, 1973, HDB PHYSIOLOGY ENDOC, P615; SIMEONS ATW, 1954, LANCET, V2, P946; Sit ASY, 2002, GYNECOL ONCOL, V86, P118, DOI 10.1006/gyno.2002.6746; SPICER DV, 1994, J NATL CANCER I, V86, P431, DOI 10.1093/jnci/86.6.431; SPICER DV, 1993, CONTRACEPTION, V47, P427, DOI 10.1016/0010-7824(93)90095-O; SPICER DV, 1991, CONTRACEPTION, V44, P289, DOI 10.1016/0010-7824(91)90019-C; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P714, DOI 10.1054/bjoc.2000.1596; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; Tung KH, 2003, AM J EPIDEMIOL, V158, P629, DOI 10.1093/aje/kwg177; Ursin G, 1998, CANCER EPIDEM BIOMAR, V7, P43; WATERHOUSE J, 1976, IARC SCI PUBLICATION, V1; WEISS NS, 1982, J NATL CANCER I, V68, P95; WELSCH CW, 1981, HORMONES BREAST CANC, P299; Whiteman DC, 2003, CANCER EPIDEM BIOMAR, V12, P42; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLIAMS DB, 1994, OBSTET GYNECOL, V84, P787; Zhou H, 2002, CANCER BIOL THER, V1, P300, DOI 10.4161/cbt.86; [No title captured]	111	103	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6379	6391		10.1038/sj.onc.1207899	http://dx.doi.org/10.1038/sj.onc.1207899			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322512	Bronze			2022-12-28	WOS:000223468800006
J	Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K				Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K			Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells	ONCOGENE			English	Article						tumor suppressor; p53; mitochondria; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL TARGET; THERAPEUTIC AGENTS; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ACTIVATION	p53 can eliminate damaged cells through the induction of mitochondria-mediated apoptosis. Recent observations have provided strong evidence that a fraction of total p53 translocates to mitochondria specifically in response to a death stimulus. Unexpectedly, mutant p53, which is expressed at much higher levels than wild type in unstressed cells, is apparently always present at the mitochondria, independent of apoptotic signal. This prompted us to ask whether cell lines with intact p53-dependent apoptosis and cell cycle arrest pathways exist in which the mitochondrial localization of wild-type p53, like that of mutant, is independent of a death stimulus and instead, correlates with the total p53 levels. Here, we document that human HCT116 colorectal carcinoma cells treated with adriamycin or 5-fluorouracil (5FU) can accumulate total p53 to equally high levels, and mitochondrial p53 to proportionate levels, although only 5FU treatment provoked p53-dependent apoptosis. Along the same line, HCT116 derivatives with increased basal p53 levels, and glioblastoma cells with a doxycycline-inducible p53, also revealed proportionate mitochondrial p53 levels, and even unstressed HCT116 cells had some p53 located at the mitochondria. Finally, mitochondrial and total p53 showed distinct post-translational modi. cations. Thus, cell lines exist in which the mitochondrial p53 levels parallel total levels independent of apoptosis.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Anat & Cell Biol, Ctr Electron Microscopy, D-66421 Homburg, Germany	Saarland University; Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@med-rz.uni-saarland.de						Attardi LD, 2000, GENE DEV, V14, P704; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Robles AI, 2001, CANCER RES, V61, P6660; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	41	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6226	6236		10.1038/sj.onc.1207637	http://dx.doi.org/10.1038/sj.onc.1207637			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247902				2022-12-28	WOS:000223399000007
J	Bren-Mattison, Y; Van Putten, V; Chan, D; Winn, R; Geraci, MW; Nemenoff, RA				Bren-Mattison, Y; Van Putten, V; Chan, D; Winn, R; Geraci, MW; Nemenoff, RA			Peroxisome proliferator-activated receptor-gamma (PPAR gamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)	ONCOGENE			English	Article						PPAR gamma; non-small-cell lung cancer; metastasis; tumorigenesis; differentiation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MACROPHAGE-GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; LIGAND TROGLITAZONE; COLORECTAL-CANCER; EPITHELIAL-CELL; BREAST-CANCER; COLON-CANCER; PHASE-II; DIFFERENTIATION	Pharmacological activators of peroxisome proliferatoractivated receptor-gamma (PPARgamma) have been shown to inhibit growth of lung tumors largely through growth inhibition and induction of apopotosis. However, since many of these agents engage other effectors, the role of PPARgamma in lung tumorigenesis remains poorly defined. To specifically examine PPARgamma-mediated events, non-small-cell lung cancer (NSCLC) cells overexpressing PPARgamma were established. Overexpression of PPARgamma in H2122 adenocarcinoma cells (H2122-PPARgamma) blocked anchorage-independent growth compared to cells transfected with empty vector (H2122-LNCX), but had no significant effect on cell proliferation or apoptosis under standard tissue culture conditions. Orthotopic implantation of H2122-PPARgamma cells into the lungs of nude rats inhibited tumor growth and metastasis in vivo and prolonged survival compared to implantation of H2122-LNCX cells. Consistent with these findings, H2122-PPARgamma cells had an impaired invasiveness as assessed in Transwell assays. In a three-dimensional culture system, H2122-PPARgamma cells formed polarized spheroid structures similar to those observed with normal lung epithelial cells. H2122-LNCX cells formed nonpolarized aggregate structures and did not show any of these epithelial properties. These data indicate that inhibitory effects of PPARgamma on lung tumorigenesis involve selective inhibition of invasive metastasis, and activation of pathways that promote a more differentiated epithelial phenotype.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.	raphael.nemenoff@uchsc.edu			NCI NIH HHS [CA58187, CA108610, CA103618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103618, R01CA108610, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Bell-Parikh LC, 2003, J CLIN INVEST, V112, P945, DOI 10.1172/JCI200318012; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Chan DC, 2002, CLIN CANCER RES, V8, P904; Chang TH, 2000, CANCER RES, V60, P1129; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kerr KM, 2001, J CLIN PATHOL, V54, P257, DOI 10.1136/jcp.54.4.257; Keshamouni VG, 2004, ONCOGENE, V23, P100, DOI 10.1038/sj.onc.1206885; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MALKINSON AM, 1979, TOXICOL APPL PHARM, V49, P551, DOI 10.1016/0041-008X(79)90457-5; March TH, 2001, VET PATHOL, V38, P483, DOI 10.1354/vp.38-5-483; Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; ROBERTS PE, 1990, AM J PHYSIOL, V259, pL415, DOI 10.1152/ajplung.1990.259.6.L415; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sasaki H, 2002, LUNG CANCER-J IASLC, V36, P71, DOI 10.1016/S0169-5002(01)00449-4; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Theocharis S, 2002, LUNG CANCER, V36, P249, DOI 10.1016/S0169-5002(02)00013-2; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Whitehead CM, 2003, MOL CANCER THER, V2, P479; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291	49	98	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1412	1422		10.1038/sj.onc.1208333	http://dx.doi.org/10.1038/sj.onc.1208333			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608671				2022-12-28	WOS:000227092600011
J	Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T				Tatsuka, M; Sato, S; Kitajima, S; Suto, S; Kawai, H; Miyauchi, M; Ogawa, I; Maeda, M; Ota, T; Takata, T			Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis	ONCOGENE			English	Article						oral cancer; susceptibility; polymorphism; Ras; Aurora-A	CENTROSOME AMPLIFICATION; LIM PROTEIN; KINASE; GENE; RAS; CANCER; CELLS; PHOSPHORYLATION; SUSCEPTIBILITY; IDENTIFICATION	Aurora kinases are known to play a key role in maintaining mitotic fidelity, and overexpression of aurora kinases has been noted in various tumors. Overexpression of aurora kinase activity is thought to promote cancer development through a loss of centrosome or chromosome number integrity. Here we observed augmentation of G12V-mutated HRAS-induced neoplastic transformation in BALB/c 3T3 A31-1-1 cells transfected with Aurora-A. Aurora-A-short hairpin RNA (shRNA) experiments showed that the expression level of Aurora-A determines susceptibility to transformation. Aurora-A gene amplification was noted in human patients with tongue or gingival squamous carcinoma (4/11). Amplification was observed even in pathologically normal epithelial tissue taken at sites distant from the tumors in two patients with tongue cancer. However, overexpression of Aurora-A mRNA was observed only within the tumors of all patients examined (11/11). Our data indicate that Aurora-A gene amplification and overexpression play a role in human carcinogenesis, largely due to the effect of Aurora-A on oncogenic cell growth, rather than a loss of maintenance of centrosomal or chromosomal integrity.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Sch Dent, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dent Hosp, Minami Ku, Hiroshima 7348553, Japan; Kanazawa Med Univ, Med Res Inst, Div Mol Oncol & Virol, Kanazawa, Ishikawa 9200293, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Kanazawa Medical University	Tatsuka, M (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regulatory Radiobiol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	haruo@hiroshima-u.ac.jp		Kitajima, Shojiro/0000-0002-4000-0473; Kawai, Hidehiko/0000-0003-2213-7166				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Goyal RK, 1999, MOL CELL BIOL, V19, P4379; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; KAKUNAGA T, 1985, TRANSF ASS EST CELL; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tatsuka M, 1997, INT J CANCER, V71, P88, DOI 10.1002/(SICI)1097-0215(19970328)71:1<88::AID-IJC15>3.3.CO;2-8; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	22	92	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1122	1127		10.1038/sj.onc.1208293	http://dx.doi.org/10.1038/sj.onc.1208293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592510				2022-12-28	WOS:000226749200020
J	Andrechek, ER; White, D; Muller, WJ				Andrechek, ER; White, D; Muller, WJ			Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth	ONCOGENE			English	Article						ErbB2; mammary gland; mouse models; epithelium	TRANSGENIC MICE REVEALS; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; LOBULOALVEOLAR DEVELOPMENT; EXPRESSION; AMPLIFICATION; NEU/ERBB-2; LACTATION; TUMORS	The ErbB2 receptor tyrosine kinase has been implicated as a critical growth factor receptor in both normal development and cancer. Amplification and overexpression of this receptor is observed in 20-30% of all human breast cancers and is inversely correlated with patient survival. Studies with transgenic mice have established that elevated expression of erbB2 in mammary epithelium can directly induce mammary carcinomas. Although these studies confirmed a role for ErbB2 in breast cancer induction, the precise role of ErbB2 in normal mammary gland development remained to be elucidated due to the embryonic lethality associated with the null mutation. Here, we demonstrate that the mammary-specific ablation of erbB2 through Cre-mediated recombination leads to a striking ductal elongation defect. In addition to the observed elongation defect, we noted that branching in the adult mammary gland was also reduced. Despite these perturbations in virgin mammary gland morphogenesis, targeted disruption of erbB2 had little impact on the ability of these animals to lactate. Taken together, these observations indicate that erbB2 plays a critical role in the initial stages of mammary gland morphogenesis.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McMaster Univ, Dept Biol, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada	McGill University; Royal Victoria Hospital; McMaster University; McMaster University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	william.muller@mcgill.ca		Andrechek, Eran/0000-0002-8680-3423				Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	22	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					932	937		10.1038/sj.onc.1208230	http://dx.doi.org/10.1038/sj.onc.1208230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580295				2022-12-28	WOS:000226577100018
J	Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB				Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB			Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis	ONCOGENE			English	Article						mda-7/IL-24; ROS; pancreatic cancer; apoptosis	DIFFERENTIATION-ASSOCIATED GENE-7; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; ARSENIC TRIOXIDE; GROWTH ARREST; MDA-7 IL-24; IN-VITRO; ENHANCES RADIOSENSITIVITY; TERMINAL DIFFERENTIATION; SELECTIVE APOPTOSIS	Pancreatic cancer is exceptionally aggressive with no long-term effective therapy. Current interventional approaches, including surgery, radiation and/or chemotherapy, have done little to quell the mortality associated with this malignancy. Subtraction hybridization identified a cancer-specific apoptosis-inducing cytokine gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/ IL-24), with a broad range of selective antitumor activity in diverse cancers both in vitro and in vivo in nude mice and recently in patients with advanced carcinomas and melanomas. Unlike most neoplasms, pancreatic cancers display innate resistance to mda-7/ IL-24-induced apoptosis, which correlates with a diminished capacity to convert mda-7/ IL-24 mRNA into protein. We presently demonstrate that this translational block can be reversed by treatment with agents that elevate reactive oxygen species (ROS). Induction of apoptosis in vitro and suppression of tumorigenesis in vivo in nude mice are induced in pancreatic cancers, irrespective of the status of their K-ras gene, only when tumor cells simultaneously express mda-7/ IL-24 and are treated with a ROS-inducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophene (NSC656240 (NSC)). In pancreatic cancer cells constitutively expressing mda-7/ IL-24 mRNA, a single treatment with arsenic trioxide, HPR or NSC656240 induces apoptosis, which correlates with production of MDA-7/IL-24 protein. The specificity of this action is documented by the ability of ROS inhibitors, including N-acetyl-L-cysteine and Tiron, to block this killing effect. Of potential clinical significance, similar treatment of normal cells does not elicit significant changes in growth nor does it induce apoptosis. Analysis of signal transduction changes in pancreatic carcinoma cells infected with Ad. mda-7 in combination with a ROS-inducer indicate that cell death correlates with modulation of discrete cassettes of multiple signaling pathways in a pancreatic cancer cell-specific manner, supporting global signaling dysregulation as a potential mediator of apoptosis induction. These findings suggest a promising combinatorial approach for safely promoting cell death in pancreatic tumors that provides a rational framework for developing a selective and effective therapy for this invariably fatal cancer.	Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [P01CA072955, R01CA088906, R01CA098712, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA98712, CA97318, CA72955, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kulke Matthew H, 2002, Curr Treat Options Oncol, V3, P449, DOI 10.1007/s11864-002-0065-5; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEBEDEVA IV, 2004, IN PRESS MOL THER; Li XQ, 2003, PANCREAS, V27, P174, DOI 10.1097/00006676-200308000-00011; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; McKenna S, 2003, ONCOLOGIST, V8, P149, DOI 10.1634/theoncologist.8-2-149; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller WH, 2002, CANCER RES, V62, P3893; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vuky J, 2002, INVEST NEW DRUG, V20, P327, DOI 10.1023/A:1016270206374; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xia Y, 2002, INT J CANCER, V102, P7, DOI 10.1002/ijc.10664; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	50	62	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					585	596		10.1038/sj.onc.1208183	http://dx.doi.org/10.1038/sj.onc.1208183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580305				2022-12-28	WOS:000226420400006
J	Elchuri, S; Oberley, TD; Qi, WB; Eisenstein, RS; Roberts, LJ; Van Remmen, H; Jepstein, CJ; Huang, TT				Elchuri, S; Oberley, TD; Qi, WB; Eisenstein, RS; Roberts, LJ; Van Remmen, H; Jepstein, CJ; Huang, TT			CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life	ONCOGENE			English	Article						CuZnSOD; hepatocellular carcinoma; aconitase; 8-oxo dG; cyclin D1; APEX1; Met	CARBONIC-ANHYDRASE-III; ZINC SUPEROXIDE-DISMUTASE; IRON REGULATORY PROTEINS; HEPATOCELLULAR-CARCINOMA; ANTIOXIDANT ENZYMES; GLUTATHIONE-PEROXIDASE; MITOCHONDRIAL-DNA; CYCLIN D1; LIVER; OVEREXPRESSION	Mice deficient in CuZn superoxide dismutase (CuZn-SOD) showed no overt abnormalities during development and early adulthood, but had a reduced lifespan and increased incidence of neoplastic changes in the liver. Greater than 70% of Sod1-/- mice developed liver nodules that were either nodular hyperplasia or hepatocellular carcinoma (HCC). Cross-sectional studies with livers collected from Sod1-/- and age-matched +/+ controls revealed extensive oxidative damage in the cytoplasm and, to a lesser extent, in the nucleus and mitochondria from as early as 3 months of age. A marked reduction in cytosolic aconitase, increased levels of 8-oxo dG and F2-isoprostanes, and a moderate reduction in glutathione peroxidase activities and porin levels were observed in all age groups of Sod1-/- mice examined. There were also age-related reductions in Mn superoxide dismutase activities and carbonic anhydrase III. Parallel to the biochemical changes, there were progressive increases in the DNA repair enzyme APEX1, the cell cycle control proteins cyclin D1 and D3, and the hepatocyte growth factor receptor Met. Increased cell proliferation in the presence of persistent oxidative damage to macromolecules likely contributes to hepatocarcinogenesis later in life.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA; VA Hosp, Pathol Serv, Madison, WI 53705 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Audie L Murphy Mem Vet Adm Med Ctr, GRECC, San Antonio, TX 78229 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94341 USA; Palo Alto VA Hlth Care Syst, GRECC, Palo Alto, CA 94304 USA	Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Health San Antonio; University of Wisconsin System; University of Wisconsin Madison; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of California System; University of California San Francisco; Geriatric Research Education & Clinical Center	Huang, TT (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, 3801 Miranda Ave,Bldg 100,Room D3-101,Mail Stop 1, Palo Alto, CA 94304 USA.	tthuang@stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK047219, R29DK047219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056, P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016633, R01AG016998] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Anzenbacher P, 2001, CELL MOL LIFE SCI, V58, P737, DOI 10.1007/PL00000897; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Bai JX, 1998, CHINESE MED J-PEKING, V111, P789; Blum HE, 2002, DIGEST DIS, V20, P81, DOI 10.1159/000063163; Bobola MS, 2001, CLIN CANCER RES, V7, P3510; Bonkovsky H L, 2000, Clin Liver Dis, V4, P409, DOI 10.1016/S1089-3261(05)70116-1; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CASARIL M, 1994, INT J CLIN LAB RES, V24, P94, DOI 10.1007/BF02593907; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Court FG, 2002, BRIT J SURG, V89, P1089, DOI 10.1046/j.1365-2168.2002.02166.x; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Crawford DHG, 1998, BAILLIERE CLIN GASTR, V12, P209, DOI 10.1016/S0950-3528(98)90131-2; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Deane NG, 2001, CANCER RES, V61, P5389; Diehl AM, 2002, FRONT BIOSCI-LANDMRK, V7, pE301, DOI 10.2741/diehl; Dominguez-Malagon H, 2001, ULTRASTRUCT PATHOL, V25, P497, DOI 10.1080/019131201753343539; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fletcher LM, 2002, J INTERN MED, V251, P181, DOI 10.1046/j.1365-2796.2002.00945.x; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Haddow JE, 2003, J MED SCREEN, V10, P11, DOI 10.1258/096914103321610743; Hamilton ML, 2001, NUCLEIC ACIDS RES, V29, P2117, DOI 10.1093/nar/29.10.2117; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; Huang C, 1990, Zhonghua Yi Xue Za Zhi, V70, P138; HUANG C, 1990, ZHONGHUA YI XUE ZA Z, V70, P12; Huang TT, 2002, METHOD ENZYMOL, V349, P191, DOI 10.1016/S0076-6879(02)49335-4; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; INAGAKI T, 1992, GASTROENTEROL JPN, V27, P382; Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kruidenier L, 2003, FREE RADICAL BIO MED, V34, P753, DOI 10.1016/S0891-5849(02)01426-0; Kuo WH, 2003, LIFE SCI, V73, P2211, DOI 10.1016/S0024-3205(03)00597-6; LEE GH, 1991, CANCER RES, V51, P3257; LEE GH, 1989, CARCINOGENESIS, V10, P2227, DOI 10.1093/carcin/10.12.2227; Lee HC, 2004, MUTAT RES-FUND MOL M, V547, P71, DOI 10.1016/j.mrfmmm.2003.12.011; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Levy L, 2002, ANN NY ACAD SCI, V963, P21; Liaw KY, 1997, AM J GASTROENTEROL, V92, P2260; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; Lin MT, 2001, HEPATO-GASTROENTEROL, V48, P1102; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Liu YL, 2004, BIOCHEM PHARMACOL, V67, P777, DOI 10.1016/j.bcp.2003.09.025; LOEB LA, 1991, CANCER RES, V51, P3075; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Moriya K, 2001, CANCER RES, V61, P4365; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; MUSE KE, 1994, HISTOCHEM J, V26, P734, DOI 10.1007/BF00158205; Neonaki M, 2002, BIOCHEM SOC T, V30, P726, DOI 10.1042/BST0300726; NOWELL PC, 1979, CLIN IMMUNOL IMMUNOP, V12, P323, DOI 10.1016/0090-1229(79)90035-7; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Oberley TD, 1999, FREE RADICAL BIO MED, V27, P695, DOI 10.1016/S0891-5849(99)00117-3; Oberley TD, 2000, PROSTATE, V44, P144, DOI 10.1002/1097-0045(20000701)44:2<144::AID-PROS7>3.0.CO;2-G; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; Ozaki M, 2002, FASEB J, V16, P889, DOI 10.1096/fj.01-0664fje; Perlmutter D H, 2000, Clin Liver Dis, V4, P387, DOI 10.1016/S1089-3261(05)70115-X; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; PUGH TD, 1992, CANCER RES, V52, P280; Puglisi F, 2001, ANTICANCER RES, V21, P4041; Raisanen SR, 1999, FASEB J, V13, P513, DOI 10.1096/fasebj.13.3.513; Robertson KA, 2001, CANCER RES, V61, P2220; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sauer H, 2004, EXP CELL RES, V294, P313, DOI 10.1016/j.yexcr.2003.10.032; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Sola B, 1999, INT J CANCER, V83, P230, DOI 10.1002/(SICI)1097-0215(19991008)83:2<230::AID-IJC14>3.0.CO;2-J; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; SUN Y, 1993, CARCINOGENESIS, V14, P1457, DOI 10.1093/carcin/14.7.1457; Takahashi K, 2002, TOXICOL PATHOL, V30, P599, DOI 10.1080/01926230290105776; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang Y, 2002, CANCER RES, V62, P1205; Zimmermann Artur, 2002, Med Sci Monit, V8, pRA53	89	455	474	1	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					367	380		10.1038/sj.onc.1208207	http://dx.doi.org/10.1038/sj.onc.1208207			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531919				2022-12-28	WOS:000226279700008
J	Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP				Kopnin, PB; Kravchenko, IV; Furalyov, VA; Pylev, LN; Kopnin, BP			Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint	ONCOGENE			English	Article						asbestos; reactive oxygen species; mesothelial cells; p21(Cip1/Waf1); G1 checkpoint	PLEURAL MESOTHELIAL CELLS; INDUCED TRANSFORMATION; CROSS-LINKING; P53; EXPRESSION; MECHANISMS; DISEASE; ANTHRACYCLINES; ACTIVATION; APOPTOSIS	Exposure to asbestos fibers increases the risk of development of mesotheliomas and lung carcinomas, but not fibrosarcomas. We present data suggesting that resistance of fibroblasts to asbestos-induced carcinogenesis is likely to be connected with their lower ability to generate reactive oxygen species (ROS) in response to asbestos exposure and stricter control of proliferation of cells bearing asbestos/ROS-induced injuries. In fact, chrysotile (Mg6Si4O10(OH)(8)) asbestos exposure (5-10 mug/cm(2)) increased intracellular ROS and 8-oxo-guanine contents in rat pleural mesothelial cells, but not in lung fibroblasts. Simultaneously, moderate dosages of chrysotile and other agents increasing ROS levels ( hydrogen peroxide, H2O2 and ethyl-methanesulfonate, EMS) inhibited cell cycle progression, in particular G1-to-S transition, in fibroblasts, but not in mesothelial cells. The arrested fibroblasts underwent cell death, while the majority of chrysotile-treated mesothelial cells survived. The differences in cell cycle response to asbestos/ROS-induced injuries correlated with distinct activity of p53-p21(Cip1/Waf1) pathway in the two cell types. Chrysotile, H2O2 and EMS caused p53 upregulation in both cell types, but mesothelial cells, unlike fibroblasts, showed no accumulation of p21(Cip1/Waf1). Of note, treatment with doxorubicin caused similar p53-dependent p21(Cip1/Waf1) upregulation and cell cycle arrest in both cell types. This suggests differential response of fibroblasts and mesothelial cells specifically to asbestos/ROS exposure rather than to all DNA-damaging insults.	Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Univ Oslo, Moscow Ctr Med Studies, Moscow, Russia	N.N. Blokhin Russian Cancer Research Center; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kopnin, BP (corresponding author), Blokhin Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 115478, Russia.	bkopnin@yahoo.com	Kopnin, Pavel/R-8213-2019; Kravchenko, Irina V/K-5414-2015; Kopnin, Boris/R-8240-2019	Kopnin, Pavel/0000-0002-2078-4274; Kravchenko, Irina V/0000-0002-1715-1281; Kopnin, Boris/0000-0003-3100-2212				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BARRETT JC, 1994, ENVIRON HEALTH PERSP, V102, P19, DOI 10.2307/3432053; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; BRODY AR, 1993, ENVIRON HEALTH PERSP, V100, P21, DOI 10.2307/3431517; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fei PW, 2002, CANCER RES, V62, P7316; Jaurand MC, 1997, ENVIRON HEALTH PERSP, V105, P1073, DOI 10.2307/3433512; JAURAND MC, 1981, IN VITRO CELL DEV B, V17, P98; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kravchenko IV, 1998, TERATOGEN CARCIN MUT, V18, P141, DOI 10.1002/(SICI)1520-6866(1998)18:3<141::AID-TCM5>3.3.CO;2-E; Kravchenko IV, 2001, TERATOGEN CARCIN MUT, V21, P315, DOI 10.1002/tcm.1019; Levresse V, 1997, AM J RESP CELL MOL, V17, P660, DOI 10.1165/ajrcmb.17.6.2854; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Luce RA, 2001, METHOD ENZYMOL, V340, P396; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Muhle H, 2000, INT ARCH OCC ENV HEA, V73, pS53, DOI 10.1007/PL00014627; Neuberger M, 2003, INT ARCH OCC ENV HEA, V76, P161, DOI 10.1007/s00420-002-0397-2; Pass HI, 1996, J CELL BIOCHEM, P142; Prives C, 1999, J PATHOL, V187, P112; PYLEV L, 2002, GIG SANIT, V3, P61; Richardson DS, 1997, BLOOD REV, V11, P201, DOI 10.1016/S0268-960X(97)90020-5; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; SKLADANOWSKI A, 1994, BIOCHEM PHARMACOL, V47, P2269, DOI 10.1016/0006-2952(94)90265-8; Torday JS, 2001, PEDIATR RES, V49, P843, DOI 10.1203/00006450-200106000-00021; Vasilieva LA, 1998, CANCER LETT, V134, P209, DOI 10.1016/S0304-3835(98)00255-9	34	26	30	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8834	8840		10.1038/sj.onc.1208108	http://dx.doi.org/10.1038/sj.onc.1208108			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480427				2022-12-28	WOS:000225165100013
J	Craig, AL; Hupp, TR				Craig, AL; Hupp, TR			The regulation of CHK2 in human cancer	ONCOGENE			English	Editorial Material						CHK2; ATM; p53; cancer; kinase; radiation	TUMOR-SUPPRESSOR; PROTEIN-KINASE; DNA-DAMAGE; CHECKPOINT PATHWAY; SPLICE VARIANTS; PHOSPHORYLATION; P53; ATM; ACTIVATION; MDM2	Exceptional progress has been made in the past two decades in mapping oncogenes and tumour suppressors, de. ning a function for these master switches, and identifying novel anti-cancer drug targets. The p53 tumour suppressor is a central component of a DNA-damage-inducible pathway controlled by the ataxia telangiectasia mutated (ATM) and CHK2 protein kinases that have a central role in cancer suppression. One limitation of current human cancer research is the difficulty in developing genetic models that reveal the post-translational regulation of a growth suppressor like CHK2 within the microenvironment of a human tumour. Gaining such insights is important since yeast models and human tissue culture cell lines do not necessarily predict how enzymes like CHK2 are regulated in vivo, and therefore what factors can affect CHK2 tumour suppressor function. Translational cancer research aims to link basic research methodologies and clinical biology by uncovering cancer-specific pathways not revealed by other approaches. This approach is exemplified by two studies in this edition of Oncogene: both use a set of well-characterized human cancers with the objective of identifying novel post-translational control of the tumour suppressor CHK2. The authors have revealed two unexpected epigenetic modi. cations of the CHK2 pathway in vivo: ( 1) constitutive phosphorylation of CHK2 at its ATM-activated site in the absence of exogenous DNA damage; and ( 2) the production of hyper-spliced and inactive isoforms of CHK2. These studies highlight the need to develop model systems to understand why CHK2-activating pathways are being triggered or suppressed in different human cancers and whether the splicing machinery can be manipulated to control the activity of CHK2 for therapeutic benefit.	Univ Edinburgh, CRUK Canc Res Ctr, Signal transduct Grp P53, Edinburgh, Midlothian, Scotland	University of Edinburgh	Hupp, TR (corresponding author), Univ Edinburgh, CRUK Canc Res Ctr, Signal transduct Grp P53, S Crewe Rd, Edinburgh, Midlothian, Scotland.	Ted.Hupp@cancer.org.uk						Abdu U, 2002, CURR BIOL, V12, P1645, DOI 10.1016/S0960-9822(02)01165-X; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bartel F, 2004, MOL CANCER RES, V2, P29; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; FABBRO M, 2004, J BIOL CHEM     0524; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Fridman JS, 2003, CANCER RES, V63, P5703; Higashitani A, 2000, FEBS LETT, V485, P35, DOI 10.1016/S0014-5793(00)02178-5; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Kim WS, 2003, INT J MOL MED, V12, P827; Koslowski M, 2002, CANCER RES, V62, P6750; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Rhind N, 2000, J CELL SCI, V113, P3889; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tereshko V, 2001, NAT STRUCT BIOL, V8, P899, DOI 10.1038/nsb1001-899; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tyler LN, 2003, MODERN PATHOL, V16, P660, DOI 10.1097/01.MP.0000077516.90063.7D; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhang PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-14; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	58	18	19	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8411	8418		10.1038/sj.onc.1208035	http://dx.doi.org/10.1038/sj.onc.1208035			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361833				2022-12-28	WOS:000224870700001
J	Palacios, EH; Weiss, A				Palacios, EH; Weiss, A			Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation	ONCOGENE			English	Review						TCR; CSK; CD45; tyrosine phosphorylation	PROTEIN-TYROSINE KINASE; CLASS-II MOLECULES; ANTIGEN RECEPTOR; THYMOCYTE DEVELOPMENT; MICE LACKING; LIPID RAFTS; ALPHA-BETA; TCR-ZETA; PRE-TCR; CD4(+)CD8(+) THYMOCYTES	The function of the Src-family kinases (SFKs) Lck and Fyn in T cells has been intensively studied over the past 15 years. Ani mal models and cell line studies both indicate a critical role for Lck and Fyn in proximal T-cell antigen receptor (TCR) signal transduction. Recruited SFKs phosphorylate TCR ITAMs (immunoreceptor tyrosine-based activation motifs) in the CD3 and zeta chains, which then serve as docking sites for Syk-family kinases. SFKs then phosphorylate and activate the recruited Syk-family kinase. Lck and Fyn are spatially segregated in cell membranes due to differential lipid raft localization, and may undergo sequential activation. In addition to the CD4 and CD8 coreceptors, a recently described adaptor, Unc119, may link SFKs to the TCR. CD45 and Csk provide positive and negative regulatory control of SFK functions, respectively, and Csk is constitutively bound to the transmembrane adapter protein, PAG/Cbp. TCR-based signaling is required at several stages of T-cell development, including at least pre-TCR signaling, positive selection, peripheral maintenance of naive T cells, and lymphopenia-induced proliferation. SFKs are required for each of these TCR-based signals, and Lck seems to be the major contributor.	Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, 533 Parnassus,Box 0795, San Francisco, CA 94143 USA.	aweiss@medicine.ucsf.edu						ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Chu DH, 1999, J IMMUNOL, V163, P2610; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Filipp D, 2004, J IMMUNOL, V172, P4266, DOI 10.4049/jimmunol.172.7.4266; Filipp D, 2003, J EXP MED, V197, P1221, DOI 10.1084/jem.20022112; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Gorska MM, 2004, J EXP MED, V199, P369, DOI 10.1084/jem.20030589; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Haks MC, 2003, J IMMUNOL, V170, P2853, DOI 10.4049/jimmunol.170.6.2853; Hashimoto K, 1996, J EXP MED, V184, P931, DOI 10.1084/jem.184.3.931; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Hernandez-Hoyos G, 2000, IMMUNITY, V12, P313, DOI 10.1016/S1074-7613(00)80184-3; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kanazawa S, 1996, BLOOD, V87, P865, DOI 10.1182/blood.V87.3.865.bloodjournal873865; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Legname G, 2000, IMMUNITY, V12, P537, DOI 10.1016/S1074-7613(00)80205-8; Levelt CN, 1995, IMMUNITY, V3, P667, DOI 10.1016/1074-7613(95)90056-X; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Lin K, 2000, J EXP MED, V191, P703, DOI 10.1084/jem.191.4.703; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; Norment AM, 1997, J EXP MED, V185, P121, DOI 10.1084/jem.185.1.121; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; OShea CC, 1997, IMMUNITY, V7, P591, DOI 10.1016/S1074-7613(00)80380-5; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; Penninger JM, 1996, J IMMUNOL, V157, P5359; Pitcher LA, 2003, IMMUNOL REV, V191, P47, DOI 10.1034/j.1600-065X.2003.00003.x; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rothenberg EV, 2002, IMMUNOL REV, V187, P96, DOI 10.1034/j.1600-065X.2002.18709.x; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Schmedt C, 2001, J EXP MED, V193, P815, DOI 10.1084/jem.193.7.815; Schweighoffer E, 2003, IMMUNITY, V18, P523, DOI 10.1016/S1074-7613(03)00082-7; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; Seddon B, 2002, J IMMUNOL, V169, P3752, DOI 10.4049/jimmunol.169.7.3752; Seddon B, 2002, J IMMUNOL, V169, P2997, DOI 10.4049/jimmunol.169.6.2997; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Singer A, 2002, CURR OPIN IMMUNOL, V14, P207, DOI 10.1016/S0952-7915(02)00323-0; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Stone JD, 1997, J IMMUNOL, V158, P5773; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Su YW, 2003, IMMUNITY, V19, P295, DOI 10.1016/S1074-7613(03)00202-4; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Utting O, 1998, J IMMUNOL, V160, P5410; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wang H, 1998, P NATL ACAD SCI USA, V95, P6831, DOI 10.1073/pnas.95.12.6831; Witherden D, 2000, J EXP MED, V191, P355, DOI 10.1084/jem.191.2.355; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	101	494	515	4	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7990	8000		10.1038/sj.onc.1208074	http://dx.doi.org/10.1038/sj.onc.1208074			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489916				2022-12-28	WOS:000224558300009
J	Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M				Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M			MRP-1/CD9 gene transduction downregulates Wnt signal pathways	ONCOGENE			English	Article						MRP-1/CD9; Wnt; microarray; real-time PCR	ENDOTHELIAL GROWTH-FACTOR; CELL MOTILITY; BREAST-CANCER; UP-REGULATION; CYCLIN D1; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MATRIX METALLOPROTEINASE-26; EPITHELIAL ORIGIN; COLON-CARCINOMA	Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.	Kagawa Univ, Fac Med, Dept Surg 2, Miki, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa 7610793, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 5308480, Japan	Kagawa University; Kagawa University; Kitano Hospital; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Fac Med, Dept Surg 2, 1750-1, Miki, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Adachi M, 1998, J CLIN ONCOL, V16, P1060, DOI 10.1200/JCO.1998.16.3.1060; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dale TC, 1998, BIOCHEM J, V329, P209; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Desnoyers L, 2001, J BIOL CHEM, V276, P47599, DOI 10.1074/jbc.M108339200; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2003, INT J ONCOL, V22, P209; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; MITCHELL CE, 1995, ANAL BIOCHEM, V224, P148, DOI 10.1006/abio.1995.1020; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyazaki YJ, 2002, ONCOGENE, V21, P798, DOI 10.1038/sj.onc.1205126; Mori M, 1998, CLIN CANCER RES, V4, P1507; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Saitoh T, 2002, INT J MOL MED, V9, P515; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uria JA, 2000, CANCER RES, V60, P4745; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xie D, 2001, CANCER RES, V61, P8917; Xu LF, 2000, GENE DEV, V14, P585; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhang XB, 2001, CANCER RES, V61, P6050	50	57	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7475	7483		10.1038/sj.onc.1208063	http://dx.doi.org/10.1038/sj.onc.1208063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334057				2022-12-28	WOS:000224176500004
J	Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM				Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM			ATM activity contributes to the tumor-suppressing functions of p14(ARF)	ONCOGENE			English	Article						ARF tumor suppressor; p53 and ATM	CELL-CYCLE ARREST; DNA-DAMAGE; P16(INK4A) GENES; TRANSCRIPTION FACTOR; P53 PROTEIN; MDM2; PATHWAY; CHECKPOINT; APOPTOSIS; P19(ARF)	P14/p19(ARF) (ARF) plays a major role in the activation of p53 by oncogenic signals. The biochemical basis of this has not been fully elucidated. We report here that forced expression of p14(ARF) enhances phosphorylation of p53 serine 15 (p53S15) in NIH3T3, IMR90 and MCF7 cells. Ectopic expression of the oncogenes c-myc, E2F1 and E1A, all of which activate p53 at least partially via ARF, lead to p53S15 phosphorylation in IMR90 cells. In addition, ectopic expression of p53 also results in p53S15 phosphorylation, suggesting that this is a common event in the ARF p53 tumor suppression system. Furthermore, p53-, p14(ARF)-, c-myc- and E2F1-, but not E1A-, induced p53S15 phosphorylation was substantially reduced in AT fibroblasts (GM05823). Downregulation of ATM in MCF7 cells using RNA interference (RNAi) technology significantly attenuated p14ARF- and p53- induced phosphorylation of p53S15. Ectopically expressed ARF in NIH3T3 cells induced ATM nuclear foci and activated ATM kinase. Functionally, ectopic expression of p14(ARF) and c-myc inhibited the proliferation of IMR90 but not ATM null GM05823 cells, and p14ARF- induced inhibition of MCF7 cell proliferation was significantly attenuated by downregulation of ATM by RNAi. Taken together, these data show a functional role for ATM in ARF-mediated tumor suppression.	St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; Peking Union Med Coll, Natl Lab Med Mol Biol, Dept Biochem, Beijing, Peoples R China; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; McMaster University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; McMaster University	Tang, DM (corresponding author), St Josephs Hosp, Father Sean OSullivan Res Inst, L305,50 Carlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Kapoor, Anil/AAQ-7184-2021; Zhu, Dahai/ABA-5315-2021; Tang, Damu/AAQ-1786-2021	Kapoor, Anil/0000-0001-9180-8029; Tang, Damu/0000-0002-3282-9521				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ichimura K, 2000, CANCER RES, V60, P417; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin SK, 2001, J CELL SCI, V114, P4139; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7355	7365		10.1038/sj.onc.1207957	http://dx.doi.org/10.1038/sj.onc.1207957			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15258567				2022-12-28	WOS:000224021400006
J	Mengwasser, J; Piau, A; Schlag, P; Sleeman, JP				Mengwasser, J; Piau, A; Schlag, P; Sleeman, JP			Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens	ONCOGENE			English	Article						prohibitin; colorectal; differential immunization; serum ELISA; diagnosis	ENDOPLASMIC-RETICULUM; PROHIBITIN; PROTEINS; MARKERS; RB; CANCER; MITOCHONDRIA; REPRESSION; RECEPTOR; RESPOND	Early diagnosis of cancer is crucial for successful treatment. Noninvasive assays for detecting tumor-derived antigens in serum and other bodily fluids have the potential to screen healthy individuals for hitherto undetected cancers. Very few such assays have been successfully developed, in part because identifying potential target antigens remains a challenge. To identify new blood-borne tumor antigens for the purpose of establishing such assays, we have developed a novel technique called differential immunization. Using this method, we have identified PHB1 and PHB2, proteins thought to function as mitochondrial chaperones and transcriptional regulators, as antigens released from colorectal tumors in vivo. Serum from colorectal patients contains significantly higher levels of these antigens compared to serum from healthy volunteers. These data demonstrate that differential immunization is an effective new method for identifying tumor-derived antigens in serum.	Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany; Humboldt Univ, Charite, Robert Rossle Clin, D-13125 Berlin, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sleeman, JP (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Postfach 3640, D-76021 Karlsruhe, Germany.	sleeman@itg.fzk.de	Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Ardekani Ali M, 2002, Expert Rev Mol Diagn, V2, P312, DOI 10.1586/14737159.2.4.312; Bacher S, 2002, BIOCHIMIE, V84, P1207; Bangma CH, 2000, MICROSC RES TECHNIQ, V51, P430, DOI 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO;2-1; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bok RA, 2002, NAT REV CANCER, V2, P918, DOI 10.1038/nrc951; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; DEXTER DL, 1979, CANCER RES, V39, P1020; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Harlow E, 1998, ANTIBODIES LAB MANUA; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; Molina R, 1996, ANTICANCER RES, V16, P2295; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Piper PW, 2002, MECH AGEING DEV, V123, P287, DOI 10.1016/S0047-6374(01)00326-8; Sleeman JP, 1999, ONCOGENE, V18, P4485, DOI 10.1038/sj.onc.1202808; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944	29	39	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7430	7435		10.1038/sj.onc.1207987	http://dx.doi.org/10.1038/sj.onc.1207987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286703				2022-12-28	WOS:000224021400013
J	Nishikawa, T; Munshi, A; Story, MD; Ismail, S; Stevens, C; Chada, S; Meyn, RE				Nishikawa, T; Munshi, A; Story, MD; Ismail, S; Stevens, C; Chada, S; Meyn, RE			Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells	ONCOGENE			English	Article						adenovirus; mda-7; radiation; lung cancer; DNA repair; nonhomologous end-joining	DIFFERENTIATION-ASSOCIATED GENE-7; DEPENDENT-PROTEIN-KINASE; DOUBLE-STRAND BREAKS; MELANOMA DIFFERENTIATION; LIGASE-IV; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; RADIATION; APOPTOSIS; GROWTH	The melanoma differentiation-associated gene-7 (mda-7) was identified by virtue of its enhanced expression in human melanoma cells induced into terminal differentiation. Enforced expression of mda-7 in human cancer cell lines of diverse origins results in the suppression of growth and induction of apoptosis. We have shown that adenoviral-mediated mda-7 (Ad-mda7) radiosensitizes non-small-cell lung cancer (NSCLC) cells by enhancing the apoptotic pathway. To identify the mechanism of this radiosensitization, we examined the level of proteins involved in the nonhomologous end-joining (NHEJ) pathway of DNA double-strand break (DSB) repair. Western blot analysis indicated that the expression of NHEJ pathway components Ku70, XRCC4, and DNA ligase IV was downregulated in NSCLC cells - A549 with Ad-mda7 treatment. No such change was observed in normal human CCD16 fibroblasts previously shown not to be radiosensitized by Ad-mda7. The biological significance of these changes of expression of proteins critical for repair of radiation-induced DSBs was confirmed via the analysis of DSB rejoining kinetics using pulsed field gel electrophoresis and assessment of host cell reactivation capacity following Ad-mda7 treatment. Based on these results, we hypothesize that Ad-mda7 sensitizes NSCLC cells to ionizing radiation by suppressing the activity of NHEJ, a pathway essential for repair of radiation-induced DSBs.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rmeyn@mdanderson.org	Story, Michael/AAX-2864-2021	Story, Michael/0000-0001-6522-4169	NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672, P01CA006294, R41CA088421] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16672, R41 CA88421, P01 CA78778, P01 CA06294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Collis SJ, 2003, CANCER RES, V63, P1550; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; EADY JJ, 1992, BRIT J CANCER, V66, P113, DOI 10.1038/bjc.1992.226; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li GC, 2003, CANCER RES, V63, P3268; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; McDonald E, 1996, CANCER RES, V56, P2250; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Olive PL, 1998, RADIAT RES, V150, pS42, DOI 10.2307/3579807; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pataer A, 2002, CANCER RES, V62, P2239; Peng YL, 2002, CANCER RES, V62, P6400; RAINBOW AJ, 1972, RADIAT RES, V50, P319, DOI 10.2307/3573492; RAINBOW AJ, 1974, RADIAT RES, V60, P155, DOI 10.2307/3574013; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Sado K, 2001, J BIOL CHEM, V276, P9742, DOI 10.1074/jbc.M010530200; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; STORY MD, 1994, INT J RADIAT BIOL, V65, P523, DOI 10.1080/09553009414550611; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000	40	25	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7125	7131		10.1038/sj.onc.1207917	http://dx.doi.org/10.1038/sj.onc.1207917			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273727				2022-12-28	WOS:000223885100013
J	Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J				Krasnoselsky, AL; Whiteford, CC; Wei, JS; Bilke, S; Westermann, F; Chen, QR; Khan, J			Altered expression of cell cycle genes distinguishes aggressive neuroblastoma	ONCOGENE			English	Article						cDNA microarray; gene expression; principal component analysis; neuroblastoma; MYCN; gene ontology	PROLIFERATIVE ACTIVITY; MYCN; AMPLIFICATION; DIFFERENTIATION; IDENTIFICATION; PREDICTION; INDUCTION	In this study, gene expression pro. ling was performed on 103 neuroblastoma (NB) tumors, stages 1-4 with and without MYCN amplification, using cDNA microarrays containing 42578 elements. Using principal component analysis (PCA) to analyse the relationships among these samples, we confirm that the global patterns of gene expression reflect the phenotype of the tumors. To explore the biological processes that may contribute to increasing aggressive phenotype of the tumors, we utilized a statistical approach based on PCA. We identified a specific subset of the cell cycle and/or chromosome segregation genes that distinguish stage 4 NB tumors from all lower stage tumors, including stage 3. Furthermore, the control of the kinetochore assembly emerges from the Gene Ontology analysis as one of the key biological processes associated with an aggressive NB phenotype. Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors.	Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Gaithersburg, MD 20877 USA; German Canc Res Ctr, Dept Tumour Genet B030, D-69120 Heidelberg, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ)	Khan, J (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Ctr Adv Technol, Room 134E,8717 Grovemont Circle, Gaithersburg, MD 20877 USA.	khanjav@mail.nih.gov	Westermann, Frank/F-7509-2013; Khan, Javed/P-9157-2014		NATIONAL CANCER INSTITUTE [ZIASC010366, Z01SC010366] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaminos M, 2003, CANCER RES, V63, P4538; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; COHN SL, 1990, AM J PATHOL, V136, P1043; DOMINICI C, 1992, ANTICANCER RES, V12, P59; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mora J, 2003, CANCER LETT, V197, P119, DOI 10.1016/S0304-3835(03)00094-6; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Sugihara E, 2004, ONCOGENE, V23, P1005, DOI 10.1038/sj.onc.1207216; Takita J, 2004, GENE CHROMOSOME CANC, V40, P120, DOI 10.1002/gcc.20021; Tonini GP, 2003, CANCER LETT, V197, P69, DOI 10.1016/S0304-3835(03)00081-8; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Zar JH., 1999, BIOSTAT ANAL, V663rd; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	50	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1533	1541		10.1038/sj.onc.1208341	http://dx.doi.org/10.1038/sj.onc.1208341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15592497				2022-12-28	WOS:000227218200006
J	Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M				Jazag, A; Ijichi, H; Kanai, F; Imamura, T; Guleng, B; Ohta, M; Imamura, J; Tanaka, Y; Tateishi, K; Ikenoue, T; Kawakami, T; Arakawa, Y; Miyagishi, M; Taira, K; Kawabe, T; Omata, M			Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta	ONCOGENE			English	Article						Smad4; TGF-beta; stable RNAi; cDNA microarray; pancreatic cancer	TUMOR-SUPPRESSOR GENE; MAMMALIAN-CELLS; MICROSATELLITE INSTABILITY; SIGNALING PATHWAY; RECEPTOR; TARGETS; DPC4; INHIBITION; PROMOTER; MUTATION	The transforming growth factor-beta (TGF-beta)-Smad signaling pathway inhibits the growth of human epithelial cells and plays a role in tumor suppression. The Smad4 gene is mutated or deleted in 50% of pancreatic cancers. In this study, we succeeded in establishing Smad4 knockdown (S4KD) pancreatic cancer cell lines using the stable RNA interference (RNAi) method. Smad4 protein expression was reduced dramatically and TGF-beta-Smad signaling was markedly inhibited in the S4KD cell lines. The S4KD and control cells were stimulated with TGF-beta and analysed using a cDNA microarray that contained 3756 genes, in order to screen for target molecules downstream of TGF-beta. The microarray analysis revealed that 187 S4KD genes and 155 genes in the control cells were regulated immediately upon TGF-beta stimulation. Quantitative RT-PCR analysis on several of these genes produced results that corroborated the outcome of the microarray analysis. Most of the genes in the S4KD and control cells identified by the array differed, which suggests signaling pathways that differ according to Smad4 status. Of the identified genes, 246 have not been reported previously as genes that lie downstream of TGF-beta. Genes that are involved in cell proliferation, adhesion, and motility were found to be regulated differentially with respect to S4KD and control cells. Cell migration induced by TGF-beta was inhibited in the S4KD cells, which might be associated with a different regulation of integrin beta7. The knock down of a specific gene using stable RNAi appears to be a promising tool for analysing endogenous gene function.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2600870, Japan; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo 1600023, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Ctr, Ibaraki 3058562, Japan	University of Tokyo; University of Tokyo; Chiba University; Asahi Life Foundation; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Ijichi, Hideaki/AAE-6692-2022; IJICHI, Hideaki/AGZ-2874-2022; Miyagishi, Makoto/L-8174-2016; Ijichi, Hideaki/V-2720-2019	Ijichi, Hideaki/0000-0002-2379-7986; IJICHI, Hideaki/0000-0002-2379-7986; Miyagishi, Makoto/0000-0001-7654-3616; Tanaka, Yasuo/0000-0002-2917-3365				Akiyoshi S, 2001, JPN J CANCER RES, V92, P257, DOI 10.1111/j.1349-7006.2001.tb01090.x; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Grau AM, 1997, CANCER RES, V57, P3929; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Lim SP, 1998, IMMUNOGENETICS, V48, P184, DOI 10.1007/s002510050422; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MORTON DM, 1995, CANCER RES, V55, P2596; Schutte M, 1996, CANCER RES, V56, P2527; Togo G, 1996, CANCER RES, V56, P5620; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wang D, 2000, CANCER RES, V60, P4507; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	36	60	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					662	671		10.1038/sj.onc.1208102	http://dx.doi.org/10.1038/sj.onc.1208102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15592526				2022-12-28	WOS:000226420400013
J	Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P				Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P			KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells	ONCOGENE			English	Article						KAI1; transcription factor; metastasis suppressor; prostate cancer	METASTASIS-SUPPRESSOR GENE; FREQUENT DOWN-REGULATION; PROSTATE-CANCER; TRANSCRIPTION FACTOR; BLADDER-CANCER; HUMAN-MELANOMA; MESSENGER-RNA; MUTANT P53; C-JUN; LINES	A molecular mechanism to explain reduced KAI1 expression in invasive and metastatic tumour cells remains elusive. In this report, we extend an earlier study in bladder cells to confirm that a 76 bp region of the KAI1 promoter ( residues - 922 to - 847), with binding motifs for p53, AP1 and AP2, is required for high level activity of a KAI1 reporter in prostate cancer cell lines. Gel shift and supershift experiments supported binding of p53, junB and heterodimers of AP2alpha/AP2gamma or AP2beta/AP2gamma to this sequence. Introduction of mutations into specific motifs demonstrated an essential requirement for p53 and junB to reporter activity, and that functional synergy between these two factors enhanced activity. A further elevation of reporter activity required AP2. Roles of individual p53, junB and AP2 proteins, as well as functional synergy between p53 and junB, were confirmed in transfection experiments. Western blotting analysis showed that an absence of wild-type p53, and/or a loss of junB and AP2 protein expression, correlated with downregulation of KAI1 mRNA levels in a series of prostate cancer cell lines. A loss of p53 function and/or expression of junB, combined with reduced expression of specific AP2 proteins may underly downregulated KAI1 expression in tumour cells.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Med, Kensington, NSW 2033, Australia; Univ Dusseldorf, Dept Urol, D-4000 Dusseldorf, Germany; Univ Sydney, Sch Mol & Microbial Sci, Camperdown, NSW, Australia	University of New South Wales Sydney; Heinrich Heine University Dusseldorf; University of Sydney	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Level 2 Clin Sci Bldg,Barker St, Randwick, NSW 2031, Australia.	paul.jackson@unsw.edu.au	Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642; Grimm, Marc-Oliver/0000-0003-3084-8654				Akita H, 2000, CANCER LETT, V153, P79, DOI 10.1016/S0304-3835(00)00352-9; Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Bosher JM, 1996, ONCOGENE, V13, P1701; BUTZ K, 1995, ONCOGENE, V10, P927; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; Dong JT, 1996, CANCER RES, V56, P4387; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Gao AC, 2003, PROSTATE, V57, P256, DOI 10.1002/pros.10309; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634; Jackson P, 2002, UROL ONCOL, V7, P99, DOI 10.1016/S1078-1439(01)00175-2; Jackson P, 2000, CANCER LETT, V157, P169, DOI 10.1016/S0304-3835(00)00483-3; Jackson P, 2000, BIOCHEM BIOPH RES CO, V278, P499, DOI 10.1006/bbrc.2000.3799; JACKSON P, 2004, IN PRESS PROGR BLADD; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Lijovic M, 2002, CANCER DETECT PREV, V26, P69, DOI 10.1016/S0361-090X(02)00012-0; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Lombardi DP, 1999, CANCER RES, V59, P5724; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; MAY E, 1991, ONCOGENE, V6, P1363; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Ow K, 2000, J PATHOL, V191, P39, DOI 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K; Ribeiro JCC, 1997, INT J RADIAT BIOL, V72, P11, DOI 10.1080/095530097143491; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schindl M, 2001, CANCER LETT, V162, P261, DOI 10.1016/S0304-3835(00)00672-8; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shinohara T, 2001, CANCER RES, V61, P673; Tagawa K, 1999, JPN J CANCER RES, V90, P970, DOI 10.1111/j.1349-7006.1999.tb00843.x; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	46	64	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					637	649		10.1038/sj.onc.1208216	http://dx.doi.org/10.1038/sj.onc.1208216			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580298				2022-12-28	WOS:000226420400011
J	Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M				Saito, T; Oda, Y; Kawaguchi, K; Sugimachi, K; Yamamoto, H; Tateishi, N; Tanaka, K; Matsuda, S; Iwamoto, Y; Ladanyi, M; Tsuneyoshi, M			E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma	ONCOGENE			English	Article						E-cadherin; Snail; CpG methylation; mutation; ELF3; synovial sarcoma; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTIONAL REPRESSOR SNAIL; CPG ISLAND METHYLATION; SOFT-TISSUE SARCOMAS; CELL-CELL-ADHESION; SSX FUSION TYPE; GENE-EXPRESSION; BREAST-CANCER; GASTRIC-CANCER; BETA-CATENIN	We have recently reported frequent E-cadherin gene mutations in synovial sarcoma (SS), suggesting mutational inactivation of E-cadherin as a potential mechanism of spindle cell morphology in SS, a spindle cell sarcoma that shows areas of glandular epithelial differentiaton in some cases (biphasic SS) and only pure spindle cell morphology in most cases (monophasic SS). However, the mechanism of downregulation of E-cadherin in SS remains unknown. To further address this issue, we analysed the mechanisms of E-cadherin silencing in 40 SS. Genetic and epigenetic changes in the E-cadherin gene, and the expression level of its transcriptional repressor Snail were examined by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP), methylation-specific PCR, and real-time quantitative PCR, respectively. Expression of E-cadherin was examined by RT-PCR and immunohistochemistry. We also examined ELF3, a transcription factor associated with epithelial differentiation in SS in a previous cDNA microarray, by RT-PCR. E-cadherin and ELF3 transcripts were detected, respectively, in 27/40 (67.5%) and in 25/40 (62.5%) of SS, and these epithelial-related genes were almost always coexpressed. Hypermethylation of the promoter of the E-cadherin gene was detected in five cases (12.5%) in SS; however, E-cadherin was silenced at mRNA level in only one of the five cases. E-cadherin missense mutations were observed in five cases (12.5%) of SS. In SS, all five cases with E-cadherin missense mutations had the SYT-SSX1 fusion and were monophasic tumors, suggesting a relationship between the SYT-SSX fusion type and E-cadherin missense mutation (P = 0.07). E-cadherin mRNA expression in SS was associated with reduced Snail expression level (P = 0.03). E-cadherin membranous expression was observed in 14/40 (35.0%) of SS, and was also correlated with SYT-SSX1 fusion type and biphasic histology. ELF3 was confirmed to be more highly expressed in biphasic than monophasic SS by real-time quantitative PCR. These results suggest that in SS the loss of E-cadherin expression occurs either by Snail trans-repression or by inactivating mutations. Thus, E-cadherin downregulation is associated with the loss or absence of glandular epithelial differentiation in certain SS.	Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka 8128582, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Kyushu University; Kyushu University; Memorial Sloan Kettering Cancer Center	Tsuneyoshi, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	masazumi@surgpath.med.kyushu-u.ac.jp	Tanaka, Kazuhiro/Q-7387-2019; Ladanyi, Marc/AAG-8585-2019	Tanaka, Kazuhiro/0000-0002-5138-8952; Matsuda, Shuichi/0000-0003-0802-1255	NCI NIH HHS [CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Antonescu CR, 2000, DIAGN MOL PATHOL, V9, P1, DOI 10.1097/00019606-200003000-00001; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Bukholm IK, 2000, J PATHOL, V190, P15; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Endo K, 2001, J PATHOL, V193, P310, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH816>3.0.CO;2-K; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1998, CANCER RES, V58, P2063; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GRAFF JR, 1995, CANCER RES, V55, P5195; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; HENNIG G, 1995, ONCOGENE, V11, P475; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiraguri S, 1998, CANCER RES, V58, P1972; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Laskin WB, 2002, ARCH PATHOL LAB MED, V126, P425; Lee YF, 2003, BRIT J CANCER, V88, P510, DOI 10.1038/sj.bjc.6600766; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Machado JC, 1999, LAB INVEST, V79, P459; Machen SK, 1999, AM J SURG PATHOL, V23, P268, DOI 10.1097/00000478-199903000-00004; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; MAYER B, 1993, CANCER RES, V53, P1690; Melki JR, 2000, BLOOD, V95, P3208; Nagayama S, 2002, CANCER RES, V62, P5859; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Noguchi SI, 1997, INT J CANCER, V72, P995; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Saito A, 1999, JPN J CANCER RES, V90, P993, DOI 10.1111/j.1349-7006.1999.tb00847.x; Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R; Saito T, 2002, LAB INVEST, V82, P97, DOI 10.1038/labinvest.3780399; Saito T, 2002, HISTOPATHOLOGY, V40, P279, DOI 10.1046/j.1365-2559.2002.01345.x; Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5; Sato H, 1999, HUM PATHOL, V30, P1344, DOI 10.1016/S0046-8177(99)90066-7; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Sefton M, 1998, DEVELOPMENT, V125, P3111; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Soares P, 1997, INT J CANCER, V70, P32; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trassard M, 2001, J CLIN ONCOL, V19, P525, DOI 10.1200/JCO.2001.19.2.525; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEISS SW, 2001, ENZINGER WEISSS SOFT; Yakushiji T, 2000, J CLIN PATHOL, V53, P525, DOI 10.1136/jcp.53.7.525; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P33	80	42	48	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8629	8638		10.1038/sj.onc.1207960	http://dx.doi.org/10.1038/sj.onc.1207960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467754				2022-12-28	WOS:000224988800009
J	Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P				Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P			Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding	ONCOGENE			English	Article						CD44; angiogenesis; hyaluronic acid	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; TUMOR-GROWTH; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; CARCINOMA-CELLS; SOLUBLE CD44; E-SELECTIN; IN-VIVO; MIGRATION; RECEPTOR	CD44 is the main cellular receptor for hyaluronic acid (HA). We previously found that overexpression of CD44 inhibited tumor growth of mouse fibrosarcoma cells in mice. Here, we show that soluble recombinant CD44 HA-binding domain (CD44-HABD) acts directly onto endothelial cells by inhibiting endothelial cell proliferation in a cell-specific manner. Consequently, soluble recombinant CD44-HABD also blocked angiogenesis in vivo in chick and mouse, and thereby inhibited tumor growth of various origins at very low doses (0.25 mg/kg x day). The antiangiogenic effect of CD44 is independent of its HA-binding capacity, since mutants deficient in HA binding still maintain their antiangiogenic and antiproliferative properties. Recombinant CD44-HABD represents a novel class of angiogenesis inhibitors based on a cell-surface receptor.	NICPB, Mol Genet Lab, EE-12618 Tallinn, Estonia; Huddinge Univ Hosp F 46, Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia	National Institute of Chemical Physics & Biophysics (NICPB); Karolinska Institutet; Tallinn University of Technology	Kogerman, P (corresponding author), NICPB, Mol Genet Lab, Akadeemia 23, EE-12618 Tallinn, Estonia.	priit@kbfi.ee	Kogerman, Priit/B-6333-2008; Gad, Annica/X-8294-2018; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brooks PC, 1999, METH MOL B, V129, P257; Cichy J, 2002, J BIOL CHEM, V277, P44440, DOI 10.1074/jbc.M207437200; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo NH, 1997, CANCER RES, V57, P1735; GUO YJ, 1994, CANCER RES, V54, P1561; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KATOH S, 1994, J IMMUNOL, V153, P3440; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kogerman P, 1997, ONCOGENE, V15, P1407, DOI 10.1038/sj.onc.1201306; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	51	10	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7874	7881		10.1038/sj.onc.1208083	http://dx.doi.org/10.1038/sj.onc.1208083			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361838				2022-12-28	WOS:000224331600013
J	Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM				Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM			Mutation of GATA3 in human breast tumors	ONCOGENE			English	Article						breast cancer; microarrays; estrogen receptor; transcription factor; GATA3	GENE-EXPRESSION PATTERNS; CELL RECEPTOR-ALPHA; TRANSCRIPTION FACTOR; ACQUIRED MUTATIONS; ESTROGEN-RECEPTOR; NERVOUS-SYSTEM; HDR SYNDROME; CANCER; BINDING; BENIGN	GATA3 is an essential transcription factor that was first identified as a regulator of immune cell function. In recent microarray analyses of human breast tumors, both normal breast luminal epithelium and estrogen receptor (ESR1)positive tumors showed high expression of GATA3. We sequenced genomic DNA from 111 breast tumors and three breast-tumor-derived cell lines and identified somatic mutations of GATA3 in five tumors and the MCF-7 cell line. These mutations cluster in the vicinity of the highly conserved second zinc-finger that is required for DNA binding. In addition to these five, we identified using cDNA sequencing a unique mis-splicing variant that caused a frameshift mutation. One of the somatic mutations we identified was identical to a germline GATA3 mutation reported in two kindreds with HDR syndrome/OMIM # 146255, which is an autosomal dominant syndrome caused by the haplo-insufficiency of GATA3. The ectopic expression of GATA3 in human 293T cells caused the induction of 73 genes including six cytokeratins, and inhibited cell line doubling times. These data suggest that GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells, and that GATA3 variants may contribute to tumorigenesis in ESR1-positive breast tumors.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; NCI, Sect Genom Variat, Pediat Oncol Branch, Ctr Adv Technol, Bethesda, MD 20892 USA; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Ullevaal Univ Hosp, Dept Surg, Oslo, Norway; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Haukeland Hosp, Dept Med, Sect Oncol, N-5021 Bergen, Norway; Inst Genom Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo; University of North Carolina; University of North Carolina Chapel Hill; University of Bergen; Haukeland University Hospital; J. Craig Venter Institute; University of North Carolina; University of North Carolina Chapel Hill	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Lonning, Per Eystein/0000-0002-8890-6303	NATIONAL CANCER INSTITUTE [P50CA058223, Z01SC010083] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223-09A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FINLIN BS, 2001, J BIOL CHEM, V31, P31; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Gruvberger S, 2001, CANCER RES, V61, P5979; GUELSTEIN VI, 1988, INT J CANCER, V42, P147, DOI 10.1002/ijc.2910420202; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hoch RV, 1999, INT J CANCER, V84, P122; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Ma GT, 1997, DEVELOPMENT, V124, P907; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muroya K, 2001, J MED GENET, V38, P374, DOI 10.1136/jmg.38.6.374; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; ORKIN SH, 1992, BLOOD, V80, P575; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Sena-Esteves M, 1999, J VIROL, V73, P10426, DOI 10.1128/JVI.73.12.10426-10439.1999; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tavassoli FA, 1992, PATHOLOGY BREAST, P193; Troester MA, 2002, TOXICOL SCI, V68, P314, DOI 10.1093/toxsci/68.2.314; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	41	198	205	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7669	7678		10.1038/sj.onc.1207966	http://dx.doi.org/10.1038/sj.onc.1207966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361840				2022-12-28	WOS:000224306700008
J	Bell, DR; Van Zant, G				Bell, DR; Van Zant, G			Stem cells, aging, and cancer: inevitabilities and outcomes	ONCOGENE			English	Review						stem cell; aging; leukemia; self-renewal; AML	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; GENETIC-CONTROL; IN-VIVO; SERIAL TRANSPLANTATION; HEMATOPOIETIC-CELLS; FLT3 MUTATIONS; BLAST CRISIS; FUSION GENE	Given the unique abilities of a stem cell to self-renew, differentiate, and proliferate, it is no wonder that they are critically important to an organism during development and to maintain homeostasis. Likewise, when something goes awry within a stem cell, it is likely to have far-reaching effects, since stem cells persist throughout the lifetime of the individual. Two significant biological phenomena that involve stem cells are the inevitable process of aging and a major health issue whose incidence increases with aging: cancer. In this review, we summarize evidence and theories concerning these two stem cell processes. The inability of stem cells to be passaged indefinitely in mice and the data supporting regular replication of the quiescent stem cell pool are discussed. Further, the current evidence indicating a stem cell origin of acute myeloid leukemia, including examples from both experimental mouse models and human clinical samples, is evaluated. Finally, we propose a model in which aging of the stem cell population of the hematopoietic system in particular can create conditions that are permissive to leukemia development; in fact, we suggest that aging is a secondary event in leukemogenesis.	Univ Kentucky, Dept Internal Med, Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Van Zant, G (corresponding author), Univ Kentucky, Dept Internal Med, Markey Canc Ctr, 800 Rose St,Rm CC 414, Lexington, KY 40536 USA.	gvzant1@uky.edu			NATIONAL INSTITUTE ON AGING [R01AG022859, R01AG016653, R01AG020917] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG016653, R01 AG20917, R01 AG022859] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Balducci L, 2003, J AM GERIATR SOC, V51, pS2; BIOLA O, 2003, NAT REV GENET, V4, P911; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BOTNICK LE, 1982, BLOOD, V60, P268; Bradford GB, 1997, EXP HEMATOL, V25, P445; Brendel C, 2000, LEUKEMIA, V14, P1711, DOI 10.1038/sj.leu.2401907; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Cesari M, 2004, J GERONTOL A-BIOL, V59, P249; Chen JC, 2000, EXP HEMATOL, V28, P442, DOI 10.1016/S0301-472X(99)00157-5; Chen JC, 2000, BLOOD, V96, P4124; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; CLAXTON DF, 1994, BLOOD, V83, P1750; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Haan G, 2000, BLOOD, V96, P1374, DOI 10.1182/blood.V96.4.1374.h8001374_1374_1379; De Haan G, 1999, FASEB J, V13, P707, DOI 10.1096/fasebj.13.6.707; de Haan G, 1999, BLOOD, V93, P3294, DOI 10.1182/blood.V93.10.3294.410k07_3294_3301; Deguchi K, 2002, LEUKEMIA, V16, P740, DOI 10.1038/sj.leu.2402500; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; deHaan G, 1997, J EXP MED, V186, P529, DOI 10.1084/jem.186.4.529; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Ershler WB, 2003, J AM GERIATR SOC, V51, pS18; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Geiger H, 2004, EXP HEMATOL, V32, P60, DOI 10.1016/j.exphem.2003.09.015; Geiger H, 2002, NAT IMMUNOL, V3, P329, DOI 10.1038/ni0402-329; Geiger H, 2001, BLOOD, V98, P2966, DOI 10.1182/blood.V98.10.2966; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Guzman Monica L, 2004, Cancer Control, V11, P97; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRISON DE, 1973, P NATL ACAD SCI USA, V70, P3184, DOI 10.1073/pnas.70.11.3184; HARRISON DE, 1987, BLOOD, V69, P773; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Jordan CT, 2002, LEUKEMIA, V16, P559, DOI 10.1038/sj.leu.2402446; KAY HEM, 1965, LANCET, V2, P418; Kim M, 2003, ANN NY ACAD SCI, V996, P195, DOI 10.1111/j.1749-6632.2003.tb03247.x; KROSL J, 2003, BLOOD, V102, P130; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liang Y, 2003, CURR OPIN HEMATOL, V10, P195, DOI 10.1097/00062752-200305000-00001; LIPSCHITZ DA, 1981, AM J HEMATOL, V11, P47, DOI 10.1002/ajh.2830110106; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Marley SB, 1999, BRIT J HAEMATOL, V106, P162; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MIRRO J, 1992, LEUKEMIA, V6, P13; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Morrison SJ, 2002, J IMMUNOL, V168, P635, DOI 10.4049/jimmunol.168.2.635; MullerSieburg CE, 1996, J EXP MED, V183, P1141, DOI 10.1084/jem.183.3.1141; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; *NCI, 2000, SEER CANC STAT REV, P1975; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Penninx BWJH, 2003, AM J MED, V115, P104, DOI 10.1016/S0002-9343(03)00263-8; PIETRZYK ME, 1985, BLOOD, V66, P1460; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rothstein G, 2003, J AM GERIATR SOC, V51, pS22; Rowley JD, 1997, BLOOD, V90, P535; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SIMINOVITCH L, 1964, J CELL COMPAR PHYSL, V64, P23, DOI 10.1002/jcp.1030640104; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Van Zant G, 2003, EXP HEMATOL, V31, P659, DOI 10.1016/S0301-472X(03)00088-2; Van Zant G, 2003, INT J HEMATOL, V77, P29, DOI 10.1007/BF02982600; VANZANT G, 1983, CELL, V35, P639, DOI 10.1016/0092-8674(83)90096-X; VANZANT G, 1990, J EXP MED, V171, P1547, DOI 10.1084/jem.171.5.1547; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vessey CJ, 2001, PATHOLOGY, V33, P130; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yamamoto K, 2000, BRIT J HAEMATOL, V109, P423, DOI 10.1046/j.1365-2141.2000.02003.x	89	70	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7290	7296		10.1038/sj.onc.1207949	http://dx.doi.org/10.1038/sj.onc.1207949			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378089				2022-12-28	WOS:000223998800015
J	Coulombel, L				Coulombel, L			Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays	ONCOGENE			English	Review						hematopoiesis; stem cells; differentiation; self-renewal; transplantation; assays	HUMAN CORD-BLOOD; EX-VIVO EXPANSION; LONG-TERM HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; ADULT BONE-MARROW; COMBINED IMMUNODEFICIENCY MICE; IN-VITRO IDENTIFICATION; EMBRYONIC STEM-CELLS; HUMAN T-CELLS; PRO-B CELLS	A major challenge in hematopoiesis is to conceive assays that could bring useful insights into experimental and clinical hematology. This means identifying separately the various classes of hematopoietic progenitors that are produced sequentially during the progression from stem cells to differentiated functional cells. Standardized short-term colony assays easily quantify lineage-committed myeloid precursors, but identification of primitive cells, which have both the ability to repopulate durably myeloid and lymphoid lineages and perhaps to self-renew, still depends on in vivo assays. Whatever the assay, two important requisites have to be solved: one is the definition of appropriate read-outs that will depend solely on the function of these cells, and the second is to evaluate precisely their numbers and proliferative potential in quantitative assays. When evaluating hematopoiesis, three parameters have to be taken into account: (1) the lack of reliable correlation between the phenotype of a given cell and its function. This is especially problematic in post-transplantation situations where cells from transplanted animals are analysed; (2) functionally heterogeneous cells are identified in a single assay; and (3) ontogeny-related changes in hematopoietic cell proliferation and self-renewal that, in human beings, hampers the exploration of adult stem cells. Nevertheless, years of progress in the manipulation of hematopoietic stem cells have recently resulted in the purification of a cell subset that repopulates irradiated recipients with absolute efficiency.	Fac Med, INSERM, U421, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Coulombel, L (corresponding author), Fac Med, INSERM, U421, 8 Rue Gen Sarrail, F-94010 Creteil, France.	coulombel@im3.inserm.fr						ABRAMSON S, 1977, J EXP MED, V145, P1567, DOI 10.1084/jem.145.6.1567; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; ASH RC, 1981, BLOOD, V58, P309; BARCENA A, 1994, J EXP MED, V180, P123, DOI 10.1084/jem.180.1.123; Barker J, 2000, LEUKEMIA, V14, P1614, DOI 10.1038/sj.leu.2401869; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bennaceur-Griscelli A, 2001, BLOOD, V97, P435, DOI 10.1182/blood.V97.2.435; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Berardi AC, 1997, BLOOD, V89, P3554, DOI 10.1182/blood.V89.10.3554.3554_3554_3564; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bonnet D, 1999, BONE MARROW TRANSPL, V23, P203, DOI 10.1038/sj.bmt.1701564; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borge OJ, 1997, BLOOD, V90, P2282, DOI 10.1182/blood.V90.6.2282.2282_2282_2292; BREEMS DA, 1994, LEUKEMIA, V8, P1095; Breems DA, 1996, BLOOD, V87, P5370, DOI 10.1182/blood.V87.12.5370.bloodjournal87125370; BROXMEYER HE, 1984, CRC CR REV ONCOL-HEM, V1, P227, DOI 10.1016/S1040-8428(84)80013-X; Brummendorf TH, 1998, J EXP MED, V188, P1117, DOI 10.1084/jem.188.6.1117; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Cashman JD, 2000, BLOOD, V96, P3979, DOI 10.1182/blood.V96.12.3979.h8003979_3979_3981; CHANG J, 1986, LANCET, V1, P294; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; COULOMBEL L, 1983, BLOOD, V62, P291; CROISILLE L, 1994, BLOOD, V84, P4116, DOI 10.1182/blood.V84.12.4116.bloodjournal84124116; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; Danet GH, 2001, EXP HEMATOL, V29, P1465, DOI 10.1016/S0301-472X(01)00750-0; Denning-Kendall P, 2003, STEM CELLS, V21, P694, DOI 10.1634/stemcells.21-6-694; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Eaves A C, 1998, Stem Cells, V16 Suppl 1, P77; EAVES CJ, 1978, BLOOD, V52, P1196; Fluckiger AC, 1998, BLOOD, V92, P4509; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; Gammaitoni L, 2003, EXP HEMATOL, V31, P261, DOI 10.1016/S0301-472X(02)01077-9; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; Hao QL, 2001, BLOOD, V97, P3683, DOI 10.1182/blood.V97.12.3683; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Hao QL, 1998, BLOOD, V91, P4145, DOI 10.1182/blood.V91.11.4145.411a10_4145_4151; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; Hogan CJ, 2002, P NATL ACAD SCI USA, V99, P413, DOI 10.1073/pnas.012336799; Hogan CJ, 1997, BLOOD, V90, P85; Holyoake TL, 1999, EXP HEMATOL, V27, P1418, DOI 10.1016/S0301-472X(99)00078-8; Horn PA, 2003, BLOOD, V102, P4329, DOI 10.1182/blood-2003-01-0082; ISCOVE NN, 1971, BLOOD-J HEMATOL, V37, P1; ISHIHARA S, 1992, JPN J CANCER RES, V83, P320, DOI 10.1111/j.1349-7006.1992.tb00108.x; ISSAAD C, 1993, BLOOD, V81, P2916; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jaleco AC, 2001, J EXP MED, V194, P991, DOI 10.1084/jem.194.7.991; Jetmore A, 2002, BLOOD, V99, P1585, DOI 10.1182/blood.V99.5.1585; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Kerre TCC, 2002, BLOOD, V99, P1620, DOI 10.1182/blood.V99.5.1620; Kincade PW, 2000, CURR TOP MICROBIOL, V251, P67; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LEARY AG, 1987, BLOOD, V69, P953; LEBIEN TW, 1989, IMMUNOL TODAY, V10, P296, DOI 10.1016/0167-5699(89)90084-4; LEMIEUX ME, 1995, BLOOD, V86, P1339, DOI 10.1182/blood.V86.4.1339.bloodjournal8641339; Lemieux ME, 1996, BLOOD, V88, P1639; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; LORD BI, 1993, STEM CELLS, V11, P212, DOI 10.1002/stem.5530110308; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; MCCULLOCH EA, 1964, RADIAT RES, V22, P383, DOI 10.2307/3571667; McNiece I, 2001, EXP HEMATOL, V29, P3, DOI 10.1016/S0301-472X(00)00610-X; METCALF D, 1975, J CELL PHYSIOL, V85, P643, DOI 10.1002/jcp.1040850317; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; Morris JC, 2004, BLOOD, V103, P492, DOI 10.1182/blood-2003-07-2324; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nakamura K, 2004, J EXP MED, V199, P243, DOI 10.1084/jem.20031193; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Norol F, 2002, BRIT J HAEMATOL, V117, P924, DOI 10.1046/j.1365-2141.2002.03531.x; Ohishi K, 2002, J CLIN INVEST, V110, P1165, DOI 10.1172/JCI200216167; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PAIGE CJ, 1984, EUR J IMMUNOL, V14, P979, DOI 10.1002/eji.1830141104; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PETTENGELL R, 1994, BLOOD, V84, P3653, DOI 10.1182/blood.V84.11.3653.bloodjournal84113653; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Pflumio F, 1996, BLOOD, V88, P3731, DOI 10.1182/blood.V88.10.3731.bloodjournal88103731; PHILLIPS RA, 1980, J SUPRAMOL STR CELL, V14, P77, DOI 10.1002/jss.400140108; PLOEMACHER RE, 1989, BLOOD, V74, P2755; PLOEMACHER RE, 1991, BLOOD, V78, P2527; PLUM J, 1994, BLOOD, V84, P1587; Plum J, 2000, ANN NY ACAD SCI, V917, P724; Punzel M, 1999, BLOOD, V93, P3750, DOI 10.1182/blood.V93.11.3750.411a37_3750_3756; Punzel M, 1999, LEUKEMIA, V13, P92, DOI 10.1038/sj.leu.2401234; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Rawlings DJ, 1997, EXP HEMATOL, V25, P66; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2003, BLOOD, V101, P4313, DOI 10.1182/blood-2002-07-2085; Robin C, 1999, BRIT J HAEMATOL, V104, P809, DOI 10.1046/j.1365-2141.1999.01266.x; Robin C, 1999, J EXP MED, V189, P1601, DOI 10.1084/jem.189.10.1601; Rollini P, 2004, BLOOD, V103, P1166, DOI 10.1182/blood-2003-06-1815; Rosenzweig M, 1996, BLOOD, V87, P4040, DOI 10.1182/blood.V87.10.4040.bloodjournal87104040; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Shultz LD, 2003, EXP HEMATOL, V31, P551, DOI 10.1016/S0301-472X(03)00076-6; Spanopoulou E, 1996, Int Rev Immunol, V13, P257, DOI 10.3109/08830189609061752; SROUR EF, 1992, BLOOD, V79, P1404; Srour EF, 2001, LEUKEMIA, V15, P1681, DOI 10.1038/sj.leu.2402256; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; SZILVASSY SJ, 1993, BLOOD, V81, P2310; Szilvassy SJ, 2003, EXP HEMATOL, V31, P331, DOI 10.1016/S0301-472X(03)00005-5; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; Thiemann FT, 1998, EXP HEMATOL, V26, P612; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; TREVISAN M, 1995, J EXP MED, V181, P93, DOI 10.1084/jem.181.1.93; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; VORMOOR J, 1994, BLOOD, V83, P2489; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Weekx SFA, 2000, BLOOD, V95, P2806, DOI 10.1182/blood.V95.9.2806.009k01_2806_2812; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; Yokota T, 2003, IMMUNITY, V19, P365, DOI 10.1016/S1074-7613(03)00231-0; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	145	80	89	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7210	7222		10.1038/sj.onc.1207941	http://dx.doi.org/10.1038/sj.onc.1207941			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378081				2022-12-28	WOS:000223998800007
J	Jordan, CT; Guzman, ML				Jordan, CT; Guzman, ML			Mechanisms controlling pathogenesis and survival of leukemic stem cells	ONCOGENE			English	Review						leukemia; stem cell; myeloid; leukemogenesis; NF-kappa B; LSC	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; ABILITY IN-VITRO; CHRONIC MYELOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOGENOUS LEUKEMIA; MYELOPROLIFERATIVE DISEASE; SIGNALING PATHWAYS; PROGENITOR CELLS; BCR-ABL	Stem cells are an integral component of normal mammalian physiology and have been intensively studied in many systems. Intriguingly, substantial evidence indicates that stem cells also play an important role in the initiation and pathogenesis of at least some cancers. In particular, myeloid leukemias have been extensively characterized with regard to stem and progenitor cell involvement. Thus, as a focal point for both scientific and therapeutic endeavors, leukemic stem cells (LSC) represent a critical area of investigation. LSC appear to retain many characteristics of normal hematopoietic stem cells (HSC) as evidenced by a hierarchical developmental pattern, a mostly quiescent cell cycle pro. le, and an immunophenotype very similar to HSC. Consequently, de. ning unique properties of LSC remains a high priority in order to elucidate the molecular mechanisms driving stem cell transformation, and for developing therapeutic strategies that specifically target the LSC population. In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells.	Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA	University of Rochester	Jordan, CT (corresponding author), Univ Rochester, Med Ctr, Dept Med, 601 Elmwood Ave,Box 703, Rochester, NY 14642 USA.	craig_jordan@urmc.rochester.edu	jordan, craig/D-7666-2014	jordan, craig/0000-0003-0869-3465	NATIONAL CANCER INSTITUTE [R01CA090446] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA90446] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRACH MA, 1992, MOL PHARMACOL, V41, P60; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Costello RT, 2000, CANCER RES, V60, P4403; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FOULDS L, 1975, NEOPLASTIC DEV; FOULDS L, 1969, NEOPLASTIC DEV; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; GUTTERIDGE JMC, 1985, BIOCHEM PHARMACOL, V34, P4099, DOI 10.1016/0006-2952(85)90200-X; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Guzman ML, 2001, BLOOD, V97, P2177, DOI 10.1182/blood.V97.7.2177; Hamann PR, 2002, BIOCONJUGATE CHEM, V13, P47, DOI 10.1021/bc010021y; HARRISON DE, 1991, BLOOD, V78, P1237; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2002, LEUKEMIA, V16, P549, DOI 10.1038/sj.leu.2402444; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jin LQ, 2003, BLOOD, V102, p620A; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mayotte N, 2002, BLOOD, V100, P4177, DOI 10.1182/blood-2002-04-1244; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perry MC, 2001, CHEMOTHERAPY SOURCE; Ravandi F, 2002, BRIT J HAEMATOL, V116, P57, DOI 10.1046/j.1365-2141.2002.03236.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Romano MF, 2000, GENE THER, V7, P1234, DOI 10.1038/sj.gt.3301216; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Stucki A, 2001, BLOOD, V97, P2121, DOI 10.1182/blood.V97.7.2121; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tomasson MH, 2001, BLOOD, V97, P1435, DOI 10.1182/blood.V97.5.1435; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Van Etten RA, 2001, CURR OPIN HEMATOL, V8, P224, DOI 10.1097/00062752-200107000-00008; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wierenga PK, 2003, EXP HEMATOL, V31, P421, DOI 10.1016/S0301-472X(03)00049-3; WODINSKY ISIDORE, 1967, CANCER CHEMOTHER REP, V51, P415; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	93	106	111	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7178	7187		10.1038/sj.onc.1207935	http://dx.doi.org/10.1038/sj.onc.1207935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378078	Green Published			2022-12-28	WOS:000223998800004
J	Gildea, JJ; Herlevsen, M; Harding, MA; Gulding, KM; Moskaluk, CA; Frierson, HF; Theodorescu, D				Gildea, JJ; Herlevsen, M; Harding, MA; Gulding, KM; Moskaluk, CA; Frierson, HF; Theodorescu, D			PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity	ONCOGENE			English	Article						PTEN; bladder neoplasms; tumor motility; tumor invasion; tumor-suppressor genes	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; FOCAL ADHESION KINASE; GLIOMA-CELLS; RADICAL CYSTECTOMY; CARCINOMA; METASTASIS; MOTILITY; ARREST; GENE	Recent studies have found a higher frequency of the PTEN tumor-suppressor gene alterations in invasive bladder carcinoma than in superficial disease, suggesting that PTEN is important in this process. A role of PTEN in bladder cancer invasion is further suggested by the fact that PTEN is a regulator of cell motility, a necessary component of tumor invasion. However, it is unknown whether PTEN is mechanistically involved in 'in vivo' tumor invasion or merely an epiphenomenon and, if the former is true, whether this process is dependent on its protein or lipid phosphatase activities. To address these issues, we stably transfected several commonly used human bladder cancer cell lines with known invasive phenotypes with either wild-type PTEN constructs or those deficient in the lipid phosphatase (G129E) or both protein and lipid phosphatase (G129R) activities. Here we show that chemotaxis was inhibited by both the wild-type and G129E mutant of PTEN but not by G129R-transfected cells. Using a novel organotypic in vitro invasion assay, we evaluated the impact of wild-type and mutant PTEN transgene expression on the invasive ability of T24T, a human bladder cancer cell line with a functionally impaired PTEN. Results indicate that the G129E mutant blocks invasion as efficiently as wild-type PTEN transfection. In contrast to the wild-type gene, this mutant has no effect on cell clonogenicity in agar. To further establish the role of PTEN in tumor invasion, we evaluated vector- and PTEN-transfected T24T cells in an orthotopic in vivo assay that faithfully reproduces human disease. Microscopic examination of murine bladders at the completion of this experiment parallels the results obtained with the organotypic assay. Our results are the first demonstration: ( 1) that the inhibitory effects of PTEN on cell motility translate into suppression of in vivo invasion; ( 2) that PTEN can inhibit tumor invasion even in the absence of its lipid phosphatase activity; ( 3) how organotypic in vitro approaches can be used as surrogates of in vivo invasion allowing rapid dissection of molecular processes leading to this phenotype while reducing the number of animals used in research.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu	Harding, Michael/C-3438-2013	Harding, Michael/0000-0001-8636-067X	NCI NIH HHS [R01CA085329] Funding Source: Medline; NIDDK NIH HHS [DK007766] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLERING TE, 1987, CANCER RES, V47, P6660; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Fontana D, 1996, EUR UROL, V29, P470; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gildea JJ, 2002, CANCER RES, V62, P6418; Gildea JJ, 2000, BIOTECHNIQUES, V29, P81, DOI 10.2144/00291st02; Gildea JJ, 2002, CANCER RES, V62, P982; Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lianes P, 1998, CLIN CANCER RES, V4, P1267; LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1999, CANCER RES, V59, P5479; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Seraj MJ, 2001, CLIN CANCER RES, V7, P1516; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Skinner DG, 1998, EUR UROL, V33, P25, DOI 10.1159/000052260; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tanaka M, 2000, ONCOGENE, V19, P5406, DOI 10.1038/sj.onc.1203918; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Weng LP, 1999, CANCER RES, V59, P5808; Wolf JS, 1996, UROLOGY, V47, P2, DOI 10.1016/S0090-4295(99)80374-4	38	65	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6788	6797		10.1038/sj.onc.1207599	http://dx.doi.org/10.1038/sj.onc.1207599			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273733				2022-12-28	WOS:000223653600010
J	Tsunoda, T; Koga, H; Yokomizo, A; Tatsugami, K; Eto, M; Inokuchi, J; Hirata, A; Masuda, K; Okumura, K; Naito, S				Tsunoda, T; Koga, H; Yokomizo, A; Tatsugami, K; Eto, M; Inokuchi, J; Hirata, A; Masuda, K; Okumura, K; Naito, S			Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP(3)R1) modulates the acouisition of cisplatin resistance in bladder cancer cell lines	ONCOGENE			English	Article						cisplatin resistance; IP(3)R1; apoptosis; bladder; cancer	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; INDUCED APOPTOSIS; CALCIUM SIGNALS; OVARIAN-CANCER; DNA-REPAIR; CIS-DIAMMINEDICHLOROPLATINUM(II); SENSITIVITY; MECHANISM	To investigate the molecules that regulate the acquisition of cis-diamminedichloroplatinum (11) (cisplatin) resistance, we performed cDNA microarrays using two pairs of parental and cisplatin-resistant bladder cancer cell lines. We found a markedly reduced expression of inositol 1,4,5-trisphosphate (IP3) receptor typel (IP(3)R1), endoplasmic reticulum membrane protein, in cisplatin-resistant cells. The suppression Of IP(3)R1 expression using small interfering RNA in parental cells prevented apoptosis and resulted in decreased sensitivity to cisplatin. Contrarily, overexpression Of IP(3)R1 in resistant cells induced apoptosis and increased sensitivity to cisplatin. These results suggest that cisplatin-induced downregulation of IP(3)R1 expression was closely associated with the acquisition of cisplatin resistance in bladder cancer cells. Published online 20 December 2004.	Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Naito, S (corresponding author), Kyushu Univ, Dept Urol, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	naito@uro.med.Kyushu-u.ac.jp	Inokuchi, Junichi/AAO-3297-2020	Inokuchi, Junichi/0000-0002-6791-905X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Furutama D, 1996, J NEUROCHEM, V66, P1793; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KOTOH S, 1994, CANCER RES, V54, P3248; Kotoh S, 1997, J UROLOGY, V157, P1054, DOI 10.1016/S0022-5347(01)65140-1; Liang XJ, 2000, BIOSCIENCE REP, V20, P129, DOI 10.1023/A:1005530501137; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; MASUDA H, 1988, CANCER RES, V48, P5713; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NIENDER H, 2001, MOL PHARMACOL, V60, P1153; Oubrahim H, 2002, J BIOL CHEM, V277, P20135, DOI 10.1074/jbc.C200226200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Suzuki T, 2001, CURR DRUG METAB, V2, P367, DOI 10.2174/1389200013338289; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TAYA T, 1977, JPN J UROL, V68, P1003, DOI 10.5980/jpnjurol1928.68.11_1003; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Vaisman A, 1997, CYTOMETRY, V27, P54, DOI 10.1002/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L; YOKOMIZO A, 1995, CANCER RES, V55, P4293	31	54	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1396	1402		10.1038/sj.onc.1208313	http://dx.doi.org/10.1038/sj.onc.1208313			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608674				2022-12-28	WOS:000227092600009
J	Fan, QW; Weiss, WA				Fan, QW; Weiss, WA			RNA interference against a glioma-derived allele of EGFR induces blockade at G(2)M	ONCOGENE			English	Article						siRNA; EGFR; Delta EGFR; PI3 kinase; LY294002; combination therapy	GROWTH-FACTOR RECEPTOR; G(1) ARREST; LUNG-CANCER; EXPRESSION; GENE; P27(KIP1); AMPLIFICATION; INHIBITION; PHASE; CELLS	Amplification and mutation of the epidermal growth factor receptor (EGFR) is common in astrocytoma. The most frequently occurring mutation (DeltaEGFR, EGFRvIII) deletes exons 2-7 from this receptor tyrosine kinase (RTK), and signals constitutively in the absence of ligand. DeltaEGFR is not found in normal tissue, and therefore represents an attractive therapeutic target. Here, we show that a small interfering RNA (siRNA) directed against the unique exon 1/exon 8 junction sequence of DeltaEGFR efficiently suppressed expression of DeltaEGFR in rodent fibroblasts and in two human glioblastoma cell lines. SiRNA-mediated depletion of DeltaEGFR led to reduction in the levels of phosphorylated Akt in glioma cells, was associated with increased apoptosis, and induced partial arrest at the G(2)M phase of the cell cycle. Inhibitors of PI3 kinase cooperated with siRNA treatment, leading to further increases in both cell cycle blockade and apoptosis. Importantly, cell cycle blockade could be reversed, and apoptosis rescued using a conditional allele of Akt, implicating Akt as a primary target of combination therapy. This study demonstrates the therapeutic potential of siRNA to impact DeltaEGFR as a glioma-specific target, and offers a mechanistic rationale for combining siRNA and small molecule inhibitor therapies against distinct components in the EGFR signaling pathway.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, 533 Parnassus Ave,Room U-441O, San Francisco, CA 94143 USA.	weiss@cgl.ucsf.edu		Weiss, William/0000-0003-2230-9132	NCI NIH HHS [U01CA84290, 1P50CA097257-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257, U01CA084290] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BIGNER SH, 1990, CANCER RES, V50, P8017; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; DEL PL, 1997, SCIENCE, V278, P687; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Fan QW, 2003, CANCER RES, V63, P8930; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hansen LA, 1997, AM J PATHOL, V150, P1959; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Luwor RB, 2001, CANCER RES, V61, P5355; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peng D, 1996, CANCER RES, V56, P3666; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Williams JI, 2001, CLIN CANCER RES, V7, P724; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu XP, 1996, ONCOGENE, V12, P1397	48	44	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					829	837		10.1038/sj.onc.1208227	http://dx.doi.org/10.1038/sj.onc.1208227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580296				2022-12-28	WOS:000226577100009
J	Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway	ONCOGENE			English	Article						2CdA; FAraA; apoptosis; FADD; CD95/Fas; caspase-8; Bcl-2	DRUG-RESISTANCE; LEUKEMIA-CELLS; WILD-TYPE; BCL-2; CASPASE; LIGAND; DNA; SENSITIVITY; DOXORUBICIN; RADIATION	The adenine deoxynucleosides cladribine (2CdA) and fludarabine (FAraA) are DNA-damaging agents that interfere with DNA repair and induce apoptosis in nonproliferating lymphoid cells. Although both drugs are clinically used for the treatment of indolent lymphoproliferative diseases, the pathways of apoptosis induction remain largely unknown. In the present work, we demonstrate that both drugs induce apoptosis independently of death receptor signaling but activate the mitochondrial cell death pathway. To dissect the signaling pathways, we employed Jurkat cells either deficient for FADD or caspase-8 or overexpressing Bcl-2. In Bcl-2 overexpressing cells, apoptosis and cytochrome c release were blocked whereas processing of caspase-9, -3 and -8 was partially inhibited. In contrast, neither the deficiency of FADD or caspase-8 nor the interference with death receptor signaling by neutralizing anti-CD95/Fas antibodies affected cell death. Inhibitor experiments revealed that caspase-8 is processed by caspase-3- like caspases. Moreover, cytochrome c release and processing of caspase-9 and - 3 occurred to an equal extent in wild-type FADD -/- and caspase-8 -/- Jurkat cells. Likewise, apoptosis induction by cladribine or fludarabine was not hampered upon inhibition of caspase-8 in MOLT-3 and MOLT-4 cells or overexpression of a dominant-negative FADD mutant in BJAB cells. Thus, we conclude that apoptosis induced by nucleoside analogues is independent from death receptor signaling as well as from a proposed direct effect on APAF-1, but rather follows the mitochondrial signaling pathway of cytochrome c release and subsequent processing of caspase-9 and -3.	Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Med Sch, Dept Radiat Oncol, Tubingen, Germany; Univ Med Sch, Inst Mol Med, Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bosanquet AG, 1996, BLOOD, V87, P1962; Bosanquet AG, 1999, BRIT J HAEMATOL, V106, P71, DOI 10.1046/j.1365-2141.1999.01516.x; BROMIDGE TJ, 1995, CYTOMETRY, V20, P257, DOI 10.1002/cyto.990200309; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang P, 1995, CLIN CANCER RES, V1, P1005; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 2001, BIOCHEM J, V359, P537, DOI 10.1042/0264-6021:3590537; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	29	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9408	9418		10.1038/sj.onc.1207975	http://dx.doi.org/10.1038/sj.onc.1207975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516989				2022-12-28	WOS:000225764100012
J	Sang, NL; Fath, DM; Giordano, A				Sang, NL; Fath, DM; Giordano, A			A gene highly expressed in tumor cells encodes novel structure proteins	ONCOGENE			English	Article						NSP; SMC; ATPase; cell division; actin-binding; protein; coiled-coil domain	COILED-COIL PROTEIN; SPINDLE POLE BODY; CENP-E; ESCHERICHIA-COLI; C-NAP1; 17P11.2-SIMILAR-TO-P12; AMPLIFICATION; INHIBITION; ACTIVATION; BIOLOGY	We isolated several related but distinct cDNA clones encoding novel structure proteins (NSP) when screening a cDNA library. Analysis revealed that these cDNAs and several similar ESTs in the public databases are derived from a single gene of 17 exons that span a minimum of 227-kb region. This gene is located at chromosome 17p11.2, a region frequently amplified in human gliomas and osteosarcomas, and involved in Birt-Hogg-Dube syndrome, a tumor-prone syndrome. The major coding sequences shared by all isolated transcripts are predicted to encode SMC (structural maintenance of chromosome)/SbcC ATPase motifs and coiled-coil domains commonly seen in motor or structure proteins. Two 5'-end and two 3'-end variants (type 5alpha/beta and 3alpha/beta, respectively) were identified, making a total of four possible transcripts. Both 5alpha and 5beta variants were detected in human testis mRNA, but only type 5alpha was detectable in RNA samples extracted from HeLa cells. The unique carboxyl-terminus of 3beta contains a Ca2+-dependent actin-binding domain. Immunohistochemistry studies revealed that NSPs were mostly localized to nuclei. Northern blot analysis demonstrated two major bands and the expression levels are tremendously high in testis while barely detectable in other normal tissues examined. Interestingly, NSP5alpha3alpha is highly expressed in some tumor cell lines. These results suggest that NSPs represent a new family of structure proteins with a possible role in nuclear dynamics during cell division, and that NSP5alpha3alpha may serve as a tumor marker.	Temple Univ, Program Mol Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Jefferson University; Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Program Mol Biol, Bio Life Sci Bldg,1900 N 12th St,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NCI NIH HHS [K01 CA098809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; AMPLE C, 1994, SEMIN CELL BIOL, V5, P175; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Grummt M, 1998, FEBS LETT, V427, P79, DOI 10.1016/S0014-5793(98)00399-8; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Ikemoto S, 2000, J CELL SCI, V113, P545; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 2002, J CELL SCI, V115, P3275; MIRZAYAN C, 1992, J CELL BIOL, V116, P1319, DOI 10.1083/jcb.116.6.1319; ROZYCKI MD, 1994, CURR OPIN CELL BIOL, V6, P87, DOI 10.1016/0955-0674(94)90121-X; Sambrook J., 2001, MOL CLONING LAB MANU; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; van Dartel M, 2003, CANCER GENET CYTOGEN, V140, P162, DOI 10.1016/S0165-4608(02)00683-0; van Dartel M, 2002, CANCER GENET CYTOGEN, V139, P91, DOI 10.1016/S0165-4608(02)00627-1; Viel A, 1999, FEBS LETT, V460, P391, DOI 10.1016/S0014-5793(99)01372-1; Volkmann N, 2001, J CELL BIOL, V153, P947, DOI 10.1083/jcb.153.5.947; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	38	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9438	9446		10.1038/sj.onc.1207988	http://dx.doi.org/10.1038/sj.onc.1207988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602574	Green Accepted			2022-12-28	WOS:000225764100016
J	del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH				del Rincon, SV; Guo, Q; Morelli, C; Shiu, HY; Surmacz, E; Miller, WH			Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism	ONCOGENE			English	Article						retinoic acid; IRS-1; ubiquitin; PKC; breast cancer	INSULIN-RECEPTOR SUBSTRATE-1; BREAST-CANCER CELLS; PROTEIN-KINASE-C; ACUTE PROMYELOCYTIC LEUKEMIA; BRONCHIAL EPITHELIAL-CELLS; GROWTH-FACTOR; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; 3T3-L1 ADIPOCYTES	Insulin receptor substrate-1 (IRS-1) mediates signaling from the insulin-like growth factor type-I receptor. We found that all-trans retinoic acid ( RA) decreases IRS-1 protein levels in MCF-7, T47-D, and ZR75.1 breast cancer cells, which are growth arrested by RA, but not in the RA-resistant MDA-MB-231 and MDA-MB-468 cells. Based on prior reports of ubiquitin-mediated degradation of IRS-1, we investigated the ubiquitination of IRS-1 in RA-treated breast cancer cells. Two proteasome inhibitors, MG-132 and lactacystin, blocked the RA-mediated degradation of IRS-1, and RA increased ubiquitination of IRS-1 in the RA-sensitive breast cancer cells. In addition, we found that RA increases serine phosphorylation of IRS-1. To elucidate the signaling pathway responsible for this phosphorylation event, pharmacologic inhibitors were used. Two PKC inhibitors, but not a MAPK inhibitor, blocked the RA-induced degradation and serine phosphorylation of IRS-1. We demonstrate that RA activates PKC-delta in the sensitive, but not in the resistant cells, with a time course that is consistent with the RA-induced decrease of IRS-1. We also show that: ( 1) RA-activated PKC-delta phosphorylates IRS-1 in vitro, ( 2) PKC-delta and IRS-1 interact in RA-treated cells, and ( 3) mutation of three PKC-delta serine sites in IRS-1 to alanines results in no RA-induced in vitro phosphorylation of IRS-1. Together, these results indicate that RA regulates IRS-1 levels by the ubiquitin - proteasome pathway, involving a PKC-sensitive mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Lady Davis Institute; McGill University; McGill University; McGill University; University of Calabria; Jefferson University	Miller, WH (corresponding author), Lady Davis Inst, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	wmiller@ldi.jgh.mcgill.ca	Morelli, Catia/AAE-1886-2019	Morelli, Catia/0000-0002-9407-0805				Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Boyle JO, 1999, J NATL CANCER I, V91, P373, DOI 10.1093/jnci/91.4.373; Brouillard F, 2003, J BIOL CHEM, V278, P39509, DOI 10.1074/jbc.M307123200; Buren J, 2002, EUR J ENDOCRINOL, V146, P419, DOI 10.1530/eje.0.1460419; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Chang Q, 2002, CANCER RES, V62, P6035; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Gonzalez C, 2001, JOP, V2, P140; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253; Huang XD, 2002, J CLIN ENDOCR METAB, V87, P255, DOI 10.1210/jc.87.1.255; Ito T, 1996, MOL CELL BIOL, V16, P943; IWAO K, 1999, NUCL ACIDS S SER, V42, P207; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lindahl T, 2004, CARCINOGENESIS, V25, P375, DOI 10.1093/carcin/bgh019; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Rosenauer A, 1998, CANCER RES, V58, P5110; Salerno M, 1999, INT J CANCER, V81, P299; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200	55	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9269	9279		10.1038/sj.onc.1208104	http://dx.doi.org/10.1038/sj.onc.1208104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516986				2022-12-28	WOS:000225638000012
J	Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A				Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A			ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; ST18; chromosome 8q11	DNA METHYLATION; ZINC-FINGER; REGION; HETEROZYGOSITY; CARCINOGENESIS; IDENTIFICATION; INVOLVEMENT; PARAMETERS; MUTATIONS	We have identified a gene, ST18 ( suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type ( configuration Cys-X-5-Cys-X-12-His-X-4-Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany; Signature Diagnost AG, D-10719 Berlin, Germany; Atugen AG, D-13125 Berlin, Germany; Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany; Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Robert Rossle Hosp, Clin Surg & Surg Oncol, D-13122 Berlin, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Jandrig, B (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany.	jandrig@mdc-berlin.de	Siebert, Reiner/A-8049-2010					Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Astrom AK, 2000, INT J ONCOL, V16, P1107; Bardet V, 2002, GENE CHROMOSOME CANC, V33, P178, DOI 10.1002/gcc.10014; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bottger V, 1999, J MOL RECOGNIT, V12, P191; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Dahiya R, 1998, INT J ONCOL, V12, P811; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osborne RJ, 2000, CANCER RES, V60, P3706; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Zhang Y, 1999, CYTOGENET CELL GENET, V87, P115, DOI 10.1159/000015375	26	64	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2004	23	57					9295	9302		10.1038/sj.onc.1208131	http://dx.doi.org/10.1038/sj.onc.1208131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489893				2022-12-28	WOS:000225638000015
J	Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S				Sisci, D; Aquila, S; Middea, E; Gentile, M; Maggiolini, M; Mastroianni, F; Montanaro, D; Ando, S			Fibronectin and type IV collagen activate ER alpha AF-1 by c-Src pathway: effect on breast cancer cell motility	ONCOGENE			English	Article						estrogen receptor alpha; extracellular matrix; fibronectin; type IV collagen; c-Src	FOCAL ADHESION KINASE; MEDIATED SIGNAL-TRANSDUCTION; STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GROWTH-FACTOR; MAP KINASE; PROTEIN-KINASE; TYROSINE KINASES; FAMILY KINASES; MAMMARY-TUMORS	The expression of estrogen receptor alpha (ERalpha) is generally associated with a less invasive and aggressive phenotype in breast carcinoma. In an attempt to understand the role of ERalpha in regulating breast cancer cells invasiveness, we have demonstrated that cell adhesion on fibronectin (Fn) and type IV Collagen (Col) induces ERalpha-mediated transcription and reduces cell migration in MCF-7 and in MDA-MB-231 cell lines expressing ERalpha. Analysis of deleted mutants of ERalpha indicates that the transcriptional activation function (AF)-1 is required for ERalpha-mediated transcription as well as for the inhibition of cell migration induced by cell adhesion on extracellular matrix(ECM) proteins. In addition, the nuclear localization signal region and some serine residues in the AF-1 of the ERalpha are both required for the regulation of cell invasiveness as we have observed in HeLa cells. It is worth noting that c-Src activation is coincident with adhesion of cells to ECM proteins and that the inhibition of c-Src activity by PP2 or the expression of a dominant-negative c-Src abolishes ERalpha-mediated transcription and partially reverts the inhibition of cell invasiveness in ERalpha-positive cancer cells. These findings address the integrated role of ECM proteins and ERalpha in influencing breast cancer cell motility through a mechanism that involves c-Src and seems not to be related to a specific cell type.	Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy; Univ Calabria, Dipartimento Farmacobiol, Arcavacata Di Rende, Italy	University of Calabria; University of Calabria	Ando, S (corresponding author), Univ Calabria, Ctr Sanitario, Dipartimento Biol Cellulare, I-87030 Cosenza, Italy.	sebastiano.ando@unical.it	Maggiolini, Marcello/Z-4729-2019; /AAD-9701-2019	/0000-0001-6577-1541; Maggiolini, Marcello/0000-0002-7485-854X; AQUILA, Saveria/0000-0003-4738-6927				Abidi SMA, 1997, CLIN EXP METASTAS, V15, P432, DOI 10.1023/A:1018458406797; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Aplin AE, 1999, J CELL SCI, V112, P695; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHEN Q, 1994, J BIOL CHEM, V6, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Couse JF, 1995, BIOCHEM SOC T, V23, P929, DOI 10.1042/bst0230929; Crowe David L., 1999, Neoplasia (New York), V1, P368, DOI 10.1038/sj.neo.7900041; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Feng WJ, 2001, MOL ENDOCRINOL, V15, P32, DOI 10.1210/me.15.1.32; FRAKER LD, 1984, CANCER RES, V44, P5757; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hynes RO, 1990, FIBRONECTINS; IGNARTROWBRIDGE DM, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432505; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; LEHRER S, 1989, MT SINAI J MED, V56, P83; Lin TH, 1997, J BIOL CHEM, V272, P8849; Liotta L A, 1991, Semin Cancer Biol, V2, P111; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MCGUIRE WL, 1986, CANCER SURV, V5, P527; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSBORNE CK, 1985, CANCER RES, V45, P584; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; PRICE JE, 1990, CANCER RES, V50, P717; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Suen PW, 1999, J CELL SCI, V112, P4067; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	54	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8920	8930		10.1038/sj.onc.1208098	http://dx.doi.org/10.1038/sj.onc.1208098			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467744				2022-12-28	WOS:000225354600007
J	Bower, KE; Fritz, JM; McGuire, KL				Bower, KE; Fritz, JM; McGuire, KL			Transcriptional repression of MMP-1 by p21(SNFT) and reduced in vitro invasiveness of hepatocarcinoma cells	ONCOGENE			English	Article						AP-1; Ets; bZIP; Jun; collagen; matrix metalloproteinase	MATRIX METALLOPROTEINASE-1; GENE-EXPRESSION; COLLAGENASE GENE; POOR-PROGNOSIS; INHIBITORS; CARCINOMA; PROTEIN	p21(SNFT) (21 kDa small nuclear factor isolated from T cells) is a human basic leucine zipper transcription factor that can repress AP-1-mediated transcription. We show here that overexpression of p21(SNFT) in HepG2 cells leads to repression of matrix metalloproteinase-1 by 70-80%. p21(SNFT) interacted with Jun at the matrix metalloproteinase-1 promoter -88 Ets/AP-1 enhancer element, where Jun is known to activate transcription via interaction with Fos and Ets proteins. When p21(SNFT)/Jun dimers bound the element in the presence of Ets, DNA was protected differently than when Fos was paired with Jun. The data suggest a difference in overall conformation between p21(SNFT)-containing and Fos-containing complexes that may be involved in the repression of matrix metalloproteinase-1 by p21(SNFT). Overexpression of p21(SNFT) led to a reduction in invasiveness of HepG2 cells through type I collagen and reconstituted basement membrane, an effect similar to that obtained via direct immunodepletion of matrix metalloproteinase-1. The results indicate that the mechanism of repression of matrix metalloproteinase-1 by p21(SNFT) may be exploited in inhibiting pathological matrix remodeling during cancer progression in vivo.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Bower, KE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd BCC239, La Jolla, CA 92037 USA.	kbower@scripps.edu						ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Blanc JF, 2002, INT J ONCOL, V20, P1129; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Bower KE, 2002, J BIOL CHEM, V277, P34967, DOI 10.1074/jbc.M205048200; Buttice G, 1996, ONCOGENE, V13, P2297; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Iacobelli M, 2000, J IMMUNOL, V165, P860, DOI 10.4049/jimmunol.165.2.860; Inoue T, 1999, INT J MOL MED, V4, P73; Ito T, 1999, MODERN PATHOL, V12, P669; Jonat C, 1992, Matrix Suppl, V1, P145; Kim JH, 2001, MOL CELLS, V12, P32; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; McGuire KL, 1997, J IMMUNOL, V159, P1319; Mengshol JA, 2002, ARTHRITIS RHEUM, V46, P13, DOI 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Ozaki I, 2002, J HEPATOL, V36, P169, DOI 10.1016/S0168-8278(01)00245-8; Siller-Lopez F, 2000, J HEPATOL, V33, P758, DOI 10.1016/S0168-8278(00)80307-4; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Tini M, 2002, COMP BIOCHEM PHYS A, V131, P569, DOI 10.1016/S1095-6433(01)00508-6; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	29	7	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8805	8814		10.1038/sj.onc.1208109	http://dx.doi.org/10.1038/sj.onc.1208109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467742				2022-12-28	WOS:000225165100010
J	Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB				Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB			Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma	ONCOGENE			English	Article						allelic imbalance; APAF-1; colorectal carcinoma; apoptosis; chromosome 12q23	DNA METHYLATION; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; TRANSCRIPTIONAL TARGET; CUTANEOUS MELANOMA; CANCER; GENE; P53; DISEASE; TUMORS	APAF-1 gene, located at chromosome locus 12q23, is a key factor in the mitochondrial apoptotic pathway downstream of p53, and is a potential tumor suppressor gene. We hypothesized that APAF-1 gene dysfunction due to allelic imbalance ( AI) contributes to the development and progression of colorectal carcinoma (CRC). AI at APAF-1 locus and microsatellite instability (MIN) in CRCs and adenomas were assessed by multiple microsatellite markers. The frequency of AI significantly increased with tumor progression; 0 of 33 (0%) adenomas, 14 of 49 (29%) primary CRCs, and 18 of 34 (53%) liver metastases had AI. A total of 12 metastases were matched with corresponding primary CRCs; in 11 of 12 (92%) pairs, the metastasis had same AI status as the corresponding primary tumor. APAF-1 mRNA transcription level was significantly decreased with AI in liver metastases (P = 0.009). Promoter hypermethylation was found in three of 35 (9%) primary CRCs and one of 15 (7%) liver metastases by methylation-specific PCR but was not correlated with AI. MIN was observed in 11 of 49 (23%) primary CRCs and was a favorable prognostic factor. Our results suggest that APAF-1 gene haploinsufficiency caused by AI increases with tumor progression, and relates to hepatic metastasis.	St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Sci Ctr, John Wayne Canc Inst, Div Gastrointestinal Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NATIONAL CANCER INSTITUTE [P01CA029605] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA29605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Baylin SB, 1998, ADV CANCER RES, V72, P141; Boland CR, 1998, CANCER RES, V58, P5248; Deng GR, 1999, CANCER RES, V59, P2029; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fujimoto A, 2004, CANCER RES, V64, P2245, DOI 10.1158/0008-5472.CAN-03-2932; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hao XP, 2002, GUT, V50, P834, DOI 10.1136/gut.50.6.834; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoon DSB, 2002, METHOD ENZYMOL, V356, P302; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kim H, 1999, CYTOGENET CELL GENET, V87, P252, DOI 10.1159/000015436; Kimura M, 1998, CANCER RES, V58, P2456; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Murty VVVS, 1996, GENOMICS, V35, P562, DOI 10.1006/geno.1996.0398; Nakayama T, 2001, AM J PATHOL, V158, P1371, DOI 10.1016/S0002-9440(10)64088-6; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robles AI, 2001, CANCER RES, V61, P6660; Schneider BG, 2003, J CLIN PATHOL-MOL PA, V56, P141, DOI 10.1136/mp.56.3.141; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2004, J CLIN ONCOL, V22, P2671, DOI 10.1200/JCO.2004.12.009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080	41	27	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8292	8300		10.1038/sj.onc.1208022	http://dx.doi.org/10.1038/sj.onc.1208022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378005				2022-12-28	WOS:000224749500011
J	von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT				von Haefen, C; Gillissen, B; Hemmati, PG; Wendt, J; Guner, D; Mrozek, A; Belka, C; Dorken, B; Daniel, PT			Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway	ONCOGENE			English	Article						TRAIL; Bax; Bak; apoptosis; mitochondrial pathway; synergy	NEGATIVE PROGNOSTIC-FACTOR; DEATH LIGAND; CELL-DEATH; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; OLIGOMERIZES BAK; BREAST-CANCER; ACTIVATION; RESISTANCE; CARCINOMA	The death ligand TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation. Here, we show that the synergism of TRAIL and 5-fluorouracil (5-FU) and cross-sensitization between TRAIL and 5-FU for induction of apoptosis, entirely depend on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to release cytochrome c and to activate caspase-3 and -9 when exposed to TRAIL and 5-FU. In contrast, TRAIL sensitized for 5-FU-induced apoptosis and vice versa upon reconstitution of Bax expression. Isobolographic analyses of ED50 doses for 5-FU at increasing TRAIL concentrations showed a clear synergism of TRAIL and 5-FU in Bax-expressing cells. In contrast, the effect was merely additive in DU145 cells lacking Bax. Notably, both DU145 and HCT116 Bax-deficient cells still express Bak. This indicates that Bak is not sufficient to mediate cross-sensitization and synergism between 5-FU and TRAIL. Stable overexpression of Bak in DU145 sensitized for epirubicin-induced apoptosis but failed to confer synergy between TRAIL and 5-FU. Moreover, we show by the use of EGFP-tagged Bax and Bak that TRAIL and 5-FU synergistically trigger oligomerization and clustering of Bax but not Bak. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade and delineate a higher degree of specificity in signaling for cell death by multidomain Bcl-2 homologs.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Tubingen, Fac Med, Dept Radiat Oncol, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Daniel, PT (corresponding author), Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bonavida B, 1999, INT J ONCOL, V15, P793; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gessner PK, 1995, TOXICOLOGY, V105, P161, DOI 10.1016/0300-483X(95)03210-7; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gliniak B, 1999, CANCER RES, V59, P6153; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; JSCHMELZ K, 2004, ONCOGENE, DOI DOI 10.1038/SJ.ONC1207848; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Leverkus M, 2000, CANCER RES, V60, P553; LUCKINGFAMIRA KM, 1994, LEUKEMIA, V8, P1825; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Rudner J, 2001, J CELL SCI, V114, P4161; Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WIEDER T, 1995, BIOCHEM J, V311, P873, DOI 10.1042/bj3110873; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	50	69	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8320	8332		10.1038/sj.onc.1207971	http://dx.doi.org/10.1038/sj.onc.1207971			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15467752				2022-12-28	WOS:000224749500014
J	De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C				De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C			Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2	ONCOGENE			English	Article						ovarian cancer; gene expression profiling; automated class discovery; epithelial-mesenchymal transition; epithelial-stromal interaction	FIBROBLAST-GROWTH-FACTOR; SURFACE EPITHELIAL-CELLS; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; ADHESION MOLECULES; SIGNALING PATHWAYS; MESSENGER-RNA; RECEPTOR; CARCINOMAS	Epithelial ovarian cancer (EOC) is the gynecological disease with the highest death rate. We applied an automatic class discovery procedure based on gene expression pro. ling to stages III-IV tumors to search for molecular signatures associated with the biological properties and progression of EOC. Using a complementary DNA microarray containing 4451 cancer-related, sequence-verified features, we identified a subset of EOC characterized by the expression of numerous genes related to the extracellular matrix (ECM) and its remodeling, along with elements of the fibroblast growth factor 2 (FGF2) signaling pathway. A total of 10 genes were validated by quantitative real-time polymerase chain reaction, and coexpression of FGF2 and fibroblast growth factor receptor 4 in tumor cells was revealed by immunohistochemistry, confirming the reliability of gene expression by cDNA microarray. Since the functional relationships among these genes clearly suggested involvement of the identified molecular signature in processes related to epithelial-stromal interactions and/or epithelial-mesenchymal cellular plasticity, we applied supervised learning analysis on ovarian-derived cell lines showing distinct cellular phenotypes in culture. This procedure enabled construction of a gene classifier able to discriminate mesenchymal-like from epithelial-like cells. Genes overexpressed in mesenchymal-like cells proved to match the FGF2 signaling and ECM molecular signature, as identified by unsupervised class discovery on advanced tumor samples. In vitro functional analysis of the cell plasticity classifier was carried out using two isogenic and immortalized cell lines derived from ovarian surface epithelium and displaying mesenchymal and epithelial morphology, respectively. The results indicated the autocrine, but not intracrine stimulation of mesenchymal conversion and cohort/scatter migration of cells by FGF2, suggesting a central role for FGF2 signaling in the maintenance of cellular plasticity of ovary-derived cells throughout the carcinogenesis process. These findings raise mechanistic hypotheses on EOC pathogenesis and progression that might provide a rational underpinning for new therapeutic modalities.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Lab Nazl CIB, I-34012 Trieste, Italy; IFOM FIRC Inst Mol Oncol, I-20139 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Surg Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; schneide@sci.area.trieste.it	De Cecco, Loris/K-7036-2016; Reid, James/G-2496-2010; Marchionni, Luigi/S-6774-2017; Raspagliesi, Francesco/K-5473-2018; Daidone, Maria Grazia/E-9232-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Mezzanzanica, Delia/C-2607-2017; Ditto, Antonino/H-2219-2017; Gariboldi, Manuela/K-4744-2016	De Cecco, Loris/0000-0002-7066-473X; Marchionni, Luigi/0000-0002-7336-8071; Raspagliesi, Francesco/0000-0001-8953-1657; Daidone, Maria Grazia/0000-0002-4786-1321; Pierotti, Marco Alessandro/0000-0002-7431-8332; Mezzanzanica, Delia/0000-0002-9664-6871; Ditto, Antonino/0000-0002-5684-8225; Reid, James/0000-0001-6997-2850; Gariboldi, Manuela/0000-0001-8406-165X				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Aunoble B, 2000, INT J ONCOL, V16, P567; Balli S, 2000, EUR J CANCER, V36, P2061, DOI 10.1016/S0959-8049(00)00193-3; Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fujimoto J, 1997, EUR J GYNAECOL ONCOL, V18, P349; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; HORI A, 1991, CANCER RES, V51, P6180; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hough CD, 2001, CANCER RES, V61, P3869; Hough CD, 2000, CANCER RES, V60, P6281; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kodama J, 2001, ANTICANCER RES, V21, P2983; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Liotta LA, 2002, JNCI-J NATL CANCER I, V94, P1113; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Matias-Guiu X, 1998, VIRCHOWS ARCH, V433, P103, DOI 10.1007/s004280050224; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Obermair A, 1998, CANCER LETT, V130, P69, DOI 10.1016/S0304-3835(98)00119-0; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Parrott JA, 2001, MOL CELL ENDOCRINOL, V175, P29, DOI 10.1016/S0303-7207(01)00436-1; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; Righetti SC, 1999, CELL GROWTH DIFFER, V10, P473; Santala M, 1999, CLIN CANCER RES, V5, P4091; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schwartz DR, 2003, CANCER RES, V63, P2913; Schwartz DR, 2002, CANCER RES, V62, P4722; Sheng GJ, 2003, CELL, V115, P603, DOI 10.1016/S0092-8674(03)00927-9; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shridhar V, 2001, CANCER RES, V61, P5895; Simojoki M, 2001, GYNECOL ONCOL, V82, P110, DOI 10.1006/gyno.2001.6212; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; VANNIEKERK CC, 1993, AM J PATHOL, V142, P157; von Heydebreck A, 2001, Bioinformatics, V17 Suppl 1, pS107; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176	64	71	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8171	8183		10.1038/sj.onc.1207979	http://dx.doi.org/10.1038/sj.onc.1207979			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377994				2022-12-28	WOS:000224692500015
J	Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O				Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O			The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway	ONCOGENE			English	Article						IGF-1R; Akt; apoptosis; dominant-negative mutants	IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; CELL-DEATH; CANCER; AUTOPHOSPHORYLATION; MITOGENESIS; EXPRESSION; MELANOMA; ANTIBODY; DOMAIN	The insulin-like growth factor-1 receptor (IGF-1R) is crucial for many functions in neoplastic cells, for example, antiapoptosis. Recently, we demonstrated that the cyclolignan PPP efficiently inhibited phosphorylation of IGF-1R without interfering with insulin receptor activity. PPP preferentially reduced phosphorylated Akt, as compared to phosphorylated Erk1/2, and caused apoptosis. Now, we aimed to investigate how PPP inhibits the IGF-1R tyrosine kinase (IGF-1RTK) and the PI3K/Akt apoptotic pathway. Using a baculovirus driven IGF-1RTK we found that PPP interfered with tyrosine phosphorylation in the activation loop of the kinase domain. Specifically, it blocked phosphorylation of tyrosine (Y) 1136, while sparing the two others (Y1131 and Y1135). To explore the impact of inhibition of Y1136 on Akt phosphorylation we transfected P6 cells (overexpressing IGF-1R) and malignant melanoma cells with different IGF-1R mutants, including Y1136F (tyrosine replaced by phenylalanine). Y1136F was found to strongly decrease IGF-1 stimulated phosphorylation of Akt. Conversely, Akt phosphorylation was weakly affected in the Y1131F transfectant. Taken together, our data suggest that the preferential inhibition of phosphorylated Akt, after PPP treatment, may be due to specific inhibition of Y1136. PPP was proven not to interfere directly with Akt or any of its downstream molecules in the apoptotic pathway.	Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; 				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; KATO H, 1993, J BIOL CHEM, V268, P2655; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LI SW, 1994, J BIOL CHEM, V269, P32558; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Yam A, 2001, J BIOL CHEM, V276, P24409, DOI 10.1074/jbc.M102358200; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	38	126	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7854	7862		10.1038/sj.onc.1208065	http://dx.doi.org/10.1038/sj.onc.1208065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334055				2022-12-28	WOS:000224331600011
J	Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y				Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y			Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway	ONCOGENE			English	Article						p53; p53-121F; p53 target gene; apoptosis; cDNA microarray; gene therapy	CELL-CYCLE CHECKPOINT; P53 GENE-TRANSFER; POTENTIAL MEDIATOR; DIRECT TARGET; LUNG-CANCER; PROTEIN; MUTATIONS; EXPRESSION; INHIBITOR; KINASES	A mutant version of p53 (p53-121F), in which phenylalanine replaces the 121st serine residue, can induce apoptosis more effectively than wild-type p53 (wt-p53). In view of this observation, we considered that one or more apoptosis-related p53-target genes might be preferentially induced by p53-121F. We carried out cDNA microarray analysis to identify such genes, using mRNAs isolated from LS174T colon-cancer cells infected by adenovirus vectors containing either p53-121F(Ad-p53-121F) or wt-p53 (Ad-p53). The STAG1 gene was one of the transcripts showing higher expression levels in cells infected with Ad-p53-121F as opposed to Ad-wtp53. The encoded product appears to contain a transmembrane domain, and binding motifs for SH3 and WW. In two other cancer cell lines, the expression of STAG1 mRNA was induced in response to various genotoxic stresses in a p53-dependent manner; moreover, enforced expression of STAG1 led to apoptosis in several additional cancer cell lines. Suppression of endogenous STAG1 using the RNA-interference method reduced the apoptotic response, whether induced by Ad-p53-121F or Ad- p53. These results suggest that STAG1, a novel transcriptional target for p53, mediates p53-dependent apoptosis, and might be a good candidate for next-generation gene therapy.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				BAKER SJ, 1990, CANCER RES, V50, P7717; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Furuhata T, 1996, ONCOGENE, V13, P1965; Habib NA, 1999, HUM GENE THER, V10, P2019, DOI 10.1089/10430349950017383; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HARPER JW, 1993, CELL, V75, P805; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; Matsuda K, 2002, CANCER RES, V62, P2883; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ono K, 2000, CANCER RES, V60, P5007; Rae FK, 2001, MOL CARCINOGEN, V32, P44, DOI 10.1002/mc.1063; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Urano T, 1997, CANCER RES, V57, P3281; Weill D, 2000, CHEST, V118, P966, DOI 10.1378/chest.118.4.966; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi T, 2001, CANCER RES, V61, P8256	29	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7621	7627		10.1038/sj.onc.1207270	http://dx.doi.org/10.1038/sj.onc.1207270			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361841				2022-12-28	WOS:000224306700003
J	Core, N; Joly, F; Boned, A; Djabali, M				Core, N; Joly, F; Boned, A; Djabali, M			Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice	ONCOGENE			English	Article						Pc-G; M33; proliferation; Ink4a	HEMATOPOIETIC STEM-CELLS; RESCUES T-LYMPHOPOIESIS; RECEPTOR-DEFICIENT MICE; POLYCOMB-GROUP GENES; B-CELL; FAMILY-MEMBERS; INK4A LOCUS; EXPRESSION; P16(INK4A); BCL-2	Polycomb group (Pc-G) proteins associate to form large complexes that repress Hox genes, thereby imposing Hox gene expression pattern required for development. However, Pc-G proteins have a Hox-independent function in controlling cell proliferation. Here we show that embryonic fibroblasts derived from M33-deficient mice are impaired in the progression into the S phase of the cell cycle, as shown by a reduced rate of incorporation of bromodeoxyuridine. These cells have a senescent phenotype, associated to an abnormal accumulation of the cyclin-dependent kinase inhibitor p16INK4a protein. We demonstrate that this defect is bypassed in mutant embryonic fibroblasts expressing a transdominant negative form of the cell cycle controlling transcription factor E2F (E2F-DB). In addition, we show that the polycomb protein M33 controls critical expansion of B- and T-lymphocyte precursors. Together, our results emphasize M33-Polycomb protein function in cell cycle control.	CNRS, INSERM, Ctr Immunol, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Djabali, M (corresponding author), CNRS, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 9, France.	djabali@cim1.univ-mrs.fr						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bel S, 1998, DEVELOPMENT, V125, P3543; Core N, 1997, DEVELOPMENT, V124, P721; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PENIT C, 1995, J IMMUNOL, V154, P5103; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	35	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7660	7668		10.1038/sj.onc.1207998	http://dx.doi.org/10.1038/sj.onc.1207998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15377996				2022-12-28	WOS:000224306700007
J	Carson, DJ; Santoro, IM; Groden, J				Carson, DJ; Santoro, IM; Groden, J			Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity	ONCOGENE			English	Article						adenomatous polyposis coli; tumor suppressor; writ signaling	TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; WILD-TYPE; GENE; ASSOCIATION; PROTEIN; CANCER	Mutation of the APC tumor suppressor gene is one of the earliest events in the development of most colorectal tumors. The APC gene encodes multiple protein isoforms through a complicated pattern of expression and alternative splicing. The role that each isoform plays in cellular physiology is unknown, although the presence of some of these isoforms in postmitotic cells suggests a role in controlling cell growth or promoting differentiation. Three APC isoforms that differ in their amino-terminal domains were evaluated by gene transfer experiments using a colon cancer cell line that lacks functional APC. All three isoforms alter cellular morphology and affect cell growth by elongating the G1 phase of the cell cycle. The conventional APC and brain-specific APC isoforms suppress the tumorigenic phenotype of cultured cells, while the 0.3 APC isoform does not. In support of these experiments, BrdU incorporation as a marker for S-phase entry occurs at a higher level in transiently transfected cells with 0.3 APC when compared to cells transfected with the other isoforms. All three APC isoforms colocalize with microtubules and dramatically reduce beta-catenin activity to the same extent in transiently transfected cancer cells, suggesting that the different effects of each isoform on tumorigenesis may be nontranscriptional in origin.	Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Howard Hughes Medical Institute; University of Cincinnati	Groden, J (corresponding author), Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	joanna.groden@uc.edu			NCI NIH HHS [CA-63057] Funding Source: Medline; NIDDK NIH HHS [T32-DK-64581-1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK064581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Pyles RB, 1998, ONCOGENE, V16, P77, DOI 10.1038/sj.onc.1201505; Santoro IM, 1997, CANCER RES, V57, P488; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, CANCER RES, V53, P2728	14	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7144	7148		10.1038/sj.onc.1207954	http://dx.doi.org/10.1038/sj.onc.1207954			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273719				2022-12-28	WOS:000223885100015
J	Maiorana, A; Tu, XA; Cheng, GJ; Baserga, R				Maiorana, A; Tu, XA; Cheng, GJ; Baserga, R			Role of pescadillo in the transformation and immortalization of mammalian cells	ONCOGENE			English	Article						pescadillo; transformation; immortalization	INSULIN-RECEPTOR SUBSTRATE-1; RNA-POLYMERASE-I; GROWTH-FACTOR-I; LARGE T-ANTIGEN; RIBOSOMAL GENE-TRANSCRIPTION; LARGE TUMOR-ANTIGEN; HUMAN-FIBROBLASTS; SIMIAN VIRUS-40; NUCLEAR TRANSLOCATION; IGF-I	The murine and human homologs of the zebrafish pescadillo protein (Pes1 and PES1, respectively) play important roles in ribosome biogenesis and DNA replication. We investigated the effect of Pes1 on the growth of mouse embryo (3T3-like) fibroblasts and conditionally immortalized human fibroblasts expressing the SV40 T antigen (AR5 cells). Increased expression of Pes1 causes transformation of mouse and human fibroblasts in culture ( colony formation in soft agar). Although Pes1 can replace the SV40 T antigen in inducing colony formation in soft agar, it cannot substitute the T antigen in the immortalization of human fibroblasts, indicating that it distinguishes between the two functions. As the biological effects of Pes1 are similar to those of the insulin receptor substrate- 1 (IRS-1), we investigated the interactions of Pes1 with IRS-1 itself and with the SV40 T antigen. The Pes1 protein ( which localizes to the nuclei and nucleoli of cells) interacts with both IRS-1 and the SV40 T antigen, and markedly decreases the interaction of T antigen with p53. Taken together, these results suggest mechanisms for the ability of Pes1 to transform cells, and its failure to immortalize them.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@mail.jci.tju.edu	Maiorana, Arianna/AAA-6517-2020	Maiorana, Arianna/0000-0001-9986-1385	NCI NIH HHS [CA89640] Funding Source: Medline; NIA NIH HHS [AG16291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHANG LS, 1985, VIROLOGY, V146, P246, DOI 10.1016/0042-6822(85)90008-X; Chang Q, 2002, CANCER RES, V62, P6035; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; FRASER RSS, 1978, NATURE, V271, P726, DOI 10.1038/271726a0; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HARTWELL LH, 1978, J CELL BIOL, V77, P627, DOI 10.1083/jcb.77.3.627; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pete G, 1999, ENDOCRINOLOGY, V140, P5478, DOI 10.1210/en.140.12.5478; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; Reeder RH, 1999, PROG NUCLEIC ACID RE, V62, P293; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOPRANO KJ, 1979, P NATL ACAD SCI USA, V76, P3885, DOI 10.1073/pnas.76.8.3885; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WHITE JA, 1992, EXP CELL RES, V203, P157, DOI 10.1016/0014-4827(92)90051-9; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	57	29	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7116	7124		10.1038/sj.onc.1207916	http://dx.doi.org/10.1038/sj.onc.1207916			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273728				2022-12-28	WOS:000223885100012
J	Han, YQ; San-Marina, S; Liu, JA; Minden, MD				Han, YQ; San-Marina, S; Liu, JA; Minden, MD			Transcriptional activation of c-myc proto-oncogene by WT1 protein	ONCOGENE			English	Article						Wilms' tumor 1 gene (WT1); c-myc; transcriptional regulation	TUMOR-SUPPRESSOR GENE; WILMS-TUMOR; INHIBITS PROLIFERATION; PROGENITOR CELLS; BREAST-CANCER; DNA-BINDING; EXPRESSION; APOPTOSIS; BCL-2; DIFFERENTIATION	The Wilms' tumor 1 gene (WT1) plays an essential role in urogenital development and malignancy. Through DNA binding, WT1 can either enhance or repress transcription depending on the context of the DNA-binding sites or the cell type in which it is expressed. WT1 is overexpressed in a variety of human cancers, including leukemia and breast cancer; in these diseases, the expression of WT1 is associated with a poor prognosis. To determine how WT1 affects c-myc expression in the context of breast cancer cells, we have examined the ability of both endogenous and exogenous WT1 proteins in breast cancer cells to bind to the c-myc promoter in vivo. Using c-myc-promoter-driven luciferase constructs, we found that different forms of WT1 could enhance the expression of the reporter. Unlike other studies where WT1 is reported to be a negative regulator of c-myc, we found that both the - and + KTS forms of WT1 could act to enhance c-myc expression, depending on the cell type. The WT1-binding site near the second major transcription start site of the cmyc promoter was confirmed to be involved in upregulation of human c-myc by WT1. Finally, we demonstrated that overexpression of WT1 induced a significant increase in the abundance of endogenous c-myc protein in breast cancer cells, consistent with the upregulation of c-myc transcription following WT1 induction. These observations strongly argue that in the case of breast cancer WT1 is functioning as an oncogene in part by stimulating the expression of c-myc.	Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Minden, MD (corresponding author), Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave,Room 5-217, Toronto, ON M5G 2M9, Canada.	minden@uhnres.utoronto.ca	San-Marina, Serban/ABF-1214-2020	San-Marina, Serban/0000-0002-5312-4774				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Algar EM, 1996, ONCOGENE, V12, P1005; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1997, CANCER RES, V57, P1429; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABER DA, 1992, NEW BIOL, V4, P97; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; HEWITT SM, 1995, CANCER RES, V55, P5386; Kreidberg JA, 1996, MED PEDIATR ONCOL, V27, P445, DOI 10.1002/(SICI)1096-911X(199611)27:5<445::AID-MPO10>3.0.CO;2-9; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menssen HD, 2000, J CANCER RES CLIN, V126, P226, DOI 10.1007/s004320050037; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NISEN PD, 1986, CANCER RES, V46, P6217; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1993, ADV EXP MED BIOL, V348, P23; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Svedberg H, 2001, LEUKEMIA, V15, P1914, DOI 10.1038/sj.leu.2402303; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TELERMAN A, 1992, ONCOGENE, V7, P2545; Udtha M, 2003, ONCOGENE, V22, P3821, DOI 10.1038/sj.onc.1206597; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896	42	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6933	6941		10.1038/sj.onc.1207609	http://dx.doi.org/10.1038/sj.onc.1207609			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286719				2022-12-28	WOS:000223750700010
J	Xia, SJJ; Barr, FG				Xia, SJJ; Barr, FG			Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein	ONCOGENE			English	Article						PAX3-FKHR; rhabdomyosarcoma; transformation; growth suppression	ALVEOLAR RHABDOMYOSARCOMA; DNA-BINDING; CRYSTAL-STRUCTURE; FUSION PROTEIN; PAIRED DOMAIN; HOMEODOMAIN; FKHR; GENE	The 2;13 chromosomal translocation occurs in most casesof the cancer alveolar rhabdomyosarcoma ( ARMS), and juxtaposes the genes encoding the PAX3 and FKHR transcription factors. The resulting chimeric protein PAX3-FKHR is a potent transcriptional activator, and is hypothesized to function as a dominant acting oncogene. To investigate its biological function, PAX3-FKHR was transduced into three immortalized murine cell lines in either a constitutive or inducible manner. These cells only tolerate expression of low PAX3-FKHR levels, which is sufficient for transformation in NIH3T3 cells. In contrast, higher PAX3-FKHR levels, which are comparable to the endogenous level expressed in ARMS cells, result in growth suppression. To determine as to which PAX3 functional domains are needed for growth suppression and transformation, inactivating mutations were introduced into the paired box and homeodomain of PAX3-FKHR. In these experiments, the homeodomain is necessary for transformation, but not growth suppression; whereas the paired box is not required for transformation but mediates growth suppression. In summary, our findings demonstrate that the transforming and growth suppressive activities of PAX3-FKHR are dominant at different activity levels and are mediated by distinct functional domains. These findings are consistent with the hypothesis that distinct expression pathways are operative in these opposing phenotypic end points.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505C, Philadelphia, PA 19104 USA	University of Pennsylvania	Barr, FG (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 505C, 422 Curie Blvd, Philadelphia, PA 19104 USA.	barrfg@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA071838, R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [CA71838, CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bridge JA, 2002, GENE CHROMOSOME CANC, V33, P310, DOI 10.1002/gcc.10026; Bridge JA, 2000, GENE CHROMOSOME CANC, V27, P337, DOI 10.1002/(SICI)1098-2264(200004)27:4<337::AID-GCC1>3.0.CO;2-1; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; TSOKOS M, 1992, ARCH PATHOL LAB MED, V116, P847; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263	20	50	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6864	6871		10.1038/sj.onc.1207850	http://dx.doi.org/10.1038/sj.onc.1207850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286710				2022-12-28	WOS:000223750700003
J	Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B				Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B			Histone deacetylase inhibitors specifically kill nonproliferating tumour cells	ONCOGENE			English	Article						histone deacetylase inhibitors; quiescent; apoptosis; chemotherapy; cell cycle	SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN LEUKEMIA-CELLS; SODIUM-BUTYRATE; P21(WAF1) EXPRESSION; APOPTOSIS; CHEMOTHERAPY; SAHA; CYTOTOXICITY; ACETYLATION; PROTECTION	Conventional chemotherapeutic drugs target proliferating cells, relying on often small differences in drug sensitivity of tumour cells compared to normal tissue to deliver a therapeutic benefit. Consequently, they have significant limiting toxicities and greatly reduced efficacy against nonproliferating compared to rapidly proliferating tumour cells. This lack of selectivity and inability to kill nonproliferating cells that exist in tumours with a low mitotic index are major failings of these drugs. A relatively new class of anticancer drugs, the histone deacetylase inhibitors (HDI), are selectively cytotoxic, killing tumour and immortalized cells but normal tissue appears resistant. Treatment of tumour cells with these drugs causes both G1 phase cell cycle arrest correlated with increase p21 expression, and cell death, but even the G1 arrested cells died although the onset of death was delayed. We have extended these observations using cells that were stably arrested by either serum starvation or expression of the cyclin-dependent kinase inhibitor p16(ink4a). We report that histone deacetylase inhibitors have similar cytotoxicity towards both proliferating and arrested tumour and immortalized cells, although the onset of apoptosis is delayed by 24 h in the arrested cells. Both proliferating and arrested normal cells are unaffected by HDI treatment. Thus, the histone deacetylase inhibitors are a class of anticancer drugs that have the desirable features of being tumour-selective cytotoxic drugs that are equally effective in killing proliferating and nonproliferating tumour cells and immortalized cells. These drugs have enormous potential for the treatment of not only rapidly proliferating tumours, but tumours with a low mitotic index.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	University of Queensland; Peter Maccallum Cancer Center	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Johnstone, Ricky w/H-3748-2014; saunders, nicholas/AAJ-6101-2020; Burgess, Andrew/C-7952-2009; McTaggart, Jill/G-4696-2010; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019	Johnstone, Ricky w/0000-0001-7053-9237; saunders, nicholas/0000-0002-2478-3420; Burgess, Andrew/0000-0003-4536-9226; McTaggart, Jill/0000-0002-9000-8529; Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; DREWINKO B, 1981, CANCER RES, V41, P2328; Fueyo J, 1998, INT J ONCOL, V12, P665; Gabrielli BG, 2002, CURR CANCER DRUG TAR, V2, P337, DOI 10.2174/1568009023333818; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Ju R, 2003, CANCER RES, V63, P2891; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; Parsons PG, 1997, BIOCHEM PHARMACOL, V53, P1719, DOI 10.1016/S0006-2952(97)00016-6; Peart MJ, 2003, CANCER RES, V63, P4460; Prabhu NS, 1999, INT J ONCOL, V15, P209; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Rahmani M, 2003, CANCER RES, V63, P8420; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2001, INT J ONCOL, V19, P181; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schmidt M, 2001, ONCOGENE, V20, P6164, DOI 10.1038/sj.onc.1204814; Stone S, 1996, CANCER RES, V56, P3199; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang XQ, 1996, CANCER RES, V56, P2510; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje	30	113	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6693	6701		10.1038/sj.onc.1207893	http://dx.doi.org/10.1038/sj.onc.1207893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15235588				2022-12-28	WOS:000223653600001
J	Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O				Muranen, T; Gronholm, MG; Renkema, GH; Carpen, O			Cell cycle-dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour suppressor merlin	ONCOGENE			English	Article						merlin; NF2; ERM; nucleus; cell cycle	TYPE-2 GENE-PRODUCT; ERM PROTEINS; P21-ACTIVATED KINASE; NUCLEAR EXPORT; GROWTH; LOCALIZATION; PHOSPHORYLATION; INHIBITION; ADHESION; SIGNAL	The neurofibromatosis 2 tumour suppressor merlin/schwannomin is structurally related to the ezrin-radixin-moesin family of proteins, which anchor actin cytoskeleton to specific membrane proteins and participate in cell signalling. Merlin inhibits cell growth with a yet unknown mechanism. As most tumour suppressors are linked to cell cycle control, we investigated merlin's behaviour during cell cycle. In glioma and osteosarcoma cells, endogenous merlin was targeted to the nucleus in a cell cycle-specific manner. Merlin accumulated perinuclearly at the G2/M phase, and shifted to the nucleus at early G1. During mitosis, merlin localized to mitotic spindles and at the contractile ring. Nuclear merlin was strongly reduced in confluent cells. Blocking of the CRM1/exportin nuclear export pathway led to accumulation of merlin in the nucleus. Activation of the p21-activated kinase or protein kinase A, which result in phosphorylation of merlin, did not affect its nuclear localization. Merlin regulates the activity of extracellular signal-regulated kinase 2 (ERK2) and nuclear localization of both proteins was induced by cell adhesion. Unlike ERK2, nuclear localization of merlin was not, however, dependent on intact actin cytoskeleton. These results link merlin to events related to cell cycle control and may help to resolve its tumour suppressor function.	Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, Helsinki 00014, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital	Muranen, T (corresponding author), Univ Helsinki, Neurosci Program, Biomedicum Helsinki, Dept Pathol, PB 63, FIN-00014 Helsinki, Finland.	taru.muranen@helsinki.fi	Renkema, Herma/L-1489-2015; Muranen, Taru/AAM-9349-2021	Renkema, Herma/0000-0002-8174-6538; Muranen, Taru/0000-0003-4158-9002; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Aplin AE, 2003, FEBS LETT, V534, P11, DOI 10.1016/S0014-5793(02)03840-1; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burke B, 2002, NAT REV MOL CELL BIO, V3, P487, DOI 10.1038/nrm860; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Giovannini M, 2000, GENE DEV, V14, P1617; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Huynh DP, 1996, ONCOGENE, V13, P73; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lallena MJ, 1997, J CELL SCI, V110, P239; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Lohez OD, 2003, J CELL BIOL, V161, P67, DOI 10.1083/jcb.200208140; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shollar D, 2004, ONCOGENE, V23, P5459, DOI 10.1038/sj.onc.1207728; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	41	46	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2005	24	7					1150	1158		10.1038/sj.onc.1208283	http://dx.doi.org/10.1038/sj.onc.1208283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580288				2022-12-28	WOS:000226898700003
J	O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ				O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ			Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity	ONCOGENE			English	Article						lymphatic metastasis; squamous cell carcinoma; microarray; gene expression pattern	MOLECULAR CLASSIFICATION; NODE METASTASIS; CHEMOKINE RECEPTORS; CDNA MICROARRAYS; DNA MICROARRAYS; BREAST-CANCER; IDENTIFICATION; HEAD; PROFILES; VALIDATION	Metastasis via the lymphatics is a major risk factor in squamous cell carcinoma of the oral cavity (OSCC). We sought to determine whether the presence of metastasis in the regional lymph node could be predicted by a gene expression signature of the primary tumor. A total of 18 OSCCs were characterized for gene expression by hybridizing RNA to Affymetrix U133A gene chips. Genes with differential expression were identified using a permutation technique and verified by quantitative RT-PCR and immunohistochemistry. A predictive rule was built using a support vector machine, and the accuracy of the rule was evaluated using crossvalidation on the original data set and prediction of an independent set of four patients. Metastatic primary tumors could be differentiated from nonmetastatic primary tumors by a signature gene set of 116 genes. This signature gene set correctly predicted the four independent patients as well as associating five lymph node metastases from the original patient set with the metastatic primary tumor group. We concluded that lymph node metastasis could be predicted by gene expression profiles of primary oral cavity squamous cell carcinomas. The presence of a gene expression signature for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasis should be possible.	Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; University of Pennsylvania	Muschel, RJ (corresponding author), Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA.	muschel@xrt.upenn.edu		O'Donnell, Rebekah/0000-0001-5878-7510				Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bei R, 2001, J PATHOL, V195, P343, DOI 10.1002/path.965; Belbin TJ, 2002, CANCER RES, V62, P1184; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Chen BS, 2000, INT J CANCER, V88, P862, DOI 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Clare Amanda, 2002, In Silico Biology, V2, P511; Datta S, 2003, BIOINFORMATICS, V19, P459, DOI 10.1093/bioinformatics/btg025; Delilbasi CB, 2004, ORAL ONCOL, V40, P154, DOI 10.1016/S1368-8375(03)00144-1; Depondt J, 1999, EUR J ORAL SCI, V107, P442, DOI 10.1046/j.0909-8836.1999.eos107605.x; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Greenberg JS, 2003, CANCER, V97, P1464, DOI 10.1002/cncr.11202; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hong WKWR, 1995, HEAD NECK CANC BASIC; Hwang D, 2003, ORAL ONCOL, V39, P259, DOI 10.1016/S1368-8375(02)00108-2; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kim Hyoun Chull, 1993, Kurume Medical Journal, V40, P183; Leethanakul C, 2003, ORAL ONCOL, V39, P248, DOI 10.1016/S1368-8375(02)00107-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loriot A, 2003, INT J CANCER, V105, P371, DOI 10.1002/ijc.11104; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Myers LL, 1998, LARYNGOSCOPE, V108, P232, DOI 10.1097/00005537-199802000-00014; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Ohta T, 1996, BRIT J CANCER, V73, P1511, DOI 10.1038/bjc.1996.285; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Schmalbach CE, 2004, ARCH OTOLARYNGOL, V130, P295, DOI 10.1001/archotol.130.3.295; Scimone ML, 2004, J EXP MED, V199, P1113, DOI 10.1084/jem.20031645; Stringer BK, 2001, CANCER RES, V61, P582; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van Kempen LCLT, 2003, EUR J CELL BIOL, V82, P539, DOI 10.1078/0171-9335-00346; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner GC, 2004, INT J CANCER, V110, P857, DOI 10.1002/ijc.20197; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	51	152	162	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1244	1251		10.1038/sj.onc.1208285	http://dx.doi.org/10.1038/sj.onc.1208285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558013				2022-12-28	WOS:000226898700011
J	Collis, SJ; DeWeese, TL; Jeggo, PA; Parker, AR				Collis, SJ; DeWeese, TL; Jeggo, PA; Parker, AR			The life and death of DNA-PK	ONCOGENE			English	Review						DNA-PK; function; protein interactions; regulation; molecular targeting; small molecule inhibitors; radiosensitization; gene therapy	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; SEVERE COMBINED IMMUNODEFICIENCY; HUMAN CANCER-CELLS; TERMINAL TRANSACTIVATION DOMAIN; DAMAGE-INDUCED PHOSPHORYLATION; HUMAN TUMOR-CELLS; CATALYTIC SUBUNIT; IN-VITRO	Double-strand breaks (DSBs) arise endogenously during normal cellular processes and exogenously by genotoxic agents such as ionizing radiation (IR). DSBs are one of the most severe types of DNA damage, which if left unrepaired are lethal to the cell. Several different DNA repair pathways combat DSBs, with nonhomologous end-joining(NHEJ) beingone of the most important in mammalian cells. Competent NHEJ catalyses repair of DSBs by joining together and ligating two free DNA ends of little homology ( microhomology) or DNA ends of no homology. The core components of mammalian NHEJ are the catalytic subunit of DNA protein kinase (DNA-PKcs), Ku subunits Ku70 and Ku80, Artemis, XRCC4 and DNA ligase IV. DNA-PK is a nuclear serine/threonine protein kinase that comprises a catalytic subunit (DNA-PKcs), with the Ku subunits actingas the regulatory element. It has been proposed that DNA-PK is a molecular sensor for DNA damage that enhances the signal via phosphorylation of many downstream targets. The crucial role of DNA-PK in the repair of DSBs is highlighted by the hypersensitivity of DNA-PK-/- mice to IR and the high levels of unrepaired DSBs after genotoxic insult. Recently, DNA-PK has emerged as a suitable genetic target for molecular therapeutics such as siRNA, antisense and novel inhibitory small molecules. This review encompasses the recent literature regarding the role of DNA-PK in the protection of genomic stability and focuses on how this knowledge has aided the development of specific DNA-PK inhibitors, via both small molecule and directed molecular targeting techniques. This review promotes the inhibition of DNA-PK as a valid approach to enhance the tumor-cell-killing effects of treatments such as IR.	Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21231 USA; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Sussex	Collis, SJ (corresponding author), Canc Res UK, Clare Hall Labs, DNA Damage Response Lab, S Mimms EN6 3LD, Herts, England.	spencer.collis@cancer.org.uk		Collis, Spencer/0000-0002-7874-1891				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Bailey SM, 2004, DNA REPAIR, V3, P349, DOI 10.1016/j.dnarep.2003.11.007; Bailey SM, 2004, DNA REPAIR, V3, P225, DOI 10.1016/j.dnarep.2003.10.013; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Beamish HJ, 2000, NUCLEIC ACIDS RES, V28, P1506, DOI 10.1093/nar/28.7.1506; Belenkov AI, 2002, CANCER RES, V62, P5888; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Block WD, 2004, NUCLEIC ACIDS RES, V32, P997, DOI 10.1093/nar/gkh265; Bogue MA, 1998, P NATL ACAD SCI USA, V95, P15559, DOI 10.1073/pnas.95.26.15559; Boskovic J, 2003, EMBO J, V22, P5875, DOI 10.1093/emboj/cdg555; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Boulton S, 2000, EUR J CANCER, V36, P535, DOI 10.1016/S0959-8049(99)00311-1; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Cervantes RB, 2002, CURR OPIN CELL BIOL, V14, P351, DOI 10.1016/S0955-0674(02)00325-3; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen Y, 2001, CANCER RES, V61, P5453; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Collis SJ, 2003, CANCER RES, V63, P1550; Collis SJ, 2003, INT J RADIAT BIOL, V79, P53, DOI 10.1080/0955300021000038626; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; CUSTER RP, 1985, AM J PATHOL, V120, P464; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Dibiase SJ, 2000, CANCER RES, V60, P1245; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Durant S, 2003, NUCLEIC ACIDS RES, V31, P5501, DOI 10.1093/nar/gkg753; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Edwards E, 2002, CANCER RES, V62, P4671; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Erdemir T, 2002, J CELL SCI, V115, P207; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; FALZON M, 1993, J BIOL CHEM, V268, P10546; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Girard PM, 2000, CANCER RES, V60, P4881; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Goudelock DM, 2003, J BIOL CHEM, V278, P29940, DOI 10.1074/jbc.M301765200; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2003, INT J RADIAT ONCOL, V56, P846, DOI 10.1016/S0360-3016(03)00214-1; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; Harris R, 2004, J MOL BIOL, V335, P573, DOI 10.1016/j.jmb.2003.10.047; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hashimoto M, 2003, J RADIAT RES, V44, P151, DOI 10.1269/jrr.44.151; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hollick JJ, 2003, BIOORG MED CHEM LETT, V13, P3083, DOI 10.1016/S0960-894X(03)00652-8; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Hu LM, 2000, CLIN CANCER RES, V6, P880; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; ISMAIL IH, 2003, ONCOGENE, V8, P8; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jeggo P, 1999, CR ACAD SCI III-VIE, V322, P109, DOI 10.1016/S0764-4469(99)80031-6; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; JEGGO PA, 2002, DNA REPAIR, V67, P1; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kienker LJ, 2000, NUCLEIC ACIDS RES, V28, P2752, DOI 10.1093/nar/28.14.2752; Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LeesMiller SP, 1996, J VIROL, V70, P7471, DOI 10.1128/JVI.70.11.7471-7477.1996; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li BM, 2002, NUCLEIC ACIDS RES, V30, P3653, DOI 10.1093/nar/gkf488; Li GC, 2003, CANCER RES, V63, P3268; Li SY, 2003, NUCLEIC ACIDS RES, V31, P5848, DOI 10.1093/nar/gkg775; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LIU SH, 1993, J BIOL CHEM, V268, P21147; Llorca O, 2004, MICRON, V35, P625, DOI 10.1016/j.micron.2004.05.004; Lou ZK, 2004, J BIOL CHEM, V279, P46359, DOI 10.1074/jbc.C400375200; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Mahajan KN, 1999, P NATL ACAD SCI USA, V96, P13926, DOI 10.1073/pnas.96.24.13926; Marangoni E, 2000, CANCER GENE THER, V7, P339, DOI 10.1038/sj.cgt.7700111; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Marples B, 2002, INT J RADIAT BIOL, V78, P1139, DOI 10.1080/09553000210166606; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; Mayo LD, 1997, CANCER RES, V57, P5013; McKenna WG, 2003, GENE CHROMOSOME CANC, V38, P330, DOI 10.1002/gcc.10296; Michaelidis TM, 2002, BIOL CHEM, V383, P1683, DOI 10.1515/BC.2002.189; Mickelsen S, 1999, J IMMUNOL, V163, P834; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; Myung K, 1997, EMBO J, V16, P3172, DOI 10.1093/emboj/16.11.3172; Nicolas N, 1996, EUR J IMMUNOL, V26, P1118, DOI 10.1002/eji.1830260524; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Oakley GG, 2003, BIOCHEMISTRY-US, V42, P3255, DOI 10.1021/bi026377u; Omori S, 2002, DNA REPAIR, V1, P299, DOI 10.1016/S1568-7864(02)00006-X; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Peng YL, 2002, CANCER RES, V62, P6400; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; Price BD, 1996, CANCER RES, V56, P246; Rebuzzini P, 2004, CANCER LETT, V203, P79, DOI 10.1016/j.canlet.2003.08.028; RIBALLO E, 2004, IN PRESS MOL CELL; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Sak A, 2002, CANCER RES, V62, P6621; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Semba S, 2002, CLIN CANCER RES, V8, P1957; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shintani S, 2003, CANCER SCI, V94, P894, DOI 10.1111/j.1349-7006.2003.tb01372.x; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Stockley M, 2001, BIOORG MED CHEM LETT, V11, P2837, DOI 10.1016/S0960-894X(01)00537-6; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TAKE Y, 1995, BIOCHEM BIOPH RES CO, V215, P41, DOI 10.1006/bbrc.1995.2431; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vaganay-Juery S, 2000, BRIT J CANCER, V83, P514, DOI 10.1054/bjoc.2000.1258; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Veuger SJ, 2003, CANCER RES, V63, P6008; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WATANABE F, 1994, BIOCHEM BIOPH RES CO, V202, P736, DOI 10.1006/bbrc.1994.1992; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Wilson CR, 2000, BRIT J CANCER, V83, P1702, DOI 10.1054/bjoc.2000.1510; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yeo TC, 2000, MOL IMMUNOL, V37, P1131, DOI 10.1016/S0161-5890(01)00026-8; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5; Yumoto Y, 1998, J BIOCHEM-TOKYO, V124, P519, DOI 10.1093/oxfordjournals.jbchem.a022143; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	200	340	384	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					949	961		10.1038/sj.onc.1208332	http://dx.doi.org/10.1038/sj.onc.1208332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592499				2022-12-28	WOS:000226749200001
J	Zaffaroni, D; Spinola, M; Galvan, A; Falvella, FS; Pazzaglia, S; Saran, A; Mancuso, MT; Galbiati, F; Pignatiello, C; Cabrera, W; Ibanez, O; Manenti, G; Dragani, TA				Zaffaroni, D; Spinola, M; Galvan, A; Falvella, FS; Pazzaglia, S; Saran, A; Mancuso, MT; Galbiati, F; Pignatiello, C; Cabrera, W; Ibanez, O; Manenti, G; Dragani, TA			Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis	ONCOGENE			English	Article						polygenic inheritance; susceptibility to disease; cancer modifier loci	CANCER MODIFIER LOCI; SUSCEPTIBILITY LOCUS; MICE; RECEPTOR; RESISTANCE; MUTATIONS; STRAINS; PREDISPOSITION; CARCINOGENESIS; KINASE	Analysis of seven candidate genes mapping in the 1-Mb region of the mouse pulmonary adenoma resistance 4 (Par4) locus revealed a single amino-acid change, consisting in a nonconservative Arg968Cys variation in the juxtamembrane domain of the Met proto-oncogene-encoded protein. The BALB/c strain ( resistant allele) carried the Arg allele, whereas the SWR/J mouse strain (Par4-susceptible allele) carried the Cys variation, recently proven to functionally modulate tumorigenesis. Seven genetic linkage crosses herein analysed and six crosses reported in the literature pointed to the candidacy of the Met gene for Par4. Analysis of genomic DNA of 126 lung adenocarcinoma patients for the Met juxtamembrane domain revealed the same Arg/Cys variation at the mouse homologous position in one patient; two other patients carried additional variants in the same domain, suggesting a potential role for rare MET juxtamembrane variants in human lung cancer.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Rome, Italy; Inst Butantan, Sao Paulo, Brazil	Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; Instituto Butantan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Zaffaroni, Daniela/I-8731-2017; Cabrera, Wafa HK/F-7189-2016; Dragani, Tommaso A./K-4493-2016; Ibañez, Olga CM/B-9627-2015; Manenti, Giacomo/J-3339-2017	Zaffaroni, Daniela/0000-0002-6995-2216; Dragani, Tommaso A./0000-0001-5915-4598; Ibañez, Olga CM/0000-0002-2672-4758; Manenti, Giacomo/0000-0002-4887-4482; Saran, Anna/0000-0002-5587-064X				Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 2003, CANCER RES, V63, P3011; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Gariboldi M, 2003, CARCINOGENESIS, V24, P1819, DOI 10.1093/carcin/bgg133; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; LINCOLN S, 1992, MAPPING GENES CONTRO; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Ma PC, 2003, CANCER RES, V63, P6272; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 2002, INT J CANCER, V99, P555, DOI 10.1002/ijc.10386; Manenti G, 1997, CANCER RES, V57, P4164; Manenti G, 2000, TOXICOL LETT, V112, P257, DOI 10.1016/S0378-4274(99)00232-5; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Obata M, 1996, ONCOGENE, V13, P1599; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Saran A, 2000, INT J CANCER, V88, P424, DOI 10.1002/1097-0215(20001101)88:3<424::AID-IJC15>3.0.CO;2-D; Saran A, 2002, INT J CANCER, V97, P580, DOI 10.1002/ijc.10104; Shultz KL, 2003, J BONE MINER RES, V18, P175, DOI 10.1359/jbmr.2003.18.2.175; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	25	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1084	1090		10.1038/sj.onc.1208324	http://dx.doi.org/10.1038/sj.onc.1208324			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592501				2022-12-28	WOS:000226749200014
J	Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G				Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G			Chemosensitization by erythropoietin through inhibition of the NF-kappa B rescue pathway	ONCOGENE			English	Article						apoptosis; renal carcinoma; jak; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN GROWTH-HORMONE; CELL-DEATH; MYELODYSPLASTIC SYNDROME; PRACTICE PATTERNS; MULTIPLE-MYELOMA; GENE-EXPRESSION; IN-VIVO; CANCER; APOPTOSIS	Two cell lines that exemplify erythropoietin (EPO) receptor-positive tumors, human renal carcinoma cell lines RCC and the myelomonocytic leukemia cell line U937, were investigated for the apoptosis-modulatory potential of EPO. Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL). Chemosensitization by EPO did not involve an increase in p53 activation, yet correlated with enhanced Bax/Bak-dependent mitochondrial membrane perturbation and caspase maturation. In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene. All these signs of NF-kappaB activation were perturbed in the presence of EPO. Inhibition of JAK2, one of the receptor-proximal elements of EPO-mediated signal transduction, greatly diminished the EPO-mediated chemosensitization and NF-kappaB inhibition. EPO lost its death-facilitating effects in the presence of an NF-kappaB inhibitor, underscoring the cause-effect relationship between EPO-mediated chemosensitization and NF-kappaB inhibition. Altogether, these results suggest that, at least in a specific subset of tumors, EPO receptor agonists can prevent activation of the NF-kappaB pathway, thereby enhancing the propensity of EPO receptor-positive tumor cells to undergo apoptosis.	Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM, U542, F-94802 Villejuif, France; IRSN, Fontenay Aux Roses, France; Fac Pharm Paris, INSERM, U461, F-92296 Chatenay Malabry, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	hirsch@babbage.infobiogen.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; lefaucheur, carmen/F-3502-2013	KROEMER, Guido/0000-0002-9334-4405; chapel, alain/0000-0002-4687-4120				Acs G, 2001, CANCER RES, V61, P3561; Adams JR, 2004, AM J MED, V116, P28, DOI 10.1016/j.amjmed.2003.06.004; Angevin E, 1999, LAB INVEST, V79, P879; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bunworasate U, 2001, BLOOD, V98, P3492, DOI 10.1182/blood.V98.12.3492; Castedo M, 2002, TRENDS CELL BIOL, V12, P446, DOI 10.1016/S0962-8924(02)02346-2; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chapel A, 1999, EXP HEMATOL, V27, P250, DOI 10.1016/S0301-472X(98)00009-5; Cherbonnier C, 2003, BRIT J CANCER, V89, P1108, DOI 10.1038/sj.bjc.6601223; Cherbonnier C, 2002, CANCER GENE THER, V9, P497, DOI 10.1038/sj.cgt.7700467; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Durrbach A, 1999, CANCER GENE THER, V6, P564, DOI 10.1038/sj.cgt.7700085; Fine BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood T, 2002, SEMIN ONCOL, V29, P40, DOI 10.1053/sonc.2002.33532; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minet E, 2000, INT J MOL MED, V5, P253; Mittelman M, 2004, EUR J HAEMATOL, V72, P155, DOI 10.1046/j.0902-4441.2003.00190.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwartzberg L, 2003, CLIN THER, V25, P2781, DOI 10.1016/S0149-2918(03)80333-8; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takeshita A, 2002, LEUKEMIA LYMPHOMA, V43, P261, DOI 10.1080/10428190290006026; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Williams SA, 2003, CANCER RES, V63, P7338; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	53	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					737	745		10.1038/sj.onc.1208205	http://dx.doi.org/10.1038/sj.onc.1208205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580299	Bronze			2022-12-28	WOS:000226577100001
J	Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S				Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S			A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8	ONCOGENE			English	Article						breast tumorigenesis; microcell-mediated chromosome transfer; expression difference analysis	CLUSTERIN EXPRESSION; SUPPRESSOR GENE; ALLELIC LOSS; REGION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-8; ASSOCIATION; METASTASIS; PROGNOSIS	Several investigations have supposed that tumor suppressor genes might be located on human chromosome 8. We used microcell-mediated transfer of chromosome 8 into MDA-MB-231 breast cancer cells and generated independent hybrids with strongly reduced tumorigenic potential. Loss of the transferred chromosome results in reappearance of the malignant phenotype. Expression analysis identified a set of 109 genes (CT8-ps) differentially expressed in microcell hybrids as compared to the tumorigenic MDA-MB-231 and rerevertant cells. Of these, 44.9% are differentially expressed in human breast tumors. The expression pattern of CT8-ps was associated with prognostic factors such as tumor size and grading as well as loss of heterozygosity at the short arm of chromosome 8. We identified CT8-ps networks suggesting that these genes act cooperatively to cause reversion of tumorigenicity in MDA-MB-231 cells. Our findings provide a conceptual basis and experimental system to identify and evaluate genes and gene networks involved in the development and/or progression of breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; Gynecol & Obstet Clin, Oncol Lab, D-24105 Kiel, Germany; Atugen AG, D-13125 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Gynecol & Obstet Clin, Dept Mol Gynecol & Oncol, D-50931 Cologne, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Heinrich Heine University Dusseldorf	Seitz, S (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	sseitz@mdc-berlin.de	Arnold, Norbert/E-3012-2010; Weimer, Jörg Paul/E-3472-2010	Arnold, Norbert/0000-0003-4523-8808; Weimer, Jörg Paul/0000-0002-4528-8509				Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Borg A, 2003, NAT MED, V9, P16, DOI 10.1038/nm0103-16; Goldberg EK, 2000, AM J HUM GENET, V67, P417, DOI 10.1086/302999; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Gustafson CE, 1996, CANCER RES, V56, P5238; HOGUE DA, 1996, AM J HUM GENET, V56, pA15; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kugoh H, 2002, MOL CARCINOGEN, V35, P148, DOI 10.1002/mc.10080; Lerebours F, 2002, CRIT REV ONCOL HEMAT, V44, P121, DOI 10.1016/S1040-8428(01)00191-3; LOGAN GJ, 2002, IMMUNOLOGY, V28; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Nihei N, 2002, CANCER RES, V62, P367; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Rennstam K, 2003, CANCER RES, V63, P8861; Saffer H, 2002, MODERN PATHOL, V15, P1221, DOI 10.1097/01.MP.0000036386.87517.AA; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Suzuki A, 1999, INT J ONCOL, V15, P443; THEILE M, 1994, INT J ONCOL, V4, P1067; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Tsuneizumi M, 2002, CANCER LETT, V180, P75, DOI 10.1016/S0304-3835(02)00010-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weimer J, 1999, CHROMOSOME RES, V7, P355, DOI 10.1023/A:1009263913478; Weimer J, 2000, CYTOGENET CELL GENET, V88, P114, DOI 10.1159/000015502; Wilson P, 2003, CANCER GENET CYTOGEN, V143, P100, DOI 10.1016/S0165-4608(02)00850-6; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHANG RD, 1991, INVAS METAST, V11, P204	43	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					869	879		10.1038/sj.onc.1208260	http://dx.doi.org/10.1038/sj.onc.1208260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580292				2022-12-28	WOS:000226577100013
J	Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H				Sultan, AS; Xie, JW; LeBaron, MJ; Ealley, EL; Nevalainen, MT; Rui, H			Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells	ONCOGENE			English	Article						Stat5; breast cancer; E-cadherin; invasion; adhesion; metastasis	MAMMARY EPITHELIAL-CELLS; PROLACTIN SIGNAL-TRANSDUCTION; E-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; CONDITIONAL KNOCKOUT; GLAND DEVELOPMENT; GENE-EXPRESSION; BETA-CATENIN; GROWTH	Signal transducer and activator of transcription-5 (Stat5) mediates prolactin (PRL)-induced differentiation and growth of breast epithelial cells. We have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast cancer, and determined that Stat5 activation is lost during metastatic progression. Here we provide novel evidence for an invasion-suppressive role of Stat5 in human breast cancer. Activation of Stat5 by PRL in human breast cancer lines was associated with increased surface levels of the invasion-suppressive adhesion molecule E-cadherin in vitro and in xenotransplant tumors in vivo. Inducible E-cadherin was blocked by dominant-negative (Dn) Stat5 or Dn-Jak2, but not by Dn-Stat3. Further experimental data indicated a role of Stat5 as a coordinate regulator of additional invasion-related characteristics of human breast cancer cells, including cell surface association of beta-catenin, homotypic cell clustering, invasion through Matrigel, cell migration, and matrix metalloproteinase activity. A role of Stat5 as a suppressor of breast cancer invasion and metastatic progression provides a biological mechanism to explain the favorable prognosis associated with active Stat5 in human breast cancer.	Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Rui, H (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, NRB E504,3970 Reservoir Rd NW, Washington, DC 20057 USA.	ruih@georgetown.edu	Sultan, Prof. Ahmed S/AFH-7788-2022	Sultan, Prof. Ahmed S/0000-0001-6568-1757; Sultan, Ahmad/0000-0001-5776-1837	NCI NIH HHS [CA101841, 1P30-CA-51008] Funding Source: Medline; NIDDK NIH HHS [DK52013] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA101841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Ahonen TJ, 2003, J BIOL CHEM, V278, P27287, DOI 10.1074/jbc.M304307200; ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; Arihiro K, 2000, Breast Cancer, V7, P221, DOI 10.1007/BF02967464; Badache A, 2001, CANCER RES, V61, P383; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Das R, 1996, ONCOGENE, V13, P1139; DUHE RJ, 1995, GENE, V158, P281, DOI 10.1016/0378-1119(95)00041-4; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lilien J, 2002, DEV DYNAM, V224, P18, DOI 10.1002/dvdy.10087; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Liu XW, 1998, CELL GROWTH DIFFER, V9, P795; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Mbalaviele G, 1996, CANCER RES, V56, P4063; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nevalainen MT, 2002, MOL ENDOCRINOL, V16, P1108, DOI 10.1210/mend.16.5.0839; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Philips N, 2004, CANCER LETT, V206, P63, DOI 10.1016/j.canlet.2003.10.019; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schaber JD, 1998, CANCER RES, V58, P1914; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SHIU RPC, 1984, CANCER RES, V44, P1178; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Sultan AS, 1997, J BIOL CHEM, V272, P2866, DOI 10.1074/jbc.272.5.2866; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Xie J, 2002, J BIOL CHEM, V277, P14020, DOI 10.1074/jbc.M112399200; Yamashita H, 1999, J BIOL CHEM, V274, P14699, DOI 10.1074/jbc.274.21.14699; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721; Zhang SS, 1999, J CELL SCI, V112, P2693	58	157	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					746	760		10.1038/sj.onc.1208203	http://dx.doi.org/10.1038/sj.onc.1208203			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592524				2022-12-28	WOS:000226577100002
J	Westmark, CJ; Bartleson, VB; Malter, JS				Westmark, CJ; Bartleson, VB; Malter, JS			RhoB mRNA is stabilized by HuR after UV light	ONCOGENE			English	Article						RhoB; HuR; ARE; mRNA stability; UVL	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; P38 SIGNALING CASCADE; AU-RICH ELEMENTS; BINDING-PROTEIN; GTPASE RHOB; DOWN-REGULATION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ULTRAVIOLET-IRRADIATION	RhoB is a small GTP-binding protein that is involved in apoptotic signal transduction. We have cloned the mouse RhoB mRNA including a 1377 nucleotide 3'-untranslated region (UTR) that contains six AU-rich elements (AREs) as well as several uridine-rich stretches. There is 94% homology overall between the mouse and rat RhoB genes and 92% homology between the mouse and a putative human clone. Ultraviolet light (UVL) induces RhoB production through regulated changes in gene transcription and mRNA stabilization although the latter mechanism is unknown. We observed that UVL increased the half-life of RhoB mRNA from 63 min to 3.3 h in NIH/3T3 cells and from 87 min to 2.7 h in normal human keratinocyte cells. In vitro mobility shift assays demonstrated that HuR bound the 3'-UTR of RhoB at three distinct locations (nucleotides 1342-1696, 1765-1920 and 1897-1977) suggesting a regulatory role for this RNA-binding protein. HuR immunoprecipitations were positive for RhoB mRNA indicating an in vivo association, and Western blot analysis and immunofluorescence demonstrated that HuR rapidly partitions from the nucleus to the cytoplasm after UVL. Therefore, we propose a model in which UVL induces stress-activated signal transduction leading to nuclear/cytoplasmic shuttling of HuR and subsequent stabilization of RhoB mRNA.	Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Waisman Ctr Rm T509,1500 Highland Ave, Madison, WI 53705 USA.	jsmalter@facstaff.wisc.edu	Westmark, Cara J/L-4647-2019; Westmark, Cara/AAX-4408-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061666] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH61666] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carninci P, 1999, METHOD ENZYMOL, V303, P19; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Malcolm T, 2003, ONCOGENE, V22, P6142, DOI 10.1038/sj.onc.1206638; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Montero L, 1999, CANCER RES, V59, P5286; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Westmark CJ, 2001, MOL BRAIN RES, V90, P193, DOI 10.1016/S0169-328X(01)00112-7; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; 1998, GENOME RES, V8, P1097	63	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					502	511		10.1038/sj.onc.1208224	http://dx.doi.org/10.1038/sj.onc.1208224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543229				2022-12-28	WOS:000226279700020
J	Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC				Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC			p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; p38 MAPK inhibitor; SCIO-469; PS-341; Hsp27	MARROW STROMAL CELLS; PROTEASOME INHIBITOR; DRUG-RESISTANCE; MITOCHONDRIAL PROTEIN; MOLECULAR-MECHANISMS; BIOLOGIC SEQUELAE; SIGNALING PATHWAY; KINASE PATHWAY; APOPTOSIS; GROWTH	Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma ( MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confers PS-341 resistance, and that inhibition of Hsp27 overcomes PS-341 resistance. Since Hsp27 is a downstream target of p38 mitogen-activated protein kinase (MAPK)/MAPK-mitogen-activated protein kinase-2 (MAPKAPK2), we hypothesized that inhibition of p38 MAPK activity could augment PS-341 cytotoxicity by downregulating Hsp27. Although p38 MAPK inhibitor SCIO-469 (Scios Inc, CA, USA) alone did not induce significant growth inhibition, it blocked baseline and PS-341-triggered phosphorylation of p38 MAPK as well as upregulation of Hsp27, associated with enhanced cytotoxicity in MM.1S cells. Importantly, SCIO-469 enhanced phosphorylation of c-Jun NH2-terminal kinase (JNK) and augmented cleavage of caspase-8 and poly(ADP)-ribose polymerase. Moreover, SCIO-469 downregulated PS-341-induced increases in G2/M-phase cells, associated with downregulation of p21(Cip1) expression. Importantly, SCIO-469 treatment augmented cytotoxicity of PS-341 even against PS-341-resistant cell lines and patient MM cells. These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Scios Inc, Fremont, CA 94555 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Scios	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020; Hamasaki, Makoto/AAO-2229-2020; Munshi, Nikhil/ABE-2338-2021	Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947, IP50 CA10070-01] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, CANCER RES, V63, P6174; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Christians U, 2002, CLIN PHARMACOKINET, V41, P813, DOI 10.2165/00003088-200241110-00003; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Guay J, 1997, J CELL SCI, V110, P357; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kisselv AF, 2001, CHEM BIOL, V21, P1; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LeBlanc R, 2002, CANCER RES, V62, P4996; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ogata A, 1997, J IMMUNOL, V159, P2212; Orlowski RZ, 2003, BLOOD, V102, p449A; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwarzenbach H, 2002, MED ONCOL, V19, P87, DOI 10.1385/MO:19:2:87; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sun JZ, 2001, CANCER RES, V61, P1280; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	48	102	119	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8766	8776		10.1038/sj.onc.1208118	http://dx.doi.org/10.1038/sj.onc.1208118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480425	Bronze			2022-12-28	WOS:000225165100006
J	Yoder, MC				Yoder, MC			Generation of HSCs in the embryo and assays to detect them	ONCOGENE			English	Review						stem cells; embryonic; transplantation; in utero	HEMATOPOIETIC STEM-CELLS; YOLK-SAC; MOUSE EMBRYO; AORTA; ENGRAFTMENT; CIRCULATION; PRECURSORS; EMERGENCE; REGION; BLOOD	The precise temporal and spatial emergence of hematopoietic stem cells (HSC) in the murine embryo has been somewhat controversial largely due to differences in the assays utilized to demonstrate HSC repopulating ability. One strategy is to determine where and when one can first detect HSC that engraft upon transplantation into lethally irradiated adult mice. However, knowing that the primary sites and patterns of hematopoiesis change during ontogeny, an alternative strategy is to select transplantation models where the recipient subjects more closely mirror the stage of development of the donor cells. In this regard, perhaps the most relevant assay to determine the presence of HSC activity in the early embryo is to transplant the donor cells in utero into recipient embryos. Other recipient models that may permit engraftment of embryonic cells include the use of submyeloablated or genetically HSC deficient newborn mice. Additional informative strategies have included co-culturing embryonic tissues that appear to lack HSC activity, with stromal cells derived from different developmental sites of hematopoiesis to induce HSC emergence, followed by transplantation as a means to determine which embryonic tissues possess HSC potential. This review will highlight some of the various transplantation assays used to identify HSC from embryonic tissues.	Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Yoder, MC (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, 1044 W Wlanut St,R4-402E, Indianapolis, IN 46202 USA.	myoder@iupui.edu						Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8; Godin I, 1999, J EXP MED, V190, P43, DOI 10.1084/jem.190.1.43; JOHNSON SA, IN PRESS DEV HEMATOP; Kumaravelu P, 2002, DEVELOPMENT, V129, P4891; Matsuoka S, 2001, BLOOD, V98, P6, DOI 10.1182/blood.V98.1.6; McGrath KE, 2003, BLOOD, V101, P1669, DOI 10.1182/blood-2002-08-2531; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Palis J, 1999, DEVELOPMENT, V126, P5073; Palis J, 2001, EXP HEMATOL, V29, P927, DOI 10.1016/S0301-472X(01)00669-5; Palis J, 2001, P NATL ACAD SCI USA, V98, P4528, DOI 10.1073/pnas.071002398; Ramshaw H S, 1995, Biol Blood Marrow Transplant, V1, P74; Rao SS, 1997, EXP HEMATOL, V25, P114; STEWART FM, 1993, BLOOD, V81, P2566; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; Weissman I, 1978, DIFFERENTIATION NORM, V5, P33; Xu MJ, 1998, BLOOD, V92, P2032, DOI 10.1182/blood.V92.6.2032.418k29_2032_2040; Yoder MC, 1997, BLOOD, V89, P2176, DOI 10.1182/blood.V89.6.2176; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	21	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2004	23	43					7161	7163		10.1038/sj.onc.1207931	http://dx.doi.org/10.1038/sj.onc.1207931			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378076				2022-12-28	WOS:000223998800002
J	Caraglia, M; D'Alessandro, AM; Marra, M; Giuberti, G; Vitale, G; Viscomi, C; Colao, A; Del Prete, S; Tagliaferri, P; Tassone, P; Budillon, A; Venuta, S; Abbruzzese, A				Caraglia, M; D'Alessandro, AM; Marra, M; Giuberti, G; Vitale, G; Viscomi, C; Colao, A; Del Prete, S; Tagliaferri, P; Tassone, P; Budillon, A; Venuta, S; Abbruzzese, A			The farnesyl transferase inhibitor R115777 (Zarnestra (R)) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa (R)) and Pamidronate	ONCOGENE			English	Article						farnesyl transferase inhibitor; bisphosphonates; epidermoid cancer; apoptosis; ras; Akt	NITROGEN-CONTAINING BISPHOSPHONATES; GERANYLGERANYLTRANSFERASE-I INHIBITORS; ACTIVATED PROTEIN-KINASE; BONE METASTASES; PYROPHOSPHATE SYNTHASE; BREAST-CANCER; NITRIC-OXIDE; VITRO; FARNESYLTRANSFERASE; PRENYLATION	Pamidronate (PAM) and zoledronic acid (ZOL) are aminobisphosphonates (BPs) able to affect the isoprenylation of intracellular small G proteins. We have investigated the antitumor activity of BPs and R115777 farnesyl transferase inhibitor (FTI) against epidermoid cancer cells. In human epidermoid head and neck KB and lung H1355 cancer cells, 48 h exposure to PAM and ZOL induced growth inhibition (IC50 25 and 10 muM, respectively) and apoptosis and abolished the proliferative and antiapoptotic stimuli induced by epidermal growth factor (EGF). In these experimental conditions, ZOL induced apoptosis through the activation of caspase 3 and a clear fragmentation of PARP was also demonstrated. A strong decrease of basal ras activity and an antagonism on its stimulation by EGF was recorded in the tumor cells exposed to BPs. These effects were paralleled by impaired activation of the survival enzymes extracellular signal regulated kinase 1 and 2 (Erk-1/2) and Akt that were not restored by EGF. Conversely, farnesol induced a recovery of ras activity and antagonized the proapoptotic effects induced by BPs. The combined treatment with BPs and R115777 resulted in a strong synergism both in growth inhibition and apoptosis in KB and H1355 cells. The synergistic activity between the drugs allowed BPs to produce tumor cell growth inhibition and apoptosis at in vivo achievable concentrations (0.1 mumolar for both drugs). Moreover, the combination was highly effective in the inhibition of ras, Erk and Akt activity, while farnesol again antagonized these effects. In conclusion, the combination of BPs and FTI leads to enhanced antitumor activity at clinically achievable drug concentrations that resides in the inhibition of farnesylation-dependent survival pathways and warrants further studies for clinical translation.	Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy; Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy; Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Catanzaro, Italy; Dept Oncol, Turin, Italy; Natl Canc Inst Naples Fdn G Pascale, Naples, Italy	Universita della Campania Vanvitelli; University of Naples Federico II; Magna Graecia University of Catanzaro	Abbruzzese, A (corresponding author), Univ Naples 2, Dept Biochem & Biophys, Via Costantinopoli 16, I-80138 Naples, Italy.	Michele.Caraglia@unina2.it; Alberto.Abbruzzese@unina2.it	Tassone, Pierfrancesco/AIA-5373-2022; Caraglia, Michele/N-5670-2015; Caraglia, Michele/AFY-9729-2022; Vitale, Giovanni/B-6548-2008; Tagliaferri, Pierosandro/K-9546-2016; Budillon, Alfredo/K-4763-2016; Caraglia, Michele/AAK-4569-2020	Tassone, Pierfrancesco/0000-0002-8298-6787; Caraglia, Michele/0000-0003-2408-6091; Caraglia, Michele/0000-0003-2408-6091; Vitale, Giovanni/0000-0003-2478-683X; Budillon, Alfredo/0000-0002-6330-6053; Caraglia, Michele/0000-0003-2408-6091				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; AVERBUCH SD, 1993, CANCER-AM CANCER SOC, V72, P3443, DOI 10.1002/1097-0142(19931201)72:11+<3443::AID-CNCR2820721611>3.0.CO;2-3; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131; Boissier S, 2000, CANCER RES, V60, P2949; Cascinu S, 1998, SUPPORT CARE CANCER, V6, P139, DOI 10.1007/s005200050148; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; COLEMAN RE, 1988, BRIT J CANCER, V58, P621, DOI 10.1038/bjc.1988.272; DeSolms SJ, 2003, J MED CHEM, V46, P2973, DOI 10.1021/jm020587n; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; Fiordalisi JJ, 2003, J BIOL CHEM, V278, P41718, DOI 10.1074/jbc.M305733200; FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495-199142060-00003; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Haluska P, 2002, EUR J CANCER, V38, P1685, DOI 10.1016/S0959-8049(02)00166-1; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Johnson DH, 2002, ARTHROSCOPY, V18, P26, DOI 10.1053/jars.2002.36506; Kelland LR, 2001, CLIN CANCER RES, V7, P3544; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lee MV, 2001, CANCER RES, V61, P2602; LIPTON A, 1994, ANN ONCOL S7, V5, P31; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Mitsui H, 2001, INT J CANCER, V92, P55, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1143>3.0.CO;2-O; MORTON AR, 1988, BRIT MED J, V297, P772, DOI 10.1136/bmj.297.6651.772; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Selleri C, 2003, BLOOD, V102, P1490, DOI 10.1182/blood-2003-01-0178; Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131; Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365-2141.1997.2713086.x; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Smalley KSM, 2002, INT J CANCER, V98, P514, DOI 10.1002/ijc.10213; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770; Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Vitale G, 2001, BRIT J CANCER, V84, P1586, DOI 10.1054/bjoc.2001.1832; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295; Yan CYI, 1998, J NEUROSCI, V18, P4042; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	56	73	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6900	6913		10.1038/sj.onc.1207814	http://dx.doi.org/10.1038/sj.onc.1207814			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286715				2022-12-28	WOS:000223750700007
J	Schmidt, HH; Dyomin, VG; Palanisamy, N; Itoyama, T; Nanjangud, G; Pirc-Danoewinata, H; Haas, OA; Chaganti, R				Schmidt, HH; Dyomin, VG; Palanisamy, N; Itoyama, T; Nanjangud, G; Pirc-Danoewinata, H; Haas, OA; Chaganti, R			Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32)	ONCOGENE			English	Article						B-CLL; translocation; carbohydrate (chondroitin 4) sulfotransferase 11; CHST11; Golgi retention	HEPARAN-SULFATE; MOLECULAR-CLONING; EXPRESSION; TRANSLOCATIONS; FAMILY; ENZYME; PROTEOGLYCANS; LOCALIZATION; MALIGNANCIES; LYMPHOMA	The t(12; 14)(q23; q32) breakpoints in a case of B-cell chronic lymphocytic leukemia (B-CLL) were mapped by fluorescence in situ hybridization ( FISH) and Southern blot analysis and cloned using an IGH switch-c probe. The translocation affected a productively rearranged IGH allele and the carbohydrate ( chondroitin 4) sulfotransferase 11 (CHST11) locus at 12q23, with a reciprocal break in intron 2 of the CHST11 gene. CHST11 belongs to the HNK1 family of Golgi-associated sulfotransferases, a group of glycosaminoglycan-modifying enzymes, and is expressed mainly in the hematopoietic lineage. Northern Blot analysis of tumor RNA using CHST11-specific probes showed expression of two CHST11 forms of abnormal size. 5'- and 3'-Rapid Amplification of cDNA Ends( RACE) revealed IGH/CHST11 as well as CHST11/IGH fusion RNAs expressed from the der(14) and der(12) chromosomes. Both fusion species contained open reading frames making possible the translation of two truncated forms of CHST11 protein. The biological consequence of t(12; 14)(q23; q32) in this case presumably is a disturbance of the cellular distribution of CHST11 leading to deregulation of a chondroitin-sulfate-dependent pathway specific to the hematopoietic lineage.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Saint Anna Children's Hospital	Schmidt, HH (corresponding author), Univ Med Ctr, Dept Internal Med, Div Hematol, Auenbruggerpl 38, A-8036 Graz, Austria.	helmut.schmidt@klinikum-graz.at	Palanisamy, Nallasivam/ABC-8844-2020; Haas, Oskar/AAM-5794-2020	Palanisamy, Nallasivam/0000-0002-0633-9772; 				Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BURKE J, 1994, J BIOL CHEM, V269, P12049; Chaganti RSK, 2000, SEMIN HEMATOL, V37, P396; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Dyomin VG, 2000, BLOOD, V95, P2666; GAHRTON G, 1982, NATURE, V297, P513, DOI 10.1038/297513a0; Greenfield B, 1999, J BIOL CHEM, V274, P2511, DOI 10.1074/jbc.274.4.2511; Hacker U, 1997, DEVELOPMENT, V124, P3565; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822	24	15	17	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2004	23	41					6991	6996		10.1038/sj.onc.1207934	http://dx.doi.org/10.1038/sj.onc.1207934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273723				2022-12-28	WOS:000223750700016
J	Boffetta, P				Boffetta, P			Epidemiology of environmental and occupational cancer	ONCOGENE			English	Review						air pollution; arsenic; environment; environmental tobacco smoke; neoplasms; occupation; radon	RESIDENTIAL RADON EXPOSURE; CHLORINATION BY-PRODUCTS; ARSENICAL AIR-POLLUTION; LUNG-CANCER; RESPIRATORY-CANCER; RISK-FACTORS; BLADDER-CANCER; NONOCCUPATIONAL EXPOSURE; ASBESTOS EXPOSURE; DRINKING-WATER	Environmental carcinogens, in a strict sense, include outdoor and indoor air pollutants, as well as soil and drinking water contaminants. An increased risk of mesothelioma has consistently been detected among individuals experiencing residential exposure to asbestos, while results for lung cancer are less consistent. Several good-quality studies have investigated lung cancer risk from outdoor air pollution based on measurement of specific agents. Their results tend to show an increased risk in the categories at highest exposure, with relative risks in the range 1.5. A causal association has been established between exposure to environmental tobacco smoke and lung cancer, with a relative risk in the order of 1.2. Radon is another carcinogen present in indoor air, with a relative risk in the order of 1.06 for exposure at 100 Bq/m(3). In several Asian populations, an increased risk of lung cancer results among women from indoor pollution from cooking and heating. There is strong evidence of an increased risk of bladder, skin and lung cancers following consumption of water with high arsenic contamination; results for other drinking water contaminants, including chlorination by-products, are inconclusive. A total of 29 occupational agents are established human carcinogens, and another 30 agents are suspected carcinogens. In addition, at least 12 exposure circumstances entail exposure to carcinogens. Exposure is still widespread for many important occupational carcinogens, such as asbestos, coal tar, arsenic and silica, in particular in developing countries. Although estimates of the global burden of occupational and environmental cancer result in figures in the order of 2% and less than 1%, respectively, these cancers concentrate in subgroups of the population; furthermore, exposure is involuntary and can, to a large extent, be avoided.	Int Agcy Res Canc, F-69008 Lyon, France; German Canc Res Ctr, D-69120 Heidelberg, Germany	World Health Organization; International Agency for Research on Cancer (IARC); Helmholtz Association; German Cancer Research Center (DKFZ)	Boffetta, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	boffetta@iarc.fr	Boffetta, Paolo/AAI-7767-2021	Boffetta, Paolo/0000-0002-3811-2791				Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373, DOI 10.1164/ajrccm.159.2.9806020; Alavanja MCR, 1999, AM J PUBLIC HEALTH, V89, P1042, DOI 10.2105/AJPH.89.7.1042; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P41; [Anonymous], 2000, IARC MON EV CARC RIS, V75; BARBONE F, 1995, AM J EPIDEMIOL, V141, P1161, DOI 10.1093/oxfordjournals.aje.a117389; Barros-Dios JM, 2002, AM J EPIDEMIOL, V156, P548, DOI 10.1093/aje/kwf070; BATES MN, 1995, AM J EPIDEMIOL, V141, P523, DOI 10.1093/oxfordjournals.aje.a117467; Beeson WL, 1998, ENVIRON HEALTH PERSP, V106, P813, DOI 10.2307/3434125; Bhopal RS, 1998, OCCUP ENVIRON MED, V55, P812, DOI 10.1136/oem.55.12.812; Biggeri A, 1996, ENVIRON HEALTH PERSP, V104, P750, DOI 10.2307/3433221; Blair A, 1997, CANCER CAUSE CONTROL, V8, P473, DOI 10.1023/A:1018417623867; BLOT WJ, 1975, LANCET, V2, P142; Boffetta, 1995, Int J Occup Environ Health, V1, P315; Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029; Boffetta P, 2002, SCAND J WORK ENV HEA, V28, P30; BOND GG, 1992, SCAND J WORK ENV HEA, V18, P145, DOI 10.5271/sjweh.1594; BOTHA JL, 1986, AM J EPIDEMIOL, V123, P30, DOI 10.1093/oxfordjournals.aje.a114221; BROWN LM, 1984, ENVIRON RES, V34, P250, DOI 10.1016/0013-9351(84)90093-8; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BUELL P, 1967, CANCER-AM CANCER SOC, V20, P2139, DOI 10.1002/1097-0142(196712)20:12<2139::AID-CNCR2820201212>3.0.CO;2-8; BUELL P, 1967, ARCH ENVIRON HEALTH, V15, P291, DOI 10.1080/00039896.1967.10664920; Camus M, 1998, NEW ENGL J MED, V338, P1565, DOI 10.1056/NEJM199805283382201; CANTOR KP, 1987, J NATL CANCER I, V79, P1269; Cantor KP, 1997, CANCER CAUSE CONTROL, V8, P292, DOI 10.1023/A:1018444902486; CARDIS E, 1994, LANCET, V344, P1039; CEDERLOF R, 1975, RELATIONSHIP SMOKING; CORDIER S, 1983, ENVIRON RES, V31, P311, DOI 10.1016/0013-9351(83)90009-9; COWLES SR, 1994, OCCUP ENVIRON MED, V51, P323, DOI 10.1136/oem.51.5.323; Dai XD, 1996, LUNG CANCER-J IASLC, V14, pS85, DOI 10.1016/S0169-5002(96)90213-5; Darby S, 1998, BRIT J CANCER, V78, P394, DOI 10.1038/bjc.1998.506; Darby S, 2001, ANN ONCOL, V12, P1341, DOI 10.1023/A:1012518223463; DEAN G, 1978, REPORT 2 RETROSPEC 2; DEAN G, 1977, REPORT 2 RETROSPEC 1; DEAN G, 1966, BMJ-BRIT MED J, V5502, P1506; Divine BJ, 1996, TOXICOLOGY, V113, P169, DOI 10.1016/0300-483X(96)03442-7; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DU YX, 1996, LUNG CANCER S1, V14, P9; Engholm G, 1996, BRIT MED J, V312, P1259, DOI 10.1136/bmj.312.7041.1259; FROST F, 1987, ARCH ENVIRON HEALTH, V42, P148, DOI 10.1080/00039896.1987.9935813; Gailey F A, 1983, Ecol Dis, V2, P419; GAILEY FAY, 1986, ENVIRON HEALTH PERSP, V68, P187, DOI 10.2307/3430263; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; GOLDSMITH JR, 1980, J ENVIRON PATHOL TOX, V3, P205; Greaves W W, 1981, Am J Ind Med, V2, P15, DOI 10.1002/ajim.4700020105; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAENSZEL W, 1964, JNCI-J NATL CANCER I, V32, P803; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HAMMOND E C, 1958, J Am Med Assoc, V166, P1159; Hammond E C, 1979, Ann N Y Acad Sci, V330, P417, DOI 10.1111/j.1749-6632.1979.tb18743.x; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; HAMMOND EC, 1980, PREV MED, V9, P206, DOI 10.1016/0091-7435(80)90077-8; HAMMOND EC, 1972, ENV FACTORS RESPIRAT, P177; Hansen J, 1998, AM J RESP CRIT CARE, V157, P69, DOI 10.1164/ajrccm.157.1.96-11086; Hayes RB, 1997, CANCER CAUSE CONTROL, V8, P371, DOI 10.1023/A:1018457305212; HE XZ, 1991, ENVIRON HEALTH PERSP, V94, P9, DOI 10.2307/3431286; HITOSUGI M, 1968, Bulletin of the Institute of Public Health (Tokyo), V17, P237; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HOLOWATY EJ, 1991, CAN J PUBLIC HEALTH, V82, P304; Howel D, 1997, OCCUP ENVIRON MED, V54, P403, DOI 10.1136/oem.54.6.403; HUGHES JM, 1994, LUNG BIOL HEALTH DIS, V74, P185; *IARC, 1992, IARC MON EV CARC RIS, V54, P41; IARC, 2004, IARC MON EV CARC RIS, V83; *IARC, 1972, IARC MON EV CARC RIS, V1; *IARC, 2001, IARC MON EV CARC RIS, V78; *IARC, 1998, IARC MON EV CARC RIS, V71, P109; *IARC, 1989, IARC MON EV CARC RIS, V46, P41; IARC (International Agency for Research on Cancer), 1987, IARC MON EV CARC R S; IARC (International Agency for Research on Cancer), 1991, IARC MON EV CARC RIS, V52; *INSERM, 1997, EFF SANT PRINC TYP E; INT AGCY RES CANC, 1990, IARC MONOG EVAL CARC, V49, P49; IPCS, 1998, ENV HLTH CRIT; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; JOCKEL KH, 1992, INT J EPIDEMIOL, V21, P202, DOI 10.1093/ije/21.2.202; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; King WD, 1996, CANCER CAUSE CONTROL, V7, P596, DOI 10.1007/BF00051702; Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24; Koo LC, 1996, LUNG CANCER, V14, pS47; Kurttio P, 1999, ENVIRON HEALTH PERSP, V107, P705, DOI 10.2307/3434654; Lagarde F, 1997, HEALTH PHYS, V72, P269, DOI 10.1097/00004032-199702000-00010; Lan Q, 2002, J NATL CANCER I, V94, P826, DOI 10.1093/jnci/94.11.826; Lan Qing, 1993, Biomedical and Environmental Sciences, V6, P112; LEVIN ML, 1960, J NATL CANCER I, V24, P1243; Liddell FDK, 2001, ANN OCCUP HYG, V45, P341, DOI 10.1093/annhyg/45.5.341; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; LLOYD OL, 1986, J SOC OCCUP MED, V36, P2; LLOYD OL, 1985, BRIT J IND MED, V42, P475; LLOYD OL, 1985, BRIT J IND MED, V42, P815; LLOYD OL, 1978, LANCET, V1, P318; Lubin JH, 1997, J NATL CANCER I, V89, P49, DOI 10.1093/jnci/89.1.49; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; Luce D, 2000, AM J EPIDEMIOL, V151, P259, DOI 10.1093/oxfordjournals.aje.a010201; Luo S, 1998, Hua Xi Yi Ke Da Xue Xue Bao, V29, P63; LYON JL, 1977, LANCET, V2, P869; Macaluso M, 1996, TOXICOLOGY, V113, P190, DOI 10.1016/0300-483X(96)03444-0; MAGNANI C, 1995, OCCUP ENVIRON MED, V52, P362, DOI 10.1136/oem.52.6.362; Magnani C, 2001, ENVIRON HEALTH PERSP, V109, P915, DOI 10.2307/3454992; Magnani C, 2000, BRIT J CANCER, V83, P104; MARCOVECCHIO JE, 1993, ENVIRON MONIT ASSESS, V25, P119, DOI 10.1007/BF00549133; Marsh GM, 1997, ENVIRON RES, V75, P56, DOI 10.1006/enrs.1997.3768; Marsh GM, 1998, ARCH ENVIRON HEALTH, V53, P15, DOI 10.1080/00039899809605685; MATANOSKI GM, 1981, ENVIRON RES, V25, P8, DOI 10.1016/0013-9351(81)90076-1; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; MCGEEHIN MA, 1993, AM J EPIDEMIOL, V138, P492, DOI 10.1093/oxfordjournals.aje.a116883; MILLS PK, 1991, ARCH ENVIRON HEALTH, V46, P271, DOI 10.1080/00039896.1991.9934387; MORRIS RD, 1992, AM J PUBLIC HEALTH, V82, P955, DOI 10.2105/AJPH.82.7.955; Mzileni O, 1999, TOB CONTROL, V8, P398, DOI 10.1136/tc.8.4.398; NEUBERGER M, 1984, ARCH ENVIRON HEALTH, V39, P261, DOI 10.1080/00039896.1984.10545846; NEWHOUSE ML, 1965, BRIT J IND MED, V22, P261; NEWMAN JA, 1976, ANN NY ACAD SCI, V271, P260, DOI 10.1111/j.1749-6632.1976.tb23120.x; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Pawlega J, 1997, ACTA ONCOL, V36, P471, DOI 10.3109/02841869709001301; PERSHAGEN G, 1985, AM J EPIDEMIOL, V122, P684, DOI 10.1093/oxfordjournals.aje.a114147; PERSHAGEN G, 1977, ENVIRON HEALTH PERSP, V19, P133; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Petrauskaite R, 2002, INT J CANCER, V99, P106, DOI 10.1002/ijc.10314; PIKE MC, 1979, ENERGY HLTH, P3; Pisa FE, 2001, ARCH ENVIRON HEALTH, V56, P208, DOI 10.1080/00039890109604444; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pott P, 1775, CHIRURGICAL OBSERVAT; QING L, 1993, AM J EPIDEMIOL, V137, P145, DOI 10.1093/oxfordjournals.aje.a116654; ROM WN, 1982, BRIT J IND MED, V39, P269; SAMET JM, 1987, AM J EPIDEMIOL, V125, P800, DOI 10.1093/oxfordjournals.aje.a114597; Sathiakumar N, 1998, OCCUP ENVIRON MED, V55, P230, DOI 10.1136/oem.55.4.230; SHEAR CL, 1980, ARCH ENVIRON HEALTH, V35, P335; SMITH GH, 1987, BRIT J IND MED, V44, P795; SOBUE T, 1990, INT J EPIDEMIOL, V19, pS62, DOI 10.1093/ije/19.Supplement_1.S62; Steenland K, 2001, CANCER CAUSE CONTROL, V12, P773, DOI 10.1023/A:1012214102061; Steenland K, 1997, CANCER CAUSE CONTROL, V8, P491, DOI 10.1023/A:1018469607938; STOCKS P, 1955, BRIT MED J, V2, P923, DOI 10.1136/bmj.2.4945.923; SWAEN GMH, 1995, INT ARCH OCC ENV HEA, V67, P85; TENKANEN L, 1985, INT J CANCER, V35, P637, DOI 10.1002/ijc.2910350511; TENKANEN L, 1987, SCAND J SOC MED, V15, P67, DOI 10.1177/140349488701500203; TENKANEN L, 1993, CANCER CAUSE CONTROL, V4, P133, DOI 10.1007/BF00053154; THERIAULT GP, 1978, ARCH ENVIRON HEALTH, V33, P15, DOI 10.1080/00039896.1978.10667302; Tomasek L, 2001, SCI TOTAL ENVIRON, V272, P43, DOI 10.1016/S0048-9697(01)00663-5; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; VENA JE, 1982, AM J EPIDEMIOL, V116, P42, DOI 10.1093/oxfordjournals.aje.a113401; Wang SY, 1996, LUNG CANCER-J IASLC, V14, pS99, DOI 10.1016/S0169-5002(96)90215-9; Wang ZY, 2002, AM J EPIDEMIOL, V155, P554, DOI 10.1093/aje/155.6.554; Ward EM, 1996, TOXICOLOGY, V113, P157, DOI 10.1016/0300-483X(96)03441-5; WILLIAMS FLR, 1988, PUBLIC HEALTH, V102, P531, DOI 10.1016/S0033-3506(88)80022-2; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; Xiao H P, 1985, Natl Cancer Inst Monogr, V69, P53; Xu Z Y, 1991, IARC Sci Publ, P460; Xu ZY, 1996, LUNG CANCER-J IASLC, V14, pS149, DOI 10.1016/S0169-5002(96)90220-2; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800; ZARIDZE DG, 1995, VESTN ROS AKAD MED, V4, P6; Zhong LJ, 1999, SCAND J WORK ENV HEA, V25, P309, DOI 10.5271/sjweh.440	150	98	100	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6392	6403		10.1038/sj.onc.1207715	http://dx.doi.org/10.1038/sj.onc.1207715			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322513				2022-12-28	WOS:000223468800007
J	Wiemann, SU; Satyanarayana, A; Buer, J; Kamino, K; Manns, MP; Rudolph, KL				Wiemann, SU; Satyanarayana, A; Buer, J; Kamino, K; Manns, MP; Rudolph, KL			Contrasting effects of telomere shortening on organ homeostasis, tumor suppression, and survival during chronic liver damage	ONCOGENE			English	Article						telomere shortening; tumor suppression; regeneration; aging; chronic disease	HEPATOCYTE PROLIFERATIVE ACTIVITY; DYSFUNCTION; MICE; CARCINOMA; REGENERATION; CIRRHOSIS; CANCER	Telomere shortening limits the regenerative capacity of cells during aging and chronic disease but at the same time inhibits tumor progression, and it has yet to be determined which of these mechanisms is dominantly affecting organismal survival. Here we show that telomere shortening in telomerase knockout (mTERC(-/-)) mice in combination with chronic liver damage significantly reduced organismal survival even though telomere shortening strongly inhibited liver tumor formation. Decreased survival induced by telomere shortening correlated with an imbalance between liver cell proliferation and liver cell apoptosis. Specific changes in gene expression were associated with telomere shortening and chronic liver damage and these gene expression changes were partially reversed by adenovirus mediated telomerase gene delivery. This study gives experimental evidence that the negative impact of telomere shortening on organ homeostasis and organismal survival can surpass the beneficial effects of telomere shortening on suppression of tumor growth in the setting of chronic organ damage.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-3000 Hannover, Germany; Hannover Med Sch, Inst Med Microbiol, D-3000 Hannover, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Rudolph, KL (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-3000 Hannover, Germany.	rudolph.lenhard@mh-hannover.de		Rudolph, Karl Lenhard/0000-0002-4839-2862; Buer, Jan/0000-0002-7602-1698				Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1998, CIBA F SYMP, V211, P160; BRISCIOLI V, 1995, AM J MED GENET, V58, P21, DOI 10.1002/ajmg.1320580106; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Delhaye M, 1999, J HEPATOL, V30, P461, DOI 10.1016/S0168-8278(99)80106-8; Djojosubroto MW, 2003, MOL CELLS, V15, P164; Edwards JE, 1942, J NATL CANCER I, V3, P19; ESCHENBRENNER AB, 1946, J NATL CANCER I, V6, P325; Farazi PA, 2003, CANCER RES, V63, P5021; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Minamishima YA, 2002, CANCER RES, V62, P995; Plentz RR, 2004, HEPATOLOGY, V40, P80, DOI 10.1002/hep.20271; Plentz RR, 2003, GUT, V52, P1304, DOI 10.1136/gut.52.9.1304; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Satyanarayana A, 2003, EMBO J, V22, P4003, DOI 10.1093/emboj/cdg367; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1996, DEV GENET, V18, P173	33	17	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1501	1509		10.1038/sj.onc.1208308	http://dx.doi.org/10.1038/sj.onc.1208308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608677				2022-12-28	WOS:000227218200003
J	Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I				Felli, MP; Vacca, A; Calce, A; Bellavia, D; Campese, AF; Grillo, R; Di Giovine, M; Checquolo, S; Talora, C; Palermo, R; Di Mario, G; Frati, L; Gulino, A; Screpanti, I			PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia	ONCOGENE			English	Article						T cells; Notch3; PKC theta; NF-kappa B; leukemia	NF-KAPPA-B; KINASE-C-THETA; PROTEIN-KINASE; TRANSGENIC MICE; ACTIVATION; RECEPTOR; EXPRESSION; LEUKEMIA/LYMPHOMA; COSTIMULATION; LYMPHOCYTES	Protein kinase (PK) Ctheta is a critical regulator of mature T-cell activation and proliferation, being implicated in TCR-triggered nuclear factor (NF)-kappaB activation and providing important survival signals to leukemic T cells. We previously showed that overexpression of pTalpha/pre-TCR and constitutive activation of NF-kappaB characterize the T-cell leukemia/lymphoma developing in Notch3-IC transgenic mice. We report here that PKCtheta is a downstream target of Notch3 signaling and that its activation and membrane translocation require a functional pre-TCR in order to trigger NF-kappaB activation in thymocytes and lymphoma cells of transgenic mice. Furthermore, deletion of PKCtheta in Notch3-IC transgenic mice reduces the incidence of leukemia, correlating with decreased NF-kappaB activation. This paper therefore suggests that PKCtheta mediates the activation of NF-kappaB by pre-TCR in immature thymocytes and contributes to the development of Notch3-dependent T-cell lymphoma.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, I-00161 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Neuromed Inst, I-86077 Pozzilli, Italy; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy	Sapienza University Rome; University of L'Aquila; IRCCS Neuromed; Fondazione Cenci Bolognetti; Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Lab Mol Pathol, Viale Regina Elena 324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Frati, Luigi/ABI-7437-2020; Campese, Antonio/A-9783-2015; Bellavia, Diana/AAO-6348-2021; Palermo, Rocco/I-5140-2016; Talora, Claduio/AIC-4932-2022	Palermo, Rocco/0000-0003-0134-9370; Talora, Claduio/0000-0002-6973-2184; CHECQUOLO, Saula/0000-0001-5109-8392; VACCA, Alessandra/0000-0002-0006-5379; CAMPESE, Antonio Francesco/0000-0002-8535-6609; FELLI, MARIA PIA/0000-0002-5765-2611				Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Cipriani B, 2002, J IMMUNOL, V169, P5761, DOI 10.4049/jimmunol.169.10.5761; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Hardwick JS, 1997, J BIOL CHEM, V272, P25429, DOI 10.1074/jbc.272.41.25429; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Maroder M, 1996, J IMMUNOL, V157, P2864; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Szamel M, 1998, J IMMUNOL, V160, P2207; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 2002, CURR CANCER DRUG TAR, V2, P125, DOI 10.2174/1568009023333908; Villunger A, 1999, EUR J IMMUNOL, V29, P3549, DOI 10.1002/(SICI)1521-4141(199911)29:11<3549::AID-IMMU3549>3.0.CO;2-Q; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433	30	61	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					992	1000		10.1038/sj.onc.1208302	http://dx.doi.org/10.1038/sj.onc.1208302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592506				2022-12-28	WOS:000226749200005
J	Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM				Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM			A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2	ONCOGENE			English	Article						GFR alpha 4; GFRA family; thyroid tumours; multiple endocrine neoplasia type 2	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE; TYROSINE KINASE; FAMILY LIGANDS; RECEPTOR; EXPRESSION; PERSEPHIN; MUTATION; GENE; ACTIVATION	Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 ( MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRalpha4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRalpha4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRalpha4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRalpha4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRa4 isoform expression that includes both activating and inhibiting co-receptors for RET.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada	Queens University - Canada; Western University (University of Western Ontario); Western University (University of Western Ontario)	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, 20 Barrie St, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca						Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BABU VR, 1984, P NATL ACAD SCI-BIOL, V81, P2525, DOI 10.1073/pnas.81.8.2525; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Feldman GL, 2000, SURGERY, V128, P93, DOI 10.1067/msy.2000.107103; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gil L, 2002, INT J CANCER, V99, P299, DOI 10.1002/ijc.10298; Gimm O, 2001, ONCOGENE, V20, P2161, DOI 10.1038/sj.onc.1204289; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hansford JR, 2001, AM J HUM GENET, V69, P366; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; SHANNON KE, 1999, J ENDOCR GENET, V1, P39; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Van Dyke D L, 1984, Henry Ford Hosp Med J, V32, P266; Vanhorne JB, 2001, HUM GENET, V108, P409, DOI 10.1007/s004390100506; Wiench M, 2001, J CLIN ONCOL, V19, P1374, DOI 10.1200/JCO.2001.19.5.1374	24	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1091	1097		10.1038/sj.onc.1207826	http://dx.doi.org/10.1038/sj.onc.1207826			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592530				2022-12-28	WOS:000226749200015
J	Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL				Cuevas, BD; Uhlik, MT; Garrington, TP; Johnson, GL			MEKK1 regulates the AP-1 dimer repertoire via control of JunB transcription and Fra-2 protein stability	ONCOGENE			English	Article						MEKK1; AP-1; dimer	NEGATIVE C-JUN; CELL-PROLIFERATION; MOUSE DEVELOPMENT; GENE DISRUPTION; DEFICIENT MICE; PHOSPHORYLATION; PLASMINOGEN; ACTIVATION; KINASE; FOS	Activator protein 1 (AP-1) transcription factor dimers are composed of Jun, Fos, and ATF member proteins, but the mechanisms that determine AP-1 composition are not clearly de. ned and the function of specific dimers is not well understood. MEKK1 is a mitogen-activated protein kinase ( MAPK) kinase kinase and an ubiquitin ligase that regulates both the extracellular signal-regulated kinase 1/2 and the c-Jun amino-terminal kinase. Herein, we demonstrate that MEKK1 regulates the AP-1 protein repertoire. Both FGF-2 and phorbol ester-inducible urokinase-type plasminogen activator (uPA) expression requires AP-1 binding to an enhancer element in the uPA promoter, and we have previously shown that FGF-2 or PMA induction of uPA expression is strongly dependent on MEKK1. JunB mRNA is significantly increased in MEKK1-/- cells, demonstrating that MEKK1 suppresses JunB mRNA expression. Upregulation of JunB expression in MEKK1-/- cells forms an inhibitory AP-1 complex that binds to the uPA promoter and inhibits uPA transcription. MEKK1 also regulates Fra-2 protein stability by inducing Fra-2 ubiquitination and degradation. MEKK1 regulates AP-1-dependent gene expression by regulating the expression, activity and degradation of component members of the AP-1 complex. Controlling the repertoire of a transcription factor complex is a newly defined function for an MAPK kinase kinase.	Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cuevas, BD (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 1108 Mary Ellen Jones Bldg,Campus Box 7365,102 Ma, Chapel Hill, NC 27599 USA.	bruce_cuevas@med.unc.edu; glj@med.unc.edu						Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Acquaviva C, 2001, BIOCHIMIE, V83, P357, DOI 10.1016/S0300-9084(01)01243-3; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Cohen D, 2001, AM SOC HEMATOL ED PR, P1; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DECESARE D, 1995, ONCOGENE, V11, P365; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125; Lund LR, 2000, DEVELOPMENT, V127, P4481; McHenry JZ, 1998, ONCOGENE, V17, P1131, DOI 10.1038/sj.onc.1202044; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OHagan RC, 1996, ONCOGENE, V13, P1323; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Roselli HT, 1998, AM J PHYSIOL-GASTR L, V275, pG1472, DOI 10.1152/ajpgi.1998.275.6.G1472; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Thompson EJ, 2002, CANCER RES, V62, P3044; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Young MR, 2002, MOL CARCINOGEN, V34, P72, DOI 10.1002/mc.10050; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	46	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					801	809		10.1038/sj.onc.1208239	http://dx.doi.org/10.1038/sj.onc.1208239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558021				2022-12-28	WOS:000226577100006
J	Kim, EH; Kim, SU; Choi, KS				Kim, EH; Kim, SU; Choi, KS			Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; rottlerin; apoptosis; glioma	PROTEIN-KINASE-C; LIGAND-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROSTATE-CANCER CELLS; MEDIATED APOPTOSIS; GLIAL-CELLS; EXPRESSION; DELTA; FAMILY; DEATH	In the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, treatment with TRAIL in combination with subtoxic doses of rottlerin induced rapid apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in these cells, treatment with rottlerin efficiently recovered TRAIL-induced activation of caspases. Treatment with rottlerin significantly decreased Cdc2 activity through the downregulation of cyclin A, cyclin B, and Cdc2 proteins, whereas the sensitizing effect of rottlerin on TRAIL-induced apoptosis was independent of PKCdelta activity. Furthermore, treatment with rottlerin downregulated the protein levels of survivin and X-chromosome-linked IAP (XIAP), two major caspase inhibitors. Forced expression of Cdc2 together with cyclin B attenuated rottlerin-potentiated TRAIL-induced apoptosis by over-riding the rottlerin-mediated downregulation of survivin and XIAP protein levels. Taken together, inhibition of Cdc2 activity and the subsequent downregulation of survivin and XIAP by subtoxic doses of rottlerin contribute to amplification of caspase cascades, thereby overcoming resistance of glioma cells to TRAIL-mediated apoptosis. Since rottlerin can sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells but not human astrocytes to TRAIL-induced apoptosis, this combined treatment may offer an attractive strategy for safely treating resistant gliomas.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea	Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Griffith TS, 2002, CANCER RES, V62, P3093; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hao CH, 2001, CANCER RES, V61, P1162; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lavia P, 1999, BIOESSAYS, V21, P221; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mandil R, 2001, CANCER RES, V61, P4612; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Susarla BTS, 2003, J NEUROCHEM, V86, P635, DOI 10.1046/j.1471-4159.2003.01886.x; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tillman DM, 2003, CANCER RES, V63, P5118; Toth R, 1999, EUR J IMMUNOL, V29, P383, DOI 10.1002/(SICI)1521-4141(199902)29:02<383::AID-IMMU383>3.0.CO;2-A; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Welters HJ, 2004, J MOL ENDOCRINOL, V32, P227, DOI 10.1677/jme.0.0320227; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	64	36	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					838	849		10.1038/sj.onc.1208241	http://dx.doi.org/10.1038/sj.onc.1208241			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531913				2022-12-28	WOS:000226577100010
J	Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK				Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK			SP100 inhibits ETS1 activity in primary endothelial cells	ONCOGENE			English	Article						ETS1; SP100; angiogenesis; microarray; migration; transcription	TISSUE GROWTH-FACTOR; TRANSCRIPTION FACTOR ETS-1; ANGIOGENESIS IN-VIVO; NF-KAPPA-B; GENE-EXPRESSION; MICROARRAY DATA; TUMOR ANGIOGENESIS; INTERFERON-ALPHA; ANTISENSE OLIGONUCLEOTIDES; PLASMINOGEN-ACTIVATOR	SP100 was first identified as a nuclear autoimmune antigen and is a constituent of the nuclear body. SP100 interacts with the ETS1 transcription factor, and we have previously shown that SP100 reduces ETS1-DNA binding and inhibits ETS1 transcriptional activity on the MMP1 and uPA promoters. We now demonstrate that SP100 expression is upregulated by interferons, which have been shown to be antiangiogenic, in primary endothelial cells. As ETS1 is functionally important in promoting angiogenesis, we tested the hypothesis that ETS1 activity is negatively modulated by SP100 in endothelial cells. SP100 directly antagonizes ETS1-mediated morphological changes in human umbilical vein endothelial cell (HUVEC) network formation and reduces HUVEC migration and invasion. To further understand the functional relationship between ETS1 and SP100, cDNA microarray analysis was utilized to assess reprogramming of gene expression by ETS1 and SP100. A subset of the differentially regulated genes, including heat-shock proteins (HSPs) H11, HSPA1L, HSPA6, HSPA8, HSPE1 and AXIN1, BRCA1, CD14, CTGF (connective tissue growth factor), GABRE (gamma-aminobutyric acid A receptor epsilon), ICAM1, SNAI1, SRD5A1 (steroid-5-alpha-reductase 1) and THY1, were validated by real-time PCR and a majority showed reciprocal expression in response to ETS1 and SP100. Interestingly, genes that are negatively regulated by ETS1 and upregulated by SP100 have antimigratory or antiangiogenic properties. Collectively, these data indicate that SP100 negatively modulates ETS1-dependent downstream biological processes.	Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Baylor Inst Immunol Res, Dallas, TX USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Baylor Scott & White Health	Watson, DK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu	Chaussabel, Damien/AAX-1909-2020	Chaussabel, Damien/0000-0002-6131-7242	NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bell SE, 2001, J CELL SCI, V114, P2755; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Chaussabel D, 2002, GENOME BIOL, V3; Chen ZQ, 1997, CANCER RES, V57, P2013; Cui Y, 2004, OMICS, V8, P106, DOI 10.1089/1536231041388320; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FOLKMAN J, 2000, CANC MED, P132; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Galea E, 2002, NEUROREPORT, V13, P1469, DOI 10.1097/00001756-200208070-00024; Gerritsen ME, 2002, PHYSIOL GENOMICS, V10, P13, DOI 10.1152/physiolgenomics.00035.2002; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Griffioen AW, 1996, CANCER RES, V56, P1111; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hastings M M, 1997, J AAPOS, V1, P226, DOI 10.1016/S1091-8531(97)90042-2; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Igarashi T, 2001, TOHOKU J EXP MED, V194, P35, DOI 10.1620/tjem.194.35; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kevil CG, 2004, J BIOL CHEM, V279, P19230, DOI 10.1074/jbc.M312025200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kita D, 2001, CANCER RES, V61, P7985; Kumar P, 2002, J THORAC CARDIOV SUR, V124, P404, DOI 10.1067/mtc.2002.122540; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lee WS, 1998, CIRC RES, V82, P845; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LI WW, 1991, INVEST OPHTH VIS SCI, V32, P2906; Lincoln DW, 2003, BREAST CANCER RES TR, V78, P167, DOI 10.1023/A:1022904624054; Marler JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e37; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Okubo T, 2001, CANCER RES, V61, P1338; Ortega A, 2003, TRENDS PHARMACOL SCI, V24, P151, DOI 10.1016/S0165-6147(03)00052-X; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505; Roca C, 2003, CANCER RES, V63, P1500; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; St Croix B, 2000, SCIENCE, V289, P1197; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Tryfonas GI, 1998, PEDIATR SURG INT, V13, P590, DOI 10.1007/s003830050411; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1992, AM J PATHOL, V140, P119; Wu XX, 2003, BIOL REPROD, V69, P1308, DOI 10.1095/biolreprod.103.015420; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891	92	35	39	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					916	931		10.1038/sj.onc.1208245	http://dx.doi.org/10.1038/sj.onc.1208245			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592518				2022-12-28	WOS:000226577100017
J	Yuan, XP; Curtin, J; Xiong, YZ; Liu, GT; Waschsmann-Hogiu, S; Farkas, DL; Black, KL; Yu, JS				Yuan, XP; Curtin, J; Xiong, YZ; Liu, GT; Waschsmann-Hogiu, S; Farkas, DL; Black, KL; Yu, JS			Isolation of cancer stem cells from adult glioblastoma multiforme	ONCOGENE			English	Article						cancer stem cells; adult brain tumors; glioblastoma multiforme; glioblastoma spheres; in vivo implantation	NEURAL PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; BRAIN-TUMORS; BONE-MARROW; IDENTIFICATION; MICE; PRECURSORS; GENERATION	Glioblastoma multiforme (GBM) is the most common adult primary brain tumor and is comprised of a heterogeneous population of cells. It is unclear which cells within the tumor mass are responsible for tumor initiation and maintenance. In this study, we report that brain tumor stem cells can be identified from adult GBMs. These tumor stem cells form neurospheres, possess the capacity for self-renewal, express genes associated with neural stem cells (NSCs), generate daughter cells of different phenotypes from one mother cell, and differentiate into the phenotypically diverse populations of cells similar to those present in the initial GBM. Having a distinguishing feature from normal NSCs, these tumor stem cells can reform spheres even after the induction of differentiation. Furthermore, only these tumor stem cells were able to form tumors and generate both neurons and glial cells after in vivo implantation into nude mice. The identification of tumor stem cells within adult GBM may represent a major step forward in understanding the origin and maintenance of GBM and lead to the identification and testing of new therapeutic targets.	Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Med & Surg, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Yu, JS (corresponding author), Maxine Dunitz Neurosurg Inst, Suite 800 E,8631 W 3rd St, Los Angeles, CA 90048 USA.	yuj@cshs.org	Curtin, James/B-1669-2008	Curtin, James/0000-0002-9320-9254; Black, Keith/0000-0002-0546-4934; Yu, John/0000-0003-1230-8494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS002232, R01NS048959] Funding Source: NIH RePORTER; NINDS NIH HHS [1K23NS02232, 1R01 NS048959] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; Katsetos CD, 2002, J NEUROPATH EXP NEUR, V61, P307, DOI 10.1093/jnen/61.4.307; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Singh SK, 2003, CANCER RES, V63, P5821; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	26	615	689	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9392	9400		10.1038/sj.onc.1208311	http://dx.doi.org/10.1038/sj.onc.1208311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15558011	Green Submitted			2022-12-28	WOS:000225764100010
J	Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM				Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM			Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines	ONCOGENE			English	Article						telomeres; aberrations; genome; immortalization; human	SURFACE EPITHELIAL-CELLS; MOLECULAR CYTOGENETIC CHARACTERIZATION; G-STRAND OVERHANG; TO-END FUSIONS; MAMMALIAN TELOMERES; HUMAN FIBROBLASTS; LENGTH; CANCER; SENESCENCE; CARCINOMA	Chromosomal aberrations are common in cancers. However, the search for chromosomal aberrations leading to development of specific solid tumors has been severely hindered because the majority of solid tumors have complex chromosomal aberrations that differ within the same tumor types. A similar phenomenon exists in immortalized cell tines. The underlying mechanisms driving these diverse aberrations are largely unknown. Telomeres play crucial roles in protecting the integrity of eucaryotic chromosomes and maintaining genomic stability of human cells. Telomere lengths on individual chromosomes in normal human somatic cells are heterogeneous and undergo progressive shortening with aging process. In this study, for the first time, a molecular cytogenetic method using sequential telomere quantitative fluorescence in situ hybridization and spectral karyotyping on the same human metaphases was applied successfully to examine the dynamic profiles of individual telomere shortening and their relationship to chromosome aberrations in multiple human cell lines undergoing immortalization. Human ovarian surface epithelial cells and esophageal epithetial cells were immortalized by the expression of HPV16 E6 and E7, which drive cells to proliferate by inactivating p53 and Rb genes. In these cell lines, we consistently detected large-scale differences in telomere signal intensities not only among nonhomologous chromosome arms but also between some homologous chromosome arms. The cell lines derived from different donors had different profiles of critically short telomeres (lacking telomere signals). Strikingly, the different profiles of chromosomal structural aberrations in multiple immortalized cell lines were highly significantly associated with the distinct distributions of critically short telomeres in whole-genome. Since cellular immortalization is one of the hallmarks of cancer, our findings suggest that distinct profiles of critically short telomeres in different human individuals might play an essential role in determining the complex and individual-specific chromosomal structural aberrations in human solid tumors.	Univ Hong Kong, Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Hong Kong, Fac Med, Dept Pediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China; Henan Med Univ, Ctr Med Expt, Canc Res Lab, Zhengzhou, Henan Province, Peoples R China	University of Hong Kong; University of Hong Kong; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Hong Kong; Zhengzhou University	Cheung, ALM (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hkucc.hku.hk	Deng, Wen/M-5208-2019; Deng, Wen/C-4154-2009; Tsao, George/C-4422-2009; /A-3639-2009; /C-4230-2009; Guan, Xin-Yuan/A-3639-2009	/0000-0003-1874-9805; /0000-0003-3217-1456; MAK, P H S/0000-0002-8474-3578; Guan, Xin-Yuan/0000-0002-4485-6017				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; BENN PA, 1976, AM J HUM GENET, V28, P465; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DELANGE T, 1995, TELOMERES, P265; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Drexler HG, 1999, LEUKEMIA, V13, P1601, DOI 10.1038/sj.leu.2401510; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Graakjaer J, 2004, AGING CELL, V3, P97, DOI 10.1111/j.1474-9728.2004.00093.x; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; KARGER S, 1995, INT SYSTEM HUMAN CYT; Karlseder J, 2003, CANCER LETT, V194, P189, DOI 10.1016/S0304-3835(02)00706-1; Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003; Keys B, 2004, AGING CELL, V3, P103, DOI 10.1111/j.1474-9728.2004.00094.x; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Masters J, 2002, INT J CANCER, V99, P154, DOI 10.1002/ijc.10315; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; van Bokhoven A, 2003, PROSTATE, V57, P226, DOI 10.1002/pros.10291; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	52	56	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9090	9101		10.1038/sj.onc.1208119	http://dx.doi.org/10.1038/sj.onc.1208119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489894				2022-12-28	WOS:000225492800010
J	Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N				Dugast-Darzacq, C; Pirity, M; Blanck, JK; Scherl, A; Schreiber-Agus, N			Mxi1-SR alpha: a novel Mxi1 isoform with enhanced transcriptional repression potential	ONCOGENE			English	Article						Mxi1; Myc; Sin3; transcriptional repression; isoforms	HISTONE DEACETYLASES; MEDIATES REPRESSION; GENE-EXPRESSION; MAX NETWORK; MYC; PROMOTERS; PROTEIN; DOMAIN; INTERACTS; HOMOLOG	Mxi1 belongs to the Myc/Max/Mad network of proteins that have been implicated in the control of multiple aspects of cellular behavior. Previously, we had reported that the mouse mxi1 gene gives rise to two distinct transcript forms that can encode proteins with dramatically different functional abilities. The Mxi1-SR protein (here termed Mxi1-SRb) can interact with Sin3/histone deacetylase and function as a potent transcriptional repressor and growth suppressor, while the Mxi1-WR protein lacks these activities. Here, we describe a new mxi1-derived transcript form (termed mxi1-SRa) whose expression is governed by its own promoter, resulting in a spatiotemporally distinct expression pro. le from that of the highly related mxi1-SRb form. Moreover, the Mxi1-SRa protein product, with its unique Sin3 interacting domain, has a greater affinity than its Mxi1-SRb counterpart for the Sin3 adapter proteins as well as an enhanced potential for transcriptional repression in transient reporter assays. Our identification of this novel Mxi1 isoform that results from alternative 50 exon usage adds an additional layer of complexity to the Mad/Mxi1 family. In addition, our findings warrant re-evaluation of mxi1 expression patterns on the cellular level and its status in human cancer samples, with a renewed focus on the distinct isoforms.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullmann 809, Bronx, NY 10461 USA.	agus@aecom.yu.edu		Dugast-Darzacq, Claire/0000-0001-8602-3534	NCI NIH HHS [1 R01 CA92558] Funding Source: Medline; NIGMS NIH HHS [T32GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Ariyanayagam-Baksh SM, 2003, MODERN PATHOL, V16, P992, DOI 10.1097/01.MP.0000087421.44975.1C; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowley SM, 2004, MOL CELL BIOL, V24, P2698, DOI 10.1128/MCB.24.7.2698-2709.2004; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KINGSTON RE, 2004, CURRENT PROTOCOLS MO; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krakauer DC, 1999, SEMIN CELL DEV BIOL, V10, P555, DOI 10.1006/scdb.1999.0337; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lee C, 2003, NUCLEIC ACIDS RES, V31, P101, DOI 10.1093/nar/gkg029; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Luo Q, 2001, J UROLOGY, V166, P1071, DOI 10.1016/S0022-5347(05)65924-1; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PIRITY M, IN PRESS CURRENT TOP; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Resch A, 2004, J PROTEOME RES, V3, P76, DOI 10.1021/pr034064v; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; Skotheim RI, 2002, CANCER RES, V62, P2359; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; van Ingen H, 2004, BIOCHEMISTRY-US, V43, P46, DOI 10.1021/bi0355645; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606	51	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8887	8899		10.1038/sj.onc.1208107	http://dx.doi.org/10.1038/sj.onc.1208107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467743				2022-12-28	WOS:000225354600004
J	Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D				Ferrer, A; Marce, S; Bellosillo, B; Villamor, N; Bosch, F; Lopez-Guillermo, A; Espinet, B; Sole, F; Montserrat, E; Campo, E; Colomer, D			Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes	ONCOGENE			English	Article						apoptosis; lymphoma; mitoxantrone	TOPOISOMERASE-II; LYMPHOPROLIFERATIVE DISORDERS; AGGRESSIVE VARIANTS; FOLLICULAR LYMPHOMA; MISSENSE MUTATIONS; CYCLE ARREST; IN-VITRO; P53; FLUDARABINE; EXPRESSION	Mantle cell lymphoma (MCL) is a mature B-cell proliferation characterized by the presence of translocation t(11;14)(q13;q32), an aggressive clinical course, and poor response to chemotherapy. The majority of drugs currently used in the treatment of lymphoproliferative disorders induce cell death by triggering apoptosis, but few data concerning drug-induced apoptosis in MCL have been reported. We have analysed the mechanisms of drug-induced cell death in four cell lines with the t(11; 14) and in primary cells from 10 patients with MCL. Mitoxantrone, a topoisomerase II inhibitor, induced a strong cytotoxic effect in three cell lines (JVM-2, REC-1, and Granta 519), and in primary MCL cells. This cytotoxic effect due to apoptosis induction was observed despite the presence of either p53 or ATM abnormalities. However, no cytotoxic effect was detected after incubation with DNA-damaging agents in the NCEB-1 cell line, carrying p53 and ATM alterations, despite the presence of functional mitochondrial machinery. These results support that mitoxantrone can be effective in the treatment of MCL but that this activity requires the integrity of functional DNA-damage response genes.	Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, E-08036 Barcelona, Spain; Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Hematopathol Unit,Dept Pathol, E-08036 Barcelona, Spain; Hosp del Mar, Dept Pathol, Lab Cytogenet & Mol Biol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Colomer, D (corresponding author), Univ Barcelona, Hosp Clin, IDIBAPS, Hematopathol Unit,Dept Hematol, Villarroel 170, E-08036 Barcelona, Spain.	dcolomer@clinic.ub.es	COLOMER, DOLORS/ABG-6894-2020; Solé, Francesc/K-8373-2012; Campo, Elias/AAC-5593-2019; MARCE, Silvia/J-6651-2017; sole, francesc/A-2430-2011; Bosch, Francesc/AAE-7052-2019	Solé, Francesc/0000-0002-3251-2161; Campo, Elias/0000-0001-9850-9793; MARCE, Silvia/0000-0001-9128-6822; Bosch, Francesc/0000-0001-9241-2886; Ana, Ferrer/0000-0002-3381-9472; Espinet, Blanca/0000-0002-4294-8145; COLOMER, DOLORS/0000-0001-7486-8484				Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; Bailly JD, 1997, LEUKEMIA, V11, P1523, DOI 10.1038/sj.leu.2400762; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Bellosillo B, 1998, BRIT J HAEMATOL, V100, P142, DOI 10.1046/j.1365-2141.1998.00520.x; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; Bertoni F, 2004, BRIT J HAEMATOL, V124, P130, DOI 10.1046/j.1365-2141.2003.04761.x; Bogner C, 2003, BRIT J HAEMATOL, V122, P260, DOI 10.1046/j.1365-2141.2003.04438.x; Bosch F, 2002, BRIT J HAEMATOL, V119, P976, DOI 10.1046/j.1365-2141.2002.03959.x; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; BOSCH F, 1994, BLOOD, V84, P2726; Camacho E, 2002, BLOOD, V99, P238, DOI 10.1182/blood.V99.1.238; Campo E, 1999, SEMIN HEMATOL, V36, P115; Campo E, 2003, HUM PATHOL, V34, P330, DOI 10.1053/hupa.2003.97; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEISABELLA P, 1991, LIFE SCI, V48, P2195, DOI 10.1016/0024-3205(91)90333-7; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Fang NY, 2003, P NATL ACAD SCI USA, V100, P5372, DOI 10.1073/pnas.0831102100; Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240; Flinn IW, 2000, BLOOD, V96, P71, DOI 10.1182/blood.V96.1.71.013k21_71_75; Hernandez L, 1996, BLOOD, V87, P3351, DOI 10.1182/blood.V87.8.3351.bloodjournal8783351; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; M'kacher R, 2003, ONCOGENE, V22, P7905, DOI 10.1038/sj.onc.1206826; Martinez N, 2003, CANCER RES, V63, P8226; Molina-Arcas M, 2003, BLOOD, V101, P2328, DOI 10.1182/blood-2002-07-2236; Muller-Hermelink, 2001, PATHOLOGY GENETICS T, P168; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pham LV, 2003, J IMMUNOL, V171, P88, DOI 10.4049/jimmunol.171.1.88; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Rasheed ZA, 2003, ONCOGENE, V22, P7296, DOI 10.1038/sj.onc.1206935; Reiman T, 2002, LEUKEMIA, V16, P1886, DOI 10.1038/sj.leu.2402579; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; Schlegelberger B, 1999, BLOOD, V94, P3114; Schrader C, 2004, LEUKEMIA, V18, P1200, DOI 10.1038/sj.leu.2403387; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SolalCeligny P, 1996, J CLIN ONCOL, V14, P514, DOI 10.1200/JCO.1996.14.2.514; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901	46	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8941	8949		10.1038/sj.onc.1208084	http://dx.doi.org/10.1038/sj.onc.1208084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480431				2022-12-28	WOS:000225354600009
J	Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS				Neary, CL; Nesterova, M; Cho, YS; Cheadle, C; Becker, KG; Cho-Chung, YS			Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion	ONCOGENE			English	Article						cAMP-dependent protein kinase; cancer; gene therapy; DNA microarray; confocal microscopy	RI-ALPHA SUBUNIT; RII(BETA) REGULATORY SUBUNIT; CANCER CELL-GROWTH; CYCLIC-AMP; CATALYTIC SUBUNIT; RESPONSE ELEMENT; GENE-EXPRESSION; BREAST-CANCER; AUTOPHOSPHORYLATION SITE; PROSTATE-CANCER	The cAMP-dependent protein kinase types I (PKA-I) and II (PKA-II), composed of identical catalytic ( C) subunits but distinct regulatory ( R) subunits (RI versus RII), are expressed in a balance of cell growth and differentiation. Distortion of this balance may underlie tumorigenesis and tumor growth. Here, we used PC3M prostate carcinoma cells as a model to overexpress wild type and mutant R and C subunit genes and examined the effects of differential expression of these genes on tumor growth. Only the RIIbeta and mutant RIalpha-P (a functional mimic of RIIbeta) transfectants exhibited growth inhibition in vitro, reverted phenotype, and apoptosis, and inhibited in vivo tumor growth. DNA microarrays demonstrated that RIIbeta and RIalpha-P overexpression upregulated a cluster of differentiation genes, while downregulating transformation and proliferation signatures. Overexpression of RIalpha and Calpha, which upregulated PKA-I, elicited the expression signatures opposite that elicited by RIIbeta overexpression. Total colocalization of Calpha and RIIbeta seen by confocal microscopy in the RIIbeta cell nucleus supports the opposed genomic regulation demonstrated between Calpha and RIIbeta cells. Differential expression of PKA R subunits may therefore serve as a tumor-target-based gene therapy for PC3M prostate and other cancers.	NCI, Cellular Biochem Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Basic Res Lab, NIH, 9000 Rockville Pike,Bldg 10,Room 5B05, Bethesda, MD 20892 USA.	yc12b@nih.gov		Becker, Kevin/0000-0002-6794-6656; Neary, Catherine/0000-0003-0562-7913; /0000-0002-6224-6685	NCI NIH HHS [N02-BC76512/C2700212] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ALPER O, 1999, ONCOGENE, V218, P55; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; BEEBE SJ, 1986, ENZYMES, V17, P43; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADBURY AW, 1994, BRIT J CANCER, V69, P738, DOI 10.1038/bjc.1994.139; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; Cho YS, 2002, P NATL ACAD SCI USA, V99, P15626, DOI 10.1073/pnas.242617799; Cho YS, 2002, CLIN CANCER RES, V8, P607; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cho-Chung Yoon S., 1999, Frontiers in Bioscience, V4, pd898, DOI 10.2741/Cho-Chung; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Cvijic ME, 2000, CLIN CANCER RES, V6, P2309; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Lee GR, 1999, MOL CELL BIOCHEM, V195, P77, DOI 10.1023/A:1006934113439; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; Neary CL, 2001, ONCOGENE, V20, P8019, DOI 10.1038/sj.onc.1204992; Nesterova M, 2000, CLIN CANCER RES, V6, P3434; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; Nesterova M, 2000, ANTISENSE NUCLEIC A, V10, P423, DOI 10.1089/oli.1.2000.10.423; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Srivastava RK, 1999, MOL CELL BIOCHEM, V195, P25, DOI 10.1023/A:1006990231186; Srivastava RK, 1998, P NATL ACAD SCI USA, V95, P6687, DOI 10.1073/pnas.95.12.6687; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; TORTORA G, 1990, J BIOL CHEM, V265, P18067; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	44	49	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8847	8856		10.1038/sj.onc.1208165	http://dx.doi.org/10.1038/sj.onc.1208165			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480415				2022-12-28	WOS:000225165100015
J	Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D				Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D			The human protein Hugl-1 substitutes for Drosophila Lethal giant larvae tumour suppressor function in vivo	ONCOGENE			English	Article						Hugl-1; Lethal giant larvae; tumour suppressor; cell polarity; epithelial cancers; Drosophila	II HEAVY-CHAIN; CELL POLARITY; GENE-EXPRESSION; HUMAN HOMOLOG; DISCS LARGE; NE-DLG; GROWTH; LGL; COMPLEX; LOCALIZATION	Drosophila lethal giant larvae (lgl), discs large (dlg) and scribble (scrib) are tumour suppressor genes acting in a common pathway, whose loss of function leads to disruption of cell polarity and tissue architecture, uncontrolled proliferation and growth of neoplastic lesions. Mammalian homologues of these genes are highly conserved and evidence is emerging concerning their role in cell proliferation control and tumorigenesis in humans. Here we investigate the functional conservation between Drosophila lethal giant larvae and its human homologue Hugl-1(Llgl1). We first show that Hugl-1 is lost in human solid malignancies, supporting its role as a tumour suppressor in humans. Hugl-1 expression in homozygous Igl Drosophila mutants is able to rescue larval lethality; imaginal tissues do not show any neoplastic features, with Dig and Scrib exhibiting the correct localization; animals undergo a complete metamorphosis and hatch as viable adults. These data demonstrate that Hugl-1 can act as a tumour suppressor in Drosophila and thus is the functional homologue of lgl. Furthermore, our data suggest that the genetic pathway including the tumour suppressors lgl, dlg and scrib may be conserved in mammals, since human scrib and mammalian dlg can also rescue their respective Drosophila mutations. Our results highlight the usefulness of fruit fly as a model system for investigating in vivo the mechanisms linking loss of cell polarity and cell proliferation control in human cancers.	Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, I-40126 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55131 Mainz, Germany; Osped Bellaria, Sez Patol, Dipartimento Oncol, Alma Mater Studiorum, I-40139 Bologna, Italy	Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, Via Selmi 3, I-40126 Bologna, Italy.	dgrifoni@alma.unibo.it	Garoia, Flavio/AAW-1313-2020; Pession, Annalisa/B-9014-2012; Garoia, Flavio/AAL-4528-2020; Galle, Peter R/T-5292-2018; Grifoni, Daniela/A-3954-2012; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Pession, Annalisa/0000-0001-9035-9698; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Laurenti, Elisa/0000-0002-9917-9092				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Jakobs R, 1996, J MOL BIOL, V264, P484, DOI 10.1006/jmbi.1996.0656; Kalmes A, 1996, J CELL SCI, V109, P1359; Kim YS, 2003, INT J ONCOL, V23, P1515; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Stowers RS, 1999, GENETICS, V152, P1631; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	37	101	107	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8688	8694		10.1038/sj.onc.1208023	http://dx.doi.org/10.1038/sj.onc.1208023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467749				2022-12-28	WOS:000224988800015
J	Fraser, A				Fraser, A			Towards full employment: using RNAi to find roles for the redundant	ONCOGENE			English	Article						synthetic lethal; redundancy; genome-wide	FUNCTIONAL GENOMIC ANALYSIS; ELEGANS VULVAL DEVELOPMENT; PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; C-ELEGANS; INTERACTION NETWORK; GENE-FUNCTION; CHROMOSOME-I; WIDE RNAI; INTERFERENCE	Cancer is a genetic disease that ultimately results from the failure of cells to respond correctly to diverse signals. Signal transduction and signal integration are highly complex, requiring the combinatorial interaction of multiple genes. Classical genetics in model organisms including Caenorhabditis elegans has been of immense use in identifying nonredundant components of conserved signalling pathways. However, it is likely that there is much functional redundancy in the informational processing machinery of metazoan cells; we therefore need to develop methods for uncovering such redundant functions in model organisms if we are to use them to understand complex gene interactions and oncogene cooperation. RNAi may provide a powerful tool to probe redundancy in informational networks. In this review, I set out some of the progress made so far by classical genetics in understanding redundancy in gene networks, and outline how RNAi may allow us to approach this problem more systematically in C. elegans. In particular, I discuss the use of genome-wide RNAi screens in C. elegans to identify synthetic lethal interactions and compare this with synthetic lethal interaction analysis in Saccharomyces cerevisiae.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Fraser, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	agf@sanger.ac.uk		Fraser, Andrew/0000-0001-9939-6014				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chang C, 1999, CANCER METAST REV, V18, P203, DOI 10.1023/A:1006317206443; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1985, GENETICS, V110, P17; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fraser AG, 2004, NAT GENET, V36, P559, DOI 10.1038/ng1370; Garigan D, 2002, GENETICS, V161, P1101; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Nelson DW, 2003, GENE DEV, V17, P813, DOI 10.1101/gad.1090203; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	36	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8346	8352		10.1038/sj.onc.1208044	http://dx.doi.org/10.1038/sj.onc.1208044			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517015				2022-12-28	WOS:000224815900004
J	Vaghefi, H; Neet, KE				Vaghefi, H; Neet, KE			Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation	ONCOGENE			English	Article						acetylation; signal transduction; apoptosis; differentiation	PROTEIN-KINASE ACTIVITY; DNA-DAMAGE; PHEOCHROMOCYTOMA CELLS; HISTONE DEACETYLASE; MEDIATED APOPTOSIS; NEURITE OUTGROWTH; CARCINOMA-CELLS; TRICHOSTATIN-A; PHOSPHORYLATION; INHIBITOR	The tumor suppressor protein p53 is a transcription factor that regulates the response to cellular insults such as DNA damage and growth factor withdrawal. Transcriptional activity of p53 requires post-translational modification by phosphorylation and acetylation. This study used site-specific antibodies to demonstrate that nerve growth factor (NGF) treatment of PC12 cells results in p53 deacetylation at lysine (Lys) 382. Histone deacetylase (HDAC) activity, measured by a direct fluorescent assay, was increased after NGF treatment and peaked before p53 deacetylation. Inhibition of HDAC by trichostatin blocked the deacetylation of p53 and its transcriptional activity toward a reporter gene construct. Comparison of PC12 with PC12 cells containing a temperature-sensitive, dominant-negative construct showed that p53 deacetylation required functional p53. Inhibitors of MAP kinase that block p53 transactivation and inhibitors of TrkA receptor also abolished HDAC activation, indicating that deacetylation of p53 is an NGF-dependent post-translational mechanism of p53 activation. Finally, NGF or serum withdrawal did not lead to p53 deacetylation. A model is proposed in which the acetylation status of Lys 382 of p53 discriminates between cell cycle arrest and apoptosis.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Neet, KE (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.neet@rosalindfranklin.edu			NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; BENDORI R, 1983, FEBS LETT, V162, P384; Billon N, 1996, ONCOGENE, V13, P2047; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heneka MT, 1998, J NEUROCHEM, V71, P88; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jabbur JR, 2001, INT J MOL MED, V7, P163; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Lad SP, 2003, CNS NEUROL DISORD-DR, V2, P315, DOI 10.2174/1568007033482724; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LEE V, 1977, P NATL ACAD SCI USA, V74, P5021, DOI 10.1073/pnas.74.11.5021; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; LIU M, 1995, ONCOGENE, V10, P1955; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Mauser A, 2002, J VIROL, V76, P12503, DOI 10.1128/JVI.76.24.12503-12512.2002; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Scotto C, 1999, MOL CELL BIOL, V19, P7168; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; Shiseki M, 2003, CANCER RES, V63, P2373; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; SLADEK TL, 1992, ONCOGENE, V7, P1305; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; TAPLEY P, 1992, ONCOGENE, V7, P371; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vaghefi H, 2004, J BIOL CHEM, V279, P15604, DOI 10.1074/jbc.M311500200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zeng LF, 2003, J BIOL CHEM, V278, P24594, DOI 10.1074/jbc.M301955200; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	86	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8078	8087		10.1038/sj.onc.1207953	http://dx.doi.org/10.1038/sj.onc.1207953			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361854				2022-12-28	WOS:000224692500005
J	Playford, MP; Schaller, MD				Playford, MP; Schaller, MD			The interplay between Src and integrins in normal and tumor biology	ONCOGENE			English	Review						Src; integrin; FAK; cell adhesion	FOCAL-ADHESION-KINASE; GROWTH-FACTOR RECEPTOR; HUMAN BREAST-CANCER; PHOSPHATIDYLINOSITOL PHOSPHATE KINASE; ELEVATED C-SRC; SIGNALING COMPLEX-FORMATION; MDIA-INTERACTING PROTEIN; VIRUS-TRANSFORMED CELLS; HUMAN-MELANOMA CELLS; TYROSINE PHOSPHORYLATION	Src family nonreceptor protein tyrosine kinases transduce signals that control normal cellular processes such as cell proliferation, adhesion and motility. Normally, cellular Src is held in an inactive state, but in several cancer types, abnormal events lead to elevated kinase activity of the protein and cause pleiotropic cellular responses inducing transformation and metastasis. A prerequisite of the ability of a cancer cell to undergo metastasis into distant tissues is to penetrate surrounding extracellular matrices. These processes are facilitated by the integrin family of cell adhesion molecules. As is the case with Src, altered integrin activity or substrate affinity can contribute to the neoplastic phenotype. Therefore, understanding the interplay between Src and integrin function has been of intense interest over the past few years. This review focuses on the role of Src and integrin signaling in normal cells and how this is deregulated in human cancer. We will identify the key players in the integrin-mediated signaling pathways involved in cell motility and apoptosis, such as FAK, paxillin and p130(CAS), and discuss how Src signaling affects the formation of focal adhesions and the extracellular matrix.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 534 Taylor Hall,CB 7090, Chapel Hill, NC 27599 USA.	crispy4@med.unc.edu			NCI NIH HHS [CA90901] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheresh DA, 2002, NAT MED, V8, P193, DOI 10.1038/nm0302-193; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Danker K, 1998, EXP CELL RES, V239, P326, DOI 10.1006/excr.1997.3916; Datta A, 2001, MOL CELL BIOL, V21, P7295, DOI 10.1128/MCB.21.21.7295-7306.2001; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; El Annabi S, 2001, FEBS LETT, V507, P247, DOI 10.1016/S0014-5793(01)02981-7; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fagerholm S, 2002, EUR J IMMUNOL, V32, P1670, DOI 10.1002/1521-4141(200206)32:6<1670::AID-IMMU1670>3.0.CO;2-M; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Fincham VJ, 1999, J CELL SCI, V112, P947; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; Genda T, 2000, LAB INVEST, V80, P387, DOI 10.1038/labinvest.3780043; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Goicoechea SM, 2002, INT J BIOCHEM CELL B, V34, P791, DOI 10.1016/S1357-2725(02)00002-X; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Hisano C, 2003, CELL BIOL INT, V27, P415, DOI 10.1016/S1065-6995(03)00032-5; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Iravani S, 1998, LAB INVEST, V78, P365; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JACOBS C, 1983, CANCER RES, V43, P1696; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Kadono Y, 1998, CANCER RES, V58, P2240; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lakkakorpi PT, 2001, J CELL SCI, V114, P149; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003; Li YS, 2001, CANCER RES, V61, P6906; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; LIU XQ, 1993, ONCOGENE, V8, P1119; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4; Matsumoto T, 2003, CANCER RES, V63, P4819; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Meng WX, 2004, EMBO J, V23, P760, DOI 10.1038/sj.emboj.7600095; Mercurio AM, 2001, J MAMMARY GLAND BIOL, V6, P299, DOI 10.1023/A:1011323608064; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OKADA M, 1989, J BIOL CHEM, V264, P20886; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Palecek SP, 1998, J CELL SCI, V111, P929; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Park HB, 2004, BIOCHEM J, V378, P559, DOI 10.1042/BJ20031392; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ren XD, 2000, J CELL SCI, V113, P3673; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; ROSEN N, 1986, J BIOL CHEM, V261, P3754; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Sanders MA, 2004, AM J PHYSIOL-GASTR L, V286, pG547, DOI 10.1152/ajpgi.00262.2003; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SANJAY A, 2001, SCI STKE, pPE40; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Shen TL, 2004, FRONT BIOSCI-LANDMRK, V9, P192, DOI 10.2741/1229; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonnenburg ED, 2003, BIOCHEMISTRY-US, V42, P7904, DOI 10.1021/bi0340503; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Volberg T, 2001, J CELL SCI, V114, P2279; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; Wierzbicka-Patynowski I, 2002, J BIOL CHEM, V277, P19703, DOI 10.1074/jbc.M200270200; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu X, 2000, J CELL SCI, V113, P2139; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	241	416	429	0	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7928	7946		10.1038/sj.onc.1208080	http://dx.doi.org/10.1038/sj.onc.1208080			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489911				2022-12-28	WOS:000224558300004
J	Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG				Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG			Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching	ONCOGENE			English	Article						RET isoforms; Tyr1062; cell branching; cell scattering; cell transformation	RECEPTOR TYROSINE KINASE; URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; C-RET; TRANSFORMING ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; GDNF FAMILY; AUTOPHOSPHORYLATION SITES	The receptor tyrosine kinase RET is alternatively spliced to yield two main isoforms, RET9 and RET51, which differ in their carboxyl terminal. Activated RET induces different biological responses such as morphological transformation, neurite outgrowth, proliferation, cell migration and branching. The two isoforms have been suggested to have separate intracellular signaling pathways and different roles in mouse development. Here we show that both isoforms are able to induce cell scattering of SK-N-MC neuroepithelioma cell line and branching tubule formation in MDCK cell line. However, the Y1062F mutation, which abrogates the transforming activity of both activated RET isoforms in NIH3T3 cells, does not abolish scattering and branching morphogenesis of RET51, whereas impairs these biological effects of RET9. The GDNF-induced biological effects of RET51 are inhibited by the simultaneous abrogation of both Tyr1062 and Tyr1096 docking sites. Thus, Tyr1096 may substitute the functions of Tyr1062. GRB2 is the only known adaptor protein binding to Tyr1096. Dominant-negative GRB2 expressed in MDCK cells together with RET9 or RET51 significantly reduces branching. Therefore, GRB2 is necessary for RET-mediated branching of MDCK cells.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-0014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Diagnost Dept Pathol, FIN-00290 Helsinki, Finland; FIRC, Inst Mol Oncol IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; mariagrazia.borrello@istitutotumori.mi.it	Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 2002, BIOCHEM BIOPH RES CO, V296, P515, DOI 10.1016/S0006-291X(02)00886-0; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; De Vita G, 2000, CANCER RES, V60, P3727; Durbec PL, 1996, DEVELOPMENT, V122, P349; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, J NEURO-ONCOL, V55, P51, DOI 10.1023/A:1012946812930; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; KAWAMOTO Y, 2004, J BIOL CHEM     0106; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lanzi C, 2000, INT J CANCER, V85, P384, DOI 10.1002/(SICI)1097-0215(20000201)85:3<384::AID-IJC15>3.3.CO;2-P; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Mograbi B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	60	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7297	7309		10.1038/sj.onc.1207862	http://dx.doi.org/10.1038/sj.onc.1207862			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326489				2022-12-28	WOS:000224021400001
J	Davies, GC; Ettenberg, SA; Coats, AO; Mussante, M; Ravichandran, S; Collins, J; Nau, MM; Lipkowitz, S				Davies, GC; Ettenberg, SA; Coats, AO; Mussante, M; Ravichandran, S; Collins, J; Nau, MM; Lipkowitz, S			Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b	ONCOGENE			English	Article						Cbl proteins; ubiquitin associated (UBA) domain; ubiquitin	GROWTH-FACTOR RECEPTOR; DAMAGE-INDUCIBLE PROTEINS; T-CELL-ACTIVATION; CUE DOMAIN; TYROSINE PHOSPHORYLATION; BINDING-PROTEIN; RING FINGER; HIV-1 VPR; V-CBL; PROTEASOME	Cbl proteins are ubiquitin protein ligases, which ubiquitinate activated tyrosine kinases and target them for degradation. Both c-Cbl and Cbl-b have an ubiquitin associated (UBA) domain at their C-terminal end. We observed that high molecular weight ubiquitinated proteins constitutively coimmunoprecipitated with transfected and endogenous Cbl-b, but not c-Cbl. The binding site for these ubiquitinated proteins was mapped to the UBA domain of Cbl-b (UBAb). GST-fusion proteins containing the UBAb interacted with ubiquitinated proteins and polyubiquitin chains in vitro, whereas those containing the UBA domain of c-Cbl (UBA(c)) did not. The UBAb had a much greater affinity for polyubiquitin chains than for monoubiquitin. Analysis of the UBA(b) and UBA(c) demonstrate that the affinity for ubiquitin is determined by multiple amino-acid differences between the two domains. Overexpression of the UBA(b), but not overexpression of the UBA(c), inhibited a variety of ubiquitin-mediated processes such as degradation of ubiquitinated proteins (i.e. EGFR, Mdm-2, and Siah-1). This in vivo result is consistent with the differences in ubiquitin binding observed in vitro between the UBA(b) and UBA(c). This difference in ubiquitin-binding may reflect distinct regulatory functions of c-Cbl and Cbl-b.	NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Adv Biomed Comp Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 2066, Bethesda, MD 20892 USA.	lipkowitz@nih.gov			NATIONAL CANCER INSTITUTE [ZIASC007263, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar RC, 2003, J BIOL CHEM, V278, P10737, DOI 10.1074/jbc.M211622200; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chim N, 2004, PROTEINS, V54, P784, DOI 10.1002/prot.10636; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HOU D, 1994, J BIOL CHEM, V269, P14244; Hu G, 1999, MOL CELL BIOL, V19, P724; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Nau MM, 2003, GENE, V308, P103, DOI 10.1016/S0378-1119(03)00471-2; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Saito T, 2002, J BIOL CHEM, V277, P33624, DOI 10.1074/jbc.M201909200; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yuan XM, 2004, EMBO J, V23, P1463, DOI 10.1038/sj.emboj.7600152; Zhang J, 2002, J IMMUNOL, V169, P2236, DOI 10.4049/jimmunol.169.5.2236	60	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7104	7115		10.1038/sj.onc.1207952	http://dx.doi.org/10.1038/sj.onc.1207952			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273720				2022-12-28	WOS:000223885100011
J	Vogel, C; Kienitz, A; Hofmann, I; Muller, R; Bastians, H				Vogel, C; Kienitz, A; Hofmann, I; Muller, R; Bastians, H			Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy	ONCOGENE			English	Article						cell cycle checkpoint; genomic instability; cell cycle; mad2	MAMMALIAN-CELLS; PROTEIN-KINASE; DNA-DAMAGE; KINETOCHORE LOCALIZATION; TETRAPLOIDY CHECKPOINT; PREMATURE ANAPHASE; PROMOTING COMPLEX; TUMOR-SUPPRESSOR; G(1) ARREST; MAD2	Treatment of cells with microtubule inhibitors results in activation of the mitotic spindle assembly checkpoint, leading to mitotic arrest before anaphase. Upon prolonged treatment, however, cells can adapt and exit mitosis aberrantly, resulting in the occurrence of tetraploid cells in G1. Those cells subsequently arrest in postmitotic G1 due to the activation of a p53-dependent G1 checkpoint. Failure of the G1 checkpoint leads to endoreduplication and further polyploidization. Using HCT116 and isogenic p53-deficient or spindle checkpoint compromised derivatives, we show here that not only p53 but also a functional spindle assembly checkpoint is required for postmitotic G1 checkpoint function. During transient mitotic arrest, p53 stabilization and activation is triggered by a pathway independent of ATM/ATR, Chk1 and Chk2. We further show that a prolonged spindle checkpoint-mediated mitotic arrest is required for proper postmitotic G1 checkpoint function. In addition, we demonstrate that polyploid cells are inhibited to re-enter mitosis by an additional checkpoint acting in G2. Thus, during a normal cell cycle, polyploidization and subsequent aneuploidization is prevented by the function of the mitotic spindle checkpoint, a p53-dependent G1 checkpoint and an additional G2 checkpoint.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Di Leonardo A, 1997, CANCER RES, V57, P1013; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jullien D, 2002, J CELL SCI, V115, P71; Khan SH, 1998, CANCER RES, V58, P396; Kohn EA, 2003, CANCER RES, V63, P31; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1	36	127	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6845	6853		10.1038/sj.onc.1207860	http://dx.doi.org/10.1038/sj.onc.1207860			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286707				2022-12-28	WOS:000223750700001
J	Ravid, D; Maor, S; Werner, H; Liscovitch, M				Ravid, D; Maor, S; Werner, H; Liscovitch, M			Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling	ONCOGENE			English	Article						Akt; anoikis; cancer; caveolin; cell survival; IGF-I; p53; signal transduction	BREAST-CANCER-CELLS; ANCHORAGE-INDEPENDENT GROWTH; FOCAL ADHESION KINASE; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN EXPRESSION; INDUCED APOPTOSIS; MATRIX ADHESION; MICE	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Utilizing MCF-7 human breast cancer cells, stably transfected with caveolin-1 (MCF-7/Cav1), we previously demonstrated that caveolin-1 expression decreases MCF-7 cell proliferation and colony formation in soft agar. However, the loss of anchor age-independent growth is associated with inhibition of anoikis, as MCF-7/ Cav1 cells exhibit increased survival after detachment. Herein we show that this phenotype is associated with suppression of detachment-induced activation of p53 and of the consequent induction of cyclin-dependent kinase inhibitor p2lWAF1/Cip1. In contrast, activation of p53 and p21 WAF1/Cipt induced by doxorubicin in MCF-7/Cav1 cells remains largely unaffected. The phenotypic changes observed in MCF-7/Cav1 cells are not accompanied by changes in caspase-6, -7, -8 and -9 and cannot be explained by changes in Bid and Bcl-2 expression. However, MCF-7/Cav1 cells exhibit a constitutively phosphorylated Akt kinase and at least one phosphorylated high molecular weight putative Akt substrate which we designated pp340. In addition, MCF-7/Cavl cells exhibit elevated expression of insulin-like growth factor-1 (IGF-1) receptor expression and increased IGF-1 signaling to Erkl/2 and to Akt, as well as IGF-1-induced stimulation of pp340 phosphorylation. The addition of IGF-I to the medium rescues the parental MCF-7 cells from anoikis, indicating that IGF-1 can act as a survival factor for suspended MCF-7 cells. Finally, the levels of caveolin-1 are dramatically elevated in a time-dependent manner upon detachment of anoikis-resistant MCF-7/ Cav1 cells and HT-29-MDR human multidrug resistant colon cancer cells. We conclude that expression of caveolin-1 in human breast cancer cells enhances matrix-independent cell survival that is mediated by upregulation of IGF-I receptor expression and signaling.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty 138,POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Cohen AW, 2003, AM J PHYSIOL-ENDOC M, V285, pE1151, DOI 10.1152/ajpendo.00324.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Duxbury MS, 2004, J BIOL CHEM, V279, P23176, DOI 10.1074/jbc.M402051200; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li WP, 2001, J CELL SCI, V114, P1397; LISCOVITCH M, 2004, MEMBRANE MICRODOMAIN, P161; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Tahir SA, 2001, CANCER RES, V61, P3882; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; WERNER H, 1994, J BIOL CHEM, V269, P12577; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	58	81	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1338	1347		10.1038/sj.onc.1208337	http://dx.doi.org/10.1038/sj.onc.1208337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15592498				2022-12-28	WOS:000227092600004
J	Kim, KM; Lee, YJ				Kim, KM; Lee, YJ			Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the PI3K-Akt pathway	ONCOGENE			English	Article						amiloride; TRAIL; apoptosis; caspase; Akt; PDK-1; PTEN; PP1	NF-KAPPA-B; TUMOR-SUPPRESSOR; PHOSPHOINOSITIDE 3-KINASE; IONIZING-RADIATION; INTRACELLULAR PH; TYROSINE-KINASE; CANCER-CELLS; AKT; RECEPTOR; ACTIVATION	We have previously shown that low extracellular pH (pHe) promotes cell killing by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we examined whether amiloride, an inhibitor of the Na+/H+ antiporter capable of lowering the intracellular pH (pHi), can potentiate TRAIL-induced apoptotic death. Human prostate adenocarcinoma DU-145 cells were treated with various concentrations of TRAIL (10-200 ng/ml) and/or amiloride (0.1-1 mM) for 4 h. Amiloride, which caused little or no cytotoxicity by itself, enhanced TRAIL-induced apoptosis. The TRAIL-mediated activation of caspase, and PARP (poly (ADP-ribose) polymerase) cleavage were both promoted by amiloride. Western blot analysis showed that combined treatment with TRAIL and amiloride did not change the levels of TRAIL receptors (death receptor (DR)4, DR5, and DcR2 (decoy recepter 2) or antiapoptotic proteins (FLICE-inhibitory protein ( FLIP), inhibitor of apoptosis (IAP), and Bcl-2). However, unlike pHe, amiloride promoted the dephosphorylation of Akt. Interestingly, amiloride also induced the dephosphorylation of PI3K (phosphatidylinositol 3-kinase) and PDK-1 (phosphoinositide-dependent kinase-1) kinases along with PTEN (phosphatase and tensin homolog deleted on chromosome 10) and PP1alpha phosphatases. In vitro kinase assays revealed that amiloride inhibited phosphorylation of kinases and phosphatases by competing with ATP. Taken together, the present studies suggest that amiloride enhances TRAIL-induced cytotoxicity by inhibiting phosphorylation of the PI3K-Akt pathway-associated kinases and phosphatases.	Univ Pittsburgh, Sch Med, Dept Surg & Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave,G-5A, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu			NCI NIH HHS [CA48000, CA96989, CA95191] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burow ME, 1998, CANCER RES, V58, P4940; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DEL PL, 1997, SCIENCE, V278, P687; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; ENDRICH B, 1982, J NATL CANCER I, V68, P475; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hetman M, 2000, J NEUROSCI, V20, P2567; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLLAND R, 1983, FEBS LETT, V154, P269, DOI 10.1016/0014-5793(83)80163-X; Kandasamy K, 2002, CANCER RES, V62, P4929; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2004, EXP CELL RES, V293, P129, DOI 10.1016/j.yexcr.2003.09.015; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nagane M, 2000, CANCER RES, V60, P847; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RALPH RK, 1982, BIOCHEM BIOPH RES CO, V104, P1054, DOI 10.1016/0006-291X(82)91356-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH RL, 1982, J BIOL CHEM, V257, P773; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Tamm I, 1998, CANCER RES, V58, P5315; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Xu WP, 2003, CANCER RES, V63, P7777	67	36	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					355	366		10.1038/sj.onc.1208213	http://dx.doi.org/10.1038/sj.onc.1208213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558024				2022-12-28	WOS:000226279700007
J	Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD				Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD			Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation	ONCOGENE			English	Article						tissue inhibitor of matrix metalloproteinase; myeloid leukemia; signal transducer and activator of transcription; retroviral vector	ERYTHROID-POTENTIATING ACTIVITY; PANCREATIC-CANCER; GROWTH-FACTOR; TUMOR-GROWTH; BONE-MARROW; CELL-DEATH; IN-VIVO; TIMP-1; EXPRESSION; LEUKEMIA	The balance between matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase ( TIMP) is important for extracellular matrix interactions of hematopoietic cells. MMP-independent growth modulating activity for TIMP-1 on B lymphocytes and erythroid progenitors has also been described, but a role for TIMP-1 in myelomonocytic differentiation has not been previously reported. In this study, we demonstrate that TIMP-1 overexpression impairs differentiation of the myeloblastic M1 cell line following interleukin (IL)-6 stimulation. We generated retroviral vectors coexpressing human TIMP-1 and the green fluorescent protein (GFP) and stably transduced murine M1 myeloid cells. TIMP-1 expressing cells showed a large reduction in IL-6-induced macrophage differentiation in vitro that was reversible with a specific monoclonal antibody. The differentiation delay in M1/TIMP-1 cells was also specifically reversible by pharmacologic phosphatidylinositol-3 kinase (PI3-K) inhibition. Additionally, overexpression of a TIMP-1/GFP fusion protein also impaired M1 differentiation and this protein was localized to the cell surface, consistent with an autocrine receptor-mediated mechanism. Surprisingly, TIMP-1 transduced cells had a selective advantage for growth in IL-6, indicating that functional effects on growth and differentiation of M1 cells were primarily through an autocrine mechanism. Intrinsic TIMP-1 expression in myeloid leukemia cells might thus impact upon survival or differentiation.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Hematopoiesis Dept, Rockville, MD 20855 USA; George Washington Univ, Inst Biomed Sci, Genet Program, Washington, DC 20037 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA; NIH, Flow Cytometry Unit, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA; NIH, Extracellular Matrix Sect, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA	American Red Cross; George Washington University; American Red Cross; George Washington University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Bunting, KD (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, 10900 Euclid Ave WRB2, Cleveland, OH 44106 USA.	kevin.bunting@case.edu	Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, Maryalice/AAV-7393-2020; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808; Bradley, Heath/0000-0001-5796-7595; Hawley, Robert/0000-0003-3512-5818	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC009373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC009179, Z01SC009179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL071171, R01HL073738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL073738, R21HL071171] Funding Source: Medline; NIDDK NIH HHS [R01DK059380] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVALOS BR, 1988, BLOOD, V71, P1720; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; de Bont ESJM, 2001, BRIT J HAEMATOL, V113, P296, DOI 10.1046/j.1365-2141.2001.02722.x; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Gronning LM, 2000, BIOL REPROD, V62, P1040, DOI 10.1095/biolreprod62.4.1040; Guedez L, 1996, CRIT REV ONCOGENESIS, V7, P205, DOI 10.1615/CritRevOncog.v7.i3-4.40; Guedez L, 2001, BLOOD, V97, P1796, DOI 10.1182/blood.V97.6.1796; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Li GY, 1999, CANCER RES, V59, P6267; Lin LI, 2002, BRIT J HAEMATOL, V117, P835, DOI 10.1046/j.1365-2141.2002.03510.x; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NISKANEN E, 1988, BLOOD, V72, P806; NISKANEN E, 1990, EUR J HAEMATOL, V45, P267; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Ries C, 1999, CLIN CANCER RES, V5, P1115; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Soloway PD, 1996, ONCOGENE, V13, P2307; STRIFE A, 1987, BLOOD, V69, P1508; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; Yamauchi K, 2001, SURG TODAY, V31, P791, DOI 10.1007/s005950170049; Zhang JY, 2001, LEUKEMIA RES, V25, P463, DOI 10.1016/S0145-2126(00)00157-0; Zhao WQ, 1998, J CELL SCI, V111, P1147	44	12	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9212	9219		10.1038/sj.onc.1208096	http://dx.doi.org/10.1038/sj.onc.1208096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516987				2022-12-28	WOS:000225638000006
J	Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y				Takahashi, M; Lin, YM; Nakamura, Y; Furukawa, Y			Isolation and characterization of a novel gene CLUAP1 whose expression is frequently upregulated in colon cancer	ONCOGENE			English	Article						CLUAP1; clusterin; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; COLORECTAL CARCINOGENESIS; CELL-DEATH; CLUSTERIN; CARCINOMAS; PROTEIN; INVOLVEMENT; ADENOMAS; COMPLEX; GAINS	To disclose mechanisms of colorectal carcinogenesis and identify novel diagnostic markers and drug targets for treatment of these tumors, we previously analysed the expression profiles of 11 colorectal cancers using a genome-wide cDNA microarray containing 23 040 genes. Among the genes commonly transactivated in the cancers, we identified a novel human gene, which we termed CLUAP1 (clusterin-associated protein 1). It encodes a nuclear protein of 413 amino acids containing a coiled-coil domain. To investigate its function, we searched for CLUAP1-interacting proteins using yeast two-hybrid system and identified nuclear Clusterin. Expression of CLUAP1 was gradually increased in the late S to G2/ M phases of cell cycle and it returned to the basal level in the G0/G1 phases. Suppression of this gene by short interfering RNAs resulted in growth retardation in the transfected cells. These data provide better understanding of colorectal carcinogenesis, and inactivation of CLUAP1 may conceivably serve in the future as a novel therapeutic intervention for treatment of colon cancer.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital	Furukawa, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Human Genome Ctr,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	furukawa@ims.u-tokyo.ac.jp		Takahashi, Meiko/0000-0002-8344-5472				Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Debure L, 2003, J CELL SCI, V116, P3109, DOI 10.1242/jcs.00619; He QJ, 2003, CANCER GENET CYTOGEN, V144, P112, DOI 10.1016/S0165-4608(02)00959-7; Hough CD, 2001, CANCER RES, V61, P3869; Kitahara O, 2001, CANCER RES, V61, P3544; Korn WM, 1999, GENE CHROMOSOME CANC, V25, P82, DOI 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; Nakao K, 1998, SURG TODAY, V28, P567, DOI 10.1007/s005950050185; Okabe H, 2003, CANCER RES, V63, P3043; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P6157, DOI 10.1021/bi952981b; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Shimokawa T, 2003, CANCER RES, V63, P6116; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wellmann A, 2000, BLOOD, V96, P398; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907	20	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9289	9294		10.1038/sj.onc.1208100	http://dx.doi.org/10.1038/sj.onc.1208100			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15480429				2022-12-28	WOS:000225638000014
J	Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E				Delmas, D; Rebe, C; Micheau, O; Athias, A; Gambert, P; Grazide, S; Laurent, G; Latruffe, N; Solary, E			Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells	ONCOGENE			English	Article						apoptosis; death receptors; lipid rafts; resveratrol	INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GROWTH-INHIBITION; CANCER-CELLS; LIPID RAFTS; ACTIVATION; CASPASE-8; SENSITIZATION; COMPOUND; PATHWAY	The natural phytoalexin resveratrol (3,5,4'-trihydroxystilbene) exhibits both chemopreventive and antitumor activities through a variety of mechanisms. We have shown previously that resveratrol-induced apoptosis of a human colon cancer cell line involved the redistribution of CD95 (Fas/Apo-1) into lipid rafts. Here, we show that, in colon cancer cells that resist to resveratrol-induced apoptosis, the polyphenol also induces a redistribution of death receptors into lipid rafts. This effect sensitizes these tumor cells to death receptor-mediated apoptosis. In resveratrol-treated cells, tumor necrosis factor (TNF), anti-CD95 antibodies and TNF-related apoptosis-inducing ligand (TRAIL) activate a caspase-dependent death pathway that escapes Bcl-2-mediated inhibition. Resveratrol does not enhance the number of death receptors at the surface of tumor cells but induces their redistribution into lipid rafts and facilitates the caspase cascade activation in response to death receptor stimulation. The cholesterol sequestering agent nystatin prevents resveratrol-induced death receptor redistribution and cell sensitization to death receptor stimulation. Thus, whatever its ability to induce apoptosis in a tumor cell, resveratrol induces redistribution of death receptors into lipid rafts. This redistribution sensitizes the cells to death receptor stimulation. Such a sensitizing effect may be of therapeutic interest if TRAIL agonists are introduced in clinics.	INSERM, U517, IFR100, Fac Med, F-21000 Dijon, France; Univ Burgundy, Mol & Cellular Biol Lab, GDR CNRS 2583, IFR92, F-21000 Dijon, France; CHU Bocage, INSERM, U498, IFR100, F-21034 Dijon, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Solary, E (corresponding author), INSERM, U517, IFR100, Fac Med, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr	Delmas, Dominique/AAD-9749-2019; micheau, olivier/C-3574-2011; REBE, Cédric/AAD-4316-2019	Delmas, Dominique/0000-0003-3576-0248; micheau, olivier/0000-0001-8499-7984; REBE, Cédric/0000-0001-8831-145X; Solary, Eric/0000-0002-8629-1341; Delmas, Dominique/0000-0002-8911-8499				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; Clement MV, 1998, BLOOD, V92, P996; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Dorrie J, 2001, CANCER RES, V61, P4731; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Keane MM, 1999, CANCER RES, V59, P734; Kubota T, 2003, ANTICANCER RES, V23, P4039; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Lacour S, 2001, CANCER RES, V61, P1645; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sun ZJ, 2002, WORLD J GASTROENTERO, V8, P79, DOI 10.3748/wjg.v8.i1.79; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zoberi I, 2002, CANCER LETT, V175, P165, DOI 10.1016/S0304-3835(01)00719-4	41	166	168	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8979	8986		10.1038/sj.onc.1208086	http://dx.doi.org/10.1038/sj.onc.1208086			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480430				2022-12-28	WOS:000225354600013
J	Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A				Iuliano, R; Le Pera, I; Cristofaro, C; Baudi, F; Arturi, F; Pallante, P; Martelli, ML; Trapasso, F; Chiariotti, L; Fusco, A			The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis	ONCOGENE			English	Article						polymorphisms; tyrosine phosphatase; thyroid; carcinoma; loss of heterozygosity	CARCINOMA CELL-LINES; ETA SUPPRESSES; CANCER CELLS; PROTEIN; EXPRESSION; GROWTH; INHIBITION; TUMORS; PROLIFERATION; DIMERIZATION	We recently isolated the r-PTPeta gene, which encodes a receptor-type tyrosine phosphatase protein that suppresses the neoplastic phenotype of retrovirally transformed rat thyroid cells. The human homologue gene PTPRJ/DEP-1 is deleted in various tumors. Moreover, the Gln276Pro polymorphism, located in the extracellular region of the gene, seems to play a critical role in susceptibility to some human neoplasias. Here we report the loss of heterozygosity ( LOH) of PTPRJ in 11/76 (14.5%) informative thyroid tumors ( including adenomas and carcinomas). We also looked for the Gln276Pro, Arg326Gln and Asp872Glu polymorphisms in exons 5, 6 and 13 of PTPRJ in 88 patients with thyroid tumors and in 54 healthy individuals. We found that the PTPRJ genotypes homozygous for the Gln276Pro and Arg326Gln polymorphisms, and the Asp872 allele were more frequent in thyroid carcinoma patients than in healthy individuals ( P = 0.032). In addition, PTPRJ LOH was more frequent in thyroid carcinomas of heterozygotes for Gln276Pro and Arg326Gln compared with homozygotes ( P = 0.006). This suggests that the presence of hemizygosity for these polymorphisms in the tumor facilitates tumor progression. These results indicate that the genotypic pro. le of PTPRJ affects susceptibility to thyroid carcinomas, and that allelic loss of this gene is involved in thyroid carcinogenesis.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulaire & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Pallante, Pierlorenzo/AAX-8758-2020; Chiariotti, Lorenzo/AAC-5262-2022	Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; ARTURI, Franco/0000-0002-1660-1228				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chiappetta G, 1998, CANCER RES, V58, P4193; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dumont JE, 2002, AM J PHYSIOL-CELL PH, V283, pC2, DOI 10.1152/ajpcell.00581.2001; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; Iuliano R, 2003, CANCER RES, V63, P882; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Keane MM, 1996, CANCER RES, V56, P4236; Kitamura Y, 2001, J CLIN ENDOCR METAB, V86, P4268, DOI 10.1210/jc.86.9.4268; Kovalerchuk B, 2000, IEEE ENG MED BIOL, V19, P26, DOI 10.1109/51.853479; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Martelli ML, 2000, EUR J ENDOCRINOL, V143, P515, DOI 10.1530/eje.0.1430515; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659	31	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8432	8438		10.1038/sj.onc.1207766	http://dx.doi.org/10.1038/sj.onc.1207766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378013				2022-12-28	WOS:000224870700003
J	Silva, CM				Silva, CM			Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis	ONCOGENE			English	Review						STAT5; STAT3; c-Src; breast cancer; tumorigenesis	GROWTH-FACTOR RECEPTOR; C-SRC; V-SRC; CONSTITUTIVE ACTIVATION; TRANSCRIPTIONAL CONTROL; TYROSINE KINASES; PATHWAYS; REQUIRES; PHOSPHORYLATION; TRANSFORMATION	The signal transducers and activators of transcription (STATs) were originally identified in the signaling pathway activated by the nontyrosine kinase containing cytokine receptors. The role of these STATs in hematopoietic cell signaling has been well described. In the case of cytokine receptors, activation of STAT tyrosine phosphorylation occurs through ligand-induced recruitment, and activation of the intracellular JAK kinases. However, STATs can also be activated by growth factor receptors, particularly the EGFR; as well as by members of the Src Family of Kinases (SFKs), particularly c-Src. In many cases, there is a differential activation of the STATs by these tyrosine kinases as compared to activation by the cytokine receptors. This difference provides for the potential of unique actions of STATs in response to growth factor receptor and SFK activation. Since there are many cancers in which SFKs and c-Src in particular, are co-overexpressed with growth factor receptors, it is not surprising that STATs play an important role in the tumorigenesis process induced by c-Src. The activation paradigm and role of STATs in these cancers, with particular emphasis on breast cancer models, is discussed.	Univ Virginia Hlth Syst, Ctr Canc, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Ctr Canc, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Silva, CM (corresponding author), Univ Virginia Hlth Syst, Ctr Canc, Dept Internal Med, Box 800578, Charlottesville, VA 22908 USA.	cms3e@virginia.edu		Silva, Corinne/0000-0002-3707-2919	NCI NIH HHS [CA085462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chin H, 1998, BLOOD, V91, P3734; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Guren TK, 2003, J CELL PHYSIOL, V196, P113, DOI 10.1002/jcp.10282; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; IHLE J, 2003, STATS ACTIVATION BIO, P559; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Laird AD, 2003, MOL CANCER THER, V2, P461; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Lund TC, 1999, J VIROL, V73, P1689, DOI 10.1128/JVI.73.2.1689-1694.1999; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; SAINSBURY J, 1987, J CLIN PATHOL, V38, P1225; SCHINDLER CW, 2003, STATS ACTIVATION BIO, P137; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; SILVA CM, 2003, SIGNAL TRANSDUCERS A, P223; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Xi SC, 2003, CANCER RES, V63, P6763; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Yu CL, 1997, J IMMUNOL, V159, P5206; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	45	313	331	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8017	8023		10.1038/sj.onc.1208159	http://dx.doi.org/10.1038/sj.onc.1208159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489919	Bronze			2022-12-28	WOS:000224558300012
J	Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E				Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E			Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters	ONCOGENE			English	Article						breast cancer; estrogen receptor alpha; nuclear insulin receptor substrate 1; insulin-like growth factor; estrogen-responsive elements	HUMAN BREAST-CANCER; FACTOR-I RECEPTOR; IRS-SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL-3-OH KINASE; CELL-LINE; T-ANTIGEN; IGF-I; GROWTH; EXPRESSION; TRANSLOCATION	Insulin receptor substrate 1 (IRS-1) is a major signaling molecule activated by the insulin and insulin-like growth factor I receptors. Recent data obtained in different cell models suggested that in addition to its conventional role as a cytoplasmic signal transducer, IRS-1 has a function in the nuclear compartment. However, the role of nuclear IRS-1 in breast cancer has never been addressed. Here we report that in estrogen receptor alpha (ERalpha)- positive MCF-7 cells, (1) a fraction of IRS-1 was translocated to the nucleus upon 17-beta-estradiol (E2) treatment; ( 2) E2-dependent nuclear translocation of IRS-1 was blocked with the antiestrogen ICI 182,780; ( 3) nuclear IRS-1 colocalized and co-precipitated with ERalpha; (4) the IRS-1: ERalpha complex was recruited to the E2-sensitive pS2 gene promoter. Notably, IRS-1 interaction with the pS2 promoter did not occur in ERalpha-negative MDA-MB-231 cells, but was observed in MDA-MB-231 cells retransfected with ERalpha. Transcription reporter assays with E2-sensitive promoters suggested that the presence of IRS-1 inhibits ERalpha activity at estrogen-responsive element-containing DNA. In summary, our data suggested that nuclear IRS-1 interacts with ERalpha and that this interaction might influence ERalpha transcriptional activity.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada; Univ Palermo, Dept Oncol, Sect Mol Oncol, Palermo, Italy; Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO 65212 USA	Jefferson University; University of Calabria; Lady Davis Institute; McGill University; University of Palermo; University of Missouri System; University of Missouri Columbia	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@jefferson.edu	Garofalo, Cecilia/B-3834-2017; /AAD-9701-2019; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; /0000-0001-6577-1541; Morelli, Catia/0000-0002-9407-0805; Cascio, Sandra/0000-0003-4234-0508; Vecchione, Andrea/0000-0002-5497-6856	NATIONAL CANCER INSTITUTE [R21CA087391] Funding Source: NIH RePORTER; NCI NIH HHS [CA87391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; Bartucci M, 2001, CANCER RES, V61, P6747; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Guvakova MA, 1997, CANCER RES, V57, P2606; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Sciacca L, 2003, ENDOCRINOLOGY, V144, P2650, DOI 10.1210/en.2002-0136; Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun M, 2001, CANCER RES, V61, P5985; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Vladusic EA, 2000, ONCOL REP, V7, P157; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	34	75	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7517	7526		10.1038/sj.onc.1208014	http://dx.doi.org/10.1038/sj.onc.1208014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15318176				2022-12-28	WOS:000224176500008
J	Ku, JL; Kang, SB; Shin, YK; Kang, HC; Hong, SH; Kim, IJ; Shin, JH; Han, IO; Park, JG				Ku, JL; Kang, SB; Shin, YK; Kang, HC; Hong, SH; Kim, IJ; Shin, JH; Han, IO; Park, JG			Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines	ONCOGENE			English	Article						RUNX3; promoter; hypermethylation colorectal cancer	5'-CPG ISLAND METHYLATION; DNA METHYLATION; CHROMOSOME 1P; ALLELIC LOSS; DELETIONS; ESTABLISHMENT; MUTATIONS; GROWTH; LUNG; FHIT	It was recently reported that RUNX3 gene expression is significantly downregulated in human gastric cancer cells due to hypermethylation of its promoter region or hemizygous deletion ( Cell, 109, 2002). To verify the genetic alterations and methylation status of the RUNX3 gene in colorectal carcinogenesis, we analysed for mutations, loss of heterozygosity (LOH), and RUNX3 gene promoter hypermethylation, in 32 colorectal cancer cell lines. RT-PCR analysis showed undetectable or low RUNX3 expression in 16 cell lines, and no mutations were found in the RUNX3 gene by PCR-SSCP analysis. Of these 16 cell lines, hypermethylation of the RUNX3 promoter was confirmed in 12. The following observations were made: (i) RUNX3 was re-expressed after 5-aza-2'-deoxycytidine treatment, (ii) the RUNX3 promoter was found to be methylated by MS-PCR, and (iii) hypermethylation of the RUNX3 promoter was confirmed by direct sequencing analysis after sodium bisulfite modification in the above 12 cell lines. RUNX3 was neither methylated nor expressed in four cell lines. Of these four, microsatellite instability (MSI) at the RUNX3 locus was found in three, SNU-61 (D1S246), SNU-769A, and SNU-769B (D1S199). This study suggests that transcriptional repression of RUNX3 is caused by promoter hypermethylation of the RUNX3 CpG island in colorectal cancer cell lines, and the results of these experiments may contribute to an understanding of the role of RUNX3 inactivation in the pathogenesis of colorectal cancers.	Seoul Natl Univ, Coll Med, Canc Res Inst, Cell Biol Lab, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Korean Cell Line Bank, Seoul 110744, South Korea; Natl Canc Ctr, Res Inst & Hosp, Goyang 411764, Gyeonggi, South Korea	Seoul National University (SNU); Seoul National University (SNU); National Cancer Center - Korea (NCC)	Park, JG (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Cell Biol Lab, 28 Yongon Dong, Seoul 110744, South Korea.	jgpark@plaza.snu.ac.kr	Ku, Ja-Lok/D-5736-2012; Kang, Sung-Bum/J-5361-2012; Park, Jae-Gahb/J-5494-2012; Shin, Joo-Ho/P-1417-2018					Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Di Vinci A, 1998, INT J CANCER, V75, P45, DOI 10.1002/(SICI)1097-0215(19980105)75:1<45::AID-IJC8>3.3.CO;2-0; Di Vinci A, 1998, CANCER-AM CANCER SOC, V83, P415; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Ezaki T, 1996, BRIT J CANCER, V73, P424, DOI 10.1038/bjc.1996.76; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Ku JL, 2002, BRIT J CANCER, V87, P187, DOI 10.1038/sj.bjc.6600440; Ku JL, 1999, EUR J CANCER, V35, P1724, DOI 10.1016/S0959-8049(99)00206-3; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Melki JR, 2000, BLOOD, V95, P3208; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Oh JH, 1999, INT J CANCER, V81, P902, DOI 10.1002/(SICI)1097-0215(19990611)81:6<902::AID-IJC11>3.0.CO;2-T; PARK JG, 1987, CANCER RES, V47, P6710; Paz MF, 2003, CANCER RES, V63, P1114; PRAML C, 1995, ONCOGENE, V11, P1357; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Song SH, 2001, CANCER RES, V61, P4628; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; TANAKA K, 1993, ONCOGENE, V8, P2253; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Yang QF, 2002, CLIN CANCER RES, V8, P2890; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	29	98	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6736	6742		10.1038/sj.onc.1207731	http://dx.doi.org/10.1038/sj.onc.1207731			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273736				2022-12-28	WOS:000223653600005
J	Soulie, P; Carrozzino, F; Pepper, MS; Strongin, AY; Poupon, MF; Montesano, R				Soulie, P; Carrozzino, F; Pepper, MS; Strongin, AY; Poupon, MF; Montesano, R			Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells	ONCOGENE			English	Article						carcinogenesis; invasion; proteolysis; MDCK; MMP	ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CANINE KIDNEY; TUMOR-CELLS; MT1-MMP EXPRESSION; CARCINOMA-CELLS; TRANSGENIC MICE; UP-REGULATION; MIGRATION; ACTIVATION	Overexpression of membrane-type-1 matrix metalloproteinase (MT1-MMP) in tumor cells has previously been shown to enhance tumor growth and metastasis. To establish if MT1-MMP is also able to confer tumorigenicity on nonmalignant epithelial cells, we transfected human MT1-MMP cDNA into Madin-Darby canine kidney (MDCK) cells expressing a tetracycline-repressible transactivator. Induction of MT1-MMP in the absence of doxycycline (Dox) was associated with activation of exogenous MMP-2 as well as with formation of large cysts and increased invasiveness in collagen matrices. Transfected cells were inoculated subcutaneously into two groups of nude mice, one of which received Dox to inhibit expression of MT1-MMP. Formation of tumor xenografts was observed in 11 of 17 mice maintained without Dox, but only in two of nine mice that received Dox ( P<0.05). The xenografts were composed of tubular structures interspersed within a highly cellular stroma. The epithelial cells delimiting the lumen were polarized, as indicated by the basolateral distribution of Na, K-ATPase. Despite their differentiated appearance, the tumors lacked a well-defined boundary, and epithelial tubules invaded adjacent muscular layers. These results demonstrate that conditional expression of MT1-MMP in nonmalignant MDCK epithelial cells is by itself sufficient to drive formation of invasive tumors.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Inst Curie, Sect Rech, F-75248 Paris, France	University of Geneva; Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Montesano, R (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	Roberto.Montesano@medecine.unige.ch	Pepper, Michael S./M-6143-2014; Montesano, Roberto/AAV-3192-2020; Strongin, Alex/R-6609-2019	Pepper, Michael S./0000-0001-6406-2380; Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BOERNER P, 1985, J CELL PHYSL, V122, P299; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Dunbar LA, 2001, J BIOL CHEM, V276, P29617, DOI 10.1074/jbc.R100023200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ha HY, 2001, CANCER RES, V61, P984; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Kadono Y, 1998, CANCER RES, V58, P2240; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTESANO R, 1993, J CELL SCI, V105, P1013; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; RABITO CA, 1978, J MEMBRANE BIOL, V43, P351, DOI 10.1007/BF01871696; Reno F, 2004, BIOMATERIALS, V25, P3439, DOI 10.1016/j.biomaterials.2003.10.047; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schenk S, 2003, TRENDS CELL BIOL, V13, P366, DOI 10.1016/S0962-8924(03)00129-6; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STILES CD, 1976, CANCER RES, V36, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Udayakumar TS, 2003, CANCER RES, V63, P2292; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	51	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1689	1697		10.1038/sj.onc.1208360	http://dx.doi.org/10.1038/sj.onc.1208360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608664				2022-12-28	WOS:000227345100005
J	Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM				Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM			An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis	ONCOGENE			English	Article						arachidonic acid; lipoxygenase; keratinocytes; differentiation; skin cancer	ARACHIDONIC-ACID METABOLISM; ACTIVATED RECEPTOR-ALPHA; ORNITHINE-DECARBOXYLASE ACTIVITY; PROTEIN-KINASE-C; MOUSE SKIN; TUMOR PROMOTION; KERATINOCYTE DIFFERENTIATION; INDUCE APOPTOSIS; CANCER-CELLS; IN-VIVO	The levels of 8S-lipoxygenase ( 8S-LOX) expression and of its arachidonic acid metabolite, 8-hydroxyeicosatetraenoic acid (8-HETE), are highly elevated in the early stages of mouse skin carcinogenesis. On the other hand, several reports showing that 8-HETE is also closely associated with keratinocyte differentiation raise a question concerning the role of 8S-LOX/8-HETE in skin carcinogenesis. To address that question, here we conducted a series of gain-of-function studies. Skin targeted loricrin 8S-LOX/C57BL/6J transgenic mice showed a more differentiated epidermal phenotype as well as a 64% reduced papilloma development in a two-stage skin carcinogenesis protocol. Forced expression of 8S-LOX in MT1/2 cells, a murine papilloma cell line, also caused a more differentiated appearance as well as keratin 1 expression. Overexpression of 8S-LOX in CH72 cells, a murine carcinoma cell line, inhibited cell proliferation by 30% in vitro and by 86% in in vivo xenografts. Exogenous addition of 5 muM 8-HETE to CH72 cells caused cell cycle arrest at the G1 phase. Finally, immunohistochemical analyses showed 8S-LOX protein expression was strictly confined to the differentiated compartment of mouse skin and throughout tumorigenesis. Collectively, these data suggest that 8S-LOX plays a role as a prodifferentiating, antitumorigenic, and tumor suppressing gene in mouse skin carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Pharmaceut Dev Ctr, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	smfischer@mdanderson.org	Benavides, Fernando/E-7872-2011; Rundhaug, Joyce E/E-9114-2011	Rundhaug, Joyce E/0000-0002-2481-6317; Benavides, Fernando/0000-0003-1275-4320	NATIONAL CANCER INSTITUTE [R01CA083794, R01CA100140, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA83794, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Burger F, 1999, MOL CARCINOGEN, V24, P108, DOI 10.1002/(SICI)1098-2744(199902)24:2<108::AID-MC5>3.0.CO;2-R; CONTI CJ, 1988, CANCER RES, V48, P435; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DuBois RN, 2003, JNCI-J NATL CANCER I, V95, P1028, DOI 10.1093/jnci/95.14.1028; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1982, CARCINOGENESIS, V3, P1243, DOI 10.1093/carcin/3.11.1243; FISCHER SM, 1987, CANCER RES, V47, P3174; Fischer SM, 2004, LIPOXYGENASES TARGET; Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; Guo YJ, 1999, MOL CARCINOGEN, V26, P32, DOI 10.1002/(SICI)1098-2744(199909)26:1<32::AID-MC4>3.3.CO;2-5; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Mahe YF, 1998, INT J DERMATOL, V37, P416, DOI 10.1046/j.1365-4362.1998.00514.x; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; Nair J, 2000, CHEM RES TOXICOL, V13, P703, DOI 10.1021/tx000045d; NAITO M, 1989, GENETIC BACKGROUND D; NAKADATE T, 1982, CARCINOGENESIS, V3, P1411, DOI 10.1093/carcin/3.12.1411; NELSON KG, 1982, CANCER RES, V42, P4176; Nie D, 1998, CANCER RES, V58, P4047; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Prigge ST, 1997, BIOCHIMIE, V79, P629, DOI 10.1016/S0300-9084(97)83495-5; Ruckert R, 2000, BRIT J DERMATOL, V143, P1036, DOI 10.1046/j.1365-2133.2000.03784.x; RUZICKA T, 1984, REV PHYSIOL BIOCH P, V100, P121; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Shureiqi I, 2001, CANCER RES, V61, P4879; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SLAGA TJ, 1984, MECH INVOLVED 2 STAG; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; Steele VE, 1999, CANCER EPIDEM BIOMAR, V8, P467; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; TANG DG, 1994, ANN NY ACAD SCI, V744, P199, DOI 10.1111/j.1749-6632.1994.tb52738.x; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; TOFTGARD R, 1985, CANCER RES, V45, P5845; VERMA AK, 1980, CANCER RES, V40, P308; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; YUSPA SH, 1985, CELLULAR MOL CHANGES; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	61	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1174	1187		10.1038/sj.onc.1208269	http://dx.doi.org/10.1038/sj.onc.1208269			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558016				2022-12-28	WOS:000226898700005
J	Dell'Era, P; Nicoli, S; Peri, G; Nieddu, M; Ennas, MG; Presta, M				Dell'Era, P; Nicoli, S; Peri, G; Nieddu, M; Ennas, MG; Presta, M			FGF2-induced upregulation of DNA polymerase-delta p12 subunit in endothelial cells	ONCOGENE			English	Article						FGF2; DNA polymerase; endothelium; angiogenesis	FIBROBLAST-GROWTH-FACTOR; REPLICATION FORK; GENE-EXPRESSION; TUMOR ANGIOGENESIS; SURFACE EXPRESSION; IN-VITRO; IDENTIFICATION; RECONSTITUTION; MECHANISMS; ALPHA	p12 represents the smallest, so far poorly characterized subunit of the mammalian DNA polymerase delta (poldelta) heterotetramer. Previously, to gain a molecular understanding of endothelial cell activation by fibroblast growth factor-2 (FGF2), we identified an upregulated transcript in FGF2-overexpressing murine aortic endothelial cells (FGF2-T-MAE cells) showing 89% identity with human p12. Here, we cloned the open reading frame of the murine p12 cDNA and confirmed the capacity of overexpressed or exogenously added FGF2 to upregulate p12 mRNA and protein in endothelial and NIH3T3 cells with no effect on the other pold subunits. p12 expression was instead unaffected by serum and different mitogens. Also, anti-p12 antibodies decorated FGF2-T-MAE cell nuclei and their chromosome outline during metaphase. Small interfering RNA-mediated knockdown of p12 caused a significant decrease in FGF2-driven proliferation rate of FGF2-T-MAE cells, in keeping with a modulatory role of p12 in pold activity. Immunoistochemistry of FGF2-embedded Matrigel plugs and FGF2-overexpressing tumor xenografts demonstrated a nuclear p12 staining of angiogenic CD31(+) endothelium. p12 immunoreactivity was also observed in the CD45(+)/ CD11b(+) inflammatory infiltrate. Thus, FGF2 upregulates p12 expression in endothelial cells in vitro and in vivo. p12 expression in infiltrating inflammatory cells may suggest additional, cell proliferation-unrelated functions for this pold subunit.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; IRFMN Mario Negri, Milan, Italy; Univ Cagliari, Dept Sci Appl Biosyst, Unit Biol & Genet, Cagliari, Italy; Univ Cagliari, Dept Cytomorphol, Cagliari, Italy	University of Brescia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Cagliari; University of Cagliari	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	presta@med.unibs.it	Dell'Era, Patrizia/ABD-5848-2020; Nicoli, Stefania/P-8627-2019; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; Nieddu, Mariella/0000-0001-8595-7001; PRESTA, Marco/0000-0002-4398-8376; Ennas, Maria Grazia/0000-0002-9448-715X				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dell'Era P, 2002, ONCOGENE, V21, P2433, DOI 10.1038/sj.onc.1205301; Dell'Era P, 2001, ONCOGENE, V20, P2655, DOI 10.1038/sj.onc.1204368; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giavazzi R, 2001, CANCER RES, V61, P309; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Ohsaka A, 2001, INFLAMM RES, V50, P270, DOI 10.1007/s000110050753; PASSANITI A, 1992, LAB INVEST, V67, P519; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; St Croix B, 2000, SCIENCE, V289, P1197; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Takagi S, 2000, ACTA HAEMATOL-BASEL, V103, P78, DOI 10.1159/000041024; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang JL, 2000, MICROVASC RES, V59, P394, DOI 10.1006/mvre.2000.2242; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027	32	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1117	1121		10.1038/sj.onc.1208359	http://dx.doi.org/10.1038/sj.onc.1208359			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15608665				2022-12-28	WOS:000226749200019
J	Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I				Baldus, SE; Schwarz, E; Lohrey, C; Zapatka, M; Landsberg, S; Hahn, SA; Schmidt, D; Dienes, HP; Schmiegel, WH; Schwarte-Waldhoff, I			Smad4 deffiency in cervical carcinoma cells	ONCOGENE			English	Article						tumor suppressor gene; TGF-beta; multistep carcinogenesis; CIN lesion	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; UTERINE CERVIX; PAPILLOMAVIRUS INFECTIONS; INTRAEPITHELIAL NEOPLASIA; GENOMIC INSTABILITY; COLORECTAL-CANCER; DPC4 INACTIVATION; TGF-BETA; EXPRESSION	Squamous cell carcinoma of the uterine cervix is one of the most frequent cancers affecting women worldwide. Carcinomas arise from cervical intraepithelial lesions, in which infection with high-risk human papillomavirus types has led to deregulated growth control through the actions of the viral E6 and E7 oncoproteins. The molecular mechanisms underlying progression to invasive tumor growth are poorly understood. One important feature, however, is the escape from growth inhibition by transforming growth factor beta (TGF-beta). Loss of chromosomal arm 18q is among the most frequent cytogenetic alterations in cervical cancers and has been associated with poor prognosis. Since the TGF-beta response is mediated by Smad proteins and the tumor suppressor gene Smad4 resides at 18q21, we have analysed the Smad4 gene for cervical cancer-associated alterations in cell lines and primary carcinomas. Here, we report Smad4 deficiency in four out of 13 cervical cancer cell lines which is due to an intronic rearrangement or deletions of 30 exons. All cell lines, however, showed either absent or moderate responsiveness to TGF-beta irrespective of their Smad4 status. In 41 primary squamous cervical carcinomas analysed, 10 samples showed loss of Smad4 protein expression and 26 samples a reduced expression. Altogether, our results strongly suggest that Smad4 gene alterations are involved in cervical carcinogenesis.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, D-44892 Bochum, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany; Inst Pathol, D-68159 Mannheim, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, D-44892 Bochum, Germany	Ruhr University Bochum; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, IMBL,Dept Internal Med, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013; Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Zapatka, Marc/0000-0001-8287-5967; Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				AUERSPERG N, 1989, CANCER RES, V49, P3007; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Chu TY, 1999, INT J CANCER, V80, P506, DOI 10.1002/(SICI)1097-0215(19990209)80:4<506::AID-IJC4>3.3.CO;2-5; Dellas A, 1999, CANCER RES, V59, P3475; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Einstein MH, 2002, CLIN CANCER RES, V8, P549; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Harima Y, 2001, INT J CANCER, V96, P286, DOI 10.1002/ijc.1027; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Kang SH, 1998, INT J CANCER, V77, P620, DOI 10.1002/(SICI)1097-0215(19980812)77:4<620::AID-IJC23>3.3.CO;2-5; Kersemaekers AMF, 1998, INT J CANCER, V79, P411, DOI 10.1002/(SICI)1097-0215(19980821)79:4<411::AID-IJC17>3.0.CO;2-7; Kersemaekers AMF, 1998, BRIT J CANCER, V77, P192, DOI 10.1038/bjc.1998.33; Klaes R, 1999, CANCER RES, V59, P6132; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee SH, 2001, INT J CANCER, V94, P500, DOI 10.1002/ijc.1494; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Maliekal TT, 2003, ONCOGENE, V22, P4889, DOI 10.1038/sj.onc.1206806; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Minami R, 1998, BBA-GENE STRUCT EXPR, V1443, P182, DOI 10.1016/S0167-4781(98)00217-6; MITRA AB, 1994, CANCER RES, V54, P4481; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Muliokandov MR, 1996, CANCER RES, V56, P197; Rader JS, 1996, ONCOGENE, V13, P2737; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Reyes G, 1996, CANCER RES, V56, P5713; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Slebos RJC, 1998, CANCER RES, V58, P5333; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 2000, CANCER RES, V60, P2002; Zhou Y, 1999, MOL CARCINOGEN, V25, P64, DOI 10.1002/(SICI)1098-2744(199905)25:1<64::AID-MC8>3.0.CO;2-Z; ZURHAUSEN H, 1995, INT J CANCER, V63, P315; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	44	26	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					810	819		10.1038/sj.onc.1208235	http://dx.doi.org/10.1038/sj.onc.1208235			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531914				2022-12-28	WOS:000226577100007
J	Kim, TH; Xiong, H; Zhang, ZH; Ren, B				Kim, TH; Xiong, H; Zhang, ZH; Ren, B			beta-Catenin activates the growth factor endothelin-1 in colon cancer cells	ONCOGENE			English	Article						beta-catenin; endothelin-1; colon cancer; ChIP; promoter arrays	C-MYC; COLORECTAL-CANCER; CARCINOMA-CELLS; EMERGING ROLE; A RECEPTOR; APC; IDENTIFICATION; INHIBITION; APOPTOSIS; LITHIUM	Endothelin-1 (EDN1) is a growth factor that is frequently produced by cancer cells and plays a critical role in tumorigenesis. However, the molecular mechanism controlling the expression of EDN1 in cancers is unknown. Constitutive activation of beta-catenin pathway is responsible for the initiation of the vast majority of colon cancers. Here we show that the EDN1 gene is directly regulated by beta-catenin in colon cancer cells. A specific DNA element within the EDN1 promoter is required for activation, and is associated with beta-catenin's cognate DNA binding partner, TCF4, in vivo. Inhibition of beta-catenin signaling results in lowered expression of EDN1, while enhancement of beta-catenin signaling leads to further activation of the gene. Significantly elevated EDN1 expression occurs in 80% of primary human colon cancers, consistent with it being a direct target of beta-catenin. Furthermore, EDN1 is able to rescue colon cancer cells from growth arrest and apoptosis resulting from inhibition of beta-catenin signaling, implicating a key role of EDN1 in promoting the oncogenic function of beta-catenin. These results indicate EDN1 overexpression as a major cause in colon cancers and reveal further details of the genetic programs responsible for tumorigenesis of colon cancers.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, La Jolla, CA 92093 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Zhang, ZH (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Lab Gene Regulat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	benzz@burnham.org; biren@ucsd.edu		Kim, Tae Hoon/0000-0003-3950-7557	NCI NIH HHS [F32 CA108313, 1F32CA108313] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA108313] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bagnato A, 2002, CANCER RES, V62, P6381; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Cohen MM, 2003, AM J MED GENET A, V122A, P303, DOI 10.1002/ajmg.a.20473; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Eberl LP, 2003, BRIT J CANCER, V88, P788, DOI 10.1038/sj.bjc.6600810; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534-5807(03)00165-5; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KUSUHARA M, 1990, CANCER RES, V50, P3257; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2003, J UROLOGY, V170, pS65, DOI 10.1097/01.ju.0000096372.07687.86; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosano L, 2003, CANCER RES, V63, P2447; Sellers WR, 2003, J UROLOGY, V170, pS67; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100	36	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					597	604		10.1038/sj.onc.1208237	http://dx.doi.org/10.1038/sj.onc.1208237			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15558022				2022-12-28	WOS:000226420400007
J	Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I				Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I			Prediction of high risk Ewing's sarcoma by gene expression profiling	ONCOGENE			English	Article						Ewing's sarcoma; high risk; gene expression signature; prediction; prognosis	METASTASIS-ASSOCIATED GENE; HUMAN MTA1 GENE; BREAST-CANCER; CADHERIN EXPRESSION; CELL-LINES; TUMORS; INVASION; DIFFERENTIATION; OVEREXPRESSION; CLASSIFICATION	Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.	Schneider Childrens Med Ctr Israel, Mol Oncol Lab, IL-49202 Petah Tiqwa, Israel; Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Serv, DNA Array Unit, IL-76100 Rehovot, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Avigad, S (corresponding author), Schneider Childrens Med Ctr Israel, Mol Oncol Lab, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.	savigad@post.tau.ac.il	Cohen, Ian/H-3358-2013					Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fouts RL, 2003, CANCER-AM CANCER SOC, V97, P1447, DOI 10.1002/cncr.11201; GINSBERG JP, 2002, PRINCIPLES PRACTICE, P973; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Iguchi H, 2000, INT J ONCOL, V16, P1211; Im YH, 2000, CANCER RES, V60, P1536; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Markus MA, 1999, J PATHOL, V187, P164, DOI 10.1002/(SICI)1096-9896(199901)187:2<164::AID-PATH208>3.0.CO;2-3; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; NAWA A, 2000, INT J MED BIOL ENV, V28, P33; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619; Pishvaian MJ, 1999, CANCER RES, V59, P947; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schulz S, 2000, J PATHOL, V191, P162; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; Shing DC, 2003, CANCER RES, V63, P4568; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	36	76	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8997	9006		10.1038/sj.onc.1208060	http://dx.doi.org/10.1038/sj.onc.1208060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467746				2022-12-28	WOS:000225354600016
J	Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A				Hartman, J; Muller, P; Foster, JS; Wimalasena, J; Gustafsson, JA; Strom, A			HES-1 inhibits 17 beta-estradiol and heregulin-beta 1-mediated upregulation of E2F-1	ONCOGENE			English	Article						all-trans retinoic acid; cell cycle; T47D; HES-6; HERP; NPAT; cyclin E	BREAST-CANCER CELLS; TRANSCRIPTION FACTOR E2F1; TRANS-RETINOIC ACID; CYCLE PROGRESSION; ESTROGEN-RECEPTOR; S-PHASE; EXPRESSION; GENE; DIFFERENTIATION; PROLIFERATION	We have previously shown that expression of the transcription factor HES-1 is required for the growth-inhibitory effect of all-trans retinoic acid on MCF-7 cells. In this study, we have used T47D cells with tetracyclin-regulated expression of wild-type or a dominant-negative form of HES-1. Expression of HES-1 in T47D cells inhibited G(1)/S-phase transition and activation of Cdk2 elicited by estrogen. Estrogen treatment of T47D cells caused increased expression of E2F-1, and this expression was inhibited by cotreatment with all-trans retinoic acid. We show that the effect is mediated through HES-1, which directly downregulates E2F-1 expression through a CACGAG-site within the E2F-1 promoter. Furthermore, proliferation caused by heregulin-beta1 treatment of T47D cells was inhibited by all-trans retinoic acid and this effect was mediated by HES-1. Interestingly, heregulin-beta1-mediated upregulation of E2F-1 expression was directly inhibited by HES-1 through the same CACGAG-site as seen with estrogen-stimulated induction. In addition, we found that two important downstream target genes of estrogen and heregulin-beta1 that are regulated through E2F-1, cyclin E and NPAT, were both regulated in a similar fashion by all-trans retinoic acid, and these effects were antagonized by dominant-negative HES-1. These findings establish that HES-1 inhibits both estrogen- and heregulin-beta1-stimulated growth of breast cancer cells, and further suggest that growth inhibition induced in these cells by all-trans retinoic acid occurs via HES-1-mediated downregulation of E2F-1 expression.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Univ Tennessee, Med Ctr, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN 37920 USA; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; University of Tennessee System; University of Tennessee Health Science Center; Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anders.strom@biosci.ki.se	Hartman, Johan/N-1406-2015	Hartman, Johan/0000-0002-6500-8527				Bae SK, 2000, DEVELOPMENT, V127, P2933; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Gao G, 2003, MOL CELL BIOL, V23, P2821, DOI 10.1128/MCB.23.8.2821-2833.2003; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTE BM, 1995, ONCOGENE, V10, P167; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muller P, 2002, J BIOL CHEM, V277, P28376, DOI 10.1074/jbc.C200340200; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Strom A, 2000, ONCOGENE, V19, P5951, DOI 10.1038/sj.onc.1203990; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tang CK, 1996, CANCER RES, V56, P3350; TSUTSUI T, 1987, CARCINOGENESIS, V8, P1715, DOI 10.1093/carcin/8.11.1715; Wang Q, 2000, CANCER RES, V60, P2040; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	35	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8826	8833		10.1038/sj.onc.1208139	http://dx.doi.org/10.1038/sj.onc.1208139			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467735				2022-12-28	WOS:000225165100012
J	Shi, SL; Noda, M; Kitayama, H				Shi, SL; Noda, M; Kitayama, H			Rap1 mutants with increased affinity for the guanine-nucleotide exchange factor C3G	ONCOGENE			English	Article						Rap1; C3G; dominant inhibitory mutant; random mutagenesis	SIGNAL-TRANSDUCTION; MAP KINASE; RAS; PROTEIN; ACTIVATION; GENE; GTPASE; CRK; ASSOCIATION; ADHESION	The mutant of Ras protein with serine to asparagine mutation at residue 17 (Ras-17N) is known to interfere with the signaling function of the wild-type Ras protein by sequestering its guanine-nucleotide exchange factors ( GEFs). The similar mutant of another Ras family protein Rap1 (Rap1-17N) fails to effectively interfere with the interaction between the wild-type Rap1 and one of its GEFs, C3G, in vitro. In the present study, we have attempted to isolate Rap1 mutants with increased affinity for C3G using random mutagenesis and yeast two-hybrid screening. Based on the pattern of mutations found among these mutants, we could design a potent C3G-binder, named Rap1-AGE, harboring mutations in three sites (17A, 29G, and 117E). The association of Rap1-AGE with C3G in the cells was confirmed by co-immunoprecipitation experiments. The ability of Rap1-AGE to inhibit C3G-mediated Rap1-activation and cell spreading was also demonstrated. On the other hand, Rap1 activation mediated by two other GEFs, Epac and smgGDS, was not inhibited by Rap1-AGE. These results suggest that Rap1-AGE acts as a dominant interfering factor against C3G and serves as a useful tool in analyzing the roles of C3G-Rap1 signaling pathway in various biological processes.	Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Kitayama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	hkitayam@virus.kyoto-u.ac.jp						BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CHEN SY, 1994, ONCOGENE, V9, P2691; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Imamura Y, 2004, NEUROSCIENCE, V127, P973, DOI 10.1016/j.neuroscience.2004.05.051; Imamura Y, 2003, NEUROREPORT, V14, P1203, DOI 10.1097/00001756-200307010-00003; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	48	5	5	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8711	8719		10.1038/sj.onc.1208132	http://dx.doi.org/10.1038/sj.onc.1208132			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480424	Green Submitted			2022-12-28	WOS:000225165100001
J	Baum, B; Craig, G				Baum, B; Craig, G			RNAi in a postmodern, postgenomic era	ONCOGENE			English	Article						functional genomics; RNAi; cell culture; post-modernism	DROSOPHILA CULTURED-CELLS; IDENTIFICATION; INTERFERENCE; GENOME; COMPONENTS; PROTEINS; PATHWAY; SCREEN	As dsRNA-mediated interference (RNAi) libraries become more widely available, genome-wide loss of function experiments in cell culture are likely to become a routine laboratory tool. RNAi screens can then be conducted to test gene functions in different assays in a variety of cell types and across species. In comparing these large phenotypic data sets, researchers will gain a new perspective, enabling them to see each gene as part of a fluid network that is remodelled in response to changes in environmental and developmental context, and with the passage of evolutionary time.	Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Baum, B (corresponding author), Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England.	buzz@ludwig.ucl.ac.uk		Baum, Buzz/0000-0002-9201-6186				Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chou TB, 1996, GENETICS, V144, P1673; Forler D, 2003, NAT BIOTECHNOL, V21, P89, DOI 10.1038/nbt773; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grosshans H, 2002, J CELL BIOL, V156, P17, DOI 10.1083/jcb.200111033; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Karim FD, 1996, GENETICS, V143, P315; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Stowers RS, 1999, GENETICS, V152, P1631; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982	21	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8336	8339		10.1038/sj.onc.1208009	http://dx.doi.org/10.1038/sj.onc.1208009			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517013				2022-12-28	WOS:000224815900002
J	Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM				Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM			Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth	ONCOGENE			English	Article						GSK-3; beta-catenin; androgen receptor; prostate cancer	ADENOMATOUS POLYPOSIS-COLI; SMALL-MOLECULE INHIBITORS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVITY; NEGATIVE REGULATOR; SIGNALING PATHWAY; GENE-EXPRESSION; AXIN; PHOSPHORYLATION; COMPLEX	The transcriptional activity of the androgen receptor (AR) is regulated by interaction with various coregulators, one of which is beta-catenin., Interest in the role of beta-catenin in prostate cancer has been stimulated by reports showing that it is aberrantly expressed in the cytoplasm and/or nucleus in up to 38% of hormone-refractory tumours and that overexpression of beta-catenin results in activation of AR transcriptional activity. We have examined the effect of depleting endogenous beta-catenin on AR activity using Axin and RNA interference. Axin, which promotes beta-catenin degradation, inhibited AR transcriptional activity. However, this did not require the beta-catenin-binding domain of Axin. Depletion of beta-catenin using RNA interference increased, rather than decreased, AR activity, suggesting that endogenous beta-catenin is not a transcriptional coactivator for the AR. The glycogen synthase kinase-3 (GSK-3)-binding domain of Axin prevented formation of a GSK-3-AR complex and was both necessary and sufficient for inhibition of AR-dependent transcription. A second GSK-3-binding protein, FRAT, also inhibited AR transcriptional activity, as did the GSK-3 inhibitors SB216763 and SB415286. Finally, inhibition of GSK-3 reduced the growth of AR-expressing prostate cancer cell lines. Our observations suggest a potential new therapeutic application for GSK-3 inhibitors in prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England	Imperial College London	Kypta, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England.	r.kypta@imperial.ac.uk	Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X				Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cronauer MV, 2003, INT J ONCOL, V23, P1095; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Giannini AL, 2000, J BIOL CHEM, V275, P21883, DOI 10.1074/jbc.M001929200; Gregory CW, 2001, CANCER RES, V61, P2892; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Truica CI, 2000, CANCER RES, V60, P4709; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; WOODGETT JR, 2001, SCI STKE, pRE12; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	42	100	113	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7882	7892		10.1038/sj.onc.1208068	http://dx.doi.org/10.1038/sj.onc.1208068			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361837				2022-12-28	WOS:000224331600014
J	Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB				Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB			Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein	ONCOGENE			English	Article						cancer gene therapy; GST-MDA-7/IL-24; apoptosis; breast cancer; radiotherapy	DIFFERENTIATION-ASSOCIATED GENE; APOPTOSIS INDUCING CYTOKINE; GLUTATHIONE-S-TRANSFERASE; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 IL-24; SUPPRESSOR GENE; IN-VITRO; GROWTH; PATHWAYS	The human mda-7/IL-24 gene product is normally expressed in melanocytes and certain lymphocyte populations. Loss of expression, a distinctive feature of many tumor suppressor genes, has been documented at RNA and protein levels in association with melanoma progression both in vitro as well as in human tumor-derived material. The MDA-7/IL-24 protein undergoes post-translational processing, including removal of an amino-terminal 48-residue signal peptide and extensive glycosylation prior to its secretion by producing cells. Its inherent cytokine properties have been documented in multiple reports, which have identified and characterized its cognate receptors and activation of the JAK/STAT signaling pathway following ligand/receptor docking. A notable and incompletely understood property of MDA-7/IL-24 is its ability to induce apoptosis in transformed cells, while having marginal growth suppressive effects on normal primary or immortalized cell lines. MDA-7/IL-24 has been delivered to cells, tumor xenografts and patients in clinical trials via a nonreplicating adenovirus (Ad.mda-7). Studies utilizing eukaryotically expressed and purified MDA-7/ IL-24 protein from several sources have recapitulated some of the molecule's reported properties including receptor binding and JAK/STAT activation. Here, we report the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein. These studies reveal that GST-MDA-7 retains its cancer-selective apoptosis-inducing properties, thereby providing a new reagent that will assist in de. ning the mechanism of action of this novel cytokine. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.	Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Urol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA	Columbia University; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 16th St, New York, NY 10027 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA097318, R01CA088906, R01CA098172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA097318, CA098172, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2001, CANCER GENE THER, V8, pS3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lorenz M, 2000, EUR J CANCER, V36, P957, DOI 10.1016/S0959-8049(00)00073-3; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Namiki S, 2003, BIOCHEM BIOPH RES CO, V305, P592, DOI 10.1016/S0006-291X(03)00807-6; NEMUNITAIS J, 2003, CANCER GENE THER, V10, pS106; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2003, CANCER RES, V63, P5105; Regine William F., 1998, Frontiers in Bioscience, V3, pE186; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, MOL CANCER THER, V2, P623; YACOUB A, 2004, IN PRESS CANC BIOL T; Zhan Y, 2001, GENE, V281, P1, DOI 10.1016/S0378-1119(01)00797-1	46	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7679	7690		10.1038/sj.onc.1207958	http://dx.doi.org/10.1038/sj.onc.1207958			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334067				2022-12-28	WOS:000224306700009
J	Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J				Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J			Mutation of TCF1 encoding hepatocyte nuclear factor 1 alpha in gynecological cancer	ONCOGENE			English	Article						endometrial cancer; ovarian cancer; breast cancer; hepatocyte nuclear factor 1; HNF1 alpha; gene mutation; liver cell adenoma; microsatellite instability; MSI-H	DNA-BINDING; POU DOMAIN; GENE; INACTIVATION; HNF-1-ALPHA; EXPRESSION; PROMOTER; LF-B1; YOUNG; PCR	TCF1 ( transcription factor 1) encoding hepatocyte nuclear factor 1alpha (HNF1alpha) is mutated in 50% of liver cell adenomas, a benign tumor closely associated with oral contraceptive use. These genetic alterations inactivate both alleles, leading to the absence of wild-type HNF1alpha expression in liver cell adenomas. To search for a role of HNF1alpha in other hormone-related neoplasias, we screened for HNF1alpha mutations in a series of 36 endometrial carcinomas, 29 breast carcinomas and 20 ovarian epithelial tumors. HNF1alpha mutations were identified in 4/ 36 (11%) of endometrial tumors. No mutation was found in ovarian and breast tumors. HNF1alpha mutations were somatic in all cases, monoallelic in three cases and biallelic in one case. These results suggest that HNF1alpha may contribute to endometrial carcinogenesis through complete HNF1alpha inactivation like in liver cell adenoma or by haploinsufficiency like in MSI-H colorectal cancer.	INSERM, U434, F-75010 Paris, France; Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75010 Paris, France; Inst Curie, Serv Anatomopathol, F-75005 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Gynecol Serv, F-75015 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; INSERM, U490, Mol Toxicol Lab, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Foundation Jean Dausset-CEPH; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Zucman-Rossi, J (corresponding author), INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013; Rosty, Christophe/F-1796-2010; Rebouissou, Sandra/O-5938-2017; zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021	Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; Rebouissou, Sandra/0000-0003-0188-2271; zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334; Rosty, Christophe/0000-0001-7671-2651				Aguanno A, 1996, J BIOL CHEM, V271, P4528; Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1016/j.gastro.2003.07.012; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Bluteau O, 1999, BIOTECHNIQUES, V27, P1100, DOI 10.2144/99276bm01; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Ellard S, 2000, HUM MUTAT, V16, P377, DOI 10.1002/1098-1004(200011)16:5<377::AID-HUMU1>3.0.CO;2-2; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HENDERSON BE, 1988, CANCER RES, V48, P246; Ishii Y, 2000, MOL PHARMACOL, V57, P940; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	19	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7588	7592		10.1038/sj.onc.1207989	http://dx.doi.org/10.1038/sj.onc.1207989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326484				2022-12-28	WOS:000224176500016
J	Harrington, L				Harrington, L			Does the reservoir for self-renewal stem from the ends?	ONCOGENE			English	Review						stem/progenitor cell; self-renewal; telomeres; telomerase	HUMAN BONE-MARROW; TELOMERASE REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT GENE; DYSKERATOSIS-CONGENITA; TERMINAL TRANSFERASE; RNA COMPONENT; LIFE-SPAN; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; SERIAL TRANSPLANTATION	Stem cell research is a burgeoning field with an alluring potential for therapeutic intervention, and thus begs a critical understanding of the long-term consequences of stem cell replacement. Operationally, a stem cell may be defined as a rarely dividing cell with the capacity for self-renewal throughout the lifetime of the organism, and an ability to reconstitute its appropriate lineages via proliferation and differentiation. In many differentiated normal and cancer cell types, the maintenance of telomeres plays a pivotal role in their continued division potential. Taken together with the presence of the enzymatic activity responsible for telomere addition, telomerase, in several progenitor cell lineages, it is presumed that telomere maintenance will be critical for the replenishment of stem cells or their successors. The purpose of this review is to discuss the role of telomere length maintenance in self-renewal, and the consequent challenges and potential pitfalls to the manipulation of normal and cancer-derived stem cells.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Harrington, L (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, 620 Univ Ave,Room 932, Toronto, ON M5G 2C1, Canada.	leah@uhnres.utoronto.ca			NATIONAL INSTITUTE ON AGING [R01AG016629] Funding Source: NIH RePORTER; NIA NIH HHS [AG16629-04] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allain JE, 2002, P NATL ACAD SCI USA, V99, P3639, DOI 10.1073/pnas.062038599; Allsopp RC, 2003, BLOOD, V102, P517, DOI 10.1182/blood-2002-07-2334; Allsopp RC, 2003, NAT MED, V9, P369, DOI 10.1038/nm0403-369; Allsopp RC, 2002, ONCOGENE, V21, P3270, DOI 10.1038/sj.onc.1205314; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Baerlocher GM, 2002, CYTOMETRY, V47, P89, DOI 10.1002/cyto.10053; Banfi A, 2002, TISSUE ENG, V8, P901, DOI 10.1089/107632702320934001; Bessler M, 2004, CURR OPIN PEDIATR, V16, P23, DOI 10.1097/00008480-200402000-00006; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Darwin Charles, 1898, DESCENT MAN SELECTIO; Erdmann N, 2004, P NATL ACAD SCI USA, V101, P6080, DOI 10.1073/pnas.0401580101; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fogarty PF, 2003, LANCET, V362, P1628, DOI 10.1016/S0140-6736(03)14797-6; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenwood MJ, 2003, ARCH MED RES, V34, P489, DOI 10.1016/j.arcmed.2003.07.003; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Harley CB, 1997, CIBA F SYMP, V211, P129; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Hemann MT, 2001, MOL BIOL CELL, V12, P2023, DOI 10.1091/mbc.12.7.2023; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; Kobune M, 2003, EXP HEMATOL, V31, P715, DOI 10.1016/S0301-472X(03)00177-2; Lansdorp PM, 1998, VOX SANG, V74, P91, DOI 10.1111/j.1423-0410.1998.tb05402.x; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KM, 2003, BIOCHEM BIOPH RES CO, V301, P1038, DOI 10.1016/S0006-291X(03)00086-X; Lendvay TS, 1996, GENETICS, V144, P1399; Limke TL, 2003, DEV NEUROSCI-BASEL, V25, P257, DOI 10.1159/000072273; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu Y, 2002, P NATL ACAD SCI USA, V99, P3597, DOI 10.1073/pnas.062549199; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Mason PJ, 2003, BIOESSAYS, V25, P126, DOI 10.1002/bies.10229; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365-2141.2003.04217.x; Miller MC, 2000, MOL CELL, V6, P827, DOI 10.1016/S1097-2765(05)00078-X; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Morales CP, 2003, GUT, V52, P327, DOI 10.1136/gut.52.3.327; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Parsch D, 2004, J MOL MED-JMM, V82, P49, DOI 10.1007/s00109-003-0506-z; Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Riha K, 2003, CHROMOSOME RES, V11, P263, DOI 10.1023/A:1022892010878; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Roth A, 2003, LEUKEMIA, V17, P2410, DOI 10.1038/sj.leu.2403177; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Samper E, 2002, BLOOD, V99, P2767, DOI 10.1182/blood.V99.8.2767; Shamblott MJ, 2001, P NATL ACAD SCI USA, V98, P113, DOI 10.1073/pnas.021537998; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Truckenmiller ME, 2002, EXP NEUROL, V175, P318, DOI 10.1006/exnr.2002.7898; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2001, INT J CANCER, V91, P644, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1103>3.3.CO;2-M; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vrana KE, 2003, P NATL ACAD SCI USA, V100, P11911, DOI 10.1073/pnas.2034195100; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Yin XX, 2004, BIOCHEM BIOPH RES CO, V315, P643, DOI 10.1016/j.bbrc.2003.01.102; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	88	52	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7283	7289		10.1038/sj.onc.1207948	http://dx.doi.org/10.1038/sj.onc.1207948			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378088				2022-12-28	WOS:000223998800014
J	Lessard, J; Faubert, A; Sauvageau, G				Lessard, J; Faubert, A; Sauvageau, G			Genetic programs regulating HSC specification, maintenance and expansion	ONCOGENE			English	Review						hematopoiesis; HSC; self-renewal	HEMATOPOIETIC STEM-CELLS; COLONY-FORMING CELLS; CREB-BINDING-PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW TRANSPLANTATION; TRANSCRIPTION FACTOR GATA-2; FETAL LIVER HEMATOPOIESIS; POLYCOMB-GROUP GENES; IKAROS MUTANT MICE; LONG-TERM	All mature blood cells originate from a small population of self-renewing pluripotent hematopoietic stem cells (HSCs). The capacity to self-renew characterizes all stem cells, whether normal or neoplastic. Interestingly, recent studies suggest that self-renewal is essential for tumor cell maintenance, implicating that this process has therapeutic relevance. Unfortunately, the molecular bases for self-renewal of vertebrate cells remain poorly defined. This article will focus on the developmental mechanisms underlying fetal and adult HSC homeostasis. Specifically, distinctions between genetic programs regulating HSC specification (identity), self-renewal (in both fetal and adult) and differentiation/commitment will be discussed with a special emphasis on transcriptional and chromatin regulators.	Univ Montreal, Lab Mol Genet Hematopoiet Stem Cells, Res Inst Immunol & Canc IRIC, Montreal, PQ H3C 3J7, Canada; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Dept Med, Montreal, PQ H3C 3J7, Canada; Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ H1T 2M2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ, Canada	Universite de Montreal; Stanford University; Universite de Montreal; McGill University	Sauvageau, G (corresponding author), Univ Montreal, Lab Mol Genet Hematopoiet Stem Cells, Res Inst Immunol & Canc IRIC, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca		Sauvageau, Guy/0000-0002-4333-7266				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cai ZL, 2000, IMMUNITY, V13, P423, DOI 10.1016/S1074-7613(00)00042-X; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dimri GP, 2002, CANCER RES, V62, P4736; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Gailani M R, 1999, Adv Dermatol, V14, P261; Garcia MJ, 2002, AM J PATHOL, V161, P1007, DOI 10.1016/S0002-9440(10)64261-7; GARDNER RV, 1988, EXP HEMATOL, V16, P49; Geiger H, 2002, NAT IMMUNOL, V3, P329, DOI 10.1038/ni0402-329; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HARRISON DE, 1990, J EXP MED, V172, P431, DOI 10.1084/jem.172.2.431; HARRISON DE, 1978, J EXP MED, V147, P1526, DOI 10.1084/jem.147.5.1526; HARRISON DE, 1982, J EXP MED, V156, P1767, DOI 10.1084/jem.156.6.1767; Harrison DE, 1997, EXP HEMATOL, V25, P293; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; JONES RJ, 1989, BLOOD, V73, P397; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kung AL, 2000, GENE DEV, V14, P272; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; LALA PK, 1978, J EXP MED, V148, P1468, DOI 10.1084/jem.148.6.1468; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LEPAULT F, 1993, BLOOD, V81, P950; LERNER C, 1990, EXP HEMATOL, V18, P114; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Liu Y, 2001, J BIOL CHEM, V276, P17985, DOI 10.1074/jbc.M100678200; Lopez RA, 2002, P NATL ACAD SCI USA, V99, P602, DOI 10.1073/pnas.022412699; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; MAUCH P, 1989, BLOOD, V74, P872; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULDER AH, 1987, EXP HEMATOL, V15, P99; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; OH IH, 2003, ASH ABSTR, P325; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Oike Y, 1999, BLOOD, V93, P2771; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; PHILLIPS RL, 1992, P NATL ACAD SCI USA, V89, P11607, DOI 10.1073/pnas.89.23.11607; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Polakis P, 2000, GENE DEV, V14, P1837; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500; Rebel VI, 1996, EXP HEMATOL, V24, P638; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Tokimasa S, 2001, EXP HEMATOL, V29, P93, DOI 10.1016/S0301-472X(00)00620-2; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANBEKKUM DW, 1979, BLOOD CELLS, V5, P143; VANDERLOO JCM, 1994, BLOOD, V83, P1769; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANZANT G, 1991, EXP HEMATOL, V19, P941; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; VISSER JWM, 1988, BLOOD CELLS, V14, P369; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Weissman IL, 2002, IMMUNOL REV, V185, P159, DOI 10.1034/j.1600-065X.2002.18514.x; WORTON RG, 1969, J EXP MED, V130, P91, DOI 10.1084/jem.130.1.91; WU AM, 1968, P NATL ACAD SCI USA, V59, P1209, DOI 10.1073/pnas.59.4.1209; WU AM, 1968, J EXP MED, V127, P455, DOI 10.1084/jem.127.3.455; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yoder MC, 1997, P NATL ACAD SCI USA, V94, P6776, DOI 10.1073/pnas.94.13.6776; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	127	51	53	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7199	7209		10.1038/sj.onc.1207940	http://dx.doi.org/10.1038/sj.onc.1207940			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378080				2022-12-28	WOS:000223998800006
J	Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ				Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ			AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity	ONCOGENE			English	Article						AKAP12; alternative promoter; DNA methylation; histone deacetylation; apoptosis	CPG ISLAND METHYLATION; C-KINASE SUBSTRATE; CANCER CELLS; SIGNALING COMPLEXES; LUNG CARCINOMAS; DNA METHYLATION; CYCLIN-D; GENE; PROTEIN; EXPRESSION	AKAP12/Gravin, one of the A-kinase anchoring proteins (AKAPs), functions as a kinase scaffold protein and as a dynamic regulator of the beta(2)-adrenergic receptor complex. However, the biological role of AKAP12 in cancer development is not well understood. The AKAP12 gene encodes two major isoforms of 305 and 287 kDa ( designated AKAP12A and AKAP12B, respectively, in this report). We found that these two isoforms are independently expressed and that they are probably under the control of two different promoters. Moreover, both isoforms were absent from the majority of human gastric cancer cells. The results from methylation-specific PCR (MSP) and bisulfite sequencing revealed that the 5' CpG islands of both AKAP12A and AKAP12B are frequently hypermethylated in gastric cancer cells. Treatment with DNA methyltransferase inhibitor and/or histone deacetylase inhibitor efficiently restored the expression of AKAP12 isoforms, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells. Hypermethylation of AKAP12A CpG island was also detected in 56% ( 10 of 18) of primary gastric tumors. The restoration of AKAP12A in AKAP12-nonexpressing cells reduced colony formation and induced apoptotic cell death. In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Canc Epigenet, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Clin Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/AAC-1146-2020; Kim, Tae-You/J-2750-2012; Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Lee, Dong soon/E-5079-2012	Lee, Jung Weon/0000-0003-2722-8200; Bang, Yung Jue/0000-0001-6000-4597; KIM, TAI YOUNG/0000-0001-8086-2476				Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Conway KE, 2000, CANCER RES, V60, P6236; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Diviani D, 2001, J CELL SCI, V114, P1431; Du Y, 2001, CANCER RES, V61, P8094; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Issa JPJ, 2001, CANCER RES, V61, P3573; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang GH, 2001, CANCER RES, V61, P2847; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Li B, 2001, CANCER RES, V61, P8014; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MILLIKIN D, 1991, CANCER RES, V51, P5449; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Park JH, 2003, CLIN CANCER RES, V9, P433; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Toyooka KO, 2001, CANCER RES, V61, P4556; Xia W, 2001, CANCER RES, V61, P5644; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	40	82	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7095	7103		10.1038/sj.onc.1207932	http://dx.doi.org/10.1038/sj.onc.1207932			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258566				2022-12-28	WOS:000223885100010
J	Stiller, CA				Stiller, CA			Epidemiology and genetics of childhood cancer	ONCOGENE			English	Review						childhood cancer; incidence; familial syndromes; genetic associations; risk factors	ACUTE LYMPHOBLASTIC-LEUKEMIA; EPSTEIN-BARR-VIRUS; IN-VITRO FERTILIZATION; BECKWITH-WIEDEMANN-SYNDROME; POPULATION-BASED COHORT; NEONATAL RISK-FACTORS; WILMS-TUMOR; GERM-LINE; HEREDITARY RETINOBLASTOMA; CHROMOSOME-ABNORMALITIES	Childhood cancer is rare everywhere in the world, with age-standardized annual incidence usually between 70 and 160 per million at age 0-14 years. Greater variation is seen between populations for some specific tumour types. Some of the largest variations are geographical and are attributable to environmental factors, whereas variation mainly on ethnic lines seems likely to be a marker of genetic predisposition. A wide range of familial and genetic syndromes is associated with an increased risk of childhood cancer. Virtually all the excess risk of cancer among first-degree relatives of children with cancer can be accounted for by known hereditary syndromes. Studies of weak predisposition and gene-environment interaction have so far shown limited consistency. There are very few established environmental or exogenous risk factors and most of these are infective agents. Many putative risk factors can hardly ever be investigated epidemiologically except by interview or questionnaire studies. Some recent examples illustrate the continuing problems of participation bias and recall bias.	Univ Oxford, Dept Paediat, Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Stiller, CA (corresponding author), Univ Oxford, Dept Paediat, Childhood Canc Res Grp, 57 Woodstock Rd, Oxford OX2 6HJ, England.	charles.stiller@ccrg.ox.ac.uk		Stiller, Charles/0000-0002-3006-7869				Ajiki W, 1998, CANCER CAUSE CONTROL, V9, P631, DOI 10.1023/A:1008897123707; Alves S, 2002, LEUKEMIA, V16, P1565, DOI 10.1038/sj.leu.2402543; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Becroft DMO, 1999, PATHOLOGY, V31, P83, DOI 10.1080/003130299105232; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Biegel JA, 1999, CANCER RES, V59, P74; Blatt J, 1997, J PEDIATR-US, V131, P666, DOI 10.1016/S0022-3476(97)70090-8; Breslow NE, 1996, MED PEDIATR ONCOL, V27, P398; Bruinsma F, 2000, HUM REPROD, V15, P604, DOI 10.1093/humrep/15.3.604; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen CL, 1997, BLOOD, V89, P1701, DOI 10.1182/blood.V89.5.1701.1701_1701_1707; CNATTINGIUS S, 1995, J NATL CANCER I, V87, P908, DOI 10.1093/jnci/87.12.908; CNATTINGIUS S, 1995, CANCER EPIDEM BIOMAR, V4, P441; Cope JU, 2000, MED PEDIATR ONCOL, V34, P195, DOI 10.1002/(SICI)1096-911X(200003)34:3<195::AID-MPO6>3.0.CO;2-B; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354; Crawford DH, 2001, PHILOS T R SOC B, V356, P461, DOI 10.1098/rstb.2000.0783; Davies SM, 2000, CANCER EPIDEM BIOMAR, V9, P563; Davies SM, 2002, BLOOD, V100, P67, DOI 10.1182/blood.V100.1.67; Dearden SP, 1996, BRIT J CANCER, V73, P603, DOI 10.1038/bjc.1996.104; DeBaun MR, 1998, J PEDIATR-US, V132, P398, DOI 10.1016/S0022-3476(98)70008-3; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; Dorak MT, 1999, BLOOD, V94, P694, DOI 10.1182/blood.V94.2.694.414k07_694_700; Dorak MT, 2002, LEUKEMIA RES, V26, P651, DOI 10.1016/S0145-2126(01)00189-8; Doyle P, 1998, LANCET, V352, P452, DOI 10.1016/S0140-6736(05)79186-8; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRAPER GJ, 1977, J MED GENET, V14, P81, DOI 10.1136/jmg.14.2.81; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Dror Y, 2002, BRIT J HAEMATOL, V118, P701, DOI 10.1046/j.1365-2141.2002.03585.x; DRUT R, 1988, Pediatric Pathology, V8, P331; Evans DGR, 1999, ARCH DIS CHILD, V81, P496, DOI 10.1136/adc.81.6.496; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Franco RF, 2001, BRIT J HAEMATOL, V115, P616, DOI 10.1046/j.1365-2141.2001.03140.x; GARBER JE, 1988, J NATL CANCER I, V80, P1626, DOI 10.1093/jnci/80.20.1626; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; Glazer ER, 1999, CANCER, V86, P1070, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1070::AID-CNCR25>3.3.CO;2-0; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; GREAVES MF, 1993, LEUKEMIA, V7, P27; Gripp KW, 2002, AM J MED GENET, V108, P80, DOI 10.1002/ajmg.10241; GUTIERREZ MI, 1992, BLOOD, V79, P3261; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Hemminki K, 1999, EPIDEMIOLOGY, V10, P271, DOI 10.1097/00001648-199905000-00014; Henneveld HT, 1999, AM J MED GENET, V86, P439, DOI 10.1002/(SICI)1096-8628(19991029)86:5<439::AID-AJMG9>3.3.CO;2-W; Hermon C, 2001, ANN HUM GENET, V65, P167, DOI 10.1017/S0003480001008508; HERSH JH, 1992, J PEDIATR-US, V120, P572, DOI 10.1016/S0022-3476(10)80004-6; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOLLY EA, 1992, AM J EPIDEMIOL, V135, P122, DOI 10.1093/oxfordjournals.aje.a116265; Hooper ML, 1999, BRIT J CANCER, V79, P1273, DOI 10.1038/sj.bjc.6690204; Hoyme HE, 1998, AM J MED GENET, V79, P274, DOI 10.1002/(SICI)1096-8628(19981002)79:4<274::AID-AJMG8>3.0.CO;2-M; Hrusak O, 2002, LEUKEMIA, V16, P720, DOI 10.1038/sj/leu/2402422; Infante-Rivard C, 2002, EPIDEMIOLOGY, V13, P277, DOI 10.1097/00001648-200205000-00007; Infante-Rivard C, 2002, ENVIRON HEALTH PERSP, V110, P591, DOI 10.1289/ehp.02110591; Infante-Rivard C, 1999, EPIDEMIOLOGY, V10, P481, DOI 10.1097/00001648-199909000-00004; Infante-Rivard C, 2000, CANCER CAUSE CONTROL, V11, P547, DOI 10.1023/A:1008976116512; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Iscovich J, 1997, INT J CANCER, V70, P649, DOI 10.1002/(SICI)1097-0215(19970317)70:6<649::AID-IJC4>3.3.CO;2-L; Jemal A, 2000, BRIT J CANCER, V82, P1875, DOI 10.1054/bjoc.2000.1215; Kleinerman RA, 2000, JNCI-J NATL CANCER I, V92, P2037, DOI 10.1093/jnci/92.24.2037; Klip H, 2001, HUM REPROD, V16, P2451, DOI 10.1093/humrep/16.11.2451; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Krajinovic M, 2002, INT J CANCER, V97, P230, DOI 10.1002/ijc.1589; Krajinovic M, 2000, CANCER EPIDEM BIOMAR, V9, P557; Krajinovic M, 1999, BLOOD, V93, P1496, DOI 10.1182/blood.V93.5.1496.405a36_1496_1501; Kramarova E, 1996, INT J CANCER, V68, P759; Law GR, 2002, BRIT J CANCER, V86, P350, DOI 10.1038/sj/bjc/6600092; Lerner-Geva L, 2000, CANCER, V88, P2845, DOI 10.1002/1097-0142(20000615)88:12<2845::AID-CNCR26>3.0.CO;2-E; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1988, PEDIATRICS, V81, P147; LIN HJ, 1994, PHARMACOGENETICS, V4, P125, DOI 10.1097/00008571-199406000-00003; Lindor NM, 1998, JNCI-J NATL CANCER I, V90, P1039, DOI 10.1093/jnci/90.14.1039; Lindsay S, 1997, J MED GENET, V34, P480, DOI 10.1136/jmg.34.6.480; LINET MS, 1991, BRIT J CANCER, V63, P424, DOI 10.1038/bjc.1991.98; Lipton JM, 2001, J PEDIAT HEMATOL ONC, V23, P39, DOI 10.1097/00043426-200101000-00009; McGaughran JM, 1999, J MED GENET, V36, P197; McNally RJQ, 2001, CANCER-AM CANCER SOC, V92, P1967, DOI 10.1002/1097-0142(20011001)92:7<1967::AID-CNCR1716>3.0.CO;2-#; MORRELL D, 1986, J NATL CANCER I, V77, P89; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; Narod SA, 1997, AM J HUM GENET, V60, P474; Newton R, 2001, INT J CANCER, V92, P622, DOI 10.1002/1097-0215(20010601)92:5&lt;622::AID-IJC1256&gt;3.0.CO;2-K; OLSEN JH, 1995, NEW ENGL J MED, V333, P1594, DOI 10.1056/NEJM199512143332403; OLSON JM, 1995, MED PEDIATR ONCOL, V24, P305, DOI 10.1002/mpo.2950240507; Opitz JM, 1998, AM J MED GENET, V79, P294, DOI 10.1002/(SICI)1096-8628(19981002)79:4<294::AID-AJMG12>3.0.CO;2-M; Paraf F, 1997, J CLIN ONCOL, V15, P2744, DOI 10.1200/JCO.1997.15.7.2744; Parkin DM, 1999, CANCER SURV, V33, P5; Perri P, 2002, ANN NY ACAD SCI, V963, P74; Powell JE, 1998, LANCET, V352, P682, DOI 10.1016/S0140-6736(97)11239-9; POWELL JE, 1995, BRIT J CANCER, V72, P1563, DOI 10.1038/bjc.1995.549; RAJALEKSHMY KR, 1994, LEUKEMIA RES, V18, P183, DOI 10.1016/0145-2126(94)90113-9; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; Reynolds P, 2002, AM J EPIDEMIOL, V155, P603, DOI 10.1093/aje/155.7.603; Ricciardone MD, 1999, CANCER RES, V59, P290; Roman E, 2002, BRIT J CANCER, V86, P63, DOI 10.1038/sj.bjc.6600007; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; Sandrini R, 1997, J CLIN ENDOCR METAB, V82, P2027, DOI 10.1210/jc.82.7.2027; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schuz J, 1999, INT J EPIDEMIOL, V28, P631, DOI 10.1093/ije/28.4.631; Shibata Y, 2001, LANCET, V358, P1965, DOI 10.1016/S0140-6736(01)06971-9; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Smith MA, 1998, J NATL CANCER I, V90, P1269, DOI 10.1093/jnci/90.17.1269; SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569; Taylor GM, 2002, HUM MOL GENET, V11, P1585; Taylor GM, 1998, BRIT J CANCER, V78, P561, DOI 10.1038/bjc.1998.540; TAYLOR GM, 1995, LEUKEMIA, V9, P440; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071; Wang LL, 2001, AM J MED GENET, V102, P11, DOI 10.1002/1096-8628(20010722)102:1<11::AID-AJMG1413>3.0.CO;2-A; Wang Q, 1999, CANCER RES, V59, P294; Webb DW, 1996, DEV MED CHILD NEUROL, V38, P146; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; Whiteside D, 2002, CANCER RES, V62, P359; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298; Wilkinson JD, 2001, CANCER, V91, P1402, DOI 10.1002/1097-0142(20010401)91:7<1402::AID-CNCR1145>3.0.CO;2-6; WINN DM, 1992, CANCER EPIDEM BIOMAR, V1, P525; Winther JF, 2001, LANCET, V358, P711, DOI 10.1016/S0140-6736(01)05838-X; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111; Ziegler JL, 1996, INT J CANCER, V65, P200, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;200::AID-IJC12&gt;3.0.CO;2-H	136	150	155	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6429	6444		10.1038/sj.onc.1207717	http://dx.doi.org/10.1038/sj.onc.1207717			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322515				2022-12-28	WOS:000223468800009
J	Gallego, MA; Joseph, B; Hemstrom, TH; Tamiji, S; Mortier, L; Kroemer, G; Formstecher, P; Zhivotovsky, B; Marchetti, P				Gallego, MA; Joseph, B; Hemstrom, TH; Tamiji, S; Mortier, L; Kroemer, G; Formstecher, P; Zhivotovsky, B; Marchetti, P			Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas	ONCOGENE			English	Article						staurosporine; apoptosis; mitochondria; caspase-independent	DNA-DEGRADATION; CANCER-CELLS; DEATH; AIF; STAUROSPORINE; PROTEASES; PROTEIN; MITOCHONDRIA; EXPRESSION; ACTIVATION	Non-small-cell lung carcinomas (NSCLCs) are resistant to the induction of apoptosis by conventional anticancer treatment. However, NSCLC cell lines are sensitive to the action of the broad protein kinase inhibitor, staurosporine (STS). In the NSCLC cell line U1810, STS induced the mitochondrial release of apoptosis-inducing factor (AIF) and cytochrome c (Cyt c) followed by activation of caspases, nuclear condensation, DNA fragmentation and finally cell death. Although preincubation of U1810 cells with the broad-spectrum caspase inhibitor z-VAD.fmk delayed the occurrence of nuclear apoptosis induced by STS, it did not impede mitochondrial alterations (such as the release of Cyt c and AIF) and cell death to occur. Moreover, the microinjection of neither Cyt c nor recombinant active caspase-3 into the cytoplasm promoted nuclear apoptosis-related changes in U1810 cells. Evaluation of the role of the caspase-independent factor AIF in STS-mediated death revealed that, upon immunodepletion of AIF, cytosols from STS-treated U1810 lost their capacity to induce nuclear condensation when incubated with isolated nuclei. In addition, microinjection of an anti-AIF antibody prevented AIF from translocating to the nuclei of STS-treated U1810 cells and reduced STS-induced cell death. Finally, although the transfection-enforced overexpression of AIF was not sufficient to induce cell death, it did enhance STS-mediated cell killing. Altogether, these results indicate that activation of caspases is not sufficient to kill U1810 cells and rather suggests an important role for the AIF-mediated mitochondrial-mediated death pathway.	Fac Med Lille, INSERM, U459, F-59045 Lille, France; Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Marchetti, P (corresponding author), Fac Med Lille, INSERM, U459, 1 Pl Verdun, F-59045 Lille, France.	philippe.marchetti@lille.inserm.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Zhivotovsky, Boris/A-4346-2014	KROEMER, Guido/0000-0002-9334-4405; Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979; MARCHETTI, Philippe/0000-0002-4663-6800				Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deas O, 1998, J IMMUNOL, V161, P3375; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Ekedahl J, 2002, EXP CELL RES, V279, P277, DOI 10.1006/excr.2002.5608; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schmitt E, 2003, CANCER RES, V63, P8233; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Volm M, 2000, ANTICANCER RES, V20, P3449; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	37	83	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6282	6291		10.1038/sj.onc.1207835	http://dx.doi.org/10.1038/sj.onc.1207835			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15286713				2022-12-28	WOS:000223399000012
J	Suzuki, M; Toyooka, S; Shivapurkar, N; Shigematsu, H; Miyajima, K; Takahashi, T; Stastny, V; Zern, AL; Fujisawa, T; Pass, HI; Carbone, M; Gazdar, AF				Suzuki, M; Toyooka, S; Shivapurkar, N; Shigematsu, H; Miyajima, K; Takahashi, T; Stastny, V; Zern, AL; Fujisawa, T; Pass, HI; Carbone, M; Gazdar, AF			Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection	ONCOGENE			English	Article						methylation; malignant mesothelioma; SV40	TUMOR-SUPPRESSOR GENE; SIMIAN-VIRUS-40 DNA-SEQUENCES; NONSMALL CELL LUNG; PROMOTER METHYLATION; BREAST-CANCER; MULTIPLE GENES; EXPRESSION; HYPERMETHYLATION; HIC-1; METHYLTRANSFERASE	Malignant mesothelioma ( MM) is associated with asbestos exposure and the presence of SV40 viral sequences. Recently, we reported that SV40 infection of human mesothelial cells (HM) causes aberrant methylation of the tumor suppressor gene (TSG) RASSF1A. We investigated methylation of 12 genes by methylation-specific PCR in 63 MMs, six MM cell lines, and two foci of SV40-infected HM. Methylation percentages of the tested genes ranged from 3 to 65%. The frequencies of HPP1, RASSF1A, Cyclin D2, and RRAD methylation, and the value of the methylation index, were significantly higher in SV40 sequence-positive MMs than in SV40-negative MMs. Methylation of TMS1 and HIC-1 was associated with shortened survival. SV40-infected HM showed progressive aberrant methylation of seven genes ( RASSF1A, HPP1, DcR1, TMS1, CRBP1, HIC-1, and RRAD) during serial passage. Our results demonstrate a relationship between SV40 and methylation of multiple genes in MM, indicating that the virus plays a role in the pathogenesis of MM.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba 2608670, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Karamanos Canc Ctr, Dept Thorac Surg, Detroit, MI 48201 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Chiba University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Loyola University Chicago	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu		Pass, Harvey/0000-0003-3222-3471	NATIONAL CANCER INSTITUTE [U01CA084971, R01CA092657, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907, 5U01CA8497102, R0-1 CA92657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baas P, 2003, CURR OPIN ONCOL, V15, P127, DOI 10.1097/00001622-200303000-00002; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; CICALA C, 1993, AM J PATHOL, V142, P1524; Conway KE, 2000, CANCER RES, V60, P6236; Du Y, 2001, CANCER RES, V61, P8094; Edwards JG, 2003, BRIT J CANCER, V88, P1553, DOI 10.1038/sj.bjc.6600920; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; Gazdar Adi F, 2003, Clin Lung Cancer, V5, P177, DOI 10.3816/CLC.2003.n.031; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Hayashi M, 2001, ANTICANCER RES, V21, P535; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Padar A, 2003, CLIN CANCER RES, V9, P4730; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Phelps RM, 1996, J CELL BIOCHEM, P32; Powers A, 2002, CANCER BIOL THER, V1, P348; Rathi A, 2002, CLIN CANCER RES, V8, P3324; Rathi A, 2003, CLIN CANCER RES, V9, P3674; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Rood BR, 2002, CANCER RES, V62, P3794; Sandberg AA, 2001, CANCER GENET CYTOGEN, V127, P93, DOI 10.1016/S0165-4608(01)00432-0; Sato F, 2002, CANCER RES, V62, P6820; Shibata DM, 2002, CANCER RES, V62, P5637; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2004, CANCER RES, V64, P3757, DOI 10.1158/0008-5472.CAN-03-3307; Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Topol LZ, 2000, CYTOGENET CELL GENET, V89, P79, DOI 10.1159/000015568; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Toyooka S, 2001, CANCER RES, V61, P5727; Tseng YH, 2001, CANCER RES, V61, P2071; van Noesel MM, 2002, CANCER RES, V62, P2157; Virmani A, 2003, INT J CANCER, V107, P341, DOI 10.1002/ijc.11393; Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wong L, 2002, LUNG CANCER, V38, P131, DOI 10.1016/S0169-5002(02)00178-2; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Zanella CL, 1996, CANCER RES, V56, P5334	48	62	64	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1302	1308		10.1038/sj.onc.1208263	http://dx.doi.org/10.1038/sj.onc.1208263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592515				2022-12-28	WOS:000226898700019
J	Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN				Romanova, LY; Willers, H; Blagosklonny, MV; Powell, SN			The interaction of p53 with replication protein A mediates suppression of homologous recombination	ONCOGENE			English	Article						p53; RPA; homologous recombination; replication	WILD-TYPE P53; STRAND BREAK REPAIR; DNA-BINDING DOMAIN; HUMAN RAD51; MUTANT P53; CELL-CYCLE; 3'-TO-5' EXONUCLEASE; HOLLIDAY JUNCTIONS; MAMMALIAN-CELLS; RPA	The tumor suppressor protein p53 is emerging as a central regulator of homologous recombination (HR) processes and DNA replication. P53 may downregulate HR through multiple mechanisms including the reported associations with the Rad51 and Rad54 recombinases, and the BLM and WRN helicases. Here, we investigated whether the interaction of p53 with human replication protein A (RPA) is necessary for the regulation of HR. By employing a plasmid-based HR assay in p53-null H1299 lung carcinoma cells, we, studied the HR-suppressing properties of a panel of p53 mutants, which varied in their ability to interact with RPA. Both wild-type p53 and a transactivation-deficient p53 mutant (L22Q/W23S) suppressed HR and prevented RPA binding to ssDNA in vitro and in vivo. Conversely, p53 mutations that specifically disrupt the RPA-binding domain, while not compromising p53 transactivation function (D48H/D49H and W53S/F54S), did not affect HR. Suppression of HR was also not seen with missense mutations in the p53 core domain (His175 and His273), which retained the ability to interact with RPA, suggesting that the disruption of additional binding interactions of p53, for example, with Rad51 or recombination intermediates, also impacts on HR. We hypothesize that sequestration of RPA by p53 at the sites of recombination is one means by which p53 can inhibit HR processes. Our data support and extend the previously formulated 'dual model' of p53's role as guardian of the genome.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA; New York Med Coll, Brander Canc Res Inst, Hawthorne, NY 10532 USA	Harvard University; Massachusetts General Hospital; New York Medical College	Powell, SN (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,Lab Mol & Celllular Radiat Biol, Charlestown, MA 02129 USA.	snpowell@partners.org			NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [CA58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Alberts B, 2003, NATURE, V421, P431, DOI 10.1038/nature01407; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Bishop AJR, 2003, EXP MOL PATHOL, V74, P94, DOI 10.1016/S0014-4800(03)00010-8; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Linke SP, 2003, CANCER RES, V63, P2596; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Walther AP, 1999, NUCLEIC ACIDS RES, V27, P656, DOI 10.1093/nar/27.2.656; Wiese C, 2001, CANCER RES, V61, P1129; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Willers H, 2001, CARCINOGENESIS, V22, P1757, DOI 10.1093/carcin/22.11.1757; Willers Henning, 2002, Journal of Biomedicine & Biotechnology, V2, P86, DOI 10.1155/S1110724302204027; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; Zhou JM, 2003, NUCLEIC ACIDS RES, V31, P3881, DOI 10.1093/nar/gkg468; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	73	72	74	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9025	9033		10.1038/sj.onc.1207982	http://dx.doi.org/10.1038/sj.onc.1207982			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489903				2022-12-28	WOS:000225492800003
J	Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A				Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A			HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF	ONCOGENE			English	Article						PLZF; HDAC; PLZF-RAR alpha	ACID RECEPTOR-ALPHA; II HISTONE DEACETYLASES; SERUM RESPONSE FACTOR; RAR-ALPHA; MUSCLE DIFFERENTIATION; NUCLEAR EXPORT; POZ DOMAIN; COREPRESSOR; COMPLEX; SMRT	PLZF, the promyelocytic leukaemia zinc-finger protein, is a transcriptional repressor essential to development. In some acute leukaemias, a chromosomal translocation fusing the PLZF gene to that encoding the retinoic acid receptor RARalpha gives rise to a fusion protein, PLZF RARa, thought to be responsible for constitutive repression of differentiation-associated genes in these cells. Repression by both PLZF and PLZF-RARalpha is sensitive to the histone deacetylase inhibitor TSA, and PLZF was previously shown to interact physically with HDAC1, a class I histone deacetylase. We here asked whether class II histone deacetylases, known to be generally involved in differentiation processes, participate in the repression mediated by PLZF and PLZF-RARalpha, and found that PLZF interacts with HDAC4 in both GST-pull-down and co-immunoprecipitation assays. Furthermore, HDAC4 is indeed involved in PLZF and PLZF-RARalpha-mediated repression, since an enzymatically dead mutant of HDAC4 released the repression, as did an siRNA that blocks HDAC4 expression. Taken together, our data indicate that recruitment of HDAC4 is necessary for PLZF-mediated repression in both normal and leukaemic cells.	Inst Andre Lwoff, CNRS, UPR 9079, F-94800 Villejuif, France; Inst Andre Lwoff, Lab Cytometrie, F-94800 Villejuif, France; Inst Pasteur, INSERM, U579, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94800 Villejuif, France.	ahbellan@vjf.cnrs.fr	Dejean, Anne/L-5145-2018; CHAUCHEREAU, Anne/B-1074-2009; Harel-Bellan, Annick/M-9795-2015; Chauchereau, Anne/N-8880-2016	Chauchereau, Anne/0000-0001-9447-3797; Harel-Bellan, Annick/0000-0002-2339-153X; MATHIEU, Marion/0000-0002-1815-2112				AHMED N, 1993, BIOCHEM MOL BIOL INT, V29, P1055; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Borghi S, 2001, J CELL SCI, V114, P4477; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Groisman R, 1996, J BIOL CHEM, V271, P5258; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	47	62	65	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8777	8784		10.1038/sj.onc.1208128	http://dx.doi.org/10.1038/sj.onc.1208128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467736				2022-12-28	WOS:000225165100007
J	Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ				Ciais, D; Cherradi, N; Bailly, S; Grenier, E; Berra, E; Pouyssegur, J; LaMarre, J; Feige, JJ			Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b	ONCOGENE			English	Article						VEGF; TIS11b; mRNA stability; AU-rich element	IN-VIVO; TRISTETRAPROLIN; STABILITY; CELLS; DEADENYLATION; STABILIZATION; DEGRADATION; HYPOXIA; PATHWAY; ELEMENT	Vascular endothelial growth factor (VEGF) is an angiogenic cytokine, which plays a major role in tumor angiogenesis. VEGF mRNA expression is controlled by hypoxia, growth factors and hormones through both transcriptional and post-transcriptional mechanisms. VEGF mRNA has a short half-life and its abundance is regulated by the binding of stabilizing (HuR, hRNP-L) and still uncharacterised destabilizing proteins to its 3'-untranslated region. Here, we report that the ACTH-regulated zinc-finger protein TIS11b and its homologs TIS11 and TIS11d interact with the 3'-untranslated region of VEGF mRNA and decrease its stability (half-life reduced from 130 to 60 min). Within the 2201 by 3'-untranslated region of VEGF mRNA, we identified a 75 by domain, containing two consensus AU-rich motifs, which binds TIS11b and mediates its destabilizing activity. Ribonucleoprotein (RNP) complex immunoprecipitation experiments allowed us to demonstrate that the interaction between TIS11b and VEGF 3'-untranslated region occurs in live cells. Knocking down TIS11b expression in primary adrenocortical cells with small interfering (si)RNAs clearly indicated that TIS11b participates in the control of both basal and, to a larger extent, ACTH-induced VEGF mRNA expression levels. TIS11b is the first VEGF mRNA-destabilizing protein identified so far and therefore appears as a new potential target in antiangiogenic therapies.	CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, F-38054 Grenoble 9, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signalling Dev Biol & Canc Res, F-06189 Nice, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Feige, JJ (corresponding author), CEA, DRDC ANGIO, INSERM EMI 01 05, Dept Cellular Responses & Dynam, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jjfeige@cea.fr	bailly, sabine/G-3540-2013; Feige, Jean-Jacques/M-8905-2017; Ciais, Delphine/O-9435-2016; Berra, Edurne/F-9692-2011; Cherradi, Nadia/K-9695-2016	bailly, sabine/0000-0003-1043-7030; Feige, Jean-Jacques/0000-0002-1354-7692; Berra, Edurne/0000-0002-3820-5744; Cherradi, Nadia/0000-0002-4292-774X; Ciais, Delphine/0000-0002-1649-897X				Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Brand C, 1998, J BIOL CHEM, V273, P6410, DOI 10.1074/jbc.273.11.6410; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chinn AM, 2002, MOL ENDOCRINOL, V16, P1417, DOI 10.1210/me.16.6.1417; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; NEGOESCU A, 1994, MOL CELL ENDOCRINOL, V105, P155, DOI 10.1016/0303-7207(94)90165-1; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS HJ, 1991, BLOOD, V77, P1787; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Stoecklin G, 2003, ONCOGENE, V22, P3554, DOI 10.1038/sj.onc.1206418; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000	22	93	96	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8673	8680		10.1038/sj.onc.1207939	http://dx.doi.org/10.1038/sj.onc.1207939			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467755				2022-12-28	WOS:000224988800013
J	Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G				Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G			Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA	ONCOGENE			English	Article						oxaliplatin; p53; Bak; Bax; cytoplasts	IN-VITRO; BAX; CISPLATIN; CANCER; P53; CHEMOTHERAPY; PHARMACOLOGY; RESISTANCE; PROTEIN; ABSENCE	We previously established a model of acquired oxaliplatin resistance derived from the HCT116 oxaliplatin-sensitive cell line (HCT116S) and consisting in two resistant clones (HCT116R1, HCT116R2) and their total or partial revertants (HCT116Rev1 and HCT116Rev2, respectively). Using this cellular model, we explored the contribution of mitochondrial apoptosis and nuclear DNA to oxaliplatin-mediated apoptosis induction and oxaliplatin resistance. We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsi(m)). In addition, we observed that p53 only contributed marginally to oxaliplatin-induced cytotoxicity and was not involved in oxaliplatin resistance. Moreover and surprisingly, depletion of the nucleus in HCT116S cells did not abolish the oxaliplatin-induced DeltaPsi(m) loss indicative of imminent apoptosis. Enucleation abolished the oxaliplatin resistance of HCT116R1 cells, while HCT116R2 cytoplasts conserved their resistant phenotype. Altogether, these data demonstrate that oxaliplatin exerts its cytotoxic effects by inducing mitochondrial apoptosis and that these effects can be initiated by interacting on other cellular structures than nuclear DNA. Resistance to oxaliplatin may imply both nuclear and cytoplasmic compartments.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Pasteur, Paris, France; CNRS, UMR 5160, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Crabbé, Laure/P-8955-2014	KROEMER, Guido/0000-0002-9334-4405; Crabbé, Laure/0000-0001-7764-3600; Andreau, Karine/0000-0002-9773-0733				Boulikas T, 2003, ONCOL REP, V10, P1663; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; ElAkawi Z, 1996, CANCER LETT, V105, P5, DOI 10.1016/0304-3835(96)04245-0; Fink D, 1997, CANCER RES, V57, P1841; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hector S, 2001, CANCER CHEMOTH PHARM, V48, P398, DOI 10.1007/s002800100363; Ibrahim A, 2004, ONCOLOGIST, V9, P8, DOI 10.1634/theoncologist.9-1-8; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Kollmannsberger C, 2004, J CLIN ONCOL, V22, P108, DOI 10.1200/JCO.2004.06.068; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mishima M, 2002, EUR J CANCER, V38, P1405, DOI 10.1016/S0959-8049(02)00096-5; Misset JL, 2000, CRIT REV ONCOL HEMAT, V35, P75, DOI 10.1016/S1040-8428(00)00070-6; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Raymond E, 2002, MOL CANCER THER, V1, P227; Reardon JT, 1999, CANCER RES, V59, P3968; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Vekris A, 2004, CANCER RES, V64, P356, DOI 10.1158/0008-5472.CAN-03-2258; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; WOYNAROWSKI JM, 1998, MOL PHARM, V54, P1998; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	31	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7449	7457		10.1038/sj.onc.1208047	http://dx.doi.org/10.1038/sj.onc.1208047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334062				2022-12-28	WOS:000224176500001
J	Fisher, SG; Fisher, RI				Fisher, SG; Fisher, RI			The epidemiology of non-Hodgkin's lymphoma	ONCOGENE			English	Review						non-Hodgkin's lymphoma; epidemiology; etiology	CARDIAC-TRANSPLANT RECIPIENTS; EPSTEIN-BARR-VIRUS; UNITED-STATES; HELICOBACTER-PYLORI; LYMPHOPROLIFERATIVE DISORDERS; GASTRIC LYMPHOMA; TIME TRENDS; RHEUMATOID-ARTHRITIS; BLOOD-TRANSFUSION; CELL LYMPHOMAS	The incidence of non-Hodgkin's lymphoma (NHL) has doubled over the past two decades in the US and most other westernized countries. While improved cancer reporting, changes in lymphoma classification, and increases in AIDS-associated lymphomas have contributed to the startling escalation of disease incidence, these factors are estimated to account for only about 50% of the increase in observed incidence. The elucidation of etiologic factors and their mechanistic role in the pathogenesis of this malignancy are critical to advancements in disease prevention and treatment. Current evidence suggests that factors/conditions that precipitate either chronic antigenic stimulation or immunosuppression may provide a preferential milieu for development of NHL. High rates of lymphoma have been observed among individuals with autoimmune disease, organ transplants, and primary or acquired immunodeficiencies. Ultraviolet radiation, previously demonstrated to have an immunosuppressive effect, has also been suggested as a possible risk factor for NHL. Several pathogens have been linked to the risk of lymphoma, including Epstein-Barr virus, human immunodeficiency virus, human T-cell lymphotropic virus-1, Helicobacter pylori, hepatitis C, and simian virus 40. Whether these microbes are responsible for specific genetic mutations that initiate tumor growth, antigenic stimulation leading to B-cell proliferation, and increased potential of random cell replication errors, or immunosuppression, which thereby promotes tumor growth, has not been clearly delineated. Other exogenous factors which have been implicated in lymphomagenesis are chemicals and agricultural exposures, hair dyes, and blood transfusions. We must build on our current knowledge regarding the etiology of NHL in order that prevention, treatment, and ultimately, cure of this malignancy becomes a reality.	Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Div Epidemiol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fisher, SG (corresponding author), Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Div Epidemiol, 601 Elmwood Ave,Box 644, Rochester, NY 14642 USA.	susan_fisher@urmc.rochester.edu						*AM CANC SOC, 2001, CANC FACTS FIG; Ambinder RF, 1999, CANC TREAT, V99, P27; Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180; BANKS PM, 1992, CANCER RES, V52, pS5453; Biggar RJ, 2001, J ACQ IMMUN DEF SYND, V26, P371, DOI 10.1097/00126334-200104010-00015; BLAIR A, 1991, OCCUP MED, V6, P335; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BRESLIN P, 1988, J OCCUP ENVIRON MED, V30, P412, DOI 10.1097/00043764-198805000-00007; Cerhan JR, 2001, CANCER EPIDEM BIOMAR, V10, P361; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; Chiu BCH, 1999, BRIT J CANCER, V80, P1476, DOI 10.1038/sj.bjc.6690547; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; CLEARY ML, 1984, LANCET, V2, P489; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; Dal Maso L, 2003, LANCET ONCOL, V4, P110, DOI 10.1016/S1470-2045(03)00983-5; DAMORE F, 1992, HEMATOL REV, V6, P183; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; De Re V, 2000, BLOOD, V96, P3578; DEVESA SS, 1992, CANCER RES, V52, pS5432; DeVita S, 1997, BLOOD, V90, P776, DOI 10.1182/blood.V90.2.776; Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204; Ferreri AJM, 2004, J NATL CANCER I, V96, P586, DOI 10.1093/jnci/djh102; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; GAIDANO G, 1997, CANC PRINCIPLES PRA, V3, P2131; Garabrant DH, 2002, CRIT REV TOXICOL, V32, P233, DOI 10.1080/20024091064237; Gisbert JP, 2003, GASTROENTEROLOGY, V125, P1723, DOI 10.1053/j.gastro.2003.09.025; Goedert JJ, 2000, SEMIN ONCOL, V27, P390; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; GROGAN TM, 1995, CANC TREATMENT, P979; Groves FD, 2000, JNCI-J NATL CANCER I, V92, P1240, DOI 10.1093/jnci/92.15.1240; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; HARRIS NL, 1994, BLOOD, V84, P1361; HARRIS OD, 1967, AM J MED, V42, P899, DOI 10.1016/0002-9343(67)90071-X; HARTGE P, 1992, CANCER RES, V52, pS5566; HAYES HM, 1991, J NATL CANCER I, V83, P1226, DOI 10.1093/jnci/83.17.1226; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; HOLFORD TR, 1992, CANCER RES, V52, pS5443; Holly EA, 1999, AM J EPIDEMIOL, V150, P375, DOI 10.1093/oxfordjournals.aje.a010017; HOOVER RN, 1992, CANCER RES, V52, pS5477; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; *INT AG RES CANC M, 1978, MON INT AG RES CANC, V16; *INT AG RES CANC W, 1996, IARC MON EV CARC RIS, V67, P67; International Agency for Research on Cancer, 1997, MON EV CARC RISKS HU; Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34; JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O; Johnson R.A., 2004, ORGANIC REACTIONS; Jonsson V, 1999, J INTERN MED, V245, P277, DOI 10.1046/j.1365-2796.1999.0443f.x; KAMEL OW, 1995, LEUKEMIA LYMPHOMA, V16, P363, DOI 10.3109/10428199509054421; KAST WM, 1998, ENCY LIFE SCI; KINLEN L, 1992, CANCER RES, V52, pS5474; KIRKLEY SA, 1995, LANCET, V345, P527, DOI 10.1016/S0140-6736(95)90627-4; Klein HG, 1999, ANESTHESIOLOGY, V91, P861, DOI 10.1097/00000542-199909000-00040; KRIPKE ML, 1994, CANCER RES, V54, P6102; Landers DF, 1996, ANESTH ANALG, V82, P187, DOI 10.1097/00000539-199601000-00035; Lecuit M, 2004, NEW ENGL J MED, V350, P239, DOI 10.1056/NEJMoa031887; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; LINET MS, 1992, CANCER RES, V52, pS5468; Luppi M, 1996, BRIT J HAEMATOL, V94, P373, DOI 10.1046/j.1365-2141.1996.d01-1791.x; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Melbye M, 1996, ACTA ONCOL, V35, P655, DOI 10.3109/02841869609083994; MELBYE M, 2002, TXB CANC EPIDEMIOLOG, V25, P535; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; MORROW RH, 1976, JNCI-J NATL CANCER I, V56, P479, DOI 10.1093/jnci/56.3.479; MORTON LM, 2004, P AACR, V45, P490; MUELLER NE, 1992, CANCER RES, V52, pS5479; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; Nakatsuka S, 2003, CANCER RES, V63, P7606; Nelson RA, 1997, BRIT J CANCER, V76, P1532, DOI 10.1038/bjc.1997.590; OFFIT K, 1991, BLOOD, V77, P1508; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OPELZ G, 1973, TRANSPLANT P, V5, P253; Palackdharry C S, 1994, Oncology (Williston Park), V8, P67; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel O, 2000, CANCER, V88, P2357, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2357::AID-CNCR21>3.3.CO;2-V; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PEARCE N, 1989, BRIT J IND MED, V46, P143; PETTERSSON T, 1992, ANN RHEUM DIS, V51, P437, DOI 10.1136/ard.51.4.437; PIMENTAL D, 1993, HDB PEST MANAGEMENT, V1, P679; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; Reed D., 1902, JOHNS HOPKINS HOS RE, V10, P133; Ries L, 2001, SEER CANC STAT REV; RIVAS JM, 1992, J IMMUNOL, V149, P3865; Rizzo P, 1999, CHEST, V116, p470S, DOI 10.1378/chest.116.suppl_3.470S; *SEER, 2003, SURV EP END RES PROG; SELIK RM, 1987, AIDS, V1, P175; SHIPP MA, 1997, CANC PRINCIPLES PRAC, V3, P2165; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; TAKATSUKI K, 1976, TOPICS HEMATOLOGY, P73; Tavani A, 2000, EUR J CANCER PREV, V9, P59, DOI 10.1097/00008469-200002000-00008; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VERMEER M, 1990, PHOTODERMATOL PHOTO, V7, P258; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vink AA, 1996, PHOTOCHEM PHOTOBIOL, V63, P383; WAHL SM, 1983, ARTHRITIS RHEUM-US, V26, P1076, DOI 10.1002/art.1780260904; Wiernik PH, 2000, BRIT J HAEMATOL, V108, P72, DOI 10.1046/j.1365-2141.2000.01815.x; WIGLE DT, 1990, J NATL CANCER I, V82, P575, DOI 10.1093/jnci/82.7.575; Willemze R, 1997, BLOOD, V90, P354; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; YE BH, 2002, CANC INVESTIG, V18, P356; YOSIDA M, 1985, RETROVIRUSES HUMAN L, P39; Zahm S H, 1990, Epidemiology, V1, P349, DOI 10.1097/00001648-199009000-00004; Zahm SH, 1997, CANCER CAUSE CONTROL, V8, P159, DOI 10.1023/A:1018412027985; Zhang YW, 2004, AM J EPIDEMIOL, V159, P148, DOI 10.1093/aje/kwh033; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I; Zhu KM, 1998, CANCER CAUSE CONTROL, V9, P77, DOI 10.1023/A:1008853421083	110	291	302	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6524	6534		10.1038/sj.onc.1207843	http://dx.doi.org/10.1038/sj.onc.1207843			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322522				2022-12-28	WOS:000223468800016
J	Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW				Domina, AM; Vrana, JA; Gregory, MA; Hann, SR; Craig, RW			MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol	ONCOGENE			English	Article						MCL1; BCL2; 12-O-tetradecanoylphorbol 13-acetate; extracellular signal regulated kinase; mitogen activated protein kinase; taxol; protein phosphorylation; protein phosphatase 1/2A	UBIQUITIN-DEPENDENT DEGRADATION; C-MYC PROTEOLYSIS; BCL-2 FAMILY; PROTEASOME PATHWAY; CYCLE PROGRESSION; GENE-PRODUCT; PROTEIN; KINASE; APOPTOSIS; SURVIVAL	BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events-mediated through separate signaling processes and involving different target sites-in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-independent sites.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Dartmouth College; Vanderbilt University	Craig, RW (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	ruth.w.craig@dartmouth.edu			NCI NIH HHS [R01-CA57359, R01 CA057359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Basu A, 1998, INT J ONCOL, V13, P659; Basu A, 2000, INT J ONCOL, V16, P497; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1997, CANCER RES, V57, P130; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Chen MC, 2000, BIOCHEM BIOPH RES CO, V279, P725, DOI 10.1006/bbrc.2000.3977; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Haldar S, 1998, CANCER RES, V58, P1609; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Matsuoka K, 2002, EUR J BIOCHEM, V269, P3511, DOI 10.1046/j.1432-1033.2002.03033.x; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RIVIERE LR, 1996, CURRENT PROTOCOLS PR, V2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vantieghem A, 2002, J BIOL CHEM, V277, P37718, DOI 10.1074/jbc.M204348200; Vrana JA, 2002, CANCER RES, V62, P892; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	62	244	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5301	5315		10.1038/sj.onc.1207692	http://dx.doi.org/10.1038/sj.onc.1207692			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15241487				2022-12-28	WOS:000222491600006
J	Suenaga, N; Mori, H; Itoh, Y; Seiki, M				Suenaga, N; Mori, H; Itoh, Y; Seiki, M			CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase	ONCOGENE			English	Article						MT-MMP; CD44; hemopexin-like domain	TUMOR-CELL MIGRATION; SURFACE; EXPRESSION; INVASION; MT1-MMP; MATRIX-METALLOPROTEINASE-9; ACTIVATION; CLEAVAGE	Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a potent modulator of pericellular environment through its proteolytic activity and promotes migration, invasion, and proliferation of tumor cells. During cell migration, MT1-MMP binds to CD44H, a major hyaluronan receptor, through the hemopexin-like (HPX) domain and localizes at the migration front. MT1-MMP is also responsible for shedding CD44H, which supports CD44H-mediated cell migration. In this study, we asked whether the binding of MT1-MMP to CD44H is a prerequisite step for the successive shedding. Deletion of the HPX domain deprived MT1-MMP of its shedding activity. Furthermore, disruption of the CD44H/MT1-MMP complex by overexpressing the HPX fragments resulted in inhibition of the shedding. Thus, the CD44H in the complex appears to be the direct substrate of MT1-MMP for shedding. Interestingly, other members of the MT-MMP family showed varied extents of CD44H shedding. Domain swapping between MT1-MMP and other MT-MMPs revealed that the ability of the HPX domains to bind CD44H is conserved among them. However, the shedding activity was different depending on the catalytic domains. The conserved binding ability of the HPX domains suggests that CD44H may act as a core molecule assembling multiple MT-MMPs on the cell surface.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823				Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Goebeler M, 1996, J CELL SCI, V109, P1957; Ha HY, 2001, CANCER RES, V61, P984; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; NAOT D, 1997, ADV CANCER RES, V71, P241; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Vivinus-Nebot M, 2004, J IMMUNOL, V172, P1397, DOI 10.4049/jimmunol.172.3.1397; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	27	83	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					859	868		10.1038/sj.onc.1208258	http://dx.doi.org/10.1038/sj.onc.1208258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558018				2022-12-28	WOS:000226577100012
J	Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF				Kishimoto, K; Liu, SM; Tsuji, T; Olson, KA; Hu, GF			Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis	ONCOGENE			English	Article						angiogenin; angiogenesis; rRNA transcription; ribosome biogenesis; nuclear translocation; angiogenic factors	NUCLEOLAR ORGANIZER REGIONS; GROWTH-FACTOR; BINDING-PROTEIN; TUMOR-GROWTH; EXPRESSION; CANCER; SERUM; MECHANISMS; ACTIN; MICE	Angiogenin is an angiogenic protein that undergoes nuclear translocation in endothelial cells where it accumulates in the nucleolus and stimulates rRNA transcription, a rate-limiting step in ribosome biogenesis, protein translation, and cell growth. Here, we report that angiogenin is required for cell proliferation induced by various other angiogenic proteins including acidic and basic fibroblast growth factors ( aFGF and bFGF), epidermal growth factor (EGF), and vascular endothelial growth factor ( VEGF). Downregulation of angiogenin in endothelial cells by small interfering RNA ( siRNA) and antisense results in a decrease in rRNA transcription, ribosome biogenesis, and cell proliferation induced by these angiogenic factors. Inhibitors of the nuclear translocation of angiogenin abolish the angiogenic activities of these factors. Stable angiogenin antisense transfection in HeLa cells reduces tumor angiogenesis in athymic mice despite the elevated expression level of bFGF and VEGF. Thus, nuclear angiogenin assumes an essential role in endothelial cell proliferation and is necessary for angiogenesis induced by other angiogenic factors. Angiogenin-stimulated rRNA transcription in endothelial cells may thus serve as a crossroad in the process of angiogenesis induced by various angiogenic factors.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hu, GF (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB 930, Boston, MA 02115 USA.	guofu_hu@hms.harvard.edu			NATIONAL CANCER INSTITUTE [R21CA091086] Funding Source: NIH RePORTER; NCI NIH HHS [CA91086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams S A, 1999, Angiogenesis, V3, P189, DOI 10.1023/A:1009015512200; AU S, 1986, ANTIMICROB AGENTS CH, V30, P395, DOI 10.1128/AAC.30.3.395; Barton DPJ, 1997, CLIN CANCER RES, V3, P1579; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; Bodner-Adler B, 2001, ANTICANCER RES, V21, P809; Eberle K, 2000, ANTICANCER RES, V20, P1679; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Folkman J, 2002, CANCER CELL, V1, P113, DOI 10.1016/S1535-6108(02)00038-7; Fu XY, 1999, GROWTH FACTORS, V17, P125, DOI 10.3109/08977199909103521; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Homer JJ, 2002, CLIN OTOLARYNGOL, V27, P32, DOI 10.1046/j.0307-7772.2001.00519.x; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; Hu GF, 2000, J CELL BIOCHEM, V76, P452, DOI 10.1002/(SICI)1097-4644(20000301)76:3<452::AID-JCB12>3.0.CO;2-Z; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; Hu GF, 1997, P NATL ACAD SCI USA, V94, P2204, DOI 10.1073/pnas.94.6.2204; Imaizumi T, 2000, THROMB HAEMOSTASIS, V83, P949; Kinoshita M, 1999, ARTERIOSCL THROM VAS, V19, P2323, DOI 10.1161/01.ATV.19.10.2323; Kushlinskii NE, 2000, B EXP BIOL MED+, V130, P691, DOI 10.1007/BF02682107; LI DC, 1994, J PATHOL, V172, P171, DOI 10.1002/path.1711720203; Liu SM, 2001, BIOCHEM BIOPH RES CO, V287, P305, DOI 10.1006/bbrc.2001.5568; MOENNER M, 1994, EUR J BIOCHEM, V226, P483, DOI 10.1111/j.1432-1033.1994.tb20073.x; Montero S, 1998, CLIN CANCER RES, V4, P2161; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; Olson KA, 2002, INT J CANCER, V98, P923, DOI 10.1002/ijc.10282; Olson KA, 2001, CLIN CANCER RES, V7, P3598; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; POLAKOWSKI IJ, 1993, AM J PATHOL, V143, P507; Ribatti D, 2000, GEN PHARMACOL-VASC S, V35, P227, DOI 10.1016/S0306-3623(01)00112-4; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUSCHOFF J, 1989, PATHOL RES PRACT, V185, P878; Shimoyama S, 1999, PANCREAS, V18, P225, DOI 10.1097/00006676-199904000-00002; Shimoyama S, 2002, ANTICANCER RES, V22, P1045; TRERE D, 1989, EXP CELL RES, V184, P131, DOI 10.1016/0014-4827(89)90371-6; Ugurel S, 2001, J CLIN ONCOL, V19, P577, DOI 10.1200/JCO.2001.19.2.577; WILLIAMS PD, 1987, ANTIMICROB AGENTS CH, V31, P570, DOI 10.1128/AAC.31.4.570; WILTING J, 1991, ANAT EMBRYOL, V183, P259; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x; Xu ZP, 2002, BIOCHEM BIOPH RES CO, V294, P287, DOI 10.1016/S0006-291X(02)00479-5	45	261	281	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					445	456		10.1038/sj.onc.1208223	http://dx.doi.org/10.1038/sj.onc.1208223			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558023				2022-12-28	WOS:000226279700015
J	Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF				Zhang, YW; Su, YL; Lanning, N; Gustafson, M; Shinomiya, N; Zhao, P; Cao, B; Tsarfaty, G; Wang, LM; Hay, R; Vande Woude, GF			Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor	ONCOGENE			English	Article						human HGF/SF; met; transgenic; SCID; tumor xenograft	SCATTER-FACTOR; ANTITUMOR-ACTIVITY; METASTASIS; MOTILITY; INVASION; CELLS; TUMORIGENICITY; NETWORK; MOUSE	Downstream signaling that results from the interaction of hepatocyte growth factor/scatter factor (HGF/SF) with the receptor tyrosine kinase Met plays critical roles in tumor development, progression, and metastasis. This ligand-receptor pair is an attractive target for new diagnostic and therapeutic agents, preclinical development of which requires suitable animal models. The growth of heterotopic and orthotopic Met-expressing human tumor xenografts in conventional strains of immunocompromised mice inadequately replicates the paracrine stimulation by human HGF/SF (hHGF/SF) that occurs in humans with cancer. We have therefore generated a mouse strain transgenic for hHGF/SF (designated hHGF-Tg) on a severe combined immunodeficiency (SCID) background. We report here that the presence of ectopically expressed hHGF/SF ligand significantly enhances growth of heterotopic subcutaneous xenografts derived from human Met-expressing cancer cells, including the lines SK-LMS-1 (human leiomyosarcoma), U118 (human glioblastoma), and DU145 (human prostate carcinoma), but not that of M14-Mel xenografts (human melanoma that expresses insignificant levels of Met). Our results indicate that ectopic hHGF/SF can specifically activate Met in human tumor xenografts. This new hHGF-Tg strain of mice should provide a powerful tool for evaluating drugs and diagnostic agents that target the various pathways influenced by Met activity.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Van Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Chaim Sheba Med Ctr, Tel Aviv, Israel; Vita Genom Inc, Taipei, Taiwan	Van Andel Institute; Van Andel Institute; Chaim Sheba Medical Center; Vita Genomics Incorporated	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Lanning, Nathan/AAI-2532-2019; Shinomiya, Nariyoshi/I-9666-2014	Lanning, Nathan/0000-0002-0983-7451; 				Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOCK TA, 1995, J EXP MED, V182, P2037, DOI 10.1084/jem.182.6.2037; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kerbel RS, 2003, CANCER BIOL THER, V2, pS134; Koochekpour S, 1997, CANCER RES, V57, P5391; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; Qian CN, 2003, J UROLOGY, V170, P994, DOI 10.1097/01.ju.0000080321.99119.df; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Webb CP, 2000, CANCER RES, V60, P342; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	21	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					101	106		10.1038/sj.onc.1208181	http://dx.doi.org/10.1038/sj.onc.1208181			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531925				2022-12-28	WOS:000226125800012
J	van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R				van Limpt, V; Schramm, A; Lakeman, A; van Sluis, P; Chan, A; van Noesel, M; Baas, F; Caron, H; Eggert, A; Versteeg, R			The Phox2B homeobox gene is mutated in sporadic neuroblastomas	ONCOGENE			English	Article						Phox2B; mutations; neuroblastoma; TrkA	N-MYC; ALLELIC LOSS; EXPRESSION; MUTATIONS; REARRANGEMENTS; AMPLIFICATION; DNA	Neuroblastomas are embryonal tumours of the sympathoadrenal lineage with a clinical course ranging from spontaneous regression to fatal progression. The Phox2B homeobox transcription factor functions in the differentiation of the sympatho-adrenal lineage. Targets of Phox2B are, for example, genes of the ( nor) adrenalin synthesis route, like Dopamine Beta Hydroxylase (DBH). Congenital Central Hypoventilation Syndrome was recently found to result from Phox2B mutations and two such patients in addition developed neuroblastoma. A germline mutation in Phox2B was identified in a family with hereditary neuroblastoma. Here, we report the first analysis of Phox2B in a series of 237 sporadic neuroblastomas and 22 cell lines. Six frameshift mutations were found in exons 2 and 3; including one in cell line SK-N-SH. Two patients showed de novo constitutional mutations. One of them was diagnosed with Haddad syndrome. All analysed cases expressed the mutated and wild-type Phox2B alleles. Ectopic expression of TrkA, the Nerve Growth Factor receptor, strongly downregulated Phox2B and DBH expression in cell line SH-SY5Y. However, TrkA and Phox2B showed a positive correlation in a panel of 66 neuroblastoma tumours. Although Phox2B mutations are infrequent ( 2.3%), they implicate a role for the Phox2B pathway in oncogenesis.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Childrens Hosp Essen, Dept Oncol Hematol & Endocrinol, D-45122 Essen, Germany; Univ Amsterdam, Acad Med Ctr, Dept Neurogenet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	r.versteeg@amc.uva.nl	Schramm, Alexander/G-5688-2010; Eggert, Angelika/AAE-6907-2022; Versteeg, Rogier/AAQ-1765-2020; Baas, Frank/F-9574-2010	Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Baas, Frank/0000-0003-3912-5428; Versteeg, Rogier/0000-0001-7172-0388				Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Bonfield JK, 1998, NUCLEIC ACIDS RES, V26, P3404, DOI 10.1093/nar/26.14.3404; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Caron H, 1996, HUM GENET, V97, P834; Easton J, 1998, CANCER RES, V58, P2624; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Huber K, 2002, ANN NY ACAD SCI, V971, P554, DOI 10.1111/j.1749-6632.2002.tb04526.x; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; Lavoie H, 2003, HUM MOL GENET, V12, P2967, DOI 10.1093/hmg/ddg329; LIMPT VA, 2003, INT J CANCER, V105, P61; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; ROSS RA, 1983, J NATL CANCER I, V71, P741; Sasaki A, 2003, HUM GENET, V114, P22, DOI 10.1007/s00439-003-1036-z; SCHULTE JH, 2004, IN PRESS ONCOGENE; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Spieker N, 2001, GENOMICS, V71, P214, DOI 10.1006/geno.2000.6408; Stanke M, 2004, MOL CELL NEUROSCI, V25, P374, DOI 10.1016/j.mcn.2003.10.021; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813	34	94	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9280	9288		10.1038/sj.onc.1208157	http://dx.doi.org/10.1038/sj.onc.1208157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516980				2022-12-28	WOS:000225638000013
J	Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D				Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D			Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks	ONCOGENE			English	Article						ATM; Chk2; DNA double-strand breaks; checkpoints	ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; CHECKPOINT KINASE-2; DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; PROTEIN-KINASE; IN-VIVO; REPAIR	The diverse checkpoint responses to DNA damage may reflect differential sensitivities by molecular components of the damage-signalling network to the type and amount of lesions. Here, we determined the kinetics of activation of the checkpoint kinases ATM and Chk2 ( the latter substrate of ATM) in relation to the initial yield of genomic DNA single-strand (SSBs) and double-strand breaks (DSBs). We show that doses of gamma-radiation (IR) as low as 0.25 Gy, which generate vast numbers of SSBs but only a few DSBs per cell (<8), promptly activate ATM kinase and induce the phosphorylation of the ATM substrates p53 - Ser15, Nbs1 - Ser343 and Chk2 - Thr68. The full activation of Chk2 kinase, however, is triggered by treatments inflicting >19 DSBs per cell (e.g. 1 Gy), which cause Chk2 autophosphorylation on Thr387, Chk2-dependent accumulation of p21(waf1) and checkpoint arrest in the S phase. Our results indicate that, in contrast to ATM, Chk2 activity is triggered by a greater number of DSBs, implying that, below a certain threshold level of lesions (<19 DSBs), DNA repair can occur through ATM, without enforcing Chk2-dependent checkpoints.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Osped S Andrea, I-00189 Rome, Italy; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Adolescent Med, Rochester, MN 55905 USA; Queensland Inst Med Res, Mol & Cellular Biol Div, Brisbane, Qld 4006, Australia	Fondazione IRCCS Istituto Nazionale Tumori Milan; Nagoya City University; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Mayo Clinic; Mayo Clinic; Mayo Clinic; QIMR Berghofer Medical Research Institute	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	delia@istitutotumori.mi.it	Buscemi, Giacomo/ABI-1170-2020; Perego, Paola/J-7647-2016	Buscemi, Giacomo/0000-0002-8404-7142; Perego, Paola/0000-0003-2806-7269; Khanna, Kum Kum/0000-0001-8650-5381	Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Birnboim HC, 1997, J CELL BIOCHEM, V66, P219, DOI 10.1002/(SICI)1097-4644(19970801)66:2<219::AID-JCB9>3.0.CO;2-T; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; CAPRANICO G, 1987, CANCER RES, V47, P3752; Chehab NH, 2000, GENE DEV, V14, P278; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Delia D, 2000, BRIT J CANCER, V82, P1938; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; GOLOS B, 1991, NEOPLASMA, V38, P559; Guidarelli A, 1997, FREE RADICAL RES, V26, P537, DOI 10.3109/10715769709097825; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HUE YK, 1994, CANCER RES, V54, P2544; Jakob B, 2003, RADIAT RES, V159, P676, DOI 10.1667/0033-7587(2003)159[0676:BIOHCT]2.0.CO;2; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KOHN KW, 1981, MEASUREMENT DNA STRA, P370; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; Mochan TA, 2003, CANCER RES, V63, P8586; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Perego P, 2000, INT J CANCER, V87, P343, DOI 10.1002/1097-0215(20000801)87:3<343::AID-IJC6>3.0.CO;2-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Plumb MA, 1999, INT J RADIAT BIOL, V75, P553, DOI 10.1080/095530099140195; Prise KM, 2001, RADIAT RES, V156, P572, DOI 10.1667/0033-7587(2001)156[0572:AROSOI]2.0.CO;2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Taylor AMR, 2001, BEST PRACT RES CL HA, V14, P631, DOI 10.1053/beha.2001.0158; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	63	85	93	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7691	7700		10.1038/sj.onc.1207986	http://dx.doi.org/10.1038/sj.onc.1207986			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361830				2022-12-28	WOS:000224306700010
J	Unoki, M; Nishidate, T; Nakamura, Y				Unoki, M; Nishidate, T; Nakamura, Y			ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain	ONCOGENE			English	Article						ICBP90; methyl-CpG-binding protein; HDAC1; SRA domain; E2F-1; UHRF1BP1	CELL-CYCLE; UBIQUITIN LIGASE; DOWN-REGULATION; PARTNER KAISO; PROTEIN; NP95; GENE; NIRF; TRANSCRIPTION; EXPRESSION	ICBP90, invertedCCA AT box-binding protein of 90 kDa, has been reported as a regulator of topoisomerase IIalpha expression. We present evidence here that ICBP90 binds to methyl-CpG when at least one symmetrically methylated-CpG dinucleotides is presented as its recognition sequence. A SET and RING finger-associated(SRA) domain accounts for the high binding affinity of ICBP90 for methyl-CpG dinucleotides. This protein constitutes a complex with HDAC1 also via its SRA domain, and bound to methylated promoter regions of various tumor suppressor genes, including p16(INK4A) and p14(ARF), in cancer cells. It has been reported that expression of ICBP90 was upregulated by E2F-1, and we confirmed that the upregulation was caused by binding of E2F-1 to the intron1 of ICBP90, which contains two E2F-1-binding motifs. Our data also revealed accumulation of ICBP90 in breast-cancer cells, where it might suppress expression of tumor suppressor genes through deacetylation of histones after recruitment of HDAC1. The data reported here suggest that ICBP90 is involved in cell proliferation by way of methylation-mediated regulation of certain genes.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shiorokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Fujimori A, 1998, MAMM GENOME, V9, P1032, DOI 10.1007/s003359900920; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Li YY, 2004, BIOCHEM BIOPH RES CO, V319, P464, DOI 10.1016/j.bbrc.2004.04.190; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; Mori T, 2004, FEBS LETT, V557, P209, DOI 10.1016/S0014-5793(03)01495-9; Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NISHIDATE T, 2004, IN PRESS INT J ONCOL; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Shimokawa T, 2003, CANCER RES, V63, P6116; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	27	224	244	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7601	7610		10.1038/sj.onc.1208053	http://dx.doi.org/10.1038/sj.onc.1208053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361834				2022-12-28	WOS:000224306700001
J	Makridakis, N; Akalu, A; Reichardt, JKV				Makridakis, N; Akalu, A; Reichardt, JKV			Identification and characterization of somatic steroid 5 alpha-reductase (SRD5A2) mutations in human prostate cancer tissue	ONCOGENE			English	Article						somatic mutations; androgen metabolism; prostate cancer; steroid 5 alpha-reductase; pharmacogenetics	ANDROGEN RECEPTOR GENE; AMPLIFICATION; SUBSTITUTION; PROGRESSION; FINASTERIDE; INHIBITOR; CARCINOMA	Prostate cancer is a very common disease in industrialized countries and it is known to be androgen-dependent. The human SRD5A2 gene encodes the prostatic ( or type II) steroid 5alpha-reductase, which catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate. We have sequenced the entire protein-coding region of this locus in 30 microdissected prostate adenocarcinomas. We identified a total of 17 de novo amino-acid substitutions in 13 of these tumors. We also identified six additional silent substitutions. In total, 18 out of 30 (60%) of the tumors examined had de novo somatic substitutions in the prostatic steroid 5alpha-reductase-coding region. We also characterized all of the SRD5A2 missense substitutions biochemically and pharmacologically, using three 5alpha-reductase inhibitors, including. nasteride. The biochemical parameters of the distinct 5alpha-reductase missense substitutions varied substantially. We note that two out of the three recurrent SRD5A2 missense substitutions increased 5alpha-reductase in vitro activity, while the third one is essentially neutral. These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients. Our pharmacologic studies also reveal substantial variability for each 5alpha-reductase inhibitor. These data, therefore, should be taken into account in both prevention as well as therapeutic trials of prostate cancer utilizing 5alpha-reductase inhibitors.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Reichardt, JKV (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 2250 Alcazar St,IGM240, Los Angeles, CA 90089 USA.	reichard@usc.edu		Reichardt, Juergen/0000-0001-6458-2773				Akalu A, 1999, J UROLOGY, V161, P1355, DOI 10.1016/S0022-5347(01)61683-5; Akalu A, 1999, GENET ANAL-BIOMOL E, V15, P229, DOI 10.1016/S1050-3862(99)00050-9; BROTHMAN AR, 1990, CANCER RES, V50, P3795; Cheng Earl, 1993, P57; di Salle E, 1998, J STEROID BIOCHEM, V64, P179, DOI 10.1016/S0960-0760(97)00158-1; Frye S V, 1998, Pharm Biotechnol, V11, P393; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Luo J, 2003, PROSTATE, V57, P134, DOI 10.1002/pros.10284; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Makridakis N, 1997, CANCER RES, V57, P1020; Makridakis NM, 2000, PHARMACOGENETICS, V10, P407, DOI 10.1097/00008571-200007000-00004; Makridakis NM, 1999, LANCET, V354, P975, DOI 10.1016/S0140-6736(98)11282-5; Nelson DL, 2000, LEHNINGER PRINCIPLES, P257; Ross RK, 1998, CANCER RES, V58, P4497; SCHRODER FH, 1992, PROSTATE, P129; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029	22	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7399	7405		10.1038/sj.onc.1207922	http://dx.doi.org/10.1038/sj.onc.1207922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326487				2022-12-28	WOS:000224021400010
J	Florin, L; Hummerich, L; Dittrich, BT; Kokocinski, F; Wrobel, G; Gack, S; Schorpp-Kistner, M; Werner, S; Hahn, M; Lichter, P; Szabowski, A; Angel, P				Florin, L; Hummerich, L; Dittrich, BT; Kokocinski, F; Wrobel, G; Gack, S; Schorpp-Kistner, M; Werner, S; Hahn, M; Lichter, P; Szabowski, A; Angel, P			Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing	ONCOGENE			English	Article						expression profiling; Jun; mesenchyme; microarray; skin	NF-KAPPA-B; C-JUN; GROWTH-FACTORS; IN-VITRO; DIFFERENTIAL EXPRESSION; TISSUE; BETA; JNK; TRANSCRIPTION; LOCALIZATION	Mesenchymal - epithelial interactions are increasingly considered to be of vital importance for epithelial homeostasis and regeneration. In skin, the transcription factor AP-1 was shown to be critically involved in the communication between keratinocytes and dermal. broblasts. After skin injury, the release of IL-1 from keratinocytes induces the activity of the AP-1 subunits c-Jun and JunB in. broblasts leading to a global change in gene expression. To identify AP-1 target genes in. broblasts, which are involved in the process of cutaneous repair, we performed gene expression pro. ling of wild-type, c-jun- and junB-deficient. broblasts in response to IL-1, mimicking the initial phase of wound healing. Using a 15K cDNA collection, over 1000 genes were found to be Jun-dependent and additional 300 clones showed IL-1 responsiveness. Combinatorial evaluation allowed for the dissection of the specific contribution of either AP-1 subunit to gene regulation. Besides previously identified genes that are involved in cutaneous repair, we have identified novel genes regulated during wound healing in vivo and showed their expression by. broblasts on wound sections. The identification of novel Jun target genes should provide a basis for understanding the molecular mechanisms underlying mesenchymal - epithelial interactions and the critical contribution of AP-1 to tissue homeostasis and repair.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Swiss Federal Institutes of Technology Domain; ETH Zurich	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz.de		Werner, Sabine/0000-0001-7397-8710; Kokocinski, Felix/0000-0002-8472-9207				Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beer HD, 1997, J INVEST DERMATOL, V109, P132, DOI 10.1111/1523-1747.ep12319188; Bodo M, 1998, CYTOKINE, V10, P353, DOI 10.1006/cyto.1997.0301; Brown DL, 1997, AM J PATHOL, V151, P715; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diehl F, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf078; Elson DA, 2000, CANCER RES, V60, P6189; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Grose R, 2002, DEVELOPMENT, V129, P2303; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hubner G, 1996, CYTOKINE, V8, P548, DOI 10.1006/cyto.1996.0074; Iwata M, 1999, HISTOCHEM CELL BIOL, V112, P283, DOI 10.1007/s004180050449; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Ko MSH, 1998, HUM MOL GENET, V7, P1967, DOI 10.1093/hmg/7.12.1967; Kralova J, 1996, ONCOGENE, V12, P2595; Lansdown ABG, 2002, WOUND REPAIR REGEN, V10, P130, DOI 10.1046/j.1524-475X.2002.20101.x; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mann A, 2001, J INVEST DERMATOL, V117, P1382, DOI 10.1046/j.0022-202x.2001.01600.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Sayani K, 2000, HISTOPATHOLOGY, V36, P262; Scheid A, 2000, PEDIATR SURG INT, V16, P232, DOI 10.1007/s003830050735; Schena M, 1996, BIOESSAYS, V18, P427, DOI 10.1002/bies.950180513; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shiina T, 2001, IMMUNOGENETICS, V53, P649, DOI 10.1007/s00251-001-0376-x; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soo C, 2000, AM J PATHOL, V157, P423, DOI 10.1016/S0002-9440(10)64555-5; SULLIVAN KM, 1995, J PEDIATR SURG, V30, P198, DOI 10.1016/0022-3468(95)90560-X; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thorey IS, 2004, J BIOL CHEM, V279, P26674, DOI 10.1074/jbc.M311467200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; WILLIAMS DH, 1992, BIOCHIM BIOPHYS ACTA, V1180, P9, DOI 10.1016/0925-4439(92)90020-N; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	62	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7005	7017		10.1038/sj.onc.1207938	http://dx.doi.org/10.1038/sj.onc.1207938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273721				2022-12-28	WOS:000223885100002
J	Dang-Tan, T; Mahmud, SM; Puntoni, R; Franco, EL				Dang-Tan, T; Mahmud, SM; Puntoni, R; Franco, EL			Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association	ONCOGENE			English	Article						Simian Virus 40; poliovirus vaccines; causality; mesothelioma; ependymoma; neoplasms	MALIGNANT MESOTHELIOMA; HUMAN TUMORS; SV40; VIRUS; POLIOMYELITIS; CONTAMINATION; EXPOSURE; RISK; CELL	In 1960, it was discovered that Simian Virus 40 (SV40) contaminated up to 30% of the poliovirus vaccines in the US. This contamination arose because the vaccines were produced in monkey kidney cell cultures harboring SV40 between 1955 and 1963. During this period, approximately 90% of children and 60% of adults in the USA were inoculated for polio and possibly exposed to SV40. Many epidemiologic and molecular pathogenesis studies have been conducted in order to identify potential cancer risks since this `natural' experiment began. Productive SV40 infection has the potential to initiate malignancy in a variety of target tissues. Epidemiological studies that investigated the relationship between SV40 infection and cancer risks have yielded mixed results. Studies can be grouped into three categories based on their exposure definition of SV40 infection: (1) use of vaccination or birth cohorts as proxy variables for infection, (2) follow-up of children of pregnant women who received polio vaccines, and (3) direct molecular detection of the virus or serologic detection of anti-SV40 antibody responses. A meta-analysis of five published studies did not support the hypothesis that SV40 exposure increases the overall risk of cancer incidence or cancer mortality. The analysis of specific cancer sites is largely inconclusive because of substantial problems that most studies have had in reliably de. ning exposure, de. ning latency effects, or dealing with confounding and other biases. A new generation of molecular epidemiologic	McGill Univ, Dept Oncol, Montreal, PQ H2W 1S6, Canada; McGill Univ, Dept Epidemiol, Montreal, PQ H2W 1S6, Canada; Natl Inst Canc Res, Dept Environm Epidemiol & Biostat, Genoa, Italy	McGill University; McGill University; University of Genoa; IRCCS AOU San Martino IST	Franco, EL (corresponding author), McGill Univ, Dept Oncol, 546 Pine Ave W, Montreal, PQ H2W 1S6, Canada.	eduardo.franco@mcgill.ca	Franco, Eduardo/C-6445-2014	Franco, Eduardo/0000-0002-4409-8084; Mahmud, Salaheddin/0000-0002-6574-0574				[Anonymous], 2002, IMMUNIZATION SAFETY; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 2000, ANTICANCER RES, V20, P875; Carbone M, 2003, ONCOGENE, V22, P5173, DOI 10.1038/sj.onc.1206552; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; Carter JJ, 2003, JNCI-J NATL CANCER I, V95, P1522, DOI 10.1093/jnci/djg074; Cerrano PG, 2003, INT J ONCOL, V22, P187; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Engels EA, 2003, JNCI-J NATL CANCER I, V95, P532, DOI 10.1093/jnci/95.7.532; Engels EA, 2003, INT J CANCER, V106, P283, DOI 10.1002/ijc.11211; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; Fisher SG, 1999, ANTICANCER RES, V19, P2173; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; JENSEN F, 1964, J NATL CANCER I, V32, P917; KIRSCHSTEIN RL, 1962, NATURE, V195, P299, DOI 10.1038/195299b0; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Puntoni R, 2003, MUTAT RES-REV MUTAT, V544, P385, DOI 10.1016/j.mrrev.2003.06.012; Rollison DEM, 2003, CANCER EPIDEM BIOMAR, V12, P460; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Strickler HD, 1999, MED PEDIATR ONCOL, V32, P77, DOI 10.1002/(SICI)1096-911X(199901)32:1<77::AID-MPO21>3.3.CO;2-6; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; Testa JR, 1998, CANCER RES, V58, P4505	28	29	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6535	6540		10.1038/sj.onc.1207877	http://dx.doi.org/10.1038/sj.onc.1207877			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322523				2022-12-28	WOS:000223468800017
